{"bottom_cover_set": ["GRM1", "PCMT1", "IFNGR1", "PDE7B", "TNFAIP3", "HBS1L", "HIVEP2", "USP45", "TFB1M", "PERP", "STXBP5", "NOX3", "ARID1B", "MYCT1", "VIP", "FBXO5", "CCNC", "PEX3", "SNX9", "MTHFD1L", "OPRM1", "REPS1", "SYNJ2", "MAP3K5", "SUMO4", "IPCEF1", "PHACTR2", "PPIL4", "CD109", "SCAF8", "MCHR2", "SIM1", "KATNA1", "IL20RA", "CITED2", "ASCC3", "NMBR", "TMEM181", "LTV1", "VTA1", "DYNLT1", "LATS1", "ESR1", "EZR", "NUP43", "PLAGL1", "TAGAP", "SF3B5", "STX11", "COL12A1", "UTRN", "SOD2", "WTAP", "GRIK2", "ACAT2", "TCP1", "MYB", "MRPL18", "IGF2R", "SYNE1", "LIN28B", "LPA", "COX7A2", "PLG", "MAP3K4", "PRDM1", "EPM2A", "AGPAT4", "ATG5", "PACRG", "QKI", "PDE10A", "RPS6KA2", "PDSS2", "FGFR1OP", "CCR6", "MYO6", "KIF25", "AHI1", "OSTM1", "THBS2", "NR2E1", "SNX3", "TCTE3", "FOXO3", "DLL1", "HTR1B", "PSMB1", "TBP", "SESN1", "PHIP", "ELOVL4", "SMPD2", "TTK", "BCKDHB", "AK9", "IBTK", "WASF1", "TPBG", "CDC40", "DDO", "SLC22A16", "CDK19", "AMD1", "GTF3C6", "RPF2", "ME1", "REV3L", "SNAP91", "FYN", "CYB5R4", "LAMA4", "NT5E", "KHDRBS2", "PTP4A1", "HDAC2", "HS3ST5", "COL10A1", "SYNCRIP", "TRAPPC3L", "HTR1E", "CGA", "GPRC6A", "COL9A1", "ORC3", "GOPC", "NUS1", "CNR1", "PLN", "RNGTT", "MCM9", "ASF1A", "MAN1A1", "SMAP1", "GABRR2", "UBE2J1", "RRAGD", "B3GAT2", "GJA1", "HSF2", "FABP7", "RIMS1", "RNF217", "TPD52L1", "MAP3K7", "EPHA7", "HEY2", "NCOA7", "UFL1", "KCNQ5", "FHL5", "NDUFAF4", "CENPW", "RSPO3", "RNF146", "FBXL4", "ECHDC1", "EEF1A1", "PTPRK", "LAMA2", "EPB41L2", "AKAP7", "ARG1", "MED23", "ENPP3", "OR2A4", "ENPP1", "CTGF", "STX7", "TAAR5", "TAAR2", "TAAR1", "SLC18B1", "RPS12", "EYA4", "SGK1", "RARS2", "TRMT11", "RNASET2", "FUT9", "RAET1G", "ULBP1", "ULBP3", "PPP1R14C", "BCLAF1", "UST", "PREP", "PGM3", "DSE", "KPNA5", "VNN1", "VNN2", "TUBE1", "FUCA2", "ADAT2"], "top_cover_set": [["TCGA.3L.AA1B.01", "Transport of small molecules"], ["TCGA.3L.AA1B.01", "Keratinization"], ["TCGA.3L.AA1B.01", "SLC-mediated transmembrane transport"], ["TCGA.3L.AA1B.01", "Phase II - Conjugation of compounds"], ["TCGA.3L.AA1B.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.3L.AA1B.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.3L.AA1B.01", "Biological oxidations"], ["TCGA.3L.AA1B.01", "Blood group systems biosynthesis"], ["TCGA.3L.AA1B.01", "Drug ADME"], ["TCGA.3L.AA1B.01", "Digestion and absorption"], ["TCGA.3L.AA1B.01", "Metabolism"], ["TCGA.3L.AA1B.01", "Lewis blood group biosynthesis"], ["TCGA.3L.AA1B.01", "Ion channel transport"], ["TCGA.3L.AA1B.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.3L.AA1B.01", "Heme degradation"], ["TCGA.3L.AA1B.01", "Class B/2 (Secretin family receptors)"], ["TCGA.3L.AA1B.01", "Peptide hormone metabolism"], ["TCGA.3L.AA1B.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.3L.AA1B.01", "Stimuli-sensing channels"], ["TCGA.3L.AA1B.01", "FGFR4 ligand binding and activation"], ["TCGA.3L.AA1B.01", "Defective GALNT12 causes CRCS1"], ["TCGA.3L.AA1B.01", "Glucuronidation"], ["TCGA.3L.AA1B.01", "RA biosynthesis pathway"], ["TCGA.3L.AA1B.01", "Cytosolic sulfonation of small molecules"], ["TCGA.3L.AA1B.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.4T.AA8H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.4T.AA8H.01", "Signaling by GPCR"], ["TCGA.4T.AA8H.01", "Neuronal System"], ["TCGA.4T.AA8H.01", "GPCR downstream signalling"], ["TCGA.4T.AA8H.01", "GPCR ligand binding"], ["TCGA.4T.AA8H.01", "Signaling Pathways"], ["TCGA.4T.AA8H.01", "Class B/2 (Secretin family receptors)"], ["TCGA.4T.AA8H.01", "G alpha (i) signalling events"], ["TCGA.4T.AA8H.01", "Transmission across Chemical Synapses"], ["TCGA.4T.AA8H.01", "Cardiac conduction"], ["TCGA.4T.AA8H.01", "Keratan sulfate biosynthesis"], ["TCGA.4T.AA8H.01", "Immune System"], ["TCGA.4T.AA8H.01", "Generation of second messenger molecules"], ["TCGA.4T.AA8H.01", "Molecules associated with elastic fibres"], ["TCGA.4T.AA8H.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.4T.AA8H.01", "Potassium Channels"], ["TCGA.4T.AA8H.01", "Extracellular matrix organization"], ["TCGA.4T.AA8H.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.4T.AA8H.01", "Leishmania infection"], ["TCGA.4T.AA8H.01", "Muscle contraction"], ["TCGA.4T.AA8H.01", "PD-1 signaling"], ["TCGA.4T.AA8H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.4T.AA8H.01", "Leishmania parasite growth and survival"], ["TCGA.4T.AA8H.01", "G alpha (s) signalling events"], ["TCGA.4T.AA8H.01", "Keratan sulfate/keratin metabolism"], ["TCGA.4T.AA8H.01", "Regulation of Complement cascade"], ["TCGA.4T.AA8H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.4T.AA8H.01", "Classical antibody-mediated complement activation"], ["TCGA.4T.AA8H.01", "G-protein beta:gamma signalling"], ["TCGA.4T.AA8H.01", "Cell surface interactions at the vascular wall"], ["TCGA.4T.AA8H.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.4T.AA8H.01", "Complement cascade"], ["TCGA.4T.AA8H.01", "Interleukin-10 signaling"], ["TCGA.4T.AA8H.01", "Glucagon-type ligand receptors"], ["TCGA.4T.AA8H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.4T.AA8H.01", "Inwardly rectifying K+ channels"], ["TCGA.4T.AA8H.01", "Platelet homeostasis"], ["TCGA.4T.AA8H.01", "Chemokine receptors bind chemokines"], ["TCGA.4T.AA8H.01", "Peptide ligand-binding receptors"], ["TCGA.4T.AA8H.01", "Activation of SMO"], ["TCGA.4T.AA8H.01", "L1CAM interactions"], ["TCGA.4T.AA8H.01", "Interaction between L1 and Ankyrins"], ["TCGA.4T.AA8H.01", "TNFs bind their physiological receptors"], ["TCGA.4T.AA8H.01", "Ca2+ pathway"], ["TCGA.4T.AA8H.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.4T.AA8H.01", "Creation of C4 and C2 activators"], ["TCGA.4T.AA8H.01", "Elastic fibre formation"], ["TCGA.4T.AA8H.01", "Glycosaminoglycan metabolism"], ["TCGA.4T.AA8H.01", "G beta:gamma signalling through BTK"], ["TCGA.4T.AA8H.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.4T.AA8H.01", "FCGR activation"], ["TCGA.4T.AA8H.01", "Biological oxidations"], ["TCGA.4T.AA8H.01", "Costimulation by the CD28 family"], ["TCGA.4T.AA8H.01", "GABA receptor activation"], ["TCGA.4T.AA8H.01", "G-protein activation"], ["TCGA.4T.AA8H.01", "Initial triggering of complement"], ["TCGA.4T.AA8H.01", "G beta:gamma signalling through CDC42"], ["TCGA.4T.AA8H.01", "GABA B receptor activation"], ["TCGA.4T.AA8H.01", "Activation of GABAB receptors"], ["TCGA.4T.AA8H.01", "Activation of G protein gated Potassium channels"], ["TCGA.4T.AA8H.01", "G protein gated Potassium channels"], ["TCGA.4T.AA8H.01", "Phase 0 - rapid depolarisation"], ["TCGA.4T.AA8H.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.4T.AA8H.01", "Ion homeostasis"], ["TCGA.4T.AA8H.01", "Developmental Biology"], ["TCGA.4T.AA8H.01", "Drug ADME"], ["TCGA.4T.AA8H.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.4T.AA8H.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.4T.AA8H.01", "Other interleukin signaling"], ["TCGA.4T.AA8H.01", "Ion transport by P-type ATPases"], ["TCGA.4T.AA8H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.4T.AA8H.01", "Integration of energy metabolism"], ["TCGA.4T.AA8H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.4T.AA8H.01", "Other semaphorin interactions"], ["TCGA.4T.AA8H.01", "Transport of small molecules"], ["TCGA.4T.AA8H.01", "G alpha (z) signalling events"], ["TCGA.4T.AA8H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.4T.AA8H.01", "Glucagon signaling in metabolic regulation"], ["TCGA.4T.AA8H.01", "Bile acid and bile salt metabolism"], ["TCGA.4T.AA8H.01", "Sialic acid metabolism"], ["TCGA.4T.AA8H.01", "CD22 mediated BCR regulation"], ["TCGA.4T.AA8H.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.4T.AA8H.01", "Thromboxane signalling through TP receptor"], ["TCGA.4T.AA8H.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.4T.AA8H.01", "Cytokine Signaling in Immune system"], ["TCGA.4T.AA8H.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.4T.AA8H.01", "G beta:gamma signalling through PLC beta"], ["TCGA.4T.AA8H.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.4T.AA8H.01", "Aquaporin-mediated transport"], ["TCGA.4T.AA8H.01", "Protein-protein interactions at synapses"], ["TCGA.4T.AA8H.01", "Presynaptic function of Kainate receptors"], ["TCGA.4T.AA8H.01", "ECM proteoglycans"], ["TCGA.4T.AA8H.01", "Calmodulin induced events"], ["TCGA.4T.AA8H.01", "CaM pathway"], ["TCGA.4T.AA8H.01", "Diseases associated with glycosaminoglycan metabolism"], ["TCGA.4T.AA8H.01", "Activation of Matrix Metalloproteinases"], ["TCGA.4T.AA8H.01", "Trafficking of AMPA receptors"], ["TCGA.4T.AA8H.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.4T.AA8H.01", "Recycling of bile acids and salts"], ["TCGA.4T.AA8H.01", "Arachidonic acid metabolism"], ["TCGA.4T.AA8H.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts"], ["TCGA.4T.AA8H.01", "Signal amplification"], ["TCGA.4T.AA8H.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.4T.AA8H.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.4T.AA8H.01", "Phase I - Functionalization of compounds"], ["TCGA.4T.AA8H.01", "G alpha (q) signalling events"], ["TCGA.4T.AA8H.01", "Integrin cell surface interactions"], ["TCGA.4T.AA8H.01", "Regulation of insulin secretion"], ["TCGA.4T.AA8H.01", "Ca-dependent events"], ["TCGA.4T.AA8H.01", "DAP12 interactions"], ["TCGA.4T.AA8H.01", "Neurotransmitter release cycle"], ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.4T.AA8H.01", "LGI-ADAM interactions"], ["TCGA.4T.AA8H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.4T.AA8H.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.4T.AA8H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.4T.AA8H.01", "Peptide hormone metabolism"], ["TCGA.4T.AA8H.01", "Scavenging by Class A Receptors"], ["TCGA.4T.AA8H.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.4T.AA8H.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.4T.AA8H.01", "Phase 4 - resting membrane potential"], ["TCGA.4T.AA8H.01", "DAP12 signaling"], ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.4T.AA8H.01", "Long-term potentiation"], ["TCGA.5M.AATA.01", "Neuronal System"], ["TCGA.5M.AATA.01", "Biological oxidations"], ["TCGA.5M.AATA.01", "RA biosynthesis pathway"], ["TCGA.5M.AATA.01", "Transmission across Chemical Synapses"], ["TCGA.5M.AATA.01", "Drug ADME"], ["TCGA.5M.AATA.01", "Signaling by GPCR"], ["TCGA.5M.AATA.01", "GPCR ligand binding"], ["TCGA.5M.AATA.01", "Phase II - Conjugation of compounds"], ["TCGA.5M.AATA.01", "Protein-protein interactions at synapses"], ["TCGA.5M.AATA.01", "Peptide hormone metabolism"], ["TCGA.5M.AATA.01", "Signaling by Retinoic Acid"], ["TCGA.5M.AATA.01", "GPCR downstream signalling"], ["TCGA.5M.AATA.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.5M.AATA.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.5M.AATA.01", "Peptide ligand-binding receptors"], ["TCGA.5M.AATA.01", "Ethanol oxidation"], ["TCGA.5M.AATA.01", "Blood group systems biosynthesis"], ["TCGA.5M.AATA.01", "Activation of Matrix Metalloproteinases"], ["TCGA.5M.AATA.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.5M.AATA.01", "Phase I - Functionalization of compounds"], ["TCGA.5M.AATA.01", "Transport of small molecules"], ["TCGA.5M.AATA.01", "Cytosolic sulfonation of small molecules"], ["TCGA.5M.AATA.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.5M.AATA.01", "Extracellular matrix organization"], ["TCGA.5M.AATA.01", "Molecules associated with elastic fibres"], ["TCGA.5M.AATA.01", "APAP ADME"], ["TCGA.5M.AATA.01", "Lewis blood group biosynthesis"], ["TCGA.5M.AATA.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.5M.AATA.01", "Interaction between L1 and Ankyrins"], ["TCGA.5M.AATA.01", "Phase 0 - rapid depolarisation"], ["TCGA.5M.AATA.01", "SLC-mediated transmembrane transport"], ["TCGA.5M.AATA.01", "G alpha (i) signalling events"], ["TCGA.5M.AATA.01", "Neurexins and neuroligins"], ["TCGA.5M.AATA.01", "Degradation of the extracellular matrix"], ["TCGA.5M.AATA.01", "Insulin processing"], ["TCGA.5M.AATA.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.A6.2678.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.2678.01", "Neuronal System"], ["TCGA.A6.2678.01", "Cardiac conduction"], ["TCGA.A6.2678.01", "L1CAM interactions"], ["TCGA.A6.2678.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.2678.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.A6.2678.01", "Biological oxidations"], ["TCGA.A6.2678.01", "Assembly of active LPL and LIPC lipase complexes"], ["TCGA.A6.2678.01", "Drug ADME"], ["TCGA.A6.2678.01", "Protein-protein interactions at synapses"], ["TCGA.A6.2678.01", "Potassium Channels"], ["TCGA.A6.2678.01", "Lewis blood group biosynthesis"], ["TCGA.A6.2678.01", "Transmission across Chemical Synapses"], ["TCGA.A6.2678.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.2678.01", "Muscle contraction"], ["TCGA.A6.2678.01", "Degradation of the extracellular matrix"], ["TCGA.A6.2678.01", "Blood group systems biosynthesis"], ["TCGA.A6.2678.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.2678.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.A6.2678.01", "GPCR downstream signalling"], ["TCGA.A6.2678.01", "Bile acid and bile salt metabolism"], ["TCGA.A6.2678.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.A6.2678.01", "G alpha (i) signalling events"], ["TCGA.A6.2678.01", "Neurexins and neuroligins"], ["TCGA.A6.2678.01", "Transport of small molecules"], ["TCGA.A6.2678.01", "Peptide hormone metabolism"], ["TCGA.A6.2678.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.A6.2678.01", "Cytosolic sulfonation of small molecules"], ["TCGA.A6.2678.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.2678.01", "TNFs bind their physiological receptors"], ["TCGA.A6.2680.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.2680.01", "Regulation of insulin secretion"], ["TCGA.A6.2680.01", "Peptide hormone metabolism"], ["TCGA.A6.2680.01", "Cardiac conduction"], ["TCGA.A6.2685.01", "Extracellular matrix organization"], ["TCGA.A6.2685.01", "Glucuronidation"], ["TCGA.A6.2685.01", "Biological oxidations"], ["TCGA.A6.2685.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.2685.01", "Integrin cell surface interactions"], ["TCGA.A6.2685.01", "ECM proteoglycans"], ["TCGA.A6.2685.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.2685.01", "GPCR ligand binding"], ["TCGA.A6.2685.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.2685.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.2685.01", "Collagen formation"], ["TCGA.A6.2686.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.2686.01", "Neuronal System"], ["TCGA.A6.2686.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.2686.01", "Cardiac conduction"], ["TCGA.A6.2686.01", "Muscle contraction"], ["TCGA.A6.2686.01", "Extracellular matrix organization"], ["TCGA.A6.2686.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.2686.01", "Axon guidance"], ["TCGA.A6.2686.01", "Nervous system development"], ["TCGA.A6.2686.01", "Degradation of the extracellular matrix"], ["TCGA.A6.2686.01", "Glucuronidation"], ["TCGA.A6.2686.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.2686.01", "Cytosolic sulfonation of small molecules"], ["TCGA.A6.2686.01", "L1CAM interactions"], ["TCGA.A6.2686.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.2686.01", "Biological oxidations"], ["TCGA.A6.2686.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.A6.2686.01", "Regulation of insulin secretion"], ["TCGA.A6.2686.01", "RA biosynthesis pathway"], ["TCGA.A6.2686.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.A6.2686.01", "Protein-protein interactions at synapses"], ["TCGA.A6.2686.01", "Metabolism"], ["TCGA.A6.2686.01", "Transmission across Chemical Synapses"], ["TCGA.A6.2686.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.2686.01", "Collagen formation"], ["TCGA.A6.2686.01", "TNFs bind their physiological receptors"], ["TCGA.A6.2686.01", "Eukaryotic Translation Elongation"], ["TCGA.A6.2686.01", "Eukaryotic Translation Termination"], ["TCGA.A6.2686.01", "Integration of energy metabolism"], ["TCGA.A6.2686.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.A6.2686.01", "Defective GALNT3 causes HFTC"], ["TCGA.A6.2686.01", "Defective GALNT12 causes CRCS1"], ["TCGA.A6.2686.01", "Viral mRNA Translation"], ["TCGA.A6.2686.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.A6.2686.01", "Transport of small molecules"], ["TCGA.A6.2686.01", "Peptide hormone metabolism"], ["TCGA.A6.2686.01", "Developmental Biology"], ["TCGA.A6.2686.01", "Peptide chain elongation"], ["TCGA.A6.2686.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.A6.2686.01", "Blood group systems biosynthesis"], ["TCGA.A6.2686.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.A6.2686.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.2686.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.2686.01", "Selenocysteine synthesis"], ["TCGA.A6.2686.01", "Glucagon-type ligand receptors"], ["TCGA.A6.2686.01", "Signaling by Retinoic Acid"], ["TCGA.A6.2686.01", "Sensory perception of taste"], ["TCGA.A6.2686.01", "GPCR ligand binding"], ["TCGA.A6.2686.01", "Striated Muscle Contraction"], ["TCGA.A6.2686.01", "Potassium Channels"], ["TCGA.A6.2686.01", "SLC-mediated transmembrane transport"], ["TCGA.A6.2686.01", "Dectin-2 family"], ["TCGA.A6.3807.01", "TNFs bind their physiological receptors"], ["TCGA.A6.3807.01", "Peptide hormone metabolism"], ["TCGA.A6.3807.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.A6.3807.01", "Glucagon-type ligand receptors"], ["TCGA.A6.3807.01", "Transport of small molecules"], ["TCGA.A6.3807.01", "Cardiac conduction"], ["TCGA.A6.3807.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.A6.3807.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.3807.01", "Neuronal System"], ["TCGA.A6.3807.01", "Integration of energy metabolism"], ["TCGA.A6.3807.01", "Signal amplification"], ["TCGA.A6.3807.01", "GPCR ligand binding"], ["TCGA.A6.3807.01", "Regulation of insulin secretion"], ["TCGA.A6.3807.01", "Signaling by Retinoic Acid"], ["TCGA.A6.3807.01", "RA biosynthesis pathway"], ["TCGA.A6.3807.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.3807.01", "Ethanol oxidation"], ["TCGA.A6.4107.01", "Peptide hormone metabolism"], ["TCGA.A6.4107.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.4107.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.A6.4107.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.4107.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.A6.4107.01", "Insulin processing"], ["TCGA.A6.4107.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.A6.4107.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.4107.01", "Digestion"], ["TCGA.A6.5660.01", "Neuronal System"], ["TCGA.A6.5660.01", "GPCR ligand binding"], ["TCGA.A6.5660.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.A6.5660.01", "Transmission across Chemical Synapses"], ["TCGA.A6.5660.01", "Signaling by GPCR"], ["TCGA.A6.5660.01", "GPCR downstream signalling"], ["TCGA.A6.5660.01", "Transport of small molecules"], ["TCGA.A6.5660.01", "Biological oxidations"], ["TCGA.A6.5660.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.5660.01", "G alpha (s) signalling events"], ["TCGA.A6.5660.01", "G alpha (i) signalling events"], ["TCGA.A6.5660.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.A6.5660.01", "Potassium Channels"], ["TCGA.A6.5660.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.5660.01", "Peptide ligand-binding receptors"], ["TCGA.A6.5660.01", "Drug ADME"], ["TCGA.A6.5660.01", "Cardiac conduction"], ["TCGA.A6.5660.01", "Voltage gated Potassium channels"], ["TCGA.A6.5660.01", "Extracellular matrix organization"], ["TCGA.A6.5660.01", "Peptide hormone metabolism"], ["TCGA.A6.5660.01", "Glucagon signaling in metabolic regulation"], ["TCGA.A6.5660.01", "Glucagon-type ligand receptors"], ["TCGA.A6.5660.01", "Signaling Pathways"], ["TCGA.A6.5660.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.5660.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.5660.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.5660.01", "Platelet homeostasis"], ["TCGA.A6.5660.01", "NCAM1 interactions"], ["TCGA.A6.5660.01", "Protein-protein interactions at synapses"], ["TCGA.A6.5660.01", "Phase I - Functionalization of compounds"], ["TCGA.A6.5660.01", "Regulation of FZD by ubiquitination"], ["TCGA.A6.5660.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.A6.5660.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.A6.5660.01", "Leishmania parasite growth and survival"], ["TCGA.A6.5660.01", "Signaling by Retinoic Acid"], ["TCGA.A6.5660.01", "Regulation of insulin secretion"], ["TCGA.A6.5660.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.A6.5660.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.A6.5660.01", "NCAM signaling for neurite out-growth"], ["TCGA.A6.6137.01", "Neuronal System"], ["TCGA.A6.6137.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.6137.01", "GPCR ligand binding"], ["TCGA.A6.6137.01", "Extracellular matrix organization"], ["TCGA.A6.6137.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.6137.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.A6.6137.01", "Protein-protein interactions at synapses"], ["TCGA.A6.6137.01", "Transmission across Chemical Synapses"], ["TCGA.A6.6137.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.A6.6137.01", "Signaling by GPCR"], ["TCGA.A6.6137.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.6137.01", "G alpha (i) signalling events"], ["TCGA.A6.6137.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.6137.01", "GPCR downstream signalling"], ["TCGA.A6.6137.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.A6.6137.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.6137.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.A6.6137.01", "Degradation of the extracellular matrix"], ["TCGA.A6.6137.01", "Glucagon-type ligand receptors"], ["TCGA.A6.6137.01", "Interleukin-6 family signaling"], ["TCGA.A6.6137.01", "Long-term potentiation"], ["TCGA.A6.6137.01", "Peptide ligand-binding receptors"], ["TCGA.A6.6137.01", "Scavenging by Class A Receptors"], ["TCGA.A6.6137.01", "Complement cascade"], ["TCGA.A6.6137.01", "Neurexins and neuroligins"], ["TCGA.A6.6137.01", "L1CAM interactions"], ["TCGA.A6.6137.01", "Trafficking of AMPA receptors"], ["TCGA.A6.6137.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.A6.6137.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.A6.6137.01", "Ras activation upon Ca2+ influx through NMDA receptor"], ["TCGA.A6.6137.01", "Regulation of FZD by ubiquitination"], ["TCGA.A6.6137.01", "Synaptic adhesion-like molecules"], ["TCGA.A6.6137.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.A6.6137.01", "Transcriptional Regulation by MECP2"], ["TCGA.A6.6137.01", "Glutathione conjugation"], ["TCGA.A6.6137.01", "Molecules associated with elastic fibres"], ["TCGA.A6.6137.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.A6.6137.01", "ABC transporters in lipid homeostasis"], ["TCGA.A6.6137.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.A6.6137.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.A6.6137.01", "Post NMDA receptor activation events"], ["TCGA.A6.6142.01", "Extracellular matrix organization"], ["TCGA.A6.6142.01", "Signaling by GPCR"], ["TCGA.A6.6142.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.A6.6142.01", "Neuronal System"], ["TCGA.A6.6142.01", "G alpha (i) signalling events"], ["TCGA.A6.6142.01", "GPCR ligand binding"], ["TCGA.A6.6142.01", "SLC-mediated transmembrane transport"], ["TCGA.A6.6142.01", "GPCR downstream signalling"], ["TCGA.A6.6142.01", "Cardiac conduction"], ["TCGA.A6.6142.01", "Transport of small molecules"], ["TCGA.A6.6142.01", "Regulation of insulin secretion"], ["TCGA.A6.6142.01", "Transmission across Chemical Synapses"], ["TCGA.A6.6142.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.6142.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.6142.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.6142.01", "Biological oxidations"], ["TCGA.A6.6142.01", "Visual phototransduction"], ["TCGA.A6.6142.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.A6.6142.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.6142.01", "Metabolism of fat-soluble vitamins"], ["TCGA.A6.6142.01", "Retinoid metabolism and transport"], ["TCGA.A6.6142.01", "Interleukin-10 signaling"], ["TCGA.A6.6142.01", "Signaling Pathways"], ["TCGA.A6.6142.01", "Cytosolic sulfonation of small molecules"], ["TCGA.A6.6142.01", "Peptide ligand-binding receptors"], ["TCGA.A6.6142.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.6142.01", "Gastrulation"], ["TCGA.A6.6142.01", "Integration of energy metabolism"], ["TCGA.A6.6142.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.A6.6142.01", "Drug ADME"], ["TCGA.A6.6142.01", "Phase 2 - plateau phase"], ["TCGA.A6.6142.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.6142.01", "Post-translational protein phosphorylation"], ["TCGA.A6.6142.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.A6.6142.01", "Muscle contraction"], ["TCGA.A6.6142.01", "Signal amplification"], ["TCGA.A6.6142.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.A6.6142.01", "WNT ligand biogenesis and trafficking"], ["TCGA.A6.6142.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.A6.6142.01", "L1CAM interactions"], ["TCGA.A6.6142.01", "Glucuronidation"], ["TCGA.A6.6142.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.A6.6142.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.A6.6142.01", "Leishmania parasite growth and survival"], ["TCGA.A6.6142.01", "Degradation of the extracellular matrix"], ["TCGA.A6.6142.01", "Ion channel transport"], ["TCGA.A6.6142.01", "Primitive streak formation"], ["TCGA.A6.6142.01", "Stimuli-sensing channels"], ["TCGA.A6.6142.01", "Potassium Channels"], ["TCGA.A6.6142.01", "TNFs bind their physiological receptors"], ["TCGA.A6.6142.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.A6.6142.01", "APAP ADME"], ["TCGA.A6.6142.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.A6.6142.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.A6.6142.01", "Long-term potentiation"], ["TCGA.A6.6142.01", "Recycling of bile acids and salts"], ["TCGA.A6.6648.01", "Neuronal System"], ["TCGA.A6.6648.01", "Protein-protein interactions at synapses"], ["TCGA.A6.6648.01", "Cardiac conduction"], ["TCGA.A6.6648.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.6648.01", "Transmission across Chemical Synapses"], ["TCGA.A6.6648.01", "Muscle contraction"], ["TCGA.A6.6648.01", "Neurexins and neuroligins"], ["TCGA.A6.6648.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.6648.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], ["TCGA.A6.6648.01", "Cell Cycle Checkpoints"], ["TCGA.A6.6648.01", "Synaptic adhesion-like molecules"], ["TCGA.A6.6648.01", "G0 and Early G1"], ["TCGA.A6.6648.01", "Presynaptic phase of homologous DNA pairing and strand exchange"], ["TCGA.A6.6648.01", "Inwardly rectifying K+ channels"], ["TCGA.A6.6648.01", "GABA receptor activation"], ["TCGA.A6.6648.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.6648.01", "GABA B receptor activation"], ["TCGA.A6.6648.01", "Activation of GABAB receptors"], ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function"], ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function"], ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function"], ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function"], ["TCGA.A6.6648.01", "Impaired BRCA2 binding to PALB2"], ["TCGA.A6.6648.01", "Homologous DNA Pairing and Strand Exchange"], ["TCGA.A6.6648.01", "Potassium Channels"], ["TCGA.A6.6648.01", "Transcription of E2F targets under negative control by DREAM complex"], ["TCGA.A6.6648.01", "Resolution of D-loop Structures through Holliday Junction Intermediates"], ["TCGA.A6.6648.01", "Cell Cycle"], ["TCGA.A6.6648.01", "Complement cascade"], ["TCGA.A6.6648.01", "Resolution of D-Loop Structures"], ["TCGA.A6.6648.01", "Diseases of DNA repair"], ["TCGA.A6.6648.01", "Diseases of DNA Double-Strand Break Repair"], ["TCGA.A6.6648.01", "Defective homologous recombination repair (HRR) due to BRCA2 loss of function"], ["TCGA.A6.6648.01", "L1CAM interactions"], ["TCGA.A6.6648.01", "Regulation of FZD by ubiquitination"], ["TCGA.A6.6648.01", "Cell Cycle, Mitotic"], ["TCGA.A6.6648.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.A6.6648.01", "Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)"], ["TCGA.A6.6648.01", "Regulation of Complement cascade"], ["TCGA.A6.6648.01", "Mitotic Spindle Checkpoint"], ["TCGA.A6.6648.01", "Activation of G protein gated Potassium channels"], ["TCGA.A6.6648.01", "G protein gated Potassium channels"], ["TCGA.A6.6648.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.A6.6648.01", "Molecules associated with elastic fibres"], ["TCGA.A6.6648.01", "Impaired BRCA2 binding to RAD51"], ["TCGA.A6.6648.01", "TP53 Regulates Transcription of Cell Cycle Genes"], ["TCGA.A6.6648.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.A6.6648.01", "Long-term potentiation"], ["TCGA.A6.6648.01", "Ion homeostasis"], ["TCGA.A6.6648.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.A6.6648.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.A6.6648.01", "G alpha (i) signalling events"], ["TCGA.A6.6648.01", "Glucagon-type ligand receptors"], ["TCGA.A6.6648.01", "HDR through Homologous Recombination (HRR)"], ["TCGA.A6.6648.01", "Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components"], ["TCGA.A6.6648.01", "Inactivation of APC/C via direct inhibition of the APC/C complex"], ["TCGA.A6.6648.01", "LGI-ADAM interactions"], ["TCGA.A6.6648.01", "Amplification of signal from the kinetochores"], ["TCGA.A6.6648.01", "Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal"], ["TCGA.A6.6648.01", "Ras activation upon Ca2+ influx through NMDA receptor"], ["TCGA.A6.6648.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.A6.6648.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], ["TCGA.A6.6648.01", "Resolution of Sister Chromatid Cohesion"], ["TCGA.A6.6648.01", "G2/M DNA damage checkpoint"], ["TCGA.A6.6648.01", "Signaling Pathways"], ["TCGA.A6.6648.01", "DNA Double-Strand Break Repair"], ["TCGA.A6.6648.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.A6.6648.01", "GPCR ligand binding"], ["TCGA.A6.6648.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.A6.6648.01", "EML4 and NUDC in mitotic spindle formation"], ["TCGA.A6.6649.01", "Transport of small molecules"], ["TCGA.A6.6649.01", "Collagen formation"], ["TCGA.A6.6649.01", "Extracellular matrix organization"], ["TCGA.A6.6649.01", "Amino acid transport across the plasma membrane"], ["TCGA.A6.6649.01", "Ethanol oxidation"], ["TCGA.A6.6649.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.6649.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.6649.01", "GPCR ligand binding"], ["TCGA.A6.6649.01", "Peptide hormone biosynthesis"], ["TCGA.A6.6649.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.A6.6652.01", "Signaling by GPCR"], ["TCGA.A6.6652.01", "GPCR downstream signalling"], ["TCGA.A6.6652.01", "Neuronal System"], ["TCGA.A6.6652.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.A6.6652.01", "G alpha (i) signalling events"], ["TCGA.A6.6652.01", "GPCR ligand binding"], ["TCGA.A6.6652.01", "Generation of second messenger molecules"], ["TCGA.A6.6652.01", "Signaling Pathways"], ["TCGA.A6.6652.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.A6.6652.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.A6.6652.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.A6.6652.01", "Transmission across Chemical Synapses"], ["TCGA.A6.6652.01", "PD-1 signaling"], ["TCGA.A6.6652.01", "Peptide ligand-binding receptors"], ["TCGA.A6.6652.01", "Regulation of insulin secretion"], ["TCGA.A6.6652.01", "Cardiac conduction"], ["TCGA.A6.6652.01", "Complement cascade"], ["TCGA.A6.6652.01", "Leishmania infection"], ["TCGA.A6.6652.01", "Visual phototransduction"], ["TCGA.A6.6652.01", "Biological oxidations"], ["TCGA.A6.6652.01", "Transport of small molecules"], ["TCGA.A6.6652.01", "G-protein mediated events"], ["TCGA.A6.6652.01", "Integration of energy metabolism"], ["TCGA.A6.6652.01", "G alpha (s) signalling events"], ["TCGA.A6.6652.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.A6.6652.01", "Leishmania parasite growth and survival"], ["TCGA.A6.6652.01", "Drug ADME"], ["TCGA.A6.6652.01", "Aspirin ADME"], ["TCGA.A6.6652.01", "Glucuronidation"], ["TCGA.A6.6652.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.A6.6652.01", "Chemokine receptors bind chemokines"], ["TCGA.A6.6652.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.6652.01", "PLC beta mediated events"], ["TCGA.A6.6652.01", "Ca-dependent events"], ["TCGA.A6.6652.01", "Metabolism of fat-soluble vitamins"], ["TCGA.A6.6652.01", "Retinoid metabolism and transport"], ["TCGA.A6.6652.01", "Immune System"], ["TCGA.A6.6652.01", "Peptide hormone metabolism"], ["TCGA.A6.6652.01", "Voltage gated Potassium channels"], ["TCGA.A6.6652.01", "Regulation of Complement cascade"], ["TCGA.A6.6652.01", "Protein-protein interactions at synapses"], ["TCGA.A6.6652.01", "Arachidonic acid metabolism"], ["TCGA.A6.6652.01", "Potassium Channels"], ["TCGA.A6.6652.01", "Calmodulin induced events"], ["TCGA.A6.6652.01", "CaM pathway"], ["TCGA.A6.6652.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.A6.6652.01", "Signal amplification"], ["TCGA.A6.6652.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.6652.01", "Platelet homeostasis"], ["TCGA.A6.6652.01", "Extracellular matrix organization"], ["TCGA.A6.6652.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.6652.01", "G alpha (q) signalling events"], ["TCGA.A6.6652.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.A6.6652.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.A6.6652.01", "G-protein beta:gamma signalling"], ["TCGA.A6.6652.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.A6.6652.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.6652.01", "Molecules associated with elastic fibres"], ["TCGA.A6.6652.01", "Muscle contraction"], ["TCGA.A6.6652.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.6652.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.A6.6652.01", "DAG and IP3 signaling"], ["TCGA.A6.6652.01", "Glucagon-type ligand receptors"], ["TCGA.A6.6652.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.A6.6652.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.A6.6652.01", "Metabolism of vitamins and cofactors"], ["TCGA.A6.6652.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.A6.6652.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.A6.6652.01", "G beta:gamma signalling through BTK"], ["TCGA.A6.6652.01", "Neurexins and neuroligins"], ["TCGA.A6.6652.01", "Activation of the phototransduction cascade"], ["TCGA.A6.6652.01", "Ethanol oxidation"], ["TCGA.A6.6652.01", "Transcriptional regulation of testis differentiation"], ["TCGA.A6.6652.01", "CD22 mediated BCR regulation"], ["TCGA.A6.6652.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.A6.6652.01", "GABA receptor activation"], ["TCGA.A6.6652.01", "Ca2+ pathway"], ["TCGA.A6.6652.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.A6.6652.01", "Glucagon signaling in metabolic regulation"], ["TCGA.A6.6652.01", "G-protein activation"], ["TCGA.A6.6652.01", "Thromboxane signalling through TP receptor"], ["TCGA.A6.6652.01", "Long-term potentiation"], ["TCGA.A6.6652.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.A6.6652.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.6652.01", "Ion channel transport"], ["TCGA.A6.6652.01", "Heme degradation"], ["TCGA.A6.6652.01", "Initial triggering of complement"], ["TCGA.A6.6652.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.A6.6652.01", "G beta:gamma signalling through CDC42"], ["TCGA.A6.6652.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.A6.6652.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.A6.6652.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.A6.6652.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.A6.6652.01", "Ion homeostasis"], ["TCGA.A6.6652.01", "Stimuli-sensing channels"], ["TCGA.A6.6652.01", "SLC-mediated transmembrane transport"], ["TCGA.A6.6652.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.A6.6652.01", "Regulation of FZD by ubiquitination"], ["TCGA.A6.6652.01", "RA biosynthesis pathway"], ["TCGA.A6.6652.01", "Sensory perception of taste"], ["TCGA.A6.6652.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.A6.6652.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.A6.6652.01", "Classical antibody-mediated complement activation"], ["TCGA.A6.6652.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.A6.6652.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.A6.6652.01", "Cell surface interactions at the vascular wall"], ["TCGA.A6.6652.01", "Costimulation by the CD28 family"], ["TCGA.A6.6652.01", "Phase I - Functionalization of compounds"], ["TCGA.A6.6652.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], ["TCGA.A6.6652.01", "Other interleukin signaling"], ["TCGA.A6.6654.01", "Extracellular matrix organization"], ["TCGA.A6.6654.01", "Degradation of the extracellular matrix"], ["TCGA.A6.6654.01", "Biological oxidations"], ["TCGA.A6.6654.01", "Drug ADME"], ["TCGA.A6.6654.01", "Transport of small molecules"], ["TCGA.A6.6654.01", "Metabolism"], ["TCGA.A6.6654.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.A6.6654.01", "Stimuli-sensing channels"], ["TCGA.A6.6654.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.6654.01", "Ion channel transport"], ["TCGA.A6.6654.01", "Glucuronidation"], ["TCGA.A6.6654.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.A6.6654.01", "Phase I - Functionalization of compounds"], ["TCGA.A6.6654.01", "APAP ADME"], ["TCGA.A6.6654.01", "Signaling by Retinoic Acid"], ["TCGA.A6.6654.01", "Post-translational protein phosphorylation"], ["TCGA.A6.6654.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.A6.6654.01", "GPCR ligand binding"], ["TCGA.A6.6654.01", "SLC-mediated transmembrane transport"], ["TCGA.A6.6654.01", "Cytosolic sulfonation of small molecules"], ["TCGA.A6.6654.01", "Aspirin ADME"], ["TCGA.A6.6654.01", "Carbohydrate metabolism"], ["TCGA.A6.A56B.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.A6.A56B.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.A6.A56B.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.A6.A56B.01", "Generation of second messenger molecules"], ["TCGA.A6.A56B.01", "Biological oxidations"], ["TCGA.A6.A56B.01", "Collagen chain trimerization"], ["TCGA.A6.A56B.01", "Extracellular matrix organization"], ["TCGA.A6.A56B.01", "Collagen formation"], ["TCGA.A6.A56B.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.A56B.01", "PD-1 signaling"], ["TCGA.A6.A56B.01", "Signaling by GPCR"], ["TCGA.A6.A56B.01", "Transport of small molecules"], ["TCGA.A6.A56B.01", "GPCR downstream signalling"], ["TCGA.A6.A56B.01", "Drug ADME"], ["TCGA.A6.A56B.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.A6.A56B.01", "G alpha (i) signalling events"], ["TCGA.A6.A56B.01", "Peptide hormone metabolism"], ["TCGA.A6.A56B.01", "Neuronal System"], ["TCGA.A6.A56B.01", "Cardiac conduction"], ["TCGA.A6.A56B.01", "O-linked glycosylation"], ["TCGA.A6.A56B.01", "Immune System"], ["TCGA.A6.A56B.01", "Phase 0 - rapid depolarisation"], ["TCGA.A6.A56B.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.A6.A56B.01", "NCAM1 interactions"], ["TCGA.A6.A56B.01", "Metabolism"], ["TCGA.A6.A56B.01", "Chemokine receptors bind chemokines"], ["TCGA.A6.A56B.01", "Regulation of insulin secretion"], ["TCGA.A6.A56B.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.A6.A56B.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.A6.A56B.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.A6.A56B.01", "Transcriptional regulation of testis differentiation"], ["TCGA.A6.A56B.01", "Defective B3GALTL causes PpS"], ["TCGA.A6.A56B.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.A56B.01", "Integration of energy metabolism"], ["TCGA.A6.A56B.01", "Insulin processing"], ["TCGA.A6.A56B.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.A6.A56B.01", "Phase I - Functionalization of compounds"], ["TCGA.A6.A56B.01", "Potassium Channels"], ["TCGA.A6.A56B.01", "CD22 mediated BCR regulation"], ["TCGA.A6.A56B.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.A6.A56B.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.A6.A56B.01", "GPCR ligand binding"], ["TCGA.A6.A56B.01", "Leishmania infection"], ["TCGA.A6.A56B.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.A6.A56B.01", "G alpha (s) signalling events"], ["TCGA.A6.A56B.01", "Signaling Pathways"], ["TCGA.A6.A56B.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.A6.A56B.01", "Leishmania parasite growth and survival"], ["TCGA.A6.A56B.01", "Signaling by Retinoic Acid"], ["TCGA.A6.A56B.01", "TNFs bind their physiological receptors"], ["TCGA.A6.A56B.01", "SLC-mediated transmembrane transport"], ["TCGA.A6.A56B.01", "Regulation of signaling by NODAL"], ["TCGA.A6.A56B.01", "Surfactant metabolism"], ["TCGA.A6.A56B.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.A6.A56B.01", "Integrin cell surface interactions"], ["TCGA.A6.A56B.01", "Stimuli-sensing channels"], ["TCGA.A6.A56B.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.A6.A56B.01", "Costimulation by the CD28 family"], ["TCGA.A6.A56B.01", "Inflammasomes"], ["TCGA.A6.A56B.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.A6.A56B.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.A6.A56B.01", "Transmission across Chemical Synapses"], ["TCGA.A6.A56B.01", "Ion channel transport"], ["TCGA.A6.A56B.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.A56B.01", "Scavenging of heme from plasma"], ["TCGA.A6.A56B.01", "TP53 Regulates Transcription of Caspase Activators and Caspases"], ["TCGA.AA.3518.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3518.01", "Neuronal System"], ["TCGA.AA.3518.01", "Extracellular matrix organization"], ["TCGA.AA.3518.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3518.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3518.01", "Drug ADME"], ["TCGA.AA.3518.01", "Molecules associated with elastic fibres"], ["TCGA.AA.3518.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3518.01", "L1CAM interactions"], ["TCGA.AA.3518.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3521.01", "Biological oxidations"], ["TCGA.AA.3521.01", "Signal amplification"], ["TCGA.AA.3521.01", "Ethanol oxidation"], ["TCGA.AA.3521.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3521.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3521.01", "Neuronal System"], ["TCGA.AA.3521.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3521.01", "Potassium Channels"], ["TCGA.AA.3521.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3521.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3521.01", "Extra-nuclear estrogen signaling"], ["TCGA.AA.3521.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3521.01", "RA biosynthesis pathway"], ["TCGA.AA.3521.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3521.01", "Regulation of insulin secretion"], ["TCGA.AA.3521.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3521.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3521.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3521.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3521.01", "Signaling by Nuclear Receptors"], ["TCGA.AA.3521.01", "GPER1 signaling"], ["TCGA.AA.3521.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3521.01", "GABA B receptor activation"], ["TCGA.AA.3521.01", "Activation of GABAB receptors"], ["TCGA.AA.3521.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3521.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3521.01", "Peptide hormone metabolism"], ["TCGA.AA.3521.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.3521.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.3556.01", "Neuronal System"], ["TCGA.AA.3556.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3556.01", "Transport of small molecules"], ["TCGA.AA.3556.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3556.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3556.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3556.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3556.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3556.01", "Biological oxidations"], ["TCGA.AA.3556.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3556.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3556.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3556.01", "Drug ADME"], ["TCGA.AA.3556.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3556.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3556.01", "Extracellular matrix organization"], ["TCGA.AA.3556.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3556.01", "Cardiac conduction"], ["TCGA.AA.3556.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3556.01", "Insulin processing"], ["TCGA.AA.3556.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AA.3556.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3556.01", "Glutathione conjugation"], ["TCGA.AA.3556.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3556.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3556.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3556.01", "Muscle contraction"], ["TCGA.AA.3556.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3556.01", "Sensory processing of sound"], ["TCGA.AA.3556.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.AA.3556.01", "GABA receptor activation"], ["TCGA.AA.3556.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3556.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.3556.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3556.01", "G protein gated Potassium channels"], ["TCGA.AA.3556.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3556.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3556.01", "Ion channel transport"], ["TCGA.AA.3556.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3560.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3560.01", "Peptide chain elongation"], ["TCGA.AA.3560.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3560.01", "Viral mRNA Translation"], ["TCGA.AA.3560.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AA.3560.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3560.01", "Selenocysteine synthesis"], ["TCGA.AA.3560.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3560.01", "Regulation of expression of SLITs and ROBOs"], ["TCGA.AA.3560.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AA.3560.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AA.3560.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AA.3560.01", "Selenoamino acid metabolism"], ["TCGA.AA.3560.01", "Eukaryotic Translation Initiation"], ["TCGA.AA.3560.01", "Cap-dependent Translation Initiation"], ["TCGA.AA.3560.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AA.3560.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AA.3560.01", "Signaling by ROBO receptors"], ["TCGA.AA.3560.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AA.3560.01", "Cellular response to starvation"], ["TCGA.AA.3560.01", "Influenza Infection"], ["TCGA.AA.3560.01", "rRNA processing"], ["TCGA.AA.3560.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.AA.3560.01", "Amino acid and derivative metabolism"], ["TCGA.AA.3560.01", "Metabolism"], ["TCGA.AA.3560.01", "SARS-CoV-1-host interactions"], ["TCGA.AA.3560.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3560.01", "Developmental Biology"], ["TCGA.AA.3560.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.AA.3560.01", "SCF(Skp2)-mediated degradation of p27/p21"], ["TCGA.AA.3560.01", "IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation"], ["TCGA.AA.3560.01", "TICAM1-dependent activation of IRF3/IRF7"], ["TCGA.AA.3560.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.AA.3560.01", "Signal amplification"], ["TCGA.AA.3560.01", "TRAF6-mediated induction of TAK1 complex within TLR4 complex"], ["TCGA.AA.3560.01", "Formation of the ternary complex, and subsequently, the 43S complex"], ["TCGA.AA.3560.01", "Transport of small molecules"], ["TCGA.AA.3560.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3560.01", "Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon"], ["TCGA.AA.3560.01", "ABC transporters in lipid homeostasis"], ["TCGA.AA.3560.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], ["TCGA.AA.3560.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], ["TCGA.AA.3560.01", "SARS-CoV-1 Infection"], ["TCGA.AA.3560.01", "Transcriptional regulation by RUNX2"], ["TCGA.AA.3560.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.3560.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3560.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3560.01", "Ribosomal scanning and start codon recognition"], ["TCGA.AA.3560.01", "Nervous system development"], ["TCGA.AA.3560.01", "APC/C-mediated degradation of cell cycle proteins"], ["TCGA.AA.3560.01", "Regulation of mitotic cell cycle"], ["TCGA.AA.3560.01", "Drug ADME"], ["TCGA.AA.3560.01", "TICAM1,TRAF6-dependent induction of TAK1 complex"], ["TCGA.AA.3560.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.3560.01", "Regulation of BACH1 activity"], ["TCGA.AA.3560.01", "Translation initiation complex formation"], ["TCGA.AA.3560.01", "APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1"], ["TCGA.AA.3560.01", "Regulation of RUNX2 expression and activity"], ["TCGA.AA.3560.01", "Formation of tubulin folding intermediates by CCT/TriC"], ["TCGA.AA.3560.01", "Nuclear Receptor transcription pathway"], ["TCGA.AA.3560.01", "Axon guidance"], ["TCGA.AA.3560.01", "Glycogen metabolism"], ["TCGA.AA.3560.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], ["TCGA.AA.3561.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.AA.3561.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3561.01", "Peptide chain elongation"], ["TCGA.AA.3561.01", "Viral mRNA Translation"], ["TCGA.AA.3561.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3561.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3561.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.AA.3561.01", "Selenoamino acid metabolism"], ["TCGA.AA.3561.01", "Selenocysteine synthesis"], ["TCGA.AA.3561.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AA.3561.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AA.3561.01", "Nervous system development"], ["TCGA.AA.3561.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AA.3561.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AA.3561.01", "Influenza Infection"], ["TCGA.AA.3561.01", "SARS-CoV-1-host interactions"], ["TCGA.AA.3561.01", "Axon guidance"], ["TCGA.AA.3561.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AA.3561.01", "Cellular response to starvation"], ["TCGA.AA.3561.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3561.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AA.3561.01", "Eukaryotic Translation Initiation"], ["TCGA.AA.3561.01", "Cap-dependent Translation Initiation"], ["TCGA.AA.3561.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AA.3561.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3561.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], ["TCGA.AA.3561.01", "Formation of the ternary complex, and subsequently, the 43S complex"], ["TCGA.AA.3561.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.3561.01", "Ribosomal scanning and start codon recognition"], ["TCGA.AA.3561.01", "Translation initiation complex formation"], ["TCGA.AA.3561.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], ["TCGA.AA.3561.01", "Developmental Biology"], ["TCGA.AA.3561.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.AA.3561.01", "Phosphorylation of the APC/C"], ["TCGA.AA.3561.01", "rRNA processing"], ["TCGA.AA.3561.01", "Biological oxidations"], ["TCGA.AA.3561.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3561.01", "Polo-like kinase mediated events"], ["TCGA.AA.3561.01", "Blood group systems biosynthesis"], ["TCGA.AA.3561.01", "LXRs regulate gene expression linked to cholesterol transport and efflux"], ["TCGA.AA.3561.01", "Metabolism"], ["TCGA.AA.3561.01", "LXR-mediated signaling"], ["TCGA.AA.3561.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3561.01", "SARS-CoV-1 Infection"], ["TCGA.AA.3561.01", "Chromosome Maintenance"], ["TCGA.AA.3561.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], ["TCGA.AA.3561.01", "Nucleosome assembly"], ["TCGA.AA.3561.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3561.01", "Amino acid and derivative metabolism"], ["TCGA.AA.3561.01", "Mitotic Spindle Checkpoint"], ["TCGA.AA.3561.01", "Signaling by ROBO receptors"], ["TCGA.AA.3561.01", "Regulation of expression of SLITs and ROBOs"], ["TCGA.AA.3561.01", "L1CAM interactions"], ["TCGA.AA.3561.01", "Cell Cycle"], ["TCGA.AA.3561.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3561.01", "Cell Cycle, Mitotic"], ["TCGA.AA.3561.01", "Glutathione conjugation"], ["TCGA.AA.3561.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3561.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3561.01", "CD22 mediated BCR regulation"], ["TCGA.AA.3561.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.AA.3561.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.AA.3561.01", "Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1"], ["TCGA.AA.3561.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3561.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3561.01", "APC/C-mediated degradation of cell cycle proteins"], ["TCGA.AA.3561.01", "Regulation of mitotic cell cycle"], ["TCGA.AA.3561.01", "Resolution of Sister Chromatid Cohesion"], ["TCGA.AA.3561.01", "Endogenous sterols"], ["TCGA.AA.3561.01", "Signaling Pathways"], ["TCGA.AA.3561.01", "Intrinsic Pathway of Fibrin Clot Formation"], ["TCGA.AA.3561.01", "G0 and Early G1"], ["TCGA.AA.3561.01", "G1/S-Specific Transcription"], ["TCGA.AA.3561.01", "Leishmania infection"], ["TCGA.AA.3561.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3561.01", "Signaling by Nuclear Receptors"], ["TCGA.AA.3655.01", "Neuronal System"], ["TCGA.AA.3655.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3655.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3655.01", "GPCR ligand binding"], ["TCGA.AA.3655.01", "RA biosynthesis pathway"], ["TCGA.AA.3655.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3655.01", "Biological oxidations"], ["TCGA.AA.3655.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3655.01", "Ethanol oxidation"], ["TCGA.AA.3655.01", "L1CAM interactions"], ["TCGA.AA.3655.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3655.01", "G alpha (i) signalling events"], ["TCGA.AA.3655.01", "Signaling by GPCR"], ["TCGA.AA.3655.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3655.01", "Extracellular matrix organization"], ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.3655.01", "Transport of small molecules"], ["TCGA.AA.3655.01", "Peptide ligand-binding receptors"], ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.3655.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.3655.01", "Synaptic adhesion-like molecules"], ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts"], ["TCGA.AA.3655.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3655.01", "GPCR downstream signalling"], ["TCGA.AA.3655.01", "Potassium Channels"], ["TCGA.AA.3655.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3655.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3655.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.3655.01", "GABA receptor activation"], ["TCGA.AA.3655.01", "Signaling Pathways"], ["TCGA.AA.3655.01", "CD22 mediated BCR regulation"], ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AA.3655.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3655.01", "Phase I - Functionalization of compounds"], ["TCGA.AA.3655.01", "Aspirin ADME"], ["TCGA.AA.3655.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3655.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3655.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3655.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3655.01", "Regulation of beta-cell development"], ["TCGA.AA.3655.01", "Glucuronidation"], ["TCGA.AA.3655.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3655.01", "Muscle contraction"], ["TCGA.AA.3655.01", "Visual phototransduction"], ["TCGA.AA.3655.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3655.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.AA.3655.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.AA.3655.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.3655.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3655.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3655.01", "Developmental Biology"], ["TCGA.AA.3655.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3655.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3655.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3655.01", "Cardiac conduction"], ["TCGA.AA.3655.01", "Metabolism of fat-soluble vitamins"], ["TCGA.AA.3655.01", "Retinoid metabolism and transport"], ["TCGA.AA.3655.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3655.01", "Peptide hormone metabolism"], ["TCGA.AA.3655.01", "Neurexins and neuroligins"], ["TCGA.AA.3655.01", "Drug ADME"], ["TCGA.AA.3655.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3655.01", "Neurotransmitter release cycle"], ["TCGA.AA.3655.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3655.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3655.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.3655.01", "LGI-ADAM interactions"], ["TCGA.AA.3655.01", "Voltage gated Potassium channels"], ["TCGA.AA.3655.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3655.01", "Regulation of gene expression in beta cells"], ["TCGA.AA.3655.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.AA.3655.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.3655.01", "Collagen formation"], ["TCGA.AA.3655.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.3655.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3655.01", "Complement cascade"], ["TCGA.AA.3655.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.3655.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.3660.01", "Neuronal System"], ["TCGA.AA.3660.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3660.01", "Keratinization"], ["TCGA.AA.3660.01", "Developmental Biology"], ["TCGA.AA.3660.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3660.01", "RA biosynthesis pathway"], ["TCGA.AA.3660.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3660.01", "Cardiac conduction"], ["TCGA.AA.3660.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3660.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.3660.01", "Drug ADME"], ["TCGA.AA.3660.01", "Stimuli-sensing channels"], ["TCGA.AA.3660.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.3660.01", "Biological oxidations"], ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.AA.3660.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3660.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3660.01", "IRS-related events triggered by IGF1R"], ["TCGA.AA.3660.01", "NCAM1 interactions"], ["TCGA.AA.3660.01", "Peptide hormone metabolism"], ["TCGA.AA.3660.01", "IGF1R signaling cascade"], ["TCGA.AA.3660.01", "Collagen chain trimerization"], ["TCGA.AA.3660.01", "Ethanol oxidation"], ["TCGA.AA.3660.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AA.3660.01", "IRS-mediated signalling"], ["TCGA.AA.3660.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.3660.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3660.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3660.01", "G alpha (s) signalling events"], ["TCGA.AA.3660.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3660.01", "Extracellular matrix organization"], ["TCGA.AA.3660.01", "L1CAM interactions"], ["TCGA.AA.3660.01", "FGFR2c ligand binding and activation"], ["TCGA.AA.3660.01", "Collagen formation"], ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts"], ["TCGA.AA.3660.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3660.01", "FGFR2 ligand binding and activation"], ["TCGA.AA.3660.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3660.01", "SHC-mediated cascade:FGFR4"], ["TCGA.AA.3660.01", "PI-3K cascade:FGFR4"], ["TCGA.AA.3660.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.AA.3660.01", "Insulin receptor signalling cascade"], ["TCGA.AA.3660.01", "Glucuronidation"], ["TCGA.AA.3660.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3660.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3660.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.AA.3660.01", "Transport of small molecules"], ["TCGA.AA.3660.01", "Integration of energy metabolism"], ["TCGA.AA.3660.01", "FGFR1 ligand binding and activation"], ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.3660.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3660.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3660.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3660.01", "FRS-mediated FGFR4 signaling"], ["TCGA.AA.3660.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3660.01", "G alpha (z) signalling events"], ["TCGA.AA.3660.01", "Ion channel transport"], ["TCGA.AA.3660.01", "Regulation of insulin secretion"], ["TCGA.AA.3660.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade: FGFR1"], ["TCGA.AA.3660.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3660.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3660.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.3660.01", "Potassium Channels"], ["TCGA.AA.3660.01", "Activated point mutants of FGFR2"], ["TCGA.AA.3660.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3660.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3660.01", "Muscle contraction"], ["TCGA.AA.3660.01", "Ca2+ pathway"], ["TCGA.AA.3660.01", "Signaling by activated point mutants of FGFR1"], ["TCGA.AA.3660.01", "FGFR1c ligand binding and activation"], ["TCGA.AA.3660.01", "GPER1 signaling"], ["TCGA.AA.3660.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade; FGFR2"], ["TCGA.AA.3660.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3664.01", "L1CAM interactions"], ["TCGA.AA.3664.01", "Molecules associated with elastic fibres"], ["TCGA.AA.3666.01", "Neuronal System"], ["TCGA.AA.3666.01", "Extracellular matrix organization"], ["TCGA.AA.3666.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3666.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3666.01", "Peptide hormone metabolism"], ["TCGA.AA.3666.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3666.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3666.01", "Cardiac conduction"], ["TCGA.AA.3666.01", "Transport of small molecules"], ["TCGA.AA.3666.01", "Regulation of insulin secretion"], ["TCGA.AA.3666.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3666.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], ["TCGA.AA.3666.01", "Ion channel transport"], ["TCGA.AA.3666.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3679.01", "Integration of energy metabolism"], ["TCGA.AA.3679.01", "Neuronal System"], ["TCGA.AA.3679.01", "Transport of small molecules"], ["TCGA.AA.3679.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3679.01", "Regulation of insulin secretion"], ["TCGA.AA.3679.01", "Extracellular matrix organization"], ["TCGA.AA.3679.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3679.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3679.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3679.01", "Signal amplification"], ["TCGA.AA.3679.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3679.01", "Axon guidance"], ["TCGA.AA.3679.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3679.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3679.01", "Plasma lipoprotein assembly"], ["TCGA.AA.3679.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3679.01", "Cardiac conduction"], ["TCGA.AA.3679.01", "NCAM1 interactions"], ["TCGA.AA.3679.01", "G-protein activation"], ["TCGA.AA.3679.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3679.01", "Nervous system development"], ["TCGA.AA.3679.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3679.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3679.01", "Collagen formation"], ["TCGA.AA.3679.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.3679.01", "Aquaporin-mediated transport"], ["TCGA.AA.3679.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3679.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.3679.01", "Developmental Biology"], ["TCGA.AA.3679.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3679.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3679.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3679.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3679.01", "Intrinsic Pathway of Fibrin Clot Formation"], ["TCGA.AA.3679.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.3679.01", "GABA receptor activation"], ["TCGA.AA.3679.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3679.01", "Biological oxidations"], ["TCGA.AA.3679.01", "Molecules associated with elastic fibres"], ["TCGA.AA.3679.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AA.3679.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3679.01", "GPER1 signaling"], ["TCGA.AA.3679.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3679.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3680.01", "Sensory perception of taste"], ["TCGA.AA.3680.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], ["TCGA.AA.3681.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3681.01", "Keratinization"], ["TCGA.AA.3681.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3681.01", "Cardiac conduction"], ["TCGA.AA.3681.01", "Extracellular matrix organization"], ["TCGA.AA.3681.01", "Formation of the cornified envelope"], ["TCGA.AA.3681.01", "L1CAM interactions"], ["TCGA.AA.3681.01", "Neuronal System"], ["TCGA.AA.3685.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3685.01", "Cellular response to starvation"], ["TCGA.AA.3685.01", "Selenoamino acid metabolism"], ["TCGA.AA.3685.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3685.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3685.01", "Viral mRNA Translation"], ["TCGA.AA.3685.01", "Peptide chain elongation"], ["TCGA.AA.3685.01", "Selenocysteine synthesis"], ["TCGA.AA.3685.01", "rRNA processing"], ["TCGA.AA.3685.01", "Neuronal System"], ["TCGA.AA.3685.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AA.3685.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.AA.3685.01", "Developmental Biology"], ["TCGA.AA.3685.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3685.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AA.3685.01", "Eukaryotic Translation Initiation"], ["TCGA.AA.3685.01", "Cap-dependent Translation Initiation"], ["TCGA.AA.3685.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AA.3685.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AA.3685.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AA.3685.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3685.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AA.3685.01", "Amino acid and derivative metabolism"], ["TCGA.AA.3685.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AA.3685.01", "Nervous system development"], ["TCGA.AA.3685.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3685.01", "Axon guidance"], ["TCGA.AA.3685.01", "Metabolism"], ["TCGA.AA.3685.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.AA.3685.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3685.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3685.01", "Signaling by ROBO receptors"], ["TCGA.AA.3685.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3685.01", "Influenza Infection"], ["TCGA.AA.3685.01", "Regulation of expression of SLITs and ROBOs"], ["TCGA.AA.3685.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3685.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.AA.3685.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3685.01", "Formation of the ternary complex, and subsequently, the 43S complex"], ["TCGA.AA.3685.01", "Biological oxidations"], ["TCGA.AA.3685.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], ["TCGA.AA.3685.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AA.3685.01", "Cardiac conduction"], ["TCGA.AA.3685.01", "Extracellular matrix organization"], ["TCGA.AA.3685.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3685.01", "Ribosomal scanning and start codon recognition"], ["TCGA.AA.3685.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3685.01", "Translation initiation complex formation"], ["TCGA.AA.3685.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3685.01", "Transport of small molecules"], ["TCGA.AA.3685.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3685.01", "Blood group systems biosynthesis"], ["TCGA.AA.3685.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3685.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3685.01", "RA biosynthesis pathway"], ["TCGA.AA.3685.01", "Translation"], ["TCGA.AA.3685.01", "Regulation of insulin secretion"], ["TCGA.AA.3685.01", "Neurexins and neuroligins"], ["TCGA.AA.3685.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3685.01", "Ethanol oxidation"], ["TCGA.AA.3685.01", "SARS-CoV-1-host interactions"], ["TCGA.AA.3685.01", "Collagen formation"], ["TCGA.AA.3685.01", "Translesion synthesis by POLK"], ["TCGA.AA.3685.01", "Translesion synthesis by POLI"], ["TCGA.AA.3685.01", "Collagen degradation"], ["TCGA.AA.3685.01", "Integration of energy metabolism"], ["TCGA.AA.3685.01", "rRNA modification in the nucleus and cytosol"], ["TCGA.AA.3685.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3685.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3685.01", "tRNA modification in the nucleus and cytosol"], ["TCGA.AA.3685.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3685.01", "Platelet homeostasis"], ["TCGA.AA.3685.01", "Drug ADME"], ["TCGA.AA.3685.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.3685.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3685.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3685.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3685.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.3696.01", "GPCR ligand binding"], ["TCGA.AA.3696.01", "Transport of small molecules"], ["TCGA.AA.3710.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3710.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3710.01", "Neuronal System"], ["TCGA.AA.3710.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3710.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3710.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3710.01", "Drug ADME"], ["TCGA.AA.3710.01", "Stimuli-sensing channels"], ["TCGA.AA.3715.01", "Extracellular matrix organization"], ["TCGA.AA.3715.01", "Collagen formation"], ["TCGA.AA.3715.01", "Keratinization"], ["TCGA.AA.3715.01", "O-linked glycosylation"], ["TCGA.AA.3715.01", "O-linked glycosylation of mucins"], ["TCGA.AA.3715.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3715.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.3715.01", "Developmental Biology"], ["TCGA.AA.3715.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3715.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3715.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AA.3715.01", "Post-translational protein phosphorylation"], ["TCGA.AA.3715.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3715.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3715.01", "Defective GALNT12 causes CRCS1"], ["TCGA.AA.3715.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.AA.3715.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3715.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3715.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3715.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3814.01", "Keratinization"], ["TCGA.AA.3814.01", "Peptide hormone metabolism"], ["TCGA.AA.3814.01", "Extracellular matrix organization"], ["TCGA.AA.3814.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3814.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3814.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3814.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3814.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3814.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3837.01", "Ethanol oxidation"], ["TCGA.AA.3837.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3837.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3837.01", "Peptide hormone metabolism"], ["TCGA.AA.3837.01", "Extracellular matrix organization"], ["TCGA.AA.3837.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.3837.01", "Keratinization"], ["TCGA.AA.3837.01", "DNA methylation"], ["TCGA.AA.3837.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.3837.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3837.01", "Digestion"], ["TCGA.AA.3837.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3837.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.3837.01", "Insulin processing"], ["TCGA.AA.3837.01", "Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)"], ["TCGA.AA.3837.01", "Recycling of bile acids and salts"], ["TCGA.AA.3837.01", "Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)"], ["TCGA.AA.3837.01", "Glucuronidation"], ["TCGA.AA.3837.01", "RA biosynthesis pathway"], ["TCGA.AA.3837.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3837.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.3837.01", "Incretin synthesis, secretion, and inactivation"], ["TCGA.AA.3837.01", "Selenoamino acid metabolism"], ["TCGA.AA.3837.01", "Collagen formation"], ["TCGA.AA.3837.01", "Digestion and absorption"], ["TCGA.AA.3837.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3837.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3837.01", "Viral mRNA Translation"], ["TCGA.AA.3837.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.3837.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3837.01", "Drug ADME"], ["TCGA.AA.3837.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3837.01", "Peptide chain elongation"], ["TCGA.AA.3837.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3837.01", "Calcitonin-like ligand receptors"], ["TCGA.AA.3837.01", "Cellular response to starvation"], ["TCGA.AA.3837.01", "Biological oxidations"], ["TCGA.AA.3837.01", "Scavenging by Class A Receptors"], ["TCGA.AA.3837.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3837.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3837.01", "Selenocysteine synthesis"], ["TCGA.AA.3837.01", "Regulation of insulin secretion"], ["TCGA.AA.3837.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3837.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3837.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.3837.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.AA.3837.01", "Scavenging of heme from plasma"], ["TCGA.AA.3837.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.3837.01", "Developmental Biology"], ["TCGA.AA.3837.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3837.01", "Integration of energy metabolism"], ["TCGA.AA.3837.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3837.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3837.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AA.3837.01", "Heme degradation"], ["TCGA.AA.3837.01", "Carnitine metabolism"], ["TCGA.AA.3837.01", "Physiological factors"], ["TCGA.AA.3837.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AA.3837.01", "Ribavirin ADME"], ["TCGA.AA.3837.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AA.3837.01", "Cardiac conduction"], ["TCGA.AA.3837.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AA.3837.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3837.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3837.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3837.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3837.01", "Methylation"], ["TCGA.AA.3837.01", "Peptide hormone biosynthesis"], ["TCGA.AA.3837.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3837.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.3837.01", "Collagen degradation"], ["TCGA.AA.3837.01", "Collagen chain trimerization"], ["TCGA.AA.3837.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AA.3837.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3837.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.3837.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], ["TCGA.AA.3837.01", "LGI-ADAM interactions"], ["TCGA.AA.3837.01", "Eukaryotic Translation Initiation"], ["TCGA.AA.3837.01", "Cap-dependent Translation Initiation"], ["TCGA.AA.3837.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3837.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3837.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AA.3837.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3837.01", "ECM proteoglycans"], ["TCGA.AA.3837.01", "Nuclear Receptor transcription pathway"], ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts"], ["TCGA.AA.3837.01", "Signaling by ALK"], ["TCGA.AA.3837.01", "Insulin receptor recycling"], ["TCGA.AA.3837.01", "Integrin cell surface interactions"], ["TCGA.AA.3837.01", "Signaling by PTK6"], ["TCGA.AA.3837.01", "Signaling by Non-Receptor Tyrosine Kinases"], ["TCGA.AA.3837.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AA.3837.01", "Aspirin ADME"], ["TCGA.AA.3837.01", "Signaling by BMP"], ["TCGA.AA.3837.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3837.01", "Diseases of Immune System"], ["TCGA.AA.3837.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AA.3837.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3837.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.3837.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3837.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3837.01", "Platelet sensitization by LDL"], ["TCGA.AA.3837.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.3837.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.3837.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3837.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AA.3837.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AA.3837.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3837.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3837.01", "Carboxyterminal post-translational modifications of tubulin"], ["TCGA.AA.3841.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3841.01", "Signal amplification"], ["TCGA.AA.3841.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3841.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3841.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3841.01", "Ion channel transport"], ["TCGA.AA.3841.01", "Protein folding"], ["TCGA.AA.3841.01", "Post-chaperonin tubulin folding pathway"], ["TCGA.AA.3841.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3841.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3841.01", "Post-translational protein phosphorylation"], ["TCGA.AA.3841.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3841.01", "RND3 GTPase cycle"], ["TCGA.AA.3841.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3841.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3841.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3841.01", "G-protein activation"], ["TCGA.AA.3841.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3841.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3841.01", "Integration of energy metabolism"], ["TCGA.AA.3841.01", "Transport of small molecules"], ["TCGA.AA.3841.01", "Extra-nuclear estrogen signaling"], ["TCGA.AA.3841.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3841.01", "RHOBTB GTPase Cycle"], ["TCGA.AA.3841.01", "Keratinization"], ["TCGA.AA.3841.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3841.01", "Ras activation upon Ca2+ influx through NMDA receptor"], ["TCGA.AA.3841.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3841.01", "Regulation of insulin secretion"], ["TCGA.AA.3841.01", "Chaperonin-mediated protein folding"], ["TCGA.AA.3841.01", "RND1 GTPase cycle"], ["TCGA.AA.3841.01", "RHOBTB2 GTPase cycle"], ["TCGA.AA.3841.01", "tRNA modification in the nucleus and cytosol"], ["TCGA.AA.3841.01", "Glycogen metabolism"], ["TCGA.AA.3841.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3841.01", "Peptide hormone metabolism"], ["TCGA.AA.3841.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3841.01", "Signaling by SCF-KIT"], ["TCGA.AA.3841.01", "GPER1 signaling"], ["TCGA.AA.3841.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3841.01", "Stimuli-sensing channels"], ["TCGA.AA.3841.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3841.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.3841.01", "Signaling by FGFR2 IIIa TM"], ["TCGA.AA.3841.01", "Selenoamino acid metabolism"], ["TCGA.AA.3841.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.3841.01", "Sealing of the nuclear envelope (NE) by ESCRT-III"], ["TCGA.AA.3841.01", "Unwinding of DNA"], ["TCGA.AA.3841.01", "Ethanol oxidation"], ["TCGA.AA.3841.01", "Digestion"], ["TCGA.AA.3841.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3841.01", "ESR-mediated signaling"], ["TCGA.AA.3841.01", "Cellular response to starvation"], ["TCGA.AA.3841.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3841.01", "Selenocysteine synthesis"], ["TCGA.AA.3841.01", "Regulation of KIT signaling"], ["TCGA.AA.3841.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3841.01", "SIRT1 negatively regulates rRNA expression"], ["TCGA.AA.3841.01", "IRS-related events triggered by IGF1R"], ["TCGA.AA.3841.01", "Ca2+ pathway"], ["TCGA.AA.3841.01", "mRNA decay by 3' to 5' exoribonuclease"], ["TCGA.AA.3841.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3841.01", "Arachidonic acid metabolism"], ["TCGA.AA.3841.01", "IGF1R signaling cascade"], ["TCGA.AA.3841.01", "IRS-mediated signalling"], ["TCGA.AA.3841.01", "G alpha (z) signalling events"], ["TCGA.AA.3841.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.3841.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.3841.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3841.01", "DNA methylation"], ["TCGA.AA.3841.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3841.01", "GABA B receptor activation"], ["TCGA.AA.3841.01", "Activation of GABAB receptors"], ["TCGA.AA.3841.01", "RHO GTPases activate IQGAPs"], ["TCGA.AA.3841.01", "Biological oxidations"], ["TCGA.AA.3841.01", "Potassium Channels"], ["TCGA.AA.3841.01", "MicroRNA (miRNA) biogenesis"], ["TCGA.AA.3841.01", "Tie2 Signaling"], ["TCGA.AA.3841.01", "Polymerase switching on the C-strand of the telomere"], ["TCGA.AA.3841.01", "Cholesterol biosynthesis"], ["TCGA.AA.3841.01", "Aquaporin-mediated transport"], ["TCGA.AA.3841.01", "Metabolism of folate and pterines"], ["TCGA.AA.3841.01", "Metabolism of nitric oxide: NOS3 activation and regulation"], ["TCGA.AA.3841.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.3841.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], ["TCGA.AA.3841.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], ["TCGA.AA.3841.01", "Glycogen synthesis"], ["TCGA.AA.3841.01", "Phase 2 - plateau phase"], ["TCGA.AA.3841.01", "LGI-ADAM interactions"], ["TCGA.AA.3841.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3841.01", "G protein gated Potassium channels"], ["TCGA.AA.3841.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], ["TCGA.AA.3841.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3841.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3841.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3841.01", "GABA receptor activation"], ["TCGA.AA.3841.01", "Viral mRNA Translation"], ["TCGA.AA.3841.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.3841.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3841.01", "Signaling by Nuclear Receptors"], ["TCGA.AA.3841.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3841.01", "Peptide chain elongation"], ["TCGA.AA.3841.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3841.01", "Metabolism of proteins"], ["TCGA.AA.3841.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3841.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.3841.01", "DNA strand elongation"], ["TCGA.AA.3841.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3841.01", "Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation"], ["TCGA.AA.3841.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.AA.3841.01", "Insulin processing"], ["TCGA.AA.3841.01", "SHC-mediated cascade:FGFR4"], ["TCGA.AA.3841.01", "Signaling by KIT in disease"], ["TCGA.AA.3841.01", "Inhibition of DNA recombination at telomere"], ["TCGA.AA.3841.01", "Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants"], ["TCGA.AA.3841.01", "Developmental Biology"], ["TCGA.AA.3841.01", "Neuronal System"], ["TCGA.AA.3841.01", "Platelet homeostasis"], ["TCGA.AA.3841.01", "Insulin receptor signalling cascade"], ["TCGA.AA.3841.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AA.3841.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3841.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.3841.01", "PIWI-interacting RNA (piRNA) biogenesis"], ["TCGA.AA.3841.01", "Signaling by Insulin receptor"], ["TCGA.AA.3841.01", "Trafficking and processing of endosomal TLR"], ["TCGA.AA.3841.01", "Regulation by c-FLIP"], ["TCGA.AA.3841.01", "Apoptotic cleavage of cell adhesion  proteins"], ["TCGA.AA.3841.01", "CASP8 activity is inhibited"], ["TCGA.AA.3841.01", "RHO GTPases activate KTN1"], ["TCGA.AA.3841.01", "Signaling by FGFR4 in disease"], ["TCGA.AA.3841.01", "Dimerization of procaspase-8"], ["TCGA.AA.3841.01", "Signaling by FGFR2 in disease"], ["TCGA.AA.3841.01", "Telomere Maintenance"], ["TCGA.AA.3841.01", "Glucuronidation"], ["TCGA.AA.3841.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3841.01", "NOTCH2 Activation and Transmission of Signal to the Nucleus"], ["TCGA.AA.3841.01", "CD209 (DC-SIGN) signaling"], ["TCGA.AA.3841.01", "SHC-mediated cascade:FGFR1"], ["TCGA.AA.3841.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.AA.3841.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3841.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3841.01", "SUMOylation of DNA methylation proteins"], ["TCGA.AA.3841.01", "Glycogen breakdown (glycogenolysis)"], ["TCGA.AA.3841.01", "RNA Polymerase I Promoter Opening"], ["TCGA.AA.3841.01", "EPHB-mediated forward signaling"], ["TCGA.AA.3841.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], ["TCGA.AA.3841.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3841.01", "rRNA processing"], ["TCGA.AA.3841.01", "RNA Pol II CTD phosphorylation and interaction with CE during HIV infection"], ["TCGA.AA.3841.01", "Caspase activation via extrinsic apoptotic signalling pathway"], ["TCGA.AA.3841.01", "RNA Pol II CTD phosphorylation and interaction with CE"], ["TCGA.AA.3842.01", "NCAM1 interactions"], ["TCGA.AA.3842.01", "Neuronal System"], ["TCGA.AA.3842.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3842.01", "Extracellular matrix organization"], ["TCGA.AA.3842.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3842.01", "CD22 mediated BCR regulation"], ["TCGA.AA.3842.01", "GPCR ligand binding"], ["TCGA.AA.3842.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.3842.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3842.01", "Biological oxidations"], ["TCGA.AA.3842.01", "Peptide ligand-binding receptors"], ["TCGA.AA.3842.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3842.01", "Transport of small molecules"], ["TCGA.AA.3842.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.3842.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.3842.01", "Peptide hormone metabolism"], ["TCGA.AA.3842.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.3842.01", "Collagen formation"], ["TCGA.AA.3842.01", "L1CAM interactions"], ["TCGA.AA.3842.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3844.01", "Biological oxidations"], ["TCGA.AA.3844.01", "Extracellular matrix organization"], ["TCGA.AA.3844.01", "Molecules associated with elastic fibres"], ["TCGA.AA.3844.01", "Neuronal System"], ["TCGA.AA.3844.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3844.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3844.01", "G alpha (i) signalling events"], ["TCGA.AA.3844.01", "Aspirin ADME"], ["TCGA.AA.3844.01", "Elastic fibre formation"], ["TCGA.AA.3844.01", "Transport of small molecules"], ["TCGA.AA.3844.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3844.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3844.01", "GPCR ligand binding"], ["TCGA.AA.3848.01", "Azathioprine ADME"], ["TCGA.AA.3848.01", "Signal amplification"], ["TCGA.AA.3848.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3848.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3848.01", "Drug ADME"], ["TCGA.AA.3848.01", "Regulation of insulin secretion"], ["TCGA.AA.3848.01", "RA biosynthesis pathway"], ["TCGA.AA.3848.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3848.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3848.01", "Integration of energy metabolism"], ["TCGA.AA.3848.01", "Peptide hormone metabolism"], ["TCGA.AA.3848.01", "Heme degradation"], ["TCGA.AA.3848.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3848.01", "Transport of small molecules"], ["TCGA.AA.3848.01", "Stimuli-sensing channels"], ["TCGA.AA.3848.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3848.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3848.01", "Sealing of the nuclear envelope (NE) by ESCRT-III"], ["TCGA.AA.3848.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3848.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.3848.01", "Glucuronidation"], ["TCGA.AA.3848.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3848.01", "DNA methylation"], ["TCGA.AA.3848.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], ["TCGA.AA.3848.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], ["TCGA.AA.3848.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3848.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3848.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3848.01", "Ion channel transport"], ["TCGA.AA.3848.01", "Unwinding of DNA"], ["TCGA.AA.3848.01", "Dermatan sulfate biosynthesis"], ["TCGA.AA.3848.01", "Post-chaperonin tubulin folding pathway"], ["TCGA.AA.3848.01", "tRNA modification in the nucleus and cytosol"], ["TCGA.AA.3848.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3848.01", "G alpha (q) signalling events"], ["TCGA.AA.3848.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3848.01", "Signaling by Nuclear Receptors"], ["TCGA.AA.3848.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3848.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3848.01", "G-protein activation"], ["TCGA.AA.3848.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.3848.01", "Interleukin-6 family signaling"], ["TCGA.AA.3848.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3848.01", "Recycling of bile acids and salts"], ["TCGA.AA.3848.01", "Peptide hormone biosynthesis"], ["TCGA.AA.3848.01", "Selenoamino acid metabolism"], ["TCGA.AA.3848.01", "Vitamin B5 (pantothenate) metabolism"], ["TCGA.AA.3848.01", "NOTCH2 Activation and Transmission of Signal to the Nucleus"], ["TCGA.AA.3848.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3848.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.3848.01", "GPER1 signaling"], ["TCGA.AA.3848.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3848.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3848.01", "Activated NOTCH1 Transmits Signal to the Nucleus"], ["TCGA.AA.3848.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3848.01", "DNA strand elongation"], ["TCGA.AA.3848.01", "Post-translational protein phosphorylation"], ["TCGA.AA.3848.01", "Metabolism of nitric oxide: NOS3 activation and regulation"], ["TCGA.AA.3848.01", "Transport of vitamins, nucleosides, and related molecules"], ["TCGA.AA.3848.01", "RNA Polymerase III Chain Elongation"], ["TCGA.AA.3848.01", "ESR-mediated signaling"], ["TCGA.AA.3848.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3848.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3848.01", "Chaperonin-mediated protein folding"], ["TCGA.AA.3848.01", "Aquaporin-mediated transport"], ["TCGA.AA.3848.01", "Activation of the pre-replicative complex"], ["TCGA.AA.3848.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3848.01", "Protein folding"], ["TCGA.AA.3848.01", "RNA Polymerase III Transcription Termination"], ["TCGA.AA.3848.01", "RND1 GTPase cycle"], ["TCGA.AA.3848.01", "RHO GTPases activate KTN1"], ["TCGA.AA.3848.01", "Signaling by FGFR4 in disease"], ["TCGA.AA.3848.01", "Ethanol oxidation"], ["TCGA.AA.3848.01", "Digestion"], ["TCGA.AA.3848.01", "Interleukin-27 signaling"], ["TCGA.AA.3848.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.3848.01", "Selenocysteine synthesis"], ["TCGA.AA.3848.01", "Signaling by FGFR2 IIIa TM"], ["TCGA.AA.3848.01", "Cellular response to starvation"], ["TCGA.AA.3848.01", "Viral mRNA Translation"], ["TCGA.AA.3848.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3848.01", "rRNA processing"], ["TCGA.AA.3848.01", "SIRT1 negatively regulates rRNA expression"], ["TCGA.AA.3848.01", "Peptide chain elongation"], ["TCGA.AA.3848.01", "Insulin processing"], ["TCGA.AA.3848.01", "Signaling by KIT in disease"], ["TCGA.AA.3848.01", "Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants"], ["TCGA.AA.3848.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AA.3848.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3848.01", "G alpha (z) signalling events"], ["TCGA.AA.3848.01", "SUMOylation of DNA methylation proteins"], ["TCGA.AA.3848.01", "Triglyceride catabolism"], ["TCGA.AA.3848.01", "mRNA decay by 3' to 5' exoribonuclease"], ["TCGA.AA.3848.01", "Nucleotide biosynthesis"], ["TCGA.AA.3848.01", "Interleukin-35 Signalling"], ["TCGA.AA.3848.01", "Signaling by PDGFR in disease"], ["TCGA.AA.3848.01", "Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants"], ["TCGA.AA.3848.01", "Signaling by PDGFRA extracellular domain mutants"], ["TCGA.AA.3848.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.AA.3848.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3848.01", "Biological oxidations"], ["TCGA.AA.3848.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.AA.3848.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3848.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.3848.01", "Formation of tubulin folding intermediates by CCT/TriC"], ["TCGA.AA.3848.01", "Ras activation upon Ca2+ influx through NMDA receptor"], ["TCGA.AA.3848.01", "CD209 (DC-SIGN) signaling"], ["TCGA.AA.3848.01", "Extra-nuclear estrogen signaling"], ["TCGA.AA.3848.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3848.01", "Sensory processing of sound"], ["TCGA.AA.3848.01", "Estrogen-dependent gene expression"], ["TCGA.AA.3848.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3848.01", "Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA"], ["TCGA.AA.3848.01", "Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA"], ["TCGA.AA.3848.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.3848.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.3848.01", "Chondroitin sulfate/dermatan sulfate metabolism"], ["TCGA.AA.3848.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.3848.01", "Purine ribonucleoside monophosphate biosynthesis"], ["TCGA.AA.3848.01", "Inhibition of replication initiation of damaged DNA by RB1/E2F1"], ["TCGA.AA.3848.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3848.01", "Methylation"], ["TCGA.AA.3848.01", "p38MAPK events"], ["TCGA.AA.3848.01", "GRB2 events in EGFR signaling"], ["TCGA.AA.3848.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3848.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3848.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3848.01", "Potassium Channels"], ["TCGA.AA.3848.01", "Telomere Maintenance"], ["TCGA.AA.3848.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3848.01", "Diseases associated with glycosaminoglycan metabolism"], ["TCGA.AA.3848.01", "NCAM1 interactions"], ["TCGA.AA.3848.01", "RND3 GTPase cycle"], ["TCGA.AA.3848.01", "Heme signaling"], ["TCGA.AA.3848.01", "L1CAM interactions"], ["TCGA.AA.3848.01", "Synthesis of PIPs at the Golgi membrane"], ["TCGA.AA.3848.01", "MicroRNA (miRNA) biogenesis"], ["TCGA.AA.3848.01", "Tie2 Signaling"], ["TCGA.AA.3848.01", "Nucleotide metabolism"], ["TCGA.AA.3848.01", "Nuclear Receptor transcription pathway"], ["TCGA.AA.3848.01", "Signaling by NOTCH1"], ["TCGA.AA.3850.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3850.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3850.01", "Metabolism of amine-derived hormones"], ["TCGA.AA.3850.01", "L1CAM interactions"], ["TCGA.AA.3850.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3852.01", "Peptide hormone metabolism"], ["TCGA.AA.3852.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3852.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3852.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3852.01", "Glucuronidation"], ["TCGA.AA.3852.01", "Extracellular matrix organization"], ["TCGA.AA.3852.01", "Peptide hormone biosynthesis"], ["TCGA.AA.3852.01", "Keratinization"], ["TCGA.AA.3852.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3852.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3854.01", "Neuronal System"], ["TCGA.AA.3854.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3854.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3854.01", "Cardiac conduction"], ["TCGA.AA.3854.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3854.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.3854.01", "Muscle contraction"], ["TCGA.AA.3854.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3854.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3854.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3854.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3854.01", "G alpha (z) signalling events"], ["TCGA.AA.3854.01", "L1CAM interactions"], ["TCGA.AA.3854.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.3854.01", "Drug ADME"], ["TCGA.AA.3854.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3854.01", "Potassium Channels"], ["TCGA.AA.3854.01", "Defective B3GALTL causes PpS"], ["TCGA.AA.3854.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3854.01", "G protein gated Potassium channels"], ["TCGA.AA.3854.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3854.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3854.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3854.01", "Regulation of insulin secretion"], ["TCGA.AA.3854.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AA.3854.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3854.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3854.01", "Ion homeostasis"], ["TCGA.AA.3854.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3854.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3854.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3854.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3854.01", "Ion transport by P-type ATPases"], ["TCGA.AA.3854.01", "Neurexins and neuroligins"], ["TCGA.AA.3854.01", "RA biosynthesis pathway"], ["TCGA.AA.3854.01", "CD22 mediated BCR regulation"], ["TCGA.AA.3854.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3854.01", "GABA B receptor activation"], ["TCGA.AA.3854.01", "Activation of GABAB receptors"], ["TCGA.AA.3854.01", "Signal amplification"], ["TCGA.AA.3854.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3854.01", "Transport of small molecules"], ["TCGA.AA.3854.01", "GABA receptor activation"], ["TCGA.AA.3854.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3854.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3854.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3854.01", "Aquaporin-mediated transport"], ["TCGA.AA.3854.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3854.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3854.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3854.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3854.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3854.01", "Peptide hormone metabolism"], ["TCGA.AA.3854.01", "G alpha (i) signalling events"], ["TCGA.AA.3854.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3854.01", "Signaling by GPCR"], ["TCGA.AA.3854.01", "Biological oxidations"], ["TCGA.AA.3854.01", "LGI-ADAM interactions"], ["TCGA.AA.3854.01", "G-protein activation"], ["TCGA.AA.3854.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.3854.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3854.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3854.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3854.01", "Insulin processing"], ["TCGA.AA.3854.01", "GPCR downstream signalling"], ["TCGA.AA.3854.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3854.01", "GPCR ligand binding"], ["TCGA.AA.3854.01", "Integration of energy metabolism"], ["TCGA.AA.3854.01", "Synaptic adhesion-like molecules"], ["TCGA.AA.3854.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.3854.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3858.01", "Biological oxidations"], ["TCGA.AA.3858.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3858.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3858.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3858.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3858.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3858.01", "Ethanol oxidation"], ["TCGA.AA.3858.01", "GABA receptor activation"], ["TCGA.AA.3858.01", "Drug ADME"], ["TCGA.AA.3858.01", "Signal amplification"], ["TCGA.AA.3858.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3858.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3858.01", "Recycling of bile acids and salts"], ["TCGA.AA.3858.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AA.3858.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3858.01", "GPER1 signaling"], ["TCGA.AA.3858.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3858.01", "GABA B receptor activation"], ["TCGA.AA.3858.01", "Activation of GABAB receptors"], ["TCGA.AA.3858.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3858.01", "Neuronal System"], ["TCGA.AA.3858.01", "Peptide hormone metabolism"], ["TCGA.AA.3858.01", "Aquaporin-mediated transport"], ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.3858.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3858.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3858.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3858.01", "RA biosynthesis pathway"], ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts"], ["TCGA.AA.3858.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3858.01", "Digestion"], ["TCGA.AA.3860.01", "Biological oxidations"], ["TCGA.AA.3860.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3860.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3860.01", "Extracellular matrix organization"], ["TCGA.AA.3860.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3860.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3860.01", "G alpha (s) signalling events"], ["TCGA.AA.3860.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3860.01", "Platelet homeostasis"], ["TCGA.AA.3860.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3860.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3860.01", "Signal amplification"], ["TCGA.AA.3860.01", "GPCR ligand binding"], ["TCGA.AA.3860.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3860.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3860.01", "Glucuronidation"], ["TCGA.AA.3860.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3860.01", "RA biosynthesis pathway"], ["TCGA.AA.3860.01", "Transport of small molecules"], ["TCGA.AA.3860.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3860.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3860.01", "Ethanol oxidation"], ["TCGA.AA.3860.01", "Digestion"], ["TCGA.AA.3860.01", "Cardiac conduction"], ["TCGA.AA.3860.01", "Digestion and absorption"], ["TCGA.AA.3860.01", "Drug ADME"], ["TCGA.AA.3860.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3860.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3860.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3860.01", "GABA receptor activation"], ["TCGA.AA.3860.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3860.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3860.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3860.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3860.01", "Blood group systems biosynthesis"], ["TCGA.AA.3860.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3860.01", "GPER1 signaling"], ["TCGA.AA.3860.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3860.01", "GABA B receptor activation"], ["TCGA.AA.3860.01", "Activation of GABAB receptors"], ["TCGA.AA.3860.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.3860.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3860.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3860.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3860.01", "Collagen formation"], ["TCGA.AA.3870.01", "Drug ADME"], ["TCGA.AA.3870.01", "Extracellular matrix organization"], ["TCGA.AA.3870.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3870.01", "Glucuronidation"], ["TCGA.AA.3870.01", "Peptide hormone metabolism"], ["TCGA.AA.3870.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.3870.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3870.01", "Stimuli-sensing channels"], ["TCGA.AA.3870.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.3870.01", "Transport of small molecules"], ["TCGA.AA.3875.01", "G0 and Early G1"], ["TCGA.AA.3875.01", "G1/S-Specific Transcription"], ["TCGA.AA.3875.01", "Blood group systems biosynthesis"], ["TCGA.AA.3875.01", "Extracellular matrix organization"], ["TCGA.AA.3875.01", "DNA methylation"], ["TCGA.AA.3875.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3875.01", "Transcription of E2F targets under negative control by DREAM complex"], ["TCGA.AA.3875.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3875.01", "Collagen formation"], ["TCGA.AA.3875.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3875.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3875.01", "Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1"], ["TCGA.AA.3875.01", "L1CAM interactions"], ["TCGA.AA.3875.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3875.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3875.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3875.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3875.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3875.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3875.01", "Phosphorylation of the APC/C"], ["TCGA.AA.3875.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3875.01", "Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components"], ["TCGA.AA.3875.01", "Inactivation of APC/C via direct inhibition of the APC/C complex"], ["TCGA.AA.3875.01", "Insulin processing"], ["TCGA.AA.3875.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.AA.3875.01", "Free fatty acids regulate insulin secretion"], ["TCGA.AA.3875.01", "RHO GTPases activate KTN1"], ["TCGA.AA.3875.01", "Digestion"], ["TCGA.AA.3875.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.3875.01", "Signal amplification"], ["TCGA.AA.3875.01", "GABA receptor activation"], ["TCGA.AA.3875.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.3875.01", "Heme degradation"], ["TCGA.AA.3875.01", "Caspase-mediated cleavage of cytoskeletal proteins"], ["TCGA.AA.3875.01", "Physiological factors"], ["TCGA.AA.3875.01", "Ribavirin ADME"], ["TCGA.AA.3875.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3875.01", "Metal ion SLC transporters"], ["TCGA.AA.3875.01", "Diseases of mitotic cell cycle"], ["TCGA.AA.3875.01", "Aberrant regulation of mitotic cell cycle due to RB1 defects"], ["TCGA.AA.3875.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3875.01", "Collagen degradation"], ["TCGA.AA.3875.01", "APC/C:Cdc20 mediated degradation of Cyclin B"], ["TCGA.AA.3875.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3875.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3875.01", "Kinesins"], ["TCGA.AA.3875.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3875.01", "Netrin-1 signaling"], ["TCGA.AA.3875.01", "G-protein activation"], ["TCGA.AA.3875.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3875.01", "NCAM1 interactions"], ["TCGA.AA.3875.01", "Neurotransmitter release cycle"], ["TCGA.AA.3875.01", "ABC transporters in lipid homeostasis"], ["TCGA.AA.3875.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], ["TCGA.AA.3875.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], ["TCGA.AA.3875.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3875.01", "APC-Cdc20 mediated degradation of Nek2A"], ["TCGA.AA.3875.01", "Basigin interactions"], ["TCGA.AA.3875.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], ["TCGA.AA.3875.01", "Cardiac conduction"], ["TCGA.AA.3875.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.3875.01", "Neuronal System"], ["TCGA.AA.3875.01", "ECM proteoglycans"], ["TCGA.AA.3875.01", "Signaling by ALK"], ["TCGA.AA.3875.01", "E2F mediated regulation of DNA replication"], ["TCGA.AA.3875.01", "SUMOylation of DNA methylation proteins"], ["TCGA.AA.3875.01", "Synthesis of very long-chain fatty acyl-CoAs"], ["TCGA.AA.3875.01", "Aspirin ADME"], ["TCGA.AA.3875.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3875.01", "Platelet homeostasis"], ["TCGA.AA.3875.01", "Meiosis"], ["TCGA.AA.3875.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3875.01", "Norepinephrine Neurotransmitter Release Cycle"], ["TCGA.AA.3875.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3875.01", "Digestion and absorption"], ["TCGA.AA.3875.01", "Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects"], ["TCGA.AA.3875.01", "Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)"], ["TCGA.AA.3875.01", "Aberrant regulation of mitotic exit in cancer due to RB1 defects"], ["TCGA.AA.3875.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3875.01", "Drug ADME"], ["TCGA.AA.3875.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3875.01", "G protein gated Potassium channels"], ["TCGA.AA.3875.01", "Formation of the beta-catenin:TCF transactivating complex"], ["TCGA.AA.3875.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], ["TCGA.AA.3875.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.AA.3875.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3875.01", "Viral mRNA Translation"], ["TCGA.AA.3875.01", "GABA B receptor activation"], ["TCGA.AA.3875.01", "Activation of GABAB receptors"], ["TCGA.AA.3875.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3875.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.3875.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], ["TCGA.AA.3875.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3875.01", "Peptide chain elongation"], ["TCGA.AA.3875.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3875.01", "Reproduction"], ["TCGA.AA.3875.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3875.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3939.01", "Eukaryotic Translation Elongation"], ["TCGA.AA.3939.01", "Viral mRNA Translation"], ["TCGA.AA.3939.01", "Peptide chain elongation"], ["TCGA.AA.3939.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.3939.01", "Developmental Biology"], ["TCGA.AA.3939.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3939.01", "Selenocysteine synthesis"], ["TCGA.AA.3939.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3939.01", "Selenoamino acid metabolism"], ["TCGA.AA.3939.01", "Eukaryotic Translation Termination"], ["TCGA.AA.3939.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AA.3939.01", "Formation of a pool of free 40S subunits"], ["TCGA.AA.3939.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AA.3939.01", "Post-translational protein phosphorylation"], ["TCGA.AA.3939.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AA.3939.01", "Eukaryotic Translation Initiation"], ["TCGA.AA.3939.01", "Cap-dependent Translation Initiation"], ["TCGA.AA.3939.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.AA.3939.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AA.3939.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AA.3939.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AA.3939.01", "Keratinization"], ["TCGA.AA.3939.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AA.3939.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3939.01", "Neuronal System"], ["TCGA.AA.3939.01", "Biological oxidations"], ["TCGA.AA.3939.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3939.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AA.3939.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.3939.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.AA.3939.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3939.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3939.01", "Extracellular matrix organization"], ["TCGA.AA.3939.01", "Defective GALNT12 causes CRCS1"], ["TCGA.AA.3939.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AA.3939.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3939.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], ["TCGA.AA.3939.01", "Blood group systems biosynthesis"], ["TCGA.AA.3939.01", "Influenza Infection"], ["TCGA.AA.3939.01", "L1CAM interactions"], ["TCGA.AA.3939.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3939.01", "Digestion"], ["TCGA.AA.3939.01", "Cellular response to starvation"], ["TCGA.AA.3939.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3939.01", "GPCR ligand binding"], ["TCGA.AA.3939.01", "Phase I - Functionalization of compounds"], ["TCGA.AA.3939.01", "Peptide hormone metabolism"], ["TCGA.AA.3939.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3939.01", "Ribosomal scanning and start codon recognition"], ["TCGA.AA.3939.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3939.01", "Heme degradation"], ["TCGA.AA.3939.01", "NCAM1 interactions"], ["TCGA.AA.3939.01", "Axon guidance"], ["TCGA.AA.3939.01", "Translation initiation complex formation"], ["TCGA.AA.3939.01", "Nervous system development"], ["TCGA.AA.3939.01", "Formation of the ternary complex, and subsequently, the 43S complex"], ["TCGA.AA.3939.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3939.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3939.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.3939.01", "Cardiac conduction"], ["TCGA.AA.3939.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3941.01", "Regulation of insulin secretion"], ["TCGA.AA.3941.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3941.01", "Integration of energy metabolism"], ["TCGA.AA.3941.01", "Ion channel transport"], ["TCGA.AA.3941.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3941.01", "Binding and entry of HIV virion"], ["TCGA.AA.3952.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3952.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3952.01", "ROS and RNS production in phagocytes"], ["TCGA.AA.3952.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.AA.3952.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.3952.01", "Ethanol oxidation"], ["TCGA.AA.3952.01", "Glucuronidation"], ["TCGA.AA.3952.01", "Binding and entry of HIV virion"], ["TCGA.AA.3952.01", "Recycling of bile acids and salts"], ["TCGA.AA.3952.01", "Peptide hormone biosynthesis"], ["TCGA.AA.3952.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3952.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3952.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3952.01", "Peptide hormone metabolism"], ["TCGA.AA.3952.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3952.01", "Ion channel transport"], ["TCGA.AA.3952.01", "Blood group systems biosynthesis"], ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.3952.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3952.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3952.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.3952.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3952.01", "Transport of small molecules"], ["TCGA.AA.3952.01", "FCERI mediated Ca+2 mobilization"], ["TCGA.AA.3952.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3952.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.AA.3952.01", "L1CAM interactions"], ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AA.3952.01", "TP53 Regulates Transcription of Death Receptors and Ligands"], ["TCGA.AA.3952.01", "Ribavirin ADME"], ["TCGA.AA.3952.01", "Cellular hexose transport"], ["TCGA.AA.3952.01", "TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway"], ["TCGA.AA.3952.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3952.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3952.01", "Transferrin endocytosis and recycling"], ["TCGA.AA.3952.01", "Cardiac conduction"], ["TCGA.AA.3952.01", "GPCR ligand binding"], ["TCGA.AA.3952.01", "Nucleotide metabolism"], ["TCGA.AA.3952.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3952.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3952.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3952.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3952.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3952.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3952.01", "Extracellular matrix organization"], ["TCGA.AA.3952.01", "G alpha (z) signalling events"], ["TCGA.AA.3952.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts"], ["TCGA.AA.3952.01", "Insulin receptor recycling"], ["TCGA.AA.3952.01", "ABC transporters in lipid homeostasis"], ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.3952.01", "Attenuation phase"], ["TCGA.AA.3952.01", "LGI-ADAM interactions"], ["TCGA.AA.3952.01", "Iron uptake and transport"], ["TCGA.AA.3952.01", "Signaling by NODAL"], ["TCGA.AA.3952.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3952.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3952.01", "RA biosynthesis pathway"], ["TCGA.AA.3952.01", "Signaling by BMP"], ["TCGA.AA.3952.01", "Antimicrobial peptides"], ["TCGA.AA.3952.01", "Purine ribonucleoside monophosphate biosynthesis"], ["TCGA.AA.3952.01", "Signaling by Activin"], ["TCGA.AA.3952.01", "NCAM1 interactions"], ["TCGA.AA.3952.01", "SARS-CoV-1 targets host intracellular signalling and regulatory pathways"], ["TCGA.AA.3952.01", "Stimuli-sensing channels"], ["TCGA.AA.3952.01", "Metal ion SLC transporters"], ["TCGA.AA.3952.01", "Other interleukin signaling"], ["TCGA.AA.3956.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3956.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3956.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3956.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3956.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3956.01", "Collagen degradation"], ["TCGA.AA.3956.01", "NCAM1 interactions"], ["TCGA.AA.3956.01", "Interleukin-6 family signaling"], ["TCGA.AA.3956.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.3956.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3956.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.3956.01", "Antimicrobial peptides"], ["TCGA.AA.3956.01", "GPCR ligand binding"], ["TCGA.AA.3956.01", "Collagen formation"], ["TCGA.AA.3956.01", "Extracellular matrix organization"], ["TCGA.AA.3956.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3956.01", "Signaling by NODAL"], ["TCGA.AA.3956.01", "Complement cascade"], ["TCGA.AA.3956.01", "Metabolism of fat-soluble vitamins"], ["TCGA.AA.3956.01", "Retinoid metabolism and transport"], ["TCGA.AA.3956.01", "Calcitonin-like ligand receptors"], ["TCGA.AA.3956.01", "Stimuli-sensing channels"], ["TCGA.AA.3966.01", "Interleukin-10 signaling"], ["TCGA.AA.3966.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3966.01", "GPCR ligand binding"], ["TCGA.AA.3966.01", "Extracellular matrix organization"], ["TCGA.AA.3966.01", "Biological oxidations"], ["TCGA.AA.3966.01", "Signaling by GPCR"], ["TCGA.AA.3966.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.3966.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3966.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AA.3966.01", "Degradation of the extracellular matrix"], ["TCGA.AA.3966.01", "Glucuronidation"], ["TCGA.AA.3966.01", "Neuronal System"], ["TCGA.AA.3966.01", "Drug ADME"], ["TCGA.AA.3966.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.3966.01", "Peptide ligand-binding receptors"], ["TCGA.AA.3966.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.3966.01", "G alpha (i) signalling events"], ["TCGA.AA.3966.01", "GPCR downstream signalling"], ["TCGA.AA.3966.01", "Collagen formation"], ["TCGA.AA.3966.01", "RA biosynthesis pathway"], ["TCGA.AA.3966.01", "Synaptic adhesion-like molecules"], ["TCGA.AA.3966.01", "L1CAM interactions"], ["TCGA.AA.3966.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3966.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.3966.01", "Peptide hormone metabolism"], ["TCGA.AA.3966.01", "Transport of small molecules"], ["TCGA.AA.3966.01", "Metabolism of amine-derived hormones"], ["TCGA.AA.3966.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3966.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.3966.01", "TNFs bind their physiological receptors"], ["TCGA.AA.3966.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3966.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3966.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3966.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3966.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3966.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3966.01", "Peptide hormone biosynthesis"], ["TCGA.AA.3966.01", "Metabolism"], ["TCGA.AA.3966.01", "Defective B3GALTL causes PpS"], ["TCGA.AA.3966.01", "Aspirin ADME"], ["TCGA.AA.3966.01", "Collagen degradation"], ["TCGA.AA.3966.01", "Post-translational protein phosphorylation"], ["TCGA.AA.3966.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3966.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AA.3966.01", "Fatty acid metabolism"], ["TCGA.AA.3966.01", "Interleukin-6 family signaling"], ["TCGA.AA.3966.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3966.01", "Voltage gated Potassium channels"], ["TCGA.AA.3966.01", "G alpha (q) signalling events"], ["TCGA.AA.3966.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.3966.01", "Stimuli-sensing channels"], ["TCGA.AA.3966.01", "Blood group systems biosynthesis"], ["TCGA.AA.3966.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.AA.3966.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.AA.3966.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3966.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3966.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.3966.01", "Potassium Channels"], ["TCGA.AA.3966.01", "Activation of the phototransduction cascade"], ["TCGA.AA.3966.01", "Ethanol oxidation"], ["TCGA.AA.3966.01", "Digestion"], ["TCGA.AA.3966.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3966.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AA.3966.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3966.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3971.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3971.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3971.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.3971.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3971.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3971.01", "Interleukin-6 family signaling"], ["TCGA.AA.3971.01", "Basigin interactions"], ["TCGA.AA.3971.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.3971.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3971.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3971.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3971.01", "G protein gated Potassium channels"], ["TCGA.AA.3971.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3971.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3971.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.3971.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3971.01", "GABA B receptor activation"], ["TCGA.AA.3971.01", "Activation of GABAB receptors"], ["TCGA.AA.3971.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.3971.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.3971.01", "GABA receptor activation"], ["TCGA.AA.3971.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.3971.01", "Ras activation upon Ca2+ influx through NMDA receptor"], ["TCGA.AA.3971.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.3971.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.AA.3971.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3971.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.3971.01", "G alpha (z) signalling events"], ["TCGA.AA.3971.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.3971.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3971.01", "G-protein activation"], ["TCGA.AA.3971.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.3971.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3971.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3971.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.3971.01", "Long-term potentiation"], ["TCGA.AA.3971.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3971.01", "Ca2+ pathway"], ["TCGA.AA.3971.01", "L1CAM interactions"], ["TCGA.AA.3971.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3971.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.3971.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], ["TCGA.AA.3971.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3971.01", "GPER1 signaling"], ["TCGA.AA.3971.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3971.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3971.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AA.3971.01", "Extra-nuclear estrogen signaling"], ["TCGA.AA.3971.01", "GPCR ligand binding"], ["TCGA.AA.3971.01", "JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1"], ["TCGA.AA.3971.01", "Aquaporin-mediated transport"], ["TCGA.AA.3971.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3971.01", "Trafficking of AMPA receptors"], ["TCGA.AA.3971.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.AA.3971.01", "NOD1/2 Signaling Pathway"], ["TCGA.AA.3971.01", "Signal amplification"], ["TCGA.AA.3971.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.3971.01", "activated TAK1 mediates p38 MAPK activation"], ["TCGA.AA.3971.01", "Phase 4 - resting membrane potential"], ["TCGA.AA.3971.01", "Neuronal System"], ["TCGA.AA.3971.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.3971.01", "G alpha (s) signalling events"], ["TCGA.AA.3971.01", "FGFR2 ligand binding and activation"], ["TCGA.AA.3971.01", "Blood group systems biosynthesis"], ["TCGA.AA.3971.01", "Collagen formation"], ["TCGA.AA.3971.01", "Striated Muscle Contraction"], ["TCGA.AA.3979.01", "Neuronal System"], ["TCGA.AA.3979.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.3979.01", "GPCR downstream signalling"], ["TCGA.AA.3979.01", "Signaling by GPCR"], ["TCGA.AA.3979.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3979.01", "Signaling Pathways"], ["TCGA.AA.3979.01", "G alpha (i) signalling events"], ["TCGA.AA.3979.01", "GABA receptor activation"], ["TCGA.AA.3979.01", "Transmission across Chemical Synapses"], ["TCGA.AA.3979.01", "Cardiac conduction"], ["TCGA.AA.3979.01", "G-protein beta:gamma signalling"], ["TCGA.AA.3979.01", "Regulation of insulin secretion"], ["TCGA.AA.3979.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3979.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.3979.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.3979.01", "Leishmania parasite growth and survival"], ["TCGA.AA.3979.01", "Protein-protein interactions at synapses"], ["TCGA.AA.3979.01", "G1/S-Specific Transcription"], ["TCGA.AA.3979.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.3979.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3979.01", "Extracellular matrix organization"], ["TCGA.AA.3979.01", "Muscle contraction"], ["TCGA.AA.3979.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3979.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.3979.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3979.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3979.01", "GPCR ligand binding"], ["TCGA.AA.3979.01", "Neurexins and neuroligins"], ["TCGA.AA.3979.01", "Generation of second messenger molecules"], ["TCGA.AA.3979.01", "DNA strand elongation"], ["TCGA.AA.3979.01", "Immune System"], ["TCGA.AA.3979.01", "GABA B receptor activation"], ["TCGA.AA.3979.01", "Activation of GABAB receptors"], ["TCGA.AA.3979.01", "Molecules associated with elastic fibres"], ["TCGA.AA.3979.01", "G0 and Early G1"], ["TCGA.AA.3979.01", "Initial triggering of complement"], ["TCGA.AA.3979.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3979.01", "NCAM1 interactions"], ["TCGA.AA.3979.01", "Signal amplification"], ["TCGA.AA.3982.01", "Signaling by Retinoic Acid"], ["TCGA.AA.3982.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.AA.3982.01", "Regulation of signaling by NODAL"], ["TCGA.AA.3982.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3982.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3982.01", "Blood group systems biosynthesis"], ["TCGA.AA.3982.01", "GRB2 events in EGFR signaling"], ["TCGA.AA.3982.01", "Signal amplification"], ["TCGA.AA.3982.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.3982.01", "GABA B receptor activation"], ["TCGA.AA.3982.01", "Activation of GABAB receptors"], ["TCGA.AA.3982.01", "Adenylate cyclase inhibitory pathway"], ["TCGA.AA.3982.01", "SHC1 events in EGFR signaling"], ["TCGA.AA.3982.01", "G alpha (s) signalling events"], ["TCGA.AA.3982.01", "Signaling by Nuclear Receptors"], ["TCGA.AA.3982.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.3982.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.3982.01", "GAB1 signalosome"], ["TCGA.AA.3982.01", "Extra-nuclear estrogen signaling"], ["TCGA.AA.3982.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3982.01", "Aspirin ADME"], ["TCGA.AA.3982.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3982.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3982.01", "Complement cascade"], ["TCGA.AA.3982.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3982.01", "GPER1 signaling"], ["TCGA.AA.3982.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.3982.01", "Regulation of Complement cascade"], ["TCGA.AA.3982.01", "GABA receptor activation"], ["TCGA.AA.3982.01", "Signaling by NODAL"], ["TCGA.AA.3982.01", "Aquaporin-mediated transport"], ["TCGA.AA.3982.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AA.3982.01", "Glucagon-type ligand receptors"], ["TCGA.AA.3982.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.3982.01", "p75NTR recruits signalling complexes"], ["TCGA.AA.3982.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3982.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.AA.3982.01", "GPCR downstream signalling"], ["TCGA.AA.3982.01", "G alpha (z) signalling events"], ["TCGA.AA.3982.01", "G-protein activation"], ["TCGA.AA.3982.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.3982.01", "Interleukin-6 family signaling"], ["TCGA.AA.3982.01", "Estrogen-dependent nuclear events downstream of ESR-membrane signaling"], ["TCGA.AA.3982.01", "G alpha (q) signalling events"], ["TCGA.AA.3982.01", "Integration of energy metabolism"], ["TCGA.AA.3982.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.3982.01", "Regulation of insulin secretion"], ["TCGA.AA.3982.01", "Phase 2 - plateau phase"], ["TCGA.AA.3982.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.AA.3982.01", "Signaling by EGFR in Cancer"], ["TCGA.AA.3982.01", "APC-Cdc20 mediated degradation of Nek2A"], ["TCGA.AA.3982.01", "GPCR ligand binding"], ["TCGA.AA.3982.01", "Signaling by GPCR"], ["TCGA.AA.3982.01", "ERBB2 Regulates Cell Motility"], ["TCGA.AA.3982.01", "p75NTR signals via NF-kB"], ["TCGA.AA.3982.01", "GRB2 events in ERBB2 signaling"], ["TCGA.AA.3982.01", "PI3K events in ERBB2 signaling"], ["TCGA.AA.3982.01", "G-protein mediated events"], ["TCGA.AA.3982.01", "Drug ADME"], ["TCGA.AA.3982.01", "PKA activation in glucagon signalling"], ["TCGA.AA.3982.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.3982.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.3982.01", "G protein gated Potassium channels"], ["TCGA.AA.3982.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.3982.01", "Biological oxidations"], ["TCGA.AA.3982.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.3982.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.3982.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3982.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.3982.01", "ESR-mediated signaling"], ["TCGA.AA.3982.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.3982.01", "EGFR downregulation"], ["TCGA.AA.3982.01", "Interleukin-12 signaling"], ["TCGA.AA.3982.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.A00A.01", "Neuronal System"], ["TCGA.AA.A00A.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A00A.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.A00A.01", "Extracellular matrix organization"], ["TCGA.AA.A00A.01", "Biological oxidations"], ["TCGA.AA.A00A.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A00A.01", "Cardiac conduction"], ["TCGA.AA.A00A.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.A00A.01", "Signaling by GPCR"], ["TCGA.AA.A00A.01", "L1CAM interactions"], ["TCGA.AA.A00A.01", "Peptide hormone metabolism"], ["TCGA.AA.A00A.01", "Muscle contraction"], ["TCGA.AA.A00A.01", "Phase I - Functionalization of compounds"], ["TCGA.AA.A00A.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A00A.01", "Glucuronidation"], ["TCGA.AA.A00A.01", "GPCR ligand binding"], ["TCGA.AA.A00A.01", "Protein-protein interactions at synapses"], ["TCGA.AA.A00A.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A00A.01", "GPCR downstream signalling"], ["TCGA.AA.A00A.01", "G alpha (s) signalling events"], ["TCGA.AA.A00A.01", "Collagen formation"], ["TCGA.AA.A00A.01", "G alpha (i) signalling events"], ["TCGA.AA.A00A.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.A00A.01", "Regulation of insulin secretion"], ["TCGA.AA.A00A.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A00A.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.A00A.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.A00A.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.A00A.01", "Potassium Channels"], ["TCGA.AA.A00A.01", "Neurexins and neuroligins"], ["TCGA.AA.A00A.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A00A.01", "Platelet homeostasis"], ["TCGA.AA.A00A.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A00A.01", "Integration of energy metabolism"], ["TCGA.AA.A00A.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A00A.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A00A.01", "Drug ADME"], ["TCGA.AA.A00A.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A00A.01", "Aspirin ADME"], ["TCGA.AA.A00A.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A00A.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.A00A.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.A00A.01", "Blood group systems biosynthesis"], ["TCGA.AA.A00A.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.A00A.01", "Signal amplification"], ["TCGA.AA.A00A.01", "Aquaporin-mediated transport"], ["TCGA.AA.A00A.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.A00A.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.A00A.01", "Presynaptic nicotinic acetylcholine receptors"], ["TCGA.AA.A00A.01", "Ethanol oxidation"], ["TCGA.AA.A00A.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.A00A.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.AA.A00A.01", "Signaling by Retinoic Acid"], ["TCGA.AA.A00A.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A00A.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.A00F.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.A00F.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A00F.01", "Post-translational protein phosphorylation"], ["TCGA.AA.A00F.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A00F.01", "Ethanol oxidation"], ["TCGA.AA.A00F.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A00F.01", "Extracellular matrix organization"], ["TCGA.AA.A00F.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.A00F.01", "Leishmania parasite growth and survival"], ["TCGA.AA.A00F.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.A00F.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.A00F.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.A00F.01", "Surfactant metabolism"], ["TCGA.AA.A00F.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AA.A00F.01", "G alpha (s) signalling events"], ["TCGA.AA.A00F.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.A00F.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A00F.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.A00F.01", "Keratinization"], ["TCGA.AA.A00F.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A00F.01", "Peptide hormone biosynthesis"], ["TCGA.AA.A00F.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.A00F.01", "GPER1 signaling"], ["TCGA.AA.A00F.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.A00F.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A00F.01", "Signaling by GPCR"], ["TCGA.AA.A00F.01", "Diseases of Immune System"], ["TCGA.AA.A00F.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AA.A00F.01", "Aquaporin-mediated transport"], ["TCGA.AA.A00F.01", "TNFs bind their physiological receptors"], ["TCGA.AA.A00F.01", "Neuronal System"], ["TCGA.AA.A00F.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AA.A00F.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.A00F.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A00F.01", "GABA receptor activation"], ["TCGA.AA.A00F.01", "Biological oxidations"], ["TCGA.AA.A00F.01", "G alpha (z) signalling events"], ["TCGA.AA.A00J.01", "Drug ADME"], ["TCGA.AA.A00J.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A00J.01", "GPCR ligand binding"], ["TCGA.AA.A00J.01", "Extracellular matrix organization"], ["TCGA.AA.A00J.01", "Signaling by GPCR"], ["TCGA.AA.A00J.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A00J.01", "GPCR downstream signalling"], ["TCGA.AA.A00J.01", "G alpha (i) signalling events"], ["TCGA.AA.A00J.01", "Neuronal System"], ["TCGA.AA.A00J.01", "Peptide ligand-binding receptors"], ["TCGA.AA.A00J.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A00J.01", "L1CAM interactions"], ["TCGA.AA.A00J.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A00J.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.A00J.01", "Digestion"], ["TCGA.AA.A00J.01", "Blood group systems biosynthesis"], ["TCGA.AA.A00J.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.A00J.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A00J.01", "RA biosynthesis pathway"], ["TCGA.AA.A00J.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.A00J.01", "Peptide hormone metabolism"], ["TCGA.AA.A00J.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.A00J.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A00J.01", "Post-translational protein phosphorylation"], ["TCGA.AA.A00O.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.A00O.01", "Drug ADME"], ["TCGA.AA.A00O.01", "Biological oxidations"], ["TCGA.AA.A00O.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A00O.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A00O.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.A00O.01", "Transport of small molecules"], ["TCGA.AA.A00O.01", "O-linked glycosylation"], ["TCGA.AA.A00O.01", "Signaling by GPCR"], ["TCGA.AA.A00O.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.A00O.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AA.A00O.01", "Peptide hormone metabolism"], ["TCGA.AA.A00O.01", "Signaling by activated point mutants of FGFR3"], ["TCGA.AA.A00O.01", "FGFR3 mutant receptor activation"], ["TCGA.AA.A00O.01", "GPCR downstream signalling"], ["TCGA.AA.A00O.01", "G alpha (i) signalling events"], ["TCGA.AA.A00O.01", "FGFR3 ligand binding and activation"], ["TCGA.AA.A00O.01", "FGFR3c ligand binding and activation"], ["TCGA.AA.A00O.01", "Phospholipase C-mediated cascade; FGFR3"], ["TCGA.AA.A00O.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AA.A00O.01", "Dectin-2 family"], ["TCGA.AA.A00O.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.A00O.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.A00O.01", "Extracellular matrix organization"], ["TCGA.AA.A00O.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.AA.A00O.01", "FRS-mediated FGFR3 signaling"], ["TCGA.AA.A017.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A017.01", "Neuronal System"], ["TCGA.AA.A017.01", "Signaling by GPCR"], ["TCGA.AA.A017.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.A017.01", "G alpha (i) signalling events"], ["TCGA.AA.A017.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A017.01", "Peptide hormone metabolism"], ["TCGA.AA.A017.01", "GPCR downstream signalling"], ["TCGA.AA.A017.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A017.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.A017.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A017.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.A017.01", "Leishmania parasite growth and survival"], ["TCGA.AA.A017.01", "Signal amplification"], ["TCGA.AA.A017.01", "Transport of small molecules"], ["TCGA.AA.A017.01", "Regulation of insulin secretion"], ["TCGA.AA.A017.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A017.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.A017.01", "Potassium Channels"], ["TCGA.AA.A017.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A017.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A017.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A017.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A017.01", "Platelet homeostasis"], ["TCGA.AA.A017.01", "L1CAM interactions"], ["TCGA.AA.A017.01", "Integration of energy metabolism"], ["TCGA.AA.A017.01", "Stimuli-sensing channels"], ["TCGA.AA.A017.01", "GABA receptor activation"], ["TCGA.AA.A017.01", "GPCR ligand binding"], ["TCGA.AA.A01D.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A01D.01", "Extracellular matrix organization"], ["TCGA.AA.A01D.01", "Collagen formation"], ["TCGA.AA.A01D.01", "TNFs bind their physiological receptors"], ["TCGA.AA.A01D.01", "Transport of small molecules"], ["TCGA.AA.A01D.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.A01D.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A01D.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A01D.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.A01D.01", "Collagen degradation"], ["TCGA.AA.A01D.01", "Collagen chain trimerization"], ["TCGA.AA.A01D.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.A01D.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.A01X.01", "Transport of small molecules"], ["TCGA.AA.A01X.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.A01X.01", "GPCR downstream signalling"], ["TCGA.AA.A01X.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.A01X.01", "Neuronal System"], ["TCGA.AA.A01X.01", "Peptide hormone metabolism"], ["TCGA.AA.A01X.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.A01X.01", "Signaling by GPCR"], ["TCGA.AA.A01X.01", "G alpha (s) signalling events"], ["TCGA.AA.A01X.01", "TNFs bind their physiological receptors"], ["TCGA.AA.A01X.01", "G alpha (i) signalling events"], ["TCGA.AA.A01X.01", "Scavenging of heme from plasma"], ["TCGA.AA.A01X.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.A01X.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A01X.01", "SLC-mediated transmembrane transport"], ["TCGA.AA.A01X.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.A01X.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.A01X.01", "IRS-related events triggered by IGF1R"], ["TCGA.AA.A01X.01", "Signaling by Retinoic Acid"], ["TCGA.AA.A01X.01", "IGF1R signaling cascade"], ["TCGA.AA.A01X.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A01X.01", "IRS-mediated signalling"], ["TCGA.AA.A01X.01", "ABC transporters in lipid homeostasis"], ["TCGA.AA.A01X.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.A01X.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.A01X.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A01X.01", "PI-3K cascade:FGFR4"], ["TCGA.AA.A01X.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.AA.A022.01", "Peptide hormone metabolism"], ["TCGA.AA.A022.01", "Extracellular matrix organization"], ["TCGA.AA.A022.01", "Neuronal System"], ["TCGA.AA.A022.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.A022.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A022.01", "Muscle contraction"], ["TCGA.AA.A022.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A022.01", "Transport of small molecules"], ["TCGA.AA.A022.01", "Cardiac conduction"], ["TCGA.AA.A022.01", "Potassium Channels"], ["TCGA.AA.A022.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.A022.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A022.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.A022.01", "Glucuronidation"], ["TCGA.AA.A022.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.A022.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.A022.01", "Ion transport by P-type ATPases"], ["TCGA.AA.A022.01", "Glycogen synthesis"], ["TCGA.AA.A022.01", "Digestion"], ["TCGA.AA.A022.01", "Ion channel transport"], ["TCGA.AA.A022.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.A022.01", "Phase 4 - resting membrane potential"], ["TCGA.AA.A022.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.A022.01", "Biological oxidations"], ["TCGA.AA.A029.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.A029.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.A029.01", "Complement cascade"], ["TCGA.AA.A029.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.A029.01", "Regulation of Complement cascade"], ["TCGA.AA.A029.01", "Cell surface interactions at the vascular wall"], ["TCGA.AA.A029.01", "Muscle contraction"], ["TCGA.AA.A029.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.A029.01", "Initial triggering of complement"], ["TCGA.AA.A029.01", "Insulin processing"], ["TCGA.AA.A029.01", "Diseases of Immune System"], ["TCGA.AA.A029.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AA.A029.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.A029.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.A029.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A029.01", "Creation of C4 and C2 activators"], ["TCGA.AA.A029.01", "Signaling by GPCR"], ["TCGA.AA.A029.01", "Regulation of insulin secretion"], ["TCGA.AA.A029.01", "Cardiac conduction"], ["TCGA.AA.A029.01", "GPVI-mediated activation cascade"], ["TCGA.AA.A029.01", "Binding and entry of HIV virion"], ["TCGA.AA.A029.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.A029.01", "GPCR ligand binding"], ["TCGA.AA.A029.01", "GPCR downstream signalling"], ["TCGA.AA.A029.01", "Ligand-dependent caspase activation"], ["TCGA.AA.A029.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.A029.01", "Signaling Pathways"], ["TCGA.AA.A029.01", "Immune System"], ["TCGA.AA.A029.01", "Extracellular matrix organization"], ["TCGA.AA.A029.01", "G alpha (i) signalling events"], ["TCGA.AA.A029.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.A029.01", "Integration of energy metabolism"], ["TCGA.AA.A029.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.A029.01", "Neuronal System"], ["TCGA.AA.A029.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A029.01", "Other semaphorin interactions"], ["TCGA.AA.A029.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AA.A029.01", "CD22 mediated BCR regulation"], ["TCGA.AA.A029.01", "Leishmania infection"], ["TCGA.AA.A029.01", "Adaptive Immune System"], ["TCGA.AA.A029.01", "L1CAM interactions"], ["TCGA.AA.A029.01", "DAP12 signaling"], ["TCGA.AA.A029.01", "TNFs bind their physiological receptors"], ["TCGA.AA.A029.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AA.A029.01", "Erythropoietin activates Phosphoinositide-3-kinase (PI3K)"], ["TCGA.AA.A02E.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A02E.01", "Transport of small molecules"], ["TCGA.AA.A02E.01", "FGFR2c ligand binding and activation"], ["TCGA.AA.A02E.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.A02E.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.A02E.01", "Activated point mutants of FGFR2"], ["TCGA.AA.A02E.01", "Ion channel transport"], ["TCGA.AA.A02E.01", "L1CAM interactions"], ["TCGA.AA.A02E.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.A02E.01", "Phospholipase C-mediated cascade; FGFR2"], ["TCGA.AA.A02E.01", "Molecules associated with elastic fibres"], ["TCGA.AA.A02E.01", "PI-3K cascade:FGFR2"], ["TCGA.AA.A02H.01", "G alpha (i) signalling events"], ["TCGA.AA.A02H.01", "GPCR ligand binding"], ["TCGA.AA.A02H.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.A02H.01", "Signaling by GPCR"], ["TCGA.AA.A02H.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A02H.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.A02H.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A02H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.A02H.01", "Signal amplification"], ["TCGA.AA.A02H.01", "Blood group systems biosynthesis"], ["TCGA.AA.A02H.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A02H.01", "GPCR downstream signalling"], ["TCGA.AA.A02H.01", "Glucuronidation"], ["TCGA.AA.A02H.01", "Peptide ligand-binding receptors"], ["TCGA.AA.A02H.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.AA.A02H.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.A02H.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A02H.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.A02H.01", "Heme degradation"], ["TCGA.AA.A02H.01", "Platelet homeostasis"], ["TCGA.AA.A02H.01", "Biological oxidations"], ["TCGA.AA.A02H.01", "SUMOylation of intracellular receptors"], ["TCGA.AA.A02H.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.A02H.01", "Interleukin-10 signaling"], ["TCGA.AA.A02H.01", "Lewis blood group biosynthesis"], ["TCGA.AA.A02H.01", "Binding and entry of HIV virion"], ["TCGA.AA.A02H.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.A02H.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.A02H.01", "Peptide hormone metabolism"], ["TCGA.AA.A02H.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A02H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A02H.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.A02H.01", "RA biosynthesis pathway"], ["TCGA.AA.A02H.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.A02H.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.A02H.01", "Transport of small molecules"], ["TCGA.AA.A02H.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.A02H.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A02H.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AA.A02H.01", "Nucleotide catabolism"], ["TCGA.AA.A02H.01", "L1CAM interactions"], ["TCGA.AA.A02H.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A02H.01", "Ligand-dependent caspase activation"], ["TCGA.AA.A02H.01", "Vitamin B5 (pantothenate) metabolism"], ["TCGA.AA.A02H.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.A02H.01", "Digestion and absorption"], ["TCGA.AA.A02H.01", "G-protein beta:gamma signalling"], ["TCGA.AA.A02H.01", "Trafficking and processing of endosomal TLR"], ["TCGA.AA.A02H.01", "Ethanol oxidation"], ["TCGA.AA.A02H.01", "Digestion"], ["TCGA.AA.A02H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.A02H.01", "Porphyrin metabolism"], ["TCGA.AA.A02H.01", "G-protein activation"], ["TCGA.AA.A02H.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.A02H.01", "Interleukin-6 family signaling"], ["TCGA.AA.A02H.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.A02H.01", "Signaling Pathways"], ["TCGA.AA.A02H.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.A02H.01", "Keratan sulfate biosynthesis"], ["TCGA.AA.A02H.01", "Potassium Channels"], ["TCGA.AA.A02H.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.A02H.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.A02H.01", "Regulation of insulin secretion"], ["TCGA.AA.A02H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.A02H.01", "GPER1 signaling"], ["TCGA.AA.A02H.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.A02H.01", "Caspase activation via extrinsic apoptotic signalling pathway"], ["TCGA.AA.A02H.01", "FGFR2c ligand binding and activation"], ["TCGA.AA.A02H.01", "Nuclear Receptor transcription pathway"], ["TCGA.AA.A02H.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.A02H.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.A02H.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.AA.A02H.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.AA.A02H.01", "Signaling by BMP"], ["TCGA.AA.A02H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A02H.01", "Aquaporin-mediated transport"], ["TCGA.AA.A02H.01", "ABC transporters in lipid homeostasis"], ["TCGA.AA.A02H.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.A02H.01", "Attenuation phase"], ["TCGA.AA.A02H.01", "LGI-ADAM interactions"], ["TCGA.AA.A02H.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.AA.A02H.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.A02H.01", "Regulation of FZD by ubiquitination"], ["TCGA.AA.A02H.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.A02H.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.AA.A02H.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.A02H.01", "Neuronal System"], ["TCGA.AA.A02H.01", "Extracellular matrix organization"], ["TCGA.AA.A02H.01", "HSP90 chaperone cycle for SHRs"], ["TCGA.AA.A02H.01", "Other interleukin signaling"], ["TCGA.AA.A02H.01", "Keratan sulfate/keratin metabolism"], ["TCGA.AA.A02H.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AA.A02H.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.AA.A02H.01", "Cardiac conduction"], ["TCGA.AA.A02H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.A02H.01", "Leishmania parasite growth and survival"], ["TCGA.AA.A02H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.A02H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.A02H.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A02H.01", "Ion transport by P-type ATPases"], ["TCGA.AA.A02H.01", "Molecules associated with elastic fibres"], ["TCGA.AA.A02H.01", "APAP ADME"], ["TCGA.AA.A02H.01", "Ion channel transport"], ["TCGA.AA.A02H.01", "Platelet activation, signaling and aggregation"], ["TCGA.AA.A02H.01", "Sensory perception of taste"], ["TCGA.AA.A02H.01", "Neurotransmitter release cycle"], ["TCGA.AA.A02H.01", "SUMOylation of DNA methylation proteins"], ["TCGA.AA.A02H.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.A02H.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AA.A02H.01", "G alpha (s) signalling events"], ["TCGA.AA.A02H.01", "Glutathione conjugation"], ["TCGA.AA.A02H.01", "PKA activation in glucagon signalling"], ["TCGA.AA.A02H.01", "Activated point mutants of FGFR2"], ["TCGA.AA.A02H.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.A02H.01", "Sulfur amino acid metabolism"], ["TCGA.AA.A02H.01", "IRS-related events triggered by IGF1R"], ["TCGA.AA.A02H.01", "Ca2+ pathway"], ["TCGA.AA.A02H.01", "GABA B receptor activation"], ["TCGA.AA.A02H.01", "Activation of GABAB receptors"], ["TCGA.AA.A02H.01", "G alpha (q) signalling events"], ["TCGA.AA.A02H.01", "Glycosaminoglycan metabolism"], ["TCGA.AA.A02H.01", "Arachidonic acid metabolism"], ["TCGA.AA.A02H.01", "IGF1R signaling cascade"], ["TCGA.AA.A02H.01", "Phospholipase C-mediated cascade; FGFR2"], ["TCGA.AA.A02H.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A02H.01", "Transcriptional Regulation by VENTX"], ["TCGA.AA.A02H.01", "Signaling by activated point mutants of FGFR1"], ["TCGA.AA.A02H.01", "FGFR1c ligand binding and activation"], ["TCGA.AA.A02H.01", "Biotin transport and metabolism"], ["TCGA.AA.A02H.01", "Dermatan sulfate biosynthesis"], ["TCGA.AA.A02H.01", "Scavenging of heme from plasma"], ["TCGA.AA.A02H.01", "Regulation by c-FLIP"], ["TCGA.AA.A02H.01", "Free fatty acids regulate insulin secretion"], ["TCGA.AA.A02H.01", "CASP8 activity is inhibited"], ["TCGA.AA.A02H.01", "Dimerization of procaspase-8"], ["TCGA.AA.A02H.01", "Interleukin-27 signaling"], ["TCGA.AA.A02H.01", "Developmental Biology"], ["TCGA.AA.A02H.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], ["TCGA.AA.A02H.01", "Other semaphorin interactions"], ["TCGA.AA.A02H.01", "DNA methylation"], ["TCGA.AA.A02H.01", "CD22 mediated BCR regulation"], ["TCGA.AA.A02H.01", "G-protein mediated events"], ["TCGA.AA.A02J.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.A02J.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AA.A02J.01", "Signaling by GPCR"], ["TCGA.AA.A02J.01", "GPCR downstream signalling"], ["TCGA.AA.A02J.01", "Immune System"], ["TCGA.AA.A02J.01", "G alpha (i) signalling events"], ["TCGA.AA.A02J.01", "Generation of second messenger molecules"], ["TCGA.AA.A02J.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AA.A02J.01", "Neuronal System"], ["TCGA.AA.A02J.01", "PD-1 signaling"], ["TCGA.AA.A02J.01", "GPCR ligand binding"], ["TCGA.AA.A02J.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.A02J.01", "Leishmania parasite growth and survival"], ["TCGA.AA.A02J.01", "Signaling Pathways"], ["TCGA.AA.A02J.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.A02J.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.A02J.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.A02J.01", "G-protein beta:gamma signalling"], ["TCGA.AA.A02J.01", "Leishmania infection"], ["TCGA.AA.A02J.01", "Muscle contraction"], ["TCGA.AA.A02J.01", "Complement cascade"], ["TCGA.AA.A02J.01", "Integration of energy metabolism"], ["TCGA.AA.A02J.01", "Extracellular matrix organization"], ["TCGA.AA.A02J.01", "Diseases of Immune System"], ["TCGA.AA.A02J.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AA.A02J.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.A02J.01", "Peptide ligand-binding receptors"], ["TCGA.AA.A02J.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A02J.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AA.A02J.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AA.A02J.01", "Cytokine Signaling in Immune system"], ["TCGA.AA.A02J.01", "Platelet homeostasis"], ["TCGA.AA.A02J.01", "Costimulation by the CD28 family"], ["TCGA.AA.A02J.01", "G alpha (q) signalling events"], ["TCGA.AA.A02J.01", "Platelet activation, signaling and aggregation"], ["TCGA.AA.A02J.01", "Signaling by Interleukins"], ["TCGA.AA.A02J.01", "Regulation of Complement cascade"], ["TCGA.AA.A02J.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.A02J.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A02J.01", "Cell surface interactions at the vascular wall"], ["TCGA.AA.A02J.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.A02J.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.AA.A02J.01", "Adaptive Immune System"], ["TCGA.AA.A02J.01", "G alpha (s) signalling events"], ["TCGA.AA.A02J.01", "Molecules associated with elastic fibres"], ["TCGA.AA.A02J.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.AA.A02J.01", "Transport of small molecules"], ["TCGA.AA.A02J.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.AA.A02J.01", "L1CAM interactions"], ["TCGA.AA.A02J.01", "Keratan sulfate biosynthesis"], ["TCGA.AA.A02J.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.A02J.01", "Other interleukin signaling"], ["TCGA.AA.A02J.01", "NCAM1 interactions"], ["TCGA.AA.A02J.01", "Interferon gamma signaling"], ["TCGA.AA.A02J.01", "Defensins"], ["TCGA.AA.A02J.01", "CD28 dependent Vav1 pathway"], ["TCGA.AA.A02J.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AA.A02O.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.A02O.01", "Recycling of bile acids and salts"], ["TCGA.AA.A02O.01", "G-protein beta:gamma signalling"], ["TCGA.AA.A02O.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.A02O.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.A02O.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A02O.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.A02O.01", "Signal amplification"], ["TCGA.AA.A02O.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A02O.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.A02O.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A02O.01", "Transport of small molecules"], ["TCGA.AA.A02O.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.A02O.01", "Regulation of insulin secretion"], ["TCGA.AA.A02O.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A02O.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.A02O.01", "G-protein activation"], ["TCGA.AA.A02O.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A02O.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A02O.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A02O.01", "Neuronal System"], ["TCGA.AA.A02O.01", "Stimuli-sensing channels"], ["TCGA.AA.A02Y.01", "Extracellular matrix organization"], ["TCGA.AA.A02Y.01", "Neuronal System"], ["TCGA.AA.A02Y.01", "Signaling Pathways"], ["TCGA.AA.A02Y.01", "Signaling by GPCR"], ["TCGA.AA.A02Y.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AA.A02Y.01", "GPCR downstream signalling"], ["TCGA.AA.A02Y.01", "Collagen formation"], ["TCGA.AA.A02Y.01", "Cardiac conduction"], ["TCGA.AA.A02Y.01", "Muscle contraction"], ["TCGA.AA.A02Y.01", "GPCR ligand binding"], ["TCGA.AA.A02Y.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AA.A02Y.01", "Elastic fibre formation"], ["TCGA.AA.A02Y.01", "Defective B3GALTL causes PpS"], ["TCGA.AA.A02Y.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AA.A02Y.01", "G alpha (i) signalling events"], ["TCGA.AA.A02Y.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AA.A02Y.01", "Transmission across Chemical Synapses"], ["TCGA.AA.A02Y.01", "Protein-protein interactions at synapses"], ["TCGA.AA.A02Y.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.A02Y.01", "Complement cascade"], ["TCGA.AA.A02Y.01", "NCAM1 interactions"], ["TCGA.AA.A02Y.01", "Platelet homeostasis"], ["TCGA.AA.A02Y.01", "G alpha (s) signalling events"], ["TCGA.AA.A02Y.01", "Integrin cell surface interactions"], ["TCGA.AA.A02Y.01", "Regulation of Complement cascade"], ["TCGA.AA.A02Y.01", "Potassium Channels"], ["TCGA.AA.A02Y.01", "Molecules associated with elastic fibres"], ["TCGA.AA.A02Y.01", "Collagen chain trimerization"], ["TCGA.AA.A02Y.01", "NCAM signaling for neurite out-growth"], ["TCGA.AA.A02Y.01", "Post-translational protein phosphorylation"], ["TCGA.AA.A02Y.01", "Ion homeostasis"], ["TCGA.AA.A02Y.01", "Transport of small molecules"], ["TCGA.AA.A02Y.01", "Signaling by Receptor Tyrosine Kinases"], ["TCGA.AA.A02Y.01", "Diseases of glycosylation"], ["TCGA.AA.A02Y.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.A02Y.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AA.A02Y.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A02Y.01", "Scavenging by Class A Receptors"], ["TCGA.AA.A02Y.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A02Y.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AA.A02Y.01", "Initial triggering of complement"], ["TCGA.AA.A02Y.01", "Creation of C4 and C2 activators"], ["TCGA.AA.A02Y.01", "L1CAM interactions"], ["TCGA.AA.A02Y.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.A02Y.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A02Y.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AA.A02Y.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AA.A02Y.01", "Metabolism of fat-soluble vitamins"], ["TCGA.AA.A02Y.01", "Retinoid metabolism and transport"], ["TCGA.AA.A02Y.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AA.A02Y.01", "Diseases of metabolism"], ["TCGA.AA.A02Y.01", "Signaling by PDGF"], ["TCGA.AA.A02Y.01", "ECM proteoglycans"], ["TCGA.AA.A02Y.01", "G-protein beta:gamma signalling"], ["TCGA.AA.A02Y.01", "G alpha (z) signalling events"], ["TCGA.AA.A02Y.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.A02Y.01", "Arachidonic acid metabolism"], ["TCGA.AA.A02Y.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.A02Y.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.A02Y.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A02Y.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.A02Y.01", "Glycosaminoglycan metabolism"], ["TCGA.AA.A02Y.01", "LGI-ADAM interactions"], ["TCGA.AA.A02Y.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AA.A02Y.01", "Synaptic adhesion-like molecules"], ["TCGA.AA.A02Y.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A02Y.01", "Cell surface interactions at the vascular wall"], ["TCGA.AA.A02Y.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.A02Y.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AA.A02Y.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AA.A02Y.01", "Ca2+ pathway"], ["TCGA.AA.A02Y.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AA.A02Y.01", "Leishmania parasite growth and survival"], ["TCGA.AA.A02Y.01", "GABA receptor activation"], ["TCGA.AA.A02Y.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.A02Y.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AA.A02Y.01", "Ion channel transport"], ["TCGA.AA.A02Y.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AA.A02Y.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.A02Y.01", "CRMPs in Sema3A signaling"], ["TCGA.AA.A02Y.01", "Diseases associated with glycosaminoglycan metabolism"], ["TCGA.AA.A02Y.01", "Aquaporin-mediated transport"], ["TCGA.AA.A02Y.01", "ERK1/ERK2 pathway"], ["TCGA.AA.A02Y.01", "Defective B4GALT7 causes EDS, progeroid type"], ["TCGA.AA.A02Y.01", "Defective B3GAT3 causes JDSSDHD"], ["TCGA.AA.A02Y.01", "Defective B3GALT6 causes EDSP2 and SEMDJL1"], ["TCGA.AA.A02Y.01", "G beta:gamma signalling through CDC42"], ["TCGA.AA.A02Y.01", "Neurexins and neuroligins"], ["TCGA.AA.A02Y.01", "Interleukin-6 family signaling"], ["TCGA.AA.A02Y.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AA.A02Y.01", "Long-term potentiation"], ["TCGA.AA.A02Y.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.A02Y.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AA.A02Y.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AA.A02Y.01", "Calcitonin-like ligand receptors"], ["TCGA.AA.A02Y.01", "Sialic acid metabolism"], ["TCGA.AA.A02Y.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A02Y.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AA.A02Y.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AA.A02Y.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.A02Y.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.A02Y.01", "Peptide ligand-binding receptors"], ["TCGA.AA.A02Y.01", "RAF/MAP kinase cascade"], ["TCGA.AA.A02Y.01", "Nervous system development"], ["TCGA.AA.A02Y.01", "Voltage gated Potassium channels"], ["TCGA.AA.A02Y.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AA.A02Y.01", "GPER1 signaling"], ["TCGA.AA.A02Y.01", "GABA B receptor activation"], ["TCGA.AA.A02Y.01", "Activation of GABAB receptors"], ["TCGA.AA.A02Y.01", "Developmental Biology"], ["TCGA.AA.A02Y.01", "Leishmania infection"], ["TCGA.AA.A02Y.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AA.A02Y.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AA.A02Y.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A02Y.01", "O-linked glycosylation"], ["TCGA.AA.A02Y.01", "Inwardly rectifying K+ channels"], ["TCGA.AA.A02Y.01", "CD22 mediated BCR regulation"], ["TCGA.AA.A02Y.01", "Dermatan sulfate biosynthesis"], ["TCGA.AA.A02Y.01", "Non-integrin membrane-ECM interactions"], ["TCGA.AA.A02Y.01", "Ion transport by P-type ATPases"], ["TCGA.AA.A02Y.01", "Axon guidance"], ["TCGA.AA.A02Y.01", "Chondroitin sulfate/dermatan sulfate metabolism"], ["TCGA.AA.A02Y.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AA.A02Y.01", "Calmodulin induced events"], ["TCGA.AA.A02Y.01", "CaM pathway"], ["TCGA.AA.A02Y.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AA.A02Y.01", "Integration of energy metabolism"], ["TCGA.AA.A02Y.01", "MAPK family signaling cascades"], ["TCGA.AA.A02Y.01", "Degradation of the extracellular matrix"], ["TCGA.AA.A02Y.01", "Signal amplification"], ["TCGA.AA.A02Y.01", "DAG and IP3 signaling"], ["TCGA.AA.A02Y.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.A02Y.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AA.A02Y.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A02Y.01", "Adherens junctions interactions"], ["TCGA.AA.A02Y.01", "Thromboxane signalling through TP receptor"], ["TCGA.AA.A02Y.01", "Regulation of insulin secretion"], ["TCGA.AA.A02Y.01", "Chondroitin sulfate biosynthesis"], ["TCGA.AA.A02Y.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.A02Y.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.AA.A02Y.01", "Ca-dependent events"], ["TCGA.AA.A02Y.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AA.A02Y.01", "Activation of G protein gated Potassium channels"], ["TCGA.AA.A02Y.01", "G protein gated Potassium channels"], ["TCGA.AA.A02Y.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AA.A02Y.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AA.A02Y.01", "Keratan sulfate biosynthesis"], ["TCGA.AA.A02Y.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AA.A02Y.01", "RA biosynthesis pathway"], ["TCGA.AA.A02Y.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.AA.A02Y.01", "Visual phototransduction"], ["TCGA.AA.A02Y.01", "Activation of SMO"], ["TCGA.AA.A02Y.01", "G-protein mediated events"], ["TCGA.AA.A02Y.01", "PLC beta mediated events"], ["TCGA.AA.A02Y.01", "A tetrasaccharide linker sequence is required for GAG synthesis"], ["TCGA.AA.A02Y.01", "G alpha (12/13) signalling events"], ["TCGA.AD.6888.01", "Signaling by GPCR"], ["TCGA.AD.6888.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AD.6888.01", "GPCR downstream signalling"], ["TCGA.AD.6888.01", "G alpha (i) signalling events"], ["TCGA.AD.6888.01", "Signaling Pathways"], ["TCGA.AD.6888.01", "GPCR ligand binding"], ["TCGA.AD.6888.01", "Extracellular matrix organization"], ["TCGA.AD.6888.01", "Neuronal System"], ["TCGA.AD.6888.01", "Cardiac conduction"], ["TCGA.AD.6888.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AD.6888.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AD.6888.01", "Muscle contraction"], ["TCGA.AD.6888.01", "Generation of second messenger molecules"], ["TCGA.AD.6888.01", "G alpha (s) signalling events"], ["TCGA.AD.6888.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AD.6888.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AD.6888.01", "Immune System"], ["TCGA.AD.6888.01", "Potassium Channels"], ["TCGA.AD.6888.01", "Platelet homeostasis"], ["TCGA.AD.6888.01", "Peptide ligand-binding receptors"], ["TCGA.AD.6888.01", "Chemokine receptors bind chemokines"], ["TCGA.AD.6888.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AD.6888.01", "Integrin cell surface interactions"], ["TCGA.AD.6888.01", "Glycosaminoglycan metabolism"], ["TCGA.AD.6888.01", "PD-1 signaling"], ["TCGA.AD.6888.01", "Elastic fibre formation"], ["TCGA.AD.6888.01", "Integration of energy metabolism"], ["TCGA.AD.6888.01", "Transport of small molecules"], ["TCGA.AD.6888.01", "Complement cascade"], ["TCGA.AD.6888.01", "Transmission across Chemical Synapses"], ["TCGA.AD.6888.01", "Regulation of Complement cascade"], ["TCGA.AD.6888.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AD.6888.01", "Leishmania parasite growth and survival"], ["TCGA.AD.6888.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AD.6888.01", "Cell surface interactions at the vascular wall"], ["TCGA.AD.6888.01", "Classical antibody-mediated complement activation"], ["TCGA.AD.6888.01", "G alpha (q) signalling events"], ["TCGA.AD.6888.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AD.6888.01", "Regulation of insulin secretion"], ["TCGA.AD.6888.01", "Molecules associated with elastic fibres"], ["TCGA.AD.6888.01", "Defective B3GALTL causes PpS"], ["TCGA.AD.6888.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AD.6888.01", "G-protein beta:gamma signalling"], ["TCGA.AD.6888.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AD.6888.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AD.6888.01", "Protein-protein interactions at synapses"], ["TCGA.AD.6888.01", "Ion channel transport"], ["TCGA.AD.6888.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AD.6888.01", "Interaction between L1 and Ankyrins"], ["TCGA.AD.6888.01", "Phase 0 - rapid depolarisation"], ["TCGA.AD.6888.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.AD.6888.01", "Leishmania infection"], ["TCGA.AD.6888.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.AD.6888.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AD.6888.01", "Voltage gated Potassium channels"], ["TCGA.AD.6888.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AD.6888.01", "Stimuli-sensing channels"], ["TCGA.AD.6888.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AD.6888.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AD.6888.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AD.6888.01", "G alpha (z) signalling events"], ["TCGA.AD.6888.01", "Creation of C4 and C2 activators"], ["TCGA.AD.6888.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AD.6888.01", "Diseases of Immune System"], ["TCGA.AD.6888.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AD.6888.01", "Peptide hormone metabolism"], ["TCGA.AD.6888.01", "NCAM1 interactions"], ["TCGA.AD.6888.01", "Developmental Biology"], ["TCGA.AD.6888.01", "Aquaporin-mediated transport"], ["TCGA.AD.6888.01", "Keratan sulfate biosynthesis"], ["TCGA.AD.6888.01", "Diseases of glycosylation"], ["TCGA.AD.6888.01", "Signaling by Interleukins"], ["TCGA.AD.6888.01", "G beta:gamma signalling through BTK"], ["TCGA.AD.6888.01", "Glucagon-type ligand receptors"], ["TCGA.AD.6888.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AD.6888.01", "Binding and entry of HIV virion"], ["TCGA.AD.6888.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AD.6888.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AD.6888.01", "HS-GAG biosynthesis"], ["TCGA.AD.6888.01", "Diseases of metabolism"], ["TCGA.AD.6888.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AD.6888.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AD.6888.01", "Ca2+ pathway"], ["TCGA.AD.6888.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AD.6888.01", "O-linked glycosylation"], ["TCGA.AD.6888.01", "NCAM signaling for neurite out-growth"], ["TCGA.AD.6888.01", "GABA receptor activation"], ["TCGA.AD.6888.01", "Innate Immune System"], ["TCGA.AD.6888.01", "Carbohydrate metabolism"], ["TCGA.AD.6888.01", "Collagen formation"], ["TCGA.AD.6888.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AD.6888.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.AD.6888.01", "Initial triggering of complement"], ["TCGA.AD.6888.01", "Inflammasomes"], ["TCGA.AD.6888.01", "G beta:gamma signalling through CDC42"], ["TCGA.AD.6888.01", "Signal amplification"], ["TCGA.AD.6888.01", "G-protein activation"], ["TCGA.AD.6888.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AD.6888.01", "Thromboxane signalling through TP receptor"], ["TCGA.AD.6888.01", "Interleukin-6 family signaling"], ["TCGA.AD.6888.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.AD.6888.01", "Ion homeostasis"], ["TCGA.AD.6888.01", "Interleukin-10 signaling"], ["TCGA.AD.6888.01", "Calcitonin-like ligand receptors"], ["TCGA.AD.6888.01", "Nervous system development"], ["TCGA.AD.6888.01", "Activation of SMO"], ["TCGA.AD.6888.01", "L1CAM interactions"], ["TCGA.AD.6888.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AD.6888.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AD.6888.01", "Presynaptic function of Kainate receptors"], ["TCGA.AD.6888.01", "TNFs bind their physiological receptors"], ["TCGA.AD.6888.01", "FGFR4 ligand binding and activation"], ["TCGA.AD.6888.01", "Metabolism of fat-soluble vitamins"], ["TCGA.AD.6888.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], ["TCGA.AD.6888.01", "Retinoid metabolism and transport"], ["TCGA.AD.6888.01", "CD22 mediated BCR regulation"], ["TCGA.AD.6888.01", "IRS-related events triggered by IGF1R"], ["TCGA.AD.6888.01", "GPER1 signaling"], ["TCGA.AD.6888.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AD.6888.01", "GABA B receptor activation"], ["TCGA.AD.6888.01", "Activation of GABAB receptors"], ["TCGA.AD.6888.01", "Axon guidance"], ["TCGA.AD.6888.01", "Keratan sulfate/keratin metabolism"], ["TCGA.AD.6888.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AD.6888.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AD.6888.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AD.6888.01", "Other interleukin signaling"], ["TCGA.AD.6888.01", "Degradation of the extracellular matrix"], ["TCGA.AD.6888.01", "Costimulation by the CD28 family"], ["TCGA.AD.6888.01", "Signaling by Receptor Tyrosine Kinases"], ["TCGA.AD.6888.01", "IGF1R signaling cascade"], ["TCGA.AD.6888.01", "Inwardly rectifying K+ channels"], ["TCGA.AD.6888.01", "ERK1/ERK2 pathway"], ["TCGA.AD.6888.01", "FGFR1 ligand binding and activation"], ["TCGA.AD.6888.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.AD.6888.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AD.6888.01", "Scavenging by Class A Receptors"], ["TCGA.AD.6888.01", "Other semaphorin interactions"], ["TCGA.AD.6888.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AD.6888.01", "Calmodulin induced events"], ["TCGA.AD.6888.01", "CaM pathway"], ["TCGA.AD.6888.01", "Platelet activation, signaling and aggregation"], ["TCGA.AD.6888.01", "Biological oxidations"], ["TCGA.AD.6888.01", "Adaptive Immune System"], ["TCGA.AD.6888.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AD.6888.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AD.6888.01", "FCGR activation"], ["TCGA.AD.6888.01", "MAPK family signaling cascades"], ["TCGA.AD.6888.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.AD.6888.01", "RAF/MAP kinase cascade"], ["TCGA.AD.6888.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AD.6888.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.AD.6888.01", "Phospholipase C-mediated cascade: FGFR1"], ["TCGA.AD.6888.01", "FGFR2 ligand binding and activation"], ["TCGA.AD.6888.01", "Insulin processing"], ["TCGA.AD.6888.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AD.6888.01", "Blood group systems biosynthesis"], ["TCGA.AD.6888.01", "Sialic acid metabolism"], ["TCGA.AD.6888.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AD.6888.01", "ECM proteoglycans"], ["TCGA.AD.6888.01", "Ca-dependent events"], ["TCGA.AD.6888.01", "DAP12 interactions"], ["TCGA.AD.6888.01", "DAP12 signaling"], ["TCGA.AD.6888.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AD.6899.01", "Extracellular matrix organization"], ["TCGA.AD.6899.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AD.6899.01", "Collagen formation"], ["TCGA.AD.6899.01", "Biological oxidations"], ["TCGA.AD.6899.01", "Ethanol oxidation"], ["TCGA.AD.6899.01", "Interaction between L1 and Ankyrins"], ["TCGA.AD.6899.01", "Phase II - Conjugation of compounds"], ["TCGA.AD.6899.01", "RA biosynthesis pathway"], ["TCGA.AD.6899.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AD.6899.01", "Signaling by Retinoic Acid"], ["TCGA.AD.6899.01", "Degradation of the extracellular matrix"], ["TCGA.AD.6899.01", "Stimuli-sensing channels"], ["TCGA.AD.6899.01", "O-linked glycosylation"], ["TCGA.AD.6899.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AD.6899.01", "Drug ADME"], ["TCGA.AD.6899.01", "GPCR ligand binding"], ["TCGA.AD.A5EK.01", "Neuronal System"], ["TCGA.AD.A5EK.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AD.A5EK.01", "Potassium Channels"], ["TCGA.AD.A5EK.01", "Signaling by GPCR"], ["TCGA.AD.A5EK.01", "GPCR downstream signalling"], ["TCGA.AD.A5EK.01", "G alpha (i) signalling events"], ["TCGA.AD.A5EK.01", "Regulation of insulin secretion"], ["TCGA.AD.A5EK.01", "Integration of energy metabolism"], ["TCGA.AD.A5EK.01", "GPCR ligand binding"], ["TCGA.AD.A5EK.01", "RA biosynthesis pathway"], ["TCGA.AD.A5EK.01", "Transport of small molecules"], ["TCGA.AD.A5EK.01", "Cardiac conduction"], ["TCGA.AD.A5EK.01", "Biological oxidations"], ["TCGA.AD.A5EK.01", "Signaling Pathways"], ["TCGA.AD.A5EK.01", "Transmission across Chemical Synapses"], ["TCGA.AD.A5EK.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AD.A5EK.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AD.A5EK.01", "Ion channel transport"], ["TCGA.AD.A5EK.01", "Complement cascade"], ["TCGA.AD.A5EK.01", "Extracellular matrix organization"], ["TCGA.AD.A5EK.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AD.A5EK.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AD.A5EK.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AD.A5EK.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AD.A5EK.01", "Initial triggering of complement"], ["TCGA.AD.A5EK.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.AD.A5EK.01", "Arachidonic acid metabolism"], ["TCGA.AD.A5EK.01", "Leishmania infection"], ["TCGA.AD.A5EK.01", "Peptide ligand-binding receptors"], ["TCGA.AD.A5EK.01", "Stimuli-sensing channels"], ["TCGA.AD.A5EK.01", "Chemokine receptors bind chemokines"], ["TCGA.AD.A5EK.01", "G alpha (q) signalling events"], ["TCGA.AD.A5EK.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AD.A5EK.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AD.A5EK.01", "Inwardly rectifying K+ channels"], ["TCGA.AD.A5EK.01", "Signaling by Retinoic Acid"], ["TCGA.AD.A5EK.01", "Peptide hormone metabolism"], ["TCGA.AD.A5EK.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AD.A5EK.01", "Leishmania parasite growth and survival"], ["TCGA.AD.A5EK.01", "Regulation of Complement cascade"], ["TCGA.AD.A5EK.01", "Other semaphorin interactions"], ["TCGA.AD.A5EK.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AD.A5EK.01", "Glucagon-type ligand receptors"], ["TCGA.AD.A5EK.01", "CD22 mediated BCR regulation"], ["TCGA.AD.A5EK.01", "Platelet homeostasis"], ["TCGA.AD.A5EK.01", "Activation of G protein gated Potassium channels"], ["TCGA.AD.A5EK.01", "G protein gated Potassium channels"], ["TCGA.AD.A5EK.01", "Interaction between L1 and Ankyrins"], ["TCGA.AD.A5EK.01", "Phase 0 - rapid depolarisation"], ["TCGA.AD.A5EK.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.AD.A5EK.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AD.A5EK.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AD.A5EK.01", "Blood group systems biosynthesis"], ["TCGA.AD.A5EK.01", "Phase II - Conjugation of compounds"], ["TCGA.AD.A5EK.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AD.A5EK.01", "GABA receptor activation"], ["TCGA.AD.A5EK.01", "PD-1 signaling"], ["TCGA.AD.A5EK.01", "G alpha (s) signalling events"], ["TCGA.AD.A5EK.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.AD.A5EK.01", "G-protein beta:gamma signalling"], ["TCGA.AD.A5EK.01", "Sensory processing of sound"], ["TCGA.AD.A5EK.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AD.A5EK.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AD.A5EK.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AD.A5EK.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.AD.A5EK.01", "Muscle contraction"], ["TCGA.AD.A5EK.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.AD.A5EK.01", "Phase I - Functionalization of compounds"], ["TCGA.AD.A5EK.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AD.A5EK.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AD.A5EK.01", "Post-translational protein phosphorylation"], ["TCGA.AD.A5EK.01", "Classical antibody-mediated complement activation"], ["TCGA.AD.A5EK.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AD.A5EK.01", "Integrin cell surface interactions"], ["TCGA.AD.A5EK.01", "Voltage gated Potassium channels"], ["TCGA.AD.A5EK.01", "GABA B receptor activation"], ["TCGA.AD.A5EK.01", "Activation of GABAB receptors"], ["TCGA.AD.A5EK.01", "G beta:gamma signalling through BTK"], ["TCGA.AD.A5EK.01", "Lewis blood group biosynthesis"], ["TCGA.AD.A5EK.01", "Sialic acid metabolism"], ["TCGA.AD.A5EK.01", "Diseases of Immune System"], ["TCGA.AD.A5EK.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AD.A5EK.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AD.A5EK.01", "Creation of C4 and C2 activators"], ["TCGA.AD.A5EK.01", "SLC-mediated transmembrane transport"], ["TCGA.AD.A5EK.01", "Aquaporin-mediated transport"], ["TCGA.AM.5820.01", "Generation of second messenger molecules"], ["TCGA.AM.5820.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AM.5820.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AM.5820.01", "PD-1 signaling"], ["TCGA.AM.5820.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AM.5820.01", "Signaling by GPCR"], ["TCGA.AM.5820.01", "GPCR ligand binding"], ["TCGA.AM.5820.01", "GPCR downstream signalling"], ["TCGA.AM.5820.01", "G alpha (i) signalling events"], ["TCGA.AM.5820.01", "Costimulation by the CD28 family"], ["TCGA.AM.5820.01", "Neuronal System"], ["TCGA.AM.5820.01", "Chemokine receptors bind chemokines"], ["TCGA.AM.5820.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AM.5820.01", "TCR signaling"], ["TCGA.AM.5820.01", "Immune System"], ["TCGA.AM.5820.01", "Peptide ligand-binding receptors"], ["TCGA.AM.5820.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AM.5820.01", "Extracellular matrix organization"], ["TCGA.AM.5820.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AM.5820.01", "Signaling Pathways"], ["TCGA.AM.5820.01", "TNFs bind their physiological receptors"], ["TCGA.AM.5820.01", "Transmission across Chemical Synapses"], ["TCGA.AM.5820.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.AM.5820.01", "Blood group systems biosynthesis"], ["TCGA.AM.5820.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AM.5820.01", "FOXO-mediated transcription"], ["TCGA.AM.5820.01", "Protein-protein interactions at synapses"], ["TCGA.AM.5820.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.AM.5820.01", "O-linked glycosylation"], ["TCGA.AM.5820.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], ["TCGA.AM.5820.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AM.5820.01", "Defective B3GALTL causes PpS"], ["TCGA.AM.5820.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.AM.5820.01", "MHC class II antigen presentation"], ["TCGA.AM.5820.01", "Inwardly rectifying K+ channels"], ["TCGA.AM.5820.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AM.5820.01", "Activation of G protein gated Potassium channels"], ["TCGA.AM.5820.01", "G protein gated Potassium channels"], ["TCGA.AM.5820.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AM.5820.01", "Lewis blood group biosynthesis"], ["TCGA.AM.5820.01", "Transport of small molecules"], ["TCGA.AM.5820.01", "GABA receptor activation"], ["TCGA.AM.5820.01", "ABC transporters in lipid homeostasis"], ["TCGA.AM.5820.01", "Adaptive Immune System"], ["TCGA.AM.5820.01", "Signaling by Activin"], ["TCGA.AM.5820.01", "Response of EIF2AK1 (HRI) to heme deficiency"], ["TCGA.AM.5820.01", "Signaling by NODAL"], ["TCGA.AM.5820.01", "RA biosynthesis pathway"], ["TCGA.AM.5820.01", "Synaptic adhesion-like molecules"], ["TCGA.AM.5820.01", "Digestion"], ["TCGA.AM.5820.01", "FOXO-mediated transcription of cell death genes"], ["TCGA.AM.5820.01", "Downstream TCR signaling"], ["TCGA.AM.5820.01", "Neurexins and neuroligins"], ["TCGA.AM.5820.01", "Cytokine Signaling in Immune system"], ["TCGA.AM.5820.01", "Potassium Channels"], ["TCGA.AM.5820.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AM.5820.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AM.5820.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AM.5820.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AM.5820.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.AM.5820.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AU.6004.01", "Extracellular matrix organization"], ["TCGA.AU.6004.01", "Neuronal System"], ["TCGA.AU.6004.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AU.6004.01", "Degradation of the extracellular matrix"], ["TCGA.AU.6004.01", "Transport of small molecules"], ["TCGA.AU.6004.01", "Transmission across Chemical Synapses"], ["TCGA.AU.6004.01", "Phase II - Conjugation of compounds"], ["TCGA.AU.6004.01", "Collagen formation"], ["TCGA.AU.6004.01", "Biological oxidations"], ["TCGA.AU.6004.01", "Drug ADME"], ["TCGA.AU.6004.01", "Stimuli-sensing channels"], ["TCGA.AU.6004.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AU.6004.01", "GPCR ligand binding"], ["TCGA.AU.6004.01", "SLC-mediated transmembrane transport"], ["TCGA.AU.6004.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AU.6004.01", "Ion channel transport"], ["TCGA.AU.6004.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AU.6004.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AU.6004.01", "Potassium Channels"], ["TCGA.AU.6004.01", "Developmental Biology"], ["TCGA.AU.6004.01", "L1CAM interactions"], ["TCGA.AU.6004.01", "NCAM1 interactions"], ["TCGA.AU.6004.01", "Integration of energy metabolism"], ["TCGA.AU.6004.01", "Peptide hormone metabolism"], ["TCGA.AU.6004.01", "Neurexins and neuroligins"], ["TCGA.AU.6004.01", "NCAM signaling for neurite out-growth"], ["TCGA.AU.6004.01", "Cardiac conduction"], ["TCGA.AU.6004.01", "Protein-protein interactions at synapses"], ["TCGA.AU.6004.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AU.6004.01", "Regulation of insulin secretion"], ["TCGA.AU.6004.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AU.6004.01", "Regulation of gene expression in beta cells"], ["TCGA.AU.6004.01", "Signaling by GPCR"], ["TCGA.AU.6004.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AU.6004.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AU.6004.01", "Integrin cell surface interactions"], ["TCGA.AU.6004.01", "Collagen degradation"], ["TCGA.AY.4070.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AY.4070.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AY.4070.01", "Blood group systems biosynthesis"], ["TCGA.AY.4070.01", "SLC-mediated transmembrane transport"], ["TCGA.AY.4070.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AY.4070.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AY.4070.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.AY.4070.01", "Visual phototransduction"], ["TCGA.AY.4070.01", "Lewis blood group biosynthesis"], ["TCGA.AY.4070.01", "Post-translational protein phosphorylation"], ["TCGA.AY.4070.01", "Interaction between L1 and Ankyrins"], ["TCGA.AY.4070.01", "Aspartate and asparagine metabolism"], ["TCGA.AY.4070.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AY.4070.01", "GPCR ligand binding"], ["TCGA.AY.4070.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AY.4070.01", "Glucuronidation"], ["TCGA.AY.4070.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AY.6196.01", "Extracellular matrix organization"], ["TCGA.AY.6196.01", "Biological oxidations"], ["TCGA.AY.6196.01", "Collagen formation"], ["TCGA.AY.6196.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AY.6196.01", "SLC-mediated transmembrane transport"], ["TCGA.AY.6196.01", "Transport of small molecules"], ["TCGA.AY.6196.01", "Collagen chain trimerization"], ["TCGA.AY.6196.01", "Metabolism"], ["TCGA.AY.6196.01", "Drug ADME"], ["TCGA.AY.6196.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AY.6196.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AY.6196.01", "O-linked glycosylation"], ["TCGA.AY.6196.01", "Diseases of glycosylation"], ["TCGA.AY.6196.01", "Phase II - Conjugation of compounds"], ["TCGA.AY.6196.01", "Stimuli-sensing channels"], ["TCGA.AY.6196.01", "APAP ADME"], ["TCGA.AY.6196.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AY.6196.01", "Diseases of metabolism"], ["TCGA.AY.6196.01", "Phase I - Functionalization of compounds"], ["TCGA.AY.6196.01", "Degradation of the extracellular matrix"], ["TCGA.AY.6196.01", "Regulation of gene expression in beta cells"], ["TCGA.AY.6196.01", "Triglyceride metabolism"], ["TCGA.AY.6196.01", "Defective B3GALTL causes PpS"], ["TCGA.AY.6196.01", "Triglyceride biosynthesis"], ["TCGA.AY.6196.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AY.6196.01", "Interaction between L1 and Ankyrins"], ["TCGA.AY.6196.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AY.6196.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AY.6196.01", "Defective GALNT12 causes CRCS1"], ["TCGA.AY.6196.01", "Developmental Biology"], ["TCGA.AY.6196.01", "Regulation of beta-cell development"], ["TCGA.AY.6196.01", "Ion channel transport"], ["TCGA.AY.6196.01", "Glucuronidation"], ["TCGA.AY.6196.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AY.6196.01", "Metal ion SLC transporters"], ["TCGA.AY.6196.01", "Digestion"], ["TCGA.AY.6196.01", "ECM proteoglycans"], ["TCGA.AY.6196.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.AY.6196.01", "Surfactant metabolism"], ["TCGA.AY.6196.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AY.6196.01", "O-linked glycosylation of mucins"], ["TCGA.AY.6196.01", "Gastrulation"], ["TCGA.AY.6196.01", "Keratinization"], ["TCGA.AY.6196.01", "Aspirin ADME"], ["TCGA.AY.6196.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AY.6196.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.AY.6196.01", "Integrin cell surface interactions"], ["TCGA.AY.6196.01", "Cobalamin (Cbl, vitamin B12) transport and metabolism"], ["TCGA.AY.6196.01", "Scavenging by Class A Receptors"], ["TCGA.AY.6196.01", "Other semaphorin interactions"], ["TCGA.AY.6196.01", "Peptide ligand-binding receptors"], ["TCGA.AY.6196.01", "Chondroitin sulfate biosynthesis"], ["TCGA.AY.6196.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AY.6196.01", "Blood group systems biosynthesis"], ["TCGA.AY.6196.01", "Defective GALNT3 causes HFTC"], ["TCGA.AY.6196.01", "Nuclear Receptor transcription pathway"], ["TCGA.AY.6196.01", "GPCR ligand binding"], ["TCGA.AY.6196.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AY.6196.01", "Termination of O-glycan biosynthesis"], ["TCGA.AY.6196.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AY.6196.01", "Signaling by Activin"], ["TCGA.AY.6196.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.AY.6196.01", "ERBB2 Regulates Cell Motility"], ["TCGA.AY.6196.01", "Visual phototransduction"], ["TCGA.AY.6197.01", "Neuronal System"], ["TCGA.AY.6197.01", "GPCR ligand binding"], ["TCGA.AY.6197.01", "Signaling by GPCR"], ["TCGA.AY.6197.01", "GPCR downstream signalling"], ["TCGA.AY.6197.01", "Chemokine receptors bind chemokines"], ["TCGA.AY.6197.01", "Transmission across Chemical Synapses"], ["TCGA.AY.6197.01", "Muscle contraction"], ["TCGA.AY.6197.01", "G alpha (i) signalling events"], ["TCGA.AY.6197.01", "L1CAM interactions"], ["TCGA.AY.6197.01", "Peptide ligand-binding receptors"], ["TCGA.AY.6197.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AY.6197.01", "Transport of small molecules"], ["TCGA.AY.6197.01", "Platelet homeostasis"], ["TCGA.AY.6197.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AY.6197.01", "Protein-protein interactions at synapses"], ["TCGA.AY.6197.01", "Ion channel transport"], ["TCGA.AY.6197.01", "Extracellular matrix organization"], ["TCGA.AY.6197.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AY.6197.01", "G alpha (s) signalling events"], ["TCGA.AY.6197.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AY.6197.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AY.6197.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AY.6197.01", "Glycosaminoglycan metabolism"], ["TCGA.AY.6197.01", "Interleukin-10 signaling"], ["TCGA.AY.6197.01", "Diseases of Immune System"], ["TCGA.AY.6197.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AY.6197.01", "O-linked glycosylation"], ["TCGA.AY.6197.01", "Complement cascade"], ["TCGA.AY.6197.01", "Signaling Pathways"], ["TCGA.AY.6197.01", "Biological oxidations"], ["TCGA.AY.6197.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AY.6197.01", "Neurexins and neuroligins"], ["TCGA.AY.6197.01", "Phase II - Conjugation of compounds"], ["TCGA.AY.6197.01", "Regulation of insulin secretion"], ["TCGA.AY.6197.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.AY.6197.01", "Stimuli-sensing channels"], ["TCGA.AY.6197.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AY.6197.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AY.A8YK.01", "Neuronal System"], ["TCGA.AY.A8YK.01", "Signaling by GPCR"], ["TCGA.AY.A8YK.01", "GPCR downstream signalling"], ["TCGA.AY.A8YK.01", "Transmission across Chemical Synapses"], ["TCGA.AY.A8YK.01", "Interaction between L1 and Ankyrins"], ["TCGA.AY.A8YK.01", "G alpha (i) signalling events"], ["TCGA.AY.A8YK.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AY.A8YK.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AY.A8YK.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AY.A8YK.01", "Signaling Pathways"], ["TCGA.AY.A8YK.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AY.A8YK.01", "SLC-mediated transmembrane transport"], ["TCGA.AY.A8YK.01", "Potassium Channels"], ["TCGA.AY.A8YK.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AY.A8YK.01", "Initial triggering of complement"], ["TCGA.AY.A8YK.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.AY.A8YK.01", "Extracellular matrix organization"], ["TCGA.AY.A8YK.01", "Arachidonic acid metabolism"], ["TCGA.AY.A8YK.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AY.A8YK.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AY.A8YK.01", "Diseases of Immune System"], ["TCGA.AY.A8YK.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AY.A8YK.01", "Transport of small molecules"], ["TCGA.AY.A8YK.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.AY.A8YK.01", "Biological oxidations"], ["TCGA.AY.A8YK.01", "Amino acid transport across the plasma membrane"], ["TCGA.AY.A8YK.01", "Platelet homeostasis"], ["TCGA.AY.A8YK.01", "Interleukin-10 signaling"], ["TCGA.AY.A8YK.01", "Acetylcholine binding and downstream events"], ["TCGA.AY.A8YK.01", "Postsynaptic nicotinic acetylcholine receptors"], ["TCGA.AY.A8YK.01", "GPCR ligand binding"], ["TCGA.AY.A8YK.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AY.A8YK.01", "Signal amplification"], ["TCGA.AY.A8YK.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AY.A8YK.01", "Complement cascade"], ["TCGA.AY.A8YK.01", "Classical antibody-mediated complement activation"], ["TCGA.AY.A8YK.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AY.A8YK.01", "Glucuronidation"], ["TCGA.AY.A8YK.01", "PD-1 signaling"], ["TCGA.AY.A8YK.01", "RA biosynthesis pathway"], ["TCGA.AY.A8YK.01", "Neurotransmitter release cycle"], ["TCGA.AY.A8YK.01", "Cardiac conduction"], ["TCGA.AY.A8YK.01", "L1CAM interactions"], ["TCGA.AY.A8YK.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AY.A8YK.01", "Ethanol oxidation"], ["TCGA.AY.A8YK.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.AY.A8YK.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AY.A8YK.01", "Voltage gated Potassium channels"], ["TCGA.AY.A8YK.01", "Phase 0 - rapid depolarisation"], ["TCGA.AY.A8YK.01", "TNFs bind their physiological receptors"], ["TCGA.AY.A8YK.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AY.A8YK.01", "Leishmania parasite growth and survival"], ["TCGA.AY.A8YK.01", "Molecules associated with elastic fibres"], ["TCGA.AY.A8YK.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AY.A8YK.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AY.A8YK.01", "Protein-protein interactions at synapses"], ["TCGA.AY.A8YK.01", "Heme degradation"], ["TCGA.AY.A8YK.01", "Regulation of insulin secretion"], ["TCGA.AY.A8YK.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AY.A8YK.01", "G beta:gamma signalling through BTK"], ["TCGA.AY.A8YK.01", "G-protein beta:gamma signalling"], ["TCGA.AY.A8YK.01", "Peptide hormone metabolism"], ["TCGA.AY.A8YK.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AY.A8YK.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AY.A8YK.01", "G alpha (q) signalling events"], ["TCGA.AY.A8YK.01", "Aspirin ADME"], ["TCGA.AY.A8YK.01", "G alpha (z) signalling events"], ["TCGA.AY.A8YK.01", "Degradation of the extracellular matrix"], ["TCGA.AY.A8YK.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AY.A8YK.01", "G beta:gamma signalling through CDC42"], ["TCGA.AY.A8YK.01", "Creation of C4 and C2 activators"], ["TCGA.AY.A8YK.01", "Post-translational protein phosphorylation"], ["TCGA.AY.A8YK.01", "G alpha (s) signalling events"], ["TCGA.AY.A8YK.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AY.A8YK.01", "Regulation of Complement cascade"], ["TCGA.AY.A8YK.01", "Regulation of FZD by ubiquitination"], ["TCGA.AZ.4616.01", "Signaling by GPCR"], ["TCGA.AZ.4616.01", "G alpha (i) signalling events"], ["TCGA.AZ.4616.01", "Neuronal System"], ["TCGA.AZ.4616.01", "GPCR downstream signalling"], ["TCGA.AZ.4616.01", "GPCR ligand binding"], ["TCGA.AZ.4616.01", "Transport of small molecules"], ["TCGA.AZ.4616.01", "Cardiac conduction"], ["TCGA.AZ.4616.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.4616.01", "Drug ADME"], ["TCGA.AZ.4616.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.4616.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AZ.4616.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AZ.4616.01", "Chemokine receptors bind chemokines"], ["TCGA.AZ.4616.01", "Peptide ligand-binding receptors"], ["TCGA.AZ.4616.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.4616.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AZ.4616.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AZ.4616.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AZ.4616.01", "Leishmania parasite growth and survival"], ["TCGA.AZ.4616.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AZ.4616.01", "Platelet homeostasis"], ["TCGA.AZ.4616.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.4616.01", "Phase 0 - rapid depolarisation"], ["TCGA.AZ.4616.01", "Signaling Pathways"], ["TCGA.AZ.4616.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.4616.01", "PKA activation in glucagon signalling"], ["TCGA.AZ.4616.01", "Extracellular matrix organization"], ["TCGA.AZ.4616.01", "Calmodulin induced events"], ["TCGA.AZ.4616.01", "CaM pathway"], ["TCGA.AZ.4616.01", "Integration of energy metabolism"], ["TCGA.AZ.4616.01", "DAG and IP3 signaling"], ["TCGA.AZ.4616.01", "SLC-mediated transmembrane transport"], ["TCGA.AZ.4616.01", "G alpha (s) signalling events"], ["TCGA.AZ.4616.01", "Ca-dependent events"], ["TCGA.AZ.4616.01", "Muscle contraction"], ["TCGA.AZ.4616.01", "Degradation of the extracellular matrix"], ["TCGA.AZ.4616.01", "G-protein mediated events"], ["TCGA.AZ.4616.01", "PLC beta mediated events"], ["TCGA.AZ.4616.01", "Azathioprine ADME"], ["TCGA.AZ.4616.01", "Aquaporin-mediated transport"], ["TCGA.AZ.4616.01", "Blood group systems biosynthesis"], ["TCGA.AZ.4616.01", "Regulation of insulin secretion"], ["TCGA.AZ.4616.01", "Ion channel transport"], ["TCGA.AZ.4616.01", "G alpha (z) signalling events"], ["TCGA.AZ.4616.01", "Ion homeostasis"], ["TCGA.AZ.4616.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AZ.4616.01", "GPER1 signaling"], ["TCGA.AZ.4616.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AZ.4616.01", "GABA B receptor activation"], ["TCGA.AZ.4616.01", "Activation of GABAB receptors"], ["TCGA.AZ.4616.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AZ.4616.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.4616.01", "Biological oxidations"], ["TCGA.AZ.4616.01", "Potassium Channels"], ["TCGA.AZ.4616.01", "GABA receptor activation"], ["TCGA.AZ.4616.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AZ.4616.01", "Lewis blood group biosynthesis"], ["TCGA.AZ.4616.01", "Leishmania infection"], ["TCGA.AZ.4616.01", "Phase II - Conjugation of compounds"], ["TCGA.AZ.4616.01", "Aspirin ADME"], ["TCGA.AZ.4616.01", "Adenylate cyclase inhibitory pathway"], ["TCGA.AZ.4616.01", "Phase 2 - plateau phase"], ["TCGA.AZ.4616.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AZ.4616.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AZ.4616.01", "L1CAM interactions"], ["TCGA.AZ.4616.01", "Other semaphorin interactions"], ["TCGA.AZ.4616.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.AZ.4616.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AZ.4616.01", "Protein-protein interactions at synapses"], ["TCGA.AZ.4616.01", "Amino acid transport across the plasma membrane"], ["TCGA.AZ.4616.01", "Platelet calcium homeostasis"], ["TCGA.AZ.4616.01", "Peptide hormone metabolism"], ["TCGA.AZ.4616.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AZ.4616.01", "Ion transport by P-type ATPases"], ["TCGA.AZ.4616.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.AZ.4616.01", "Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3"], ["TCGA.AZ.4616.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.AZ.4681.01", "Binding and entry of HIV virion"], ["TCGA.AZ.4681.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AZ.4681.01", "Immune System"], ["TCGA.AZ.4681.01", "rRNA processing"], ["TCGA.AZ.4681.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AZ.4681.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.AZ.4681.01", "Cellular response to starvation"], ["TCGA.AZ.4681.01", "Viral mRNA Translation"], ["TCGA.AZ.4681.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.AZ.4681.01", "Eukaryotic Translation Elongation"], ["TCGA.AZ.4681.01", "Eukaryotic Translation Termination"], ["TCGA.AZ.4681.01", "Formation of a pool of free 40S subunits"], ["TCGA.AZ.4681.01", "Peptide chain elongation"], ["TCGA.AZ.4681.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AZ.4681.01", "Leishmania parasite growth and survival"], ["TCGA.AZ.4681.01", "G-protein beta:gamma signalling"], ["TCGA.AZ.4681.01", "Selenocysteine synthesis"], ["TCGA.AZ.4681.01", "G alpha (i) signalling events"], ["TCGA.AZ.4681.01", "Selenoamino acid metabolism"], ["TCGA.AZ.4681.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AZ.4681.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.AZ.4681.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.AZ.4681.01", "Regulation of insulin secretion"], ["TCGA.AZ.4681.01", "Signaling Pathways"], ["TCGA.AZ.4681.01", "G beta:gamma signalling through CDC42"], ["TCGA.AZ.4681.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.AZ.4681.01", "Leishmania infection"], ["TCGA.AZ.4681.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.AZ.4681.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.AZ.4681.01", "Azathioprine ADME"], ["TCGA.AZ.4681.01", "Nervous system development"], ["TCGA.AZ.4681.01", "Integration of energy metabolism"], ["TCGA.AZ.4681.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AZ.4681.01", "Eukaryotic Translation Initiation"], ["TCGA.AZ.4681.01", "Cap-dependent Translation Initiation"], ["TCGA.AZ.4681.01", "G alpha (z) signalling events"], ["TCGA.AZ.4681.01", "Influenza Infection"], ["TCGA.AZ.4681.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AZ.4681.01", "GPER1 signaling"], ["TCGA.AZ.4681.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.AZ.4681.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.AZ.4681.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.AZ.4681.01", "Axon guidance"], ["TCGA.AZ.4681.01", "Platelet homeostasis"], ["TCGA.AZ.4681.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.AZ.4681.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.AZ.4681.01", "Interleukin-10 signaling"], ["TCGA.AZ.4681.01", "Cell surface interactions at the vascular wall"], ["TCGA.AZ.4681.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AZ.4681.01", "Chemokine receptors bind chemokines"], ["TCGA.AZ.4681.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.AZ.4681.01", "B Cell Activation"], ["TCGA.AZ.4681.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.AZ.4681.01", "Infectious disease"], ["TCGA.AZ.4681.01", "Molecules associated with elastic fibres"], ["TCGA.AZ.4681.01", "GPCR downstream signalling"], ["TCGA.AZ.4681.01", "G-protein activation"], ["TCGA.AZ.4681.01", "Diseases of Immune System"], ["TCGA.AZ.4681.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.AZ.4681.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.AZ.4681.01", "Aquaporin-mediated transport"], ["TCGA.AZ.4681.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AZ.4681.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AZ.4681.01", "Translesion synthesis by POLK"], ["TCGA.AZ.4681.01", "Translesion synthesis by POLI"], ["TCGA.AZ.4681.01", "Cytokine Signaling in Immune system"], ["TCGA.AZ.4681.01", "Early Phase of HIV Life Cycle"], ["TCGA.AZ.4681.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AZ.4681.01", "CD22 mediated BCR regulation"], ["TCGA.AZ.4681.01", "Extra-nuclear estrogen signaling"], ["TCGA.AZ.4681.01", "Protein folding"], ["TCGA.AZ.4681.01", "CD28 dependent PI3K/Akt signaling"], ["TCGA.AZ.4681.01", "Innate Immune System"], ["TCGA.AZ.4681.01", "Developmental Biology"], ["TCGA.AZ.4681.01", "Regulation of TLR by endogenous ligand"], ["TCGA.AZ.4681.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.AZ.6598.01", "Neuronal System"], ["TCGA.AZ.6598.01", "G alpha (i) signalling events"], ["TCGA.AZ.6598.01", "Signaling by GPCR"], ["TCGA.AZ.6598.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.6598.01", "GPCR downstream signalling"], ["TCGA.AZ.6598.01", "GPCR ligand binding"], ["TCGA.AZ.6598.01", "Transport of small molecules"], ["TCGA.AZ.6598.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AZ.6598.01", "Cardiac conduction"], ["TCGA.AZ.6598.01", "Extracellular matrix organization"], ["TCGA.AZ.6598.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.6598.01", "Phase 0 - rapid depolarisation"], ["TCGA.AZ.6598.01", "Protein-protein interactions at synapses"], ["TCGA.AZ.6598.01", "NCAM1 interactions"], ["TCGA.AZ.6598.01", "Peptide ligand-binding receptors"], ["TCGA.AZ.6598.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.6598.01", "Regulation of insulin secretion"], ["TCGA.AZ.6598.01", "Ion homeostasis"], ["TCGA.AZ.6598.01", "Signaling Pathways"], ["TCGA.AZ.6598.01", "Muscle contraction"], ["TCGA.AZ.6598.01", "Neurexins and neuroligins"], ["TCGA.AZ.6598.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AZ.6598.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AZ.6598.01", "Integration of energy metabolism"], ["TCGA.AZ.6598.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.6598.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AZ.6598.01", "Biological oxidations"], ["TCGA.AZ.6598.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.AZ.6598.01", "Collagen chain trimerization"], ["TCGA.AZ.6598.01", "Calmodulin induced events"], ["TCGA.AZ.6598.01", "CaM pathway"], ["TCGA.AZ.6598.01", "Long-term potentiation"], ["TCGA.AZ.6598.01", "DAG and IP3 signaling"], ["TCGA.AZ.6598.01", "L1CAM interactions"], ["TCGA.AZ.6598.01", "Bile acid and bile salt metabolism"], ["TCGA.AZ.6598.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AZ.6598.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.AZ.6598.01", "NCAM signaling for neurite out-growth"], ["TCGA.AZ.6598.01", "Ca-dependent events"], ["TCGA.AZ.6598.01", "RA biosynthesis pathway"], ["TCGA.AZ.6598.01", "Drug ADME"], ["TCGA.AZ.6598.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AZ.6598.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AZ.6598.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AZ.6598.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AZ.6598.01", "G-protein mediated events"], ["TCGA.AZ.6598.01", "PLC beta mediated events"], ["TCGA.AZ.6598.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.6598.01", "G alpha (q) signalling events"], ["TCGA.AZ.6598.01", "G alpha (s) signalling events"], ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts"], ["TCGA.AZ.6598.01", "CD22 mediated BCR regulation"], ["TCGA.AZ.6598.01", "SLC-mediated transmembrane transport"], ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.AZ.6598.01", "ERBB2 Regulates Cell Motility"], ["TCGA.AZ.6598.01", "GABA receptor activation"], ["TCGA.AZ.6598.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AZ.6598.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AZ.6598.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AZ.6598.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AZ.6598.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.6598.01", "Arachidonic acid metabolism"], ["TCGA.AZ.6598.01", "Peptide hormone metabolism"], ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AZ.6598.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AZ.6598.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AZ.6598.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AZ.6598.01", "Degradation of the extracellular matrix"], ["TCGA.AZ.6598.01", "Collagen formation"], ["TCGA.AZ.6598.01", "GRB2 events in ERBB2 signaling"], ["TCGA.AZ.6598.01", "PI3K events in ERBB2 signaling"], ["TCGA.AZ.6598.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AZ.6598.01", "Stimuli-sensing channels"], ["TCGA.AZ.6598.01", "Amino acid transport across the plasma membrane"], ["TCGA.AZ.6598.01", "Glucuronidation"], ["TCGA.AZ.6598.01", "Synaptic adhesion-like molecules"], ["TCGA.AZ.6598.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.AZ.6600.01", "Extracellular matrix organization"], ["TCGA.AZ.6600.01", "Collagen formation"], ["TCGA.AZ.6600.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AZ.6600.01", "Glucuronidation"], ["TCGA.AZ.6600.01", "Keratinization"], ["TCGA.AZ.6600.01", "Collagen chain trimerization"], ["TCGA.AZ.6600.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AZ.6600.01", "Biological oxidations"], ["TCGA.AZ.6600.01", "Phase II - Conjugation of compounds"], ["TCGA.AZ.6600.01", "Aspirin ADME"], ["TCGA.AZ.6600.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.6600.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.6600.01", "Formation of the cornified envelope"], ["TCGA.AZ.6600.01", "Antimicrobial peptides"], ["TCGA.AZ.6600.01", "GPCR ligand binding"], ["TCGA.AZ.6600.01", "Drug ADME"], ["TCGA.AZ.6600.01", "G alpha (i) signalling events"], ["TCGA.AZ.6600.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AZ.6600.01", "Transport of small molecules"], ["TCGA.AZ.6600.01", "G alpha (s) signalling events"], ["TCGA.AZ.6600.01", "Signaling by GPCR"], ["TCGA.AZ.6600.01", "Inwardly rectifying K+ channels"], ["TCGA.AZ.6600.01", "mitochondrial fatty acid beta-oxidation of saturated fatty acids"], ["TCGA.AZ.6600.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], ["TCGA.AZ.6600.01", "Metabolism"], ["TCGA.AZ.6600.01", "Ethanol oxidation"], ["TCGA.AZ.6600.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AZ.6600.01", "GPCR downstream signalling"], ["TCGA.AZ.6600.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.6600.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AZ.6600.01", "Sensory perception of taste"], ["TCGA.AZ.6600.01", "Degradation of the extracellular matrix"], ["TCGA.AZ.6600.01", "Physiological factors"], ["TCGA.AZ.6600.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.6600.01", "Peptide ligand-binding receptors"], ["TCGA.AZ.6600.01", "Cardiac conduction"], ["TCGA.AZ.6600.01", "Signal amplification"], ["TCGA.AZ.6600.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AZ.6600.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.6600.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AZ.6600.01", "NCAM signaling for neurite out-growth"], ["TCGA.AZ.6600.01", "Mitochondrial Fatty Acid Beta-Oxidation"], ["TCGA.AZ.6600.01", "ABC transporters in lipid homeostasis"], ["TCGA.AZ.6600.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], ["TCGA.AZ.6600.01", "Glycogen synthesis"], ["TCGA.AZ.6603.01", "Biological oxidations"], ["TCGA.AZ.6603.01", "Phase II - Conjugation of compounds"], ["TCGA.AZ.6603.01", "Neuronal System"], ["TCGA.AZ.6603.01", "Glucuronidation"], ["TCGA.AZ.6603.01", "Ethanol oxidation"], ["TCGA.AZ.6603.01", "Drug ADME"], ["TCGA.AZ.6603.01", "GPCR ligand binding"], ["TCGA.AZ.6603.01", "Transport of small molecules"], ["TCGA.AZ.6603.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AZ.6603.01", "Stimuli-sensing channels"], ["TCGA.AZ.6603.01", "Signaling by GPCR"], ["TCGA.AZ.6603.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AZ.6603.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.6603.01", "NCAM signaling for neurite out-growth"], ["TCGA.AZ.6603.01", "GPCR downstream signalling"], ["TCGA.AZ.6603.01", "Peptide hormone metabolism"], ["TCGA.AZ.6603.01", "Ion channel transport"], ["TCGA.AZ.6603.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AZ.6603.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AZ.6603.01", "Signaling by Retinoic Acid"], ["TCGA.AZ.6603.01", "Signal amplification"], ["TCGA.AZ.6603.01", "G alpha (q) signalling events"], ["TCGA.AZ.6603.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.6603.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.AZ.6603.01", "Extracellular matrix organization"], ["TCGA.AZ.6603.01", "G alpha (s) signalling events"], ["TCGA.AZ.6603.01", "Regulation of insulin secretion"], ["TCGA.AZ.6603.01", "Metabolism"], ["TCGA.AZ.6603.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AZ.6606.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AZ.6606.01", "Cardiac conduction"], ["TCGA.AZ.6606.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.6606.01", "Ion channel transport"], ["TCGA.AZ.6606.01", "Signaling by GPCR"], ["TCGA.AZ.6606.01", "GPCR downstream signalling"], ["TCGA.AZ.6606.01", "Neuronal System"], ["TCGA.AZ.6606.01", "G alpha (i) signalling events"], ["TCGA.AZ.6606.01", "Transport of small molecules"], ["TCGA.AZ.6606.01", "Stimuli-sensing channels"], ["TCGA.AZ.6606.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AZ.6606.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AZ.6606.01", "Platelet homeostasis"], ["TCGA.AZ.6606.01", "GPCR ligand binding"], ["TCGA.AZ.6606.01", "Muscle contraction"], ["TCGA.AZ.6606.01", "PD-1 signaling"], ["TCGA.AZ.6606.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AZ.6606.01", "Extracellular matrix organization"], ["TCGA.AZ.6606.01", "Biological oxidations"], ["TCGA.AZ.6606.01", "Generation of second messenger molecules"], ["TCGA.AZ.6606.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.6606.01", "Developmental Biology"], ["TCGA.AZ.6606.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.6606.01", "Classical antibody-mediated complement activation"], ["TCGA.AZ.6606.01", "G alpha (s) signalling events"], ["TCGA.AZ.6606.01", "Keratinization"], ["TCGA.AZ.6606.01", "Protein-protein interactions at synapses"], ["TCGA.AZ.6606.01", "Peptide ligand-binding receptors"], ["TCGA.AZ.6606.01", "L1CAM interactions"], ["TCGA.AZ.6606.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AZ.6606.01", "Creation of C4 and C2 activators"], ["TCGA.AZ.6606.01", "Molecules associated with elastic fibres"], ["TCGA.AZ.6606.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.6606.01", "Ethanol oxidation"], ["TCGA.AZ.6606.01", "Other semaphorin interactions"], ["TCGA.AZ.6606.01", "Sialic acid metabolism"], ["TCGA.AZ.6606.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.6606.01", "Ion homeostasis"], ["TCGA.AZ.6606.01", "Phase 0 - rapid depolarisation"], ["TCGA.AZ.6606.01", "Potassium Channels"], ["TCGA.AZ.6606.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.6606.01", "Initial triggering of complement"], ["TCGA.AZ.6606.01", "Amino acid transport across the plasma membrane"], ["TCGA.AZ.6606.01", "Cell surface interactions at the vascular wall"], ["TCGA.AZ.6606.01", "Synaptic adhesion-like molecules"], ["TCGA.AZ.6606.01", "G-protein beta:gamma signalling"], ["TCGA.AZ.6606.01", "Activation of SMO"], ["TCGA.AZ.6606.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AZ.6606.01", "Arachidonic acid metabolism"], ["TCGA.AZ.6606.01", "Phase I - Functionalization of compounds"], ["TCGA.AZ.6606.01", "Other interleukin signaling"], ["TCGA.AZ.6606.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AZ.6606.01", "Complement cascade"], ["TCGA.AZ.6607.01", "Extracellular matrix organization"], ["TCGA.AZ.6607.01", "Collagen formation"], ["TCGA.AZ.6607.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AZ.6607.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.AZ.6607.01", "Collagen chain trimerization"], ["TCGA.AZ.6607.01", "ECM proteoglycans"], ["TCGA.AZ.6607.01", "Biological oxidations"], ["TCGA.AZ.6607.01", "Ethanol oxidation"], ["TCGA.AZ.6607.01", "Metabolism"], ["TCGA.AZ.6607.01", "Integrin cell surface interactions"], ["TCGA.AZ.6607.01", "Degradation of the extracellular matrix"], ["TCGA.AZ.6607.01", "Transport of small molecules"], ["TCGA.AZ.6607.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.6607.01", "Phase I - Functionalization of compounds"], ["TCGA.AZ.6607.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AZ.6607.01", "Molecules associated with elastic fibres"], ["TCGA.AZ.6607.01", "Laminin interactions"], ["TCGA.AZ.6607.01", "Drug ADME"], ["TCGA.AZ.6607.01", "Elastic fibre formation"], ["TCGA.AZ.6607.01", "SLC-mediated transmembrane transport"], ["TCGA.AZ.6607.01", "Signaling by PDGF"], ["TCGA.AZ.6607.01", "NCAM1 interactions"], ["TCGA.AZ.6607.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AZ.6607.01", "Collagen degradation"], ["TCGA.AZ.6607.01", "Phase 2 - plateau phase"], ["TCGA.AZ.6607.01", "Phase II - Conjugation of compounds"], ["TCGA.AZ.6607.01", "Glycosaminoglycan metabolism"], ["TCGA.AZ.6607.01", "Non-integrin membrane-ECM interactions"], ["TCGA.AZ.6607.01", "Stimuli-sensing channels"], ["TCGA.AZ.6607.01", "Ion channel transport"], ["TCGA.AZ.6607.01", "Chondroitin sulfate biosynthesis"], ["TCGA.AZ.6607.01", "WNT ligand biogenesis and trafficking"], ["TCGA.AZ.6607.01", "Keratinization"], ["TCGA.AZ.6607.01", "GPCR ligand binding"], ["TCGA.AZ.6607.01", "TGF-beta receptor signaling activates SMADs"], ["TCGA.AZ.6607.01", "Digestion and absorption"], ["TCGA.AZ.6607.01", "Bile acid and bile salt metabolism"], ["TCGA.AZ.6607.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AZ.6607.01", "Defective B3GALTL causes PpS"], ["TCGA.AZ.6607.01", "Cellular hexose transport"], ["TCGA.AZ.6607.01", "MET activates PTK2 signaling"], ["TCGA.AZ.6607.01", "Inwardly rectifying K+ channels"], ["TCGA.AZ.6607.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AZ.6607.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AZ.6607.01", "mitochondrial fatty acid beta-oxidation of saturated fatty acids"], ["TCGA.AZ.6607.01", "Chondroitin sulfate/dermatan sulfate metabolism"], ["TCGA.AZ.6607.01", "NCAM signaling for neurite out-growth"], ["TCGA.AZ.6607.01", "Syndecan interactions"], ["TCGA.AZ.6607.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AZ.6607.01", "Metabolism of fat-soluble vitamins"], ["TCGA.AZ.6607.01", "Retinoid metabolism and transport"], ["TCGA.AZ.6607.01", "Neuronal System"], ["TCGA.AZ.6607.01", "Signaling by GPCR"], ["TCGA.AZ.6607.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AZ.6607.01", "Digestion"], ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts"], ["TCGA.AZ.6607.01", "Diseases of glycosylation"], ["TCGA.AZ.6607.01", "Signaling by Retinoic Acid"], ["TCGA.AZ.6607.01", "Signaling Pathways"], ["TCGA.AZ.6607.01", "Metal ion SLC transporters"], ["TCGA.AZ.6607.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AZ.6607.01", "Glutathione synthesis and recycling"], ["TCGA.AZ.6607.01", "Carnitine metabolism"], ["TCGA.AZ.6607.01", "Fatty acid metabolism"], ["TCGA.AZ.6607.01", "Regulation of insulin secretion"], ["TCGA.AZ.6607.01", "Activation of G protein gated Potassium channels"], ["TCGA.AZ.6607.01", "G protein gated Potassium channels"], ["TCGA.AZ.6607.01", "Phase 0 - rapid depolarisation"], ["TCGA.AZ.6607.01", "MET promotes cell motility"], ["TCGA.AZ.6607.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.AZ.6607.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AZ.6607.01", "APAP ADME"], ["TCGA.AZ.6608.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.AZ.6608.01", "Neuronal System"], ["TCGA.AZ.6608.01", "Signaling by GPCR"], ["TCGA.AZ.6608.01", "GPCR downstream signalling"], ["TCGA.AZ.6608.01", "G alpha (i) signalling events"], ["TCGA.AZ.6608.01", "Signaling Pathways"], ["TCGA.AZ.6608.01", "Platelet homeostasis"], ["TCGA.AZ.6608.01", "GPCR ligand binding"], ["TCGA.AZ.6608.01", "Transmission across Chemical Synapses"], ["TCGA.AZ.6608.01", "Extracellular matrix organization"], ["TCGA.AZ.6608.01", "Cardiac conduction"], ["TCGA.AZ.6608.01", "Generation of second messenger molecules"], ["TCGA.AZ.6608.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.AZ.6608.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.6608.01", "Transport of small molecules"], ["TCGA.AZ.6608.01", "Muscle contraction"], ["TCGA.AZ.6608.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.AZ.6608.01", "Immune System"], ["TCGA.AZ.6608.01", "PD-1 signaling"], ["TCGA.AZ.6608.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.AZ.6608.01", "Potassium Channels"], ["TCGA.AZ.6608.01", "Peptide ligand-binding receptors"], ["TCGA.AZ.6608.01", "Chemokine receptors bind chemokines"], ["TCGA.AZ.6608.01", "Initial triggering of complement"], ["TCGA.AZ.6608.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.AZ.6608.01", "G alpha (s) signalling events"], ["TCGA.AZ.6608.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.AZ.6608.01", "Leishmania parasite growth and survival"], ["TCGA.AZ.6608.01", "G alpha (q) signalling events"], ["TCGA.AZ.6608.01", "Integration of energy metabolism"], ["TCGA.AZ.6608.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AZ.6608.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AZ.6608.01", "Regulation of insulin secretion"], ["TCGA.AZ.6608.01", "G-protein beta:gamma signalling"], ["TCGA.AZ.6608.01", "Classical antibody-mediated complement activation"], ["TCGA.AZ.6608.01", "Complement cascade"], ["TCGA.AZ.6608.01", "Signal amplification"], ["TCGA.AZ.6608.01", "Leishmania infection"], ["TCGA.AZ.6608.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AZ.6608.01", "NCAM1 interactions"], ["TCGA.AZ.6608.01", "Biological oxidations"], ["TCGA.AZ.6608.01", "L1CAM interactions"], ["TCGA.AZ.6608.01", "Glycosaminoglycan metabolism"], ["TCGA.AZ.6608.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.6608.01", "Molecules associated with elastic fibres"], ["TCGA.AZ.6608.01", "Platelet calcium homeostasis"], ["TCGA.AZ.6608.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.AZ.6608.01", "Elastic fibre formation"], ["TCGA.AZ.6608.01", "Ion homeostasis"], ["TCGA.AZ.6608.01", "G-protein activation"], ["TCGA.AZ.6608.01", "Regulation of Complement cascade"], ["TCGA.AZ.6608.01", "Protein-protein interactions at synapses"], ["TCGA.AZ.6608.01", "G beta:gamma signalling through BTK"], ["TCGA.AZ.6608.01", "Ion channel transport"], ["TCGA.AZ.6608.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AZ.6608.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.AZ.6608.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.6608.01", "Post-translational protein phosphorylation"], ["TCGA.AZ.6608.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AZ.6608.01", "Defective B3GALTL causes PpS"], ["TCGA.AZ.6608.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AZ.6608.01", "G beta:gamma signalling through CDC42"], ["TCGA.AZ.6608.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.AZ.6608.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.AZ.6608.01", "Diseases of glycosylation"], ["TCGA.AZ.6608.01", "GABA B receptor activation"], ["TCGA.AZ.6608.01", "Activation of GABAB receptors"], ["TCGA.AZ.6608.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.AZ.6608.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AZ.6608.01", "Thromboxane signalling through TP receptor"], ["TCGA.AZ.6608.01", "Creation of C4 and C2 activators"], ["TCGA.AZ.6608.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AZ.6608.01", "Integrin cell surface interactions"], ["TCGA.AZ.6608.01", "Arachidonic acid metabolism"], ["TCGA.AZ.6608.01", "Neurotransmitter release cycle"], ["TCGA.AZ.6608.01", "Costimulation by the CD28 family"], ["TCGA.AZ.6608.01", "Interleukin-10 signaling"], ["TCGA.AZ.6608.01", "Activation of G protein gated Potassium channels"], ["TCGA.AZ.6608.01", "G protein gated Potassium channels"], ["TCGA.AZ.6608.01", "Phase 0 - rapid depolarisation"], ["TCGA.AZ.6608.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AZ.6608.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AZ.6608.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AZ.6608.01", "Binding and entry of HIV virion"], ["TCGA.AZ.6608.01", "Drug ADME"], ["TCGA.AZ.6608.01", "Developmental Biology"], ["TCGA.AZ.6608.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.AZ.6608.01", "Heme degradation"], ["TCGA.AZ.6608.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], ["TCGA.AZ.6608.01", "Amino acid transport across the plasma membrane"], ["TCGA.AZ.6608.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.AZ.6608.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AZ.6608.01", "Other semaphorin interactions"], ["TCGA.AZ.6608.01", "ECM proteoglycans"], ["TCGA.AZ.6608.01", "Inwardly rectifying K+ channels"], ["TCGA.AZ.6608.01", "Activation of Matrix Metalloproteinases"], ["TCGA.AZ.6608.01", "Cell surface interactions at the vascular wall"], ["TCGA.AZ.6608.01", "NCAM signaling for neurite out-growth"], ["TCGA.AZ.6608.01", "GABA receptor activation"], ["TCGA.AZ.6608.01", "O-linked glycosylation"], ["TCGA.AZ.6608.01", "Phase I - Functionalization of compounds"], ["TCGA.AZ.6608.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AZ.6608.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.AZ.6608.01", "Stimuli-sensing channels"], ["TCGA.AZ.6608.01", "G-protein mediated events"], ["TCGA.AZ.6608.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AZ.6608.01", "Sialic acid metabolism"], ["TCGA.AZ.6608.01", "Glucuronidation"], ["TCGA.AZ.6608.01", "Presynaptic function of Kainate receptors"], ["TCGA.AZ.6608.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.AZ.6608.01", "Keratan sulfate biosynthesis"], ["TCGA.AZ.6608.01", "CD22 mediated BCR regulation"], ["TCGA.AZ.6608.01", "Ethanol oxidation"], ["TCGA.AZ.6608.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AZ.6608.01", "Ca2+ pathway"], ["TCGA.AZ.6608.01", "HS-GAG biosynthesis"], ["TCGA.AZ.6608.01", "Voltage gated Potassium channels"], ["TCGA.AZ.6608.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.AZ.6608.01", "Other interleukin signaling"], ["TCGA.AZ.6608.01", "Phase II - Conjugation of compounds"], ["TCGA.AZ.6608.01", "Diseases of metabolism"], ["TCGA.AZ.6608.01", "EPH-ephrin mediated repulsion of cells"], ["TCGA.AZ.6608.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.AZ.6608.01", "Aspirin ADME"], ["TCGA.AZ.6608.01", "Scavenging by Class A Receptors"], ["TCGA.AZ.6608.01", "Aquaporin-mediated transport"], ["TCGA.AZ.6608.01", "Adaptive Immune System"], ["TCGA.AZ.6608.01", "PLC beta mediated events"], ["TCGA.AZ.6608.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AZ.6608.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.AZ.6608.01", "Neurexins and neuroligins"], ["TCGA.CA.5254.01", "Neuronal System"], ["TCGA.CA.5254.01", "Transmission across Chemical Synapses"], ["TCGA.CA.5254.01", "Signaling by GPCR"], ["TCGA.CA.5254.01", "Drug ADME"], ["TCGA.CA.5254.01", "Extracellular matrix organization"], ["TCGA.CA.5254.01", "GPCR ligand binding"], ["TCGA.CA.5254.01", "GPCR downstream signalling"], ["TCGA.CA.5254.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CA.5254.01", "G alpha (i) signalling events"], ["TCGA.CA.5254.01", "Cardiac conduction"], ["TCGA.CA.5254.01", "Protein-protein interactions at synapses"], ["TCGA.CA.5254.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CA.5254.01", "Interaction between L1 and Ankyrins"], ["TCGA.CA.5254.01", "Phase 0 - rapid depolarisation"], ["TCGA.CA.5254.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CA.5254.01", "Collagen formation"], ["TCGA.CA.5254.01", "Peptide ligand-binding receptors"], ["TCGA.CA.5254.01", "Aspirin ADME"], ["TCGA.CA.5254.01", "O-linked glycosylation"], ["TCGA.CA.5254.01", "Glucagon-type ligand receptors"], ["TCGA.CA.5254.01", "Glucuronidation"], ["TCGA.CA.5254.01", "O-linked glycosylation of mucins"], ["TCGA.CA.5254.01", "Muscle contraction"], ["TCGA.CA.5254.01", "Transport of small molecules"], ["TCGA.CA.5254.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CA.5254.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.CA.5254.01", "Regulation of insulin secretion"], ["TCGA.CA.5254.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CA.5254.01", "Degradation of the extracellular matrix"], ["TCGA.CA.5254.01", "Termination of O-glycan biosynthesis"], ["TCGA.CA.5254.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CA.5254.01", "Biological oxidations"], ["TCGA.CA.5254.01", "Integration of energy metabolism"], ["TCGA.CA.5254.01", "Potassium Channels"], ["TCGA.CA.5254.01", "Chemokine receptors bind chemokines"], ["TCGA.CA.5254.01", "Integrin cell surface interactions"], ["TCGA.CA.5254.01", "Collagen chain trimerization"], ["TCGA.CA.5254.01", "Neurotransmitter release cycle"], ["TCGA.CA.5254.01", "G alpha (q) signalling events"], ["TCGA.CA.5254.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CA.5254.01", "Neurexins and neuroligins"], ["TCGA.CA.5254.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.CA.5254.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CA.5254.01", "Blood group systems biosynthesis"], ["TCGA.CA.5254.01", "ECM proteoglycans"], ["TCGA.CA.5254.01", "G alpha (s) signalling events"], ["TCGA.CA.5254.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.CA.5254.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CA.5254.01", "Heme degradation"], ["TCGA.CA.5254.01", "Phase II - Conjugation of compounds"], ["TCGA.CA.5254.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CA.5254.01", "Trafficking of AMPA receptors"], ["TCGA.CA.5254.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CA.5254.01", "Synaptic adhesion-like molecules"], ["TCGA.CA.5254.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.CA.5254.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.CA.5254.01", "Signaling Pathways"], ["TCGA.CA.5254.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.CA.5254.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.CA.5254.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CA.5254.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CA.5254.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.CA.5254.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CA.5254.01", "Recycling of bile acids and salts"], ["TCGA.CA.5254.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.CA.5254.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.CA.5254.01", "Lewis blood group biosynthesis"], ["TCGA.CA.5254.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CA.5254.01", "Collagen degradation"], ["TCGA.CA.5254.01", "Dectin-2 family"], ["TCGA.CA.5254.01", "APAP ADME"], ["TCGA.CA.5254.01", "Sensory processing of sound"], ["TCGA.CA.5254.01", "Platelet homeostasis"], ["TCGA.CA.5254.01", "ABC transporters in lipid homeostasis"], ["TCGA.CA.5254.01", "Defective GALNT3 causes HFTC"], ["TCGA.CA.5254.01", "Defective GALNT12 causes CRCS1"], ["TCGA.CA.5254.01", "Phase 2 - plateau phase"], ["TCGA.CA.5254.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CA.5254.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.CA.5254.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.CA.5254.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CA.5254.01", "L1CAM interactions"], ["TCGA.CA.5254.01", "Scavenging of heme from plasma"], ["TCGA.CA.5254.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CA.5255.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CA.5255.01", "Signaling by GPCR"], ["TCGA.CA.5255.01", "GPCR downstream signalling"], ["TCGA.CA.5255.01", "G alpha (i) signalling events"], ["TCGA.CA.5255.01", "Interaction between L1 and Ankyrins"], ["TCGA.CA.5255.01", "GPCR ligand binding"], ["TCGA.CA.5255.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.CA.5255.01", "Immune System"], ["TCGA.CA.5255.01", "Neuronal System"], ["TCGA.CA.5255.01", "Peptide ligand-binding receptors"], ["TCGA.CA.5255.01", "Extracellular matrix organization"], ["TCGA.CA.5255.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CA.5255.01", "Transport of small molecules"], ["TCGA.CA.5255.01", "Signaling Pathways"], ["TCGA.CA.5255.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.CA.5255.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CA.5255.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CA.5255.01", "Phase 0 - rapid depolarisation"], ["TCGA.CA.5255.01", "Transmission across Chemical Synapses"], ["TCGA.CA.5255.01", "Generation of second messenger molecules"], ["TCGA.CA.5255.01", "Complement cascade"], ["TCGA.CA.5255.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CA.5255.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.CA.5255.01", "Leishmania parasite growth and survival"], ["TCGA.CA.5255.01", "Integrin cell surface interactions"], ["TCGA.CA.5255.01", "Initial triggering of complement"], ["TCGA.CA.5255.01", "Leishmania infection"], ["TCGA.CA.5255.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CA.5255.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CA.5255.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.CA.5255.01", "Chemokine receptors bind chemokines"], ["TCGA.CA.5255.01", "Stimuli-sensing channels"], ["TCGA.CA.5255.01", "Interleukin-10 signaling"], ["TCGA.CA.5255.01", "G-protein beta:gamma signalling"], ["TCGA.CA.5255.01", "G alpha (q) signalling events"], ["TCGA.CA.5255.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CA.5255.01", "Platelet homeostasis"], ["TCGA.CA.5255.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CA.5255.01", "Classical antibody-mediated complement activation"], ["TCGA.CA.5255.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.CA.5255.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CA.5255.01", "Regulation of Complement cascade"], ["TCGA.CA.5255.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.CA.5255.01", "L1CAM interactions"], ["TCGA.CA.5255.01", "Cell surface interactions at the vascular wall"], ["TCGA.CA.5255.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CA.5255.01", "Cardiac conduction"], ["TCGA.CA.5255.01", "Biological oxidations"], ["TCGA.CA.5255.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CA.5255.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.CA.5255.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.CA.5255.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.CA.5255.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.CA.5255.01", "Post-translational protein phosphorylation"], ["TCGA.CA.5255.01", "Calmodulin induced events"], ["TCGA.CA.5255.01", "CaM pathway"], ["TCGA.CA.5255.01", "NCAM1 interactions"], ["TCGA.CA.5255.01", "Peptide hormone metabolism"], ["TCGA.CA.5255.01", "Creation of C4 and C2 activators"], ["TCGA.CA.5255.01", "G beta:gamma signalling through BTK"], ["TCGA.CA.5255.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.CA.5255.01", "G alpha (s) signalling events"], ["TCGA.CA.5255.01", "Molecules associated with elastic fibres"], ["TCGA.CA.5255.01", "Dectin-2 family"], ["TCGA.CA.5255.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CA.5255.01", "Ca-dependent events"], ["TCGA.CA.5255.01", "DAP12 interactions"], ["TCGA.CA.5255.01", "GRB2:SOS provides linkage to MAPK signaling for Integrins"], ["TCGA.CA.5255.01", "p130Cas linkage to MAPK signaling for integrins"], ["TCGA.CA.5255.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CA.5255.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CA.5255.01", "G-protein activation"], ["TCGA.CA.5255.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CA.5255.01", "Interleukin-6 family signaling"], ["TCGA.CA.5255.01", "TNFs bind their physiological receptors"], ["TCGA.CA.5255.01", "Elastic fibre formation"], ["TCGA.CA.5255.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CA.5255.01", "G beta:gamma signalling through CDC42"], ["TCGA.CA.5255.01", "Aquaporin-mediated transport"], ["TCGA.CA.5255.01", "Protein-protein interactions at synapses"], ["TCGA.CA.5255.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CA.5255.01", "FCERI mediated Ca+2 mobilization"], ["TCGA.CA.5255.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.CA.5255.01", "Glycosaminoglycan metabolism"], ["TCGA.CA.5255.01", "SLC-mediated transmembrane transport"], ["TCGA.CA.5255.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.CA.5255.01", "Platelet activation, signaling and aggregation"], ["TCGA.CA.5255.01", "Drug ADME"], ["TCGA.CA.5255.01", "PD-1 signaling"], ["TCGA.CA.5255.01", "Presynaptic function of Kainate receptors"], ["TCGA.CA.5255.01", "Synaptic adhesion-like molecules"], ["TCGA.CA.5255.01", "Muscle contraction"], ["TCGA.CA.5255.01", "O-linked glycosylation"], ["TCGA.CA.5255.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CA.5255.01", "Trafficking of AMPA receptors"], ["TCGA.CA.5255.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CA.5255.01", "Innate Immune System"], ["TCGA.CA.5255.01", "Adaptive Immune System"], ["TCGA.CA.5255.01", "DAG and IP3 signaling"], ["TCGA.CA.5255.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.CA.5255.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CA.5255.01", "Potassium Channels"], ["TCGA.CA.5255.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.CA.5255.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CA.5255.01", "Other interleukin signaling"], ["TCGA.CA.5255.01", "Signal amplification"], ["TCGA.CA.5255.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.CA.5255.01", "O-linked glycosylation of mucins"], ["TCGA.CA.5255.01", "Sialic acid metabolism"], ["TCGA.CA.5255.01", "Glucagon-type ligand receptors"], ["TCGA.CA.5255.01", "Diseases of Immune System"], ["TCGA.CA.5255.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.CA.5255.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.CA.5255.01", "PLC beta mediated events"], ["TCGA.CA.5255.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.CA.5255.01", "Ion channel transport"], ["TCGA.CA.5255.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.CA.5255.01", "NCAM signaling for neurite out-growth"], ["TCGA.CA.5255.01", "Integration of energy metabolism"], ["TCGA.CA.5255.01", "Scavenging by Class A Receptors"], ["TCGA.CA.5255.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.CA.5255.01", "Activation of G protein gated Potassium channels"], ["TCGA.CA.5255.01", "G protein gated Potassium channels"], ["TCGA.CA.5255.01", "DAP12 signaling"], ["TCGA.CA.5255.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CA.5255.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CA.5255.01", "Thromboxane signalling through TP receptor"], ["TCGA.CA.5255.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CA.5255.01", "Ca2+ pathway"], ["TCGA.CA.5255.01", "G alpha (12/13) signalling events"], ["TCGA.CA.5255.01", "Signaling by Interleukins"], ["TCGA.CA.5255.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.CA.5255.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.CA.5255.01", "Regulation of TLR by endogenous ligand"], ["TCGA.CA.5255.01", "Arachidonic acid metabolism"], ["TCGA.CA.5255.01", "Regulation of insulin secretion"], ["TCGA.CA.5255.01", "Keratan sulfate biosynthesis"], ["TCGA.CA.5255.01", "Chondroitin sulfate biosynthesis"], ["TCGA.CA.5255.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.CA.5255.01", "Insulin processing"], ["TCGA.CA.5255.01", "G beta:gamma signalling through PLC beta"], ["TCGA.CA.5255.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CA.5255.01", "Diseases of metabolism"], ["TCGA.CA.5255.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.CA.5255.01", "G alpha (z) signalling events"], ["TCGA.CA.5255.01", "Diseases of glycosylation"], ["TCGA.CA.5255.01", "Costimulation by the CD28 family"], ["TCGA.CA.5255.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.CA.5255.01", "G-protein mediated events"], ["TCGA.CA.5255.01", "GPER1 signaling"], ["TCGA.CA.5255.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.CA.5255.01", "GABA B receptor activation"], ["TCGA.CA.5255.01", "Activation of GABAB receptors"], ["TCGA.CA.5255.01", "Termination of O-glycan biosynthesis"], ["TCGA.CA.5256.01", "Viral mRNA Translation"], ["TCGA.CA.5256.01", "Peptide chain elongation"], ["TCGA.CA.5256.01", "Eukaryotic Translation Elongation"], ["TCGA.CA.5256.01", "Selenocysteine synthesis"], ["TCGA.CA.5256.01", "Eukaryotic Translation Termination"], ["TCGA.CA.5256.01", "Formation of a pool of free 40S subunits"], ["TCGA.CA.5256.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], ["TCGA.CA.5256.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], ["TCGA.CA.5256.01", "Selenoamino acid metabolism"], ["TCGA.CA.5256.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], ["TCGA.CA.5256.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], ["TCGA.CA.5256.01", "Eukaryotic Translation Initiation"], ["TCGA.CA.5256.01", "Cap-dependent Translation Initiation"], ["TCGA.CA.5256.01", "SRP-dependent cotranslational protein targeting to membrane"], ["TCGA.CA.5256.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], ["TCGA.CA.5256.01", "Nonsense-Mediated Decay (NMD)"], ["TCGA.CA.5256.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], ["TCGA.CA.5256.01", "rRNA processing in the nucleus and cytosol"], ["TCGA.CA.5256.01", "Influenza Viral RNA Transcription and Replication"], ["TCGA.CA.5256.01", "rRNA processing"], ["TCGA.CA.5256.01", "Cellular response to starvation"], ["TCGA.CA.5256.01", "SARS-CoV-2 modulates host translation machinery"], ["TCGA.CA.5256.01", "SARS-CoV-1 modulates host translation machinery"], ["TCGA.CA.5256.01", "Nervous system development"], ["TCGA.CA.5256.01", "Neuronal System"], ["TCGA.CA.5256.01", "Influenza Infection"], ["TCGA.CA.5256.01", "Axon guidance"], ["TCGA.CA.5256.01", "Regulation of expression of SLITs and ROBOs"], ["TCGA.CA.5256.01", "Transmission across Chemical Synapses"], ["TCGA.CA.5256.01", "Formation of the ternary complex, and subsequently, the 43S complex"], ["TCGA.CA.5256.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], ["TCGA.CA.5256.01", "Signaling by ROBO receptors"], ["TCGA.CA.5256.01", "Translation"], ["TCGA.CA.5256.01", "Ribosomal scanning and start codon recognition"], ["TCGA.CA.5256.01", "Developmental Biology"], ["TCGA.CA.5256.01", "Translation initiation complex formation"], ["TCGA.CA.5256.01", "Metabolism"], ["TCGA.CA.5256.01", "Amino acid and derivative metabolism"], ["TCGA.CA.5256.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CA.5256.01", "SARS-CoV-1-host interactions"], ["TCGA.CA.5256.01", "Interaction between L1 and Ankyrins"], ["TCGA.CA.5256.01", "Phase 0 - rapid depolarisation"], ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.CA.5256.01", "Biological oxidations"], ["TCGA.CA.5256.01", "Ribavirin ADME"], ["TCGA.CA.5256.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CA.5256.01", "SARS-CoV-1 Infection"], ["TCGA.CA.5256.01", "Signaling Pathways"], ["TCGA.CA.5256.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], ["TCGA.CA.5256.01", "Nucleosome assembly"], ["TCGA.CA.5256.01", "Drug ADME"], ["TCGA.CA.5256.01", "Nucleotide metabolism"], ["TCGA.CA.5256.01", "Regulation of insulin secretion"], ["TCGA.CA.5256.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CA.5256.01", "GABA receptor activation"], ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts"], ["TCGA.CA.5256.01", "Peptide hormone metabolism"], ["TCGA.CA.5256.01", "Protein-protein interactions at synapses"], ["TCGA.CA.5256.01", "Chromosome Maintenance"], ["TCGA.CA.5256.01", "Extracellular matrix organization"], ["TCGA.CA.5256.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.CA.5256.01", "Ion channel transport"], ["TCGA.CA.5256.01", "Bile acid and bile salt metabolism"], ["TCGA.CA.5256.01", "Signaling by GPCR"], ["TCGA.CA.5256.01", "Glycosaminoglycan metabolism"], ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.CA.5256.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CA.5256.01", "Long-term potentiation"], ["TCGA.CA.5256.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CA.5256.01", "Integration of energy metabolism"], ["TCGA.CA.5256.01", "Blood group systems biosynthesis"], ["TCGA.CA.5256.01", "GPCR downstream signalling"], ["TCGA.CA.5256.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.CA.5256.01", "RA biosynthesis pathway"], ["TCGA.CA.5256.01", "L1CAM interactions"], ["TCGA.CA.5256.01", "Stimuli-sensing channels"], ["TCGA.CA.5256.01", "G-protein beta:gamma signalling"], ["TCGA.CA.5256.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.CA.5256.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.CA.5256.01", "Sensory processing of sound"], ["TCGA.CA.5256.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.CA.5256.01", "Metabolism of proteins"], ["TCGA.CA.5256.01", "Cellular responses to stimuli"], ["TCGA.CA.5256.01", "Platelet activation, signaling and aggregation"], ["TCGA.CA.5256.01", "G alpha (z) signalling events"], ["TCGA.CA.5256.01", "G0 and Early G1"], ["TCGA.CA.5256.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.CA.5256.01", "GABA B receptor activation"], ["TCGA.CA.5256.01", "Activation of GABAB receptors"], ["TCGA.CA.5256.01", "Lewis blood group biosynthesis"], ["TCGA.CA.5256.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CA.5256.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.CA.5256.01", "Cellular responses to stress"], ["TCGA.CA.5256.01", "Neurotransmitter release cycle"], ["TCGA.CA.5256.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CA.5256.01", "Molecules associated with elastic fibres"], ["TCGA.CA.5256.01", "Adenylate cyclase inhibitory pathway"], ["TCGA.CA.5256.01", "Phase II - Conjugation of compounds"], ["TCGA.CK.4952.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CK.4952.01", "Neuronal System"], ["TCGA.CK.4952.01", "Protein-protein interactions at synapses"], ["TCGA.CK.4952.01", "Transmission across Chemical Synapses"], ["TCGA.CK.4952.01", "Unwinding of DNA"], ["TCGA.CK.4952.01", "Signaling by GPCR"], ["TCGA.CK.4952.01", "Activation of the pre-replicative complex"], ["TCGA.CK.4952.01", "Activation of ATR in response to replication stress"], ["TCGA.CK.4952.01", "Transport of small molecules"], ["TCGA.CK.4952.01", "Biological oxidations"], ["TCGA.CK.4952.01", "DNA strand elongation"], ["TCGA.CK.4952.01", "GPCR downstream signalling"], ["TCGA.CK.4952.01", "GPCR ligand binding"], ["TCGA.CK.4952.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.CK.4952.01", "G alpha (i) signalling events"], ["TCGA.CK.4952.01", "Drug ADME"], ["TCGA.CK.4952.01", "Synaptic adhesion-like molecules"], ["TCGA.CK.4952.01", "Interaction between L1 and Ankyrins"], ["TCGA.CK.4952.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CK.4952.01", "CD22 mediated BCR regulation"], ["TCGA.CK.4952.01", "Complement cascade"], ["TCGA.CK.4952.01", "Generation of second messenger molecules"], ["TCGA.CK.4952.01", "Neurexins and neuroligins"], ["TCGA.CK.4952.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CK.4952.01", "Regulation of Complement cascade"], ["TCGA.CK.4952.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CK.4952.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.CK.4952.01", "Cardiac conduction"], ["TCGA.CK.4952.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CK.4952.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CK.4952.01", "Chemokine receptors bind chemokines"], ["TCGA.CK.4952.01", "Resolution of D-loop Structures through Holliday Junction Intermediates"], ["TCGA.CK.4952.01", "Signaling Pathways"], ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function"], ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function"], ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function"], ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function"], ["TCGA.CK.4952.01", "Impaired BRCA2 binding to PALB2"], ["TCGA.CK.4952.01", "Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)"], ["TCGA.CK.4952.01", "Resolution of D-Loop Structures"], ["TCGA.CK.4952.01", "Amino acid transport across the plasma membrane"], ["TCGA.CK.4952.01", "Carnitine metabolism"], ["TCGA.CK.4952.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CK.4952.01", "Neurotransmitter release cycle"], ["TCGA.CK.4952.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CK.4952.01", "SLC-mediated transmembrane transport"], ["TCGA.CK.4952.01", "Peptide ligand-binding receptors"], ["TCGA.CK.4952.01", "Initial triggering of complement"], ["TCGA.CK.4952.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CK.4952.01", "Homologous DNA Pairing and Strand Exchange"], ["TCGA.CK.4952.01", "Phase I - Functionalization of compounds"], ["TCGA.CK.4952.01", "Sialic acid metabolism"], ["TCGA.CK.4952.01", "DAG and IP3 signaling"], ["TCGA.CK.4952.01", "DAP12 signaling"], ["TCGA.CK.4952.01", "RA biosynthesis pathway"], ["TCGA.CK.4952.01", "DAP12 interactions"], ["TCGA.CK.4952.01", "Metabolism of fat-soluble vitamins"], ["TCGA.CK.4952.01", "Retinoid metabolism and transport"], ["TCGA.CK.4952.01", "Presynaptic phase of homologous DNA pairing and strand exchange"], ["TCGA.CK.4952.01", "SUMOylation of intracellular receptors"], ["TCGA.CK.4952.01", "L1CAM interactions"], ["TCGA.CK.4952.01", "Muscle contraction"], ["TCGA.CK.4952.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CK.4952.01", "Condensation of Prometaphase Chromosomes"], ["TCGA.CK.4952.01", "Ethanol oxidation"], ["TCGA.CK.4952.01", "Trafficking of AMPA receptors"], ["TCGA.CK.4952.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CK.4952.01", "Extracellular matrix organization"], ["TCGA.CK.4952.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.CK.4952.01", "Calmodulin induced events"], ["TCGA.CK.4952.01", "CaM pathway"], ["TCGA.CK.4952.01", "Molecules associated with elastic fibres"], ["TCGA.CK.4952.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CK.5915.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CK.5915.01", "Neuronal System"], ["TCGA.CK.5915.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.CK.5915.01", "Generation of second messenger molecules"], ["TCGA.CK.5915.01", "Signaling by GPCR"], ["TCGA.CK.5915.01", "Immune System"], ["TCGA.CK.5915.01", "GPCR downstream signalling"], ["TCGA.CK.5915.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.CK.5915.01", "PD-1 signaling"], ["TCGA.CK.5915.01", "GPCR ligand binding"], ["TCGA.CK.5915.01", "G alpha (i) signalling events"], ["TCGA.CK.5915.01", "Transmission across Chemical Synapses"], ["TCGA.CK.5915.01", "Potassium Channels"], ["TCGA.CK.5915.01", "Cardiac conduction"], ["TCGA.CK.5915.01", "Complement cascade"], ["TCGA.CK.5915.01", "Signaling Pathways"], ["TCGA.CK.5915.01", "Muscle contraction"], ["TCGA.CK.5915.01", "Regulation of Complement cascade"], ["TCGA.CK.5915.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CK.5915.01", "Peptide ligand-binding receptors"], ["TCGA.CK.5915.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CK.5915.01", "Adaptive Immune System"], ["TCGA.CK.5915.01", "Chemokine receptors bind chemokines"], ["TCGA.CK.5915.01", "G alpha (q) signalling events"], ["TCGA.CK.5915.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CK.5915.01", "Leishmania infection"], ["TCGA.CK.5915.01", "Interaction between L1 and Ankyrins"], ["TCGA.CK.5915.01", "Phase 0 - rapid depolarisation"], ["TCGA.CK.5915.01", "Other semaphorin interactions"], ["TCGA.CK.5915.01", "Glucagon-type ligand receptors"], ["TCGA.CK.5915.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.CK.5915.01", "Leishmania parasite growth and survival"], ["TCGA.CK.5915.01", "Interferon gamma signaling"], ["TCGA.CK.5915.01", "Initial triggering of complement"], ["TCGA.CK.5915.01", "GABA B receptor activation"], ["TCGA.CK.5915.01", "Activation of GABAB receptors"], ["TCGA.CK.5915.01", "G alpha (s) signalling events"], ["TCGA.CK.5915.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CK.5915.01", "Innate Immune System"], ["TCGA.CK.5915.01", "Platelet homeostasis"], ["TCGA.CK.5915.01", "GABA receptor activation"], ["TCGA.CK.5915.01", "Peptide hormone metabolism"], ["TCGA.CK.5915.01", "Cell surface interactions at the vascular wall"], ["TCGA.CK.5915.01", "Costimulation by the CD28 family"], ["TCGA.CK.5915.01", "Protein-protein interactions at synapses"], ["TCGA.CK.5915.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CK.5915.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CK.5915.01", "Transport of small molecules"], ["TCGA.CK.5915.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CK.5915.01", "Blood group systems biosynthesis"], ["TCGA.CK.5915.01", "Arachidonic acid metabolism"], ["TCGA.CK.5915.01", "Endosomal/Vacuolar pathway"], ["TCGA.CK.5915.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CK.5915.01", "NCAM1 interactions"], ["TCGA.CK.5915.01", "Creation of C4 and C2 activators"], ["TCGA.CK.5915.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.CK.5915.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CK.5915.01", "Sialic acid metabolism"], ["TCGA.CK.5915.01", "Activation of G protein gated Potassium channels"], ["TCGA.CK.5915.01", "G protein gated Potassium channels"], ["TCGA.CK.5915.01", "DAP12 signaling"], ["TCGA.CK.5915.01", "TNFs bind their physiological receptors"], ["TCGA.CK.5915.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CK.5915.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CK.5915.01", "Lewis blood group biosynthesis"], ["TCGA.CK.5915.01", "Classical antibody-mediated complement activation"], ["TCGA.CK.5915.01", "DAP12 interactions"], ["TCGA.CK.5915.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CK.5915.01", "Drug ADME"], ["TCGA.CK.5915.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CK.5915.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.CK.5915.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CK.5915.01", "G alpha (z) signalling events"], ["TCGA.CK.5915.01", "Scavenging by Class A Receptors"], ["TCGA.CK.5915.01", "Phase 4 - resting membrane potential"], ["TCGA.CK.5915.01", "Inwardly rectifying K+ channels"], ["TCGA.CK.5915.01", "G-protein beta:gamma signalling"], ["TCGA.CK.5915.01", "Integration of energy metabolism"], ["TCGA.CK.5915.01", "Aspirin ADME"], ["TCGA.CK.5915.01", "Regulation of insulin secretion"], ["TCGA.CK.5915.01", "Cytokine Signaling in Immune system"], ["TCGA.CK.5915.01", "Ion homeostasis"], ["TCGA.CK.5915.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CK.5915.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CK.5915.01", "Biosynthesis of DHA-derived SPMs"], ["TCGA.CK.5915.01", "RA biosynthesis pathway"], ["TCGA.CK.5915.01", "Synaptic adhesion-like molecules"], ["TCGA.CK.5915.01", "Keratan sulfate biosynthesis"], ["TCGA.CK.5915.01", "Ca2+ pathway"], ["TCGA.CK.5915.01", "NCAM signaling for neurite out-growth"], ["TCGA.CK.5915.01", "Voltage gated Potassium channels"], ["TCGA.CK.5915.01", "Stimuli-sensing channels"], ["TCGA.CK.5915.01", "ABC transporters in lipid homeostasis"], ["TCGA.CK.5915.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.CK.5915.01", "TCR signaling"], ["TCGA.CK.5915.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CK.5915.01", "L1CAM interactions"], ["TCGA.CK.5915.01", "G beta:gamma signalling through BTK"], ["TCGA.CK.5915.01", "CD22 mediated BCR regulation"], ["TCGA.CK.5915.01", "Semaphorin interactions"], ["TCGA.CK.5915.01", "Ion channel transport"], ["TCGA.CK.5915.01", "Molecules associated with elastic fibres"], ["TCGA.CK.5915.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.CK.5915.01", "Biological oxidations"], ["TCGA.CK.5915.01", "GPVI-mediated activation cascade"], ["TCGA.CK.5915.01", "Developmental Biology"], ["TCGA.CK.5915.01", "FCGR activation"], ["TCGA.CK.5915.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CK.5915.01", "RHO GTPases Activate NADPH Oxidases"], ["TCGA.CK.5915.01", "Long-term potentiation"], ["TCGA.CK.5915.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.CK.5915.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.CK.5915.01", "Insulin processing"], ["TCGA.CK.5915.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CK.5915.01", "G beta:gamma signalling through CDC42"], ["TCGA.CK.5915.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.CK.5915.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.CK.5915.01", "Extracellular matrix organization"], ["TCGA.CK.5915.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.CK.5915.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.CK.5915.01", "GPER1 signaling"], ["TCGA.CK.5915.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.CK.5915.01", "Netrin-1 signaling"], ["TCGA.CK.5915.01", "Phase I - Functionalization of compounds"], ["TCGA.CK.6746.01", "Neuronal System"], ["TCGA.CK.6746.01", "Biological oxidations"], ["TCGA.CK.6746.01", "Drug ADME"], ["TCGA.CK.6746.01", "Transmission across Chemical Synapses"], ["TCGA.CK.6746.01", "Protein-protein interactions at synapses"], ["TCGA.CK.6746.01", "Phase I - Functionalization of compounds"], ["TCGA.CK.6746.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CK.6746.01", "Extracellular matrix organization"], ["TCGA.CK.6746.01", "Regulation of insulin secretion"], ["TCGA.CK.6746.01", "GPCR ligand binding"], ["TCGA.CK.6746.01", "Muscle contraction"], ["TCGA.CK.6746.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CK.6746.01", "Cardiac conduction"], ["TCGA.CK.6746.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CK.6746.01", "Bile acid and bile salt metabolism"], ["TCGA.CK.6746.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CK.6746.01", "Integration of energy metabolism"], ["TCGA.CK.6746.01", "Signaling by GPCR"], ["TCGA.CK.6746.01", "O-linked glycosylation"], ["TCGA.CK.6746.01", "G alpha (i) signalling events"], ["TCGA.CK.6746.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CK.6746.01", "Metabolism"], ["TCGA.CK.6746.01", "Neurotransmitter release cycle"], ["TCGA.CK.6746.01", "Peptide ligand-binding receptors"], ["TCGA.CK.6746.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CK.6746.01", "Phase 0 - rapid depolarisation"], ["TCGA.CK.6746.01", "Neurexins and neuroligins"], ["TCGA.CK.6746.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.CK.6746.01", "Cytochrome P450 - arranged by substrate type"], ["TCGA.CK.6746.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.CK.6746.01", "Arachidonic acid metabolism"], ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts"], ["TCGA.CK.6746.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CK.6746.01", "Transport of small molecules"], ["TCGA.CK.6746.01", "GPCR downstream signalling"], ["TCGA.CK.6746.01", "NCAM1 interactions"], ["TCGA.CK.6746.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CK.6746.01", "SLC-mediated transmembrane transport"], ["TCGA.CK.6746.01", "Platelet homeostasis"], ["TCGA.CK.6746.01", "Adherens junctions interactions"], ["TCGA.CK.6746.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.CK.6746.01", "Regulation of beta-cell development"], ["TCGA.CK.6746.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CK.6746.01", "Diseases of glycosylation"], ["TCGA.CK.6746.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CK.6746.01", "Interaction between L1 and Ankyrins"], ["TCGA.CK.6746.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.CK.6746.01", "Regulation of gene expression in beta cells"], ["TCGA.CK.6746.01", "Glycosaminoglycan metabolism"], ["TCGA.CK.6746.01", "Ion channel transport"], ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.CK.6746.01", "Stimuli-sensing channels"], ["TCGA.CK.6746.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CK.6746.01", "Ion homeostasis"], ["TCGA.CK.6746.01", "Trafficking of AMPA receptors"], ["TCGA.CK.6746.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CK.6746.01", "Signaling by Retinoic Acid"], ["TCGA.CK.6746.01", "Triglyceride metabolism"], ["TCGA.CK.6746.01", "Diseases of metabolism"], ["TCGA.CK.6746.01", "Scavenging by Class A Receptors"], ["TCGA.CK.6746.01", "Collagen formation"], ["TCGA.CK.6746.01", "Developmental Biology"], ["TCGA.CK.6746.01", "G alpha (q) signalling events"], ["TCGA.CK.6746.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.CK.6746.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.CK.6746.01", "L1CAM interactions"], ["TCGA.CK.6746.01", "Initial triggering of complement"], ["TCGA.CK.6746.01", "NPAS4 regulates expression of target genes"], ["TCGA.CM.4743.01", "Signaling by GPCR"], ["TCGA.CM.4743.01", "GPCR ligand binding"], ["TCGA.CM.4743.01", "GPCR downstream signalling"], ["TCGA.CM.4743.01", "Neuronal System"], ["TCGA.CM.4743.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.4743.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.4743.01", "G alpha (i) signalling events"], ["TCGA.CM.4743.01", "Peptide ligand-binding receptors"], ["TCGA.CM.4743.01", "Biological oxidations"], ["TCGA.CM.4743.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.4743.01", "Drug ADME"], ["TCGA.CM.4743.01", "Transport of small molecules"], ["TCGA.CM.4743.01", "Signaling Pathways"], ["TCGA.CM.4743.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.4743.01", "Extracellular matrix organization"], ["TCGA.CM.4743.01", "Transmission across Chemical Synapses"], ["TCGA.CM.4743.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CM.4743.01", "Protein-protein interactions at synapses"], ["TCGA.CM.4743.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CM.4743.01", "Developmental Biology"], ["TCGA.CM.4743.01", "Metabolism of fat-soluble vitamins"], ["TCGA.CM.4743.01", "Retinoid metabolism and transport"], ["TCGA.CM.4743.01", "Amino acid transport across the plasma membrane"], ["TCGA.CM.4743.01", "Muscle contraction"], ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.CM.4743.01", "Cardiac conduction"], ["TCGA.CM.4743.01", "NCAM1 interactions"], ["TCGA.CM.4743.01", "Ion channel transport"], ["TCGA.CM.4743.01", "Stimuli-sensing channels"], ["TCGA.CM.4743.01", "Phase I - Functionalization of compounds"], ["TCGA.CM.4743.01", "Regulation of Complement cascade"], ["TCGA.CM.4743.01", "Complement cascade"], ["TCGA.CM.4743.01", "Regulation of signaling by NODAL"], ["TCGA.CM.4743.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.4743.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CM.4743.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts"], ["TCGA.CM.4743.01", "Ethanol oxidation"], ["TCGA.CM.4743.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.4743.01", "Collagen chain trimerization"], ["TCGA.CM.4743.01", "G alpha (s) signalling events"], ["TCGA.CM.4743.01", "Scavenging by Class A Receptors"], ["TCGA.CM.4743.01", "Other semaphorin interactions"], ["TCGA.CM.4743.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.CM.4743.01", "CD22 mediated BCR regulation"], ["TCGA.CM.4743.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.4743.01", "Arachidonic acid metabolism"], ["TCGA.CM.4743.01", "Bile acid and bile salt metabolism"], ["TCGA.CM.4743.01", "Glucagon-type ligand receptors"], ["TCGA.CM.4743.01", "L1CAM interactions"], ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.CM.4743.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.CM.4743.01", "PI3K events in ERBB2 signaling"], ["TCGA.CM.4743.01", "Glycosaminoglycan metabolism"], ["TCGA.CM.4743.01", "Neurexins and neuroligins"], ["TCGA.CM.4743.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.4743.01", "Glucuronidation"], ["TCGA.CM.4743.01", "Regulation of gene expression in beta cells"], ["TCGA.CM.4743.01", "Synaptic adhesion-like molecules"], ["TCGA.CM.4743.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.CM.4743.01", "Peptide hormone metabolism"], ["TCGA.CM.4743.01", "Regulation of beta-cell development"], ["TCGA.CM.4743.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.4743.01", "Recycling of bile acids and salts"], ["TCGA.CM.4743.01", "Endogenous sterols"], ["TCGA.CM.4743.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.CM.4743.01", "ECM proteoglycans"], ["TCGA.CM.4747.01", "Signaling by GPCR"], ["TCGA.CM.4747.01", "Neuronal System"], ["TCGA.CM.4747.01", "GPCR downstream signalling"], ["TCGA.CM.4747.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.4747.01", "G alpha (i) signalling events"], ["TCGA.CM.4747.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CM.4747.01", "Signaling Pathways"], ["TCGA.CM.4747.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.4747.01", "Biological oxidations"], ["TCGA.CM.4747.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.4747.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.4747.01", "Transmission across Chemical Synapses"], ["TCGA.CM.4747.01", "GPCR ligand binding"], ["TCGA.CM.4747.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CM.4747.01", "Ethanol oxidation"], ["TCGA.CM.4747.01", "Peptide hormone metabolism"], ["TCGA.CM.4747.01", "Glucuronidation"], ["TCGA.CM.4747.01", "Transport of small molecules"], ["TCGA.CM.4747.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.4747.01", "Heme degradation"], ["TCGA.CM.4747.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.CM.4747.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.CM.4747.01", "Leishmania infection"], ["TCGA.CM.4747.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.4747.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.4747.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.CM.4747.01", "G-protein beta:gamma signalling"], ["TCGA.CM.4747.01", "Cardiac conduction"], ["TCGA.CM.4747.01", "Drug ADME"], ["TCGA.CM.4747.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.4747.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.CM.4747.01", "Regulation of TLR by endogenous ligand"], ["TCGA.CM.4747.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.CM.4747.01", "Potassium Channels"], ["TCGA.CM.4747.01", "RA biosynthesis pathway"], ["TCGA.CM.4747.01", "O-linked glycosylation of mucins"], ["TCGA.CM.4747.01", "Peptide ligand-binding receptors"], ["TCGA.CM.4747.01", "Scavenging of heme from plasma"], ["TCGA.CM.4747.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CM.4747.01", "Diseases of Immune System"], ["TCGA.CM.4747.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.CM.4747.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.CM.4747.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.CM.4747.01", "GABA receptor activation"], ["TCGA.CM.4747.01", "Physiological factors"], ["TCGA.CM.4747.01", "Erythropoietin activates Phosphoinositide-3-kinase (PI3K)"], ["TCGA.CM.4747.01", "ERK1/ERK2 pathway"], ["TCGA.CM.4747.01", "Stimuli-sensing channels"], ["TCGA.CM.4747.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.CM.4747.01", "Leishmania parasite growth and survival"], ["TCGA.CM.4747.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.CM.4747.01", "IRS-related events triggered by IGF1R"], ["TCGA.CM.4747.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CM.4747.01", "Porphyrin metabolism"], ["TCGA.CM.4747.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CM.4747.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CM.4747.01", "Interleukin-10 signaling"], ["TCGA.CM.4747.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.4747.01", "G alpha (q) signalling events"], ["TCGA.CM.4747.01", "Arachidonic acid metabolism"], ["TCGA.CM.4747.01", "IGF1R signaling cascade"], ["TCGA.CM.4747.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CM.4747.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.CM.4747.01", "O-linked glycosylation"], ["TCGA.CM.4747.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.CM.4747.01", "Keratan sulfate biosynthesis"], ["TCGA.CM.4747.01", "Signaling by Erythropoietin"], ["TCGA.CM.4747.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.4747.01", "Other semaphorin interactions"], ["TCGA.CM.4747.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.CM.4747.01", "Extracellular matrix organization"], ["TCGA.CM.4747.01", "Signaling by Retinoic Acid"], ["TCGA.CM.4747.01", "Aspirin ADME"], ["TCGA.CM.4747.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CM.4747.01", "IRS-mediated signalling"], ["TCGA.CM.4747.01", "L1CAM interactions"], ["TCGA.CM.4747.01", "ABC transporters in lipid homeostasis"], ["TCGA.CM.4747.01", "FGFR4 ligand binding and activation"], ["TCGA.CM.4747.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.CM.4747.01", "Defective GALNT12 causes CRCS1"], ["TCGA.CM.4747.01", "G beta:gamma signalling through CDC42"], ["TCGA.CM.4747.01", "Blood group systems biosynthesis"], ["TCGA.CM.4747.01", "MAPK family signaling cascades"], ["TCGA.CM.4747.01", "RAF/MAP kinase cascade"], ["TCGA.CM.4752.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CM.4752.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.4752.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CM.4752.01", "GABA receptor activation"], ["TCGA.CM.4752.01", "G alpha (s) signalling events"], ["TCGA.CM.4752.01", "Transmission across Chemical Synapses"], ["TCGA.CM.4752.01", "Signal amplification"], ["TCGA.CM.4752.01", "Presynaptic function of Kainate receptors"], ["TCGA.CM.4752.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.CM.4752.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.CM.4752.01", "GPER1 signaling"], ["TCGA.CM.4752.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.CM.4752.01", "Neuronal System"], ["TCGA.CM.4752.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.4752.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CM.4752.01", "Aquaporin-mediated transport"], ["TCGA.CM.4752.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.4752.01", "Regulation of insulin secretion"], ["TCGA.CM.4752.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.CM.4752.01", "Biological oxidations"], ["TCGA.CM.4752.01", "Integration of energy metabolism"], ["TCGA.CM.4752.01", "G beta:gamma signalling through PLC beta"], ["TCGA.CM.4752.01", "G beta:gamma signalling through CDC42"], ["TCGA.CM.4752.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CM.4752.01", "Platelet homeostasis"], ["TCGA.CM.4752.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.CM.4752.01", "Peptide hormone metabolism"], ["TCGA.CM.4752.01", "L1CAM interactions"], ["TCGA.CM.4752.01", "G-protein activation"], ["TCGA.CM.4752.01", "Thromboxane signalling through TP receptor"], ["TCGA.CM.4752.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.4752.01", "G-protein beta:gamma signalling"], ["TCGA.CM.4752.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.CM.4752.01", "G alpha (z) signalling events"], ["TCGA.CM.4752.01", "Glucagon-type ligand receptors"], ["TCGA.CM.4752.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.4752.01", "GPCR ligand binding"], ["TCGA.CM.4752.01", "GABA B receptor activation"], ["TCGA.CM.4752.01", "Activation of GABAB receptors"], ["TCGA.CM.5348.01", "Extracellular matrix organization"], ["TCGA.CM.5348.01", "Collagen formation"], ["TCGA.CM.5348.01", "GPCR ligand binding"], ["TCGA.CM.5348.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.CM.5348.01", "Biological oxidations"], ["TCGA.CM.5348.01", "Transport of small molecules"], ["TCGA.CM.5348.01", "Glucuronidation"], ["TCGA.CM.5348.01", "Stimuli-sensing channels"], ["TCGA.CM.5348.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.5348.01", "Collagen chain trimerization"], ["TCGA.CM.5348.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.5348.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.5348.01", "Neuronal System"], ["TCGA.CM.5348.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.5348.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.CM.5348.01", "Peptide ligand-binding receptors"], ["TCGA.CM.5348.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.5348.01", "Drug ADME"], ["TCGA.CM.5348.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.5348.01", "GABA receptor activation"], ["TCGA.CM.5348.01", "Glucagon-type ligand receptors"], ["TCGA.CM.5348.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.5348.01", "Peptide hormone biosynthesis"], ["TCGA.CM.5348.01", "Ion channel transport"], ["TCGA.CM.5348.01", "Degradation of the extracellular matrix"], ["TCGA.CM.5348.01", "Potassium Channels"], ["TCGA.CM.5348.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.5348.01", "Signaling by GPCR"], ["TCGA.CM.5348.01", "Transmission across Chemical Synapses"], ["TCGA.CM.5348.01", "LGI-ADAM interactions"], ["TCGA.CM.5348.01", "RA biosynthesis pathway"], ["TCGA.CM.5348.01", "Activation of G protein gated Potassium channels"], ["TCGA.CM.5348.01", "G protein gated Potassium channels"], ["TCGA.CM.5348.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CM.5348.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CM.5860.01", "Extracellular matrix organization"], ["TCGA.CM.5860.01", "Collagen formation"], ["TCGA.CM.5860.01", "Neuronal System"], ["TCGA.CM.5860.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.5860.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.CM.5860.01", "Collagen chain trimerization"], ["TCGA.CM.5860.01", "Degradation of the extracellular matrix"], ["TCGA.CM.5860.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.5860.01", "Transmission across Chemical Synapses"], ["TCGA.CM.5860.01", "Protein-protein interactions at synapses"], ["TCGA.CM.5860.01", "Collagen degradation"], ["TCGA.CM.5860.01", "GPCR downstream signalling"], ["TCGA.CM.5860.01", "Biological oxidations"], ["TCGA.CM.5860.01", "NCAM1 interactions"], ["TCGA.CM.5860.01", "GPCR ligand binding"], ["TCGA.CM.5860.01", "Signaling by GPCR"], ["TCGA.CM.5860.01", "ECM proteoglycans"], ["TCGA.CM.5860.01", "Transport of small molecules"], ["TCGA.CM.5860.01", "Cardiac conduction"], ["TCGA.CM.5860.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.CM.5860.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.5860.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CM.5860.01", "Drug ADME"], ["TCGA.CM.5860.01", "Neurexins and neuroligins"], ["TCGA.CM.5860.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.5860.01", "Potassium Channels"], ["TCGA.CM.5860.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.5860.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.5860.01", "Phase I - Functionalization of compounds"], ["TCGA.CM.5860.01", "Peptide hormone metabolism"], ["TCGA.CM.5860.01", "Voltage gated Potassium channels"], ["TCGA.CM.5860.01", "Integrin cell surface interactions"], ["TCGA.CM.5860.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.5860.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.5860.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.5860.01", "Synaptic adhesion-like molecules"], ["TCGA.CM.5860.01", "Defective B3GALTL causes PpS"], ["TCGA.CM.5860.01", "Ethanol oxidation"], ["TCGA.CM.5860.01", "G alpha (i) signalling events"], ["TCGA.CM.5860.01", "NCAM signaling for neurite out-growth"], ["TCGA.CM.5860.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.CM.5860.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.5860.01", "TNFs bind their physiological receptors"], ["TCGA.CM.5860.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CM.5860.01", "APAP ADME"], ["TCGA.CM.5860.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CM.5860.01", "Peptide ligand-binding receptors"], ["TCGA.CM.5860.01", "Heme degradation"], ["TCGA.CM.5860.01", "Response to elevated platelet cytosolic Ca2+"], ["TCGA.CM.5860.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.CM.5860.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.5860.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CM.5860.01", "Long-term potentiation"], ["TCGA.CM.5860.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.CM.5860.01", "Regulation of insulin secretion"], ["TCGA.CM.5860.01", "G alpha (s) signalling events"], ["TCGA.CM.5860.01", "Diseases of glycosylation"], ["TCGA.CM.5860.01", "Peptide hormone biosynthesis"], ["TCGA.CM.5860.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.CM.5860.01", "Integration of energy metabolism"], ["TCGA.CM.5860.01", "Signaling by Retinoic Acid"], ["TCGA.CM.5860.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.CM.5860.01", "Glucagon-type ligand receptors"], ["TCGA.CM.5860.01", "G alpha (q) signalling events"], ["TCGA.CM.5860.01", "Insulin processing"], ["TCGA.CM.5860.01", "Blood group systems biosynthesis"], ["TCGA.CM.5863.01", "Extracellular matrix organization"], ["TCGA.CM.5863.01", "Collagen formation"], ["TCGA.CM.5863.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.5863.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.5863.01", "Transport of small molecules"], ["TCGA.CM.5863.01", "Basigin interactions"], ["TCGA.CM.5863.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.5863.01", "GPCR ligand binding"], ["TCGA.CM.5863.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.5863.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.CM.5863.01", "Peptide ligand-binding receptors"], ["TCGA.CM.5863.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.5863.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.5863.01", "Stimuli-sensing channels"], ["TCGA.CM.5863.01", "Keratinization"], ["TCGA.CM.5863.01", "TNFs bind their physiological receptors"], ["TCGA.CM.5863.01", "LGI-ADAM interactions"], ["TCGA.CM.5863.01", "Signaling by GPCR"], ["TCGA.CM.5863.01", "Amino acid transport across the plasma membrane"], ["TCGA.CM.5863.01", "Collagen chain trimerization"], ["TCGA.CM.5863.01", "Neuronal System"], ["TCGA.CM.5863.01", "Degradation of the extracellular matrix"], ["TCGA.CM.5863.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.CM.5863.01", "GPCR downstream signalling"], ["TCGA.CM.5863.01", "Ethanol oxidation"], ["TCGA.CM.5863.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.CM.5863.01", "Biological oxidations"], ["TCGA.CM.5863.01", "Drug ADME"], ["TCGA.CM.5868.01", "Signaling by GPCR"], ["TCGA.CM.5868.01", "GPCR downstream signalling"], ["TCGA.CM.5868.01", "G alpha (i) signalling events"], ["TCGA.CM.5868.01", "GPCR ligand binding"], ["TCGA.CM.5868.01", "Signaling Pathways"], ["TCGA.CM.5868.01", "Neuronal System"], ["TCGA.CM.5868.01", "Peptide ligand-binding receptors"], ["TCGA.CM.5868.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.5868.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.5868.01", "Transmission across Chemical Synapses"], ["TCGA.CM.5868.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.5868.01", "G alpha (q) signalling events"], ["TCGA.CM.5868.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.5868.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.CM.5868.01", "Extracellular matrix organization"], ["TCGA.CM.5868.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.CM.5868.01", "Generation of second messenger molecules"], ["TCGA.CM.5868.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.5868.01", "PD-1 signaling"], ["TCGA.CM.5868.01", "Signal amplification"], ["TCGA.CM.5868.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.5868.01", "L1CAM interactions"], ["TCGA.CM.5868.01", "Glucagon-type ligand receptors"], ["TCGA.CM.5868.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.CM.5868.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.5868.01", "Cardiac conduction"], ["TCGA.CM.5868.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CM.5868.01", "Scavenging of heme from plasma"], ["TCGA.CM.5868.01", "Platelet homeostasis"], ["TCGA.CM.5868.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.5868.01", "GABA receptor activation"], ["TCGA.CM.5868.01", "Peptide hormone metabolism"], ["TCGA.CM.5868.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.5868.01", "G alpha (s) signalling events"], ["TCGA.CM.5868.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.5868.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.CM.5868.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.5868.01", "Collagen chain trimerization"], ["TCGA.CM.5868.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.CM.5868.01", "Leishmania parasite growth and survival"], ["TCGA.CM.5868.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.5868.01", "Visual phototransduction"], ["TCGA.CM.5868.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CM.5868.01", "NCAM1 interactions"], ["TCGA.CM.5868.01", "GABA B receptor activation"], ["TCGA.CM.5868.01", "Activation of GABAB receptors"], ["TCGA.CM.5868.01", "Potassium Channels"], ["TCGA.CM.5868.01", "G-protein beta:gamma signalling"], ["TCGA.CM.5868.01", "Blood group systems biosynthesis"], ["TCGA.CM.5868.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.CM.5868.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.5868.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CM.5868.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.CM.5868.01", "Presynaptic function of Kainate receptors"], ["TCGA.CM.5868.01", "Trafficking and processing of endosomal TLR"], ["TCGA.CM.5868.01", "Activation of the phototransduction cascade"], ["TCGA.CM.5868.01", "Ethanol oxidation"], ["TCGA.CM.5868.01", "Digestion"], ["TCGA.CM.5868.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CM.5868.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.CM.5868.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CM.5868.01", "Protein-protein interactions at synapses"], ["TCGA.CM.5868.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CM.5868.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.5868.01", "Transport of small molecules"], ["TCGA.CM.5868.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.5868.01", "Inwardly rectifying K+ channels"], ["TCGA.CM.5868.01", "Activation of G protein gated Potassium channels"], ["TCGA.CM.5868.01", "G protein gated Potassium channels"], ["TCGA.CM.5868.01", "TNFs bind their physiological receptors"], ["TCGA.CM.5868.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CM.5868.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CM.5868.01", "NCAM signaling for neurite out-growth"], ["TCGA.CM.5868.01", "Collagen formation"], ["TCGA.CM.5868.01", "Biological oxidations"], ["TCGA.CM.5868.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.5868.01", "Developmental Biology"], ["TCGA.CM.5868.01", "SUMOylation of intracellular receptors"], ["TCGA.CM.5868.01", "Binding and entry of HIV virion"], ["TCGA.CM.5868.01", "Cell surface interactions at the vascular wall"], ["TCGA.CM.5868.01", "Lewis blood group biosynthesis"], ["TCGA.CM.5868.01", "G-protein activation"], ["TCGA.CM.5868.01", "Thromboxane signalling through TP receptor"], ["TCGA.CM.5868.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.CM.5868.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CM.5868.01", "Long-term potentiation"], ["TCGA.CM.5868.01", "Costimulation by the CD28 family"], ["TCGA.CM.5868.01", "ECM proteoglycans"], ["TCGA.CM.5868.01", "Ca2+ pathway"], ["TCGA.CM.5868.01", "Trafficking of AMPA receptors"], ["TCGA.CM.5868.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CM.5868.01", "Recycling of bile acids and salts"], ["TCGA.CM.5868.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.CM.5868.01", "Stimuli-sensing channels"], ["TCGA.CM.5868.01", "Arachidonic acid metabolism"], ["TCGA.CM.5868.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CM.5868.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.CM.5868.01", "Regulation of insulin secretion"], ["TCGA.CM.5868.01", "Acetylcholine binding and downstream events"], ["TCGA.CM.5868.01", "LGI-ADAM interactions"], ["TCGA.CM.5868.01", "Postsynaptic nicotinic acetylcholine receptors"], ["TCGA.CM.5868.01", "G-protein mediated events"], ["TCGA.CM.5868.01", "Neurexins and neuroligins"], ["TCGA.CM.5868.01", "Signaling by Retinoic Acid"], ["TCGA.CM.5868.01", "Sensory perception of taste"], ["TCGA.CM.5868.01", "G beta:gamma signalling through PLC beta"], ["TCGA.CM.5868.01", "G beta:gamma signalling through CDC42"], ["TCGA.CM.5868.01", "Ion channel transport"], ["TCGA.CM.6161.01", "Neuronal System"], ["TCGA.CM.6161.01", "Keratinization"], ["TCGA.CM.6161.01", "Transport of small molecules"], ["TCGA.CM.6161.01", "Lewis blood group biosynthesis"], ["TCGA.CM.6161.01", "Transmission across Chemical Synapses"], ["TCGA.CM.6161.01", "Blood group systems biosynthesis"], ["TCGA.CM.6161.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.6161.01", "Biological oxidations"], ["TCGA.CM.6161.01", "Metabolism"], ["TCGA.CM.6161.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.6161.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.6161.01", "GPCR ligand binding"], ["TCGA.CM.6161.01", "Glucuronidation"], ["TCGA.CM.6161.01", "RA biosynthesis pathway"], ["TCGA.CM.6161.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.6161.01", "Drug ADME"], ["TCGA.CM.6161.01", "Defective GALNT12 causes CRCS1"], ["TCGA.CM.6161.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.6161.01", "Formation of the cornified envelope"], ["TCGA.CM.6161.01", "Sialic acid metabolism"], ["TCGA.CM.6161.01", "Glucagon-type ligand receptors"], ["TCGA.CM.6161.01", "Signaling by Retinoic Acid"], ["TCGA.CM.6161.01", "Aspirin ADME"], ["TCGA.CM.6161.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.CM.6161.01", "Termination of O-glycan biosynthesis"], ["TCGA.CM.6161.01", "Ethanol oxidation"], ["TCGA.CM.6161.01", "Cardiac conduction"], ["TCGA.CM.6161.01", "NCAM1 interactions"], ["TCGA.CM.6167.01", "Extracellular matrix organization"], ["TCGA.CM.6167.01", "Biological oxidations"], ["TCGA.CM.6167.01", "Metabolism"], ["TCGA.CM.6167.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.6167.01", "Collagen formation"], ["TCGA.CM.6167.01", "Keratinization"], ["TCGA.CM.6167.01", "Collagen chain trimerization"], ["TCGA.CM.6167.01", "Stimuli-sensing channels"], ["TCGA.CM.6167.01", "RA biosynthesis pathway"], ["TCGA.CM.6167.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.6167.01", "O-linked glycosylation"], ["TCGA.CM.6167.01", "Defective B3GALTL causes PpS"], ["TCGA.CM.6167.01", "Transport of small molecules"], ["TCGA.CM.6167.01", "Aflatoxin activation and detoxification"], ["TCGA.CM.6167.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.6167.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.CM.6167.01", "Lewis blood group biosynthesis"], ["TCGA.CM.6167.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.CM.6167.01", "Ion channel transport"], ["TCGA.CM.6167.01", "Digestion"], ["TCGA.CM.6167.01", "Scavenging by Class A Receptors"], ["TCGA.CM.6167.01", "GPCR ligand binding"], ["TCGA.CM.6167.01", "Regulation of beta-cell development"], ["TCGA.CM.6167.01", "Blood group systems biosynthesis"], ["TCGA.CM.6167.01", "Phase I - Functionalization of compounds"], ["TCGA.CM.6167.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.6167.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.CM.6167.01", "Signaling by GPCR"], ["TCGA.CM.6167.01", "GPCR downstream signalling"], ["TCGA.CM.6167.01", "Peptide ligand-binding receptors"], ["TCGA.CM.6167.01", "Nucleotide catabolism"], ["TCGA.CM.6167.01", "APAP ADME"], ["TCGA.CM.6167.01", "G alpha (q) signalling events"], ["TCGA.CM.6169.01", "Metabolism"], ["TCGA.CM.6169.01", "Drug ADME"], ["TCGA.CM.6169.01", "Extracellular matrix organization"], ["TCGA.CM.6169.01", "Transport of small molecules"], ["TCGA.CM.6169.01", "SLC-mediated transmembrane transport"], ["TCGA.CM.6169.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.6169.01", "APAP ADME"], ["TCGA.CM.6169.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.6169.01", "Biological oxidations"], ["TCGA.CM.6169.01", "Glycosaminoglycan metabolism"], ["TCGA.CM.6169.01", "GPCR ligand binding"], ["TCGA.CM.6169.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CM.6169.01", "Transmission across Chemical Synapses"], ["TCGA.CM.6169.01", "Ethanol oxidation"], ["TCGA.CM.6169.01", "Signaling by Retinoic Acid"], ["TCGA.CM.6169.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.6169.01", "Glucagon-type ligand receptors"], ["TCGA.CM.6169.01", "Blood group systems biosynthesis"], ["TCGA.CM.6169.01", "Neuronal System"], ["TCGA.CM.6169.01", "Synaptic adhesion-like molecules"], ["TCGA.CM.6169.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.CM.6169.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.6169.01", "Degradation of the extracellular matrix"], ["TCGA.CM.6169.01", "Aspirin ADME"], ["TCGA.CM.6169.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.CM.6169.01", "Keratinization"], ["TCGA.CM.6169.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.CM.6169.01", "Long-term potentiation"], ["TCGA.CM.6169.01", "G alpha (q) signalling events"], ["TCGA.CM.6172.01", "GPCR ligand binding"], ["TCGA.CM.6172.01", "Signaling by GPCR"], ["TCGA.CM.6172.01", "GPCR downstream signalling"], ["TCGA.CM.6172.01", "G alpha (i) signalling events"], ["TCGA.CM.6172.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.6172.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.6172.01", "G alpha (s) signalling events"], ["TCGA.CM.6172.01", "Signaling Pathways"], ["TCGA.CM.6172.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.6172.01", "Glucagon-type ligand receptors"], ["TCGA.CM.6172.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.6172.01", "Peptide ligand-binding receptors"], ["TCGA.CM.6172.01", "RA biosynthesis pathway"], ["TCGA.CM.6172.01", "Peptide hormone metabolism"], ["TCGA.CM.6172.01", "Signaling by Retinoic Acid"], ["TCGA.CM.6172.01", "Platelet homeostasis"], ["TCGA.CM.6172.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.6172.01", "Transport of small molecules"], ["TCGA.CM.6172.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.6172.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.CM.6172.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.6172.01", "Thrombin signalling through proteinase activated receptors (PARs)"], ["TCGA.CM.6172.01", "G alpha (q) signalling events"], ["TCGA.CM.6172.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CM.6172.01", "Complement cascade"], ["TCGA.CM.6172.01", "G-protein activation"], ["TCGA.CM.6172.01", "Neuronal System"], ["TCGA.CM.6172.01", "GABA receptor activation"], ["TCGA.CM.6172.01", "Signaling by Nuclear Receptors"], ["TCGA.CM.6172.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.6172.01", "G alpha (z) signalling events"], ["TCGA.CM.6172.01", "Ethanol oxidation"], ["TCGA.CM.6172.01", "Transcriptional regulation of testis differentiation"], ["TCGA.CM.6172.01", "Metabolism of fat-soluble vitamins"], ["TCGA.CM.6172.01", "Retinoid metabolism and transport"], ["TCGA.CM.6172.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CM.6172.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.CM.6172.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.6172.01", "Heme degradation"], ["TCGA.CM.6172.01", "Insulin processing"], ["TCGA.CM.6172.01", "Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)"], ["TCGA.CM.6172.01", "G beta:gamma signalling through PLC beta"], ["TCGA.CM.6172.01", "G beta:gamma signalling through CDC42"], ["TCGA.CM.6172.01", "Potassium Channels"], ["TCGA.CM.6172.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.6172.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.CM.6172.01", "Presynaptic function of Kainate receptors"], ["TCGA.CM.6172.01", "Peptide hormone biosynthesis"], ["TCGA.CM.6172.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.CM.6172.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.6172.01", "Signal amplification"], ["TCGA.CM.6172.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.CM.6172.01", "Regulation of Complement cascade"], ["TCGA.CM.6675.01", "Neuronal System"], ["TCGA.CM.6675.01", "Signaling by GPCR"], ["TCGA.CM.6675.01", "GPCR downstream signalling"], ["TCGA.CM.6675.01", "Transmission across Chemical Synapses"], ["TCGA.CM.6675.01", "Cardiac conduction"], ["TCGA.CM.6675.01", "Potassium Channels"], ["TCGA.CM.6675.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.6675.01", "GPCR ligand binding"], ["TCGA.CM.6675.01", "Muscle contraction"], ["TCGA.CM.6675.01", "G alpha (i) signalling events"], ["TCGA.CM.6675.01", "Stimuli-sensing channels"], ["TCGA.CM.6675.01", "Ion channel transport"], ["TCGA.CM.6675.01", "Transport of small molecules"], ["TCGA.CM.6675.01", "Voltage gated Potassium channels"], ["TCGA.CM.6675.01", "G alpha (q) signalling events"], ["TCGA.CM.6675.01", "Protein-protein interactions at synapses"], ["TCGA.CM.6675.01", "Extracellular matrix organization"], ["TCGA.CM.6675.01", "Platelet homeostasis"], ["TCGA.CM.6675.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CM.6675.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.6675.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.6675.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.6675.01", "Regulation of insulin secretion"], ["TCGA.CM.6675.01", "Peptide ligand-binding receptors"], ["TCGA.CM.6675.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.CM.6675.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.CM.6675.01", "Signaling Pathways"], ["TCGA.CM.6675.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.6675.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CM.6675.01", "Synaptic adhesion-like molecules"], ["TCGA.CM.6675.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.CM.6675.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.CM.6675.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.6675.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.CM.6675.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], ["TCGA.CM.6675.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CM.6675.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.6675.01", "G-protein beta:gamma signalling"], ["TCGA.CM.6675.01", "NCAM1 interactions"], ["TCGA.CM.6675.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.CM.6675.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.6675.01", "CD22 mediated BCR regulation"], ["TCGA.CM.6675.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.CM.6675.01", "G alpha (s) signalling events"], ["TCGA.CM.6675.01", "Glucagon-type ligand receptors"], ["TCGA.CM.6675.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CM.6675.01", "Long-term potentiation"], ["TCGA.CM.6675.01", "Ion homeostasis"], ["TCGA.CM.6675.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CM.6675.01", "G beta:gamma signalling through CDC42"], ["TCGA.CM.6675.01", "Activation of G protein gated Potassium channels"], ["TCGA.CM.6675.01", "G protein gated Potassium channels"], ["TCGA.CM.6675.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CM.6675.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.CM.6676.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.6676.01", "Neuronal System"], ["TCGA.CM.6676.01", "Transmission across Chemical Synapses"], ["TCGA.CM.6676.01", "Signaling by GPCR"], ["TCGA.CM.6676.01", "GPCR downstream signalling"], ["TCGA.CM.6676.01", "GPCR ligand binding"], ["TCGA.CM.6676.01", "Biological oxidations"], ["TCGA.CM.6676.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CM.6676.01", "Phase II - Conjugation of compounds"], ["TCGA.CM.6676.01", "Visual phototransduction"], ["TCGA.CM.6676.01", "Immune System"], ["TCGA.CM.6676.01", "Complement cascade"], ["TCGA.CM.6676.01", "Glucuronidation"], ["TCGA.CM.6676.01", "RA biosynthesis pathway"], ["TCGA.CM.6676.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.CM.6676.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.CM.6676.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.CM.6676.01", "Signaling Pathways"], ["TCGA.CM.6676.01", "G alpha (i) signalling events"], ["TCGA.CM.6676.01", "Diseases of Immune System"], ["TCGA.CM.6676.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.CM.6676.01", "Ca2+ pathway"], ["TCGA.CM.6676.01", "Activation of the phototransduction cascade"], ["TCGA.CM.6676.01", "Initial triggering of complement"], ["TCGA.CM.6676.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.CM.6676.01", "Metabolism of fat-soluble vitamins"], ["TCGA.CM.6676.01", "Retinoid metabolism and transport"], ["TCGA.CM.6676.01", "Drug ADME"], ["TCGA.CM.6676.01", "Endosomal/Vacuolar pathway"], ["TCGA.CM.6676.01", "Cardiac conduction"], ["TCGA.CM.6676.01", "Glucagon-type ligand receptors"], ["TCGA.CM.6676.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CM.6676.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.6676.01", "Regulation of beta-cell development"], ["TCGA.CM.6676.01", "G beta:gamma signalling through BTK"], ["TCGA.CM.6676.01", "Transport of small molecules"], ["TCGA.CM.6676.01", "Inwardly rectifying K+ channels"], ["TCGA.CM.6676.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.6676.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.CM.6676.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.6676.01", "Protein-protein interactions at synapses"], ["TCGA.CM.6676.01", "Creation of C4 and C2 activators"], ["TCGA.CM.6676.01", "Regulation of Complement cascade"], ["TCGA.CM.6676.01", "Peptide ligand-binding receptors"], ["TCGA.CM.6676.01", "Classical antibody-mediated complement activation"], ["TCGA.CM.6676.01", "G-protein beta:gamma signalling"], ["TCGA.CM.6676.01", "Trafficking of AMPA receptors"], ["TCGA.CM.6676.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.CM.6676.01", "Peptide hormone metabolism"], ["TCGA.CM.6676.01", "Adaptive Immune System"], ["TCGA.CM.6676.01", "Regulation of TLR by endogenous ligand"], ["TCGA.CM.6676.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.6676.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.CM.6676.01", "Presynaptic function of Kainate receptors"], ["TCGA.CM.6676.01", "Signaling by Retinoic Acid"], ["TCGA.CM.6676.01", "Aspirin ADME"], ["TCGA.CM.6676.01", "Trafficking and processing of endosomal TLR"], ["TCGA.CM.6676.01", "Ethanol oxidation"], ["TCGA.CM.6676.01", "Digestion"], ["TCGA.CM.6676.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.6676.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.CM.6676.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.CM.6676.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.CM.6676.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CM.6676.01", "Potassium Channels"], ["TCGA.CM.6676.01", "Ligand-dependent caspase activation"], ["TCGA.CM.6676.01", "Digestion and absorption"], ["TCGA.CM.6676.01", "Activation of G protein gated Potassium channels"], ["TCGA.CM.6676.01", "G protein gated Potassium channels"], ["TCGA.CM.6676.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.6676.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.CM.6676.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.6676.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CM.6676.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.CM.6676.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.CM.6676.01", "Ion channel transport"], ["TCGA.CM.6676.01", "Extracellular matrix organization"], ["TCGA.CM.6676.01", "Recycling of bile acids and salts"], ["TCGA.CM.6676.01", "G alpha (s) signalling events"], ["TCGA.CM.6678.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.CM.6678.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.CM.6678.01", "Generation of second messenger molecules"], ["TCGA.CM.6678.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.CM.6678.01", "PD-1 signaling"], ["TCGA.CM.6678.01", "Immune System"], ["TCGA.CM.6678.01", "GPCR downstream signalling"], ["TCGA.CM.6678.01", "Signaling by GPCR"], ["TCGA.CM.6678.01", "G alpha (i) signalling events"], ["TCGA.CM.6678.01", "Transport of small molecules"], ["TCGA.CM.6678.01", "Adaptive Immune System"], ["TCGA.CM.6678.01", "Extracellular matrix organization"], ["TCGA.CM.6678.01", "Costimulation by the CD28 family"], ["TCGA.CM.6678.01", "Activation of Matrix Metalloproteinases"], ["TCGA.CM.6678.01", "Signaling Pathways"], ["TCGA.CM.6678.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.CM.6678.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.CM.6678.01", "Peptide ligand-binding receptors"], ["TCGA.CM.6678.01", "GPCR ligand binding"], ["TCGA.CM.6678.01", "Complement cascade"], ["TCGA.CM.6678.01", "Regulation of Complement cascade"], ["TCGA.CM.6678.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.CM.6678.01", "CD22 mediated BCR regulation"], ["TCGA.CM.6678.01", "Chemokine receptors bind chemokines"], ["TCGA.CM.6678.01", "Ion channel transport"], ["TCGA.CM.6678.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.6678.01", "Interaction between L1 and Ankyrins"], ["TCGA.CM.6678.01", "TNFs bind their physiological receptors"], ["TCGA.CM.6678.01", "Other semaphorin interactions"], ["TCGA.CM.6678.01", "TCR signaling"], ["TCGA.CM.6678.01", "Classical antibody-mediated complement activation"], ["TCGA.CM.6678.01", "G alpha (q) signalling events"], ["TCGA.CM.6678.01", "Degradation of the extracellular matrix"], ["TCGA.CM.6678.01", "Stimuli-sensing channels"], ["TCGA.CM.6678.01", "Glucagon signaling in metabolic regulation"], ["TCGA.CM.6678.01", "Leishmania infection"], ["TCGA.CM.6678.01", "Glucuronidation"], ["TCGA.CM.6678.01", "Regulation of FZD by ubiquitination"], ["TCGA.CM.6678.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.CM.6678.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.CM.6678.01", "Digestion"], ["TCGA.CM.6678.01", "Diseases of Immune System"], ["TCGA.CM.6678.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.CM.6678.01", "Innate Immune System"], ["TCGA.CM.6678.01", "Neuronal System"], ["TCGA.CM.6678.01", "Collagen formation"], ["TCGA.CM.6678.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.6678.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.CM.6678.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.CM.6678.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.CM.6678.01", "Digestion and absorption"], ["TCGA.CM.6678.01", "G alpha (s) signalling events"], ["TCGA.CM.6678.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.CM.6678.01", "SUMOylation of intracellular receptors"], ["TCGA.CM.6678.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.CM.6678.01", "Leishmania parasite growth and survival"], ["TCGA.CM.6678.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.CM.6678.01", "Potassium Channels"], ["TCGA.D5.5537.01", "Neuronal System"], ["TCGA.D5.5537.01", "Transport of small molecules"], ["TCGA.D5.5537.01", "Signaling by GPCR"], ["TCGA.D5.5537.01", "Transmission across Chemical Synapses"], ["TCGA.D5.5537.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.5537.01", "GPCR downstream signalling"], ["TCGA.D5.5537.01", "Cardiac conduction"], ["TCGA.D5.5537.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.D5.5537.01", "G alpha (i) signalling events"], ["TCGA.D5.5537.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.5537.01", "Ion channel transport"], ["TCGA.D5.5537.01", "Peptide hormone metabolism"], ["TCGA.D5.5537.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.5537.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.D5.5537.01", "L1CAM interactions"], ["TCGA.D5.5537.01", "Signaling Pathways"], ["TCGA.D5.5537.01", "GPCR ligand binding"], ["TCGA.D5.5537.01", "Extracellular matrix organization"], ["TCGA.D5.5537.01", "Potassium Channels"], ["TCGA.D5.5537.01", "G alpha (s) signalling events"], ["TCGA.D5.5537.01", "Scavenging of heme from plasma"], ["TCGA.D5.5537.01", "Ethanol oxidation"], ["TCGA.D5.5537.01", "Regulation of insulin secretion"], ["TCGA.D5.5537.01", "Protein-protein interactions at synapses"], ["TCGA.D5.5537.01", "RA biosynthesis pathway"], ["TCGA.D5.5537.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.D5.5537.01", "Heme degradation"], ["TCGA.D5.5537.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], ["TCGA.D5.5537.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.5537.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.5537.01", "Muscle contraction"], ["TCGA.D5.5537.01", "Signaling by Retinoic Acid"], ["TCGA.D5.5537.01", "Complement cascade"], ["TCGA.D5.5537.01", "Integration of energy metabolism"], ["TCGA.D5.5537.01", "Stimuli-sensing channels"], ["TCGA.D5.5537.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.D5.5537.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.D5.5537.01", "NCAM signaling for neurite out-growth"], ["TCGA.D5.5537.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.5537.01", "O-linked glycosylation"], ["TCGA.D5.5537.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.D5.5537.01", "LGI-ADAM interactions"], ["TCGA.D5.5537.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.5537.01", "G-protein beta:gamma signalling"], ["TCGA.D5.5537.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.5537.01", "Signal amplification"], ["TCGA.D5.5537.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.D5.5537.01", "Leishmania parasite growth and survival"], ["TCGA.D5.5537.01", "Glucagon-type ligand receptors"], ["TCGA.D5.5537.01", "Regulation of FZD by ubiquitination"], ["TCGA.D5.5537.01", "Chemokine receptors bind chemokines"], ["TCGA.D5.5537.01", "Ion homeostasis"], ["TCGA.D5.5537.01", "Digestion"], ["TCGA.D5.5537.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.D5.5537.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.D5.5537.01", "FOXO-mediated transcription"], ["TCGA.D5.5537.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.5537.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.D5.5537.01", "Neurotransmitter release cycle"], ["TCGA.D5.5537.01", "Digestion and absorption"], ["TCGA.D5.5537.01", "GABA receptor activation"], ["TCGA.D5.5537.01", "Collagen chain trimerization"], ["TCGA.D5.5537.01", "NCAM1 interactions"], ["TCGA.D5.5537.01", "Regulation of Complement cascade"], ["TCGA.D5.5537.01", "Peptide ligand-binding receptors"], ["TCGA.D5.5537.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.5537.01", "G alpha (q) signalling events"], ["TCGA.D5.5537.01", "G beta:gamma signalling through BTK"], ["TCGA.D5.5537.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.D5.5537.01", "Long-term potentiation"], ["TCGA.D5.5537.01", "Platelet homeostasis"], ["TCGA.D5.5537.01", "Leishmania infection"], ["TCGA.D5.5537.01", "Aquaporin-mediated transport"], ["TCGA.D5.5537.01", "Drug ADME"], ["TCGA.D5.5537.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.D5.5537.01", "Phase 4 - resting membrane potential"], ["TCGA.D5.5538.01", "Neuronal System"], ["TCGA.D5.5538.01", "Transmission across Chemical Synapses"], ["TCGA.D5.5538.01", "Protein-protein interactions at synapses"], ["TCGA.D5.5538.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.5538.01", "Extracellular matrix organization"], ["TCGA.D5.5538.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.5538.01", "Degradation of the extracellular matrix"], ["TCGA.D5.5538.01", "GPCR ligand binding"], ["TCGA.D5.5538.01", "O-linked glycosylation"], ["TCGA.D5.5538.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.5538.01", "L1CAM interactions"], ["TCGA.D5.5538.01", "Long-term potentiation"], ["TCGA.D5.5538.01", "Signaling by GPCR"], ["TCGA.D5.5538.01", "Transport of small molecules"], ["TCGA.D5.5538.01", "Muscle contraction"], ["TCGA.D5.5538.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.5538.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.D5.5538.01", "Transcriptional regulation of testis differentiation"], ["TCGA.D5.5538.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.D5.5538.01", "G alpha (i) signalling events"], ["TCGA.D5.5538.01", "G alpha (s) signalling events"], ["TCGA.D5.5538.01", "Peptide hormone metabolism"], ["TCGA.D5.5538.01", "Defective B3GALTL causes PpS"], ["TCGA.D5.5538.01", "GPCR downstream signalling"], ["TCGA.D5.5538.01", "Synaptic adhesion-like molecules"], ["TCGA.D5.5538.01", "Drug ADME"], ["TCGA.D5.5538.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.D5.5538.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.D5.5538.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.D5.5538.01", "Post NMDA receptor activation events"], ["TCGA.D5.5538.01", "Diseases of glycosylation"], ["TCGA.D5.5538.01", "NCAM1 interactions"], ["TCGA.D5.5541.01", "Neuronal System"], ["TCGA.D5.5541.01", "Transport of small molecules"], ["TCGA.D5.5541.01", "Extracellular matrix organization"], ["TCGA.D5.5541.01", "Biological oxidations"], ["TCGA.D5.5541.01", "Drug ADME"], ["TCGA.D5.5541.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.5541.01", "Transmission across Chemical Synapses"], ["TCGA.D5.5541.01", "Degradation of the extracellular matrix"], ["TCGA.D5.5541.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.5541.01", "Blood group systems biosynthesis"], ["TCGA.D5.5541.01", "RA biosynthesis pathway"], ["TCGA.D5.5541.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.5541.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.D5.5541.01", "Cardiac conduction"], ["TCGA.D5.5541.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.5541.01", "Phase I - Functionalization of compounds"], ["TCGA.D5.5541.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.5541.01", "Signaling by GPCR"], ["TCGA.D5.5541.01", "Ion channel transport"], ["TCGA.D5.5541.01", "Ethanol oxidation"], ["TCGA.D5.5541.01", "O-linked glycosylation"], ["TCGA.D5.5541.01", "G alpha (i) signalling events"], ["TCGA.D5.5541.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.D5.5541.01", "Signaling by Retinoic Acid"], ["TCGA.D5.5541.01", "Aspirin ADME"], ["TCGA.D5.5541.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.5541.01", "G alpha (s) signalling events"], ["TCGA.D5.5541.01", "O-linked glycosylation of mucins"], ["TCGA.D5.5541.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.5541.01", "APAP ADME"], ["TCGA.D5.5541.01", "GPCR downstream signalling"], ["TCGA.D5.5541.01", "Lewis blood group biosynthesis"], ["TCGA.D5.5541.01", "GABA receptor activation"], ["TCGA.D5.5541.01", "Defective GALNT12 causes CRCS1"], ["TCGA.D5.5541.01", "GPCR ligand binding"], ["TCGA.D5.5541.01", "Platelet homeostasis"], ["TCGA.D5.5541.01", "Stimuli-sensing channels"], ["TCGA.D5.5541.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.5541.01", "Glucuronidation"], ["TCGA.D5.5541.01", "Scavenging of heme from plasma"], ["TCGA.D5.5541.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.5541.01", "Collagen formation"], ["TCGA.D5.5541.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.5541.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.5541.01", "Collagen degradation"], ["TCGA.D5.5541.01", "Platelet calcium homeostasis"], ["TCGA.D5.5541.01", "ECM proteoglycans"], ["TCGA.D5.5541.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.D5.5541.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.D5.5541.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.D5.5541.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.D5.5541.01", "Arachidonic acid metabolism"], ["TCGA.D5.5541.01", "Protein-protein interactions at synapses"], ["TCGA.D5.5541.01", "Signal amplification"], ["TCGA.D5.5541.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.D5.5541.01", "Transcription of E2F targets under negative control by DREAM complex"], ["TCGA.D5.5541.01", "Metabolism"], ["TCGA.D5.6529.01", "Extracellular matrix organization"], ["TCGA.D5.6529.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6529.01", "Collagen formation"], ["TCGA.D5.6529.01", "Degradation of the extracellular matrix"], ["TCGA.D5.6529.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.D5.6529.01", "Neuronal System"], ["TCGA.D5.6529.01", "Collagen chain trimerization"], ["TCGA.D5.6529.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.D5.6529.01", "Biological oxidations"], ["TCGA.D5.6529.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6529.01", "Metabolism"], ["TCGA.D5.6529.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6529.01", "Drug ADME"], ["TCGA.D5.6529.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6529.01", "Heme degradation"], ["TCGA.D5.6529.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.D5.6529.01", "Glucagon-type ligand receptors"], ["TCGA.D5.6529.01", "Regulation of insulin secretion"], ["TCGA.D5.6529.01", "Glucuronidation"], ["TCGA.D5.6529.01", "Keratinization"], ["TCGA.D5.6529.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.6529.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6529.01", "Ethanol oxidation"], ["TCGA.D5.6529.01", "Cardiac conduction"], ["TCGA.D5.6529.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6529.01", "O-linked glycosylation"], ["TCGA.D5.6529.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.D5.6529.01", "Protein-protein interactions at synapses"], ["TCGA.D5.6529.01", "GABA receptor activation"], ["TCGA.D5.6529.01", "Signaling by Retinoic Acid"], ["TCGA.D5.6529.01", "Signal amplification"], ["TCGA.D5.6529.01", "Integration of energy metabolism"], ["TCGA.D5.6529.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.6529.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.6529.01", "Transport of small molecules"], ["TCGA.D5.6529.01", "Scavenging by Class A Receptors"], ["TCGA.D5.6529.01", "Defective B3GALTL causes PpS"], ["TCGA.D5.6529.01", "FGFR2c ligand binding and activation"], ["TCGA.D5.6529.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.D5.6529.01", "FGFR2 ligand binding and activation"], ["TCGA.D5.6529.01", "Blood group systems biosynthesis"], ["TCGA.D5.6529.01", "NCAM1 interactions"], ["TCGA.D5.6529.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.6529.01", "Developmental Biology"], ["TCGA.D5.6529.01", "FGFR4 ligand binding and activation"], ["TCGA.D5.6529.01", "Presynaptic function of Kainate receptors"], ["TCGA.D5.6529.01", "RA biosynthesis pathway"], ["TCGA.D5.6529.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.D5.6529.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.D5.6529.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.6529.01", "NCAM signaling for neurite out-growth"], ["TCGA.D5.6529.01", "GPCR ligand binding"], ["TCGA.D5.6529.01", "L1CAM interactions"], ["TCGA.D5.6529.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.6529.01", "Collagen degradation"], ["TCGA.D5.6529.01", "Signaling by GPCR"], ["TCGA.D5.6529.01", "Aspirin ADME"], ["TCGA.D5.6529.01", "Glycogen breakdown (glycogenolysis)"], ["TCGA.D5.6529.01", "Peptide hormone metabolism"], ["TCGA.D5.6529.01", "G alpha (i) signalling events"], ["TCGA.D5.6529.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.D5.6529.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.D5.6529.01", "GPCR downstream signalling"], ["TCGA.D5.6529.01", "Porphyrin metabolism"], ["TCGA.D5.6529.01", "G-protein activation"], ["TCGA.D5.6529.01", "Thromboxane signalling through TP receptor"], ["TCGA.D5.6529.01", "Interleukin-6 family signaling"], ["TCGA.D5.6529.01", "G alpha (q) signalling events"], ["TCGA.D5.6529.01", "Activated point mutants of FGFR2"], ["TCGA.D5.6529.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.D5.6529.01", "Digestion and absorption"], ["TCGA.D5.6529.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.D5.6529.01", "Bile acid and bile salt metabolism"], ["TCGA.D5.6529.01", "GABA B receptor activation"], ["TCGA.D5.6529.01", "Activation of GABAB receptors"], ["TCGA.D5.6529.01", "Signaling by activated point mutants of FGFR1"], ["TCGA.D5.6529.01", "FGFR1c ligand binding and activation"], ["TCGA.D5.6529.01", "Digestion"], ["TCGA.D5.6529.01", "Phospholipase C-mediated cascade; FGFR2"], ["TCGA.D5.6529.01", "G beta:gamma signalling through BTK"], ["TCGA.D5.6529.01", "Carbohydrate metabolism"], ["TCGA.D5.6529.01", "Inwardly rectifying K+ channels"], ["TCGA.D5.6529.01", "Aquaporin-mediated transport"], ["TCGA.D5.6529.01", "Neurexins and neuroligins"], ["TCGA.D5.6531.01", "Transport of small molecules"], ["TCGA.D5.6531.01", "Neuronal System"], ["TCGA.D5.6531.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6531.01", "Cardiac conduction"], ["TCGA.D5.6531.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6531.01", "Ion channel transport"], ["TCGA.D5.6531.01", "Drug ADME"], ["TCGA.D5.6531.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6531.01", "Signaling by GPCR"], ["TCGA.D5.6531.01", "RA biosynthesis pathway"], ["TCGA.D5.6531.01", "G alpha (i) signalling events"], ["TCGA.D5.6531.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6531.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6531.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.6531.01", "Muscle contraction"], ["TCGA.D5.6531.01", "O-linked glycosylation"], ["TCGA.D5.6531.01", "Extracellular matrix organization"], ["TCGA.D5.6531.01", "GPCR downstream signalling"], ["TCGA.D5.6531.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.6531.01", "Signaling by Retinoic Acid"], ["TCGA.D5.6531.01", "Regulation of insulin secretion"], ["TCGA.D5.6531.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.D5.6531.01", "Amino acid transport across the plasma membrane"], ["TCGA.D5.6531.01", "Stimuli-sensing channels"], ["TCGA.D5.6531.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.D5.6531.01", "Biological oxidations"], ["TCGA.D5.6531.01", "Keratinization"], ["TCGA.D5.6531.01", "Sialic acid metabolism"], ["TCGA.D5.6531.01", "Integration of energy metabolism"], ["TCGA.D5.6531.01", "Defective B3GALTL causes PpS"], ["TCGA.D5.6531.01", "Peptide hormone metabolism"], ["TCGA.D5.6531.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6531.01", "Regulation of beta-cell development"], ["TCGA.D5.6531.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.D5.6531.01", "Ion homeostasis"], ["TCGA.D5.6531.01", "Defective GALNT12 causes CRCS1"], ["TCGA.D5.6531.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.D5.6531.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.D5.6531.01", "Metabolism of vitamins and cofactors"], ["TCGA.D5.6531.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.6531.01", "Developmental Biology"], ["TCGA.D5.6531.01", "Insulin processing"], ["TCGA.D5.6531.01", "Blood group systems biosynthesis"], ["TCGA.D5.6531.01", "Visual phototransduction"], ["TCGA.D5.6535.01", "Neuronal System"], ["TCGA.D5.6535.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6535.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6535.01", "Platelet homeostasis"], ["TCGA.D5.6535.01", "Transport of small molecules"], ["TCGA.D5.6535.01", "Cardiac conduction"], ["TCGA.D5.6535.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.D5.6535.01", "Biological oxidations"], ["TCGA.D5.6535.01", "GABA receptor activation"], ["TCGA.D5.6535.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.6535.01", "Drug ADME"], ["TCGA.D5.6535.01", "G alpha (i) signalling events"], ["TCGA.D5.6535.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6535.01", "Ethanol oxidation"], ["TCGA.D5.6535.01", "Glucagon-type ligand receptors"], ["TCGA.D5.6535.01", "Potassium Channels"], ["TCGA.D5.6535.01", "Protein-protein interactions at synapses"], ["TCGA.D5.6535.01", "Regulation of insulin secretion"], ["TCGA.D5.6535.01", "Muscle contraction"], ["TCGA.D5.6535.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.D5.6535.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.6535.01", "Heme degradation"], ["TCGA.D5.6535.01", "G alpha (s) signalling events"], ["TCGA.D5.6535.01", "GPCR ligand binding"], ["TCGA.D5.6535.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6535.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.6535.01", "Integration of energy metabolism"], ["TCGA.D5.6535.01", "GABA B receptor activation"], ["TCGA.D5.6535.01", "Activation of GABAB receptors"], ["TCGA.D5.6535.01", "Stimuli-sensing channels"], ["TCGA.D5.6535.01", "Signaling by GPCR"], ["TCGA.D5.6535.01", "Signal amplification"], ["TCGA.D5.6535.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.D5.6535.01", "GPCR downstream signalling"], ["TCGA.D5.6535.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6535.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.6535.01", "RA biosynthesis pathway"], ["TCGA.D5.6535.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.D5.6535.01", "Ion channel transport"], ["TCGA.D5.6535.01", "Inwardly rectifying K+ channels"], ["TCGA.D5.6535.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.6535.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6535.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.D5.6535.01", "Aspartate and asparagine metabolism"], ["TCGA.D5.6535.01", "Activation of G protein gated Potassium channels"], ["TCGA.D5.6535.01", "G protein gated Potassium channels"], ["TCGA.D5.6535.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.D5.6535.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.D5.6535.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.D5.6535.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.D5.6535.01", "L1CAM interactions"], ["TCGA.D5.6535.01", "G beta:gamma signalling through BTK"], ["TCGA.D5.6535.01", "Keratan sulfate biosynthesis"], ["TCGA.D5.6535.01", "Degradation of the extracellular matrix"], ["TCGA.D5.6535.01", "G alpha (z) signalling events"], ["TCGA.D5.6535.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.D5.6535.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.D5.6535.01", "Phase 4 - resting membrane potential"], ["TCGA.D5.6535.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.6535.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.D5.6535.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.D5.6535.01", "G beta:gamma signalling through PLC beta"], ["TCGA.D5.6535.01", "G beta:gamma signalling through CDC42"], ["TCGA.D5.6535.01", "Acetylcholine binding and downstream events"], ["TCGA.D5.6535.01", "Attenuation phase"], ["TCGA.D5.6535.01", "Postsynaptic nicotinic acetylcholine receptors"], ["TCGA.D5.6535.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.D5.6535.01", "Regulation of FZD by ubiquitination"], ["TCGA.D5.6535.01", "Presynaptic function of Kainate receptors"], ["TCGA.D5.6535.01", "Synaptic adhesion-like molecules"], ["TCGA.D5.6535.01", "Peptide hormone metabolism"], ["TCGA.D5.6535.01", "Arachidonic acid metabolism"], ["TCGA.D5.6535.01", "TNFs bind their physiological receptors"], ["TCGA.D5.6535.01", "Metal ion SLC transporters"], ["TCGA.D5.6537.01", "Neuronal System"], ["TCGA.D5.6537.01", "Signaling by GPCR"], ["TCGA.D5.6537.01", "GPCR downstream signalling"], ["TCGA.D5.6537.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6537.01", "G alpha (i) signalling events"], ["TCGA.D5.6537.01", "Signaling Pathways"], ["TCGA.D5.6537.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6537.01", "GPCR ligand binding"], ["TCGA.D5.6537.01", "Cardiac conduction"], ["TCGA.D5.6537.01", "G-protein mediated events"], ["TCGA.D5.6537.01", "Ca-dependent events"], ["TCGA.D5.6537.01", "PLC beta mediated events"], ["TCGA.D5.6537.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.D5.6537.01", "Calmodulin induced events"], ["TCGA.D5.6537.01", "CaM pathway"], ["TCGA.D5.6537.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6537.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.6537.01", "DAG and IP3 signaling"], ["TCGA.D5.6537.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.D5.6537.01", "Potassium Channels"], ["TCGA.D5.6537.01", "Muscle contraction"], ["TCGA.D5.6537.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.6537.01", "Complement cascade"], ["TCGA.D5.6537.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.D5.6537.01", "Regulation of Complement cascade"], ["TCGA.D5.6537.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.D5.6537.01", "G alpha (s) signalling events"], ["TCGA.D5.6537.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.D5.6537.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.D5.6537.01", "Biological oxidations"], ["TCGA.D5.6537.01", "Chemokine receptors bind chemokines"], ["TCGA.D5.6537.01", "Integration of energy metabolism"], ["TCGA.D5.6537.01", "Regulation of insulin secretion"], ["TCGA.D5.6537.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.6537.01", "Platelet homeostasis"], ["TCGA.D5.6537.01", "Transport of small molecules"], ["TCGA.D5.6537.01", "Generation of second messenger molecules"], ["TCGA.D5.6537.01", "Drug ADME"], ["TCGA.D5.6537.01", "Recycling of bile acids and salts"], ["TCGA.D5.6537.01", "Initial triggering of complement"], ["TCGA.D5.6537.01", "Ion homeostasis"], ["TCGA.D5.6537.01", "L1CAM interactions"], ["TCGA.D5.6537.01", "PD-1 signaling"], ["TCGA.D5.6537.01", "Glucagon-type ligand receptors"], ["TCGA.D5.6537.01", "Protein-protein interactions at synapses"], ["TCGA.D5.6537.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.D5.6537.01", "Leishmania parasite growth and survival"], ["TCGA.D5.6537.01", "Peptide ligand-binding receptors"], ["TCGA.D5.6537.01", "GABA receptor activation"], ["TCGA.D5.6537.01", "GABA B receptor activation"], ["TCGA.D5.6537.01", "Activation of GABAB receptors"], ["TCGA.D5.6537.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.6537.01", "Classical antibody-mediated complement activation"], ["TCGA.D5.6537.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.D5.6537.01", "Extracellular matrix organization"], ["TCGA.D5.6537.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.D5.6537.01", "Post NMDA receptor activation events"], ["TCGA.D5.6537.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6537.01", "G-protein beta:gamma signalling"], ["TCGA.D5.6537.01", "Other semaphorin interactions"], ["TCGA.D5.6537.01", "Molecules associated with elastic fibres"], ["TCGA.D5.6537.01", "Signal amplification"], ["TCGA.D5.6537.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.D5.6537.01", "Developmental Biology"], ["TCGA.D5.6537.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.D5.6537.01", "Blood group systems biosynthesis"], ["TCGA.D5.6537.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.D5.6537.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.D5.6537.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.D5.6537.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.D5.6537.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.D5.6537.01", "Metabolism of fat-soluble vitamins"], ["TCGA.D5.6537.01", "Retinoid metabolism and transport"], ["TCGA.D5.6537.01", "Ion channel transport"], ["TCGA.D5.6537.01", "Voltage gated Potassium channels"], ["TCGA.D5.6537.01", "Regulation of FZD by ubiquitination"], ["TCGA.D5.6537.01", "Phase I - Functionalization of compounds"], ["TCGA.D5.6537.01", "SUMOylation of intracellular receptors"], ["TCGA.D5.6537.01", "Adenylate cyclase inhibitory pathway"], ["TCGA.D5.6537.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.D5.6537.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.6537.01", "Visual phototransduction"], ["TCGA.D5.6537.01", "Lewis blood group biosynthesis"], ["TCGA.D5.6537.01", "Aspirin ADME"], ["TCGA.D5.6537.01", "Trafficking of AMPA receptors"], ["TCGA.D5.6537.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.D5.6537.01", "Ion transport by P-type ATPases"], ["TCGA.D5.6537.01", "Platelet activation, signaling and aggregation"], ["TCGA.D5.6537.01", "Activation of the phototransduction cascade"], ["TCGA.D5.6537.01", "CD22 mediated BCR regulation"], ["TCGA.D5.6537.01", "Ca2+ pathway"], ["TCGA.D5.6537.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.D5.6537.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.6537.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.D5.6537.01", "Bile acid and bile salt metabolism"], ["TCGA.D5.6537.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.D5.6537.01", "Long-term potentiation"], ["TCGA.D5.6537.01", "G alpha (z) signalling events"], ["TCGA.D5.6537.01", "GPER1 signaling"], ["TCGA.D5.6537.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.D5.6537.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.D5.6537.01", "Heme degradation"], ["TCGA.D5.6537.01", "Defective B3GALTL causes PpS"], ["TCGA.D5.6537.01", "Neurotransmitter release cycle"], ["TCGA.D5.6537.01", "MHC class II antigen presentation"], ["TCGA.D5.6537.01", "Leishmania infection"], ["TCGA.D5.6537.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.D5.6537.01", "Aquaporin-mediated transport"], ["TCGA.D5.6537.01", "Inwardly rectifying K+ channels"], ["TCGA.D5.6537.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.D5.6537.01", "PKA activation in glucagon signalling"], ["TCGA.D5.6537.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.D5.6537.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.D5.6537.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.D5.6537.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.D5.6537.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.D5.6537.01", "Glycosaminoglycan metabolism"], ["TCGA.D5.6537.01", "NCAM1 interactions"], ["TCGA.D5.6537.01", "NCAM signaling for neurite out-growth"], ["TCGA.D5.6537.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.D5.6537.01", "Other interleukin signaling"], ["TCGA.D5.6537.01", "Nuclear Receptor transcription pathway"], ["TCGA.D5.6537.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6898.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6898.01", "Drug ADME"], ["TCGA.D5.6898.01", "GPCR ligand binding"], ["TCGA.D5.6898.01", "Blood group systems biosynthesis"], ["TCGA.D5.6898.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.D5.6898.01", "Ethanol oxidation"], ["TCGA.D5.6898.01", "Biological oxidations"], ["TCGA.D5.6898.01", "Peptide ligand-binding receptors"], ["TCGA.D5.6898.01", "Lewis blood group biosynthesis"], ["TCGA.D5.6898.01", "Neuronal System"], ["TCGA.D5.6898.01", "Glucuronidation"], ["TCGA.D5.6898.01", "RA biosynthesis pathway"], ["TCGA.D5.6898.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6898.01", "Digestion"], ["TCGA.D5.6898.01", "Degradation of the extracellular matrix"], ["TCGA.D5.6898.01", "APAP ADME"], ["TCGA.D5.6898.01", "Digestion and absorption"], ["TCGA.D5.6898.01", "Signaling by Retinoic Acid"], ["TCGA.D5.6898.01", "Aspirin ADME"], ["TCGA.D5.6898.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.D5.6898.01", "Keratinization"], ["TCGA.D5.6898.01", "Extracellular matrix organization"], ["TCGA.D5.6898.01", "Peptide hormone metabolism"], ["TCGA.D5.6898.01", "G alpha (i) signalling events"], ["TCGA.D5.6898.01", "Potassium Channels"], ["TCGA.D5.6898.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.6898.01", "Regulation of FZD by ubiquitination"], ["TCGA.D5.6898.01", "Transport of small molecules"], ["TCGA.D5.6931.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6931.01", "Neuronal System"], ["TCGA.D5.6931.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6931.01", "Keratinization"], ["TCGA.D5.6931.01", "Signaling by Retinoic Acid"], ["TCGA.D5.6931.01", "Protein-protein interactions at synapses"], ["TCGA.D5.6931.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6931.01", "GABA receptor activation"], ["TCGA.D5.6931.01", "L1CAM interactions"], ["TCGA.D5.6931.01", "Developmental Biology"], ["TCGA.D5.6931.01", "RA biosynthesis pathway"], ["TCGA.D5.6931.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.D5.6931.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6931.01", "Class B/2 (Secretin family receptors)"], ["TCGA.D5.6931.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.D5.6931.01", "Collagen formation"], ["TCGA.D5.6931.01", "Synaptic adhesion-like molecules"], ["TCGA.D5.6931.01", "Signaling by Nuclear Receptors"], ["TCGA.D5.6931.01", "Extracellular matrix organization"], ["TCGA.D5.6931.01", "Integration of energy metabolism"], ["TCGA.D5.6931.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.6931.01", "Drug ADME"], ["TCGA.D5.6931.01", "Interleukin-6 family signaling"], ["TCGA.D5.6931.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6931.01", "Defective B3GALTL causes PpS"], ["TCGA.D5.6931.01", "Neurexins and neuroligins"], ["TCGA.D5.6931.01", "Basigin interactions"], ["TCGA.D5.6931.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.D5.6931.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.D5.6931.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.D5.6931.01", "Formation of the cornified envelope"], ["TCGA.D5.6931.01", "Recycling pathway of L1"], ["TCGA.D5.6931.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.6931.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.D5.6931.01", "Transport of small molecules"], ["TCGA.D5.6931.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6931.01", "Neurotransmitter release cycle"], ["TCGA.D5.6931.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.D5.6931.01", "Heme degradation"], ["TCGA.D5.6931.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.D5.6931.01", "Activation of G protein gated Potassium channels"], ["TCGA.D5.6931.01", "G protein gated Potassium channels"], ["TCGA.D5.6931.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.D5.6932.01", "Neuronal System"], ["TCGA.D5.6932.01", "Biological oxidations"], ["TCGA.D5.6932.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.6932.01", "Drug ADME"], ["TCGA.D5.6932.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.6932.01", "Transport of small molecules"], ["TCGA.D5.6932.01", "Activation of Matrix Metalloproteinases"], ["TCGA.D5.6932.01", "Transmission across Chemical Synapses"], ["TCGA.D5.6932.01", "Extracellular matrix organization"], ["TCGA.D5.6932.01", "Signaling by GPCR"], ["TCGA.D5.6932.01", "GPCR downstream signalling"], ["TCGA.D5.6932.01", "GPCR ligand binding"], ["TCGA.D5.6932.01", "G alpha (i) signalling events"], ["TCGA.D5.6932.01", "SLC-mediated transmembrane transport"], ["TCGA.D5.6932.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.6932.01", "Voltage gated Potassium channels"], ["TCGA.D5.6932.01", "Potassium Channels"], ["TCGA.D5.6932.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.D5.6932.01", "Cardiac conduction"], ["TCGA.D5.6932.01", "Peptide hormone metabolism"], ["TCGA.D5.6932.01", "G alpha (s) signalling events"], ["TCGA.D5.6932.01", "L1CAM interactions"], ["TCGA.D5.6932.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.D5.6932.01", "Regulation of insulin secretion"], ["TCGA.D5.6932.01", "Peptide ligand-binding receptors"], ["TCGA.D5.6932.01", "Glucagon signaling in metabolic regulation"], ["TCGA.D5.6932.01", "Ion channel transport"], ["TCGA.D5.6932.01", "Collagen formation"], ["TCGA.D5.6932.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.6932.01", "Integration of energy metabolism"], ["TCGA.D5.6932.01", "Signaling Pathways"], ["TCGA.D5.6932.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.D5.6932.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.6932.01", "TNFs bind their physiological receptors"], ["TCGA.DM.A0X9.01", "Neuronal System"], ["TCGA.DM.A0X9.01", "Interaction between L1 and Ankyrins"], ["TCGA.DM.A0X9.01", "Potassium Channels"], ["TCGA.DM.A0X9.01", "Signaling by GPCR"], ["TCGA.DM.A0X9.01", "Protein-protein interactions at synapses"], ["TCGA.DM.A0X9.01", "Activation of Matrix Metalloproteinases"], ["TCGA.DM.A0X9.01", "G alpha (i) signalling events"], ["TCGA.DM.A0X9.01", "GPCR downstream signalling"], ["TCGA.DM.A0X9.01", "GPCR ligand binding"], ["TCGA.DM.A0X9.01", "Transmission across Chemical Synapses"], ["TCGA.DM.A0X9.01", "Cardiac conduction"], ["TCGA.DM.A0X9.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.DM.A0X9.01", "Phase 0 - rapid depolarisation"], ["TCGA.DM.A0X9.01", "Digestion"], ["TCGA.DM.A0X9.01", "Platelet homeostasis"], ["TCGA.DM.A0X9.01", "Phase II - Conjugation of compounds"], ["TCGA.DM.A0X9.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.DM.A0X9.01", "Blood group systems biosynthesis"], ["TCGA.DM.A0X9.01", "NCAM1 interactions"], ["TCGA.DM.A0X9.01", "Drug ADME"], ["TCGA.DM.A0X9.01", "CD22 mediated BCR regulation"], ["TCGA.DM.A0X9.01", "Heme degradation"], ["TCGA.DM.A0X9.01", "Class B/2 (Secretin family receptors)"], ["TCGA.DM.A0X9.01", "Cytosolic sulfonation of small molecules"], ["TCGA.DM.A0X9.01", "NCAM signaling for neurite out-growth"], ["TCGA.DM.A0X9.01", "Glucagon-type ligand receptors"], ["TCGA.DM.A0X9.01", "Biological oxidations"], ["TCGA.DM.A0X9.01", "Lewis blood group biosynthesis"], ["TCGA.DM.A0X9.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.DM.A0X9.01", "Peptide hormone metabolism"], ["TCGA.DM.A0X9.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.DM.A0X9.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.DM.A0X9.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.DM.A1D7.01", "Neuronal System"], ["TCGA.DM.A1D7.01", "Signaling by GPCR"], ["TCGA.DM.A1D7.01", "GPCR downstream signalling"], ["TCGA.DM.A1D7.01", "GPCR ligand binding"], ["TCGA.DM.A1D7.01", "G alpha (i) signalling events"], ["TCGA.DM.A1D7.01", "Peptide ligand-binding receptors"], ["TCGA.DM.A1D7.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.DM.A1D7.01", "Biological oxidations"], ["TCGA.DM.A1D7.01", "Transmission across Chemical Synapses"], ["TCGA.DM.A1D7.01", "Chemokine receptors bind chemokines"], ["TCGA.DM.A1D7.01", "Protein-protein interactions at synapses"], ["TCGA.DM.A1D7.01", "Cardiac conduction"], ["TCGA.DM.A1D7.01", "Phase 0 - rapid depolarisation"], ["TCGA.DM.A1D7.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.DM.A1D7.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.DM.A1D7.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.DM.A1D7.01", "Signaling Pathways"], ["TCGA.DM.A1D7.01", "Interaction between L1 and Ankyrins"], ["TCGA.DM.A1D7.01", "RA biosynthesis pathway"], ["TCGA.DM.A1D7.01", "Synaptic adhesion-like molecules"], ["TCGA.DM.A1D7.01", "Transport of small molecules"], ["TCGA.DM.A1D7.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.DM.A1D7.01", "Drug ADME"], ["TCGA.DM.A1D7.01", "Molecules associated with elastic fibres"], ["TCGA.DM.A1D7.01", "Potassium Channels"], ["TCGA.DM.A1D7.01", "Phase II - Conjugation of compounds"], ["TCGA.DM.A1D7.01", "Interleukin-6 family signaling"], ["TCGA.DM.A1D7.01", "Trafficking and processing of endosomal TLR"], ["TCGA.DM.A1D7.01", "Arachidonic acid metabolism"], ["TCGA.DM.A1D7.01", "Trafficking of AMPA receptors"], ["TCGA.DM.A1D7.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.DM.A1D7.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.DM.A1D7.01", "Class B/2 (Secretin family receptors)"], ["TCGA.DM.A1D7.01", "Digestion and absorption"], ["TCGA.DM.A1D7.01", "Interleukin-10 signaling"], ["TCGA.DM.A1D7.01", "Regulation of insulin secretion"], ["TCGA.DM.A1D7.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.DM.A1D7.01", "Signaling by Retinoic Acid"], ["TCGA.DM.A1D7.01", "Aspirin ADME"], ["TCGA.DM.A1D7.01", "G alpha (q) signalling events"], ["TCGA.DM.A1D7.01", "TNFs bind their physiological receptors"], ["TCGA.DM.A1D7.01", "Ion homeostasis"], ["TCGA.DM.A1D7.01", "Phase I - Functionalization of compounds"], ["TCGA.DM.A1D7.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.DM.A1D7.01", "Long-term potentiation"], ["TCGA.DM.A1D7.01", "G alpha (s) signalling events"], ["TCGA.DM.A1D7.01", "Platelet homeostasis"], ["TCGA.DM.A1D7.01", "Activation of Matrix Metalloproteinases"], ["TCGA.DM.A1D7.01", "Extracellular matrix organization"], ["TCGA.DM.A1D7.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.DM.A1D7.01", "Ca-dependent events"], ["TCGA.DM.A1D7.01", "Muscle contraction"], ["TCGA.DM.A1D7.01", "Ethanol oxidation"], ["TCGA.DM.A1D7.01", "Digestion"], ["TCGA.DM.A1D7.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.DM.A1D7.01", "Glucagon-type ligand receptors"], ["TCGA.DM.A28F.01", "Neuronal System"], ["TCGA.DM.A28F.01", "Transmission across Chemical Synapses"], ["TCGA.DM.A28F.01", "Potassium Channels"], ["TCGA.DM.A28F.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.DM.A28F.01", "Signaling by GPCR"], ["TCGA.DM.A28F.01", "GPCR downstream signalling"], ["TCGA.DM.A28F.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.DM.A28F.01", "Biological oxidations"], ["TCGA.DM.A28F.01", "Cardiac conduction"], ["TCGA.DM.A28F.01", "Interaction between L1 and Ankyrins"], ["TCGA.DM.A28F.01", "G alpha (i) signalling events"], ["TCGA.DM.A28F.01", "Platelet homeostasis"], ["TCGA.DM.A28F.01", "Signaling Pathways"], ["TCGA.DM.A28F.01", "Phase I - Functionalization of compounds"], ["TCGA.DM.A28F.01", "GPCR ligand binding"], ["TCGA.DM.A28F.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.DM.A28F.01", "Stimuli-sensing channels"], ["TCGA.DM.A28F.01", "Ion channel transport"], ["TCGA.DM.A28F.01", "GABA receptor activation"], ["TCGA.DM.A28F.01", "Transport of small molecules"], ["TCGA.DM.A28F.01", "Arachidonic acid metabolism"], ["TCGA.DM.A28F.01", "Protein-protein interactions at synapses"], ["TCGA.DM.A28F.01", "Voltage gated Potassium channels"], ["TCGA.DM.A28F.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.DM.A28F.01", "Molecules associated with elastic fibres"], ["TCGA.DM.A28F.01", "L1CAM interactions"], ["TCGA.DM.A28F.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.DM.A28F.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.DM.A28F.01", "Interleukin-10 signaling"], ["TCGA.DM.A28F.01", "Insulin processing"], ["TCGA.DM.A28F.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.DM.A28F.01", "Peptide ligand-binding receptors"], ["TCGA.DM.A28F.01", "GABA B receptor activation"], ["TCGA.DM.A28F.01", "Activation of GABAB receptors"], ["TCGA.DM.A28F.01", "G alpha (q) signalling events"], ["TCGA.DM.A28F.01", "G alpha (s) signalling events"], ["TCGA.DM.A28F.01", "Muscle contraction"], ["TCGA.DM.A28F.01", "Inwardly rectifying K+ channels"], ["TCGA.DM.A28F.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.DM.A28F.01", "Peptide hormone metabolism"], ["TCGA.DM.A28F.01", "G-protein beta:gamma signalling"], ["TCGA.DM.A28F.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.DM.A28F.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.DM.A28F.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.DM.A28F.01", "Extracellular matrix organization"], ["TCGA.DM.A28F.01", "Activation of G protein gated Potassium channels"], ["TCGA.DM.A28F.01", "G protein gated Potassium channels"], ["TCGA.DM.A28F.01", "Phase 0 - rapid depolarisation"], ["TCGA.DM.A28F.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.DM.A28F.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.DM.A28F.01", "Elastic fibre formation"], ["TCGA.DM.A28F.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.DM.A28F.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.DM.A28F.01", "Glucuronidation"], ["TCGA.DM.A28F.01", "RA biosynthesis pathway"], ["TCGA.DM.A28F.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.DM.A28F.01", "Leishmania parasite growth and survival"], ["TCGA.DM.A28F.01", "Aspirin ADME"], ["TCGA.DM.A28F.01", "Other interleukin signaling"], ["TCGA.DM.A28F.01", "Drug ADME"], ["TCGA.DM.A28F.01", "Ethanol oxidation"], ["TCGA.DM.A28F.01", "Transcriptional regulation of testis differentiation"], ["TCGA.DM.A28F.01", "Nuclear signaling by ERBB4"], ["TCGA.DM.A28F.01", "Phase 4 - resting membrane potential"], ["TCGA.DM.A28F.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.DM.A28F.01", "Regulation of TLR by endogenous ligand"], ["TCGA.DM.A28F.01", "ERBB2 Regulates Cell Motility"], ["TCGA.DM.A28F.01", "Netrin-1 signaling"], ["TCGA.DM.A28F.01", "Cytochrome P450 - arranged by substrate type"], ["TCGA.DM.A28F.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.DM.A28F.01", "Complement cascade"], ["TCGA.DM.A28F.01", "Neurotransmitter release cycle"], ["TCGA.DM.A28F.01", "Initial triggering of complement"], ["TCGA.DM.A28F.01", "GRB2 events in ERBB2 signaling"], ["TCGA.DM.A28F.01", "PI3K events in ERBB2 signaling"], ["TCGA.DM.A28F.01", "Neurexins and neuroligins"], ["TCGA.DM.A28F.01", "Keratan sulfate biosynthesis"], ["TCGA.DM.A28F.01", "PI3K/AKT Signaling in Cancer"], ["TCGA.DM.A28F.01", "Amino acid transport across the plasma membrane"], ["TCGA.DM.A28F.01", "Synaptic adhesion-like molecules"], ["TCGA.DM.A28F.01", "Leishmania infection"], ["TCGA.DM.A28F.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.DM.A28F.01", "Biosynthesis of DHA-derived SPMs"], ["TCGA.DM.A28F.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.DM.A28F.01", "Phase II - Conjugation of compounds"], ["TCGA.DM.A28F.01", "Endogenous sterols"], ["TCGA.DM.A28F.01", "NCAM1 interactions"], ["TCGA.DM.A28F.01", "Classical antibody-mediated complement activation"], ["TCGA.DM.A28F.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.DM.A28F.01", "Signaling by ERBB4"], ["TCGA.DM.A28F.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.DM.A28F.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.DM.A28F.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.DM.A28F.01", "Cell surface interactions at the vascular wall"], ["TCGA.DM.A28F.01", "Signal amplification"], ["TCGA.DM.A28F.01", "G beta:gamma signalling through BTK"], ["TCGA.DM.A28H.01", "GPCR downstream signalling"], ["TCGA.DM.A28H.01", "Signaling by GPCR"], ["TCGA.DM.A28H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.DM.A28H.01", "Signaling Pathways"], ["TCGA.DM.A28H.01", "Immune System"], ["TCGA.DM.A28H.01", "Neuronal System"], ["TCGA.DM.A28H.01", "GPCR ligand binding"], ["TCGA.DM.A28H.01", "G alpha (i) signalling events"], ["TCGA.DM.A28H.01", "Peptide ligand-binding receptors"], ["TCGA.DM.A28H.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.DM.A28H.01", "Complement cascade"], ["TCGA.DM.A28H.01", "DNA strand elongation"], ["TCGA.DM.A28H.01", "G alpha (q) signalling events"], ["TCGA.DM.A28H.01", "Interferon gamma signaling"], ["TCGA.DM.A28H.01", "Inflammasomes"], ["TCGA.DM.A28H.01", "Transmission across Chemical Synapses"], ["TCGA.DM.A28H.01", "Potassium Channels"], ["TCGA.DM.A28H.01", "Cytokine Signaling in Immune system"], ["TCGA.DM.A28H.01", "Regulation of Complement cascade"], ["TCGA.DM.A28H.01", "G alpha (s) signalling events"], ["TCGA.DM.A28H.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.DM.A28H.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.DM.A28H.01", "Extracellular matrix organization"], ["TCGA.DM.A28H.01", "MHC class II antigen presentation"], ["TCGA.DM.A28H.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], ["TCGA.DM.A28H.01", "Nucleosome assembly"], ["TCGA.DM.A28H.01", "Regulation of insulin secretion"], ["TCGA.DM.A28H.01", "Phase 0 - rapid depolarisation"], ["TCGA.DM.A28H.01", "Other interleukin signaling"], ["TCGA.DM.A28H.01", "Cardiac conduction"], ["TCGA.DM.A28H.01", "Glucagon-type ligand receptors"], ["TCGA.DM.A28H.01", "Polo-like kinase mediated events"], ["TCGA.DM.A28H.01", "The NLRP3 inflammasome"], ["TCGA.DM.A28H.01", "Chemokine receptors bind chemokines"], ["TCGA.DM.A28H.01", "Adaptive Immune System"], ["TCGA.DM.A28H.01", "Activation of the pre-replicative complex"], ["TCGA.DM.A28H.01", "Cell Cycle, Mitotic"], ["TCGA.DM.A28H.01", "Platelet homeostasis"], ["TCGA.DM.A28H.01", "Biological oxidations"], ["TCGA.DM.A28H.01", "Resolution of Sister Chromatid Cohesion"], ["TCGA.DM.A28H.01", "Leishmania infection"], ["TCGA.DM.A28H.01", "Class B/2 (Secretin family receptors)"], ["TCGA.DM.A28H.01", "Chromosome Maintenance"], ["TCGA.DM.A28H.01", "Interferon alpha/beta signaling"], ["TCGA.DM.A28H.01", "Binding and entry of HIV virion"], ["TCGA.DM.A28H.01", "Cell Cycle"], ["TCGA.DM.A28H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.DM.A28H.01", "Interferon Signaling"], ["TCGA.DM.A28H.01", "Condensation of Prophase Chromosomes"], ["TCGA.DM.A28H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.DM.A28H.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.DM.A28H.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.DM.A28H.01", "Lagging Strand Synthesis"], ["TCGA.DM.A28H.01", "G0 and Early G1"], ["TCGA.DM.A28H.01", "G1/S-Specific Transcription"], ["TCGA.DM.A28H.01", "Peptide hormone metabolism"], ["TCGA.DM.A28H.01", "Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex"], ["TCGA.DM.A28H.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.DM.A28H.01", "Signal amplification"], ["TCGA.DM.A28H.01", "Innate Immune System"], ["TCGA.DM.A28H.01", "Cell Cycle Checkpoints"], ["TCGA.DM.A28H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.DM.A28H.01", "Integration of energy metabolism"], ["TCGA.DM.A28H.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], ["TCGA.DM.A28H.01", "Glucagon signaling in metabolic regulation"], ["TCGA.DM.A28H.01", "Transcriptional regulation of granulopoiesis"], ["TCGA.DM.A28H.01", "Cyclin A/B1/B2 associated events during G2/M transition"], ["TCGA.DM.A28H.01", "Polymerase switching"], ["TCGA.DM.A28H.01", "Leading Strand Synthesis"], ["TCGA.DM.A28H.01", "Removal of the Flap Intermediate"], ["TCGA.DM.A28H.01", "Processive synthesis on the lagging strand"], ["TCGA.DM.A28H.01", "Extension of Telomeres"], ["TCGA.DM.A28H.01", "Elastic fibre formation"], ["TCGA.DM.A28H.01", "G beta:gamma signalling through BTK"], ["TCGA.DM.A28H.01", "Condensation of Prometaphase Chromosomes"], ["TCGA.DM.A28H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.DM.A28H.01", "Leishmania parasite growth and survival"], ["TCGA.DM.A28H.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.DM.A28H.01", "Costimulation by the CD28 family"], ["TCGA.DM.A28H.01", "Amplification of signal from the kinetochores"], ["TCGA.DM.A28H.01", "Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal"], ["TCGA.DM.A28H.01", "Telomere C-strand (Lagging Strand) Synthesis"], ["TCGA.DM.A28H.01", "G-protein beta:gamma signalling"], ["TCGA.DM.A28H.01", "RAF-independent MAPK1/3 activation"], ["TCGA.DM.A28H.01", "Ion homeostasis"], ["TCGA.DM.A28K.01", "Signaling by GPCR"], ["TCGA.DM.A28K.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.DM.A28K.01", "Neuronal System"], ["TCGA.DM.A28K.01", "GPCR ligand binding"], ["TCGA.DM.A28K.01", "GPCR downstream signalling"], ["TCGA.DM.A28K.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.DM.A28K.01", "Interaction between L1 and Ankyrins"], ["TCGA.DM.A28K.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.DM.A28K.01", "Generation of second messenger molecules"], ["TCGA.DM.A28K.01", "G alpha (i) signalling events"], ["TCGA.DM.A28K.01", "Transport of small molecules"], ["TCGA.DM.A28K.01", "Transmission across Chemical Synapses"], ["TCGA.DM.A28K.01", "Chemokine receptors bind chemokines"], ["TCGA.DM.A28K.01", "Biological oxidations"], ["TCGA.DM.A28K.01", "Cardiac conduction"], ["TCGA.DM.A28K.01", "Drug ADME"], ["TCGA.DM.A28K.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.DM.A28K.01", "Peptide ligand-binding receptors"], ["TCGA.DM.A28K.01", "PD-1 signaling"], ["TCGA.DM.A28K.01", "Signaling Pathways"], ["TCGA.DM.A28K.01", "Complement cascade"], ["TCGA.DM.A28K.01", "Immune System"], ["TCGA.DM.A28K.01", "SUMOylation of intracellular receptors"], ["TCGA.DM.A28K.01", "Protein-protein interactions at synapses"], ["TCGA.DM.A28K.01", "Neurotransmitter release cycle"], ["TCGA.DM.A28K.01", "Calmodulin induced events"], ["TCGA.DM.A28K.01", "CaM pathway"], ["TCGA.DM.A28K.01", "Transcriptional regulation of testis differentiation"], ["TCGA.DM.A28K.01", "Glucagon signaling in metabolic regulation"], ["TCGA.DM.A28K.01", "Class B/2 (Secretin family receptors)"], ["TCGA.DM.A28K.01", "Phase 0 - rapid depolarisation"], ["TCGA.DM.A28K.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.DM.A28K.01", "DAG and IP3 signaling"], ["TCGA.DM.A28K.01", "Ca-dependent events"], ["TCGA.DM.A28K.01", "G alpha (s) signalling events"], ["TCGA.DM.A28K.01", "Regulation of Complement cascade"], ["TCGA.DM.A28K.01", "L1CAM interactions"], ["TCGA.DM.A28K.01", "Muscle contraction"], ["TCGA.DM.A28K.01", "Molecules associated with elastic fibres"], ["TCGA.DM.A28K.01", "Extracellular matrix organization"], ["TCGA.DM.A28K.01", "PLC beta mediated events"], ["TCGA.DM.A28K.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.DM.A28K.01", "Phase I - Functionalization of compounds"], ["TCGA.DM.A28K.01", "G-protein mediated events"], ["TCGA.DM.A28K.01", "Initial triggering of complement"], ["TCGA.DM.A28K.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.DM.A28K.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.DM.A28K.01", "Leishmania parasite growth and survival"], ["TCGA.DM.A28K.01", "Leishmania infection"], ["TCGA.DM.A28K.01", "Glucagon-type ligand receptors"], ["TCGA.DM.A28K.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.DM.A28K.01", "Activation of SMO"], ["TCGA.DM.A28K.01", "Digestion and absorption"], ["TCGA.DM.A28K.01", "SLC-mediated transmembrane transport"], ["TCGA.DM.A28K.01", "Synaptic adhesion-like molecules"], ["TCGA.DM.A28K.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.DM.A28K.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.DM.A28K.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.DM.A28K.01", "Creation of C4 and C2 activators"], ["TCGA.DM.A28K.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.DM.A28K.01", "Cytosolic sulfonation of small molecules"], ["TCGA.DM.A28K.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.DM.A28K.01", "Integration of energy metabolism"], ["TCGA.DM.A28K.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.DM.A28K.01", "Aquaporin-mediated transport"], ["TCGA.DM.A28K.01", "Scavenging of heme from plasma"], ["TCGA.DM.A28K.01", "Digestion"], ["TCGA.DM.A28K.01", "CD22 mediated BCR regulation"], ["TCGA.DM.A28K.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], ["TCGA.DM.A28K.01", "GABA synthesis, release, reuptake and degradation"], ["TCGA.DM.A28K.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.DM.A28K.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.DM.A28K.01", "G alpha (z) signalling events"], ["TCGA.DM.A28K.01", "TNFs bind their physiological receptors"], ["TCGA.DM.A28K.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.DM.A28K.01", "Elastic fibre formation"], ["TCGA.DM.A28K.01", "Ion homeostasis"], ["TCGA.F4.6459.01", "Extracellular matrix organization"], ["TCGA.F4.6459.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.F4.6459.01", "Activation of Matrix Metalloproteinases"], ["TCGA.F4.6459.01", "Collagen formation"], ["TCGA.F4.6459.01", "Common Pathway of Fibrin Clot Formation"], ["TCGA.F4.6459.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.F4.6459.01", "Collagen chain trimerization"], ["TCGA.F4.6459.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.F4.6459.01", "Post-translational protein phosphorylation"], ["TCGA.F4.6459.01", "Blood group systems biosynthesis"], ["TCGA.F4.6459.01", "RA biosynthesis pathway"], ["TCGA.F4.6459.01", "TNFs bind their physiological receptors"], ["TCGA.F4.6459.01", "O-linked glycosylation"], ["TCGA.F4.6459.01", "Transport of small molecules"], ["TCGA.F4.6459.01", "Regulation of beta-cell development"], ["TCGA.F4.6459.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.F4.6459.01", "Physiological factors"], ["TCGA.F4.6459.01", "Stimuli-sensing channels"], ["TCGA.F4.6459.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.F4.6459.01", "O-linked glycosylation of mucins"], ["TCGA.F4.6459.01", "Defective GALNT3 causes HFTC"], ["TCGA.F4.6459.01", "Defective GALNT12 causes CRCS1"], ["TCGA.F4.6459.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.F4.6459.01", "GPCR ligand binding"], ["TCGA.F4.6459.01", "Signaling by Retinoic Acid"], ["TCGA.F4.6459.01", "Dectin-2 family"], ["TCGA.F4.6459.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.F4.6460.01", "Biological oxidations"], ["TCGA.F4.6460.01", "Phase II - Conjugation of compounds"], ["TCGA.F4.6460.01", "Glucuronidation"], ["TCGA.F4.6460.01", "Metabolism"], ["TCGA.F4.6460.01", "SLC-mediated transmembrane transport"], ["TCGA.F4.6460.01", "Transport of small molecules"], ["TCGA.F4.6460.01", "Cytosolic sulfonation of small molecules"], ["TCGA.F4.6460.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.F4.6460.01", "Aspirin ADME"], ["TCGA.F4.6460.01", "Drug ADME"], ["TCGA.F4.6460.01", "Peptide hormone metabolism"], ["TCGA.F4.6460.01", "FGFR4 ligand binding and activation"], ["TCGA.F4.6460.01", "Activation of Matrix Metalloproteinases"], ["TCGA.F4.6460.01", "IRS-related events triggered by IGF1R"], ["TCGA.F4.6460.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.F4.6460.01", "Phospholipase C-mediated cascade; FGFR4"], ["TCGA.F4.6460.01", "IGF1R signaling cascade"], ["TCGA.F4.6460.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], ["TCGA.F4.6460.01", "Activated point mutants of FGFR2"], ["TCGA.F4.6460.01", "Phase I - Functionalization of compounds"], ["TCGA.F4.6460.01", "Phospholipase C-mediated cascade; FGFR2"], ["TCGA.F4.6460.01", "IRS-mediated signalling"], ["TCGA.F4.6460.01", "Ethanol oxidation"], ["TCGA.F4.6704.01", "Biological oxidations"], ["TCGA.F4.6704.01", "Extracellular matrix organization"], ["TCGA.F4.6704.01", "Drug ADME"], ["TCGA.F4.6704.01", "Phase II - Conjugation of compounds"], ["TCGA.F4.6704.01", "Glucuronidation"], ["TCGA.F4.6704.01", "Collagen formation"], ["TCGA.F4.6704.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.F4.6704.01", "Aspirin ADME"], ["TCGA.F4.6704.01", "Metabolism"], ["TCGA.F4.6704.01", "Transport of small molecules"], ["TCGA.F4.6704.01", "SLC-mediated transmembrane transport"], ["TCGA.F4.6704.01", "Keratinization"], ["TCGA.F4.6704.01", "Ethanol oxidation"], ["TCGA.F4.6704.01", "Formation of the cornified envelope"], ["TCGA.F4.6704.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.F4.6704.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.F4.6704.01", "Phase I - Functionalization of compounds"], ["TCGA.F4.6704.01", "Transmission across Chemical Synapses"], ["TCGA.F4.6704.01", "Collagen chain trimerization"], ["TCGA.F4.6704.01", "Neuronal System"], ["TCGA.F4.6704.01", "Activation of Matrix Metalloproteinases"], ["TCGA.F4.6704.01", "GPCR ligand binding"], ["TCGA.F4.6704.01", "Cytosolic sulfonation of small molecules"], ["TCGA.F4.6704.01", "Biosynthesis of DHA-derived SPMs"], ["TCGA.F4.6704.01", "Peptide hormone metabolism"], ["TCGA.F4.6704.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.F4.6704.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.F4.6704.01", "Blood group systems biosynthesis"], ["TCGA.F4.6704.01", "Neurotransmitter release cycle"], ["TCGA.F4.6704.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.F4.6704.01", "APAP ADME"], ["TCGA.F4.6704.01", "Digestion and absorption"], ["TCGA.F4.6704.01", "Signaling by GPCR"], ["TCGA.F4.6704.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.F4.6704.01", "Adherens junctions interactions"], ["TCGA.F4.6704.01", "G alpha (q) signalling events"], ["TCGA.F4.6704.01", "Lewis blood group biosynthesis"], ["TCGA.F4.6704.01", "Class B/2 (Secretin family receptors)"], ["TCGA.F4.6704.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.F4.6704.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.F4.6704.01", "GRB2 events in EGFR signaling"], ["TCGA.F4.6704.01", "Peptide hormone biosynthesis"], ["TCGA.F4.6704.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.F4.6704.01", "Sensory processing of sound by outer hair cells of the cochlea"], ["TCGA.F4.6704.01", "Degradation of the extracellular matrix"], ["TCGA.F4.6704.01", "Visual phototransduction"], ["TCGA.F4.6704.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.F4.6704.01", "Glutathione conjugation"], ["TCGA.F4.6704.01", "Glucagon-type ligand receptors"], ["TCGA.F4.6704.01", "Chondroitin sulfate biosynthesis"], ["TCGA.F4.6704.01", "SHC1 events in EGFR signaling"], ["TCGA.F4.6704.01", "Peptide ligand-binding receptors"], ["TCGA.F4.6704.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.F4.6854.01", "Activation of Matrix Metalloproteinases"], ["TCGA.F4.6854.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.F4.6854.01", "Digestion"], ["TCGA.F4.6854.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.F4.6854.01", "Biological oxidations"], ["TCGA.F4.6854.01", "Phase II - Conjugation of compounds"], ["TCGA.F4.6854.01", "GPCR downstream signalling"], ["TCGA.F4.6854.01", "Signaling by GPCR"], ["TCGA.F4.6854.01", "G alpha (i) signalling events"], ["TCGA.F4.6854.01", "Drug ADME"], ["TCGA.F4.6854.01", "SLC-mediated transmembrane transport"], ["TCGA.F4.6854.01", "Digestion and absorption"], ["TCGA.F4.6854.01", "Transport of small molecules"], ["TCGA.F4.6854.01", "Peptide hormone metabolism"], ["TCGA.F4.6854.01", "Degradation of the extracellular matrix"], ["TCGA.F4.6854.01", "Metabolism"], ["TCGA.F4.6854.01", "Neuronal System"], ["TCGA.F4.6854.01", "Blood group systems biosynthesis"], ["TCGA.F4.6854.01", "GPCR ligand binding"], ["TCGA.F4.6854.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], ["TCGA.F4.6854.01", "Peptide ligand-binding receptors"], ["TCGA.F4.6854.01", "Glucuronidation"], ["TCGA.F4.6854.01", "Regulation of gene expression in beta cells"], ["TCGA.F4.6856.01", "Interaction between L1 and Ankyrins"], ["TCGA.F4.6856.01", "Transport of small molecules"], ["TCGA.F4.6856.01", "Signaling by GPCR"], ["TCGA.F4.6856.01", "G alpha (i) signalling events"], ["TCGA.F4.6856.01", "Neuronal System"], ["TCGA.F4.6856.01", "Transmission across Chemical Synapses"], ["TCGA.F4.6856.01", "GPCR downstream signalling"], ["TCGA.F4.6856.01", "Extracellular matrix organization"], ["TCGA.F4.6856.01", "GPCR ligand binding"], ["TCGA.F4.6856.01", "Phase 0 - rapid depolarisation"], ["TCGA.F4.6856.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.F4.6856.01", "L1CAM interactions"], ["TCGA.F4.6856.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.F4.6856.01", "Signaling Pathways"], ["TCGA.F4.6856.01", "Cardiac conduction"], ["TCGA.F4.6856.01", "Protein-protein interactions at synapses"], ["TCGA.F4.6856.01", "Activation of Matrix Metalloproteinases"], ["TCGA.F4.6856.01", "Leishmania infection"], ["TCGA.F4.6856.01", "Peptide hormone metabolism"], ["TCGA.F4.6856.01", "RA biosynthesis pathway"], ["TCGA.F4.6856.01", "Peptide ligand-binding receptors"], ["TCGA.F4.6856.01", "Ion channel transport"], ["TCGA.F4.6856.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.F4.6856.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.F4.6856.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.F4.6856.01", "Regulation of Complement cascade"], ["TCGA.F4.6856.01", "Trafficking of AMPA receptors"], ["TCGA.F4.6856.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.F4.6856.01", "Glucagon signaling in metabolic regulation"], ["TCGA.F4.6856.01", "Glucagon-type ligand receptors"], ["TCGA.F4.6856.01", "Signaling by Retinoic Acid"], ["TCGA.F4.6856.01", "Synaptic adhesion-like molecules"], ["TCGA.F4.6856.01", "Neurexins and neuroligins"], ["TCGA.F4.6856.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.F4.6856.01", "Muscle contraction"], ["TCGA.F4.6856.01", "Ethanol oxidation"], ["TCGA.F4.6856.01", "Digestion"], ["TCGA.F4.6856.01", "SLC-mediated transmembrane transport"], ["TCGA.F4.6856.01", "GABA receptor activation"], ["TCGA.F4.6856.01", "Metabolism of water-soluble vitamins and cofactors"], ["TCGA.F4.6856.01", "Class B/2 (Secretin family receptors)"], ["TCGA.F4.6856.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.F4.6856.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.F4.6856.01", "Drug ADME"], ["TCGA.F4.6856.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.F4.6856.01", "Defensins"], ["TCGA.F4.6856.01", "Heme degradation"], ["TCGA.F4.6856.01", "SUMOylation of intracellular receptors"], ["TCGA.F4.6856.01", "Stimuli-sensing channels"], ["TCGA.F4.6856.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.F4.6856.01", "Leishmania parasite growth and survival"], ["TCGA.F4.6856.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.F4.6856.01", "Long-term potentiation"], ["TCGA.F4.6856.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.F4.6856.01", "G beta:gamma signalling through BTK"], ["TCGA.F4.6856.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.F4.6856.01", "Formation of Fibrin Clot (Clotting Cascade)"], ["TCGA.F4.6856.01", "G-protein beta:gamma signalling"], ["TCGA.F4.6856.01", "Complement cascade"], ["TCGA.F4.6856.01", "Chemokine receptors bind chemokines"], ["TCGA.F4.6856.01", "Ion homeostasis"], ["TCGA.F4.6856.01", "G alpha (s) signalling events"], ["TCGA.F4.6856.01", "O-linked glycosylation of mucins"], ["TCGA.F4.6856.01", "Sensory perception of taste"], ["TCGA.F4.6856.01", "Collagen formation"], ["TCGA.F4.6856.01", "Biological oxidations"], ["TCGA.G4.6297.01", "Extracellular matrix organization"], ["TCGA.G4.6297.01", "Collagen formation"], ["TCGA.G4.6297.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.G4.6297.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.G4.6297.01", "Collagen chain trimerization"], ["TCGA.G4.6297.01", "Activation of Matrix Metalloproteinases"], ["TCGA.G4.6297.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.G4.6297.01", "Degradation of the extracellular matrix"], ["TCGA.G4.6297.01", "Biological oxidations"], ["TCGA.G4.6297.01", "Ethanol oxidation"], ["TCGA.G4.6297.01", "Transport of small molecules"], ["TCGA.G4.6297.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.G4.6297.01", "RA biosynthesis pathway"], ["TCGA.G4.6297.01", "Phase II - Conjugation of compounds"], ["TCGA.G4.6297.01", "NCAM signaling for neurite out-growth"], ["TCGA.G4.6297.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.G4.6297.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.G4.6297.01", "ECM proteoglycans"], ["TCGA.G4.6297.01", "Scavenging by Class A Receptors"], ["TCGA.G4.6297.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.G4.6297.01", "Keratinization"], ["TCGA.G4.6297.01", "NCAM1 interactions"], ["TCGA.G4.6297.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.G4.6297.01", "Defective GALNT12 causes CRCS1"], ["TCGA.G4.6297.01", "Glucuronidation"], ["TCGA.G4.6297.01", "Signaling by GPCR"], ["TCGA.G4.6297.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6297.01", "Metal ion SLC transporters"], ["TCGA.G4.6297.01", "Signaling by Retinoic Acid"], ["TCGA.G4.6297.01", "Diseases of glycosylation"], ["TCGA.G4.6297.01", "GPCR ligand binding"], ["TCGA.G4.6297.01", "Regulation of beta-cell development"], ["TCGA.G4.6297.01", "Glucagon signaling in metabolic regulation"], ["TCGA.G4.6297.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.G4.6297.01", "Defective B3GALTL causes PpS"], ["TCGA.G4.6297.01", "Drug ADME"], ["TCGA.G4.6297.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.G4.6297.01", "Diseases of metabolism"], ["TCGA.G4.6297.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6297.01", "Regulation of gene expression by Hypoxia-inducible Factor"], ["TCGA.G4.6299.01", "Neuronal System"], ["TCGA.G4.6299.01", "Transmission across Chemical Synapses"], ["TCGA.G4.6299.01", "Transport of small molecules"], ["TCGA.G4.6299.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.G4.6299.01", "Biological oxidations"], ["TCGA.G4.6299.01", "Phase I - Functionalization of compounds"], ["TCGA.G4.6299.01", "RA biosynthesis pathway"], ["TCGA.G4.6299.01", "Ethanol oxidation"], ["TCGA.G4.6299.01", "SLC-mediated transmembrane transport"], ["TCGA.G4.6299.01", "Regulation of insulin secretion"], ["TCGA.G4.6299.01", "Extracellular matrix organization"], ["TCGA.G4.6299.01", "GABA receptor activation"], ["TCGA.G4.6299.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.G4.6299.01", "Neurotransmitter release cycle"], ["TCGA.G4.6299.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.G4.6299.01", "Peptide hormone metabolism"], ["TCGA.G4.6299.01", "Integration of energy metabolism"], ["TCGA.G4.6299.01", "O-linked glycosylation"], ["TCGA.G4.6299.01", "Arachidonic acid metabolism"], ["TCGA.G4.6299.01", "Signaling by GPCR"], ["TCGA.G4.6299.01", "Signal amplification"], ["TCGA.G4.6299.01", "Ion channel transport"], ["TCGA.G4.6299.01", "Protein-protein interactions at synapses"], ["TCGA.G4.6299.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.G4.6299.01", "Signaling by Retinoic Acid"], ["TCGA.G4.6299.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6299.01", "Blood group systems biosynthesis"], ["TCGA.G4.6299.01", "Cardiac conduction"], ["TCGA.G4.6299.01", "GPCR ligand binding"], ["TCGA.G4.6299.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.G4.6299.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.G4.6299.01", "Activation of Matrix Metalloproteinases"], ["TCGA.G4.6299.01", "Glucuronidation"], ["TCGA.G4.6299.01", "Drug ADME"], ["TCGA.G4.6299.01", "G-protein mediated events"], ["TCGA.G4.6299.01", "O-linked glycosylation of mucins"], ["TCGA.G4.6299.01", "G alpha (i) signalling events"], ["TCGA.G4.6299.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.G4.6299.01", "Norepinephrine Neurotransmitter Release Cycle"], ["TCGA.G4.6299.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.G4.6299.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], ["TCGA.G4.6299.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6299.01", "Metal ion SLC transporters"], ["TCGA.G4.6299.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.G4.6299.01", "Glucagon-type ligand receptors"], ["TCGA.G4.6299.01", "Phase II - Conjugation of compounds"], ["TCGA.G4.6299.01", "Lewis blood group biosynthesis"], ["TCGA.G4.6299.01", "Stimuli-sensing channels"], ["TCGA.G4.6299.01", "Interaction between L1 and Ankyrins"], ["TCGA.G4.6299.01", "Phase 0 - rapid depolarisation"], ["TCGA.G4.6299.01", "Defective GALNT12 causes CRCS1"], ["TCGA.G4.6299.01", "Phase 2 - plateau phase"], ["TCGA.G4.6299.01", "Inwardly rectifying K+ channels"], ["TCGA.G4.6299.01", "G-protein activation"], ["TCGA.G4.6299.01", "Thromboxane signalling through TP receptor"], ["TCGA.G4.6299.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.G4.6299.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.G4.6299.01", "GABA synthesis, release, reuptake and degradation"], ["TCGA.G4.6299.01", "GPCR downstream signalling"], ["TCGA.G4.6299.01", "Potassium Channels"], ["TCGA.G4.6299.01", "Insulin processing"], ["TCGA.G4.6299.01", "Muscle contraction"], ["TCGA.G4.6299.01", "GABA B receptor activation"], ["TCGA.G4.6299.01", "Activation of GABAB receptors"], ["TCGA.G4.6299.01", "PLC beta mediated events"], ["TCGA.G4.6299.01", "WNT ligand biogenesis and trafficking"], ["TCGA.G4.6299.01", "Keratinization"], ["TCGA.G4.6299.01", "Free fatty acids regulate insulin secretion"], ["TCGA.G4.6299.01", "Digestion"], ["TCGA.G4.6299.01", "G alpha (s) signalling events"], ["TCGA.G4.6299.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.G4.6299.01", "Metabolism of Angiotensinogen to Angiotensins"], ["TCGA.G4.6306.01", "Extracellular matrix organization"], ["TCGA.G4.6306.01", "Signaling by GPCR"], ["TCGA.G4.6306.01", "Neuronal System"], ["TCGA.G4.6306.01", "GPCR downstream signalling"], ["TCGA.G4.6306.01", "Elastic fibre formation"], ["TCGA.G4.6306.01", "Interaction between L1 and Ankyrins"], ["TCGA.G4.6306.01", "Signaling Pathways"], ["TCGA.G4.6306.01", "G alpha (s) signalling events"], ["TCGA.G4.6306.01", "Molecules associated with elastic fibres"], ["TCGA.G4.6306.01", "Initial triggering of complement"], ["TCGA.G4.6306.01", "Cardiac conduction"], ["TCGA.G4.6306.01", "GPCR ligand binding"], ["TCGA.G4.6306.01", "Transmission across Chemical Synapses"], ["TCGA.G4.6306.01", "Muscle contraction"], ["TCGA.G4.6306.01", "L1CAM interactions"], ["TCGA.G4.6306.01", "Phase 0 - rapid depolarisation"], ["TCGA.G4.6306.01", "Complement cascade"], ["TCGA.G4.6306.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.G4.6306.01", "Classical antibody-mediated complement activation"], ["TCGA.G4.6306.01", "G alpha (i) signalling events"], ["TCGA.G4.6306.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.G4.6306.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6306.01", "Creation of C4 and C2 activators"], ["TCGA.G4.6306.01", "Protein-protein interactions at synapses"], ["TCGA.G4.6306.01", "Platelet homeostasis"], ["TCGA.G4.6306.01", "Defective B3GALTL causes PpS"], ["TCGA.G4.6306.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.G4.6306.01", "Regulation of Complement cascade"], ["TCGA.G4.6306.01", "Developmental Biology"], ["TCGA.G4.6306.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.G4.6306.01", "G-protein beta:gamma signalling"], ["TCGA.G4.6306.01", "Nervous system development"], ["TCGA.G4.6306.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.G4.6306.01", "Glucagon signaling in metabolic regulation"], ["TCGA.G4.6306.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.G4.6306.01", "Leishmania parasite growth and survival"], ["TCGA.G4.6306.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.G4.6306.01", "Cell surface interactions at the vascular wall"], ["TCGA.G4.6306.01", "Amino acid transport across the plasma membrane"], ["TCGA.G4.6306.01", "Regulation of insulin secretion"], ["TCGA.G4.6306.01", "Transport of small molecules"], ["TCGA.G4.6306.01", "Biological oxidations"], ["TCGA.G4.6306.01", "Integration of energy metabolism"], ["TCGA.G4.6306.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.G4.6306.01", "Signal amplification"], ["TCGA.G4.6306.01", "Integrin cell surface interactions"], ["TCGA.G4.6306.01", "CRMPs in Sema3A signaling"], ["TCGA.G4.6306.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.G4.6306.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.G4.6306.01", "Blood group systems biosynthesis"], ["TCGA.G4.6306.01", "Glucagon-type ligand receptors"], ["TCGA.G4.6306.01", "GABA receptor activation"], ["TCGA.G4.6306.01", "ECM proteoglycans"], ["TCGA.G4.6306.01", "Ca2+ pathway"], ["TCGA.G4.6306.01", "Axon guidance"], ["TCGA.G4.6306.01", "Diseases of glycosylation"], ["TCGA.G4.6306.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.G4.6306.01", "GABA B receptor activation"], ["TCGA.G4.6306.01", "Activation of GABAB receptors"], ["TCGA.G4.6306.01", "Presynaptic function of Kainate receptors"], ["TCGA.G4.6306.01", "Calcitonin-like ligand receptors"], ["TCGA.G4.6306.01", "Chemokine receptors bind chemokines"], ["TCGA.G4.6306.01", "G alpha (q) signalling events"], ["TCGA.G4.6306.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.G4.6306.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6306.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.G4.6306.01", "G beta:gamma signalling through BTK"], ["TCGA.G4.6306.01", "Lewis blood group biosynthesis"], ["TCGA.G4.6306.01", "Ethanol oxidation"], ["TCGA.G4.6306.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.G4.6306.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.G4.6306.01", "Phase I - Functionalization of compounds"], ["TCGA.G4.6306.01", "Scavenging by Class A Receptors"], ["TCGA.G4.6306.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.G4.6306.01", "Potassium Channels"], ["TCGA.G4.6306.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.G4.6306.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.G4.6306.01", "Thromboxane signalling through TP receptor"], ["TCGA.G4.6306.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.G4.6306.01", "Diseases of metabolism"], ["TCGA.G4.6306.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.G4.6306.01", "G beta:gamma signalling through PLC beta"], ["TCGA.G4.6306.01", "G beta:gamma signalling through CDC42"], ["TCGA.G4.6306.01", "Ion homeostasis"], ["TCGA.G4.6306.01", "Activation of G protein gated Potassium channels"], ["TCGA.G4.6306.01", "G protein gated Potassium channels"], ["TCGA.G4.6306.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.G4.6306.01", "Leishmania infection"], ["TCGA.G4.6306.01", "G-protein mediated events"], ["TCGA.G4.6306.01", "Neurexins and neuroligins"], ["TCGA.G4.6306.01", "Peptide ligand-binding receptors"], ["TCGA.G4.6306.01", "O-linked glycosylation"], ["TCGA.G4.6306.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.G4.6306.01", "Regulation of FZD by ubiquitination"], ["TCGA.G4.6306.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.G4.6306.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.G4.6306.01", "Activation of SMO"], ["TCGA.G4.6306.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.G4.6306.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.G4.6306.01", "Activation of Matrix Metalloproteinases"], ["TCGA.G4.6306.01", "NCAM1 interactions"], ["TCGA.G4.6306.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.G4.6306.01", "Other interleukin signaling"], ["TCGA.G4.6314.01", "Collagen formation"], ["TCGA.G4.6314.01", "Extracellular matrix organization"], ["TCGA.G4.6314.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.G4.6314.01", "Biological oxidations"], ["TCGA.G4.6314.01", "Metabolism"], ["TCGA.G4.6314.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.G4.6314.01", "Collagen chain trimerization"], ["TCGA.G4.6314.01", "Drug ADME"], ["TCGA.G4.6314.01", "Transport of small molecules"], ["TCGA.G4.6314.01", "Degradation of the extracellular matrix"], ["TCGA.G4.6314.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.G4.6314.01", "Collagen degradation"], ["TCGA.G4.6314.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6314.01", "Stimuli-sensing channels"], ["TCGA.G4.6314.01", "GPCR ligand binding"], ["TCGA.G4.6314.01", "Peptide hormone biosynthesis"], ["TCGA.G4.6314.01", "Phase I - Functionalization of compounds"], ["TCGA.G4.6314.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.G4.6314.01", "Signaling by Activin"], ["TCGA.G4.6314.01", "Aspirin ADME"], ["TCGA.G4.6314.01", "ECM proteoglycans"], ["TCGA.G4.6322.01", "Biological oxidations"], ["TCGA.G4.6322.01", "GPCR ligand binding"], ["TCGA.G4.6322.01", "Signaling by GPCR"], ["TCGA.G4.6322.01", "GPCR downstream signalling"], ["TCGA.G4.6322.01", "Neuronal System"], ["TCGA.G4.6322.01", "Drug ADME"], ["TCGA.G4.6322.01", "Activation of Matrix Metalloproteinases"], ["TCGA.G4.6322.01", "L1CAM interactions"], ["TCGA.G4.6322.01", "Protein-protein interactions at synapses"], ["TCGA.G4.6322.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.G4.6322.01", "G alpha (i) signalling events"], ["TCGA.G4.6322.01", "Degradation of the extracellular matrix"], ["TCGA.G4.6322.01", "Peptide hormone metabolism"], ["TCGA.G4.6322.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6322.01", "Phase II - Conjugation of compounds"], ["TCGA.G4.6322.01", "Peptide ligand-binding receptors"], ["TCGA.G4.6322.01", "Transmission across Chemical Synapses"], ["TCGA.G4.6322.01", "Molecules associated with elastic fibres"], ["TCGA.G4.6322.01", "Complement cascade"], ["TCGA.G4.6322.01", "Chemokine receptors bind chemokines"], ["TCGA.G4.6322.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.G4.6322.01", "Adherens junctions interactions"], ["TCGA.G4.6322.01", "Glycosaminoglycan metabolism"], ["TCGA.G4.6322.01", "Chondroitin sulfate/dermatan sulfate metabolism"], ["TCGA.G4.6322.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.G4.6626.01", "Signaling by GPCR"], ["TCGA.G4.6626.01", "GPCR downstream signalling"], ["TCGA.G4.6626.01", "Neuronal System"], ["TCGA.G4.6626.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.G4.6626.01", "GPCR ligand binding"], ["TCGA.G4.6626.01", "G alpha (i) signalling events"], ["TCGA.G4.6626.01", "Signaling Pathways"], ["TCGA.G4.6626.01", "Potassium Channels"], ["TCGA.G4.6626.01", "Transmission across Chemical Synapses"], ["TCGA.G4.6626.01", "G alpha (q) signalling events"], ["TCGA.G4.6626.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.G4.6626.01", "Leishmania parasite growth and survival"], ["TCGA.G4.6626.01", "Glucagon-type ligand receptors"], ["TCGA.G4.6626.01", "Extracellular matrix organization"], ["TCGA.G4.6626.01", "Biological oxidations"], ["TCGA.G4.6626.01", "Platelet homeostasis"], ["TCGA.G4.6626.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.G4.6626.01", "GABA B receptor activation"], ["TCGA.G4.6626.01", "Activation of GABAB receptors"], ["TCGA.G4.6626.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.G4.6626.01", "Glucagon signaling in metabolic regulation"], ["TCGA.G4.6626.01", "GABA receptor activation"], ["TCGA.G4.6626.01", "G alpha (s) signalling events"], ["TCGA.G4.6626.01", "Class B/2 (Secretin family receptors)"], ["TCGA.G4.6626.01", "G-protein beta:gamma signalling"], ["TCGA.G4.6626.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.G4.6626.01", "Inwardly rectifying K+ channels"], ["TCGA.G4.6626.01", "G beta:gamma signalling through BTK"], ["TCGA.G4.6626.01", "Integration of energy metabolism"], ["TCGA.G4.6626.01", "Activation of G protein gated Potassium channels"], ["TCGA.G4.6626.01", "G protein gated Potassium channels"], ["TCGA.G4.6626.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.G4.6626.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.G4.6626.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.G4.6626.01", "Cardiac conduction"], ["TCGA.G4.6626.01", "Regulation of insulin secretion"], ["TCGA.G4.6626.01", "G beta:gamma signalling through CDC42"], ["TCGA.G4.6626.01", "G alpha (z) signalling events"], ["TCGA.G4.6626.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.G4.6626.01", "Signal amplification"], ["TCGA.G4.6626.01", "Drug ADME"], ["TCGA.G4.6626.01", "Unwinding of DNA"], ["TCGA.G4.6626.01", "Aquaporin-mediated transport"], ["TCGA.G4.6626.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.G4.6626.01", "Transport of small molecules"], ["TCGA.G4.6626.01", "Muscle contraction"], ["TCGA.G4.6626.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.G4.6626.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.G4.6626.01", "GPER1 signaling"], ["TCGA.G4.6626.01", "ADORA2B mediated anti-inflammatory cytokines production"], ["TCGA.G4.6626.01", "Transcription of E2F targets under negative control by DREAM complex"], ["TCGA.G4.6626.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.G4.6626.01", "Leishmania infection"], ["TCGA.G4.6626.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.G4.6626.01", "Activation of ATR in response to replication stress"], ["TCGA.G4.6626.01", "G0 and Early G1"], ["TCGA.G4.6626.01", "G beta:gamma signalling through PLC beta"], ["TCGA.G4.6626.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.G4.6626.01", "G-protein activation"], ["TCGA.G4.6626.01", "Thromboxane signalling through TP receptor"], ["TCGA.G4.6626.01", "Transcriptional regulation of pluripotent stem cells"], ["TCGA.G4.6626.01", "Interaction between L1 and Ankyrins"], ["TCGA.G4.6626.01", "Phase I - Functionalization of compounds"], ["TCGA.G4.6626.01", "Presynaptic function of Kainate receptors"], ["TCGA.G4.6626.01", "Protein-protein interactions at synapses"], ["TCGA.G4.6626.01", "Voltage gated Potassium channels"], ["TCGA.G4.6626.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.G4.6626.01", "Generation of second messenger molecules"], ["TCGA.G4.6626.01", "Immune System"], ["TCGA.G4.6626.01", "Molecules associated with elastic fibres"], ["TCGA.G4.6626.01", "G-protein mediated events"], ["TCGA.G4.6626.01", "Neurexins and neuroligins"], ["TCGA.G4.6626.01", "Caspase-mediated cleavage of cytoskeletal proteins"], ["TCGA.G4.6626.01", "Ca2+ pathway"], ["TCGA.NH.A6GA.01", "Neuronal System"], ["TCGA.NH.A6GA.01", "Transport of small molecules"], ["TCGA.NH.A6GA.01", "Peptide hormone metabolism"], ["TCGA.NH.A6GA.01", "Potassium Channels"], ["TCGA.NH.A6GA.01", "Cardiac conduction"], ["TCGA.NH.A6GA.01", "Interaction between L1 and Ankyrins"], ["TCGA.NH.A6GA.01", "Blood group systems biosynthesis"], ["TCGA.NH.A6GA.01", "Keratinization"], ["TCGA.NH.A6GA.01", "Signaling by GPCR"], ["TCGA.NH.A6GA.01", "G alpha (i) signalling events"], ["TCGA.NH.A6GA.01", "Biological oxidations"], ["TCGA.NH.A6GA.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.NH.A6GA.01", "SLC-mediated transmembrane transport"], ["TCGA.NH.A6GA.01", "Lewis blood group biosynthesis"], ["TCGA.NH.A6GA.01", "GPCR downstream signalling"], ["TCGA.NH.A6GA.01", "Drug ADME"], ["TCGA.NH.A6GA.01", "GPCR ligand binding"], ["TCGA.NH.A6GA.01", "Ion homeostasis"], ["TCGA.NH.A6GA.01", "Transmission across Chemical Synapses"], ["TCGA.NH.A6GA.01", "Glucuronidation"], ["TCGA.NH.A6GA.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.NH.A6GA.01", "Cytosolic sulfonation of small molecules"], ["TCGA.NH.A6GA.01", "Ion channel transport"], ["TCGA.NH.A6GA.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.NH.A6GA.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.NH.A6GA.01", "Peptide hormone biosynthesis"], ["TCGA.NH.A6GA.01", "Inwardly rectifying K+ channels"], ["TCGA.NH.A6GA.01", "Formation of the cornified envelope"], ["TCGA.NH.A6GA.01", "LGI-ADAM interactions"], ["TCGA.NH.A6GA.01", "Protein-protein interactions at synapses"], ["TCGA.NH.A6GA.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.NH.A6GA.01", "Peptide ligand-binding receptors"], ["TCGA.NH.A6GA.01", "Muscle contraction"], ["TCGA.NH.A6GA.01", "Phase II - Conjugation of compounds"], ["TCGA.NH.A6GA.01", "Developmental Biology"], ["TCGA.NH.A6GA.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.NH.A6GA.01", "L1CAM interactions"], ["TCGA.NH.A6GA.01", "Sialic acid metabolism"], ["TCGA.NH.A6GA.01", "Tryptophan catabolism"], ["TCGA.NH.A6GA.01", "Ethanol oxidation"], ["TCGA.NH.A6GA.01", "Aspirin ADME"], ["TCGA.NH.A6GA.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.NH.A6GA.01", "Vitamin B5 (pantothenate) metabolism"], ["TCGA.NH.A6GA.01", "Trafficking of GluR2-containing AMPA receptors"], ["TCGA.NH.A6GA.01", "Activation of G protein gated Potassium channels"], ["TCGA.NH.A6GA.01", "G protein gated Potassium channels"], ["TCGA.NH.A6GA.01", "Phase 0 - rapid depolarisation"], ["TCGA.NH.A6GA.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.NH.A6GA.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.NH.A6GB.01", "Neuronal System"], ["TCGA.NH.A6GB.01", "Interaction between L1 and Ankyrins"], ["TCGA.NH.A6GB.01", "Transmission across Chemical Synapses"], ["TCGA.NH.A6GB.01", "Cardiac conduction"], ["TCGA.NH.A6GB.01", "Transport of small molecules"], ["TCGA.NH.A6GB.01", "Biological oxidations"], ["TCGA.NH.A6GB.01", "Phase 0 - rapid depolarisation"], ["TCGA.NH.A6GB.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.NH.A6GB.01", "Activation of Matrix Metalloproteinases"], ["TCGA.NH.A6GB.01", "Muscle contraction"], ["TCGA.NH.A6GB.01", "GPCR ligand binding"], ["TCGA.NH.A6GB.01", "L1CAM interactions"], ["TCGA.NH.A6GB.01", "Integration of energy metabolism"], ["TCGA.NH.A6GB.01", "Glucuronidation"], ["TCGA.NH.A6GB.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.NH.A6GB.01", "Phase II - Conjugation of compounds"], ["TCGA.NH.A6GB.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.NH.A6GB.01", "O-linked glycosylation"], ["TCGA.NH.A6GB.01", "G alpha (s) signalling events"], ["TCGA.NH.A6GB.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.NH.A6GB.01", "G alpha (i) signalling events"], ["TCGA.NH.A6GB.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.NH.A6GB.01", "Ion channel transport"], ["TCGA.NH.A6GB.01", "Chemokine receptors bind chemokines"], ["TCGA.NH.A6GB.01", "Regulation of insulin secretion"], ["TCGA.NH.A6GB.01", "Extracellular matrix organization"], ["TCGA.NH.A6GB.01", "Aspirin ADME"], ["TCGA.NH.A6GB.01", "Peptide ligand-binding receptors"], ["TCGA.NH.A6GB.01", "Ion transport by P-type ATPases"], ["TCGA.NH.A6GB.01", "Protein-protein interactions at synapses"], ["TCGA.NH.A6GB.01", "Signaling by GPCR"], ["TCGA.NH.A6GB.01", "GPCR downstream signalling"], ["TCGA.NH.A6GB.01", "Drug ADME"], ["TCGA.NH.A6GB.01", "Molecules associated with elastic fibres"], ["TCGA.NH.A6GB.01", "Ion homeostasis"], ["TCGA.NH.A6GB.01", "SLC-mediated transmembrane transport"], ["TCGA.NH.A6GB.01", "Glucagon signaling in metabolic regulation"], ["TCGA.NH.A6GB.01", "Sialic acid metabolism"], ["TCGA.NH.A6GB.01", "Glucagon-type ligand receptors"], ["TCGA.NH.A6GB.01", "Developmental Biology"], ["TCGA.NH.A6GB.01", "Platelet homeostasis"], ["TCGA.NH.A6GB.01", "O-linked glycosylation of mucins"], ["TCGA.NH.A6GB.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.NH.A6GB.01", "Peptide hormone metabolism"], ["TCGA.NH.A6GB.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.NH.A6GB.01", "Sensory processing of sound by inner hair cells of the cochlea"], ["TCGA.NH.A6GB.01", "Sensory processing of sound"], ["TCGA.NH.A6GB.01", "Synaptic adhesion-like molecules"], ["TCGA.NH.A6GB.01", "Termination of O-glycan biosynthesis"], ["TCGA.NH.A6GB.01", "Phase I - Functionalization of compounds"], ["TCGA.NH.A6GB.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.NH.A6GB.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.NH.A6GB.01", "Cytosolic sulfonation of small molecules"], ["TCGA.NH.A6GB.01", "Degradation of the extracellular matrix"], ["TCGA.NH.A6GB.01", "Stimuli-sensing channels"], ["TCGA.NH.A6GB.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.QL.A97D.01", "Neuronal System"], ["TCGA.QL.A97D.01", "Transmission across Chemical Synapses"], ["TCGA.QL.A97D.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.QL.A97D.01", "Biological oxidations"], ["TCGA.QL.A97D.01", "Interaction between L1 and Ankyrins"], ["TCGA.QL.A97D.01", "Signaling by GPCR"], ["TCGA.QL.A97D.01", "Phase 0 - rapid depolarisation"], ["TCGA.QL.A97D.01", "Transport of small molecules"], ["TCGA.QL.A97D.01", "Cardiac conduction"], ["TCGA.QL.A97D.01", "RA biosynthesis pathway"], ["TCGA.QL.A97D.01", "GPCR downstream signalling"], ["TCGA.QL.A97D.01", "Phase II - Conjugation of compounds"], ["TCGA.QL.A97D.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.QL.A97D.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.QL.A97D.01", "Peptide hormone metabolism"], ["TCGA.QL.A97D.01", "G alpha (s) signalling events"], ["TCGA.QL.A97D.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.QL.A97D.01", "L1CAM interactions"], ["TCGA.QL.A97D.01", "Protein-protein interactions at synapses"], ["TCGA.QL.A97D.01", "Ion channel transport"], ["TCGA.QL.A97D.01", "Keratan sulfate biosynthesis"], ["TCGA.QL.A97D.01", "G alpha (i) signalling events"], ["TCGA.QL.A97D.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.QL.A97D.01", "Muscle contraction"], ["TCGA.QL.A97D.01", "Glucuronidation"], ["TCGA.QL.A97D.01", "Cytosolic sulfonation of small molecules"], ["TCGA.QL.A97D.01", "GPCR ligand binding"], ["TCGA.QL.A97D.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.QL.A97D.01", "Signaling by Retinoic Acid"], ["TCGA.QL.A97D.01", "Potassium Channels"], ["TCGA.QL.A97D.01", "Long-term potentiation"], ["TCGA.QL.A97D.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.QL.A97D.01", "Glycosaminoglycan metabolism"], ["TCGA.QL.A97D.01", "G-protein mediated events"], ["TCGA.QL.A97D.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.QL.A97D.01", "Keratan sulfate/keratin metabolism"], ["TCGA.QL.A97D.01", "Amino acid transport across the plasma membrane"], ["TCGA.QL.A97D.01", "Calmodulin induced events"], ["TCGA.QL.A97D.01", "CaM pathway"], ["TCGA.QL.A97D.01", "Platelet homeostasis"], ["TCGA.QL.A97D.01", "Activation of Matrix Metalloproteinases"], ["TCGA.QL.A97D.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.QL.A97D.01", "Ca-dependent events"], ["TCGA.QL.A97D.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.QL.A97D.01", "Regulation of gene expression in beta cells"], ["TCGA.QL.A97D.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.QL.A97D.01", "Synaptic adhesion-like molecules"], ["TCGA.QL.A97D.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.QL.A97D.01", "Ethanol oxidation"], ["TCGA.QL.A97D.01", "Transcriptional regulation of testis differentiation"], ["TCGA.QL.A97D.01", "Phase I - Functionalization of compounds"], ["TCGA.QL.A97D.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.QL.A97D.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.QL.A97D.01", "Arachidonic acid metabolism"], ["TCGA.QL.A97D.01", "Class B/2 (Secretin family receptors)"], ["TCGA.T9.A92H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], ["TCGA.T9.A92H.01", "Neuronal System"], ["TCGA.T9.A92H.01", "Transmission across Chemical Synapses"], ["TCGA.T9.A92H.01", "Signaling by GPCR"], ["TCGA.T9.A92H.01", "G alpha (i) signalling events"], ["TCGA.T9.A92H.01", "GPCR downstream signalling"], ["TCGA.T9.A92H.01", "Complement cascade"], ["TCGA.T9.A92H.01", "Platelet homeostasis"], ["TCGA.T9.A92H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], ["TCGA.T9.A92H.01", "GPCR ligand binding"], ["TCGA.T9.A92H.01", "Initial triggering of complement"], ["TCGA.T9.A92H.01", "Signaling Pathways"], ["TCGA.T9.A92H.01", "Protein-protein interactions at synapses"], ["TCGA.T9.A92H.01", "Regulation of Complement cascade"], ["TCGA.T9.A92H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.T9.A92H.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.T9.A92H.01", "Peptide ligand-binding receptors"], ["TCGA.T9.A92H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], ["TCGA.T9.A92H.01", "Leishmania parasite growth and survival"], ["TCGA.T9.A92H.01", "Neurotransmitter release cycle"], ["TCGA.T9.A92H.01", "Leishmania infection"], ["TCGA.T9.A92H.01", "Unblocking of NMDA receptors, glutamate binding and activation"], ["TCGA.T9.A92H.01", "Transport of small molecules"], ["TCGA.T9.A92H.01", "Muscle contraction"], ["TCGA.T9.A92H.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.T9.A92H.01", "Immune System"], ["TCGA.T9.A92H.01", "G alpha (s) signalling events"], ["TCGA.T9.A92H.01", "Synaptic adhesion-like molecules"], ["TCGA.T9.A92H.01", "Metabolism of fat-soluble vitamins"], ["TCGA.T9.A92H.01", "Retinoid metabolism and transport"], ["TCGA.T9.A92H.01", "Regulation of insulin secretion"], ["TCGA.T9.A92H.01", "Extracellular matrix organization"], ["TCGA.T9.A92H.01", "Biological oxidations"], ["TCGA.T9.A92H.01", "Ion channel transport"], ["TCGA.T9.A92H.01", "G-protein beta:gamma signalling"], ["TCGA.T9.A92H.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], ["TCGA.T9.A92H.01", "GABA receptor activation"], ["TCGA.T9.A92H.01", "G alpha (q) signalling events"], ["TCGA.T9.A92H.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.T9.A92H.01", "Long-term potentiation"], ["TCGA.T9.A92H.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.T9.A92H.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.T9.A92H.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.T9.A92H.01", "Generation of second messenger molecules"], ["TCGA.T9.A92H.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.T9.A92H.01", "Signal amplification"], ["TCGA.T9.A92H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.T9.A92H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.T9.A92H.01", "Molecules associated with elastic fibres"], ["TCGA.T9.A92H.01", "Scavenging of heme from plasma"], ["TCGA.T9.A92H.01", "Scavenging by Class A Receptors"], ["TCGA.T9.A92H.01", "CD22 mediated BCR regulation"], ["TCGA.T9.A92H.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.T9.A92H.01", "Drug ADME"], ["TCGA.T9.A92H.01", "DAP12 signaling"], ["TCGA.T9.A92H.01", "Interaction between L1 and Ankyrins"], ["TCGA.T9.A92H.01", "Neurexins and neuroligins"], ["TCGA.T9.A92H.01", "Integration of energy metabolism"], ["TCGA.T9.A92H.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.T9.A92H.01", "G beta:gamma signalling through CDC42"], ["TCGA.T9.A92H.01", "Phase I - Functionalization of compounds"], ["TCGA.T9.A92H.01", "FCGR activation"], ["TCGA.T9.A92H.01", "Aquaporin-mediated transport"], ["TCGA.T9.A92H.01", "PD-1 signaling"], ["TCGA.T9.A92H.01", "Ca2+ pathway"], ["TCGA.T9.A92H.01", "Activation of NMDA receptors and postsynaptic events"], ["TCGA.T9.A92H.01", "Trafficking of AMPA receptors"], ["TCGA.T9.A92H.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], ["TCGA.T9.A92H.01", "Norepinephrine Neurotransmitter Release Cycle"], ["TCGA.T9.A92H.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.T9.A92H.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], ["TCGA.T9.A92H.01", "Negative regulation of the PI3K/AKT network"], ["TCGA.T9.A92H.01", "Interleukin-4 and Interleukin-13 signaling"], ["TCGA.T9.A92H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], ["TCGA.T9.A92H.01", "Class B/2 (Secretin family receptors)"], ["TCGA.T9.A92H.01", "DAP12 interactions"], ["TCGA.T9.A92H.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.T9.A92H.01", "Visual phototransduction"], ["TCGA.T9.A92H.01", "Peptide hormone metabolism"], ["TCGA.T9.A92H.01", "GABA synthesis, release, reuptake and degradation"], ["TCGA.T9.A92H.01", "Elastic fibre formation"], ["TCGA.T9.A92H.01", "Stimuli-sensing channels"], ["TCGA.T9.A92H.01", "Innate Immune System"], ["TCGA.T9.A92H.01", "Glycosaminoglycan metabolism"], ["TCGA.WS.AB45.01", "Extracellular matrix organization"], ["TCGA.WS.AB45.01", "Signaling by GPCR"], ["TCGA.WS.AB45.01", "Transport of small molecules"], ["TCGA.WS.AB45.01", "Biological oxidations"], ["TCGA.WS.AB45.01", "Integrin cell surface interactions"], ["TCGA.WS.AB45.01", "GPCR ligand binding"], ["TCGA.WS.AB45.01", "GPCR downstream signalling"], ["TCGA.WS.AB45.01", "Degradation of the extracellular matrix"], ["TCGA.WS.AB45.01", "Activation of Matrix Metalloproteinases"], ["TCGA.WS.AB45.01", "Signaling Pathways"], ["TCGA.WS.AB45.01", "ECM proteoglycans"], ["TCGA.WS.AB45.01", "Drug ADME"], ["TCGA.WS.AB45.01", "SLC-mediated transmembrane transport"], ["TCGA.WS.AB45.01", "Phase II - Conjugation of compounds"], ["TCGA.WS.AB45.01", "Adherens junctions interactions"], ["TCGA.WS.AB45.01", "G alpha (i) signalling events"], ["TCGA.WS.AB45.01", "Regulation of IGF Activity by IGFBP"], ["TCGA.WS.AB45.01", "Phase I - Functionalization of compounds"], ["TCGA.WS.AB45.01", "Diseases of metabolism"], ["TCGA.WS.AB45.01", "Peptide ligand-binding receptors"], ["TCGA.WS.AB45.01", "Metabolism"], ["TCGA.WS.AB45.01", "NCAM1 interactions"], ["TCGA.WS.AB45.01", "Post-translational protein phosphorylation"], ["TCGA.WS.AB45.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.WS.AB45.01", "Fatty acid metabolism"], ["TCGA.WS.AB45.01", "Ion channel transport"], ["TCGA.WS.AB45.01", "Cell-cell junction organization"], ["TCGA.WS.AB45.01", "Class B/2 (Secretin family receptors)"], ["TCGA.WS.AB45.01", "G alpha (q) signalling events"], ["TCGA.WS.AB45.01", "Signaling by PDGF"], ["TCGA.WS.AB45.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.WS.AB45.01", "Neuronal System"], ["TCGA.WS.AB45.01", "Stimuli-sensing channels"], ["TCGA.WS.AB45.01", "Cell junction organization"], ["TCGA.WS.AB45.01", "Transmission across Chemical Synapses"], ["TCGA.WS.AB45.01", "RHO GTPases Activate NADPH Oxidases"], ["TCGA.WS.AB45.01", "NCAM signaling for neurite out-growth"], ["TCGA.WS.AB45.01", "Regulation of beta-cell development"], ["TCGA.WS.AB45.01", "Digestion and absorption"], ["TCGA.WS.AB45.01", "G alpha (s) signalling events"], ["TCGA.WS.AB45.01", "Synthesis of bile acids and bile salts"], ["TCGA.WS.AB45.01", "Bile acid and bile salt metabolism"], ["TCGA.WS.AB45.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.WS.AB45.01", "Carbohydrate metabolism"], ["TCGA.WS.AB45.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], ["TCGA.WS.AB45.01", "Signaling by Receptor Tyrosine Kinases"], ["TCGA.WS.AB45.01", "Neurotransmitter release cycle"], ["TCGA.WS.AB45.01", "Digestion"], ["TCGA.WS.AB45.01", "GABA receptor activation"], ["TCGA.WS.AB45.01", "Regulation of gene expression in beta cells"], ["TCGA.WS.AB45.01", "Metabolism of Angiotensinogen to Angiotensins"]], "chosen_edges": [["CYB5R4", ["TCGA.3L.AA1B.01", "Transport of small molecules"], {"weight": 0.895925260622873}], ["GRM1", ["TCGA.4T.AA8H.01", "Ca2+ pathway"], {"weight": 0.883709145964115}], ["GRM1", ["TCGA.A6.6652.01", "PLC beta mediated events"], {"weight": 0.894439322855407}], ["GRM1", ["TCGA.A6.6652.01", "Ca2+ pathway"], {"weight": 0.913416141001499}], ["GRM1", ["TCGA.A6.A56B.01", "Collagen chain trimerization"], {"weight": 0.896099046697354}], ["GRM1", ["TCGA.A6.A56B.01", "Collagen formation"], {"weight": 0.92370070182768}], ["GRM1", ["TCGA.A6.A56B.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.927942394368435}], ["GRM1", ["TCGA.A6.A56B.01", "Signaling by GPCR"], {"weight": 0.947741129794425}], ["GRM1", ["TCGA.A6.A56B.01", "GPCR downstream signalling"], {"weight": 0.961383141536159}], ["GRM1", ["TCGA.A6.A56B.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.886536992201135}], ["GRM1", ["TCGA.A6.A56B.01", "Peptide hormone metabolism"], {"weight": 0.775877432410199}], ["GRM1", ["TCGA.A6.A56B.01", "Neuronal System"], {"weight": 0.917020518145094}], ["GRM1", ["TCGA.A6.A56B.01", "O-linked glycosylation"], {"weight": -0.011102389993968}], ["GRM1", ["TCGA.A6.A56B.01", "NCAM1 interactions"], {"weight": 0.882094344066278}], ["GRM1", ["TCGA.A6.A56B.01", "Metabolism"], {"weight": 0.911587875021768}], ["GRM1", ["TCGA.A6.A56B.01", "Chemokine receptors bind chemokines"], {"weight": 0.908460885810712}], ["GRM1", ["TCGA.A6.A56B.01", "Regulation of insulin secretion"], {"weight": 0.91810750135722}], ["GRM1", ["TCGA.A6.A56B.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.918291992552867}], ["GRM1", ["TCGA.A6.A56B.01", "Defective B3GALTL causes PpS"], {"weight": 0.759118594678687}], ["GRM1", ["TCGA.A6.A56B.01", "Integration of energy metabolism"], {"weight": 0.92466857523149}], ["GRM1", ["TCGA.A6.A56B.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.755527534127194}], ["GRM1", ["TCGA.A6.A56B.01", "Potassium Channels"], {"weight": 0.93470293675757}], ["GRM1", ["TCGA.A6.A56B.01", "GPCR ligand binding"], {"weight": 0.91557685341991}], ["GRM1", ["TCGA.A6.A56B.01", "Leishmania infection"], {"weight": 0.833373017651933}], ["GRM1", ["TCGA.A6.A56B.01", "G alpha (s) signalling events"], {"weight": 0.949576475338719}], ["GRM1", ["TCGA.A6.A56B.01", "Signaling Pathways"], {"weight": 0.890433120609206}], ["GRM1", ["TCGA.A6.A56B.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.87885750689162}], ["GRM1", ["TCGA.A6.A56B.01", "Leishmania parasite growth and survival"], {"weight": 0.87885750689162}], ["GRM1", ["TCGA.A6.A56B.01", "Regulation of signaling by NODAL"], {"weight": 0.797057343708511}], ["GRM1", ["TCGA.A6.A56B.01", "Surfactant metabolism"], {"weight": 0.655601201247064}], ["GRM1", ["TCGA.A6.A56B.01", "Scavenging of heme from plasma"], {"weight": 0.743699355710063}], ["GRM1", ["TCGA.AA.3655.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.850146381805629}], ["GRM1", ["TCGA.AA.3660.01", "Neuronal System"], {"weight": 0.88944652534532}], ["GRM1", ["TCGA.AA.3854.01", "Protein-protein interactions at synapses"], {"weight": 0.919446929984838}], ["GRM1", ["TCGA.AA.3854.01", "Neurexins and neuroligins"], {"weight": 0.917433523042972}], ["GRM1", ["TCGA.AA.3854.01", "Integration of energy metabolism"], {"weight": 0.859856347670451}], ["GRM1", ["TCGA.AA.3875.01", "Neuronal System"], {"weight": 0.757593673686658}], ["GRM1", ["TCGA.AA.A02Y.01", "Ca2+ pathway"], {"weight": 0.901877409609533}], ["GRM1", ["TCGA.AA.A02Y.01", "PLC beta mediated events"], {"weight": 0.883753426479176}], ["GRM1", ["TCGA.AY.A8YK.01", "Neuronal System"], {"weight": 0.932852206850518}], ["GRM1", ["TCGA.AZ.4616.01", "Phase 0 - rapid depolarisation"], {"weight": 0.864118152545449}], ["GRM1", ["TCGA.AZ.4616.01", "Protein-protein interactions at synapses"], {"weight": 0.859348571355764}], ["GRM1", ["TCGA.AZ.6598.01", "PLC beta mediated events"], {"weight": 0.905289218718843}], ["GRM1", ["TCGA.AZ.6608.01", "Ca2+ pathway"], {"weight": 0.898810206040733}], ["GRM1", ["TCGA.AZ.6608.01", "PLC beta mediated events"], {"weight": 0.913434312311098}], ["GRM1", ["TCGA.CA.5255.01", "PLC beta mediated events"], {"weight": 0.900650377091356}], ["GRM1", ["TCGA.CA.5255.01", "G-protein mediated events"], {"weight": 0.900650377091356}], ["GRM1", ["TCGA.CK.5915.01", "Interferon gamma signaling"], {"weight": 0.925220497012751}], ["GRM1", ["TCGA.CK.5915.01", "Ca2+ pathway"], {"weight": 0.894238567519037}], ["GRM1", ["TCGA.CK.5915.01", "Long-term potentiation"], {"weight": 0.897574158599299}], ["GRM1", ["TCGA.CM.6676.01", "Signaling by GPCR"], {"weight": 0.936075317840646}], ["GRM1", ["TCGA.CM.6676.01", "GPCR downstream signalling"], {"weight": 0.944485086637731}], ["GRM1", ["TCGA.CM.6676.01", "G alpha (i) signalling events"], {"weight": 0.953089108953976}], ["GRM1", ["TCGA.CM.6676.01", "Ca2+ pathway"], {"weight": 0.867295525929518}], ["GRM1", ["TCGA.CM.6676.01", "Transport of small molecules"], {"weight": 0.934582593979649}], ["GRM1", ["TCGA.CM.6678.01", "Neuronal System"], {"weight": 0.876169926195352}], ["GRM1", ["TCGA.D5.6531.01", "Extracellular matrix organization"], {"weight": 0.838510333061952}], ["GRM1", ["TCGA.D5.6535.01", "Phase 0 - rapid depolarisation"], {"weight": 0.90399662414742}], ["GRM1", ["TCGA.D5.6537.01", "Ca2+ pathway"], {"weight": 0.879410293110438}], ["GRM1", ["TCGA.D5.6898.01", "Neuronal System"], {"weight": 0.868180422075485}], ["GRM1", ["TCGA.F4.6704.01", "Neuronal System"], {"weight": 0.86944569807996}], ["GRM1", ["TCGA.NH.A6GA.01", "Neuronal System"], {"weight": 0.86465551345011}], ["GRM1", ["TCGA.QL.A97D.01", "Signaling by GPCR"], {"weight": 0.941276895265089}], ["GRM1", ["TCGA.QL.A97D.01", "GPCR downstream signalling"], {"weight": 0.948428587967116}], ["PCMT1", ["TCGA.4T.AA8H.01", "Bile acid and bile salt metabolism"], {"weight": 0.941958285524688}], ["PCMT1", ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts"], {"weight": 0.921651258910536}], ["PCMT1", ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.805574390768641}], ["PCMT1", ["TCGA.4T.AA8H.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.861103382993598}], ["PCMT1", ["TCGA.5M.AATA.01", "RA biosynthesis pathway"], {"weight": 0.911270087468007}], ["PCMT1", ["TCGA.A6.2678.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.807368671208167}], ["PCMT1", ["TCGA.A6.2678.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.84096262193275}], ["PCMT1", ["TCGA.A6.2678.01", "Bile acid and bile salt metabolism"], {"weight": 0.760048070860038}], ["PCMT1", ["TCGA.AA.3521.01", "RA biosynthesis pathway"], {"weight": 0.829646800053641}], ["PCMT1", ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.837041741634009}], ["PCMT1", ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.837081807778685}], ["PCMT1", ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts"], {"weight": 0.878115957529402}], ["PCMT1", ["TCGA.AA.3655.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.867484986603478}], ["PCMT1", ["TCGA.AA.3655.01", "Bile acid and bile salt metabolism"], {"weight": 0.876700784458477}], ["PCMT1", ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.697562258483723}], ["PCMT1", ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.743179544728538}], ["PCMT1", ["TCGA.AA.3660.01", "Bile acid and bile salt metabolism"], {"weight": 0.727778113866401}], ["PCMT1", ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts"], {"weight": 0.750134176886338}], ["PCMT1", ["TCGA.AA.3660.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.758104436911781}], ["PCMT1", ["TCGA.AA.3854.01", "RA biosynthesis pathway"], {"weight": 0.782817715021324}], ["PCMT1", ["TCGA.AA.3854.01", "Synaptic adhesion-like molecules"], {"weight": 0.776592695793111}], ["PCMT1", ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.765295182136662}], ["PCMT1", ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.768756223087742}], ["PCMT1", ["TCGA.AA.3858.01", "Bile acid and bile salt metabolism"], {"weight": 0.816070695990949}], ["PCMT1", ["TCGA.AA.3858.01", "RA biosynthesis pathway"], {"weight": 0.843338138673219}], ["PCMT1", ["TCGA.AA.3858.01", "Synthesis of bile acids and bile salts"], {"weight": 0.766781209343359}], ["PCMT1", ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.593545916651687}], ["PCMT1", ["TCGA.AA.A02H.01", "RA biosynthesis pathway"], {"weight": 0.818158091850906}], ["PCMT1", ["TCGA.AZ.6598.01", "Bile acid and bile salt metabolism"], {"weight": 0.847821787602546}], ["PCMT1", ["TCGA.AZ.6598.01", "RA biosynthesis pathway"], {"weight": 0.900061875826124}], ["PCMT1", ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.791605265072118}], ["PCMT1", ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts"], {"weight": 0.824233255762559}], ["PCMT1", ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.819744238020845}], ["PCMT1", ["TCGA.AZ.6598.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.805630604305403}], ["PCMT1", ["TCGA.AZ.6607.01", "Bile acid and bile salt metabolism"], {"weight": 0.809182238228708}], ["PCMT1", ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.81770300696486}], ["PCMT1", ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.829078368032756}], ["PCMT1", ["TCGA.AZ.6607.01", "Synthesis of bile acids and bile salts"], {"weight": 0.811100928989127}], ["PCMT1", ["TCGA.CA.5255.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.811993974384634}], ["PCMT1", ["TCGA.CA.5255.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.823495784526362}], ["PCMT1", ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.752331123718137}], ["PCMT1", ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts"], {"weight": 0.886570950772122}], ["PCMT1", ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.787585612317822}], ["PCMT1", ["TCGA.CA.5256.01", "Bile acid and bile salt metabolism"], {"weight": 0.897676386530044}], ["PCMT1", ["TCGA.CA.5256.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.834204059720311}], ["PCMT1", ["TCGA.CA.5256.01", "RA biosynthesis pathway"], {"weight": 0.902953465890359}], ["PCMT1", ["TCGA.CK.5915.01", "RA biosynthesis pathway"], {"weight": 0.918009828198585}], ["PCMT1", ["TCGA.CM.6161.01", "RA biosynthesis pathway"], {"weight": 0.856317932571792}], ["PCMT1", ["TCGA.CM.6676.01", "RA biosynthesis pathway"], {"weight": 0.86104047101557}], ["PCMT1", ["TCGA.CM.6676.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.783812482681428}], ["PCMT1", ["TCGA.D5.6529.01", "RA biosynthesis pathway"], {"weight": 0.857875093099652}], ["PCMT1", ["TCGA.D5.6529.01", "Bile acid and bile salt metabolism"], {"weight": 0.792859735350302}], ["PCMT1", ["TCGA.D5.6531.01", "RA biosynthesis pathway"], {"weight": 0.877274453084219}], ["PCMT1", ["TCGA.D5.6537.01", "Bile acid and bile salt metabolism"], {"weight": 0.922136860126889}], ["PCMT1", ["TCGA.DM.A28K.01", "Synaptic adhesion-like molecules"], {"weight": 0.813977022831475}], ["PCMT1", ["TCGA.G4.6297.01", "RA biosynthesis pathway"], {"weight": 0.821582488607503}], ["PCMT1", ["TCGA.G4.6297.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.725223829455053}], ["IFNGR1", ["TCGA.4T.AA8H.01", "Other interleukin signaling"], {"weight": 0.741144557538894}], ["IFNGR1", ["TCGA.A6.A56B.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.819474903800912}], ["IFNGR1", ["TCGA.A6.A56B.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.900547024943096}], ["IFNGR1", ["TCGA.A6.A56B.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.906491089086866}], ["IFNGR1", ["TCGA.A6.A56B.01", "Generation of second messenger molecules"], {"weight": 0.894654875337905}], ["IFNGR1", ["TCGA.A6.A56B.01", "Biological oxidations"], {"weight": 0.928012911430421}], ["IFNGR1", ["TCGA.A6.A56B.01", "Extracellular matrix organization"], {"weight": 0.886757935444439}], ["IFNGR1", ["TCGA.A6.A56B.01", "PD-1 signaling"], {"weight": 0.878709201523233}], ["IFNGR1", ["TCGA.A6.A56B.01", "Transport of small molecules"], {"weight": 0.921791952589692}], ["IFNGR1", ["TCGA.A6.A56B.01", "Drug ADME"], {"weight": 0.868723771405061}], ["IFNGR1", ["TCGA.A6.A56B.01", "G alpha (i) signalling events"], {"weight": 0.963115149708963}], ["IFNGR1", ["TCGA.A6.A56B.01", "Cardiac conduction"], {"weight": 0.912214326480325}], ["IFNGR1", ["TCGA.A6.A56B.01", "Immune System"], {"weight": 0.866431259694775}], ["IFNGR1", ["TCGA.A6.A56B.01", "Phase 0 - rapid depolarisation"], {"weight": 0.916431414573023}], ["IFNGR1", ["TCGA.A6.A56B.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.908423521917846}], ["IFNGR1", ["TCGA.A6.A56B.01", "Diseases associated with O-glycosylation of proteins"], {"weight": -0.0173516167454317}], ["IFNGR1", ["TCGA.A6.A56B.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.66989713625161}], ["IFNGR1", ["TCGA.A6.A56B.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.784207008543382}], ["IFNGR1", ["TCGA.A6.A56B.01", "Interaction between L1 and Ankyrins"], {"weight": 0.885952168408464}], ["IFNGR1", ["TCGA.A6.A56B.01", "Insulin processing"], {"weight": 0.626772967166046}], ["IFNGR1", ["TCGA.A6.A56B.01", "Phase I - Functionalization of compounds"], {"weight": 0.892766536573099}], ["IFNGR1", ["TCGA.A6.A56B.01", "CD22 mediated BCR regulation"], {"weight": 0.789041948163752}], ["IFNGR1", ["TCGA.A6.A56B.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.698330855590188}], ["IFNGR1", ["TCGA.A6.A56B.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.893578744615917}], ["IFNGR1", ["TCGA.A6.A56B.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.855019045953987}], ["IFNGR1", ["TCGA.A6.A56B.01", "Signaling by Retinoic Acid"], {"weight": 0.82071204681733}], ["IFNGR1", ["TCGA.A6.A56B.01", "TNFs bind their physiological receptors"], {"weight": 0.453547441976593}], ["IFNGR1", ["TCGA.A6.A56B.01", "SLC-mediated transmembrane transport"], {"weight": 0.907937174664919}], ["IFNGR1", ["TCGA.A6.A56B.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], {"weight": -0.024587114542019}], ["IFNGR1", ["TCGA.A6.A56B.01", "Integrin cell surface interactions"], {"weight": 0.861439563354822}], ["IFNGR1", ["TCGA.A6.A56B.01", "Stimuli-sensing channels"], {"weight": 0.874743451431583}], ["IFNGR1", ["TCGA.A6.A56B.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.670851945738165}], ["IFNGR1", ["TCGA.A6.A56B.01", "Costimulation by the CD28 family"], {"weight": 0.879105170969491}], ["IFNGR1", ["TCGA.A6.A56B.01", "Inflammasomes"], {"weight": 0.372781719981872}], ["IFNGR1", ["TCGA.A6.A56B.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.595743492955004}], ["IFNGR1", ["TCGA.A6.A56B.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.595743492955004}], ["IFNGR1", ["TCGA.A6.A56B.01", "Transmission across Chemical Synapses"], {"weight": 0.89930862557223}], ["IFNGR1", ["TCGA.A6.A56B.01", "Ion channel transport"], {"weight": 0.910020923293692}], ["IFNGR1", ["TCGA.A6.A56B.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.917102576066362}], ["IFNGR1", ["TCGA.A6.A56B.01", "TP53 Regulates Transcription of Caspase Activators and Caspases"], {"weight": 0.445965614858201}], ["IFNGR1", ["TCGA.AA.3854.01", "CD22 mediated BCR regulation"], {"weight": 0.707421755439147}], ["IFNGR1", ["TCGA.AD.6888.01", "Other interleukin signaling"], {"weight": 0.821675507075714}], ["IFNGR1", ["TCGA.AZ.6606.01", "Other interleukin signaling"], {"weight": 0.625466515070505}], ["IFNGR1", ["TCGA.CA.5255.01", "Other interleukin signaling"], {"weight": 0.695451964252705}], ["IFNGR1", ["TCGA.G4.6306.01", "Other interleukin signaling"], {"weight": 0.65682864056137}], ["PDE7B", ["TCGA.4T.AA8H.01", "Calmodulin induced events"], {"weight": 0.893161506051731}], ["PDE7B", ["TCGA.4T.AA8H.01", "CaM pathway"], {"weight": 0.893161506051731}], ["PDE7B", ["TCGA.4T.AA8H.01", "Ca-dependent events"], {"weight": 0.893161506051731}], ["PDE7B", ["TCGA.AA.3854.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.922755292232438}], ["PDE7B", ["TCGA.AA.3854.01", "G alpha (z) signalling events"], {"weight": 0.880348776418817}], ["PDE7B", ["TCGA.AA.3854.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.894592209985453}], ["PDE7B", ["TCGA.AA.3854.01", "GABA B receptor activation"], {"weight": 0.935488835949616}], ["PDE7B", ["TCGA.AA.3854.01", "Activation of GABAB receptors"], {"weight": 0.935488835949616}], ["PDE7B", ["TCGA.AA.3854.01", "GABA receptor activation"], {"weight": 0.889862090628033}], ["PDE7B", ["TCGA.AA.3854.01", "Aquaporin-mediated transport"], {"weight": 0.894592209985453}], ["PDE7B", ["TCGA.AA.3854.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.926640890458635}], ["PDE7B", ["TCGA.AA.3854.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.922024929712643}], ["PDE7B", ["TCGA.AA.3854.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.906248089796945}], ["PDE7B", ["TCGA.AA.A017.01", "Neuronal System"], {"weight": 0.937683374829862}], ["PDE7B", ["TCGA.AA.A017.01", "G alpha (i) signalling events"], {"weight": 0.959293444260076}], ["PDE7B", ["TCGA.AA.A017.01", "Transmission across Chemical Synapses"], {"weight": 0.925756931017096}], ["PDE7B", ["TCGA.AA.A017.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.920208820456493}], ["PDE7B", ["TCGA.AA.A017.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.923955314432948}], ["PDE7B", ["TCGA.AA.A017.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.881163605444414}], ["PDE7B", ["TCGA.AA.A017.01", "Leishmania parasite growth and survival"], {"weight": 0.881163605444414}], ["PDE7B", ["TCGA.AA.A017.01", "Transport of small molecules"], {"weight": 0.918357644872544}], ["PDE7B", ["TCGA.AA.A017.01", "Regulation of insulin secretion"], {"weight": 0.905521964225778}], ["PDE7B", ["TCGA.AA.A017.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.914940800992208}], ["PDE7B", ["TCGA.AA.A017.01", "Integration of energy metabolism"], {"weight": 0.917025165263007}], ["PDE7B", ["TCGA.AA.A017.01", "GABA receptor activation"], {"weight": 0.66258446176688}], ["PDE7B", ["TCGA.CM.6167.01", "Nucleotide catabolism"], {"weight": 0.776788997607115}], ["PDE7B", ["TCGA.F4.6854.01", "G alpha (i) signalling events"], {"weight": 0.929204069697328}], ["PDE7B", ["TCGA.F4.6854.01", "Metabolism"], {"weight": 0.890623714376911}], ["TNFAIP3", ["TCGA.AA.3685.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.312800451982197}], ["TNFAIP3", ["TCGA.AA.3837.01", "Signaling by BMP"], {"weight": 0.504998778528523}], ["TNFAIP3", ["TCGA.AA.3841.01", "Regulation of FZD by ubiquitination"], {"weight": 0.904394564740505}], ["TNFAIP3", ["TCGA.AA.3952.01", "TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway"], {"weight": 0.853560500448258}], ["TNFAIP3", ["TCGA.D5.6535.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.75116612461188}], ["TNFAIP3", ["TCGA.F4.6459.01", "TNFs bind their physiological receptors"], {"weight": 0.296696533392352}], ["HBS1L", ["TCGA.AA.3679.01", "Collagen formation"], {"weight": 0.889933687407803}], ["HBS1L", ["TCGA.AA.3685.01", "Eukaryotic Translation Elongation"], {"weight": 0.904975716637488}], ["HBS1L", ["TCGA.AA.3841.01", "mRNA decay by 3' to 5' exoribonuclease"], {"weight": 0.629404009001069}], ["HBS1L", ["TCGA.AA.3841.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.938575699101929}], ["HBS1L", ["TCGA.AA.3841.01", "rRNA processing"], {"weight": 0.909041368575311}], ["HBS1L", ["TCGA.AA.3842.01", "Biological oxidations"], {"weight": 0.863443366994786}], ["HBS1L", ["TCGA.AA.3842.01", "Phase II - Conjugation of compounds"], {"weight": 0.73440066633264}], ["HBS1L", ["TCGA.AA.3842.01", "Chemokine receptors bind chemokines"], {"weight": 0.868371192820635}], ["HBS1L", ["TCGA.AA.3956.01", "Collagen formation"], {"weight": 0.823315674217339}], ["HBS1L", ["TCGA.AA.3956.01", "Stimuli-sensing channels"], {"weight": 0.375025469422409}], ["HBS1L", ["TCGA.AY.6197.01", "GPCR ligand binding"], {"weight": 0.90566856280944}], ["HBS1L", ["TCGA.AY.6197.01", "Chemokine receptors bind chemokines"], {"weight": 0.903131452792847}], ["HBS1L", ["TCGA.AY.6197.01", "G alpha (i) signalling events"], {"weight": 0.905505592665092}], ["HBS1L", ["TCGA.AY.6197.01", "Peptide ligand-binding receptors"], {"weight": 0.911748360269466}], ["HBS1L", ["TCGA.AY.6197.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.913561119553396}], ["HBS1L", ["TCGA.AY.6197.01", "Glycosaminoglycan metabolism"], {"weight": 0.819602379571443}], ["HBS1L", ["TCGA.AY.6197.01", "Biological oxidations"], {"weight": 0.862975370696161}], ["HBS1L", ["TCGA.AY.6197.01", "Phase II - Conjugation of compounds"], {"weight": 0.599845011823905}], ["HBS1L", ["TCGA.AZ.4681.01", "rRNA processing"], {"weight": 0.928014625023043}], ["HBS1L", ["TCGA.AZ.4681.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.943621887271329}], ["HBS1L", ["TCGA.AZ.4681.01", "Cellular response to starvation"], {"weight": 0.923590934153821}], ["HBS1L", ["TCGA.AZ.4681.01", "Viral mRNA Translation"], {"weight": 0.93588282795082}], ["HBS1L", ["TCGA.AZ.4681.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.953719445172053}], ["HBS1L", ["TCGA.AZ.4681.01", "Eukaryotic Translation Elongation"], {"weight": 0.921579282756632}], ["HBS1L", ["TCGA.AZ.4681.01", "Eukaryotic Translation Termination"], {"weight": 0.920831928223339}], ["HBS1L", ["TCGA.AZ.4681.01", "Formation of a pool of free 40S subunits"], {"weight": 0.935005817374292}], ["HBS1L", ["TCGA.AZ.4681.01", "Peptide chain elongation"], {"weight": 0.93588282795082}], ["HBS1L", ["TCGA.AZ.4681.01", "Selenocysteine synthesis"], {"weight": 0.93588282795082}], ["HBS1L", ["TCGA.AZ.4681.01", "Selenoamino acid metabolism"], {"weight": 0.925468618463585}], ["HBS1L", ["TCGA.AZ.4681.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.93588282795082}], ["HBS1L", ["TCGA.AZ.4681.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.924395254629074}], ["HBS1L", ["TCGA.AZ.4681.01", "Signaling Pathways"], {"weight": 0.926174014957103}], ["HBS1L", ["TCGA.AZ.4681.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.937723594627782}], ["HBS1L", ["TCGA.AZ.4681.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.918167776621822}], ["HBS1L", ["TCGA.AZ.4681.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.935005817374292}], ["HBS1L", ["TCGA.AZ.4681.01", "Eukaryotic Translation Initiation"], {"weight": 0.921829960263703}], ["HBS1L", ["TCGA.AZ.4681.01", "Cap-dependent Translation Initiation"], {"weight": 0.921829960263703}], ["HBS1L", ["TCGA.AZ.4681.01", "Influenza Infection"], {"weight": 0.93912941620759}], ["HBS1L", ["TCGA.AZ.4681.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.936195135486605}], ["HBS1L", ["TCGA.AZ.4681.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.936195135486605}], ["HBS1L", ["TCGA.AZ.4681.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.93588282795082}], ["HBS1L", ["TCGA.AZ.4681.01", "Translesion synthesis by POLK"], {"weight": 0.816646128400892}], ["HBS1L", ["TCGA.AZ.4681.01", "Translesion synthesis by POLI"], {"weight": 0.816646128400892}], ["HBS1L", ["TCGA.AZ.4681.01", "Cytokine Signaling in Immune system"], {"weight": 0.873777787408307}], ["HBS1L", ["TCGA.AZ.4681.01", "APOBEC3G mediated resistance to HIV-1 infection"], {"weight": 0.59548671489615}], ["HBS1L", ["TCGA.AZ.4681.01", "Protein folding"], {"weight": 0.906951216664852}], ["HBS1L", ["TCGA.AZ.4681.01", "Innate Immune System"], {"weight": 0.920313601758512}], ["HBS1L", ["TCGA.AZ.4681.01", "Developmental Biology"], {"weight": 0.907075404901581}], ["HBS1L", ["TCGA.AZ.4681.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.847919096604043}], ["HIVEP2", ["TCGA.AZ.6603.01", "G alpha (s) signalling events"], {"weight": 0.835282349994184}], ["HIVEP2", ["TCGA.D5.6537.01", "Signaling Pathways"], {"weight": 0.927741549229847}], ["USP45", ["TCGA.AA.3560.01", "Eukaryotic Translation Elongation"], {"weight": 0.953947872448072}], ["USP45", ["TCGA.AA.3560.01", "Peptide chain elongation"], {"weight": 0.953772772475792}], ["USP45", ["TCGA.AA.3560.01", "Eukaryotic Translation Termination"], {"weight": 0.953624305361309}], ["USP45", ["TCGA.AA.3560.01", "Viral mRNA Translation"], {"weight": 0.953448951544556}], ["USP45", ["TCGA.AA.3560.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.953624305361309}], ["USP45", ["TCGA.AA.3560.01", "Formation of a pool of free 40S subunits"], {"weight": 0.953329438937466}], ["USP45", ["TCGA.AA.3560.01", "Selenocysteine synthesis"], {"weight": 0.953448951544556}], ["USP45", ["TCGA.AA.3560.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.939888710779219}], ["USP45", ["TCGA.AA.3560.01", "Regulation of expression of SLITs and ROBOs"], {"weight": 0.940741056251541}], ["USP45", ["TCGA.AA.3560.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.948238621549249}], ["USP45", ["TCGA.AA.3560.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.952328212474278}], ["USP45", ["TCGA.AA.3560.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.953329438937466}], ["USP45", ["TCGA.AA.3560.01", "Selenoamino acid metabolism"], {"weight": 0.938770472997175}], ["USP45", ["TCGA.AA.3560.01", "Eukaryotic Translation Initiation"], {"weight": 0.953329438937466}], ["USP45", ["TCGA.AA.3560.01", "Cap-dependent Translation Initiation"], {"weight": 0.953329438937466}], ["USP45", ["TCGA.AA.3560.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.953624305361309}], ["USP45", ["TCGA.AA.3560.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.953624305361309}], ["USP45", ["TCGA.AA.3560.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.951879690603464}], ["USP45", ["TCGA.AA.3560.01", "Influenza Infection"], {"weight": 0.952223792044326}], ["USP45", ["TCGA.AA.3560.01", "SARS-CoV-1-host interactions"], {"weight": 0.896098945909852}], ["USP45", ["TCGA.AA.3560.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.949441675232016}], ["USP45", ["TCGA.AA.3560.01", "SCF(Skp2)-mediated degradation of p27/p21"], {"weight": 0.919381471014362}], ["USP45", ["TCGA.AA.3560.01", "IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation"], {"weight": 0.884908711888983}], ["USP45", ["TCGA.AA.3560.01", "TICAM1-dependent activation of IRF3/IRF7"], {"weight": 0.841641409054319}], ["USP45", ["TCGA.AA.3560.01", "TRAF6-mediated induction of TAK1 complex within TLR4 complex"], {"weight": 0.884908711888983}], ["USP45", ["TCGA.AA.3560.01", "Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon"], {"weight": 0.884013045001216}], ["USP45", ["TCGA.AA.3560.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], {"weight": 0.874260542771085}], ["USP45", ["TCGA.AA.3560.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], {"weight": 0.874260542771085}], ["USP45", ["TCGA.AA.3560.01", "SARS-CoV-1 Infection"], {"weight": 0.896098945909852}], ["USP45", ["TCGA.AA.3560.01", "TICAM1,TRAF6-dependent induction of TAK1 complex"], {"weight": 0.818297966018968}], ["USP45", ["TCGA.AA.3560.01", "Regulation of BACH1 activity"], {"weight": 0.736353971277059}], ["USP45", ["TCGA.AA.3560.01", "Glycogen metabolism"], {"weight": 0.820518809153549}], ["USP45", ["TCGA.AA.3561.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], {"weight": 0.815050327323475}], ["USP45", ["TCGA.AA.3561.01", "Nucleosome assembly"], {"weight": 0.815050327323475}], ["USP45", ["TCGA.AA.3841.01", "Ion channel transport"], {"weight": 0.920361296665182}], ["USP45", ["TCGA.AA.3841.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], {"weight": 0.813283163732452}], ["USP45", ["TCGA.AA.3841.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], {"weight": 0.813283163732452}], ["USP45", ["TCGA.AA.3841.01", "NOTCH2 Activation and Transmission of Signal to the Nucleus"], {"weight": 0.638528840984645}], ["USP45", ["TCGA.AA.3848.01", "Transport of small molecules"], {"weight": 0.91515112922887}], ["USP45", ["TCGA.AA.3848.01", "Stimuli-sensing channels"], {"weight": 0.914388295815032}], ["USP45", ["TCGA.AA.3848.01", "Regulation of FZD by ubiquitination"], {"weight": 0.917249286628257}], ["USP45", ["TCGA.AA.3848.01", "Ion channel transport"], {"weight": 0.92974462369109}], ["USP45", ["TCGA.AA.3848.01", "NOTCH2 Activation and Transmission of Signal to the Nucleus"], {"weight": 0.897638002953242}], ["USP45", ["TCGA.AA.3848.01", "Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA"], {"weight": 0.73601421589317}], ["USP45", ["TCGA.AA.3848.01", "Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA"], {"weight": 0.73601421589317}], ["USP45", ["TCGA.AA.3952.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.856761029841281}], ["USP45", ["TCGA.F4.6460.01", "FGFR4 ligand binding and activation"], {"weight": 0.798775202540085}], ["USP45", ["TCGA.F4.6460.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.798775202540085}], ["TFB1M", ["TCGA.AA.3854.01", "Signaling by Retinoic Acid"], {"weight": 0.717105848891413}], ["TFB1M", ["TCGA.AY.4070.01", "SLC-mediated transmembrane transport"], {"weight": 0.908086387313102}], ["TFB1M", ["TCGA.AY.6196.01", "SLC-mediated transmembrane transport"], {"weight": 0.889837949007969}], ["TFB1M", ["TCGA.AY.6196.01", "Nuclear Receptor transcription pathway"], {"weight": 0.675534256498694}], ["TFB1M", ["TCGA.AZ.4616.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.820889439088128}], ["TFB1M", ["TCGA.AZ.6607.01", "Cellular hexose transport"], {"weight": 0.765908866861698}], ["TFB1M", ["TCGA.CK.5915.01", "Integration of energy metabolism"], {"weight": 0.914664989361668}], ["TFB1M", ["TCGA.D5.5537.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], {"weight": 0.927068235667459}], ["TFB1M", ["TCGA.D5.5537.01", "FOXO-mediated transcription"], {"weight": 0.934642909802652}], ["TFB1M", ["TCGA.DM.A28K.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], {"weight": 0.949351414294809}], ["TFB1M", ["TCGA.G4.6299.01", "Signaling by Retinoic Acid"], {"weight": 0.879149466115285}], ["PERP", ["TCGA.3L.AA1B.01", "Keratinization"], {"weight": 0.76308219834025}], ["PERP", ["TCGA.AA.3660.01", "Keratinization"], {"weight": 0.900130947069812}], ["PERP", ["TCGA.AA.3841.01", "Keratinization"], {"weight": 0.769957658557008}], ["PERP", ["TCGA.AZ.6600.01", "Formation of the cornified envelope"], {"weight": 0.877118440375494}], ["PERP", ["TCGA.CM.6161.01", "Keratinization"], {"weight": 0.928986782293532}], ["PERP", ["TCGA.CM.6161.01", "Formation of the cornified envelope"], {"weight": 0.92622714643643}], ["PERP", ["TCGA.D5.6898.01", "Keratinization"], {"weight": 0.88900017903846}], ["PERP", ["TCGA.NH.A6GA.01", "Keratinization"], {"weight": 0.92480446167097}], ["PERP", ["TCGA.NH.A6GA.01", "Formation of the cornified envelope"], {"weight": 0.929144498040917}], ["STXBP5", ["TCGA.AA.3854.01", "LGI-ADAM interactions"], {"weight": 0.839230412640217}], ["NOX3", ["TCGA.4T.AA8H.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.833542160635421}], ["NOX3", ["TCGA.AA.3685.01", "Platelet homeostasis"], {"weight": 0.831824111996651}], ["NOX3", ["TCGA.AA.3715.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.945958602500408}], ["NOX3", ["TCGA.AA.3854.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.853420127459021}], ["NOX3", ["TCGA.AA.3854.01", "GPCR ligand binding"], {"weight": 0.908805813997825}], ["NOX3", ["TCGA.AA.A01D.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.930856506786053}], ["NOX3", ["TCGA.AA.A01D.01", "Collagen formation"], {"weight": 0.945051682123725}], ["NOX3", ["TCGA.AA.A01D.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.936213490600679}], ["NOX3", ["TCGA.AA.A02H.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.583167735318323}], ["NOX3", ["TCGA.AA.A02H.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.583167735318323}], ["NOX3", ["TCGA.AA.A02Y.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.869829441836441}], ["NOX3", ["TCGA.AD.6888.01", "Integrin cell surface interactions"], {"weight": 0.936008765001498}], ["NOX3", ["TCGA.AD.6888.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.873182809053359}], ["NOX3", ["TCGA.AY.6196.01", "Keratinization"], {"weight": 0.851510933310436}], ["NOX3", ["TCGA.AZ.6608.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.877719360862726}], ["NOX3", ["TCGA.CA.5254.01", "Integrin cell surface interactions"], {"weight": 0.937026110167884}], ["NOX3", ["TCGA.CA.5255.01", "Signaling Pathways"], {"weight": 0.903479180733985}], ["NOX3", ["TCGA.CK.5915.01", "RHO GTPases Activate NADPH Oxidases"], {"weight": 0.903160220574052}], ["NOX3", ["TCGA.CM.5348.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.929586196795683}], ["NOX3", ["TCGA.G4.6299.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.902622684482233}], ["NOX3", ["TCGA.G4.6299.01", "GPCR ligand binding"], {"weight": 0.926359581224391}], ["NOX3", ["TCGA.G4.6299.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.865449714662731}], ["NOX3", ["TCGA.G4.6299.01", "Free fatty acids regulate insulin secretion"], {"weight": 0.667105827924529}], ["NOX3", ["TCGA.G4.6306.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.943754973293429}], ["ARID1B", ["TCGA.AY.4070.01", "Glucuronidation"], {"weight": 0.759728937880757}], ["ARID1B", ["TCGA.AY.4070.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.914644593981579}], ["ARID1B", ["TCGA.AY.6196.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.914323119853621}], ["ARID1B", ["TCGA.AY.6196.01", "Glucuronidation"], {"weight": 0.830450903193451}], ["ARID1B", ["TCGA.AZ.6608.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.847384937672236}], ["ARID1B", ["TCGA.D5.5541.01", "Biological oxidations"], {"weight": 0.951680587467333}], ["ARID1B", ["TCGA.D5.5541.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.930864815444263}], ["ARID1B", ["TCGA.D5.5541.01", "Aspirin ADME"], {"weight": 0.874349288507496}], ["ARID1B", ["TCGA.D5.5541.01", "SLC-mediated transmembrane transport"], {"weight": 0.909540566082167}], ["ARID1B", ["TCGA.D5.5541.01", "Glucuronidation"], {"weight": 0.816882007827222}], ["ARID1B", ["TCGA.D5.5541.01", "Phase II - Conjugation of compounds"], {"weight": 0.82861421217447}], ["ARID1B", ["TCGA.G4.6299.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.940566248793812}], ["ARID1B", ["TCGA.G4.6299.01", "Glucuronidation"], {"weight": 0.86940269402579}], ["ARID1B", ["TCGA.G4.6299.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.864385003063321}], ["MYCT1", ["TCGA.AA.3655.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.838659825901074}], ["MYCT1", ["TCGA.AA.3660.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.812744930189939}], ["MYCT1", ["TCGA.AA.3814.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.6911094610154}], ["MYCT1", ["TCGA.AA.3837.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.606809039834974}], ["MYCT1", ["TCGA.AA.3837.01", "Signaling by ALK"], {"weight": 0.69032142220614}], ["MYCT1", ["TCGA.AA.3841.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.719992674546813}], ["MYCT1", ["TCGA.AA.3875.01", "G0 and Early G1"], {"weight": 0.850915143106958}], ["MYCT1", ["TCGA.AA.3875.01", "Transcription of E2F targets under negative control by DREAM complex"], {"weight": 0.804429315169064}], ["MYCT1", ["TCGA.AA.3875.01", "Signaling by ALK"], {"weight": 0.655098822552859}], ["MYCT1", ["TCGA.AA.3875.01", "Formation of the beta-catenin:TCF transactivating complex"], {"weight": 0.782301757278043}], ["MYCT1", ["TCGA.AA.3875.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.604234053356631}], ["MYCT1", ["TCGA.AA.3952.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.794394235934598}], ["MYCT1", ["TCGA.AA.A02H.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.584176002224745}], ["MYCT1", ["TCGA.AA.A02Y.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.865934014381872}], ["MYCT1", ["TCGA.AD.A5EK.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.86173323298656}], ["MYCT1", ["TCGA.AD.A5EK.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.929101128183212}], ["MYCT1", ["TCGA.AY.6196.01", "Gastrulation"], {"weight": 0.797247973957395}], ["MYCT1", ["TCGA.AY.6196.01", "Signaling by Activin"], {"weight": 0.733106990302829}], ["MYCT1", ["TCGA.AZ.4616.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.8802536576343}], ["MYCT1", ["TCGA.CA.5256.01", "G0 and Early G1"], {"weight": 0.879349117887309}], ["MYCT1", ["TCGA.CM.5348.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.829821291443563}], ["MYCT1", ["TCGA.CM.6167.01", "Scavenging by Class A Receptors"], {"weight": 0.680994680288663}], ["MYCT1", ["TCGA.D5.6529.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.556591325302021}], ["MYCT1", ["TCGA.D5.6529.01", "Scavenging by Class A Receptors"], {"weight": 0.549724830192382}], ["MYCT1", ["TCGA.DM.A28K.01", "SUMOylation of intracellular receptors"], {"weight": 0.689759274441729}], ["MYCT1", ["TCGA.DM.A28K.01", "SLC-mediated transmembrane transport"], {"weight": 0.914057519395087}], ["MYCT1", ["TCGA.G4.6297.01", "Scavenging by Class A Receptors"], {"weight": 0.6123914053079}], ["MYCT1", ["TCGA.G4.6299.01", "SLC-mediated transmembrane transport"], {"weight": 0.918172053876323}], ["VIP", ["TCGA.AA.3814.01", "Peptide hormone metabolism"], {"weight": 0.713423917049007}], ["VIP", ["TCGA.AA.3814.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.870865892068536}], ["VIP", ["TCGA.AA.3814.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.879989622665922}], ["VIP", ["TCGA.AD.6899.01", "GPCR ligand binding"], {"weight": 0.876809228414113}], ["VIP", ["TCGA.AY.6196.01", "Surfactant metabolism"], {"weight": 0.859428247143024}], ["VIP", ["TCGA.AZ.4616.01", "GPCR ligand binding"], {"weight": 0.92590994263851}], ["VIP", ["TCGA.AZ.4616.01", "Peptide ligand-binding receptors"], {"weight": 0.936691067600827}], ["VIP", ["TCGA.AZ.4616.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.771325870152528}], ["VIP", ["TCGA.AZ.4616.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.886766577317005}], ["VIP", ["TCGA.AZ.4616.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.936691067600827}], ["VIP", ["TCGA.AZ.4616.01", "Glucagon-type ligand receptors"], {"weight": 0.922732265879686}], ["VIP", ["TCGA.AZ.6608.01", "Phase I - Functionalization of compounds"], {"weight": 0.958087332390556}], ["VIP", ["TCGA.DM.A0X9.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.758628740392137}], ["VIP", ["TCGA.DM.A28K.01", "Biological oxidations"], {"weight": 0.91819610028016}], ["VIP", ["TCGA.DM.A28K.01", "Phase I - Functionalization of compounds"], {"weight": 0.955721525016121}], ["VIP", ["TCGA.G4.6299.01", "GABA B receptor activation"], {"weight": 0.928131268125833}], ["VIP", ["TCGA.G4.6299.01", "Activation of GABAB receptors"], {"weight": 0.928131268125833}], ["FBXO5", ["TCGA.AA.3814.01", "Keratinization"], {"weight": -0.0149736890038887}], ["FBXO5", ["TCGA.AA.3875.01", "G1/S-Specific Transcription"], {"weight": 0.849708216308091}], ["CCNC", ["TCGA.AA.3521.01", "Signaling by Nuclear Receptors"], {"weight": 0.897552584367522}], ["CCNC", ["TCGA.AA.3560.01", "Transcriptional regulation by RUNX2"], {"weight": 0.813823134397836}], ["CCNC", ["TCGA.AA.3681.01", "Keratinization"], {"weight": 0.877159047248974}], ["CCNC", ["TCGA.AA.3681.01", "Extracellular matrix organization"], {"weight": 0.771863611854273}], ["CCNC", ["TCGA.AA.3844.01", "Molecules associated with elastic fibres"], {"weight": 0.716210155438258}], ["CCNC", ["TCGA.AA.3844.01", "Elastic fibre formation"], {"weight": 0.719299849065583}], ["CCNC", ["TCGA.AA.A00A.01", "Extracellular matrix organization"], {"weight": 0.801307635166939}], ["CCNC", ["TCGA.AA.A00A.01", "Glucuronidation"], {"weight": 0.847744569887694}], ["CCNC", ["TCGA.AA.A00A.01", "Regulation of insulin secretion"], {"weight": 0.920473182939064}], ["CCNC", ["TCGA.AA.A00A.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.865120057334158}], ["CCNC", ["TCGA.AA.A00A.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.763037121160133}], ["CCNC", ["TCGA.AA.A00A.01", "Integration of energy metabolism"], {"weight": 0.926612449058624}], ["CCNC", ["TCGA.AA.A00A.01", "Drug ADME"], {"weight": 0.814614481171124}], ["CCNC", ["TCGA.AA.A00A.01", "Aspirin ADME"], {"weight": 0.774836421498972}], ["CCNC", ["TCGA.AA.A00A.01", "Ethanol oxidation"], {"weight": 0.780665985054836}], ["CCNC", ["TCGA.AA.A00A.01", "Signaling by Retinoic Acid"], {"weight": 0.744197559987988}], ["CCNC", ["TCGA.AM.5820.01", "Signaling by Activin"], {"weight": 0.902243918726797}], ["CCNC", ["TCGA.CM.5860.01", "Peptide hormone biosynthesis"], {"weight": 0.476603542552279}], ["CCNC", ["TCGA.CM.6675.01", "Signaling Pathways"], {"weight": 0.927911995002221}], ["CCNC", ["TCGA.DM.A28F.01", "Molecules associated with elastic fibres"], {"weight": 0.807575289755449}], ["CCNC", ["TCGA.DM.A28F.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.024144086484424}], ["CCNC", ["TCGA.DM.A28F.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": -0.0273194939515593}], ["CCNC", ["TCGA.DM.A28F.01", "Elastic fibre formation"], {"weight": 0.827019992428591}], ["CCNC", ["TCGA.F4.6459.01", "O-linked glycosylation"], {"weight": 0.859445870138698}], ["CCNC", ["TCGA.F4.6854.01", "Drug ADME"], {"weight": 0.747893672279521}], ["PEX3", ["TCGA.AA.3660.01", "Transport of small molecules"], {"weight": 0.933143527224982}], ["PEX3", ["TCGA.AA.A01X.01", "ABC transporters in lipid homeostasis"], {"weight": 0.768610896730585}], ["PEX3", ["TCGA.AM.5820.01", "ABC transporters in lipid homeostasis"], {"weight": 0.744812859982085}], ["PEX3", ["TCGA.AY.A8YK.01", "Transport of small molecules"], {"weight": 0.909214664766006}], ["PEX3", ["TCGA.CA.5254.01", "ABC transporters in lipid homeostasis"], {"weight": 0.813220859322793}], ["PEX3", ["TCGA.CK.5915.01", "ABC transporters in lipid homeostasis"], {"weight": 0.882291068085093}], ["SNX9", ["TCGA.A6.6137.01", "Extracellular matrix organization"], {"weight": 0.653602838278604}], ["SNX9", ["TCGA.A6.6137.01", "Scavenging by Class A Receptors"], {"weight": 0.225186187459105}], ["SNX9", ["TCGA.A6.6137.01", "Regulation of FZD by ubiquitination"], {"weight": 0.709822281564443}], ["SNX9", ["TCGA.A6.6137.01", "Synaptic adhesion-like molecules"], {"weight": 0.720596053767771}], ["SNX9", ["TCGA.A6.6652.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.713199418206815}], ["SNX9", ["TCGA.AA.A02Y.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.807599805084606}], ["SNX9", ["TCGA.AY.6196.01", "Extracellular matrix organization"], {"weight": 0.864220472689111}], ["SNX9", ["TCGA.AY.6196.01", "Ion channel transport"], {"weight": 0.870161318153564}], ["SNX9", ["TCGA.AY.6196.01", "Cobalamin (Cbl, vitamin B12) transport and metabolism"], {"weight": 0.788476418243901}], ["SNX9", ["TCGA.AY.6196.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.799475210164495}], ["SNX9", ["TCGA.AY.6196.01", "Visual phototransduction"], {"weight": 0.731322953062881}], ["SNX9", ["TCGA.AZ.6598.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.802828360996426}], ["SNX9", ["TCGA.AZ.6606.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.707981338759288}], ["SNX9", ["TCGA.CA.5254.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.753662297805801}], ["SNX9", ["TCGA.CK.5915.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.806609559305472}], ["SNX9", ["TCGA.D5.5541.01", "GABA receptor activation"], {"weight": 0.875657965239037}], ["SNX9", ["TCGA.DM.A28F.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.805830116851559}], ["SNX9", ["TCGA.DM.A28K.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.934383795515505}], ["SNX9", ["TCGA.DM.A28K.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.936093357993768}], ["SNX9", ["TCGA.DM.A28K.01", "Generation of second messenger molecules"], {"weight": 0.91247050035874}], ["SNX9", ["TCGA.DM.A28K.01", "PD-1 signaling"], {"weight": 0.931622937359827}], ["SNX9", ["TCGA.DM.A28K.01", "Neurotransmitter release cycle"], {"weight": 0.800415550093523}], ["SNX9", ["TCGA.DM.A28K.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.633460335185366}], ["SNX9", ["TCGA.DM.A28K.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.916371371637864}], ["SNX9", ["TCGA.DM.A28K.01", "GABA synthesis, release, reuptake and degradation"], {"weight": 0.887532774299156}], ["SNX9", ["TCGA.G4.6299.01", "Neurotransmitter release cycle"], {"weight": 0.835830946956764}], ["SNX9", ["TCGA.G4.6299.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.743279838771757}], ["MTHFD1L", ["TCGA.AA.3837.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.872872495744098}], ["MTHFD1L", ["TCGA.AA.3837.01", "Viral mRNA Translation"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "Formation of a pool of free 40S subunits"], {"weight": 0.936327119239342}], ["MTHFD1L", ["TCGA.AA.3837.01", "Selenocysteine synthesis"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "Eukaryotic Translation Termination"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.936327119239342}], ["MTHFD1L", ["TCGA.AA.3837.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.936327119239342}], ["MTHFD1L", ["TCGA.AA.3837.01", "Eukaryotic Translation Initiation"], {"weight": 0.936327119239342}], ["MTHFD1L", ["TCGA.AA.3837.01", "Cap-dependent Translation Initiation"], {"weight": 0.936327119239342}], ["MTHFD1L", ["TCGA.AA.3837.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.935891464349839}], ["MTHFD1L", ["TCGA.AA.3837.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3837.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.934409111257466}], ["MTHFD1L", ["TCGA.AA.3841.01", "Selenoamino acid metabolism"], {"weight": 0.886664107809524}], ["MTHFD1L", ["TCGA.AA.3841.01", "Selenocysteine synthesis"], {"weight": 0.906180967791345}], ["MTHFD1L", ["TCGA.AA.3841.01", "Metabolism of folate and pterines"], {"weight": 0.827119911375319}], ["MTHFD1L", ["TCGA.AA.3841.01", "Viral mRNA Translation"], {"weight": 0.941835443510964}], ["MTHFD1L", ["TCGA.AA.3841.01", "Formation of a pool of free 40S subunits"], {"weight": 0.939828361875042}], ["MTHFD1L", ["TCGA.AA.3841.01", "Eukaryotic Translation Termination"], {"weight": 0.941835443510964}], ["MTHFD1L", ["TCGA.AZ.4616.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.948752649319606}], ["MTHFD1L", ["TCGA.AZ.4616.01", "SLC-mediated transmembrane transport"], {"weight": 0.92597168386616}], ["MTHFD1L", ["TCGA.AZ.4616.01", "Blood group systems biosynthesis"], {"weight": 0.674221055884408}], ["MTHFD1L", ["TCGA.AZ.4616.01", "Lewis blood group biosynthesis"], {"weight": 0.63818992387285}], ["MTHFD1L", ["TCGA.AZ.6607.01", "Metabolism"], {"weight": 0.926487022561757}], ["MTHFD1L", ["TCGA.CM.6161.01", "Metabolism"], {"weight": 0.917313284026692}], ["MTHFD1L", ["TCGA.CM.6167.01", "Metabolism"], {"weight": 0.853847616420337}], ["MTHFD1L", ["TCGA.CM.6167.01", "Lewis blood group biosynthesis"], {"weight": 0.497506739008517}], ["MTHFD1L", ["TCGA.CM.6167.01", "Blood group systems biosynthesis"], {"weight": 0.602472124305517}], ["MTHFD1L", ["TCGA.DM.A28K.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.947225656217901}], ["MTHFD1L", ["TCGA.F4.6704.01", "Metabolism"], {"weight": 0.910569439325174}], ["MTHFD1L", ["TCGA.G4.6322.01", "Biological oxidations"], {"weight": 0.919308675574709}], ["MTHFD1L", ["TCGA.G4.6322.01", "Neuronal System"], {"weight": 0.90369429133131}], ["MTHFD1L", ["TCGA.G4.6322.01", "Phase II - Conjugation of compounds"], {"weight": 0.748493231327299}], ["MTHFD1L", ["TCGA.G4.6322.01", "Transmission across Chemical Synapses"], {"weight": 0.891783749922324}], ["MTHFD1L", ["TCGA.G4.6322.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.877105619743554}], ["MTHFD1L", ["TCGA.G4.6322.01", "Adherens junctions interactions"], {"weight": 0.807841828652501}], ["MTHFD1L", ["TCGA.G4.6322.01", "Glycosaminoglycan metabolism"], {"weight": 0.737503411727699}], ["OPRM1", ["TCGA.AA.3814.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.851156207216963}], ["OPRM1", ["TCGA.AA.3814.01", "Glucagon-type ligand receptors"], {"weight": 0.885972415617681}], ["OPRM1", ["TCGA.AA.3854.01", "G-protein activation"], {"weight": 0.923053429477704}], ["OPRM1", ["TCGA.AA.A02H.01", "Signaling by GPCR"], {"weight": 0.93008034972454}], ["OPRM1", ["TCGA.AZ.6608.01", "G-protein activation"], {"weight": 0.933960063848462}], ["OPRM1", ["TCGA.G4.6299.01", "G-protein activation"], {"weight": 0.897779085417374}], ["REPS1", ["TCGA.4T.AA8H.01", "FCGR activation"], {"weight": 0.900434320431857}], ["REPS1", ["TCGA.5M.AATA.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.919239533473658}], ["REPS1", ["TCGA.AD.6888.01", "FCGR activation"], {"weight": 0.886373742269188}], ["REPS1", ["TCGA.CA.5254.01", "Neuronal System"], {"weight": 0.937517616187839}], ["SYNJ2", ["TCGA.A6.6137.01", "Protein-protein interactions at synapses"], {"weight": 0.733825091129325}], ["SYNJ2", ["TCGA.AA.3655.01", "Protein-protein interactions at synapses"], {"weight": 0.914058901464114}], ["SYNJ2", ["TCGA.AA.3680.01", "Sensory perception of taste"], {"weight": 0.856194339276068}], ["SYNJ2", ["TCGA.AA.A029.01", "Erythropoietin activates Phosphoinositide-3-kinase (PI3K)"], {"weight": 0.874172235772591}], ["SYNJ2", ["TCGA.AM.5820.01", "Protein-protein interactions at synapses"], {"weight": 0.826515315567821}], ["SYNJ2", ["TCGA.AY.4070.01", "Post-translational protein phosphorylation"], {"weight": 0.876701567201835}], ["SYNJ2", ["TCGA.AY.6196.01", "Metabolism"], {"weight": 0.918387391523026}], ["SYNJ2", ["TCGA.AZ.4616.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.904153598335358}], ["SYNJ2", ["TCGA.CA.5255.01", "Signaling by Interleukins"], {"weight": 0.879014932658253}], ["SYNJ2", ["TCGA.CM.6675.01", "Protein-protein interactions at synapses"], {"weight": 0.943447190227952}], ["SYNJ2", ["TCGA.DM.A0X9.01", "Protein-protein interactions at synapses"], {"weight": 0.892164733390974}], ["SYNJ2", ["TCGA.DM.A28K.01", "Protein-protein interactions at synapses"], {"weight": 0.948053519869269}], ["SYNJ2", ["TCGA.DM.A28K.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.938600769889846}], ["SYNJ2", ["TCGA.DM.A28K.01", "CD22 mediated BCR regulation"], {"weight": 0.827872281294625}], ["SYNJ2", ["TCGA.G4.6299.01", "Muscle contraction"], {"weight": 0.895804076602184}], ["MAP3K5", ["TCGA.4T.AA8H.01", "Interleukin-10 signaling"], {"weight": 0.931785715615345}], ["MAP3K5", ["TCGA.4T.AA8H.01", "TNFs bind their physiological receptors"], {"weight": 0.472038353172892}], ["MAP3K5", ["TCGA.4T.AA8H.01", "Cytokine Signaling in Immune system"], {"weight": 0.854603792965653}], ["MAP3K5", ["TCGA.AA.3521.01", "TNFs bind their physiological receptors"], {"weight": 0.243030379512474}], ["MAP3K5", ["TCGA.AA.3837.01", "TNFs bind their physiological receptors"], {"weight": 0.176256022172662}], ["MAP3K5", ["TCGA.AA.3841.01", "TNFs bind their physiological receptors"], {"weight": 0.291496764705632}], ["MAP3K5", ["TCGA.AA.3841.01", "Regulation by c-FLIP"], {"weight": 0.759364836282247}], ["MAP3K5", ["TCGA.AA.3841.01", "CASP8 activity is inhibited"], {"weight": 0.759364836282247}], ["MAP3K5", ["TCGA.AA.3841.01", "Dimerization of procaspase-8"], {"weight": 0.759364836282247}], ["MAP3K5", ["TCGA.AA.3854.01", "Cardiac conduction"], {"weight": 0.934793131517942}], ["MAP3K5", ["TCGA.AA.3854.01", "Phase 0 - rapid depolarisation"], {"weight": 0.936092705545671}], ["MAP3K5", ["TCGA.AA.3854.01", "Ion homeostasis"], {"weight": 0.935528614567235}], ["MAP3K5", ["TCGA.AA.3854.01", "Ion transport by P-type ATPases"], {"weight": 0.886781758800172}], ["MAP3K5", ["TCGA.AA.3854.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.924729382823097}], ["MAP3K5", ["TCGA.AA.3952.01", "TNFs bind their physiological receptors"], {"weight": 0.342893910878542}], ["MAP3K5", ["TCGA.AA.A017.01", "Phase 0 - rapid depolarisation"], {"weight": 0.925622586595186}], ["MAP3K5", ["TCGA.AA.A017.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.611568402763771}], ["MAP3K5", ["TCGA.AA.A01X.01", "TNFs bind their physiological receptors"], {"weight": 0.360555938973814}], ["MAP3K5", ["TCGA.AA.A029.01", "Ligand-dependent caspase activation"], {"weight": 0.816649992805871}], ["MAP3K5", ["TCGA.AA.A029.01", "Leishmania infection"], {"weight": 0.867983752368118}], ["MAP3K5", ["TCGA.AA.A029.01", "TNFs bind their physiological receptors"], {"weight": 0.568932719066162}], ["MAP3K5", ["TCGA.AA.A02H.01", "Interleukin-10 signaling"], {"weight": 0.829850808230871}], ["MAP3K5", ["TCGA.AA.A02H.01", "Regulation by c-FLIP"], {"weight": 0.706940480900318}], ["MAP3K5", ["TCGA.AA.A02H.01", "CASP8 activity is inhibited"], {"weight": 0.706940480900318}], ["MAP3K5", ["TCGA.AA.A02H.01", "Dimerization of procaspase-8"], {"weight": 0.706940480900318}], ["MAP3K5", ["TCGA.AD.6888.01", "Interleukin-10 signaling"], {"weight": 0.953034944730335}], ["MAP3K5", ["TCGA.AM.5820.01", "TNFs bind their physiological receptors"], {"weight": 0.635057027375226}], ["MAP3K5", ["TCGA.AY.A8YK.01", "Interleukin-10 signaling"], {"weight": 0.92276979190101}], ["MAP3K5", ["TCGA.AZ.6598.01", "Signaling Pathways"], {"weight": 0.913362453889598}], ["MAP3K5", ["TCGA.CA.5255.01", "Interleukin-10 signaling"], {"weight": 0.945119463782425}], ["MAP3K5", ["TCGA.CA.5255.01", "TNFs bind their physiological receptors"], {"weight": 0.647364395663882}], ["MAP3K5", ["TCGA.CA.5255.01", "Muscle contraction"], {"weight": 0.927544741509723}], ["MAP3K5", ["TCGA.CA.5255.01", "Costimulation by the CD28 family"], {"weight": 0.892775407075343}], ["MAP3K5", ["TCGA.CM.6678.01", "TNFs bind their physiological receptors"], {"weight": 0.456977930433894}], ["MAP3K5", ["TCGA.D5.6535.01", "TNFs bind their physiological receptors"], {"weight": 0.476640317980078}], ["MAP3K5", ["TCGA.DM.A28F.01", "Interleukin-10 signaling"], {"weight": 0.945619788352845}], ["SUMO4", ["TCGA.AA.3841.01", "SUMOylation of intracellular receptors"], {"weight": 0.914500610610872}], ["IPCEF1", ["TCGA.AA.3521.01", "FGFR4 ligand binding and activation"], {"weight": 0.66739166653905}], ["IPCEF1", ["TCGA.AA.3814.01", "Extracellular matrix organization"], {"weight": 0.816589769826753}], ["IPCEF1", ["TCGA.AA.3814.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.78899391210017}], ["IPCEF1", ["TCGA.AA.3939.01", "L1CAM interactions"], {"weight": 0.892108144598064}], ["IPCEF1", ["TCGA.AD.A5EK.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.894216179920924}], ["IPCEF1", ["TCGA.AY.6196.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.850246407771491}], ["IPCEF1", ["TCGA.AY.6196.01", "ERBB2 Regulates Cell Motility"], {"weight": 0.850246407771491}], ["IPCEF1", ["TCGA.AZ.6598.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.925462548666903}], ["IPCEF1", ["TCGA.AZ.6598.01", "ERBB2 Regulates Cell Motility"], {"weight": 0.925462548666903}], ["IPCEF1", ["TCGA.AZ.6598.01", "GRB2 events in ERBB2 signaling"], {"weight": 0.925462548666903}], ["IPCEF1", ["TCGA.AZ.6598.01", "PI3K events in ERBB2 signaling"], {"weight": 0.925462548666903}], ["IPCEF1", ["TCGA.CM.6676.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.876825708607139}], ["IPCEF1", ["TCGA.DM.A28F.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.900386948967202}], ["IPCEF1", ["TCGA.DM.A28F.01", "ERBB2 Regulates Cell Motility"], {"weight": 0.900386948967202}], ["IPCEF1", ["TCGA.DM.A28F.01", "GRB2 events in ERBB2 signaling"], {"weight": 0.900386948967202}], ["IPCEF1", ["TCGA.DM.A28F.01", "PI3K events in ERBB2 signaling"], {"weight": 0.900386948967202}], ["IPCEF1", ["TCGA.DM.A28K.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.882764279954232}], ["IPCEF1", ["TCGA.F4.6704.01", "GRB2 events in EGFR signaling"], {"weight": 0.811813599658585}], ["IPCEF1", ["TCGA.F4.6704.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.88878337494515}], ["IPCEF1", ["TCGA.F4.6704.01", "SHC1 events in EGFR signaling"], {"weight": 0.811793038396768}], ["IPCEF1", ["TCGA.G4.6299.01", "Insulin processing"], {"weight": 0.801202452286467}], ["PHACTR2", ["TCGA.A6.6652.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.914972467518894}], ["PHACTR2", ["TCGA.A6.6652.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.914972467518894}], ["PHACTR2", ["TCGA.AA.3837.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.585204771244085}], ["PHACTR2", ["TCGA.AA.3837.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.585204771244085}], ["PHACTR2", ["TCGA.AA.3837.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.585204771244085}], ["PHACTR2", ["TCGA.AA.3875.01", "Free fatty acids regulate insulin secretion"], {"weight": 0.196217543392776}], ["PHACTR2", ["TCGA.AA.A01X.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.652348814140259}], ["PHACTR2", ["TCGA.AA.A029.01", "Diseases of Immune System"], {"weight": 0.900000658983212}], ["PHACTR2", ["TCGA.AA.A029.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.900000658983212}], ["PHACTR2", ["TCGA.AA.A029.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.919756160901201}], ["PHACTR2", ["TCGA.AA.A029.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.919756160901201}], ["PHACTR2", ["TCGA.AA.A029.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.908566370894883}], ["PHACTR2", ["TCGA.AA.A02Y.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.931750150379371}], ["PHACTR2", ["TCGA.AA.A02Y.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.931750150379371}], ["PHACTR2", ["TCGA.AD.6888.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.923734918751213}], ["PHACTR2", ["TCGA.AD.6888.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.923734918751213}], ["PHACTR2", ["TCGA.AD.6888.01", "Diseases of Immune System"], {"weight": 0.897821266689302}], ["PHACTR2", ["TCGA.AD.6888.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.897821266689302}], ["PHACTR2", ["TCGA.AD.6888.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.90567757876086}], ["PHACTR2", ["TCGA.AD.A5EK.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.909405154286623}], ["PHACTR2", ["TCGA.AD.A5EK.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.909405154286623}], ["PHACTR2", ["TCGA.AD.A5EK.01", "Diseases of Immune System"], {"weight": 0.874806923165786}], ["PHACTR2", ["TCGA.AD.A5EK.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.874806923165786}], ["PHACTR2", ["TCGA.AY.6197.01", "Neuronal System"], {"weight": 0.929336832561279}], ["PHACTR2", ["TCGA.AY.6197.01", "Signaling by GPCR"], {"weight": 0.911329979485159}], ["PHACTR2", ["TCGA.AY.6197.01", "GPCR downstream signalling"], {"weight": 0.917774687172916}], ["PHACTR2", ["TCGA.AY.6197.01", "Transmission across Chemical Synapses"], {"weight": 0.924431253247618}], ["PHACTR2", ["TCGA.AY.6197.01", "Muscle contraction"], {"weight": 0.912501654413951}], ["PHACTR2", ["TCGA.AY.6197.01", "L1CAM interactions"], {"weight": 0.913890380174278}], ["PHACTR2", ["TCGA.AY.6197.01", "Transport of small molecules"], {"weight": 0.913261448815859}], ["PHACTR2", ["TCGA.AY.6197.01", "Platelet homeostasis"], {"weight": 0.833611013342515}], ["PHACTR2", ["TCGA.AY.6197.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.892284969973344}], ["PHACTR2", ["TCGA.AY.6197.01", "Protein-protein interactions at synapses"], {"weight": 0.866404683522012}], ["PHACTR2", ["TCGA.AY.6197.01", "Ion channel transport"], {"weight": 0.921346454719019}], ["PHACTR2", ["TCGA.AY.6197.01", "Extracellular matrix organization"], {"weight": 0.843852639983117}], ["PHACTR2", ["TCGA.AY.6197.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.900723359846544}], ["PHACTR2", ["TCGA.AY.6197.01", "G alpha (s) signalling events"], {"weight": 0.923379083104402}], ["PHACTR2", ["TCGA.AY.6197.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.829889452329733}], ["PHACTR2", ["TCGA.AY.6197.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.896276066756312}], ["PHACTR2", ["TCGA.AY.6197.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.896276066756312}], ["PHACTR2", ["TCGA.AY.6197.01", "Interleukin-10 signaling"], {"weight": 0.695433751638163}], ["PHACTR2", ["TCGA.AY.6197.01", "Diseases of Immune System"], {"weight": 0.858873519244619}], ["PHACTR2", ["TCGA.AY.6197.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.858873519244619}], ["PHACTR2", ["TCGA.AY.6197.01", "O-linked glycosylation"], {"weight": 0.852356312899548}], ["PHACTR2", ["TCGA.AY.6197.01", "Complement cascade"], {"weight": 0.795557321033503}], ["PHACTR2", ["TCGA.AY.6197.01", "Signaling Pathways"], {"weight": 0.896369340608034}], ["PHACTR2", ["TCGA.AY.6197.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.858869062254345}], ["PHACTR2", ["TCGA.AY.6197.01", "Neurexins and neuroligins"], {"weight": 0.893087372386615}], ["PHACTR2", ["TCGA.AY.6197.01", "Regulation of insulin secretion"], {"weight": 0.873836236190644}], ["PHACTR2", ["TCGA.AY.6197.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.807677838876814}], ["PHACTR2", ["TCGA.AY.6197.01", "Stimuli-sensing channels"], {"weight": 0.886649739579787}], ["PHACTR2", ["TCGA.AY.6197.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.895413700194368}], ["PHACTR2", ["TCGA.AY.6197.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.517637676127651}], ["PHACTR2", ["TCGA.AY.A8YK.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.923631671755032}], ["PHACTR2", ["TCGA.AY.A8YK.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.923631671755032}], ["PHACTR2", ["TCGA.AY.A8YK.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.797409068377325}], ["PHACTR2", ["TCGA.AZ.4616.01", "Transport of small molecules"], {"weight": 0.908636748360812}], ["PHACTR2", ["TCGA.AZ.4616.01", "Integration of energy metabolism"], {"weight": 0.92264119770051}], ["PHACTR2", ["TCGA.AZ.4616.01", "Regulation of insulin secretion"], {"weight": 0.910071837832353}], ["PHACTR2", ["TCGA.CA.5255.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.826386521743566}], ["PHACTR2", ["TCGA.CA.5255.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.930361846700679}], ["PHACTR2", ["TCGA.CA.5255.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.930361846700679}], ["PHACTR2", ["TCGA.CA.5255.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.806072028873403}], ["PPIL4", ["TCGA.AA.A02O.01", "Transport of small molecules"], {"weight": 0.921827465765315}], ["CD109", ["TCGA.A6.2686.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.841294482297408}], ["CD109", ["TCGA.A6.6652.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0284917579938877}], ["CD109", ["TCGA.AA.3561.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.914638726805435}], ["CD109", ["TCGA.AA.3848.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.909917099133475}], ["CD109", ["TCGA.AA.3848.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.909917099133475}], ["CD109", ["TCGA.AA.3870.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.879266318815246}], ["CD109", ["TCGA.AD.A5EK.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.875764965265001}], ["CD109", ["TCGA.AY.A8YK.01", "Diseases of Immune System"], {"weight": 0.883488324858029}], ["CD109", ["TCGA.AY.A8YK.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.883488324858029}], ["CD109", ["TCGA.CA.5255.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.965033419410505}], ["CD109", ["TCGA.CA.5255.01", "Diseases of Immune System"], {"weight": 0.89877208198214}], ["CD109", ["TCGA.CA.5255.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.89877208198214}], ["CD109", ["TCGA.CK.5915.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.910439045494268}], ["CD109", ["TCGA.CM.6675.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.935301037141485}], ["CD109", ["TCGA.CM.6676.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.886893298943816}], ["CD109", ["TCGA.CM.6676.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.886893298943816}], ["CD109", ["TCGA.CM.6676.01", "Diseases of Immune System"], {"weight": 0.855763406073}], ["CD109", ["TCGA.CM.6676.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.855763406073}], ["CD109", ["TCGA.CM.6676.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.860682022915424}], ["CD109", ["TCGA.CM.6678.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.880684430263652}], ["CD109", ["TCGA.CM.6678.01", "Diseases of Immune System"], {"weight": 0.868579923754271}], ["CD109", ["TCGA.CM.6678.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.868579923754271}], ["CD109", ["TCGA.CM.6678.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.906448749511191}], ["CD109", ["TCGA.CM.6678.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.906448749511191}], ["CD109", ["TCGA.D5.5537.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0285728016989237}], ["CD109", ["TCGA.D5.5537.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.902119711318968}], ["CD109", ["TCGA.D5.6537.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.899271202325524}], ["CD109", ["TCGA.D5.6537.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.899271202325524}], ["CD109", ["TCGA.DM.A0X9.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.867733991318809}], ["CD109", ["TCGA.DM.A28F.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.912346576942419}], ["CD109", ["TCGA.DM.A28F.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.912346576942419}], ["CD109", ["TCGA.F4.6459.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.388903745865887}], ["CD109", ["TCGA.F4.6856.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.853847011455479}], ["CD109", ["TCGA.F4.6856.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.853847011455479}], ["CD109", ["TCGA.F4.6856.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.910146577474718}], ["CD109", ["TCGA.G4.6306.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.922791488860927}], ["CD109", ["TCGA.G4.6306.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.922791488860927}], ["CD109", ["TCGA.NH.A6GA.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.861215716603219}], ["SCAF8", ["TCGA.AA.3854.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.768345819902162}], ["SCAF8", ["TCGA.AA.3860.01", "Drug ADME"], {"weight": 0.745813860182649}], ["SCAF8", ["TCGA.AA.3952.01", "Insulin receptor recycling"], {"weight": 0.853203995377794}], ["SCAF8", ["TCGA.AY.6196.01", "Phase II - Conjugation of compounds"], {"weight": 0.80887071577935}], ["SCAF8", ["TCGA.AY.6196.01", "APAP ADME"], {"weight": 0.872770607963822}], ["SCAF8", ["TCGA.AY.6196.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.826827304777991}], ["SCAF8", ["TCGA.AY.6196.01", "Regulation of beta-cell development"], {"weight": 0.743093447376061}], ["SCAF8", ["TCGA.AY.6196.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.819994061643814}], ["SCAF8", ["TCGA.AZ.4616.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.898943058394919}], ["SCAF8", ["TCGA.AZ.4616.01", "Phase II - Conjugation of compounds"], {"weight": 0.831179840680537}], ["SCAF8", ["TCGA.DM.A28K.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.615352155017156}], ["SCAF8", ["TCGA.G4.6299.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.728708679880691}], ["MCHR2", ["TCGA.A6.6652.01", "Complement cascade"], {"weight": 0.876555788541077}], ["MCHR2", ["TCGA.A6.6652.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.685525987794916}], ["MCHR2", ["TCGA.A6.6652.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.685525987794916}], ["MCHR2", ["TCGA.AA.3561.01", "Intrinsic Pathway of Fibrin Clot Formation"], {"weight": 0.866567839363056}], ["MCHR2", ["TCGA.AA.3655.01", "Complement cascade"], {"weight": 0.845445920128313}], ["MCHR2", ["TCGA.AA.A00A.01", "Signaling by GPCR"], {"weight": 0.928256565696318}], ["MCHR2", ["TCGA.AA.A00A.01", "Peptide hormone metabolism"], {"weight": 0.777245573140956}], ["MCHR2", ["TCGA.AA.A00A.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.913911955527222}], ["MCHR2", ["TCGA.AA.A00A.01", "GPCR ligand binding"], {"weight": 0.938512975449962}], ["MCHR2", ["TCGA.AA.A00A.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.921861474755705}], ["MCHR2", ["TCGA.AA.A00A.01", "GPCR downstream signalling"], {"weight": 0.935074605857235}], ["MCHR2", ["TCGA.AA.A00A.01", "G alpha (s) signalling events"], {"weight": 0.950327125368772}], ["MCHR2", ["TCGA.AA.A00A.01", "G alpha (i) signalling events"], {"weight": 0.929800399360451}], ["MCHR2", ["TCGA.AA.A00A.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.778956007686033}], ["MCHR2", ["TCGA.AA.A00A.01", "Potassium Channels"], {"weight": 0.952495676420192}], ["MCHR2", ["TCGA.AA.A00A.01", "Neurexins and neuroligins"], {"weight": 0.948727193118861}], ["MCHR2", ["TCGA.AA.A00A.01", "Platelet homeostasis"], {"weight": 0.866455857262592}], ["MCHR2", ["TCGA.AA.A00A.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.911331136891064}], ["MCHR2", ["TCGA.AA.A00A.01", "Glucagon-type ligand receptors"], {"weight": 0.919086589554122}], ["MCHR2", ["TCGA.AA.A00A.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.91119876233217}], ["MCHR2", ["TCGA.AA.A00A.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.850542449985381}], ["MCHR2", ["TCGA.AA.A00A.01", "Signal amplification"], {"weight": 0.864431232443014}], ["MCHR2", ["TCGA.AA.A00A.01", "Aquaporin-mediated transport"], {"weight": 0.815137219201484}], ["MCHR2", ["TCGA.AA.A00A.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.910470899670445}], ["MCHR2", ["TCGA.AA.A00A.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.901275983575836}], ["MCHR2", ["TCGA.CM.5860.01", "GPCR ligand binding"], {"weight": 0.919786133208467}], ["MCHR2", ["TCGA.CM.5860.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.878452862397241}], ["MCHR2", ["TCGA.CM.5860.01", "Potassium Channels"], {"weight": 0.953554822745282}], ["MCHR2", ["TCGA.CM.5860.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.914774359747483}], ["MCHR2", ["TCGA.CM.5860.01", "Chemokine receptors bind chemokines"], {"weight": 0.918955750621107}], ["MCHR2", ["TCGA.CM.5860.01", "G alpha (i) signalling events"], {"weight": 0.941787466336799}], ["MCHR2", ["TCGA.CM.5860.01", "Peptide ligand-binding receptors"], {"weight": 0.908341120273362}], ["MCHR2", ["TCGA.CM.5860.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.893439561123244}], ["MCHR2", ["TCGA.CM.5860.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.64328498748115}], ["MCHR2", ["TCGA.CM.5860.01", "Glucagon-type ligand receptors"], {"weight": 0.915247723773633}], ["MCHR2", ["TCGA.CM.5868.01", "G alpha (i) signalling events"], {"weight": 0.96254844611246}], ["MCHR2", ["TCGA.CM.6678.01", "Complement cascade"], {"weight": 0.827381542427364}], ["MCHR2", ["TCGA.CM.6678.01", "Regulation of Complement cascade"], {"weight": 0.786155000375414}], ["MCHR2", ["TCGA.CM.6678.01", "Innate Immune System"], {"weight": 0.872648361129773}], ["MCHR2", ["TCGA.D5.6931.01", "Transmission across Chemical Synapses"], {"weight": 0.88871858174412}], ["MCHR2", ["TCGA.F4.6856.01", "GPCR downstream signalling"], {"weight": 0.953287129398611}], ["MCHR2", ["TCGA.F4.6856.01", "Complement cascade"], {"weight": 0.666095118870242}], ["SIM1", ["TCGA.3L.AA1B.01", "Heme degradation"], {"weight": 0.621531740655596}], ["SIM1", ["TCGA.5M.AATA.01", "APAP ADME"], {"weight": 0.812983020771005}], ["SIM1", ["TCGA.A6.6652.01", "Metabolism of vitamins and cofactors"], {"weight": 0.780210139931968}], ["SIM1", ["TCGA.A6.6652.01", "Heme degradation"], {"weight": 0.776652113114899}], ["SIM1", ["TCGA.AA.3560.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.882851714687408}], ["SIM1", ["TCGA.AA.3848.01", "Post-translational protein phosphorylation"], {"weight": 0.857821480731718}], ["SIM1", ["TCGA.AA.3848.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.879213684134865}], ["SIM1", ["TCGA.AA.3875.01", "Metal ion SLC transporters"], {"weight": 0.576202653971624}], ["SIM1", ["TCGA.AA.3939.01", "Heme degradation"], {"weight": 0.629271145396139}], ["SIM1", ["TCGA.AA.3952.01", "Metal ion SLC transporters"], {"weight": 0.673714443661023}], ["SIM1", ["TCGA.AA.A00A.01", "Biological oxidations"], {"weight": 0.910217092045051}], ["SIM1", ["TCGA.AA.A00A.01", "Phase I - Functionalization of compounds"], {"weight": 0.921956883396867}], ["SIM1", ["TCGA.AA.A02H.01", "Heme degradation"], {"weight": 0.744033749972252}], ["SIM1", ["TCGA.AA.A02H.01", "Porphyrin metabolism"], {"weight": 0.707263539126513}], ["SIM1", ["TCGA.AA.A02H.01", "APAP ADME"], {"weight": 0.529532191586633}], ["SIM1", ["TCGA.AY.A8YK.01", "Heme degradation"], {"weight": 0.603442901971463}], ["SIM1", ["TCGA.AZ.6607.01", "Metal ion SLC transporters"], {"weight": 0.795452558887959}], ["SIM1", ["TCGA.AZ.6607.01", "APAP ADME"], {"weight": 0.753250951752414}], ["SIM1", ["TCGA.AZ.6608.01", "Heme degradation"], {"weight": 0.842852613399028}], ["SIM1", ["TCGA.CA.5254.01", "Heme degradation"], {"weight": 0.7931710656382}], ["SIM1", ["TCGA.CA.5254.01", "APAP ADME"], {"weight": 0.909882363503401}], ["SIM1", ["TCGA.CM.5860.01", "Drug ADME"], {"weight": 0.907695096202528}], ["SIM1", ["TCGA.CM.5860.01", "APAP ADME"], {"weight": 0.81657538887126}], ["SIM1", ["TCGA.CM.5860.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.857020441241033}], ["SIM1", ["TCGA.CM.5860.01", "Heme degradation"], {"weight": 0.704446886291449}], ["SIM1", ["TCGA.CM.5868.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.798878558804211}], ["SIM1", ["TCGA.CM.6169.01", "APAP ADME"], {"weight": 0.682575041370881}], ["SIM1", ["TCGA.CM.6172.01", "Heme degradation"], {"weight": 0.322863681706365}], ["SIM1", ["TCGA.CM.6676.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], {"weight": 0.755022056157082}], ["SIM1", ["TCGA.D5.5537.01", "Heme degradation"], {"weight": 0.732303139845459}], ["SIM1", ["TCGA.D5.6535.01", "Heme degradation"], {"weight": 0.730069877334922}], ["SIM1", ["TCGA.D5.6535.01", "Metal ion SLC transporters"], {"weight": 0.72103864869472}], ["SIM1", ["TCGA.D5.6898.01", "APAP ADME"], {"weight": 0.792841889806255}], ["SIM1", ["TCGA.D5.6931.01", "Formation of the cornified envelope"], {"weight": 0.776982906523336}], ["SIM1", ["TCGA.D5.6931.01", "Transport of small molecules"], {"weight": 0.881086726307537}], ["SIM1", ["TCGA.D5.6931.01", "Heme degradation"], {"weight": 0.103179726051122}], ["SIM1", ["TCGA.F4.6704.01", "APAP ADME"], {"weight": 0.786910901737142}], ["SIM1", ["TCGA.F4.6854.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.88843293763385}], ["SIM1", ["TCGA.F4.6854.01", "Transport of small molecules"], {"weight": 0.894448812008008}], ["SIM1", ["TCGA.F4.6854.01", "Regulation of gene expression in beta cells"], {"weight": 0.764786723408418}], ["SIM1", ["TCGA.F4.6856.01", "Heme degradation"], {"weight": 0.626920568816115}], ["SIM1", ["TCGA.F4.6856.01", "Stimuli-sensing channels"], {"weight": 0.869193220436749}], ["SIM1", ["TCGA.G4.6297.01", "Metal ion SLC transporters"], {"weight": 0.726165685013178}], ["SIM1", ["TCGA.G4.6297.01", "Drug ADME"], {"weight": 0.869730425429356}], ["SIM1", ["TCGA.NH.A6GA.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], {"weight": 0.838143557154404}], ["KATNA1", ["TCGA.AA.A02H.01", "Arachidonic acid metabolism"], {"weight": 0.835694749796243}], ["KATNA1", ["TCGA.AY.6196.01", "Interaction between L1 and Ankyrins"], {"weight": 0.853819013003155}], ["KATNA1", ["TCGA.AZ.4616.01", "Interaction between L1 and Ankyrins"], {"weight": 0.911360947500368}], ["KATNA1", ["TCGA.D5.6535.01", "Arachidonic acid metabolism"], {"weight": 0.853556745706995}], ["KATNA1", ["TCGA.DM.A28K.01", "Interaction between L1 and Ankyrins"], {"weight": 0.937155650287611}], ["IL20RA", ["TCGA.AA.A02H.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.878742333978403}], ["IL20RA", ["TCGA.AA.A02H.01", "Interleukin-6 family signaling"], {"weight": 0.896654959516384}], ["IL20RA", ["TCGA.AA.A02Y.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.928287603758662}], ["IL20RA", ["TCGA.AA.A02Y.01", "Interleukin-6 family signaling"], {"weight": 0.931481402504108}], ["IL20RA", ["TCGA.AD.6888.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.923787464211304}], ["IL20RA", ["TCGA.AD.6888.01", "Interleukin-6 family signaling"], {"weight": 0.922452640794664}], ["IL20RA", ["TCGA.AY.A8YK.01", "Acetylcholine binding and downstream events"], {"weight": 0.823533646900086}], ["IL20RA", ["TCGA.AY.A8YK.01", "Postsynaptic nicotinic acetylcholine receptors"], {"weight": 0.828680939848344}], ["IL20RA", ["TCGA.AZ.6606.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.922422818321121}], ["IL20RA", ["TCGA.CA.5255.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.905074274965963}], ["IL20RA", ["TCGA.CA.5255.01", "Interleukin-6 family signaling"], {"weight": 0.913776786197915}], ["IL20RA", ["TCGA.CK.5915.01", "TNFs bind their physiological receptors"], {"weight": 0.538538647985192}], ["IL20RA", ["TCGA.D5.6535.01", "Acetylcholine binding and downstream events"], {"weight": 0.763089714814512}], ["IL20RA", ["TCGA.D5.6535.01", "Postsynaptic nicotinic acetylcholine receptors"], {"weight": 0.77066276633942}], ["IL20RA", ["TCGA.D5.6537.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.919154028103285}], ["CITED2", ["TCGA.A6.2678.01", "Assembly of active LPL and LIPC lipase complexes"], {"weight": 0.758887147229611}], ["CITED2", ["TCGA.AA.3655.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.82689245630204}], ["CITED2", ["TCGA.AA.3685.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.833200785253655}], ["CITED2", ["TCGA.AA.3939.01", "Post-translational protein phosphorylation"], {"weight": 0.843613230766481}], ["CITED2", ["TCGA.AA.3939.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.775123877369398}], ["CITED2", ["TCGA.AA.3952.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.890282247951472}], ["CITED2", ["TCGA.AA.A02H.01", "Scavenging of heme from plasma"], {"weight": 0.609336454785195}], ["CITED2", ["TCGA.AZ.6607.01", "Carnitine metabolism"], {"weight": 0.836980048589423}], ["CITED2", ["TCGA.CA.5254.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.884179339532912}], ["CITED2", ["TCGA.CK.5915.01", "G alpha (q) signalling events"], {"weight": 0.907299564514152}], ["CITED2", ["TCGA.D5.6535.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.895107388652398}], ["CITED2", ["TCGA.D5.6537.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.907860444206119}], ["CITED2", ["TCGA.DM.A28F.01", "Endogenous sterols"], {"weight": 0.585091310764615}], ["CITED2", ["TCGA.G4.6297.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.680069466448177}], ["ASCC3", ["TCGA.AA.3561.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.890275220798672}], ["ASCC3", ["TCGA.G4.6626.01", "Neuronal System"], {"weight": 0.927486497566989}], ["ASCC3", ["TCGA.G4.6626.01", "Transmission across Chemical Synapses"], {"weight": 0.911909772158008}], ["ASCC3", ["TCGA.G4.6626.01", "Biological oxidations"], {"weight": 0.888326773553645}], ["ASCC3", ["TCGA.G4.6626.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.901210420930741}], ["ASCC3", ["TCGA.G4.6626.01", "Cardiac conduction"], {"weight": 0.924995381471696}], ["ASCC3", ["TCGA.G4.6626.01", "Drug ADME"], {"weight": 0.878413649483758}], ["ASCC3", ["TCGA.G4.6626.01", "Unwinding of DNA"], {"weight": 0.76072265335743}], ["ASCC3", ["TCGA.G4.6626.01", "Muscle contraction"], {"weight": 0.927711301471016}], ["ASCC3", ["TCGA.G4.6626.01", "Transcription of E2F targets under negative control by DREAM complex"], {"weight": 0.817890599195262}], ["ASCC3", ["TCGA.G4.6626.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.730611615390799}], ["ASCC3", ["TCGA.G4.6626.01", "Activation of ATR in response to replication stress"], {"weight": 0.83105640154909}], ["ASCC3", ["TCGA.G4.6626.01", "G0 and Early G1"], {"weight": 0.842644299263902}], ["ASCC3", ["TCGA.G4.6626.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.845634847233162}], ["ASCC3", ["TCGA.G4.6626.01", "Phase I - Functionalization of compounds"], {"weight": 0.893632035480019}], ["ASCC3", ["TCGA.G4.6626.01", "Immune System"], {"weight": 0.874159382171676}], ["ASCC3", ["TCGA.G4.6626.01", "Molecules associated with elastic fibres"], {"weight": 0.847131351389877}], ["NMBR", ["TCGA.4T.AA8H.01", "Peptide ligand-binding receptors"], {"weight": 0.932587581453147}], ["NMBR", ["TCGA.4T.AA8H.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.933906716400462}], ["NMBR", ["TCGA.AA.3837.01", "Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)"], {"weight": 0.642612840151054}], ["NMBR", ["TCGA.AA.A029.01", "GPCR ligand binding"], {"weight": 0.93836354973114}], ["NMBR", ["TCGA.AA.A02H.01", "Peptide ligand-binding receptors"], {"weight": 0.921190885559217}], ["NMBR", ["TCGA.AA.A02H.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.922701970652257}], ["NMBR", ["TCGA.AD.6888.01", "GPCR ligand binding"], {"weight": 0.952115816484012}], ["NMBR", ["TCGA.AD.6888.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.955489461602159}], ["NMBR", ["TCGA.AD.6888.01", "Peptide ligand-binding receptors"], {"weight": 0.954667558989911}], ["NMBR", ["TCGA.AZ.4616.01", "Platelet homeostasis"], {"weight": 0.880577556211272}], ["NMBR", ["TCGA.AZ.6606.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.935972479339132}], ["NMBR", ["TCGA.AZ.6608.01", "GPCR ligand binding"], {"weight": 0.940418114819612}], ["NMBR", ["TCGA.AZ.6608.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.946174748862772}], ["NMBR", ["TCGA.AZ.6608.01", "Peptide ligand-binding receptors"], {"weight": 0.945087304316649}], ["NMBR", ["TCGA.CA.5254.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.926828100630724}], ["NMBR", ["TCGA.CA.5255.01", "Peptide ligand-binding receptors"], {"weight": 0.94248993441903}], ["NMBR", ["TCGA.CA.5255.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.942385060360408}], ["NMBR", ["TCGA.CM.6172.01", "Chemokine receptors bind chemokines"], {"weight": 0.842841855222542}], ["NMBR", ["TCGA.CM.6676.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.922383927438169}], ["NMBR", ["TCGA.CM.6676.01", "Peptide ligand-binding receptors"], {"weight": 0.91017874859496}], ["NMBR", ["TCGA.CM.6678.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.901318545623038}], ["NMBR", ["TCGA.D5.6898.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.908711193081705}], ["NMBR", ["TCGA.D5.6898.01", "Peptide ligand-binding receptors"], {"weight": 0.906084064637951}], ["NMBR", ["TCGA.DM.A28F.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.937021783006391}], ["NMBR", ["TCGA.F4.6460.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.90830896552676}], ["TMEM181", ["TCGA.AA.3666.01", "Peptide hormone metabolism"], {"weight": 0.793767710001784}], ["TMEM181", ["TCGA.AA.3685.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.801901680510088}], ["TMEM181", ["TCGA.AA.3841.01", "Apoptotic cleavage of cell adhesion  proteins"], {"weight": 0.75571527483135}], ["TMEM181", ["TCGA.AA.3841.01", "Caspase activation via extrinsic apoptotic signalling pathway"], {"weight": 0.784397004752951}], ["TMEM181", ["TCGA.AA.3858.01", "Peptide hormone metabolism"], {"weight": 0.757803001469168}], ["TMEM181", ["TCGA.AA.3875.01", "GABA receptor activation"], {"weight": 0.758700647675461}], ["TMEM181", ["TCGA.AA.A01X.01", "Peptide hormone metabolism"], {"weight": 0.86156072439068}], ["TMEM181", ["TCGA.AA.A02Y.01", "Degradation of the extracellular matrix"], {"weight": 0.841903193097176}], ["TMEM181", ["TCGA.AD.6888.01", "Degradation of the extracellular matrix"], {"weight": 0.856294052789158}], ["TMEM181", ["TCGA.AZ.4616.01", "GABA receptor activation"], {"weight": 0.858277667759843}], ["TMEM181", ["TCGA.AZ.4616.01", "Peptide hormone metabolism"], {"weight": 0.754864743280142}], ["TMEM181", ["TCGA.AZ.6608.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.869304448014277}], ["TMEM181", ["TCGA.CK.5915.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.845306271678668}], ["TMEM181", ["TCGA.CM.6675.01", "Extracellular matrix organization"], {"weight": 0.839891972538931}], ["TMEM181", ["TCGA.CM.6676.01", "Peptide hormone metabolism"], {"weight": 0.773917093425262}], ["TMEM181", ["TCGA.D5.5537.01", "GABA receptor activation"], {"weight": 0.863429984432426}], ["TMEM181", ["TCGA.D5.5541.01", "Signaling by GPCR"], {"weight": 0.940955673426773}], ["TMEM181", ["TCGA.D5.5541.01", "GPCR downstream signalling"], {"weight": 0.950250804388513}], ["LTV1", ["TCGA.AA.3875.01", "Formation of a pool of free 40S subunits"], {"weight": 0.922840244552714}], ["LTV1", ["TCGA.AA.3875.01", "Viral mRNA Translation"], {"weight": 0.923960195915748}], ["VTA1", ["TCGA.AA.3841.01", "Sealing of the nuclear envelope (NE) by ESCRT-III"], {"weight": 0.911005416713674}], ["DYNLT1", ["TCGA.D5.5541.01", "Arachidonic acid metabolism"], {"weight": 0.850382416830419}], ["DYNLT1", ["TCGA.G4.6299.01", "Arachidonic acid metabolism"], {"weight": 0.883297161905666}], ["DYNLT1", ["TCGA.G4.6299.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.857302980460804}], ["DYNLT1", ["TCGA.G4.6299.01", "Norepinephrine Neurotransmitter Release Cycle"], {"weight": 0.655335469071887}], ["DYNLT1", ["TCGA.G4.6299.01", "GABA synthesis, release, reuptake and degradation"], {"weight": 0.833960455698326}], ["LATS1", ["TCGA.4T.AA8H.01", "Cardiac conduction"], {"weight": 0.938486806279584}], ["ESR1", ["TCGA.4T.AA8H.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.907935337649552}], ["ESR1", ["TCGA.4T.AA8H.01", "Leishmania infection"], {"weight": 0.886862183429683}], ["ESR1", ["TCGA.4T.AA8H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.915644857277665}], ["ESR1", ["TCGA.4T.AA8H.01", "Leishmania parasite growth and survival"], {"weight": 0.915644857277665}], ["ESR1", ["TCGA.4T.AA8H.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.911595614776179}], ["ESR1", ["TCGA.4T.AA8H.01", "G-protein activation"], {"weight": 0.919641779840493}], ["ESR1", ["TCGA.4T.AA8H.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.918558981007441}], ["ESR1", ["TCGA.4T.AA8H.01", "Regulation of insulin secretion"], {"weight": 0.876013850566445}], ["ESR1", ["TCGA.A6.2680.01", "Regulation of insulin secretion"], {"weight": 0.842264897825434}], ["ESR1", ["TCGA.A6.2680.01", "Peptide hormone metabolism"], {"weight": 0.791644075356598}], ["ESR1", ["TCGA.A6.2685.01", "Glucuronidation"], {"weight": 0.73667677180794}], ["ESR1", ["TCGA.A6.2685.01", "Biological oxidations"], {"weight": 0.835703639003087}], ["ESR1", ["TCGA.A6.2685.01", "GPCR ligand binding"], {"weight": 0.847073957179648}], ["ESR1", ["TCGA.A6.2685.01", "Phase II - Conjugation of compounds"], {"weight": 0.812468486604629}], ["ESR1", ["TCGA.A6.2685.01", "Collagen formation"], {"weight": 0.85427281744998}], ["ESR1", ["TCGA.A6.6649.01", "GPCR ligand binding"], {"weight": 0.803922573399731}], ["ESR1", ["TCGA.AA.3655.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.918815759204872}], ["ESR1", ["TCGA.AA.3660.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.86300742671798}], ["ESR1", ["TCGA.AA.3660.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.894451683088169}], ["ESR1", ["TCGA.AA.3715.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.951471965172249}], ["ESR1", ["TCGA.AA.3837.01", "Nuclear Receptor transcription pathway"], {"weight": 0.633958327611381}], ["ESR1", ["TCGA.AA.3837.01", "Signaling by PTK6"], {"weight": 0.635800549326743}], ["ESR1", ["TCGA.AA.3837.01", "Signaling by Non-Receptor Tyrosine Kinases"], {"weight": 0.635800549326743}], ["ESR1", ["TCGA.AA.3837.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.640091015302293}], ["ESR1", ["TCGA.AA.3841.01", "Extra-nuclear estrogen signaling"], {"weight": 0.861971346654596}], ["ESR1", ["TCGA.AA.3841.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.860419671084831}], ["ESR1", ["TCGA.AA.3841.01", "ESR-mediated signaling"], {"weight": 0.899464368671595}], ["ESR1", ["TCGA.AA.3841.01", "IRS-related events triggered by IGF1R"], {"weight": 0.85228917188603}], ["ESR1", ["TCGA.AA.3841.01", "Ca2+ pathway"], {"weight": 0.836456966457946}], ["ESR1", ["TCGA.AA.3841.01", "IGF1R signaling cascade"], {"weight": 0.85228917188603}], ["ESR1", ["TCGA.AA.3841.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.882290221951624}], ["ESR1", ["TCGA.AA.3854.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.913845169892796}], ["ESR1", ["TCGA.AA.3854.01", "Regulation of insulin secretion"], {"weight": 0.868046451558058}], ["ESR1", ["TCGA.AA.3854.01", "Trafficking of AMPA receptors"], {"weight": 0.92918191101261}], ["ESR1", ["TCGA.AA.3854.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.92918191101261}], ["ESR1", ["TCGA.AA.A02H.01", "HSP90 chaperone cycle for SHRs"], {"weight": 0.659412931014628}], ["ESR1", ["TCGA.AA.A02H.01", "Ca2+ pathway"], {"weight": 0.826981010012562}], ["ESR1", ["TCGA.AA.A02H.01", "Free fatty acids regulate insulin secretion"], {"weight": 0.539754785642785}], ["ESR1", ["TCGA.AA.A02H.01", "G-protein mediated events"], {"weight": 0.88659772013029}], ["ESR1", ["TCGA.AA.A02O.01", "G beta:gamma signalling through BTK"], {"weight": 0.917021971456391}], ["ESR1", ["TCGA.AA.A02O.01", "G-protein beta:gamma signalling"], {"weight": 0.928035137865621}], ["ESR1", ["TCGA.AA.A02O.01", "G beta:gamma signalling through CDC42"], {"weight": 0.915478810047942}], ["ESR1", ["TCGA.AA.A02O.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.921772044345517}], ["ESR1", ["TCGA.AA.A02O.01", "Presynaptic function of Kainate receptors"], {"weight": 0.916809805272904}], ["ESR1", ["TCGA.AA.A02O.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.922106730213905}], ["ESR1", ["TCGA.AA.A02O.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.911110627389869}], ["ESR1", ["TCGA.AA.A02O.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.911110627389869}], ["ESR1", ["TCGA.AA.A02O.01", "G-protein activation"], {"weight": 0.918371768265827}], ["ESR1", ["TCGA.AA.A02O.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.922813437067306}], ["ESR1", ["TCGA.AA.A02O.01", "Glucagon-type ligand receptors"], {"weight": 0.925695926064222}], ["ESR1", ["TCGA.AA.A02Y.01", "G alpha (i) signalling events"], {"weight": 0.948719448663318}], ["ESR1", ["TCGA.AA.A02Y.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.946443757895011}], ["ESR1", ["TCGA.AA.A02Y.01", "Signal amplification"], {"weight": 0.937148605405693}], ["ESR1", ["TCGA.AA.A02Y.01", "G-protein mediated events"], {"weight": 0.893241172609865}], ["ESR1", ["TCGA.AD.6888.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.937067034550294}], ["ESR1", ["TCGA.AD.6888.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.914997101319184}], ["ESR1", ["TCGA.AD.6888.01", "IRS-related events triggered by IGF1R"], {"weight": 0.902416618704642}], ["ESR1", ["TCGA.AD.6888.01", "IGF1R signaling cascade"], {"weight": 0.902416618704642}], ["ESR1", ["TCGA.AD.A5EK.01", "Complement cascade"], {"weight": 0.888296756091337}], ["ESR1", ["TCGA.AY.6196.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.945164879067753}], ["ESR1", ["TCGA.AY.6196.01", "Collagen chain trimerization"], {"weight": 0.920435228813909}], ["ESR1", ["TCGA.AY.6196.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.558503573891951}], ["ESR1", ["TCGA.AY.6196.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.826293683969995}], ["ESR1", ["TCGA.AY.6196.01", "O-linked glycosylation of mucins"], {"weight": 0.899982829047781}], ["ESR1", ["TCGA.AY.6196.01", "Scavenging by Class A Receptors"], {"weight": 0.593447420690731}], ["ESR1", ["TCGA.AY.6196.01", "Defective GALNT3 causes HFTC"], {"weight": 0.808503467052538}], ["ESR1", ["TCGA.AY.6196.01", "Termination of O-glycan biosynthesis"], {"weight": 0.840407239649523}], ["ESR1", ["TCGA.AY.6196.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.808503467052538}], ["ESR1", ["TCGA.AY.A8YK.01", "Initial triggering of complement"], {"weight": 0.777418785238513}], ["ESR1", ["TCGA.AY.A8YK.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.87799941455463}], ["ESR1", ["TCGA.AZ.4616.01", "Transmission across Chemical Synapses"], {"weight": 0.902959059661451}], ["ESR1", ["TCGA.AZ.4616.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.88637082202724}], ["ESR1", ["TCGA.AZ.4616.01", "Signaling Pathways"], {"weight": 0.891853958733958}], ["ESR1", ["TCGA.AZ.4616.01", "G-protein mediated events"], {"weight": 0.924479170997273}], ["ESR1", ["TCGA.AZ.4616.01", "PLC beta mediated events"], {"weight": 0.889935415930716}], ["ESR1", ["TCGA.AZ.4616.01", "Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3"], {"weight": 0.820530405424768}], ["ESR1", ["TCGA.AZ.6598.01", "Long-term potentiation"], {"weight": 0.946369749938818}], ["ESR1", ["TCGA.AZ.6600.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.931336259424567}], ["ESR1", ["TCGA.AZ.6600.01", "Keratinization"], {"weight": 0.859735668950529}], ["ESR1", ["TCGA.AZ.6607.01", "Degradation of the extracellular matrix"], {"weight": 0.896430074304511}], ["ESR1", ["TCGA.AZ.6607.01", "Signaling Pathways"], {"weight": 0.887532999793133}], ["ESR1", ["TCGA.AZ.6607.01", "Regulation of insulin secretion"], {"weight": 0.898592374539733}], ["ESR1", ["TCGA.AZ.6608.01", "Complement cascade"], {"weight": 0.942032752871591}], ["ESR1", ["TCGA.AZ.6608.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.931273723782303}], ["ESR1", ["TCGA.AZ.6608.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.916949444181521}], ["ESR1", ["TCGA.AZ.6608.01", "Activation of G protein gated Potassium channels"], {"weight": 0.93784210575324}], ["ESR1", ["TCGA.AZ.6608.01", "G protein gated Potassium channels"], {"weight": 0.93784210575324}], ["ESR1", ["TCGA.AZ.6608.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.93784210575324}], ["ESR1", ["TCGA.AZ.6608.01", "Inwardly rectifying K+ channels"], {"weight": 0.913579138426946}], ["ESR1", ["TCGA.AZ.6608.01", "GABA receptor activation"], {"weight": 0.917154799191534}], ["ESR1", ["TCGA.AZ.6608.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.939993347084796}], ["ESR1", ["TCGA.CA.5254.01", "Signaling Pathways"], {"weight": 0.90520503502186}], ["ESR1", ["TCGA.CA.5255.01", "Complement cascade"], {"weight": 0.88136588141142}], ["ESR1", ["TCGA.CA.5255.01", "Initial triggering of complement"], {"weight": 0.841918542240845}], ["ESR1", ["TCGA.CA.5255.01", "G-protein activation"], {"weight": 0.921800008367304}], ["ESR1", ["TCGA.CK.5915.01", "Complement cascade"], {"weight": 0.931252263791887}], ["ESR1", ["TCGA.CK.5915.01", "GABA receptor activation"], {"weight": 0.920930309715462}], ["ESR1", ["TCGA.CM.6167.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.924247612813006}], ["ESR1", ["TCGA.CM.6675.01", "Chemokine receptors bind chemokines"], {"weight": 0.941212189310331}], ["ESR1", ["TCGA.D5.5537.01", "Signaling Pathways"], {"weight": 0.88291593588289}], ["ESR1", ["TCGA.D5.6529.01", "Collagen formation"], {"weight": 0.934749650162455}], ["ESR1", ["TCGA.D5.6529.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.943913214032786}], ["ESR1", ["TCGA.D5.6535.01", "GABA B receptor activation"], {"weight": 0.921765860492094}], ["ESR1", ["TCGA.D5.6535.01", "Activation of GABAB receptors"], {"weight": 0.921765860492094}], ["ESR1", ["TCGA.D5.6535.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.736940328234175}], ["ESR1", ["TCGA.D5.6537.01", "Complement cascade"], {"weight": 0.911749280957759}], ["ESR1", ["TCGA.D5.6537.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.892530190731755}], ["ESR1", ["TCGA.DM.A28F.01", "Transport of small molecules"], {"weight": 0.934777731125841}], ["ESR1", ["TCGA.DM.A28F.01", "G alpha (q) signalling events"], {"weight": 0.928942140955367}], ["ESR1", ["TCGA.DM.A28F.01", "Signal amplification"], {"weight": 0.893553997431328}], ["ESR1", ["TCGA.DM.A28K.01", "Complement cascade"], {"weight": 0.938994927766881}], ["ESR1", ["TCGA.DM.A28K.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.930153825092556}], ["ESR1", ["TCGA.DM.A28K.01", "PLC beta mediated events"], {"weight": 0.889433012133597}], ["ESR1", ["TCGA.DM.A28K.01", "G-protein mediated events"], {"weight": 0.917381494455643}], ["ESR1", ["TCGA.DM.A28K.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.904211533818886}], ["ESR1", ["TCGA.DM.A28K.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.90414002981769}], ["ESR1", ["TCGA.DM.A28K.01", "Leishmania parasite growth and survival"], {"weight": 0.90414002981769}], ["ESR1", ["TCGA.DM.A28K.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.927868536408437}], ["ESR1", ["TCGA.G4.6297.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.591448088125985}], ["ESR1", ["TCGA.G4.6299.01", "Transport of small molecules"], {"weight": 0.929997812929351}], ["ESR1", ["TCGA.G4.6299.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.928305016496786}], ["ESR1", ["TCGA.G4.6299.01", "GABA receptor activation"], {"weight": 0.91874498268883}], ["ESR1", ["TCGA.G4.6299.01", "Drug ADME"], {"weight": 0.926280737422162}], ["ESR1", ["TCGA.G4.6299.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.759327870902207}], ["ESR1", ["TCGA.G4.6306.01", "Neuronal System"], {"weight": 0.948821758054279}], ["ESR1", ["TCGA.G4.6306.01", "Signal amplification"], {"weight": 0.930960536840213}], ["EZR", ["TCGA.4T.AA8H.01", "Extracellular matrix organization"], {"weight": 0.902835840833578}], ["EZR", ["TCGA.4T.AA8H.01", "Chemokine receptors bind chemokines"], {"weight": 0.928717568974686}], ["EZR", ["TCGA.4T.AA8H.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.772720673349442}], ["EZR", ["TCGA.4T.AA8H.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.811514606801112}], ["EZR", ["TCGA.5M.AATA.01", "Peptide ligand-binding receptors"], {"weight": 0.91751101085635}], ["EZR", ["TCGA.5M.AATA.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.930648768698758}], ["EZR", ["TCGA.5M.AATA.01", "Extracellular matrix organization"], {"weight": 0.804274713661986}], ["EZR", ["TCGA.5M.AATA.01", "Degradation of the extracellular matrix"], {"weight": 0.772144918809653}], ["EZR", ["TCGA.A6.2678.01", "Degradation of the extracellular matrix"], {"weight": 0.802353670582791}], ["EZR", ["TCGA.A6.6652.01", "Chemokine receptors bind chemokines"], {"weight": 0.946183857345488}], ["EZR", ["TCGA.A6.6652.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.946360010961077}], ["EZR", ["TCGA.AA.3655.01", "L1CAM interactions"], {"weight": 0.893889579796236}], ["EZR", ["TCGA.AA.3655.01", "Transport of small molecules"], {"weight": 0.918214273299757}], ["EZR", ["TCGA.AA.3655.01", "Peptide ligand-binding receptors"], {"weight": 0.899655587906933}], ["EZR", ["TCGA.AA.3655.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.912794738801113}], ["EZR", ["TCGA.AA.3655.01", "Chemokine receptors bind chemokines"], {"weight": 0.915811732781227}], ["EZR", ["TCGA.AA.3660.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.714617066580027}], ["EZR", ["TCGA.AA.3680.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], {"weight": 0.839009839733846}], ["EZR", ["TCGA.AA.3685.01", "Transport of small molecules"], {"weight": 0.86560690713438}], ["EZR", ["TCGA.AA.3715.01", "Extracellular matrix organization"], {"weight": 0.90868069589777}], ["EZR", ["TCGA.AA.3837.01", "Trafficking of AMPA receptors"], {"weight": 0.660028694437813}], ["EZR", ["TCGA.AA.3837.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.660028694437813}], ["EZR", ["TCGA.AA.3837.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.474626628465787}], ["EZR", ["TCGA.AA.3837.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.502890710481961}], ["EZR", ["TCGA.AA.3841.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.894822535946892}], ["EZR", ["TCGA.AA.3844.01", "TNFs bind their physiological receptors"], {"weight": 0.401933592199343}], ["EZR", ["TCGA.AA.3854.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.929130069282137}], ["EZR", ["TCGA.AA.3854.01", "Presynaptic function of Kainate receptors"], {"weight": 0.923046790857345}], ["EZR", ["TCGA.AA.3854.01", "Glucagon-type ligand receptors"], {"weight": 0.921814669942156}], ["EZR", ["TCGA.AA.3854.01", "Potassium Channels"], {"weight": 0.95414083392441}], ["EZR", ["TCGA.AA.3854.01", "Activation of G protein gated Potassium channels"], {"weight": 0.930519388894002}], ["EZR", ["TCGA.AA.3854.01", "G protein gated Potassium channels"], {"weight": 0.930519388894002}], ["EZR", ["TCGA.AA.3854.01", "TNFs bind their physiological receptors"], {"weight": 0.326739334606499}], ["EZR", ["TCGA.AA.3854.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.930519388894002}], ["EZR", ["TCGA.AA.3854.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.916325132380642}], ["EZR", ["TCGA.AA.3854.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.919947820272743}], ["EZR", ["TCGA.AA.3854.01", "Signal amplification"], {"weight": 0.920857355009755}], ["EZR", ["TCGA.AA.3854.01", "Transport of small molecules"], {"weight": 0.926589533730316}], ["EZR", ["TCGA.AA.3854.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.918563016868151}], ["EZR", ["TCGA.AA.3854.01", "G beta:gamma signalling through BTK"], {"weight": 0.895042243156071}], ["EZR", ["TCGA.AA.3854.01", "Inwardly rectifying K+ channels"], {"weight": 0.930519388894002}], ["EZR", ["TCGA.AA.3854.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.913475482006334}], ["EZR", ["TCGA.AA.3854.01", "Thromboxane signalling through TP receptor"], {"weight": 0.907402355658311}], ["EZR", ["TCGA.AA.3854.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.895042243156071}], ["EZR", ["TCGA.AA.3854.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.726610792316995}], ["EZR", ["TCGA.AA.3875.01", "Netrin-1 signaling"], {"weight": 0.551139020714402}], ["EZR", ["TCGA.AA.3875.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.567713839368765}], ["EZR", ["TCGA.AA.3939.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.825274600298777}], ["EZR", ["TCGA.AA.3952.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.921608242685515}], ["EZR", ["TCGA.AA.3952.01", "Transport of small molecules"], {"weight": 0.924087540136299}], ["EZR", ["TCGA.AA.A00J.01", "Degradation of the extracellular matrix"], {"weight": 0.85728893884627}], ["EZR", ["TCGA.AA.A01D.01", "TNFs bind their physiological receptors"], {"weight": 0.414571108099177}], ["EZR", ["TCGA.AA.A01X.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.925049620332949}], ["EZR", ["TCGA.AA.A029.01", "Chemokine receptors bind chemokines"], {"weight": 0.940323073685352}], ["EZR", ["TCGA.AA.A02H.01", "Chemokine receptors bind chemokines"], {"weight": 0.919850321583603}], ["EZR", ["TCGA.AA.A02H.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.732549148378057}], ["EZR", ["TCGA.AA.A02H.01", "Ligand-dependent caspase activation"], {"weight": 0.748311672130499}], ["EZR", ["TCGA.AA.A02H.01", "Caspase activation via extrinsic apoptotic signalling pathway"], {"weight": 0.7084066683742}], ["EZR", ["TCGA.AA.A02H.01", "Extracellular matrix organization"], {"weight": 0.793199836393556}], ["EZR", ["TCGA.AA.A02H.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.781975087835952}], ["EZR", ["TCGA.AA.A02H.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.903989830942493}], ["EZR", ["TCGA.AA.A02O.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.917116485995171}], ["EZR", ["TCGA.AA.A02O.01", "Thromboxane signalling through TP receptor"], {"weight": 0.916497399072437}], ["EZR", ["TCGA.AA.A02O.01", "Signal amplification"], {"weight": 0.927923130214745}], ["EZR", ["TCGA.AA.A02O.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.923596813403864}], ["EZR", ["TCGA.AA.A02Y.01", "Extracellular matrix organization"], {"weight": 0.939452256069511}], ["EZR", ["TCGA.AA.A02Y.01", "Chemokine receptors bind chemokines"], {"weight": 0.945710687721978}], ["EZR", ["TCGA.AA.A02Y.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.835371057013189}], ["EZR", ["TCGA.AD.6888.01", "Chemokine receptors bind chemokines"], {"weight": 0.947271875334781}], ["EZR", ["TCGA.AD.6888.01", "Complement cascade"], {"weight": 0.934002537646766}], ["EZR", ["TCGA.AD.6888.01", "Regulation of Complement cascade"], {"weight": 0.909009232619157}], ["EZR", ["TCGA.AD.6888.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.897830266881613}], ["EZR", ["TCGA.AD.6888.01", "Carbohydrate metabolism"], {"weight": 0.934322294003254}], ["EZR", ["TCGA.AD.6888.01", "Axon guidance"], {"weight": 0.911721490263904}], ["EZR", ["TCGA.AD.6888.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.898503532714303}], ["EZR", ["TCGA.AD.6888.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.938305263885816}], ["EZR", ["TCGA.AD.6899.01", "Degradation of the extracellular matrix"], {"weight": 0.863924379196076}], ["EZR", ["TCGA.AD.A5EK.01", "Extracellular matrix organization"], {"weight": 0.864715998795465}], ["EZR", ["TCGA.AD.A5EK.01", "Chemokine receptors bind chemokines"], {"weight": 0.943026917233341}], ["EZR", ["TCGA.AD.A5EK.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.824801306556803}], ["EZR", ["TCGA.AM.5820.01", "Neuronal System"], {"weight": 0.904431013448706}], ["EZR", ["TCGA.AM.5820.01", "Chemokine receptors bind chemokines"], {"weight": 0.929537556210232}], ["EZR", ["TCGA.AM.5820.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.902730510257996}], ["EZR", ["TCGA.AM.5820.01", "Peptide ligand-binding receptors"], {"weight": 0.899891124593463}], ["EZR", ["TCGA.AM.5820.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.896075604174136}], ["EZR", ["TCGA.AM.5820.01", "Transmission across Chemical Synapses"], {"weight": 0.899922070172608}], ["EZR", ["TCGA.AY.4070.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.895426151237555}], ["EZR", ["TCGA.AY.4070.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.891390466822791}], ["EZR", ["TCGA.AY.4070.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.900367561117085}], ["EZR", ["TCGA.AY.4070.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.850515524477417}], ["EZR", ["TCGA.AY.6196.01", "Developmental Biology"], {"weight": 0.832076317922466}], ["EZR", ["TCGA.AY.A8YK.01", "Extracellular matrix organization"], {"weight": 0.845391442903393}], ["EZR", ["TCGA.AY.A8YK.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.853399309510324}], ["EZR", ["TCGA.AY.A8YK.01", "TNFs bind their physiological receptors"], {"weight": 0.687134395681664}], ["EZR", ["TCGA.AY.A8YK.01", "Degradation of the extracellular matrix"], {"weight": 0.770809695845132}], ["EZR", ["TCGA.AZ.4616.01", "Chemokine receptors bind chemokines"], {"weight": 0.936240373416351}], ["EZR", ["TCGA.AZ.4616.01", "Degradation of the extracellular matrix"], {"weight": 0.881097635228685}], ["EZR", ["TCGA.AZ.4616.01", "Other semaphorin interactions"], {"weight": 0.472515615663189}], ["EZR", ["TCGA.AZ.6598.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.935823827345352}], ["EZR", ["TCGA.AZ.6607.01", "Extracellular matrix organization"], {"weight": 0.939507811646863}], ["EZR", ["TCGA.AZ.6607.01", "Integrin cell surface interactions"], {"weight": 0.906360424561565}], ["EZR", ["TCGA.AZ.6608.01", "GPCR downstream signalling"], {"weight": 0.953403405162288}], ["EZR", ["TCGA.AZ.6608.01", "Chemokine receptors bind chemokines"], {"weight": 0.953546652055928}], ["EZR", ["TCGA.AZ.6608.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.845867441359585}], ["EZR", ["TCGA.AZ.6608.01", "Developmental Biology"], {"weight": 0.911951503259391}], ["EZR", ["TCGA.CA.5254.01", "Peptide ligand-binding receptors"], {"weight": 0.924899848583006}], ["EZR", ["TCGA.CA.5254.01", "Degradation of the extracellular matrix"], {"weight": 0.819896930350021}], ["EZR", ["TCGA.CA.5254.01", "Chemokine receptors bind chemokines"], {"weight": 0.931651441308074}], ["EZR", ["TCGA.CA.5255.01", "Chemokine receptors bind chemokines"], {"weight": 0.938604131804982}], ["EZR", ["TCGA.CA.5255.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.752138682964064}], ["EZR", ["TCGA.CA.5256.01", "Nervous system development"], {"weight": 0.906308238754927}], ["EZR", ["TCGA.CA.5256.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.929226337443517}], ["EZR", ["TCGA.CA.5256.01", "L1CAM interactions"], {"weight": 0.890411667381951}], ["EZR", ["TCGA.CK.5915.01", "Chemokine receptors bind chemokines"], {"weight": 0.954341485689647}], ["EZR", ["TCGA.CK.5915.01", "Cell surface interactions at the vascular wall"], {"weight": 0.800388072387587}], ["EZR", ["TCGA.CK.5915.01", "L1CAM interactions"], {"weight": 0.911638114541765}], ["EZR", ["TCGA.CK.5915.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.943575262580435}], ["EZR", ["TCGA.CK.5915.01", "Extracellular matrix organization"], {"weight": 0.900713399576324}], ["EZR", ["TCGA.CM.6167.01", "Peptide ligand-binding receptors"], {"weight": 0.823384834929972}], ["EZR", ["TCGA.CM.6172.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.895813360770832}], ["EZR", ["TCGA.CM.6676.01", "Chemokine receptors bind chemokines"], {"weight": 0.888092704175291}], ["EZR", ["TCGA.CM.6676.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.791708967889305}], ["EZR", ["TCGA.CM.6676.01", "Ligand-dependent caspase activation"], {"weight": 0.73885464093676}], ["EZR", ["TCGA.CM.6678.01", "Extracellular matrix organization"], {"weight": 0.860777532304339}], ["EZR", ["TCGA.CM.6678.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.768741146511485}], ["EZR", ["TCGA.CM.6678.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.905825754491042}], ["EZR", ["TCGA.CM.6678.01", "Peptide ligand-binding receptors"], {"weight": 0.891468647106309}], ["EZR", ["TCGA.CM.6678.01", "Chemokine receptors bind chemokines"], {"weight": 0.889865626263423}], ["EZR", ["TCGA.D5.5537.01", "Chemokine receptors bind chemokines"], {"weight": 0.928874202680094}], ["EZR", ["TCGA.D5.5537.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.920804596211374}], ["EZR", ["TCGA.D5.5537.01", "Peptide ligand-binding receptors"], {"weight": 0.919199483649629}], ["EZR", ["TCGA.D5.5541.01", "Degradation of the extracellular matrix"], {"weight": 0.848167604843531}], ["EZR", ["TCGA.D5.5541.01", "G alpha (s) signalling events"], {"weight": 0.951590992968334}], ["EZR", ["TCGA.D5.5541.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.852703177838828}], ["EZR", ["TCGA.D5.6529.01", "Degradation of the extracellular matrix"], {"weight": 0.88232078649773}], ["EZR", ["TCGA.D5.6529.01", "Signaling by GPCR"], {"weight": 0.928545562441996}], ["EZR", ["TCGA.D5.6535.01", "Degradation of the extracellular matrix"], {"weight": 0.786324374788848}], ["EZR", ["TCGA.D5.6537.01", "Chemokine receptors bind chemokines"], {"weight": 0.938680659696239}], ["EZR", ["TCGA.D5.6537.01", "Peptide ligand-binding receptors"], {"weight": 0.918053820036917}], ["EZR", ["TCGA.D5.6537.01", "Extracellular matrix organization"], {"weight": 0.908341979466504}], ["EZR", ["TCGA.DM.A0X9.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.766428734169547}], ["EZR", ["TCGA.DM.A28F.01", "L1CAM interactions"], {"weight": 0.918843750223659}], ["EZR", ["TCGA.DM.A28K.01", "Transport of small molecules"], {"weight": 0.937455792366795}], ["EZR", ["TCGA.DM.A28K.01", "Chemokine receptors bind chemokines"], {"weight": 0.945591878747105}], ["EZR", ["TCGA.DM.A28K.01", "TNFs bind their physiological receptors"], {"weight": 0.472120856582507}], ["EZR", ["TCGA.F4.6704.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.790063803445866}], ["EZR", ["TCGA.F4.6704.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.887709044986676}], ["EZR", ["TCGA.F4.6704.01", "Sensory processing of sound by outer hair cells of the cochlea"], {"weight": 0.916748299452574}], ["EZR", ["TCGA.G4.6297.01", "Degradation of the extracellular matrix"], {"weight": 0.843544627298867}], ["EZR", ["TCGA.G4.6299.01", "Extracellular matrix organization"], {"weight": 0.869524663503195}], ["EZR", ["TCGA.G4.6299.01", "Signaling by GPCR"], {"weight": 0.92765276612419}], ["EZR", ["TCGA.G4.6299.01", "Phase 0 - rapid depolarisation"], {"weight": 0.820506400624324}], ["EZR", ["TCGA.G4.6299.01", "GPCR downstream signalling"], {"weight": 0.937829995348521}], ["EZR", ["TCGA.G4.6299.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.834200715450666}], ["EZR", ["TCGA.G4.6306.01", "Extracellular matrix organization"], {"weight": 0.934128281302674}], ["EZR", ["TCGA.G4.6306.01", "L1CAM interactions"], {"weight": 0.931133232945945}], ["EZR", ["TCGA.G4.6306.01", "Chemokine receptors bind chemokines"], {"weight": 0.940977982589595}], ["NUP43", ["TCGA.AA.3939.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.890685525534246}], ["NUP43", ["TCGA.CA.5256.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.918353312009105}], ["NUP43", ["TCGA.QL.A97D.01", "Regulation of gene expression in beta cells"], {"weight": 0.86791142691141}], ["PLAGL1", ["TCGA.A6.4107.01", "Phase 0 - rapid depolarisation"], {"weight": 0.865522526212849}], ["PLAGL1", ["TCGA.AA.3666.01", "Phase 0 - rapid depolarisation"], {"weight": 0.848293627131293}], ["PLAGL1", ["TCGA.AA.3685.01", "Neuronal System"], {"weight": 0.857376734031206}], ["PLAGL1", ["TCGA.AA.3685.01", "Transmission across Chemical Synapses"], {"weight": 0.905396696875799}], ["PLAGL1", ["TCGA.AA.3685.01", "Phase 0 - rapid depolarisation"], {"weight": 0.853753074146923}], ["PLAGL1", ["TCGA.AA.3837.01", "Cardiac conduction"], {"weight": 0.810958595224035}], ["PLAGL1", ["TCGA.AA.3854.01", "Interaction between L1 and Ankyrins"], {"weight": 0.925875759025117}], ["PLAGL1", ["TCGA.AA.3860.01", "Interaction between L1 and Ankyrins"], {"weight": 0.862190670221897}], ["PLAGL1", ["TCGA.AA.3875.01", "Interaction between L1 and Ankyrins"], {"weight": 0.72956794097374}], ["PLAGL1", ["TCGA.AA.3939.01", "Phase 0 - rapid depolarisation"], {"weight": 0.820575843957952}], ["PLAGL1", ["TCGA.AA.3952.01", "TP53 Regulates Transcription of Death Receptors and Ligands"], {"weight": 0.830083684400981}], ["PLAGL1", ["TCGA.AD.A5EK.01", "Phase 0 - rapid depolarisation"], {"weight": 0.84959094317555}], ["PLAGL1", ["TCGA.AY.A8YK.01", "Phase 0 - rapid depolarisation"], {"weight": 0.878910470257442}], ["PLAGL1", ["TCGA.CM.6675.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], {"weight": 0.880076194816066}], ["PLAGL1", ["TCGA.D5.6529.01", "Interleukin-6 family signaling"], {"weight": 0.822296495343269}], ["PLAGL1", ["TCGA.D5.6529.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.815404002027355}], ["PLAGL1", ["TCGA.D5.6535.01", "Drug ADME"], {"weight": 0.865029435023471}], ["PLAGL1", ["TCGA.DM.A28F.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.856515998512157}], ["PLAGL1", ["TCGA.G4.6306.01", "Interaction between L1 and Ankyrins"], {"weight": 0.940136528395431}], ["TAGAP", ["TCGA.AA.3841.01", "RHO GTPases activate IQGAPs"], {"weight": 0.855824704852444}], ["TAGAP", ["TCGA.AA.3841.01", "RHO GTPases activate KTN1"], {"weight": 0.836351369079671}], ["TAGAP", ["TCGA.AA.3841.01", "EPHB-mediated forward signaling"], {"weight": 0.855979703012926}], ["SF3B5", ["TCGA.AZ.6608.01", "Drug ADME"], {"weight": 0.901102641806639}], ["SF3B5", ["TCGA.F4.6460.01", "Drug ADME"], {"weight": 0.775418280573904}], ["STX11", ["TCGA.4T.AA8H.01", "Neurotransmitter release cycle"], {"weight": 0.800680539153825}], ["STX11", ["TCGA.4T.AA8H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.62496126957945}], ["STX11", ["TCGA.4T.AA8H.01", "Scavenging by Class A Receptors"], {"weight": 0.528901463434484}], ["STX11", ["TCGA.A6.6652.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.587365554354314}], ["STX11", ["TCGA.A6.6652.01", "Other interleukin signaling"], {"weight": 0.79254201763323}], ["STX11", ["TCGA.AA.3655.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.926559640559708}], ["STX11", ["TCGA.AA.3655.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.689055804835556}], ["STX11", ["TCGA.AA.3655.01", "Neurotransmitter release cycle"], {"weight": 0.81897167371381}], ["STX11", ["TCGA.AA.3837.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.5929935969981}], ["STX11", ["TCGA.AA.3854.01", "Neuronal System"], {"weight": 0.941224623888849}], ["STX11", ["TCGA.AA.3854.01", "Transmission across Chemical Synapses"], {"weight": 0.933143404387155}], ["STX11", ["TCGA.AA.3875.01", "Insulin processing"], {"weight": 0.557013841177287}], ["STX11", ["TCGA.AA.3939.01", "Transmission across Chemical Synapses"], {"weight": 0.909275235044264}], ["STX11", ["TCGA.AA.A029.01", "Insulin processing"], {"weight": 0.835573869818069}], ["STX11", ["TCGA.AA.A02H.01", "Other interleukin signaling"], {"weight": 0.662000808660648}], ["STX11", ["TCGA.AA.A02H.01", "Neurotransmitter release cycle"], {"weight": 0.848971600391461}], ["STX11", ["TCGA.AA.A02H.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.638341624658824}], ["STX11", ["TCGA.AA.A02Y.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.597946418173301}], ["STX11", ["TCGA.AD.6888.01", "Peptide hormone metabolism"], {"weight": 0.872360535789446}], ["STX11", ["TCGA.AD.6888.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.620652791401845}], ["STX11", ["TCGA.AD.6888.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.581887458999781}], ["STX11", ["TCGA.AD.6888.01", "Insulin processing"], {"weight": 0.827628811353903}], ["STX11", ["TCGA.AD.A5EK.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.950150565505083}], ["STX11", ["TCGA.AD.A5EK.01", "Sensory processing of sound"], {"weight": 0.951401298119549}], ["STX11", ["TCGA.AY.A8YK.01", "Transmission across Chemical Synapses"], {"weight": 0.919692997755849}], ["STX11", ["TCGA.AY.A8YK.01", "Neurotransmitter release cycle"], {"weight": 0.796207190844437}], ["STX11", ["TCGA.AY.A8YK.01", "Dopamine Neurotransmitter Release Cycle"], {"weight": 0.90836215520264}], ["STX11", ["TCGA.AZ.4616.01", "Ion homeostasis"], {"weight": 0.889819594216316}], ["STX11", ["TCGA.AZ.4616.01", "Platelet calcium homeostasis"], {"weight": 0.881407064421654}], ["STX11", ["TCGA.AZ.6600.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.83460042086403}], ["STX11", ["TCGA.AZ.6608.01", "Neurotransmitter release cycle"], {"weight": 0.761559159053422}], ["STX11", ["TCGA.CA.5254.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.651896960148394}], ["STX11", ["TCGA.CA.5254.01", "Neurotransmitter release cycle"], {"weight": 0.725782114863114}], ["STX11", ["TCGA.CA.5254.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.917680129252533}], ["STX11", ["TCGA.CA.5254.01", "Dopamine Neurotransmitter Release Cycle"], {"weight": 0.919549802781017}], ["STX11", ["TCGA.CA.5254.01", "Sensory processing of sound"], {"weight": 0.948678366364834}], ["STX11", ["TCGA.CA.5255.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.720132191337221}], ["STX11", ["TCGA.CA.5255.01", "Scavenging by Class A Receptors"], {"weight": 0.511375084686723}], ["STX11", ["TCGA.CA.5256.01", "Peptide hormone metabolism"], {"weight": 0.849804867078928}], ["STX11", ["TCGA.CA.5256.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.907709346501372}], ["STX11", ["TCGA.CA.5256.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.944746761988304}], ["STX11", ["TCGA.CA.5256.01", "Sensory processing of sound"], {"weight": 0.945602734687438}], ["STX11", ["TCGA.CA.5256.01", "Dopamine Neurotransmitter Release Cycle"], {"weight": 0.911142460971088}], ["STX11", ["TCGA.CA.5256.01", "Neurotransmitter release cycle"], {"weight": 0.777466983611406}], ["STX11", ["TCGA.CK.5915.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.573351999341085}], ["STX11", ["TCGA.CM.6675.01", "Regulation of insulin secretion"], {"weight": 0.919432255105304}], ["STX11", ["TCGA.CM.6678.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.780030853434172}], ["STX11", ["TCGA.D5.5537.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.674561637918721}], ["STX11", ["TCGA.D5.5537.01", "Neurotransmitter release cycle"], {"weight": 0.84526464705446}], ["STX11", ["TCGA.D5.6535.01", "Regulation of insulin secretion"], {"weight": 0.885314798285826}], ["STX11", ["TCGA.D5.6537.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.585399930673894}], ["STX11", ["TCGA.D5.6537.01", "Neurotransmitter release cycle"], {"weight": 0.752782003875343}], ["STX11", ["TCGA.D5.6537.01", "Other interleukin signaling"], {"weight": 0.795804106645347}], ["STX11", ["TCGA.DM.A28F.01", "Insulin processing"], {"weight": 0.820725830373542}], ["STX11", ["TCGA.DM.A28F.01", "Neurotransmitter release cycle"], {"weight": 0.701467355559873}], ["STX11", ["TCGA.DM.A28F.01", "Dopamine Neurotransmitter Release Cycle"], {"weight": 0.914857932277922}], ["STX11", ["TCGA.F4.6704.01", "Neurotransmitter release cycle"], {"weight": 0.732706499211294}], ["STX11", ["TCGA.QL.A97D.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.709718644239506}], ["COL12A1", ["TCGA.A6.2686.01", "Degradation of the extracellular matrix"], {"weight": 0.778910125699032}], ["COL12A1", ["TCGA.A6.6649.01", "Collagen formation"], {"weight": 0.917232014234844}], ["COL12A1", ["TCGA.A6.6649.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.910933218305806}], ["COL12A1", ["TCGA.AA.3561.01", "Degradation of the extracellular matrix"], {"weight": 0.87473962397117}], ["COL12A1", ["TCGA.AA.3837.01", "Collagen formation"], {"weight": 0.93291872040154}], ["COL12A1", ["TCGA.AA.3837.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.916510884745145}], ["COL12A1", ["TCGA.AA.3837.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.916019549064051}], ["COL12A1", ["TCGA.AA.3837.01", "Collagen chain trimerization"], {"weight": 0.856681961706898}], ["COL12A1", ["TCGA.AA.3860.01", "Degradation of the extracellular matrix"], {"weight": 0.825221112821081}], ["COL12A1", ["TCGA.AA.3875.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.868497584262895}], ["COL12A1", ["TCGA.AA.3939.01", "Degradation of the extracellular matrix"], {"weight": 0.8260719938982}], ["COL12A1", ["TCGA.AA.3966.01", "Degradation of the extracellular matrix"], {"weight": 0.874543115546501}], ["COL12A1", ["TCGA.AA.3966.01", "Defective B3GALTL causes PpS"], {"weight": 0.859648136691836}], ["COL12A1", ["TCGA.AA.3966.01", "Collagen degradation"], {"weight": 0.94153080474798}], ["COL12A1", ["TCGA.AA.3966.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.859648136691836}], ["COL12A1", ["TCGA.AA.3966.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.940090537212377}], ["COL12A1", ["TCGA.AA.3966.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.623532132383083}], ["COL12A1", ["TCGA.AA.A01D.01", "Degradation of the extracellular matrix"], {"weight": 0.921082867277398}], ["COL12A1", ["TCGA.AA.A01D.01", "Collagen degradation"], {"weight": 0.925821984724954}], ["COL12A1", ["TCGA.AA.A02Y.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.958321440357224}], ["COL12A1", ["TCGA.AZ.6608.01", "NCAM signaling for neurite out-growth"], {"weight": 0.951040066021396}], ["COL12A1", ["TCGA.CA.5254.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.953335737154399}], ["COL12A1", ["TCGA.CA.5254.01", "Collagen formation"], {"weight": 0.944497163049084}], ["COL12A1", ["TCGA.CA.5254.01", "Collagen degradation"], {"weight": 0.892569733589971}], ["COL12A1", ["TCGA.CA.5255.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.940178382370056}], ["COL12A1", ["TCGA.CM.5348.01", "Collagen formation"], {"weight": 0.950507921190087}], ["COL12A1", ["TCGA.CM.5348.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.948510412236737}], ["COL12A1", ["TCGA.CM.6161.01", "NCAM1 interactions"], {"weight": 0.767459144197323}], ["COL12A1", ["TCGA.DM.A0X9.01", "NCAM1 interactions"], {"weight": 0.816854373566397}], ["COL12A1", ["TCGA.F4.6854.01", "Degradation of the extracellular matrix"], {"weight": 0.872326917056669}], ["UTRN", ["TCGA.AA.3556.01", "Interaction between L1 and Ankyrins"], {"weight": 0.89004958812945}], ["UTRN", ["TCGA.AA.3556.01", "Protein-protein interactions at synapses"], {"weight": 0.893067185001859}], ["UTRN", ["TCGA.AA.3556.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.904962959683027}], ["UTRN", ["TCGA.AA.3556.01", "Biological oxidations"], {"weight": 0.887160684628233}], ["UTRN", ["TCGA.AA.3556.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.883091909371746}], ["UTRN", ["TCGA.AA.3556.01", "Drug ADME"], {"weight": 0.776467049796746}], ["UTRN", ["TCGA.AA.3556.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.880941787354124}], ["UTRN", ["TCGA.AA.3556.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.884175738699888}], ["UTRN", ["TCGA.AA.3556.01", "Extracellular matrix organization"], {"weight": 0.845377512699221}], ["UTRN", ["TCGA.AA.3556.01", "Phase II - Conjugation of compounds"], {"weight": 0.797096358782519}], ["UTRN", ["TCGA.AA.3556.01", "Cardiac conduction"], {"weight": 0.901459510547084}], ["UTRN", ["TCGA.AA.3556.01", "Degradation of the extracellular matrix"], {"weight": 0.84576462252894}], ["UTRN", ["TCGA.AA.3556.01", "Glutathione conjugation"], {"weight": 0.793151075650144}], ["UTRN", ["TCGA.AA.3556.01", "Glucagon-type ligand receptors"], {"weight": 0.860120516149292}], ["UTRN", ["TCGA.AA.3556.01", "Presynaptic function of Kainate receptors"], {"weight": 0.82769749446205}], ["UTRN", ["TCGA.AA.3556.01", "Muscle contraction"], {"weight": 0.900694274001783}], ["UTRN", ["TCGA.AA.3556.01", "SLC-mediated transmembrane transport"], {"weight": 0.872896930519018}], ["UTRN", ["TCGA.AA.3556.01", "GABA receptor activation"], {"weight": 0.612178156617563}], ["UTRN", ["TCGA.AA.3556.01", "Activation of G protein gated Potassium channels"], {"weight": 0.854518629709852}], ["UTRN", ["TCGA.AA.3556.01", "G protein gated Potassium channels"], {"weight": 0.854518629709852}], ["UTRN", ["TCGA.AA.3556.01", "Phase 0 - rapid depolarisation"], {"weight": 0.86586757160901}], ["UTRN", ["TCGA.AA.3556.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.854518629709852}], ["UTRN", ["TCGA.AA.3556.01", "Amino acid transport across the plasma membrane"], {"weight": 0.659405273557433}], ["UTRN", ["TCGA.AA.3715.01", "Collagen formation"], {"weight": 0.950756207264867}], ["UTRN", ["TCGA.AA.3854.01", "G beta:gamma signalling through CDC42"], {"weight": 0.920156776502375}], ["UTRN", ["TCGA.AA.3854.01", "G-protein beta:gamma signalling"], {"weight": 0.926297662612137}], ["UTRN", ["TCGA.AA.A01D.01", "Amino acid transport across the plasma membrane"], {"weight": 0.747660439392256}], ["UTRN", ["TCGA.AA.A029.01", "Muscle contraction"], {"weight": 0.938844356609597}], ["UTRN", ["TCGA.AZ.4616.01", "Amino acid transport across the plasma membrane"], {"weight": 0.681286695049852}], ["UTRN", ["TCGA.AZ.6608.01", "G-protein beta:gamma signalling"], {"weight": 0.946717428825542}], ["UTRN", ["TCGA.AZ.6608.01", "G beta:gamma signalling through CDC42"], {"weight": 0.92809268090959}], ["UTRN", ["TCGA.CM.4752.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.876133578955466}], ["UTRN", ["TCGA.CM.4752.01", "Interaction between L1 and Ankyrins"], {"weight": 0.871905978650988}], ["UTRN", ["TCGA.CM.4752.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.817604639203545}], ["UTRN", ["TCGA.CM.4752.01", "GABA receptor activation"], {"weight": 0.874902756842302}], ["UTRN", ["TCGA.CM.4752.01", "G alpha (s) signalling events"], {"weight": 0.925027950132406}], ["UTRN", ["TCGA.CM.4752.01", "Transmission across Chemical Synapses"], {"weight": 0.890786783520621}], ["UTRN", ["TCGA.CM.4752.01", "Signal amplification"], {"weight": 0.827460676272142}], ["UTRN", ["TCGA.CM.4752.01", "Presynaptic function of Kainate receptors"], {"weight": 0.841022179266984}], ["UTRN", ["TCGA.CM.4752.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.847963374312724}], ["UTRN", ["TCGA.CM.4752.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.861034739793349}], ["UTRN", ["TCGA.CM.4752.01", "GPER1 signaling"], {"weight": 0.857730227272411}], ["UTRN", ["TCGA.CM.4752.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.85888995786312}], ["UTRN", ["TCGA.CM.4752.01", "Neuronal System"], {"weight": 0.88807806662591}], ["UTRN", ["TCGA.CM.4752.01", "G beta:gamma signalling through BTK"], {"weight": 0.820861359023932}], ["UTRN", ["TCGA.CM.4752.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.850420882634851}], ["UTRN", ["TCGA.CM.4752.01", "Aquaporin-mediated transport"], {"weight": 0.774481905945092}], ["UTRN", ["TCGA.CM.4752.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.899790985432415}], ["UTRN", ["TCGA.CM.4752.01", "Regulation of insulin secretion"], {"weight": 0.862029723031535}], ["UTRN", ["TCGA.CM.4752.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.820861359023932}], ["UTRN", ["TCGA.CM.4752.01", "Biological oxidations"], {"weight": 0.853919856826463}], ["UTRN", ["TCGA.CM.4752.01", "Integration of energy metabolism"], {"weight": 0.880571262417398}], ["UTRN", ["TCGA.CM.4752.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.820861359023932}], ["UTRN", ["TCGA.CM.4752.01", "G beta:gamma signalling through CDC42"], {"weight": 0.819065701911684}], ["UTRN", ["TCGA.CM.4752.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.836071894004024}], ["UTRN", ["TCGA.CM.4752.01", "Platelet homeostasis"], {"weight": 0.708913499066465}], ["UTRN", ["TCGA.CM.4752.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.854577541208102}], ["UTRN", ["TCGA.CM.4752.01", "Peptide hormone metabolism"], {"weight": 0.599865745902621}], ["UTRN", ["TCGA.CM.4752.01", "L1CAM interactions"], {"weight": 0.883024494764635}], ["UTRN", ["TCGA.CM.4752.01", "G-protein activation"], {"weight": 0.820861359023932}], ["UTRN", ["TCGA.CM.4752.01", "Thromboxane signalling through TP receptor"], {"weight": 0.820861359023932}], ["UTRN", ["TCGA.CM.4752.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.880915743213881}], ["UTRN", ["TCGA.CM.4752.01", "G-protein beta:gamma signalling"], {"weight": 0.848834408511691}], ["UTRN", ["TCGA.CM.4752.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.841022179266984}], ["UTRN", ["TCGA.CM.4752.01", "G alpha (z) signalling events"], {"weight": 0.876133578955466}], ["UTRN", ["TCGA.CM.4752.01", "Glucagon-type ligand receptors"], {"weight": 0.843214760681254}], ["UTRN", ["TCGA.CM.4752.01", "Phase II - Conjugation of compounds"], {"weight": 0.636732171803288}], ["UTRN", ["TCGA.CM.4752.01", "GPCR ligand binding"], {"weight": 0.878404377009706}], ["UTRN", ["TCGA.CM.4752.01", "GABA B receptor activation"], {"weight": 0.848707041604903}], ["UTRN", ["TCGA.CM.4752.01", "Activation of GABAB receptors"], {"weight": 0.848707041604903}], ["UTRN", ["TCGA.G4.6306.01", "Amino acid transport across the plasma membrane"], {"weight": 0.851276808513252}], ["SOD2", ["TCGA.A6.6137.01", "Glutathione conjugation"], {"weight": 0.756575164600034}], ["SOD2", ["TCGA.A6.6137.01", "ABC transporters in lipid homeostasis"], {"weight": 0.239211910402099}], ["SOD2", ["TCGA.AA.3521.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.740413093475743}], ["SOD2", ["TCGA.AA.3655.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.722576805635211}], ["SOD2", ["TCGA.AA.3841.01", "SIRT1 negatively regulates rRNA expression"], {"weight": 0.801566812188047}], ["SOD2", ["TCGA.AA.3841.01", "Arachidonic acid metabolism"], {"weight": 0.902677478586057}], ["SOD2", ["TCGA.AA.3841.01", "Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation"], {"weight": 0.92088682123991}], ["SOD2", ["TCGA.AA.3841.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.709893253391051}], ["SOD2", ["TCGA.AA.3860.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.728273486072364}], ["SOD2", ["TCGA.AA.A01X.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.869865225036728}], ["SOD2", ["TCGA.AA.A01X.01", "IRS-related events triggered by IGF1R"], {"weight": 0.863997610816356}], ["SOD2", ["TCGA.AA.A01X.01", "IGF1R signaling cascade"], {"weight": 0.863914234793566}], ["SOD2", ["TCGA.AA.A01X.01", "IRS-mediated signalling"], {"weight": 0.868383054561992}], ["SOD2", ["TCGA.AA.A02H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.834915835618743}], ["SOD2", ["TCGA.AA.A02Y.01", "Arachidonic acid metabolism"], {"weight": 0.950278035586876}], ["SOD2", ["TCGA.AD.A5EK.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.822642100643503}], ["SOD2", ["TCGA.AZ.4616.01", "Azathioprine ADME"], {"weight": 0.71577627857056}], ["SOD2", ["TCGA.CA.5255.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.716491078663865}], ["SOD2", ["TCGA.CM.6167.01", "Aflatoxin activation and detoxification"], {"weight": 0.553931279238138}], ["SOD2", ["TCGA.CM.6167.01", "Phase I - Functionalization of compounds"], {"weight": 0.775017378705539}], ["SOD2", ["TCGA.CM.6167.01", "APAP ADME"], {"weight": 0.13393722663717}], ["SOD2", ["TCGA.D5.5541.01", "APAP ADME"], {"weight": 0.759501466541859}], ["SOD2", ["TCGA.G4.6299.01", "Ion channel transport"], {"weight": 0.931804382252032}], ["SOD2", ["TCGA.G4.6299.01", "Phase II - Conjugation of compounds"], {"weight": 0.880611909358562}], ["SOD2", ["TCGA.G4.6299.01", "Stimuli-sensing channels"], {"weight": 0.930762899766533}], ["WTAP", ["TCGA.A6.6137.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.781238034619721}], ["WTAP", ["TCGA.A6.6137.01", "Degradation of the extracellular matrix"], {"weight": 0.799251194217984}], ["WTAP", ["TCGA.A6.6137.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.779957960541276}], ["WTAP", ["TCGA.AA.3841.01", "Signaling by FGFR2 IIIa TM"], {"weight": 0.88744216948841}], ["WTAP", ["TCGA.AA.3841.01", "MicroRNA (miRNA) biogenesis"], {"weight": 0.736513187707182}], ["WTAP", ["TCGA.AA.3841.01", "Inhibition of DNA recombination at telomere"], {"weight": 0.735173290506531}], ["WTAP", ["TCGA.AA.3841.01", "PIWI-interacting RNA (piRNA) biogenesis"], {"weight": 0.763934130247418}], ["WTAP", ["TCGA.AA.3841.01", "Signaling by FGFR2 in disease"], {"weight": 0.905589356995702}], ["WTAP", ["TCGA.AA.3841.01", "Telomere Maintenance"], {"weight": 0.864567668979994}], ["WTAP", ["TCGA.AA.3841.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.626500929758559}], ["WTAP", ["TCGA.AA.3841.01", "RNA Pol II CTD phosphorylation and interaction with CE during HIV infection"], {"weight": 0.851177080537497}], ["WTAP", ["TCGA.AA.3841.01", "RNA Pol II CTD phosphorylation and interaction with CE"], {"weight": 0.851177080537497}], ["WTAP", ["TCGA.AY.6196.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.821491132241153}], ["WTAP", ["TCGA.G4.6299.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.837652312999479}], ["GRIK2", ["TCGA.A6.6652.01", "Neuronal System"], {"weight": 0.947433894026554}], ["GRIK2", ["TCGA.A6.6652.01", "Transmission across Chemical Synapses"], {"weight": 0.944599672980806}], ["GRIK2", ["TCGA.A6.6652.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.930714902169777}], ["GRIK2", ["TCGA.AA.3521.01", "Presynaptic function of Kainate receptors"], {"weight": 0.892574120154438}], ["GRIK2", ["TCGA.AA.3660.01", "Presynaptic function of Kainate receptors"], {"weight": 0.865589272752677}], ["GRIK2", ["TCGA.AA.3660.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.884050656439584}], ["GRIK2", ["TCGA.AA.3679.01", "Integration of energy metabolism"], {"weight": 0.905310521651372}], ["GRIK2", ["TCGA.AA.3679.01", "Neuronal System"], {"weight": 0.913093609376108}], ["GRIK2", ["TCGA.AA.3679.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.873146806149338}], ["GRIK2", ["TCGA.AA.3679.01", "Regulation of insulin secretion"], {"weight": 0.894189751454}], ["GRIK2", ["TCGA.AA.3679.01", "Extracellular matrix organization"], {"weight": 0.810738028717222}], ["GRIK2", ["TCGA.AA.3679.01", "Transmission across Chemical Synapses"], {"weight": 0.898425972255346}], ["GRIK2", ["TCGA.AA.3679.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.890059288429515}], ["GRIK2", ["TCGA.AA.3679.01", "Signal amplification"], {"weight": 0.873146806149338}], ["GRIK2", ["TCGA.AA.3679.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.884846257577853}], ["GRIK2", ["TCGA.AA.3679.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.90097456150187}], ["GRIK2", ["TCGA.AA.3679.01", "Thromboxane signalling through TP receptor"], {"weight": 0.85070057299444}], ["GRIK2", ["TCGA.AA.3679.01", "G-protein beta:gamma signalling"], {"weight": 0.879345109613224}], ["GRIK2", ["TCGA.AA.3679.01", "G beta:gamma signalling through CDC42"], {"weight": 0.862412750575969}], ["GRIK2", ["TCGA.AA.3679.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.871213634016334}], ["GRIK2", ["TCGA.AA.3679.01", "Glucagon-type ligand receptors"], {"weight": 0.874346814564575}], ["GRIK2", ["TCGA.AA.3679.01", "Presynaptic function of Kainate receptors"], {"weight": 0.910874054812568}], ["GRIK2", ["TCGA.AA.3679.01", "GABA receptor activation"], {"weight": 0.654937367913529}], ["GRIK2", ["TCGA.AA.3679.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.770588060585262}], ["GRIK2", ["TCGA.AA.3715.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.907330379955525}], ["GRIK2", ["TCGA.AA.3841.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.849164787571863}], ["GRIK2", ["TCGA.AA.3858.01", "Presynaptic function of Kainate receptors"], {"weight": 0.896516045151008}], ["GRIK2", ["TCGA.AA.3860.01", "Presynaptic function of Kainate receptors"], {"weight": 0.900960186094061}], ["GRIK2", ["TCGA.AA.3875.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.717087663700154}], ["GRIK2", ["TCGA.AA.3939.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.795267125555591}], ["GRIK2", ["TCGA.AA.A00A.01", "Neuronal System"], {"weight": 0.894665713263981}], ["GRIK2", ["TCGA.AA.A00A.01", "Phase 0 - rapid depolarisation"], {"weight": 0.918976958565911}], ["GRIK2", ["TCGA.AA.A00A.01", "Transmission across Chemical Synapses"], {"weight": 0.925012773378828}], ["GRIK2", ["TCGA.AA.A00A.01", "Cardiac conduction"], {"weight": 0.925180432797624}], ["GRIK2", ["TCGA.AA.A00A.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.915706411164248}], ["GRIK2", ["TCGA.AA.A00A.01", "Muscle contraction"], {"weight": 0.926265400628255}], ["GRIK2", ["TCGA.AA.A00A.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.837205632376258}], ["GRIK2", ["TCGA.AA.A00A.01", "Presynaptic function of Kainate receptors"], {"weight": 0.906705703180925}], ["GRIK2", ["TCGA.AA.A00A.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.874396318969537}], ["GRIK2", ["TCGA.AA.A00A.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.872210575383046}], ["GRIK2", ["TCGA.AA.A01X.01", "Transmission across Chemical Synapses"], {"weight": 0.888558133762784}], ["GRIK2", ["TCGA.AA.A02H.01", "Presynaptic function of Kainate receptors"], {"weight": 0.880960768898607}], ["GRIK2", ["TCGA.AA.A02Y.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.885195767157174}], ["GRIK2", ["TCGA.AA.A02Y.01", "Presynaptic function of Kainate receptors"], {"weight": 0.93428916473578}], ["GRIK2", ["TCGA.AD.6888.01", "Presynaptic function of Kainate receptors"], {"weight": 0.929338056374851}], ["GRIK2", ["TCGA.AZ.6598.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.875495059609921}], ["GRIK2", ["TCGA.AZ.6608.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.894631842316529}], ["GRIK2", ["TCGA.CA.5255.01", "Presynaptic function of Kainate receptors"], {"weight": 0.913130420826504}], ["GRIK2", ["TCGA.CA.5256.01", "Transmission across Chemical Synapses"], {"weight": 0.93639899448165}], ["GRIK2", ["TCGA.CA.5256.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.929538241041773}], ["GRIK2", ["TCGA.CA.5256.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.849601181562021}], ["GRIK2", ["TCGA.CM.5860.01", "Transmission across Chemical Synapses"], {"weight": 0.92444092623696}], ["GRIK2", ["TCGA.CM.5860.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.827072158417065}], ["GRIK2", ["TCGA.CM.5868.01", "Phase 0 - rapid depolarisation"], {"weight": 0.882728960706613}], ["GRIK2", ["TCGA.CM.5868.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.910491731471491}], ["GRIK2", ["TCGA.CM.5868.01", "Presynaptic function of Kainate receptors"], {"weight": 0.903831279300402}], ["GRIK2", ["TCGA.CM.5868.01", "Trafficking of AMPA receptors"], {"weight": 0.88385518854848}], ["GRIK2", ["TCGA.CM.5868.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.88385518854848}], ["GRIK2", ["TCGA.CM.5868.01", "LGI-ADAM interactions"], {"weight": 0.642350441993361}], ["GRIK2", ["TCGA.CM.6172.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.797985955205533}], ["GRIK2", ["TCGA.CM.6675.01", "Neuronal System"], {"weight": 0.950649479220634}], ["GRIK2", ["TCGA.CM.6675.01", "Transmission across Chemical Synapses"], {"weight": 0.940159796768976}], ["GRIK2", ["TCGA.CM.6675.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.925229349700227}], ["GRIK2", ["TCGA.CM.6676.01", "Presynaptic function of Kainate receptors"], {"weight": 0.87704908034904}], ["GRIK2", ["TCGA.D5.6537.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.865746837124107}], ["GRIK2", ["TCGA.D5.6931.01", "Neuronal System"], {"weight": 0.794744968262981}], ["GRIK2", ["TCGA.D5.6931.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.881678655533639}], ["GRIK2", ["TCGA.D5.6931.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.765847391910599}], ["GRIK2", ["TCGA.D5.6932.01", "Neuronal System"], {"weight": 0.93080784924724}], ["GRIK2", ["TCGA.D5.6932.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.907866036156248}], ["GRIK2", ["TCGA.D5.6932.01", "Transmission across Chemical Synapses"], {"weight": 0.925614644352477}], ["GRIK2", ["TCGA.D5.6932.01", "Extracellular matrix organization"], {"weight": 0.845495689535099}], ["GRIK2", ["TCGA.D5.6932.01", "GPCR ligand binding"], {"weight": 0.913769877242941}], ["GRIK2", ["TCGA.D5.6932.01", "SLC-mediated transmembrane transport"], {"weight": 0.900745558693089}], ["GRIK2", ["TCGA.D5.6932.01", "Interaction between L1 and Ankyrins"], {"weight": 0.829548711541427}], ["GRIK2", ["TCGA.D5.6932.01", "Voltage gated Potassium channels"], {"weight": 0.867291704619804}], ["GRIK2", ["TCGA.D5.6932.01", "Potassium Channels"], {"weight": 0.86539540801052}], ["GRIK2", ["TCGA.D5.6932.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.908571378654999}], ["GRIK2", ["TCGA.D5.6932.01", "Peptide hormone metabolism"], {"weight": 0.742391146440249}], ["GRIK2", ["TCGA.D5.6932.01", "Regulation of insulin secretion"], {"weight": 0.883095502530855}], ["GRIK2", ["TCGA.D5.6932.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.846907710150267}], ["GRIK2", ["TCGA.D5.6932.01", "Integration of energy metabolism"], {"weight": 0.893060630795979}], ["GRIK2", ["TCGA.D5.6932.01", "Phase 0 - rapid depolarisation"], {"weight": 0.716510286349767}], ["GRIK2", ["TCGA.F4.6854.01", "Neuronal System"], {"weight": 0.907916826904495}], ["GRIK2", ["TCGA.F4.6856.01", "Neuronal System"], {"weight": 0.946833124531435}], ["GRIK2", ["TCGA.G4.6306.01", "Presynaptic function of Kainate receptors"], {"weight": 0.914393833763105}], ["GRIK2", ["TCGA.G4.6306.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.87253749402764}], ["GRIK2", ["TCGA.G4.6626.01", "Signaling by GPCR"], {"weight": 0.946548969512777}], ["GRIK2", ["TCGA.G4.6626.01", "GPCR downstream signalling"], {"weight": 0.952974989274118}], ["GRIK2", ["TCGA.G4.6626.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.768125307898436}], ["GRIK2", ["TCGA.G4.6626.01", "GPCR ligand binding"], {"weight": 0.925743041321212}], ["GRIK2", ["TCGA.G4.6626.01", "G alpha (i) signalling events"], {"weight": 0.951354026172499}], ["GRIK2", ["TCGA.G4.6626.01", "Signaling Pathways"], {"weight": 0.917941128633252}], ["GRIK2", ["TCGA.G4.6626.01", "Potassium Channels"], {"weight": 0.957119826189659}], ["GRIK2", ["TCGA.G4.6626.01", "G alpha (q) signalling events"], {"weight": 0.93027063337434}], ["GRIK2", ["TCGA.G4.6626.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.924895794901111}], ["GRIK2", ["TCGA.G4.6626.01", "Leishmania parasite growth and survival"], {"weight": 0.924895794901111}], ["GRIK2", ["TCGA.G4.6626.01", "Glucagon-type ligand receptors"], {"weight": 0.931696721922864}], ["GRIK2", ["TCGA.G4.6626.01", "Extracellular matrix organization"], {"weight": 0.892775482460549}], ["GRIK2", ["TCGA.G4.6626.01", "Platelet homeostasis"], {"weight": 0.881783509602424}], ["GRIK2", ["TCGA.G4.6626.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.916546590487065}], ["GRIK2", ["TCGA.G4.6626.01", "GABA B receptor activation"], {"weight": 0.926114812052818}], ["GRIK2", ["TCGA.G4.6626.01", "Activation of GABAB receptors"], {"weight": 0.926114812052818}], ["GRIK2", ["TCGA.G4.6626.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.917848433339407}], ["GRIK2", ["TCGA.G4.6626.01", "GABA receptor activation"], {"weight": 0.904580146721128}], ["GRIK2", ["TCGA.G4.6626.01", "G alpha (s) signalling events"], {"weight": 0.957687295142078}], ["GRIK2", ["TCGA.G4.6626.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.905198719459942}], ["GRIK2", ["TCGA.G4.6626.01", "G-protein beta:gamma signalling"], {"weight": 0.917597395312821}], ["GRIK2", ["TCGA.G4.6626.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.90847334127072}], ["GRIK2", ["TCGA.G4.6626.01", "Inwardly rectifying K+ channels"], {"weight": 0.920373036001196}], ["GRIK2", ["TCGA.G4.6626.01", "G beta:gamma signalling through BTK"], {"weight": 0.891934823049745}], ["GRIK2", ["TCGA.G4.6626.01", "Integration of energy metabolism"], {"weight": 0.927913360923752}], ["GRIK2", ["TCGA.G4.6626.01", "Activation of G protein gated Potassium channels"], {"weight": 0.912859683002898}], ["GRIK2", ["TCGA.G4.6626.01", "G protein gated Potassium channels"], {"weight": 0.912859683002898}], ["GRIK2", ["TCGA.G4.6626.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.912859683002898}], ["GRIK2", ["TCGA.G4.6626.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.900070072260766}], ["GRIK2", ["TCGA.G4.6626.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.771358597642742}], ["GRIK2", ["TCGA.G4.6626.01", "Regulation of insulin secretion"], {"weight": 0.916211545534146}], ["GRIK2", ["TCGA.G4.6626.01", "G beta:gamma signalling through CDC42"], {"weight": 0.890603562847143}], ["GRIK2", ["TCGA.G4.6626.01", "G alpha (z) signalling events"], {"weight": 0.918517050828641}], ["GRIK2", ["TCGA.G4.6626.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.899878636487646}], ["GRIK2", ["TCGA.G4.6626.01", "Signal amplification"], {"weight": 0.91170585497279}], ["GRIK2", ["TCGA.G4.6626.01", "Aquaporin-mediated transport"], {"weight": 0.814916661823306}], ["GRIK2", ["TCGA.G4.6626.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.834637538588202}], ["GRIK2", ["TCGA.G4.6626.01", "Transport of small molecules"], {"weight": 0.933965189046234}], ["GRIK2", ["TCGA.G4.6626.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.919764617309523}], ["GRIK2", ["TCGA.G4.6626.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.884297958334057}], ["GRIK2", ["TCGA.G4.6626.01", "GPER1 signaling"], {"weight": 0.913865382779464}], ["GRIK2", ["TCGA.G4.6626.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.913865382779464}], ["GRIK2", ["TCGA.G4.6626.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.881493966795972}], ["GRIK2", ["TCGA.G4.6626.01", "Leishmania infection"], {"weight": 0.900156802534197}], ["GRIK2", ["TCGA.G4.6626.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.881171463968173}], ["GRIK2", ["TCGA.G4.6626.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.818543365012836}], ["GRIK2", ["TCGA.G4.6626.01", "G-protein activation"], {"weight": 0.88987564995947}], ["GRIK2", ["TCGA.G4.6626.01", "Thromboxane signalling through TP receptor"], {"weight": 0.88987564995947}], ["GRIK2", ["TCGA.G4.6626.01", "Interaction between L1 and Ankyrins"], {"weight": 0.891060482817586}], ["GRIK2", ["TCGA.G4.6626.01", "Presynaptic function of Kainate receptors"], {"weight": 0.879569105027637}], ["GRIK2", ["TCGA.G4.6626.01", "Protein-protein interactions at synapses"], {"weight": 0.899102034820025}], ["GRIK2", ["TCGA.G4.6626.01", "Voltage gated Potassium channels"], {"weight": 0.904324693451419}], ["GRIK2", ["TCGA.G4.6626.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.905416675272769}], ["GRIK2", ["TCGA.G4.6626.01", "Generation of second messenger molecules"], {"weight": 0.787920150308024}], ["GRIK2", ["TCGA.G4.6626.01", "G-protein mediated events"], {"weight": 0.888861622082094}], ["GRIK2", ["TCGA.G4.6626.01", "Neurexins and neuroligins"], {"weight": 0.936863687101161}], ["GRIK2", ["TCGA.G4.6626.01", "Caspase-mediated cleavage of cytoskeletal proteins"], {"weight": 0.66296716187248}], ["GRIK2", ["TCGA.G4.6626.01", "Ca2+ pathway"], {"weight": 0.856177962154663}], ["ACAT2", ["TCGA.4T.AA8H.01", "Biological oxidations"], {"weight": 0.894511733688419}], ["ACAT2", ["TCGA.5M.AATA.01", "Drug ADME"], {"weight": 0.905203456306917}], ["ACAT2", ["TCGA.A6.2678.01", "Biological oxidations"], {"weight": 0.889161733745186}], ["ACAT2", ["TCGA.A6.2678.01", "Drug ADME"], {"weight": 0.777714530231767}], ["ACAT2", ["TCGA.A6.6652.01", "Drug ADME"], {"weight": 0.924199530347356}], ["ACAT2", ["TCGA.AA.3655.01", "Drug ADME"], {"weight": 0.853294058288923}], ["ACAT2", ["TCGA.AA.3660.01", "Biological oxidations"], {"weight": 0.881767647004035}], ["ACAT2", ["TCGA.AA.3685.01", "Drug ADME"], {"weight": 0.76700540753827}], ["ACAT2", ["TCGA.AA.3837.01", "Biological oxidations"], {"weight": 0.829206896407669}], ["ACAT2", ["TCGA.AA.3854.01", "Drug ADME"], {"weight": 0.837394093937255}], ["ACAT2", ["TCGA.AA.3854.01", "Biological oxidations"], {"weight": 0.896829814617148}], ["ACAT2", ["TCGA.AY.6196.01", "Biological oxidations"], {"weight": 0.936854744527193}], ["ACAT2", ["TCGA.AY.6196.01", "Drug ADME"], {"weight": 0.892036035940009}], ["ACAT2", ["TCGA.AY.6196.01", "Phase I - Functionalization of compounds"], {"weight": 0.914164330097235}], ["ACAT2", ["TCGA.AY.A8YK.01", "Biological oxidations"], {"weight": 0.873583800488789}], ["ACAT2", ["TCGA.AZ.4616.01", "Drug ADME"], {"weight": 0.884400733936382}], ["ACAT2", ["TCGA.AZ.4616.01", "Biological oxidations"], {"weight": 0.924529935078869}], ["ACAT2", ["TCGA.AZ.6606.01", "Biological oxidations"], {"weight": 0.901075758187069}], ["ACAT2", ["TCGA.CA.5254.01", "Biological oxidations"], {"weight": 0.92739971586121}], ["ACAT2", ["TCGA.CA.5255.01", "Biological oxidations"], {"weight": 0.878202595172256}], ["ACAT2", ["TCGA.CA.5255.01", "Drug ADME"], {"weight": 0.844775781812517}], ["ACAT2", ["TCGA.CK.5915.01", "Drug ADME"], {"weight": 0.895465863480139}], ["ACAT2", ["TCGA.CM.6161.01", "Drug ADME"], {"weight": 0.869183024885536}], ["ACAT2", ["TCGA.D5.5541.01", "RA biosynthesis pathway"], {"weight": 0.864903947301411}], ["ACAT2", ["TCGA.D5.5541.01", "Phase I - Functionalization of compounds"], {"weight": 0.93802366620066}], ["ACAT2", ["TCGA.D5.5541.01", "Ethanol oxidation"], {"weight": 0.855148501539513}], ["ACAT2", ["TCGA.D5.5541.01", "Signaling by Retinoic Acid"], {"weight": 0.789938310577835}], ["ACAT2", ["TCGA.D5.6537.01", "Drug ADME"], {"weight": 0.903785694390937}], ["ACAT2", ["TCGA.D5.6898.01", "Biological oxidations"], {"weight": 0.848618702635646}], ["ACAT2", ["TCGA.DM.A0X9.01", "Drug ADME"], {"weight": 0.896721963905471}], ["ACAT2", ["TCGA.DM.A0X9.01", "Biological oxidations"], {"weight": 0.914024171351106}], ["ACAT2", ["TCGA.DM.A28F.01", "Biological oxidations"], {"weight": 0.927096516477147}], ["ACAT2", ["TCGA.DM.A28K.01", "Drug ADME"], {"weight": 0.891121826218808}], ["ACAT2", ["TCGA.DM.A28K.01", "Integration of energy metabolism"], {"weight": 0.920603555951811}], ["ACAT2", ["TCGA.G4.6297.01", "Biological oxidations"], {"weight": 0.909833718853666}], ["ACAT2", ["TCGA.G4.6299.01", "Biological oxidations"], {"weight": 0.94699051098931}], ["ACAT2", ["TCGA.G4.6299.01", "Phase I - Functionalization of compounds"], {"weight": 0.963944961002194}], ["ACAT2", ["TCGA.G4.6299.01", "RA biosynthesis pathway"], {"weight": 0.896187913584716}], ["ACAT2", ["TCGA.G4.6299.01", "Ethanol oxidation"], {"weight": 0.94430377909208}], ["ACAT2", ["TCGA.QL.A97D.01", "Biological oxidations"], {"weight": 0.891328550554336}], ["TCP1", ["TCGA.5M.AATA.01", "Signaling by GPCR"], {"weight": 0.920398880322416}], ["TCP1", ["TCGA.5M.AATA.01", "GPCR downstream signalling"], {"weight": 0.929167519548599}], ["TCP1", ["TCGA.5M.AATA.01", "G alpha (i) signalling events"], {"weight": 0.941946800241462}], ["TCP1", ["TCGA.A6.6137.01", "Neuronal System"], {"weight": 0.845585684845648}], ["TCP1", ["TCGA.A6.6137.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.839763794965361}], ["TCP1", ["TCGA.A6.6137.01", "GPCR ligand binding"], {"weight": 0.876952109686787}], ["TCP1", ["TCGA.A6.6137.01", "Interaction between L1 and Ankyrins"], {"weight": 0.874201121311568}], ["TCP1", ["TCGA.A6.6137.01", "Transmission across Chemical Synapses"], {"weight": 0.842157456644234}], ["TCP1", ["TCGA.A6.6137.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.821201564636075}], ["TCP1", ["TCGA.A6.6137.01", "Signaling by GPCR"], {"weight": 0.867656410143182}], ["TCP1", ["TCGA.A6.6137.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.857556469513614}], ["TCP1", ["TCGA.A6.6137.01", "G alpha (i) signalling events"], {"weight": 0.866664359944858}], ["TCP1", ["TCGA.A6.6137.01", "GPCR downstream signalling"], {"weight": 0.877988845605241}], ["TCP1", ["TCGA.A6.6137.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.850770136913009}], ["TCP1", ["TCGA.A6.6137.01", "Glucagon-type ligand receptors"], {"weight": 0.885228544119013}], ["TCP1", ["TCGA.A6.6137.01", "Interleukin-6 family signaling"], {"weight": 0.821201564636075}], ["TCP1", ["TCGA.A6.6137.01", "Peptide ligand-binding receptors"], {"weight": 0.851428384952241}], ["TCP1", ["TCGA.A6.6137.01", "Complement cascade"], {"weight": 0.615838301824845}], ["TCP1", ["TCGA.A6.6137.01", "Neurexins and neuroligins"], {"weight": 0.759281400803117}], ["TCP1", ["TCGA.A6.6137.01", "L1CAM interactions"], {"weight": 0.810387816399919}], ["TCP1", ["TCGA.A6.6137.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.851428384952241}], ["TCP1", ["TCGA.A6.6652.01", "GPCR ligand binding"], {"weight": 0.92724107516756}], ["TCP1", ["TCGA.AA.3655.01", "G alpha (i) signalling events"], {"weight": 0.93488300798177}], ["TCP1", ["TCGA.AA.3655.01", "Signaling by GPCR"], {"weight": 0.927177828807503}], ["TCP1", ["TCGA.AA.3655.01", "GPCR downstream signalling"], {"weight": 0.939664603134749}], ["TCP1", ["TCGA.AA.3660.01", "Regulation of insulin secretion"], {"weight": 0.827757786077071}], ["TCP1", ["TCGA.AA.3685.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.932596819307868}], ["TCP1", ["TCGA.AA.3685.01", "Regulation of insulin secretion"], {"weight": 0.880104811741547}], ["TCP1", ["TCGA.AA.3837.01", "Regulation of insulin secretion"], {"weight": 0.723876542319545}], ["TCP1", ["TCGA.AA.3837.01", "Phase 0 - rapid depolarisation"], {"weight": 0.621466341235617}], ["TCP1", ["TCGA.AA.3841.01", "Protein folding"], {"weight": 0.937781576589109}], ["TCP1", ["TCGA.AA.3841.01", "Chaperonin-mediated protein folding"], {"weight": 0.936955072815712}], ["TCP1", ["TCGA.AA.3844.01", "G alpha (i) signalling events"], {"weight": 0.94814626169599}], ["TCP1", ["TCGA.AA.3844.01", "GPCR ligand binding"], {"weight": 0.889738960944398}], ["TCP1", ["TCGA.AA.3854.01", "Peptide hormone metabolism"], {"weight": 0.725500622675395}], ["TCP1", ["TCGA.AA.3875.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], {"weight": 0.832297254854957}], ["TCP1", ["TCGA.AA.A00J.01", "GPCR ligand binding"], {"weight": 0.919818432174327}], ["TCP1", ["TCGA.AA.A00J.01", "Peptide ligand-binding receptors"], {"weight": 0.900651174176952}], ["TCP1", ["TCGA.AA.A00J.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.900651174176952}], ["TCP1", ["TCGA.AA.A029.01", "Signaling by GPCR"], {"weight": 0.932328619961096}], ["TCP1", ["TCGA.AA.A029.01", "GPCR downstream signalling"], {"weight": 0.942053282675257}], ["TCP1", ["TCGA.AA.A029.01", "G alpha (i) signalling events"], {"weight": 0.939064993949828}], ["TCP1", ["TCGA.AA.A02Y.01", "Signaling by GPCR"], {"weight": 0.950497311284756}], ["TCP1", ["TCGA.AA.A02Y.01", "GPCR downstream signalling"], {"weight": 0.945263323627919}], ["TCP1", ["TCGA.AD.6888.01", "Signaling by GPCR"], {"weight": 0.948392219362646}], ["TCP1", ["TCGA.AD.6888.01", "GPCR downstream signalling"], {"weight": 0.958354554097262}], ["TCP1", ["TCGA.AD.6888.01", "G alpha (i) signalling events"], {"weight": 0.946252491851797}], ["TCP1", ["TCGA.AM.5820.01", "Signaling by GPCR"], {"weight": 0.942428571099962}], ["TCP1", ["TCGA.AM.5820.01", "GPCR ligand binding"], {"weight": 0.904567360259237}], ["TCP1", ["TCGA.AM.5820.01", "GPCR downstream signalling"], {"weight": 0.955147817935548}], ["TCP1", ["TCGA.AM.5820.01", "G alpha (i) signalling events"], {"weight": 0.950079860219765}], ["TCP1", ["TCGA.AY.4070.01", "GPCR ligand binding"], {"weight": 0.884708726637819}], ["TCP1", ["TCGA.AY.6196.01", "GPCR ligand binding"], {"weight": 0.913494181021702}], ["TCP1", ["TCGA.AY.A8YK.01", "Regulation of insulin secretion"], {"weight": 0.859232175289409}], ["TCP1", ["TCGA.AZ.4616.01", "Potassium Channels"], {"weight": 0.945409619439014}], ["TCP1", ["TCGA.AZ.6598.01", "GPCR ligand binding"], {"weight": 0.928814541259879}], ["TCP1", ["TCGA.AZ.6608.01", "G alpha (q) signalling events"], {"weight": 0.947460822856884}], ["TCP1", ["TCGA.AZ.6608.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.915965852391678}], ["TCP1", ["TCGA.AZ.6608.01", "Signal amplification"], {"weight": 0.922885529977886}], ["TCP1", ["TCGA.AZ.6608.01", "Glucagon-type ligand receptors"], {"weight": 0.951565175076062}], ["TCP1", ["TCGA.AZ.6608.01", "G beta:gamma signalling through BTK"], {"weight": 0.929406586255266}], ["TCP1", ["TCGA.AZ.6608.01", "Thromboxane signalling through TP receptor"], {"weight": 0.905518995734463}], ["TCP1", ["TCGA.AZ.6608.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], {"weight": 0.924751927195393}], ["TCP1", ["TCGA.AZ.6608.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.919940016894844}], ["TCP1", ["TCGA.AZ.6608.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.919940016894844}], ["TCP1", ["TCGA.AZ.6608.01", "Presynaptic function of Kainate receptors"], {"weight": 0.919940016894844}], ["TCP1", ["TCGA.AZ.6608.01", "Adaptive Immune System"], {"weight": 0.893487305820609}], ["TCP1", ["TCGA.AZ.6608.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.905518995734463}], ["TCP1", ["TCGA.CA.5254.01", "Signaling by GPCR"], {"weight": 0.948374460182776}], ["TCP1", ["TCGA.CA.5254.01", "GPCR downstream signalling"], {"weight": 0.95308808846372}], ["TCP1", ["TCGA.CA.5254.01", "G alpha (i) signalling events"], {"weight": 0.957906059220688}], ["TCP1", ["TCGA.CA.5255.01", "Signaling by GPCR"], {"weight": 0.938556829938977}], ["TCP1", ["TCGA.CA.5255.01", "GPCR downstream signalling"], {"weight": 0.944287802910579}], ["TCP1", ["TCGA.CA.5255.01", "G alpha (i) signalling events"], {"weight": 0.944537792518527}], ["TCP1", ["TCGA.CA.5256.01", "Signaling by GPCR"], {"weight": 0.91838193742685}], ["TCP1", ["TCGA.CA.5256.01", "GPCR downstream signalling"], {"weight": 0.927629510347937}], ["TCP1", ["TCGA.CM.5348.01", "Signaling by GPCR"], {"weight": 0.903273112687643}], ["TCP1", ["TCGA.CM.6161.01", "Transport of small molecules"], {"weight": 0.896735308596044}], ["TCP1", ["TCGA.CM.6161.01", "GPCR ligand binding"], {"weight": 0.896727611975623}], ["TCP1", ["TCGA.CM.6172.01", "Signaling by GPCR"], {"weight": 0.931093598935299}], ["TCP1", ["TCGA.CM.6172.01", "GPCR downstream signalling"], {"weight": 0.942507565966223}], ["TCP1", ["TCGA.CM.6172.01", "G alpha (i) signalling events"], {"weight": 0.939061730877571}], ["TCP1", ["TCGA.CM.6675.01", "Signaling by GPCR"], {"weight": 0.946110886861568}], ["TCP1", ["TCGA.CM.6675.01", "GPCR downstream signalling"], {"weight": 0.952792889332244}], ["TCP1", ["TCGA.CM.6675.01", "G alpha (i) signalling events"], {"weight": 0.963048802368002}], ["TCP1", ["TCGA.CM.6678.01", "GPCR downstream signalling"], {"weight": 0.941524443292126}], ["TCP1", ["TCGA.CM.6678.01", "Signaling by GPCR"], {"weight": 0.92985219133259}], ["TCP1", ["TCGA.CM.6678.01", "G alpha (i) signalling events"], {"weight": 0.955799779863428}], ["TCP1", ["TCGA.D5.5541.01", "GPCR ligand binding"], {"weight": 0.905208833059023}], ["TCP1", ["TCGA.D5.5541.01", "Platelet homeostasis"], {"weight": 0.831112186402043}], ["TCP1", ["TCGA.D5.5541.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.890410669334821}], ["TCP1", ["TCGA.D5.5541.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.846302996820809}], ["TCP1", ["TCGA.D5.5541.01", "Signal amplification"], {"weight": 0.860279982756391}], ["TCP1", ["TCGA.D5.5541.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.910419172210111}], ["TCP1", ["TCGA.D5.6529.01", "G alpha (i) signalling events"], {"weight": 0.936265467517667}], ["TCP1", ["TCGA.D5.6529.01", "GPCR downstream signalling"], {"weight": 0.931308438004723}], ["TCP1", ["TCGA.D5.6531.01", "G alpha (i) signalling events"], {"weight": 0.945996250527428}], ["TCP1", ["TCGA.D5.6898.01", "G alpha (i) signalling events"], {"weight": 0.944278387957599}], ["TCP1", ["TCGA.DM.A0X9.01", "Potassium Channels"], {"weight": 0.954110444383055}], ["TCP1", ["TCGA.DM.A0X9.01", "Signaling by GPCR"], {"weight": 0.934642004203833}], ["TCP1", ["TCGA.DM.A0X9.01", "G alpha (i) signalling events"], {"weight": 0.94752714434672}], ["TCP1", ["TCGA.DM.A0X9.01", "GPCR downstream signalling"], {"weight": 0.941000641628963}], ["TCP1", ["TCGA.DM.A0X9.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.898187143690952}], ["TCP1", ["TCGA.DM.A0X9.01", "Glucagon-type ligand receptors"], {"weight": 0.924703896056016}], ["TCP1", ["TCGA.DM.A28K.01", "Signaling by GPCR"], {"weight": 0.947117793907176}], ["TCP1", ["TCGA.DM.A28K.01", "GPCR downstream signalling"], {"weight": 0.957963919064713}], ["TCP1", ["TCGA.DM.A28K.01", "G alpha (i) signalling events"], {"weight": 0.949586663679002}], ["TCP1", ["TCGA.DM.A28K.01", "Glucagon-type ligand receptors"], {"weight": 0.934936969976178}], ["TCP1", ["TCGA.G4.6299.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.896386905135133}], ["TCP1", ["TCGA.G4.6299.01", "Peptide hormone metabolism"], {"weight": 0.842060218392143}], ["TCP1", ["TCGA.G4.6299.01", "O-linked glycosylation"], {"weight": 0.911858542872881}], ["TCP1", ["TCGA.G4.6299.01", "Signal amplification"], {"weight": 0.903626945558434}], ["TCP1", ["TCGA.G4.6299.01", "O-linked glycosylation of mucins"], {"weight": 0.927274772758935}], ["TCP1", ["TCGA.G4.6299.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], {"weight": 0.908324997349895}], ["TCP1", ["TCGA.G4.6299.01", "Glucagon-type ligand receptors"], {"weight": 0.92947225181952}], ["TCP1", ["TCGA.G4.6299.01", "Inwardly rectifying K+ channels"], {"weight": 0.921952387066659}], ["TCP1", ["TCGA.G4.6299.01", "Thromboxane signalling through TP receptor"], {"weight": 0.875261977240511}], ["TCP1", ["TCGA.G4.6299.01", "Potassium Channels"], {"weight": 0.955342520972489}], ["TCP1", ["TCGA.NH.A6GA.01", "GPCR ligand binding"], {"weight": 0.889712612233366}], ["MYB", ["TCGA.4T.AA8H.01", "Complement cascade"], {"weight": 0.885481706426961}], ["MYB", ["TCGA.4T.AA8H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.904627177650282}], ["MYB", ["TCGA.4T.AA8H.01", "Arachidonic acid metabolism"], {"weight": 0.944507115566852}], ["MYB", ["TCGA.5M.AATA.01", "Signaling by Retinoic Acid"], {"weight": 0.831606322568886}], ["MYB", ["TCGA.A6.2678.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.817823972137059}], ["MYB", ["TCGA.A6.4107.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.826084897749809}], ["MYB", ["TCGA.AA.3521.01", "Extra-nuclear estrogen signaling"], {"weight": 0.899041986877383}], ["MYB", ["TCGA.AA.3655.01", "Signaling by Retinoic Acid"], {"weight": 0.866444707796151}], ["MYB", ["TCGA.AA.3655.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.736609377511467}], ["MYB", ["TCGA.AA.3660.01", "Signaling by Retinoic Acid"], {"weight": 0.804289123286944}], ["MYB", ["TCGA.AA.3837.01", "Ribavirin ADME"], {"weight": 0.453096582001832}], ["MYB", ["TCGA.AA.3841.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.92176581378745}], ["MYB", ["TCGA.AA.3841.01", "Developmental Biology"], {"weight": 0.855989473335986}], ["MYB", ["TCGA.AA.3858.01", "Signaling by Retinoic Acid"], {"weight": 0.741424499864769}], ["MYB", ["TCGA.AA.3860.01", "Signaling by Retinoic Acid"], {"weight": 0.742220069247317}], ["MYB", ["TCGA.AA.3875.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.528000175802762}], ["MYB", ["TCGA.AA.3952.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.738358780589676}], ["MYB", ["TCGA.AA.3952.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.644008382696118}], ["MYB", ["TCGA.AA.3952.01", "Signaling by Retinoic Acid"], {"weight": 0.637293460836421}], ["MYB", ["TCGA.AA.3952.01", "Other interleukin signaling"], {"weight": 0.660326020078629}], ["MYB", ["TCGA.AA.A01X.01", "Signaling by Retinoic Acid"], {"weight": 0.671548490531946}], ["MYB", ["TCGA.AA.A02H.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.78189880788951}], ["MYB", ["TCGA.AA.A02H.01", "Transcriptional Regulation by VENTX"], {"weight": 0.668470065102086}], ["MYB", ["TCGA.AA.A02Y.01", "Collagen formation"], {"weight": 0.955894560185581}], ["MYB", ["TCGA.AA.A02Y.01", "Regulation of Complement cascade"], {"weight": 0.879912032932071}], ["MYB", ["TCGA.AD.6888.01", "Signaling by Interleukins"], {"weight": 0.898214898155685}], ["MYB", ["TCGA.AD.6888.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.826752753776246}], ["MYB", ["TCGA.AD.6888.01", "Inflammasomes"], {"weight": 0.743371408870523}], ["MYB", ["TCGA.AD.6899.01", "Signaling by Retinoic Acid"], {"weight": 0.598688532106806}], ["MYB", ["TCGA.AD.A5EK.01", "Signaling by Retinoic Acid"], {"weight": 0.912217400639842}], ["MYB", ["TCGA.AM.5820.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.779379099478854}], ["MYB", ["TCGA.AY.A8YK.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.798362463202182}], ["MYB", ["TCGA.AY.A8YK.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.675694484217095}], ["MYB", ["TCGA.AY.A8YK.01", "Complement cascade"], {"weight": 0.811012354870012}], ["MYB", ["TCGA.AY.A8YK.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.75423298254441}], ["MYB", ["TCGA.AZ.6600.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.840937840735069}], ["MYB", ["TCGA.AZ.6600.01", "Drug ADME"], {"weight": 0.773970946446383}], ["MYB", ["TCGA.AZ.6606.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.765074707867313}], ["MYB", ["TCGA.AZ.6606.01", "Keratinization"], {"weight": 0.918776851562315}], ["MYB", ["TCGA.AZ.6606.01", "Complement cascade"], {"weight": 0.789822810963369}], ["MYB", ["TCGA.AZ.6607.01", "Collagen chain trimerization"], {"weight": 0.941632653320486}], ["MYB", ["TCGA.AZ.6607.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.745574505409965}], ["MYB", ["TCGA.CA.5254.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.846721467036949}], ["MYB", ["TCGA.CA.5254.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.816434169843386}], ["MYB", ["TCGA.CA.5255.01", "Innate Immune System"], {"weight": 0.89597957012661}], ["MYB", ["TCGA.CA.5256.01", "Developmental Biology"], {"weight": 0.901406142501728}], ["MYB", ["TCGA.CK.5915.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.879037917937983}], ["MYB", ["TCGA.CK.5915.01", "Developmental Biology"], {"weight": 0.90140977809656}], ["MYB", ["TCGA.CM.6161.01", "Signaling by Retinoic Acid"], {"weight": 0.76888128493883}], ["MYB", ["TCGA.CM.6167.01", "Keratinization"], {"weight": 0.814881660071716}], ["MYB", ["TCGA.CM.6167.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.901570074837307}], ["MYB", ["TCGA.CM.6172.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.750418268306194}], ["MYB", ["TCGA.CM.6172.01", "Signaling by Retinoic Acid"], {"weight": 0.777529691151603}], ["MYB", ["TCGA.CM.6172.01", "Complement cascade"], {"weight": 0.768694040611277}], ["MYB", ["TCGA.CM.6172.01", "Regulation of Complement cascade"], {"weight": 0.753241937267692}], ["MYB", ["TCGA.CM.6675.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.856187503721033}], ["MYB", ["TCGA.CM.6676.01", "Signaling by Retinoic Acid"], {"weight": 0.834610287363636}], ["MYB", ["TCGA.D5.5537.01", "Signaling by Retinoic Acid"], {"weight": 0.787782025336424}], ["MYB", ["TCGA.D5.5537.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.76090019754856}], ["MYB", ["TCGA.D5.6529.01", "Signaling by Retinoic Acid"], {"weight": 0.765881024858729}], ["MYB", ["TCGA.D5.6531.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.84010089523925}], ["MYB", ["TCGA.D5.6531.01", "Signaling by Retinoic Acid"], {"weight": 0.816203144411856}], ["MYB", ["TCGA.D5.6537.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.813051719092732}], ["MYB", ["TCGA.D5.6898.01", "Signaling by Retinoic Acid"], {"weight": 0.737943420063002}], ["MYB", ["TCGA.DM.A28F.01", "Complement cascade"], {"weight": 0.897554892475576}], ["MYB", ["TCGA.F4.6459.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.80030820441722}], ["MYB", ["TCGA.F4.6460.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.71281707660945}], ["MYB", ["TCGA.G4.6297.01", "Signaling by Retinoic Acid"], {"weight": 0.79219562140962}], ["MYB", ["TCGA.G4.6306.01", "Complement cascade"], {"weight": 0.923375323902606}], ["MYB", ["TCGA.G4.6306.01", "Regulation of Complement cascade"], {"weight": 0.917455301903055}], ["MYB", ["TCGA.QL.A97D.01", "Signaling by Retinoic Acid"], {"weight": 0.86599607763124}], ["MYB", ["TCGA.QL.A97D.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.813272143318959}], ["MRPL18", ["TCGA.A6.6137.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.621511218490537}], ["IGF2R", ["TCGA.AA.3875.01", "Transmission across Chemical Synapses"], {"weight": 0.76959983652704}], ["IGF2R", ["TCGA.AA.3875.01", "Caspase-mediated cleavage of cytoskeletal proteins"], {"weight": -0.039510386197897}], ["IGF2R", ["TCGA.CA.5256.01", "GABA receptor activation"], {"weight": 0.891653042544583}], ["IGF2R", ["TCGA.CM.6161.01", "Neuronal System"], {"weight": 0.901527635469897}], ["IGF2R", ["TCGA.CM.6161.01", "Transmission across Chemical Synapses"], {"weight": 0.883116024183361}], ["IGF2R", ["TCGA.D5.6529.01", "GABA receptor activation"], {"weight": 0.843858707892679}], ["IGF2R", ["TCGA.G4.6299.01", "Protein-protein interactions at synapses"], {"weight": 0.893083986790454}], ["IGF2R", ["TCGA.G4.6306.01", "GABA receptor activation"], {"weight": 0.89751233368925}], ["SYNE1", ["TCGA.4T.AA8H.01", "Initial triggering of complement"], {"weight": 0.858927417653315}], ["SYNE1", ["TCGA.A6.6652.01", "Regulation of Complement cascade"], {"weight": 0.825452726779297}], ["SYNE1", ["TCGA.AA.3875.01", "Meiosis"], {"weight": 0.74994940089251}], ["SYNE1", ["TCGA.AA.3875.01", "Reproduction"], {"weight": 0.640416264881879}], ["SYNE1", ["TCGA.AA.A029.01", "Complement cascade"], {"weight": 0.946206330634304}], ["SYNE1", ["TCGA.AA.A029.01", "Initial triggering of complement"], {"weight": 0.827739781195712}], ["SYNE1", ["TCGA.AA.A02H.01", "Attenuation phase"], {"weight": 0.620926529922473}], ["SYNE1", ["TCGA.AD.A5EK.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.939532503677489}], ["SYNE1", ["TCGA.AD.A5EK.01", "Initial triggering of complement"], {"weight": 0.835756576984728}], ["SYNE1", ["TCGA.AD.A5EK.01", "Peptide ligand-binding receptors"], {"weight": 0.929750121702213}], ["SYNE1", ["TCGA.AY.A8YK.01", "Regulation of Complement cascade"], {"weight": 0.555620452304119}], ["SYNE1", ["TCGA.AZ.6608.01", "Initial triggering of complement"], {"weight": 0.940758354431947}], ["SYNE1", ["TCGA.AZ.6608.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.788211514680953}], ["SYNE1", ["TCGA.AZ.6608.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.788211514680953}], ["SYNE1", ["TCGA.CK.5915.01", "GPCR ligand binding"], {"weight": 0.952643118608897}], ["SYNE1", ["TCGA.CK.5915.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.955698082168339}], ["SYNE1", ["TCGA.CK.5915.01", "Peptide ligand-binding receptors"], {"weight": 0.954491445121535}], ["SYNE1", ["TCGA.CK.5915.01", "Initial triggering of complement"], {"weight": 0.873348869098343}], ["SYNE1", ["TCGA.CK.5915.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.793430067543267}], ["SYNE1", ["TCGA.CK.5915.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.793430067543267}], ["SYNE1", ["TCGA.CM.6675.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.94823264406577}], ["SYNE1", ["TCGA.CM.6675.01", "Peptide ligand-binding receptors"], {"weight": 0.947293882344667}], ["SYNE1", ["TCGA.CM.6676.01", "Complement cascade"], {"weight": 0.771398503303574}], ["SYNE1", ["TCGA.D5.5537.01", "Complement cascade"], {"weight": 0.836604685792506}], ["SYNE1", ["TCGA.D5.5537.01", "Regulation of Complement cascade"], {"weight": 0.779298171490998}], ["SYNE1", ["TCGA.D5.6535.01", "Attenuation phase"], {"weight": 0.829742064135015}], ["SYNE1", ["TCGA.D5.6537.01", "Initial triggering of complement"], {"weight": 0.918313301083172}], ["SYNE1", ["TCGA.DM.A28K.01", "GPCR ligand binding"], {"weight": 0.927036383264173}], ["SYNE1", ["TCGA.DM.A28K.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.932914081872107}], ["SYNE1", ["TCGA.DM.A28K.01", "Peptide ligand-binding receptors"], {"weight": 0.931474492080125}], ["SYNE1", ["TCGA.DM.A28K.01", "Initial triggering of complement"], {"weight": 0.851179834095057}], ["SYNE1", ["TCGA.DM.A28K.01", "Leishmania infection"], {"weight": 0.903387615943714}], ["SYNE1", ["TCGA.G4.6306.01", "Initial triggering of complement"], {"weight": 0.916445249666455}], ["SYNE1", ["TCGA.G4.6306.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.941353552588053}], ["SYNE1", ["TCGA.G4.6306.01", "Peptide ligand-binding receptors"], {"weight": 0.939509853489551}], ["SYNE1", ["TCGA.WS.AB45.01", "Extracellular matrix organization"], {"weight": 0.935592644623247}], ["SYNE1", ["TCGA.WS.AB45.01", "Signaling by GPCR"], {"weight": 0.920709074777526}], ["SYNE1", ["TCGA.WS.AB45.01", "Integrin cell surface interactions"], {"weight": 0.88945730641543}], ["SYNE1", ["TCGA.WS.AB45.01", "GPCR downstream signalling"], {"weight": 0.927170436827179}], ["SYNE1", ["TCGA.WS.AB45.01", "Degradation of the extracellular matrix"], {"weight": 0.893395471228729}], ["SYNE1", ["TCGA.WS.AB45.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.894278350516462}], ["SYNE1", ["TCGA.WS.AB45.01", "Signaling Pathways"], {"weight": 0.900007017550232}], ["SYNE1", ["TCGA.WS.AB45.01", "ECM proteoglycans"], {"weight": 0.899971695211404}], ["SYNE1", ["TCGA.WS.AB45.01", "Adherens junctions interactions"], {"weight": 0.800763499495651}], ["SYNE1", ["TCGA.WS.AB45.01", "Phase I - Functionalization of compounds"], {"weight": 0.949467578249497}], ["SYNE1", ["TCGA.WS.AB45.01", "Diseases of metabolism"], {"weight": 0.829305719357032}], ["SYNE1", ["TCGA.WS.AB45.01", "NCAM1 interactions"], {"weight": 0.832984696001837}], ["SYNE1", ["TCGA.WS.AB45.01", "Fatty acid metabolism"], {"weight": 0.871619733521019}], ["SYNE1", ["TCGA.WS.AB45.01", "Cell-cell junction organization"], {"weight": 0.800763499495651}], ["SYNE1", ["TCGA.WS.AB45.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.876101387586684}], ["SYNE1", ["TCGA.WS.AB45.01", "Signaling by PDGF"], {"weight": 0.882104089511247}], ["SYNE1", ["TCGA.WS.AB45.01", "Cell junction organization"], {"weight": 0.837171285633431}], ["SYNE1", ["TCGA.WS.AB45.01", "RHO GTPases Activate NADPH Oxidases"], {"weight": 0.885722902465102}], ["SYNE1", ["TCGA.WS.AB45.01", "NCAM signaling for neurite out-growth"], {"weight": 0.776122430791074}], ["SYNE1", ["TCGA.WS.AB45.01", "G alpha (s) signalling events"], {"weight": 0.930713161871063}], ["SYNE1", ["TCGA.WS.AB45.01", "Synthesis of bile acids and bile salts"], {"weight": 0.745008808685199}], ["SYNE1", ["TCGA.WS.AB45.01", "Bile acid and bile salt metabolism"], {"weight": 0.762280939274591}], ["SYNE1", ["TCGA.WS.AB45.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.697340867488428}], ["SYNE1", ["TCGA.WS.AB45.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.677753238046078}], ["SYNE1", ["TCGA.WS.AB45.01", "Neurotransmitter release cycle"], {"weight": 0.617344559131575}], ["SYNE1", ["TCGA.WS.AB45.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.763212985761313}], ["LIN28B", ["TCGA.AA.3560.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.856864653821654}], ["LIN28B", ["TCGA.AA.3561.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.862745739173758}], ["LIN28B", ["TCGA.AA.3848.01", "Signaling by Nuclear Receptors"], {"weight": 0.884140436598958}], ["LIN28B", ["TCGA.AA.3848.01", "ESR-mediated signaling"], {"weight": 0.887113778133703}], ["LIN28B", ["TCGA.AA.3848.01", "Estrogen-dependent gene expression"], {"weight": 0.852699788630489}], ["LIN28B", ["TCGA.AA.3848.01", "Signaling by NOTCH1"], {"weight": 0.935912085218163}], ["LIN28B", ["TCGA.AA.A00A.01", "Collagen formation"], {"weight": 0.915470099972524}], ["LIN28B", ["TCGA.AA.A00A.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.8994761405752}], ["LIN28B", ["TCGA.AA.A00A.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.881957024262321}], ["LIN28B", ["TCGA.CM.5860.01", "Collagen formation"], {"weight": 0.940048452068975}], ["LIN28B", ["TCGA.CM.5860.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.928629643367644}], ["LIN28B", ["TCGA.CM.5860.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.926575683587495}], ["LIN28B", ["TCGA.CM.5860.01", "Collagen chain trimerization"], {"weight": 0.900107392763923}], ["LIN28B", ["TCGA.CM.5860.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.626587318370014}], ["LIN28B", ["TCGA.CM.5868.01", "SUMOylation of intracellular receptors"], {"weight": 0.570809886943037}], ["LIN28B", ["TCGA.F4.6460.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.741034889420353}], ["LPA", ["TCGA.4T.AA8H.01", "Transport of small molecules"], {"weight": 0.915636599056452}], ["LPA", ["TCGA.4T.AA8H.01", "Integrin cell surface interactions"], {"weight": 0.941912290183987}], ["LPA", ["TCGA.A6.6652.01", "Visual phototransduction"], {"weight": 0.904590515199225}], ["LPA", ["TCGA.A6.6652.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.881270475956313}], ["LPA", ["TCGA.A6.6652.01", "Retinoid metabolism and transport"], {"weight": 0.881270475956313}], ["LPA", ["TCGA.A6.6652.01", "Platelet homeostasis"], {"weight": 0.918188503547726}], ["LPA", ["TCGA.A6.6652.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.840680545206682}], ["LPA", ["TCGA.AA.3655.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.751795031141539}], ["LPA", ["TCGA.AA.3685.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.74765474299702}], ["LPA", ["TCGA.AA.3842.01", "NCAM1 interactions"], {"weight": 0.85285541952659}], ["LPA", ["TCGA.AA.3842.01", "Neuronal System"], {"weight": 0.873880837745068}], ["LPA", ["TCGA.AA.3842.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.859168277683933}], ["LPA", ["TCGA.AA.3842.01", "Extracellular matrix organization"], {"weight": 0.820310883628264}], ["LPA", ["TCGA.AA.3842.01", "Transmission across Chemical Synapses"], {"weight": 0.866418425142204}], ["LPA", ["TCGA.AA.3842.01", "CD22 mediated BCR regulation"], {"weight": 0.632423057493185}], ["LPA", ["TCGA.AA.3842.01", "GPCR ligand binding"], {"weight": 0.931199774805878}], ["LPA", ["TCGA.AA.3842.01", "NCAM signaling for neurite out-growth"], {"weight": 0.859062017487366}], ["LPA", ["TCGA.AA.3842.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.87483029074031}], ["LPA", ["TCGA.AA.3842.01", "Peptide ligand-binding receptors"], {"weight": 0.921855326729442}], ["LPA", ["TCGA.AA.3842.01", "Transport of small molecules"], {"weight": 0.903086149357753}], ["LPA", ["TCGA.AA.3842.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.923597960523006}], ["LPA", ["TCGA.AA.3842.01", "Peptide hormone metabolism"], {"weight": 0.686648120650062}], ["LPA", ["TCGA.AA.3842.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.7353699802237}], ["LPA", ["TCGA.AA.3842.01", "Collagen formation"], {"weight": 0.900926706618133}], ["LPA", ["TCGA.AA.3842.01", "L1CAM interactions"], {"weight": 0.81385209133578}], ["LPA", ["TCGA.AA.3842.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.601148659614338}], ["LPA", ["TCGA.AA.3854.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.574223557835727}], ["LPA", ["TCGA.AA.A02H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.731785107394023}], ["LPA", ["TCGA.AA.A02H.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.539827320200685}], ["LPA", ["TCGA.AA.A02Y.01", "Platelet homeostasis"], {"weight": 0.952770315670468}], ["LPA", ["TCGA.AA.A02Y.01", "Integrin cell surface interactions"], {"weight": 0.920493045115191}], ["LPA", ["TCGA.AA.A02Y.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.923640585000654}], ["LPA", ["TCGA.AA.A02Y.01", "Retinoid metabolism and transport"], {"weight": 0.923640585000654}], ["LPA", ["TCGA.AA.A02Y.01", "Cell surface interactions at the vascular wall"], {"weight": 0.871185787215537}], ["LPA", ["TCGA.AA.A02Y.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.88780666638678}], ["LPA", ["TCGA.AA.A02Y.01", "Visual phototransduction"], {"weight": 0.887705195987055}], ["LPA", ["TCGA.AD.A5EK.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.703137593930441}], ["LPA", ["TCGA.AD.A5EK.01", "Integrin cell surface interactions"], {"weight": 0.932265007488558}], ["LPA", ["TCGA.AY.6196.01", "Transport of small molecules"], {"weight": 0.914596893512795}], ["LPA", ["TCGA.AY.6196.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.6056734442021}], ["LPA", ["TCGA.AZ.4616.01", "G alpha (i) signalling events"], {"weight": 0.946721866560085}], ["LPA", ["TCGA.AZ.4616.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.56055499767875}], ["LPA", ["TCGA.AZ.6607.01", "Defective B3GALTL causes PpS"], {"weight": 0.885772272211704}], ["LPA", ["TCGA.AZ.6607.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.885772272211704}], ["LPA", ["TCGA.AZ.6608.01", "Regulation of insulin secretion"], {"weight": 0.923251181653283}], ["LPA", ["TCGA.AZ.6608.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.715956220920438}], ["LPA", ["TCGA.AZ.6608.01", "Integrin cell surface interactions"], {"weight": 0.952146290551519}], ["LPA", ["TCGA.CA.5255.01", "Integrin cell surface interactions"], {"weight": 0.923607569358923}], ["LPA", ["TCGA.CA.5256.01", "Regulation of insulin secretion"], {"weight": 0.914972756662253}], ["LPA", ["TCGA.CK.5915.01", "Platelet homeostasis"], {"weight": 0.917344075659968}], ["LPA", ["TCGA.CM.6161.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.772461907683878}], ["LPA", ["TCGA.CM.6172.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.593109501553429}], ["LPA", ["TCGA.CM.6676.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.582572441944349}], ["LPA", ["TCGA.D5.5541.01", "Scavenging of heme from plasma"], {"weight": 0.480936892730078}], ["LPA", ["TCGA.D5.6529.01", "Defective B3GALTL causes PpS"], {"weight": 0.784433879384483}], ["LPA", ["TCGA.D5.6529.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.779738020785498}], ["LPA", ["TCGA.DM.A28F.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.914694623682408}], ["LPA", ["TCGA.DM.A28K.01", "Scavenging of heme from plasma"], {"weight": 0.613372176725934}], ["LPA", ["TCGA.G4.6297.01", "Defective B3GALTL causes PpS"], {"weight": 0.831758286610808}], ["LPA", ["TCGA.G4.6297.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.831758286610808}], ["LPA", ["TCGA.G4.6299.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.779005893493262}], ["LPA", ["TCGA.G4.6306.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.721957050592422}], ["LPA", ["TCGA.G4.6306.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.745285278064624}], ["LPA", ["TCGA.G4.6306.01", "Integrin cell surface interactions"], {"weight": 0.940630316493129}], ["LPA", ["TCGA.T9.A92H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.780186484200851}], ["LPA", ["TCGA.T9.A92H.01", "Neuronal System"], {"weight": 0.957176421565455}], ["LPA", ["TCGA.T9.A92H.01", "Transmission across Chemical Synapses"], {"weight": 0.947862807795211}], ["LPA", ["TCGA.T9.A92H.01", "Signaling by GPCR"], {"weight": 0.949888680353596}], ["LPA", ["TCGA.T9.A92H.01", "G alpha (i) signalling events"], {"weight": 0.952648142935692}], ["LPA", ["TCGA.T9.A92H.01", "GPCR downstream signalling"], {"weight": 0.955062295502067}], ["LPA", ["TCGA.T9.A92H.01", "Complement cascade"], {"weight": 0.921025398247588}], ["LPA", ["TCGA.T9.A92H.01", "Platelet homeostasis"], {"weight": 0.889963567567392}], ["LPA", ["TCGA.T9.A92H.01", "GPCR ligand binding"], {"weight": 0.908666495726965}], ["LPA", ["TCGA.T9.A92H.01", "Initial triggering of complement"], {"weight": 0.838266268288032}], ["LPA", ["TCGA.T9.A92H.01", "Signaling Pathways"], {"weight": 0.907436714932344}], ["LPA", ["TCGA.T9.A92H.01", "Protein-protein interactions at synapses"], {"weight": 0.948392215720957}], ["LPA", ["TCGA.T9.A92H.01", "Regulation of Complement cascade"], {"weight": 0.886503999598888}], ["LPA", ["TCGA.T9.A92H.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.762855188424827}], ["LPA", ["TCGA.T9.A92H.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.903926701224857}], ["LPA", ["TCGA.T9.A92H.01", "Peptide ligand-binding receptors"], {"weight": 0.899761748733528}], ["LPA", ["TCGA.T9.A92H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.888616338103285}], ["LPA", ["TCGA.T9.A92H.01", "Leishmania parasite growth and survival"], {"weight": 0.888616338103285}], ["LPA", ["TCGA.T9.A92H.01", "Neurotransmitter release cycle"], {"weight": 0.781292729620745}], ["LPA", ["TCGA.T9.A92H.01", "Leishmania infection"], {"weight": 0.88424941111897}], ["LPA", ["TCGA.T9.A92H.01", "Transport of small molecules"], {"weight": 0.924097537619976}], ["LPA", ["TCGA.T9.A92H.01", "Muscle contraction"], {"weight": 0.923290524280678}], ["LPA", ["TCGA.T9.A92H.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.585700271189748}], ["LPA", ["TCGA.T9.A92H.01", "Immune System"], {"weight": 0.860455776220657}], ["LPA", ["TCGA.T9.A92H.01", "G alpha (s) signalling events"], {"weight": 0.953767247559012}], ["LPA", ["TCGA.T9.A92H.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.925273117097861}], ["LPA", ["TCGA.T9.A92H.01", "Retinoid metabolism and transport"], {"weight": 0.925273117097861}], ["LPA", ["TCGA.T9.A92H.01", "Regulation of insulin secretion"], {"weight": 0.91568076942296}], ["LPA", ["TCGA.T9.A92H.01", "Extracellular matrix organization"], {"weight": 0.848749960287418}], ["LPA", ["TCGA.T9.A92H.01", "Biological oxidations"], {"weight": 0.896258110279278}], ["LPA", ["TCGA.T9.A92H.01", "Ion channel transport"], {"weight": 0.89908222320529}], ["LPA", ["TCGA.T9.A92H.01", "G-protein beta:gamma signalling"], {"weight": 0.907512092485886}], ["LPA", ["TCGA.T9.A92H.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.84398626212764}], ["LPA", ["TCGA.T9.A92H.01", "G alpha (q) signalling events"], {"weight": 0.932279444806232}], ["LPA", ["TCGA.T9.A92H.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.887602970961728}], ["LPA", ["TCGA.T9.A92H.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.894300606161769}], ["LPA", ["TCGA.T9.A92H.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.878294321947794}], ["LPA", ["TCGA.T9.A92H.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.733228587143208}], ["LPA", ["TCGA.T9.A92H.01", "Generation of second messenger molecules"], {"weight": 0.867133706809104}], ["LPA", ["TCGA.T9.A92H.01", "Dopamine Neurotransmitter Release Cycle"], {"weight": 0.886749370684262}], ["LPA", ["TCGA.T9.A92H.01", "Signal amplification"], {"weight": 0.818781413473837}], ["LPA", ["TCGA.T9.A92H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.867128039327097}], ["LPA", ["TCGA.T9.A92H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.846771191476578}], ["LPA", ["TCGA.T9.A92H.01", "Molecules associated with elastic fibres"], {"weight": -0.0352937605867941}], ["LPA", ["TCGA.T9.A92H.01", "Scavenging of heme from plasma"], {"weight": 0.790217201558174}], ["LPA", ["TCGA.T9.A92H.01", "Scavenging by Class A Receptors"], {"weight": 0.451592416272685}], ["LPA", ["TCGA.T9.A92H.01", "CD22 mediated BCR regulation"], {"weight": 0.652184947840931}], ["LPA", ["TCGA.T9.A92H.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.785863063275972}], ["LPA", ["TCGA.T9.A92H.01", "Drug ADME"], {"weight": 0.834155311267253}], ["LPA", ["TCGA.T9.A92H.01", "DAP12 signaling"], {"weight": 0.812283391167421}], ["LPA", ["TCGA.T9.A92H.01", "Neurexins and neuroligins"], {"weight": 0.930728978401207}], ["LPA", ["TCGA.T9.A92H.01", "Integration of energy metabolism"], {"weight": 0.90500284232154}], ["LPA", ["TCGA.T9.A92H.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.84302360725221}], ["LPA", ["TCGA.T9.A92H.01", "Phase I - Functionalization of compounds"], {"weight": 0.920508850134165}], ["LPA", ["TCGA.T9.A92H.01", "FCGR activation"], {"weight": 0.797547004546397}], ["LPA", ["TCGA.T9.A92H.01", "Aquaporin-mediated transport"], {"weight": 0.780969919970624}], ["LPA", ["TCGA.T9.A92H.01", "PD-1 signaling"], {"weight": 0.835481308403127}], ["LPA", ["TCGA.T9.A92H.01", "Ca2+ pathway"], {"weight": 0.810003579421178}], ["LPA", ["TCGA.T9.A92H.01", "Norepinephrine Neurotransmitter Release Cycle"], {"weight": 0.701691452637421}], ["LPA", ["TCGA.T9.A92H.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.818862636032046}], ["LPA", ["TCGA.T9.A92H.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.819504263008176}], ["LPA", ["TCGA.T9.A92H.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.810097564024858}], ["LPA", ["TCGA.T9.A92H.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.707963192145695}], ["LPA", ["TCGA.T9.A92H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.865709394075984}], ["LPA", ["TCGA.T9.A92H.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.863529070368787}], ["LPA", ["TCGA.T9.A92H.01", "DAP12 interactions"], {"weight": 0.827257561698032}], ["LPA", ["TCGA.T9.A92H.01", "FCGR3A-mediated IL10 synthesis"], {"weight": 0.866183852808403}], ["LPA", ["TCGA.T9.A92H.01", "Visual phototransduction"], {"weight": 0.909702478863317}], ["LPA", ["TCGA.T9.A92H.01", "Peptide hormone metabolism"], {"weight": 0.76267470493389}], ["LPA", ["TCGA.T9.A92H.01", "GABA synthesis, release, reuptake and degradation"], {"weight": 0.848410319842375}], ["LPA", ["TCGA.T9.A92H.01", "Elastic fibre formation"], {"weight": -0.0317658217566327}], ["LPA", ["TCGA.T9.A92H.01", "Innate Immune System"], {"weight": 0.889372265608931}], ["LPA", ["TCGA.T9.A92H.01", "Glycosaminoglycan metabolism"], {"weight": 0.929272205766657}], ["COX7A2", ["TCGA.A6.6652.01", "Arachidonic acid metabolism"], {"weight": 0.908459322425929}], ["COX7A2", ["TCGA.A6.6652.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.855413607439561}], ["COX7A2", ["TCGA.AA.A02Y.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.875206183549937}], ["COX7A2", ["TCGA.AD.A5EK.01", "Arachidonic acid metabolism"], {"weight": 0.9187332158103}], ["COX7A2", ["TCGA.AY.A8YK.01", "Arachidonic acid metabolism"], {"weight": 0.84278595551136}], ["COX7A2", ["TCGA.AZ.6598.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.863479475236157}], ["COX7A2", ["TCGA.AZ.6598.01", "Arachidonic acid metabolism"], {"weight": 0.8360902708964}], ["COX7A2", ["TCGA.AZ.6606.01", "Arachidonic acid metabolism"], {"weight": 0.880019553306721}], ["COX7A2", ["TCGA.AZ.6608.01", "Arachidonic acid metabolism"], {"weight": 0.942152231356197}], ["COX7A2", ["TCGA.CA.5255.01", "Arachidonic acid metabolism"], {"weight": 0.825314898288191}], ["COX7A2", ["TCGA.CK.5915.01", "Arachidonic acid metabolism"], {"weight": 0.923232076592174}], ["COX7A2", ["TCGA.CK.5915.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.887457541947223}], ["COX7A2", ["TCGA.DM.A0X9.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.851683412087539}], ["COX7A2", ["TCGA.DM.A28F.01", "Arachidonic acid metabolism"], {"weight": 0.920070699076951}], ["COX7A2", ["TCGA.F4.6856.01", "Biological oxidations"], {"weight": 0.855199848852063}], ["COX7A2", ["TCGA.QL.A97D.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.832752521768054}], ["COX7A2", ["TCGA.QL.A97D.01", "Arachidonic acid metabolism"], {"weight": 0.845869129046583}], ["PLG", ["TCGA.4T.AA8H.01", "Regulation of Complement cascade"], {"weight": 0.906289891778653}], ["PLG", ["TCGA.4T.AA8H.01", "Classical antibody-mediated complement activation"], {"weight": 0.833725738913049}], ["PLG", ["TCGA.4T.AA8H.01", "Creation of C4 and C2 activators"], {"weight": 0.791822111432071}], ["PLG", ["TCGA.A6.4107.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.826626055082388}], ["PLG", ["TCGA.A6.4107.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.773334384863445}], ["PLG", ["TCGA.A6.6649.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.903374176903422}], ["PLG", ["TCGA.A6.6652.01", "Signaling by GPCR"], {"weight": 0.948141265693625}], ["PLG", ["TCGA.A6.6652.01", "GPCR downstream signalling"], {"weight": 0.954890995207064}], ["PLG", ["TCGA.A6.6652.01", "G alpha (q) signalling events"], {"weight": 0.949836253658376}], ["PLG", ["TCGA.A6.6652.01", "Initial triggering of complement"], {"weight": 0.806934866192869}], ["PLG", ["TCGA.A6.6652.01", "Classical antibody-mediated complement activation"], {"weight": 0.766889190881483}], ["PLG", ["TCGA.AA.3655.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.897684336094792}], ["PLG", ["TCGA.AA.3655.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.732726108584073}], ["PLG", ["TCGA.AA.3685.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.924323793228275}], ["PLG", ["TCGA.AA.3685.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.813282895654386}], ["PLG", ["TCGA.AA.3715.01", "O-linked glycosylation"], {"weight": 0.925640967322227}], ["PLG", ["TCGA.AA.3715.01", "Post-translational protein phosphorylation"], {"weight": 0.843045916344603}], ["PLG", ["TCGA.AA.3837.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.861680768790511}], ["PLG", ["TCGA.AA.3837.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.728155321970291}], ["PLG", ["TCGA.AA.3837.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.765129411233895}], ["PLG", ["TCGA.AA.3837.01", "Regulation of signaling by NODAL"], {"weight": 0.852827068753228}], ["PLG", ["TCGA.AA.3837.01", "Heme degradation"], {"weight": 0.466354840404884}], ["PLG", ["TCGA.AA.3837.01", "Degradation of the extracellular matrix"], {"weight": 0.807738346896399}], ["PLG", ["TCGA.AA.3841.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.907822559623656}], ["PLG", ["TCGA.AA.3841.01", "Regulation of signaling by NODAL"], {"weight": 0.83506164016924}], ["PLG", ["TCGA.AA.3854.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.950199482133853}], ["PLG", ["TCGA.AA.3854.01", "Signaling by GPCR"], {"weight": 0.936849370561352}], ["PLG", ["TCGA.AA.3854.01", "GPCR downstream signalling"], {"weight": 0.949774088353957}], ["PLG", ["TCGA.AA.3860.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.911403916220533}], ["PLG", ["TCGA.AA.3875.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.921261364423742}], ["PLG", ["TCGA.AA.3875.01", "Regulation of signaling by NODAL"], {"weight": 0.745027977085998}], ["PLG", ["TCGA.AA.3875.01", "Heme degradation"], {"weight": 0.313378136613467}], ["PLG", ["TCGA.AA.3875.01", "Basigin interactions"], {"weight": 0.697037992206312}], ["PLG", ["TCGA.AA.3939.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.868477999759694}], ["PLG", ["TCGA.AA.3939.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.875741019268534}], ["PLG", ["TCGA.AA.3939.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.929820921305897}], ["PLG", ["TCGA.AA.A00J.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.930916060996805}], ["PLG", ["TCGA.AA.A00J.01", "Signaling by GPCR"], {"weight": 0.938526326199398}], ["PLG", ["TCGA.AA.A00J.01", "GPCR downstream signalling"], {"weight": 0.944206852952662}], ["PLG", ["TCGA.AA.A00J.01", "Post-translational protein phosphorylation"], {"weight": 0.851859747829907}], ["PLG", ["TCGA.AA.A01X.01", "Classical antibody-mediated complement activation"], {"weight": 0.60864635416184}], ["PLG", ["TCGA.AA.A029.01", "Classical antibody-mediated complement activation"], {"weight": 0.754894644508039}], ["PLG", ["TCGA.AA.A029.01", "Regulation of Complement cascade"], {"weight": 0.941525706762197}], ["PLG", ["TCGA.AA.A029.01", "Cell surface interactions at the vascular wall"], {"weight": 0.786804318656131}], ["PLG", ["TCGA.AA.A029.01", "Creation of C4 and C2 activators"], {"weight": 0.84301541283585}], ["PLG", ["TCGA.AA.A029.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.90768557723722}], ["PLG", ["TCGA.AA.A029.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.890624816683073}], ["PLG", ["TCGA.AA.A02Y.01", "Defective B3GALTL causes PpS"], {"weight": 0.915539454232521}], ["PLG", ["TCGA.AA.A02Y.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.914055892592484}], ["PLG", ["TCGA.AA.A02Y.01", "Complement cascade"], {"weight": 0.89889982174155}], ["PLG", ["TCGA.AA.A02Y.01", "Classical antibody-mediated complement activation"], {"weight": 0.768830715942157}], ["PLG", ["TCGA.AA.A02Y.01", "Scavenging by Class A Receptors"], {"weight": 0.682422591793758}], ["PLG", ["TCGA.AA.A02Y.01", "Initial triggering of complement"], {"weight": 0.883662690343832}], ["PLG", ["TCGA.AA.A02Y.01", "Creation of C4 and C2 activators"], {"weight": 0.865780394855752}], ["PLG", ["TCGA.AA.A02Y.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.92635069318879}], ["PLG", ["TCGA.AA.A02Y.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.881461378414756}], ["PLG", ["TCGA.AA.A02Y.01", "Signaling by PDGF"], {"weight": 0.950172852054008}], ["PLG", ["TCGA.AA.A02Y.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.905197135653667}], ["PLG", ["TCGA.AA.A02Y.01", "O-linked glycosylation"], {"weight": 0.889490330851367}], ["PLG", ["TCGA.AD.6888.01", "Classical antibody-mediated complement activation"], {"weight": 0.829986629431063}], ["PLG", ["TCGA.AD.6888.01", "Creation of C4 and C2 activators"], {"weight": 0.88433421961779}], ["PLG", ["TCGA.AD.6888.01", "Initial triggering of complement"], {"weight": 0.867126225528227}], ["PLG", ["TCGA.AD.6888.01", "Scavenging by Class A Receptors"], {"weight": 0.557165051397319}], ["PLG", ["TCGA.AD.6888.01", "MAPK family signaling cascades"], {"weight": 0.914797028632471}], ["PLG", ["TCGA.AD.6899.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.935387142793083}], ["PLG", ["TCGA.AD.6899.01", "O-linked glycosylation"], {"weight": 0.84917140227439}], ["PLG", ["TCGA.AD.6899.01", "Drug ADME"], {"weight": 0.773936211949233}], ["PLG", ["TCGA.AD.A5EK.01", "Classical antibody-mediated complement activation"], {"weight": 0.643035032425204}], ["PLG", ["TCGA.AD.A5EK.01", "Creation of C4 and C2 activators"], {"weight": 0.800694988936489}], ["PLG", ["TCGA.AM.5820.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.842620898033007}], ["PLG", ["TCGA.AY.6196.01", "Collagen formation"], {"weight": 0.913305786078259}], ["PLG", ["TCGA.AY.6196.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.87321150979218}], ["PLG", ["TCGA.AY.6196.01", "O-linked glycosylation"], {"weight": 0.919352197811549}], ["PLG", ["TCGA.AY.6196.01", "Degradation of the extracellular matrix"], {"weight": 0.781064274039865}], ["PLG", ["TCGA.AY.6196.01", "Defective B3GALTL causes PpS"], {"weight": 0.901766497534664}], ["PLG", ["TCGA.AY.6196.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.901766497534664}], ["PLG", ["TCGA.AY.6196.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.8052247512054}], ["PLG", ["TCGA.AY.6196.01", "Peptide ligand-binding receptors"], {"weight": 0.893283113166344}], ["PLG", ["TCGA.AY.A8YK.01", "Signaling by GPCR"], {"weight": 0.928721638292241}], ["PLG", ["TCGA.AY.A8YK.01", "GPCR downstream signalling"], {"weight": 0.941751327977475}], ["PLG", ["TCGA.AY.A8YK.01", "Classical antibody-mediated complement activation"], {"weight": 0.604443988090537}], ["PLG", ["TCGA.AY.A8YK.01", "Creation of C4 and C2 activators"], {"weight": 0.585090964649139}], ["PLG", ["TCGA.AY.A8YK.01", "Post-translational protein phosphorylation"], {"weight": 0.852888929099193}], ["PLG", ["TCGA.AZ.4616.01", "Signaling by GPCR"], {"weight": 0.940832070186251}], ["PLG", ["TCGA.AZ.4616.01", "GPCR downstream signalling"], {"weight": 0.952232417868088}], ["PLG", ["TCGA.AZ.4616.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.951931923660536}], ["PLG", ["TCGA.AZ.6598.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.916892150877424}], ["PLG", ["TCGA.AZ.6606.01", "Signaling by GPCR"], {"weight": 0.942695009201982}], ["PLG", ["TCGA.AZ.6606.01", "GPCR downstream signalling"], {"weight": 0.951655872405439}], ["PLG", ["TCGA.AZ.6606.01", "Classical antibody-mediated complement activation"], {"weight": 0.748017413054935}], ["PLG", ["TCGA.AZ.6606.01", "Creation of C4 and C2 activators"], {"weight": 0.844213011397691}], ["PLG", ["TCGA.AZ.6606.01", "Initial triggering of complement"], {"weight": 0.762351162452522}], ["PLG", ["TCGA.AZ.6607.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.955914201880849}], ["PLG", ["TCGA.AZ.6608.01", "Classical antibody-mediated complement activation"], {"weight": 0.833088224876606}], ["PLG", ["TCGA.AZ.6608.01", "Regulation of Complement cascade"], {"weight": 0.932219368281281}], ["PLG", ["TCGA.AZ.6608.01", "Defective B3GALTL causes PpS"], {"weight": 0.914355404938365}], ["PLG", ["TCGA.AZ.6608.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.912555289717773}], ["PLG", ["TCGA.AZ.6608.01", "Creation of C4 and C2 activators"], {"weight": 0.884435483732143}], ["PLG", ["TCGA.AZ.6608.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.891442916276498}], ["PLG", ["TCGA.AZ.6608.01", "O-linked glycosylation"], {"weight": 0.927571973340032}], ["PLG", ["TCGA.AZ.6608.01", "Scavenging by Class A Receptors"], {"weight": 0.595363746973535}], ["PLG", ["TCGA.CA.5254.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.859676125203791}], ["PLG", ["TCGA.CA.5255.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.940683302696165}], ["PLG", ["TCGA.CA.5255.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.940311404944934}], ["PLG", ["TCGA.CA.5255.01", "Classical antibody-mediated complement activation"], {"weight": 0.754698920934225}], ["PLG", ["TCGA.CA.5255.01", "Regulation of Complement cascade"], {"weight": 0.874342657311459}], ["PLG", ["TCGA.CA.5255.01", "Creation of C4 and C2 activators"], {"weight": 0.720374060396208}], ["PLG", ["TCGA.CA.5255.01", "GRB2:SOS provides linkage to MAPK signaling for Integrins"], {"weight": 0.901094153553612}], ["PLG", ["TCGA.CA.5255.01", "p130Cas linkage to MAPK signaling for integrins"], {"weight": 0.901094153553612}], ["PLG", ["TCGA.CA.5255.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.812292620946842}], ["PLG", ["TCGA.CA.5256.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.844798294829345}], ["PLG", ["TCGA.CK.5915.01", "Signaling by GPCR"], {"weight": 0.951275187528322}], ["PLG", ["TCGA.CK.5915.01", "GPCR downstream signalling"], {"weight": 0.954223501417238}], ["PLG", ["TCGA.CK.5915.01", "Regulation of Complement cascade"], {"weight": 0.917686970516027}], ["PLG", ["TCGA.CK.5915.01", "Creation of C4 and C2 activators"], {"weight": 0.874570611074031}], ["PLG", ["TCGA.CK.5915.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.792888457328058}], ["PLG", ["TCGA.CK.5915.01", "Classical antibody-mediated complement activation"], {"weight": 0.758338536733348}], ["PLG", ["TCGA.CK.5915.01", "Scavenging by Class A Receptors"], {"weight": 0.671916337809648}], ["PLG", ["TCGA.CK.5915.01", "Cytokine Signaling in Immune system"], {"weight": 0.869747808342395}], ["PLG", ["TCGA.CM.5348.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.93551796074682}], ["PLG", ["TCGA.CM.5348.01", "Degradation of the extracellular matrix"], {"weight": 0.856981687907756}], ["PLG", ["TCGA.CM.6167.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.863573588054099}], ["PLG", ["TCGA.CM.6172.01", "G alpha (q) signalling events"], {"weight": 0.944928576743781}], ["PLG", ["TCGA.CM.6675.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.887079900797488}], ["PLG", ["TCGA.CM.6676.01", "Initial triggering of complement"], {"weight": 0.723829974766553}], ["PLG", ["TCGA.CM.6676.01", "Creation of C4 and C2 activators"], {"weight": 0.583483322817618}], ["PLG", ["TCGA.CM.6676.01", "Classical antibody-mediated complement activation"], {"weight": 0.599841225930776}], ["PLG", ["TCGA.CM.6678.01", "Classical antibody-mediated complement activation"], {"weight": 0.698269849376775}], ["PLG", ["TCGA.D5.5541.01", "Extracellular matrix organization"], {"weight": 0.845769835974086}], ["PLG", ["TCGA.D5.5541.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.914648812604338}], ["PLG", ["TCGA.D5.5541.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.798957519754301}], ["PLG", ["TCGA.D5.5541.01", "Collagen formation"], {"weight": 0.946212755492595}], ["PLG", ["TCGA.D5.5541.01", "Collagen degradation"], {"weight": 0.913005057026318}], ["PLG", ["TCGA.D5.5541.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.877399064158387}], ["PLG", ["TCGA.D5.5541.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.800117082380361}], ["PLG", ["TCGA.D5.6529.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.946033330774761}], ["PLG", ["TCGA.D5.6529.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.820918945284581}], ["PLG", ["TCGA.D5.6529.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.727510435285416}], ["PLG", ["TCGA.D5.6531.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.832180839977198}], ["PLG", ["TCGA.D5.6537.01", "Signaling by GPCR"], {"weight": 0.943507440091526}], ["PLG", ["TCGA.D5.6537.01", "GPCR downstream signalling"], {"weight": 0.949633664678249}], ["PLG", ["TCGA.D5.6537.01", "Regulation of Complement cascade"], {"weight": 0.899426434606453}], ["PLG", ["TCGA.D5.6537.01", "Classical antibody-mediated complement activation"], {"weight": 0.756844486573741}], ["PLG", ["TCGA.D5.6537.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.93364378233824}], ["PLG", ["TCGA.D5.6898.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.923900525333007}], ["PLG", ["TCGA.D5.6898.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.853512450995495}], ["PLG", ["TCGA.DM.A28F.01", "Initial triggering of complement"], {"weight": 0.815605175993373}], ["PLG", ["TCGA.DM.A28F.01", "Classical antibody-mediated complement activation"], {"weight": 0.676149608837197}], ["PLG", ["TCGA.DM.A28K.01", "Regulation of Complement cascade"], {"weight": 0.925477379365243}], ["PLG", ["TCGA.DM.A28K.01", "Extracellular matrix organization"], {"weight": 0.863024572701245}], ["PLG", ["TCGA.DM.A28K.01", "Creation of C4 and C2 activators"], {"weight": 0.841754363954169}], ["PLG", ["TCGA.F4.6459.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.838348336984061}], ["PLG", ["TCGA.F4.6459.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.888895437094439}], ["PLG", ["TCGA.F4.6459.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.845022872159611}], ["PLG", ["TCGA.F4.6704.01", "Extracellular matrix organization"], {"weight": 0.888085689732595}], ["PLG", ["TCGA.F4.6704.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.854455104997037}], ["PLG", ["TCGA.F4.6704.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.828111213881388}], ["PLG", ["TCGA.G4.6297.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.924084200109456}], ["PLG", ["TCGA.G4.6297.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.822663778321668}], ["PLG", ["TCGA.G4.6299.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.911910687558519}], ["PLG", ["TCGA.G4.6299.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.825487951540188}], ["PLG", ["TCGA.G4.6306.01", "Signaling by GPCR"], {"weight": 0.948169636722563}], ["PLG", ["TCGA.G4.6306.01", "GPCR downstream signalling"], {"weight": 0.951058415702889}], ["PLG", ["TCGA.G4.6306.01", "Classical antibody-mediated complement activation"], {"weight": 0.80918997387465}], ["PLG", ["TCGA.G4.6306.01", "Creation of C4 and C2 activators"], {"weight": 0.876681887962252}], ["PLG", ["TCGA.G4.6306.01", "Scavenging by Class A Receptors"], {"weight": 0.526969814336177}], ["PLG", ["TCGA.QL.A97D.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.533434770805809}], ["MAP3K4", ["TCGA.A6.6137.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.855725709375941}], ["MAP3K4", ["TCGA.A6.6137.01", "Phase 0 - rapid depolarisation"], {"weight": 0.841277344857629}], ["MAP3K4", ["TCGA.A6.6137.01", "Long-term potentiation"], {"weight": 0.836317409157534}], ["MAP3K4", ["TCGA.A6.6137.01", "Trafficking of AMPA receptors"], {"weight": 0.812717209927726}], ["MAP3K4", ["TCGA.A6.6137.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.812717209927726}], ["MAP3K4", ["TCGA.A6.6137.01", "Ras activation upon Ca2+ influx through NMDA receptor"], {"weight": 0.802459504152551}], ["MAP3K4", ["TCGA.A6.6137.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.802459504152551}], ["MAP3K4", ["TCGA.A6.6137.01", "Transcriptional Regulation by MECP2"], {"weight": 0.563146519276623}], ["MAP3K4", ["TCGA.A6.6137.01", "Molecules associated with elastic fibres"], {"weight": 0.530175904600908}], ["MAP3K4", ["TCGA.A6.6137.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.785001790923837}], ["MAP3K4", ["TCGA.A6.6137.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.802459504152551}], ["MAP3K4", ["TCGA.A6.6137.01", "Post NMDA receptor activation events"], {"weight": 0.755057151369242}], ["MAP3K4", ["TCGA.AA.A02H.01", "Interleukin-27 signaling"], {"weight": 0.47048647293099}], ["MAP3K4", ["TCGA.DM.A28K.01", "Phase 0 - rapid depolarisation"], {"weight": 0.925716055101213}], ["MAP3K4", ["TCGA.DM.A28K.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.844999627680167}], ["MAP3K4", ["TCGA.DM.A28K.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.893667137353287}], ["MAP3K4", ["TCGA.DM.A28K.01", "Ion homeostasis"], {"weight": 0.934586746033115}], ["MAP3K4", ["TCGA.G4.6299.01", "Keratinization"], {"weight": 0.800489762874034}], ["PRDM1", ["TCGA.A6.2686.01", "Interaction between L1 and Ankyrins"], {"weight": 0.913591004942943}], ["PRDM1", ["TCGA.A6.2686.01", "Phase 0 - rapid depolarisation"], {"weight": 0.872909194892575}], ["PRDM1", ["TCGA.CM.5860.01", "Cardiac conduction"], {"weight": 0.906533517569651}], ["PRDM1", ["TCGA.CM.5860.01", "Phase 0 - rapid depolarisation"], {"weight": 0.859618947457138}], ["PRDM1", ["TCGA.CM.6169.01", "Extracellular matrix organization"], {"weight": 0.789717923741623}], ["PRDM1", ["TCGA.D5.6931.01", "Neurotransmitter release cycle"], {"weight": 0.798186028020852}], ["EPM2A", ["TCGA.AA.3679.01", "Transport of small molecules"], {"weight": 0.853425411102122}], ["EPM2A", ["TCGA.AA.3679.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.856792708497922}], ["EPM2A", ["TCGA.AA.3679.01", "Axon guidance"], {"weight": 0.826557934701946}], ["EPM2A", ["TCGA.AA.3679.01", "Plasma lipoprotein assembly"], {"weight": 0.180744770331715}], ["EPM2A", ["TCGA.AA.3679.01", "Cardiac conduction"], {"weight": 0.840965822782054}], ["EPM2A", ["TCGA.AA.3679.01", "Nervous system development"], {"weight": 0.818639410650385}], ["EPM2A", ["TCGA.AA.3679.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.815133249178184}], ["EPM2A", ["TCGA.AA.3679.01", "Aquaporin-mediated transport"], {"weight": 0.798540974284245}], ["EPM2A", ["TCGA.AA.3679.01", "Developmental Biology"], {"weight": 0.816358254965559}], ["EPM2A", ["TCGA.AA.3679.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.636535042243761}], ["EPM2A", ["TCGA.AA.3679.01", "Biological oxidations"], {"weight": 0.88454981379911}], ["EPM2A", ["TCGA.AA.3679.01", "Molecules associated with elastic fibres"], {"weight": 0.543069124129009}], ["EPM2A", ["TCGA.AA.3679.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.869247412548718}], ["EPM2A", ["TCGA.AA.3679.01", "GPER1 signaling"], {"weight": 0.869247412548718}], ["EPM2A", ["TCGA.AA.3679.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.869247412548718}], ["EPM2A", ["TCGA.AA.3679.01", "Phase II - Conjugation of compounds"], {"weight": 0.810581008260426}], ["EPM2A", ["TCGA.AA.3841.01", "Glycogen metabolism"], {"weight": 0.890518791925762}], ["EPM2A", ["TCGA.AA.3841.01", "Glycogen synthesis"], {"weight": 0.739222964978402}], ["EPM2A", ["TCGA.AZ.6600.01", "Glycogen synthesis"], {"weight": 0.566926471384374}], ["AGPAT4", ["TCGA.AA.3664.01", "L1CAM interactions"], {"weight": 0.889534337732011}], ["AGPAT4", ["TCGA.AY.6196.01", "Triglyceride metabolism"], {"weight": 0.84489408550214}], ["AGPAT4", ["TCGA.AY.6196.01", "Triglyceride biosynthesis"], {"weight": 0.833299461077836}], ["ATG5", ["TCGA.A6.2686.01", "Developmental Biology"], {"weight": 0.844939224135108}], ["ATG5", ["TCGA.AA.3655.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.768877221602497}], ["ATG5", ["TCGA.AA.3660.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.847302753682879}], ["ATG5", ["TCGA.AA.3660.01", "IRS-related events triggered by IGF1R"], {"weight": 0.832209678588192}], ["ATG5", ["TCGA.AA.3660.01", "IGF1R signaling cascade"], {"weight": 0.832209678588192}], ["ATG5", ["TCGA.AA.3660.01", "IRS-mediated signalling"], {"weight": 0.827230815653034}], ["ATG5", ["TCGA.AA.3660.01", "Insulin receptor signalling cascade"], {"weight": 0.826989600824961}], ["ATG5", ["TCGA.AA.3848.01", "Synthesis of PIPs at the Golgi membrane"], {"weight": 0.849500460778926}], ["ATG5", ["TCGA.AA.A02H.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.828902765032056}], ["ATG5", ["TCGA.AA.A02H.01", "IRS-related events triggered by IGF1R"], {"weight": 0.80816049231165}], ["ATG5", ["TCGA.AA.A02H.01", "IGF1R signaling cascade"], {"weight": 0.80816049231165}], ["ATG5", ["TCGA.AA.A02Y.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.886251396059067}], ["ATG5", ["TCGA.CA.5255.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.792988567031208}], ["ATG5", ["TCGA.CM.5860.01", "NCAM1 interactions"], {"weight": 0.81418147390895}], ["ATG5", ["TCGA.CM.6161.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.888736858686501}], ["PACRG", ["TCGA.A6.6142.01", "Degradation of the extracellular matrix"], {"weight": 0.859966573404057}], ["PACRG", ["TCGA.A6.6142.01", "Ion channel transport"], {"weight": 0.882641620453545}], ["PACRG", ["TCGA.A6.6654.01", "Degradation of the extracellular matrix"], {"weight": 0.768431528008029}], ["PACRG", ["TCGA.A6.6654.01", "Stimuli-sensing channels"], {"weight": 0.856768262133306}], ["PACRG", ["TCGA.A6.6654.01", "Ion channel transport"], {"weight": 0.886024326503105}], ["PACRG", ["TCGA.A6.6654.01", "Carbohydrate metabolism"], {"weight": 0.584354349749786}], ["PACRG", ["TCGA.AA.A02J.01", "G alpha (i) signalling events"], {"weight": 0.9407841385265}], ["PACRG", ["TCGA.AA.A02J.01", "G-protein beta:gamma signalling"], {"weight": 0.900316162123906}], ["PACRG", ["TCGA.AA.A02J.01", "Integration of energy metabolism"], {"weight": 0.917700060936423}], ["PACRG", ["TCGA.AA.A02J.01", "G beta:gamma signalling through CDC42"], {"weight": 0.864241599772294}], ["PACRG", ["TCGA.AA.A02J.01", "CD28 dependent Vav1 pathway"], {"weight": 0.741459937362791}], ["PACRG", ["TCGA.CA.5256.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], {"weight": 0.866707465051258}], ["PACRG", ["TCGA.CA.5256.01", "Nucleosome assembly"], {"weight": 0.866707465051258}], ["PACRG", ["TCGA.CA.5256.01", "Chromosome Maintenance"], {"weight": 0.887024738302471}], ["PACRG", ["TCGA.DM.A28H.01", "MHC class II antigen presentation"], {"weight": 0.918608432664488}], ["PACRG", ["TCGA.DM.A28H.01", "Polo-like kinase mediated events"], {"weight": 0.832929707962203}], ["PACRG", ["TCGA.DM.A28H.01", "Adaptive Immune System"], {"weight": 0.896043913684742}], ["PACRG", ["TCGA.DM.A28H.01", "Resolution of Sister Chromatid Cohesion"], {"weight": 0.883511577921771}], ["PACRG", ["TCGA.DM.A28H.01", "Condensation of Prophase Chromosomes"], {"weight": 0.788034893017834}], ["PACRG", ["TCGA.DM.A28H.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.792575659679386}], ["PACRG", ["TCGA.DM.A28H.01", "G0 and Early G1"], {"weight": 0.846876995202112}], ["PACRG", ["TCGA.DM.A28H.01", "G1/S-Specific Transcription"], {"weight": 0.855517678606757}], ["PACRG", ["TCGA.DM.A28H.01", "Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex"], {"weight": 0.774386216194768}], ["PACRG", ["TCGA.DM.A28H.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.790847846834244}], ["PACRG", ["TCGA.DM.A28H.01", "Cyclin A/B1/B2 associated events during G2/M transition"], {"weight": 0.832762405723798}], ["PACRG", ["TCGA.DM.A28H.01", "Extension of Telomeres"], {"weight": 0.875638962690242}], ["PACRG", ["TCGA.DM.A28H.01", "Condensation of Prometaphase Chromosomes"], {"weight": 0.741215881548678}], ["PACRG", ["TCGA.DM.A28H.01", "Amplification of signal from the kinetochores"], {"weight": 0.895089922944173}], ["PACRG", ["TCGA.DM.A28H.01", "Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal"], {"weight": 0.895089922944173}], ["PACRG", ["TCGA.DM.A28H.01", "RAF-independent MAPK1/3 activation"], {"weight": 0.714530385085255}], ["PACRG", ["TCGA.T9.A92H.01", "G beta:gamma signalling through CDC42"], {"weight": 0.811387161789884}], ["PACRG", ["TCGA.T9.A92H.01", "Stimuli-sensing channels"], {"weight": -0.014432608646685}], ["QKI", ["TCGA.A6.6142.01", "Phase II - Conjugation of compounds"], {"weight": 0.781699049300701}], ["QKI", ["TCGA.A6.6142.01", "Biological oxidations"], {"weight": 0.886370079697334}], ["QKI", ["TCGA.A6.6142.01", "Visual phototransduction"], {"weight": 0.884295216292993}], ["QKI", ["TCGA.A6.6142.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.803023919435012}], ["QKI", ["TCGA.A6.6142.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.901949933856991}], ["QKI", ["TCGA.A6.6142.01", "Retinoid metabolism and transport"], {"weight": 0.901949933856991}], ["QKI", ["TCGA.A6.6142.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.745594212453741}], ["QKI", ["TCGA.A6.6142.01", "Drug ADME"], {"weight": 0.893953349887847}], ["QKI", ["TCGA.A6.6142.01", "Post-translational protein phosphorylation"], {"weight": 0.830453977731611}], ["QKI", ["TCGA.A6.6142.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.863125280019435}], ["QKI", ["TCGA.A6.6142.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.812600898248271}], ["QKI", ["TCGA.A6.6142.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.720274454128486}], ["QKI", ["TCGA.A6.6142.01", "L1CAM interactions"], {"weight": 0.818738365548334}], ["QKI", ["TCGA.A6.6142.01", "Glucuronidation"], {"weight": 0.810746019350766}], ["QKI", ["TCGA.A6.6142.01", "TNFs bind their physiological receptors"], {"weight": 0.310641900165792}], ["QKI", ["TCGA.A6.6142.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.801845185977237}], ["QKI", ["TCGA.A6.6142.01", "APAP ADME"], {"weight": 0.575071270038066}], ["QKI", ["TCGA.A6.6142.01", "Recycling of bile acids and salts"], {"weight": 0.797204347773452}], ["QKI", ["TCGA.A6.6654.01", "Extracellular matrix organization"], {"weight": 0.860403134627135}], ["QKI", ["TCGA.A6.6654.01", "Biological oxidations"], {"weight": 0.91327200081056}], ["QKI", ["TCGA.A6.6654.01", "Drug ADME"], {"weight": 0.927384515608075}], ["QKI", ["TCGA.A6.6654.01", "Transport of small molecules"], {"weight": 0.912815911317062}], ["QKI", ["TCGA.A6.6654.01", "Metabolism"], {"weight": 0.883005532601375}], ["QKI", ["TCGA.A6.6654.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.710926696247585}], ["QKI", ["TCGA.A6.6654.01", "Phase II - Conjugation of compounds"], {"weight": 0.802839018280641}], ["QKI", ["TCGA.A6.6654.01", "Glucuronidation"], {"weight": 0.737834308480605}], ["QKI", ["TCGA.A6.6654.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.782858869262965}], ["QKI", ["TCGA.A6.6654.01", "Phase I - Functionalization of compounds"], {"weight": 0.872159902237225}], ["QKI", ["TCGA.A6.6654.01", "APAP ADME"], {"weight": 0.686702479365447}], ["QKI", ["TCGA.A6.6654.01", "Signaling by Retinoic Acid"], {"weight": 0.816152587047925}], ["QKI", ["TCGA.A6.6654.01", "Post-translational protein phosphorylation"], {"weight": 0.66821565949056}], ["QKI", ["TCGA.A6.6654.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.603599863757161}], ["QKI", ["TCGA.A6.6654.01", "GPCR ligand binding"], {"weight": 0.878615585182278}], ["QKI", ["TCGA.A6.6654.01", "SLC-mediated transmembrane transport"], {"weight": 0.861547399478475}], ["QKI", ["TCGA.A6.6654.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.78564725069483}], ["QKI", ["TCGA.A6.6654.01", "Aspirin ADME"], {"weight": 0.838858498817314}], ["QKI", ["TCGA.AA.A022.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.871230102094237}], ["QKI", ["TCGA.AA.A022.01", "Phase II - Conjugation of compounds"], {"weight": 0.925185410779431}], ["QKI", ["TCGA.AA.A022.01", "Glucuronidation"], {"weight": 0.899189181457998}], ["QKI", ["TCGA.AY.6196.01", "Regulation of gene expression in beta cells"], {"weight": 0.650981222945105}], ["QKI", ["TCGA.NH.A6GB.01", "Glucuronidation"], {"weight": 0.831681384582523}], ["QKI", ["TCGA.NH.A6GB.01", "Phase II - Conjugation of compounds"], {"weight": 0.831233115674985}], ["QKI", ["TCGA.NH.A6GB.01", "Aspirin ADME"], {"weight": 0.796912504608832}], ["QKI", ["TCGA.NH.A6GB.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.85275405279474}], ["PDE10A", ["TCGA.4T.AA8H.01", "G alpha (s) signalling events"], {"weight": 0.960620119048855}], ["PDE10A", ["TCGA.A6.4107.01", "Digestion"], {"weight": 0.409039432126956}], ["PDE10A", ["TCGA.A6.6142.01", "Extracellular matrix organization"], {"weight": 0.915086980607979}], ["PDE10A", ["TCGA.A6.6142.01", "Signaling by GPCR"], {"weight": 0.92833407805223}], ["PDE10A", ["TCGA.A6.6142.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.596030690029592}], ["PDE10A", ["TCGA.A6.6142.01", "Neuronal System"], {"weight": 0.907381465001119}], ["PDE10A", ["TCGA.A6.6142.01", "G alpha (i) signalling events"], {"weight": 0.963744085641551}], ["PDE10A", ["TCGA.A6.6142.01", "GPCR ligand binding"], {"weight": 0.88200794128358}], ["PDE10A", ["TCGA.A6.6142.01", "SLC-mediated transmembrane transport"], {"weight": 0.904879730171385}], ["PDE10A", ["TCGA.A6.6142.01", "GPCR downstream signalling"], {"weight": 0.942321020541275}], ["PDE10A", ["TCGA.A6.6142.01", "Cardiac conduction"], {"weight": 0.881571338419878}], ["PDE10A", ["TCGA.A6.6142.01", "Transport of small molecules"], {"weight": 0.940609461510276}], ["PDE10A", ["TCGA.A6.6142.01", "Regulation of insulin secretion"], {"weight": 0.909402822599087}], ["PDE10A", ["TCGA.A6.6142.01", "Transmission across Chemical Synapses"], {"weight": 0.893062290955295}], ["PDE10A", ["TCGA.A6.6142.01", "Phase 0 - rapid depolarisation"], {"weight": 0.805243704017168}], ["PDE10A", ["TCGA.A6.6142.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.867757625055979}], ["PDE10A", ["TCGA.A6.6142.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.896322341106351}], ["PDE10A", ["TCGA.A6.6142.01", "Interleukin-10 signaling"], {"weight": 0.667447192405921}], ["PDE10A", ["TCGA.A6.6142.01", "Signaling Pathways"], {"weight": 0.88337129721466}], ["PDE10A", ["TCGA.A6.6142.01", "Peptide ligand-binding receptors"], {"weight": 0.865958918101854}], ["PDE10A", ["TCGA.A6.6142.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.915023555580413}], ["PDE10A", ["TCGA.A6.6142.01", "Gastrulation"], {"weight": 0.721709580175768}], ["PDE10A", ["TCGA.A6.6142.01", "Integration of energy metabolism"], {"weight": 0.910837877630702}], ["PDE10A", ["TCGA.A6.6142.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.856917543169658}], ["PDE10A", ["TCGA.A6.6142.01", "Phase 2 - plateau phase"], {"weight": 0.74162844962766}], ["PDE10A", ["TCGA.A6.6142.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.908794086252612}], ["PDE10A", ["TCGA.A6.6142.01", "Muscle contraction"], {"weight": 0.885037504459214}], ["PDE10A", ["TCGA.A6.6142.01", "Signal amplification"], {"weight": 0.852372488494533}], ["PDE10A", ["TCGA.A6.6142.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.861315315100238}], ["PDE10A", ["TCGA.A6.6142.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.790368350753707}], ["PDE10A", ["TCGA.A6.6142.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.836770233320034}], ["PDE10A", ["TCGA.A6.6142.01", "Leishmania parasite growth and survival"], {"weight": 0.836770233320034}], ["PDE10A", ["TCGA.A6.6142.01", "Primitive streak formation"], {"weight": 0.67245108390466}], ["PDE10A", ["TCGA.A6.6142.01", "Stimuli-sensing channels"], {"weight": 0.853737681601468}], ["PDE10A", ["TCGA.A6.6142.01", "Potassium Channels"], {"weight": 0.847339825765262}], ["PDE10A", ["TCGA.A6.6142.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.81190373130066}], ["PDE10A", ["TCGA.A6.6142.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.781711451139269}], ["PDE10A", ["TCGA.A6.6142.01", "Long-term potentiation"], {"weight": 0.785466253902426}], ["PDE10A", ["TCGA.A6.6652.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.874838530785994}], ["PDE10A", ["TCGA.A6.6652.01", "GABA receptor activation"], {"weight": 0.917857619312214}], ["PDE10A", ["TCGA.AA.3837.01", "Digestion"], {"weight": 0.373671563899885}], ["PDE10A", ["TCGA.AA.3837.01", "Digestion and absorption"], {"weight": 0.373671563899885}], ["PDE10A", ["TCGA.AA.3841.01", "Digestion"], {"weight": 0.317443177998036}], ["PDE10A", ["TCGA.AA.3841.01", "GABA receptor activation"], {"weight": 0.885654148388155}], ["PDE10A", ["TCGA.AA.3850.01", "Metabolism of amine-derived hormones"], {"weight": 0.384036207524424}], ["PDE10A", ["TCGA.AA.3854.01", "Muscle contraction"], {"weight": 0.931202328374815}], ["PDE10A", ["TCGA.AA.3860.01", "Digestion"], {"weight": 0.384247120431433}], ["PDE10A", ["TCGA.AA.3939.01", "Digestion"], {"weight": 0.423654541501595}], ["PDE10A", ["TCGA.AA.3952.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.811760198614285}], ["PDE10A", ["TCGA.AA.3971.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.868352031124574}], ["PDE10A", ["TCGA.AA.3971.01", "GABA B receptor activation"], {"weight": 0.872637141905947}], ["PDE10A", ["TCGA.AA.3971.01", "Activation of GABAB receptors"], {"weight": 0.872637141905947}], ["PDE10A", ["TCGA.AA.3971.01", "GABA receptor activation"], {"weight": 0.74246656561716}], ["PDE10A", ["TCGA.AA.3971.01", "G alpha (z) signalling events"], {"weight": 0.874337983772693}], ["PDE10A", ["TCGA.AA.3971.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.828558570910829}], ["PDE10A", ["TCGA.AA.3971.01", "Transmission across Chemical Synapses"], {"weight": 0.776574258257064}], ["PDE10A", ["TCGA.AA.3971.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.845414855940644}], ["PDE10A", ["TCGA.AA.3971.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], {"weight": 0.711265446129888}], ["PDE10A", ["TCGA.AA.3971.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.845414855940644}], ["PDE10A", ["TCGA.AA.3971.01", "GPER1 signaling"], {"weight": 0.845414855940644}], ["PDE10A", ["TCGA.AA.3971.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.845414855940644}], ["PDE10A", ["TCGA.AA.3971.01", "Aquaporin-mediated transport"], {"weight": 0.845414855940644}], ["PDE10A", ["TCGA.AA.3971.01", "Neuronal System"], {"weight": 0.775691333799527}], ["PDE10A", ["TCGA.AA.3971.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.808818018193755}], ["PDE10A", ["TCGA.AA.3971.01", "G alpha (s) signalling events"], {"weight": 0.925529118815235}], ["PDE10A", ["TCGA.AA.A00J.01", "Digestion"], {"weight": 0.442329240605722}], ["PDE10A", ["TCGA.AA.A022.01", "Digestion"], {"weight": 0.459099255830223}], ["PDE10A", ["TCGA.AA.A02E.01", "Transport of small molecules"], {"weight": 0.899794088587525}], ["PDE10A", ["TCGA.AA.A02H.01", "Digestion and absorption"], {"weight": 0.347800534816651}], ["PDE10A", ["TCGA.AA.A02H.01", "Digestion"], {"weight": 0.411912659826848}], ["PDE10A", ["TCGA.AA.A02O.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.922585530841215}], ["PDE10A", ["TCGA.AM.5820.01", "Digestion"], {"weight": 0.489841512706771}], ["PDE10A", ["TCGA.AY.4070.01", "Visual phototransduction"], {"weight": 0.867228192552283}], ["PDE10A", ["TCGA.AY.6196.01", "Digestion"], {"weight": 0.704095079963134}], ["PDE10A", ["TCGA.AZ.4616.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.919312430688255}], ["PDE10A", ["TCGA.AZ.4616.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.917897600696929}], ["PDE10A", ["TCGA.AZ.4616.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.864290857461933}], ["PDE10A", ["TCGA.AZ.4616.01", "Leishmania parasite growth and survival"], {"weight": 0.864290857461933}], ["PDE10A", ["TCGA.AZ.4616.01", "PKA activation in glucagon signalling"], {"weight": 0.884660748071672}], ["PDE10A", ["TCGA.AZ.4616.01", "Calmodulin induced events"], {"weight": 0.920135677908676}], ["PDE10A", ["TCGA.AZ.4616.01", "CaM pathway"], {"weight": 0.920135677908676}], ["PDE10A", ["TCGA.AZ.4616.01", "DAG and IP3 signaling"], {"weight": 0.920413258240236}], ["PDE10A", ["TCGA.AZ.4616.01", "G alpha (s) signalling events"], {"weight": 0.954745237698587}], ["PDE10A", ["TCGA.AZ.4616.01", "Ca-dependent events"], {"weight": 0.920135677908676}], ["PDE10A", ["TCGA.AZ.4616.01", "Aquaporin-mediated transport"], {"weight": 0.828753963720389}], ["PDE10A", ["TCGA.AZ.4616.01", "G alpha (z) signalling events"], {"weight": 0.878027860268022}], ["PDE10A", ["TCGA.AZ.4616.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.902016377083975}], ["PDE10A", ["TCGA.AZ.4616.01", "GPER1 signaling"], {"weight": 0.902016377083975}], ["PDE10A", ["TCGA.AZ.4616.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.902016377083975}], ["PDE10A", ["TCGA.AZ.4616.01", "GABA B receptor activation"], {"weight": 0.910162613515856}], ["PDE10A", ["TCGA.AZ.4616.01", "Activation of GABAB receptors"], {"weight": 0.910162613515856}], ["PDE10A", ["TCGA.AZ.4616.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.902336407790691}], ["PDE10A", ["TCGA.AZ.4616.01", "Leishmania infection"], {"weight": 0.839533460121522}], ["PDE10A", ["TCGA.AZ.4616.01", "Adenylate cyclase inhibitory pathway"], {"weight": 0.869644385561441}], ["PDE10A", ["TCGA.AZ.6607.01", "Digestion"], {"weight": 0.775639497101267}], ["PDE10A", ["TCGA.AZ.6608.01", "GABA B receptor activation"], {"weight": 0.943238815655347}], ["PDE10A", ["TCGA.AZ.6608.01", "Activation of GABAB receptors"], {"weight": 0.943238815655347}], ["PDE10A", ["TCGA.AZ.6608.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.931597595965284}], ["PDE10A", ["TCGA.AZ.6608.01", "Aquaporin-mediated transport"], {"weight": 0.838954806482687}], ["PDE10A", ["TCGA.CA.5256.01", "Ribavirin ADME"], {"weight": 0.85130203851043}], ["PDE10A", ["TCGA.CA.5256.01", "Drug ADME"], {"weight": 0.838619382224709}], ["PDE10A", ["TCGA.CK.5915.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.905672026748926}], ["PDE10A", ["TCGA.CM.6167.01", "Digestion"], {"weight": 0.50552243892639}], ["PDE10A", ["TCGA.CM.6676.01", "Digestion"], {"weight": 0.48046016148305}], ["PDE10A", ["TCGA.CM.6678.01", "Digestion"], {"weight": 0.45983416320178}], ["PDE10A", ["TCGA.D5.5537.01", "Digestion"], {"weight": 0.411896930180857}], ["PDE10A", ["TCGA.D5.5541.01", "Transport of small molecules"], {"weight": 0.922254566483068}], ["PDE10A", ["TCGA.D5.5541.01", "Transmission across Chemical Synapses"], {"weight": 0.926130363144799}], ["PDE10A", ["TCGA.D5.5541.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.921802355794601}], ["PDE10A", ["TCGA.D5.5541.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.905847102234909}], ["PDE10A", ["TCGA.D5.5541.01", "Metabolism"], {"weight": 0.92300341340174}], ["PDE10A", ["TCGA.D5.6529.01", "Digestion"], {"weight": 0.48953290650455}], ["PDE10A", ["TCGA.D5.6898.01", "Digestion"], {"weight": 0.688027016327297}], ["PDE10A", ["TCGA.DM.A0X9.01", "Digestion"], {"weight": 0.409943710941413}], ["PDE10A", ["TCGA.DM.A28K.01", "Signaling Pathways"], {"weight": 0.915299142315256}], ["PDE10A", ["TCGA.DM.A28K.01", "Calmodulin induced events"], {"weight": 0.903002618582333}], ["PDE10A", ["TCGA.DM.A28K.01", "CaM pathway"], {"weight": 0.903002618582333}], ["PDE10A", ["TCGA.DM.A28K.01", "DAG and IP3 signaling"], {"weight": 0.905829772463205}], ["PDE10A", ["TCGA.DM.A28K.01", "Ca-dependent events"], {"weight": 0.903002618582333}], ["PDE10A", ["TCGA.DM.A28K.01", "G alpha (s) signalling events"], {"weight": 0.959418476431078}], ["PDE10A", ["TCGA.DM.A28K.01", "Muscle contraction"], {"weight": 0.946054617627001}], ["PDE10A", ["TCGA.DM.A28K.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.928846239751619}], ["PDE10A", ["TCGA.DM.A28K.01", "Aquaporin-mediated transport"], {"weight": 0.928846239751619}], ["PDE10A", ["TCGA.DM.A28K.01", "Digestion"], {"weight": 0.460949444460516}], ["PDE10A", ["TCGA.DM.A28K.01", "G alpha (z) signalling events"], {"weight": 0.912161349951359}], ["PDE10A", ["TCGA.F4.6854.01", "Digestion"], {"weight": 0.242261633335945}], ["PDE10A", ["TCGA.F4.6854.01", "GPCR downstream signalling"], {"weight": 0.941071181407036}], ["PDE10A", ["TCGA.F4.6854.01", "Signaling by GPCR"], {"weight": 0.92252247351226}], ["PDE10A", ["TCGA.G4.6299.01", "Neuronal System"], {"weight": 0.944228628473309}], ["PDE10A", ["TCGA.G4.6299.01", "Regulation of insulin secretion"], {"weight": 0.923680741698202}], ["PDE10A", ["TCGA.G4.6299.01", "Integration of energy metabolism"], {"weight": 0.927490431446491}], ["PDE10A", ["TCGA.G4.6299.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.927362910138327}], ["PDE10A", ["TCGA.G4.6299.01", "G-protein mediated events"], {"weight": 0.904758004486944}], ["PDE10A", ["TCGA.G4.6299.01", "PLC beta mediated events"], {"weight": 0.895926262642852}], ["PDE10A", ["TCGA.G4.6299.01", "Digestion"], {"weight": 0.712281149935931}], ["PDE10A", ["TCGA.G4.6299.01", "G alpha (s) signalling events"], {"weight": 0.955039277449589}], ["PDE10A", ["TCGA.NH.A6GB.01", "Transport of small molecules"], {"weight": 0.910218406153142}], ["PDE10A", ["TCGA.NH.A6GB.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.915269593986487}], ["PDE10A", ["TCGA.NH.A6GB.01", "Integration of energy metabolism"], {"weight": 0.937828352428833}], ["PDE10A", ["TCGA.NH.A6GB.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.811760845745573}], ["PDE10A", ["TCGA.NH.A6GB.01", "Signaling by GPCR"], {"weight": 0.942272121476319}], ["PDE10A", ["TCGA.NH.A6GB.01", "GPCR downstream signalling"], {"weight": 0.951377919032324}], ["PDE10A", ["TCGA.NH.A6GB.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.925411197996648}], ["PDE10A", ["TCGA.NH.A6GB.01", "Platelet homeostasis"], {"weight": 0.834977737511783}], ["PDE10A", ["TCGA.NH.A6GB.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.907941763109874}], ["PDE10A", ["TCGA.WS.AB45.01", "Transport of small molecules"], {"weight": 0.928997670660359}], ["PDE10A", ["TCGA.WS.AB45.01", "Biological oxidations"], {"weight": 0.916196893784414}], ["PDE10A", ["TCGA.WS.AB45.01", "GPCR ligand binding"], {"weight": 0.914759527287947}], ["PDE10A", ["TCGA.WS.AB45.01", "Drug ADME"], {"weight": 0.872449503643986}], ["PDE10A", ["TCGA.WS.AB45.01", "SLC-mediated transmembrane transport"], {"weight": 0.937595658759732}], ["PDE10A", ["TCGA.WS.AB45.01", "Phase II - Conjugation of compounds"], {"weight": 0.755031878335508}], ["PDE10A", ["TCGA.WS.AB45.01", "G alpha (i) signalling events"], {"weight": 0.940633624271833}], ["PDE10A", ["TCGA.WS.AB45.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.795737261012319}], ["PDE10A", ["TCGA.WS.AB45.01", "Peptide ligand-binding receptors"], {"weight": 0.911703973783993}], ["PDE10A", ["TCGA.WS.AB45.01", "Metabolism"], {"weight": 0.933572853212644}], ["PDE10A", ["TCGA.WS.AB45.01", "Post-translational protein phosphorylation"], {"weight": 0.762414093733414}], ["PDE10A", ["TCGA.WS.AB45.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.912315569722838}], ["PDE10A", ["TCGA.WS.AB45.01", "Ion channel transport"], {"weight": 0.925830594401306}], ["PDE10A", ["TCGA.WS.AB45.01", "G alpha (q) signalling events"], {"weight": 0.92195941868011}], ["PDE10A", ["TCGA.WS.AB45.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.942372666060541}], ["PDE10A", ["TCGA.WS.AB45.01", "Neuronal System"], {"weight": 0.914353507539379}], ["PDE10A", ["TCGA.WS.AB45.01", "Stimuli-sensing channels"], {"weight": 0.888802766894065}], ["PDE10A", ["TCGA.WS.AB45.01", "Transmission across Chemical Synapses"], {"weight": 0.905571637433825}], ["PDE10A", ["TCGA.WS.AB45.01", "Regulation of beta-cell development"], {"weight": 0.849718709514092}], ["PDE10A", ["TCGA.WS.AB45.01", "Digestion and absorption"], {"weight": 0.517751328316002}], ["PDE10A", ["TCGA.WS.AB45.01", "Carbohydrate metabolism"], {"weight": 0.839855177098742}], ["PDE10A", ["TCGA.WS.AB45.01", "Signaling by Receptor Tyrosine Kinases"], {"weight": 0.858981461093739}], ["PDE10A", ["TCGA.WS.AB45.01", "Digestion"], {"weight": 0.705513436851642}], ["PDE10A", ["TCGA.WS.AB45.01", "GABA receptor activation"], {"weight": 0.592155922636462}], ["PDE10A", ["TCGA.WS.AB45.01", "Regulation of gene expression in beta cells"], {"weight": 0.728090888760222}], ["RPS6KA2", ["TCGA.A6.2678.01", "L1CAM interactions"], {"weight": 0.889397133829912}], ["RPS6KA2", ["TCGA.A6.2680.01", "Interaction between L1 and Ankyrins"], {"weight": 0.893721795180917}], ["RPS6KA2", ["TCGA.A6.2680.01", "Cardiac conduction"], {"weight": 0.853935723454986}], ["RPS6KA2", ["TCGA.AA.3660.01", "L1CAM interactions"], {"weight": 0.839945581585973}], ["RPS6KA2", ["TCGA.AA.3685.01", "Cellular response to starvation"], {"weight": 0.90592166218979}], ["RPS6KA2", ["TCGA.AA.3841.01", "Ras activation upon Ca2+ influx through NMDA receptor"], {"weight": 0.901872912573223}], ["RPS6KA2", ["TCGA.AA.3841.01", "Signaling by SCF-KIT"], {"weight": 0.92722951784372}], ["RPS6KA2", ["TCGA.AA.3841.01", "Tie2 Signaling"], {"weight": 0.845343256640926}], ["RPS6KA2", ["TCGA.AA.3841.01", "SHC-mediated cascade:FGFR4"], {"weight": 0.858780591552699}], ["RPS6KA2", ["TCGA.AA.3841.01", "Signaling by KIT in disease"], {"weight": 0.851792558807631}], ["RPS6KA2", ["TCGA.AA.3841.01", "Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants"], {"weight": 0.851792558807631}], ["RPS6KA2", ["TCGA.AA.3841.01", "Signaling by FGFR4 in disease"], {"weight": 0.758155018854291}], ["RPS6KA2", ["TCGA.AA.3841.01", "SHC-mediated cascade:FGFR1"], {"weight": 0.865306699315397}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by FGFR4 in disease"], {"weight": 0.825255346817794}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by KIT in disease"], {"weight": 0.880484433457787}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants"], {"weight": 0.880484433457787}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by PDGFR in disease"], {"weight": 0.81417672284742}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants"], {"weight": 0.81417672284742}], ["RPS6KA2", ["TCGA.AA.3848.01", "Signaling by PDGFRA extracellular domain mutants"], {"weight": 0.81417672284742}], ["RPS6KA2", ["TCGA.AA.3848.01", "Ras activation upon Ca2+ influx through NMDA receptor"], {"weight": 0.902531556034459}], ["RPS6KA2", ["TCGA.AA.3848.01", "Extra-nuclear estrogen signaling"], {"weight": 0.85821669297078}], ["RPS6KA2", ["TCGA.AA.3848.01", "p38MAPK events"], {"weight": 0.803775074972212}], ["RPS6KA2", ["TCGA.AA.3848.01", "GRB2 events in EGFR signaling"], {"weight": 0.841193962845338}], ["RPS6KA2", ["TCGA.AA.3848.01", "Tie2 Signaling"], {"weight": 0.859123083665439}], ["RPS6KA2", ["TCGA.AA.3852.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.916705390779202}], ["RPS6KA2", ["TCGA.AA.3852.01", "Glucuronidation"], {"weight": 0.716905696878297}], ["RPS6KA2", ["TCGA.AA.3852.01", "Peptide hormone biosynthesis"], {"weight": 0.613188601790075}], ["RPS6KA2", ["TCGA.AA.3852.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.75467265438174}], ["RPS6KA2", ["TCGA.AA.3854.01", "L1CAM interactions"], {"weight": 0.883108737581628}], ["RPS6KA2", ["TCGA.AA.3875.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], {"weight": 0.666121577440617}], ["RPS6KA2", ["TCGA.AA.3939.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.912669199008004}], ["RPS6KA2", ["TCGA.AA.3971.01", "Interleukin-6 family signaling"], {"weight": 0.734778701593079}], ["RPS6KA2", ["TCGA.AA.3971.01", "Basigin interactions"], {"weight": 0.59606981580869}], ["RPS6KA2", ["TCGA.AA.3971.01", "Phase 0 - rapid depolarisation"], {"weight": 0.620789268855478}], ["RPS6KA2", ["TCGA.AA.3971.01", "Ras activation upon Ca2+ influx through NMDA receptor"], {"weight": 0.714358714407236}], ["RPS6KA2", ["TCGA.AA.3971.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.713408402222636}], ["RPS6KA2", ["TCGA.AA.3971.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.714358714407236}], ["RPS6KA2", ["TCGA.AA.3971.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.714358714407236}], ["RPS6KA2", ["TCGA.AA.3971.01", "Long-term potentiation"], {"weight": 0.714358714407236}], ["RPS6KA2", ["TCGA.AA.3971.01", "L1CAM interactions"], {"weight": 0.764916143655078}], ["RPS6KA2", ["TCGA.AA.3971.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.275794651087171}], ["RPS6KA2", ["TCGA.AA.3971.01", "Striated Muscle Contraction"], {"weight": 0.685010455683986}], ["RPS6KA2", ["TCGA.AA.A00J.01", "L1CAM interactions"], {"weight": 0.938190339492381}], ["RPS6KA2", ["TCGA.AA.A022.01", "Neuronal System"], {"weight": 0.936795296242946}], ["RPS6KA2", ["TCGA.AA.A022.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.868091490714922}], ["RPS6KA2", ["TCGA.AA.A022.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.843311232024856}], ["RPS6KA2", ["TCGA.AA.A022.01", "Degradation of the extracellular matrix"], {"weight": 0.837428085100564}], ["RPS6KA2", ["TCGA.AA.A022.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.698719897803319}], ["RPS6KA2", ["TCGA.AA.A022.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.748521299944452}], ["RPS6KA2", ["TCGA.AA.A022.01", "Biological oxidations"], {"weight": 0.954678366175081}], ["RPS6KA2", ["TCGA.AA.A02E.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.728713778136147}], ["RPS6KA2", ["TCGA.AA.A02E.01", "L1CAM interactions"], {"weight": 0.895548697787205}], ["RPS6KA2", ["TCGA.AA.A02Y.01", "Diseases of metabolism"], {"weight": 0.888138369835684}], ["RPS6KA2", ["TCGA.AD.A5EK.01", "Signaling by GPCR"], {"weight": 0.947384938397232}], ["RPS6KA2", ["TCGA.AD.A5EK.01", "GPCR downstream signalling"], {"weight": 0.953897981845432}], ["RPS6KA2", ["TCGA.AD.A5EK.01", "G alpha (q) signalling events"], {"weight": 0.944030533746309}], ["RPS6KA2", ["TCGA.AY.4070.01", "Aspartate and asparagine metabolism"], {"weight": 0.746973446560027}], ["RPS6KA2", ["TCGA.AY.6196.01", "Stimuli-sensing channels"], {"weight": 0.877172284853209}], ["RPS6KA2", ["TCGA.AY.A8YK.01", "L1CAM interactions"], {"weight": 0.868397836527388}], ["RPS6KA2", ["TCGA.AZ.4616.01", "Neuronal System"], {"weight": 0.914151520212016}], ["RPS6KA2", ["TCGA.AZ.4616.01", "Ion channel transport"], {"weight": 0.919444965516718}], ["RPS6KA2", ["TCGA.AZ.4616.01", "L1CAM interactions"], {"weight": 0.910977446660839}], ["RPS6KA2", ["TCGA.AZ.4616.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.846241156460801}], ["RPS6KA2", ["TCGA.AZ.6608.01", "Diseases of metabolism"], {"weight": 0.873599164756998}], ["RPS6KA2", ["TCGA.CA.5254.01", "L1CAM interactions"], {"weight": 0.936463422344982}], ["RPS6KA2", ["TCGA.CA.5255.01", "L1CAM interactions"], {"weight": 0.952759249668257}], ["RPS6KA2", ["TCGA.CA.5256.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.922881871221253}], ["RPS6KA2", ["TCGA.CA.5256.01", "Eukaryotic Translation Initiation"], {"weight": 0.922239408710136}], ["RPS6KA2", ["TCGA.CA.5256.01", "Cap-dependent Translation Initiation"], {"weight": 0.922239408710136}], ["RPS6KA2", ["TCGA.CA.5256.01", "Cellular response to starvation"], {"weight": 0.916596059588378}], ["RPS6KA2", ["TCGA.CA.5256.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], {"weight": 0.889187042543125}], ["RPS6KA2", ["TCGA.CM.6167.01", "Stimuli-sensing channels"], {"weight": 0.811573427566048}], ["RPS6KA2", ["TCGA.D5.5537.01", "L1CAM interactions"], {"weight": 0.884681882610569}], ["RPS6KA2", ["TCGA.D5.5541.01", "Neuronal System"], {"weight": 0.914918869195652}], ["RPS6KA2", ["TCGA.D5.5541.01", "Phase 0 - rapid depolarisation"], {"weight": 0.886208268234507}], ["RPS6KA2", ["TCGA.D5.5541.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.936535039508329}], ["RPS6KA2", ["TCGA.D5.5541.01", "Stimuli-sensing channels"], {"weight": 0.872093732163461}], ["RPS6KA2", ["TCGA.D5.6535.01", "L1CAM interactions"], {"weight": 0.853295271938781}], ["RPS6KA2", ["TCGA.D5.6537.01", "Platelet activation, signaling and aggregation"], {"weight": 0.897918589197015}], ["RPS6KA2", ["TCGA.DM.A28K.01", "L1CAM interactions"], {"weight": 0.905197069670111}], ["RPS6KA2", ["TCGA.G4.6299.01", "Transmission across Chemical Synapses"], {"weight": 0.938815985871799}], ["RPS6KA2", ["TCGA.G4.6299.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.850386947764319}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Neuronal System"], {"weight": 0.93795421487014}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Transmission across Chemical Synapses"], {"weight": 0.937941297053931}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Phase 0 - rapid depolarisation"], {"weight": 0.915668042612752}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.915024666253479}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "L1CAM interactions"], {"weight": 0.909656337969936}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.92635025107759}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.893737189227283}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Protein-protein interactions at synapses"], {"weight": 0.888625387519414}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Developmental Biology"], {"weight": 0.897602484394039}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.856387307470935}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.887753142145649}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Synaptic adhesion-like molecules"], {"weight": 0.773348906612014}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Degradation of the extracellular matrix"], {"weight": 0.852728984352669}], ["RPS6KA2", ["TCGA.NH.A6GB.01", "Stimuli-sensing channels"], {"weight": 0.895316507172068}], ["RPS6KA2", ["TCGA.QL.A97D.01", "L1CAM interactions"], {"weight": 0.891868503249413}], ["PDSS2", ["TCGA.AA.A00F.01", "Glucagon-type ligand receptors"], {"weight": 0.835272865428267}], ["PDSS2", ["TCGA.AA.A00F.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.801735326659946}], ["FGFR1OP", ["TCGA.3L.AA1B.01", "FGFR4 ligand binding and activation"], {"weight": 0.824713863609515}], ["FGFR1OP", ["TCGA.3L.AA1B.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.824713863609515}], ["FGFR1OP", ["TCGA.AA.3655.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.693238304198835}], ["FGFR1OP", ["TCGA.AA.3660.01", "FGFR4 ligand binding and activation"], {"weight": 0.874284144569196}], ["FGFR1OP", ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.874284144569196}], ["FGFR1OP", ["TCGA.AA.3660.01", "FGFR2c ligand binding and activation"], {"weight": 0.872704039422464}], ["FGFR1OP", ["TCGA.AA.3660.01", "FGFR2 ligand binding and activation"], {"weight": 0.89035450214666}], ["FGFR1OP", ["TCGA.AA.3660.01", "SHC-mediated cascade:FGFR4"], {"weight": 0.874284144569196}], ["FGFR1OP", ["TCGA.AA.3660.01", "PI-3K cascade:FGFR4"], {"weight": 0.874284144569196}], ["FGFR1OP", ["TCGA.AA.3660.01", "FGFR1 ligand binding and activation"], {"weight": 0.852105545792809}], ["FGFR1OP", ["TCGA.AA.3660.01", "FRS-mediated FGFR4 signaling"], {"weight": 0.874284144569196}], ["FGFR1OP", ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade: FGFR1"], {"weight": 0.852105545792809}], ["FGFR1OP", ["TCGA.AA.3660.01", "Activated point mutants of FGFR2"], {"weight": 0.872704039422464}], ["FGFR1OP", ["TCGA.AA.3660.01", "Signaling by activated point mutants of FGFR1"], {"weight": 0.82738290838241}], ["FGFR1OP", ["TCGA.AA.3660.01", "FGFR1c ligand binding and activation"], {"weight": 0.82738290838241}], ["FGFR1OP", ["TCGA.AA.3660.01", "Phospholipase C-mediated cascade; FGFR2"], {"weight": 0.872704039422464}], ["FGFR1OP", ["TCGA.AA.3971.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.687145205681197}], ["FGFR1OP", ["TCGA.AA.A01X.01", "FGFR4 ligand binding and activation"], {"weight": 0.906662208989516}], ["FGFR1OP", ["TCGA.AA.A01X.01", "PI-3K cascade:FGFR4"], {"weight": 0.910682920154839}], ["FGFR1OP", ["TCGA.AA.A01X.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.906662208989516}], ["FGFR1OP", ["TCGA.AA.A029.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.853685514287541}], ["FGFR1OP", ["TCGA.AA.A02E.01", "FGFR2c ligand binding and activation"], {"weight": 0.922921131406583}], ["FGFR1OP", ["TCGA.AA.A02E.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.921764330960148}], ["FGFR1OP", ["TCGA.AA.A02E.01", "Activated point mutants of FGFR2"], {"weight": 0.930833025516589}], ["FGFR1OP", ["TCGA.AA.A02E.01", "FGFR4 ligand binding and activation"], {"weight": 0.869931567772103}], ["FGFR1OP", ["TCGA.AA.A02E.01", "Phospholipase C-mediated cascade; FGFR2"], {"weight": 0.930833025516589}], ["FGFR1OP", ["TCGA.AA.A02E.01", "PI-3K cascade:FGFR2"], {"weight": 0.929751932231385}], ["FGFR1OP", ["TCGA.AA.A02H.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.680082304699866}], ["FGFR1OP", ["TCGA.AA.A02H.01", "FGFR2c ligand binding and activation"], {"weight": 0.861129911707247}], ["FGFR1OP", ["TCGA.AA.A02H.01", "FGFR4 ligand binding and activation"], {"weight": 0.742377921215666}], ["FGFR1OP", ["TCGA.AA.A02H.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.742377921215666}], ["FGFR1OP", ["TCGA.AA.A02H.01", "Activated point mutants of FGFR2"], {"weight": 0.861129911707247}], ["FGFR1OP", ["TCGA.AA.A02H.01", "Phospholipase C-mediated cascade; FGFR2"], {"weight": 0.861129911707247}], ["FGFR1OP", ["TCGA.AA.A02H.01", "Signaling by activated point mutants of FGFR1"], {"weight": 0.623837616167536}], ["FGFR1OP", ["TCGA.AA.A02H.01", "FGFR1c ligand binding and activation"], {"weight": 0.643261271177084}], ["FGFR1OP", ["TCGA.AA.A02Y.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.8758885037101}], ["FGFR1OP", ["TCGA.AD.6888.01", "FGFR4 ligand binding and activation"], {"weight": 0.894115136993326}], ["FGFR1OP", ["TCGA.AD.6888.01", "FGFR1 ligand binding and activation"], {"weight": 0.922505987540166}], ["FGFR1OP", ["TCGA.AD.6888.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.894115136993326}], ["FGFR1OP", ["TCGA.AD.6888.01", "Phospholipase C-mediated cascade: FGFR1"], {"weight": 0.918587167518327}], ["FGFR1OP", ["TCGA.AD.6888.01", "FGFR2 ligand binding and activation"], {"weight": 0.921665369805713}], ["FGFR1OP", ["TCGA.AZ.4616.01", "Phase 2 - plateau phase"], {"weight": 0.75675441156183}], ["FGFR1OP", ["TCGA.AZ.4616.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.904633953147804}], ["FGFR1OP", ["TCGA.AZ.6608.01", "G alpha (i) signalling events"], {"weight": 0.955956307518914}], ["FGFR1OP", ["TCGA.CA.5256.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.841752491526956}], ["FGFR1OP", ["TCGA.D5.6529.01", "FGFR2c ligand binding and activation"], {"weight": 0.872970769866926}], ["FGFR1OP", ["TCGA.D5.6529.01", "FGFR2 ligand binding and activation"], {"weight": 0.893571240866516}], ["FGFR1OP", ["TCGA.D5.6529.01", "FGFR4 ligand binding and activation"], {"weight": 0.766677459613404}], ["FGFR1OP", ["TCGA.D5.6529.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.766677459613404}], ["FGFR1OP", ["TCGA.D5.6529.01", "Activated point mutants of FGFR2"], {"weight": 0.872970769866926}], ["FGFR1OP", ["TCGA.D5.6529.01", "Signaling by activated point mutants of FGFR1"], {"weight": 0.704445942177828}], ["FGFR1OP", ["TCGA.D5.6529.01", "FGFR1c ligand binding and activation"], {"weight": 0.718753294966146}], ["FGFR1OP", ["TCGA.D5.6529.01", "Phospholipase C-mediated cascade; FGFR2"], {"weight": 0.872970769866926}], ["FGFR1OP", ["TCGA.DM.A28K.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.846397227597486}], ["FGFR1OP", ["TCGA.G4.6299.01", "Phase 2 - plateau phase"], {"weight": 0.736316887986389}], ["FGFR1OP", ["TCGA.NH.A6GB.01", "G alpha (s) signalling events"], {"weight": 0.959274267946588}], ["FGFR1OP", ["TCGA.QL.A97D.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.704584810752654}], ["CCR6", ["TCGA.AA.3852.01", "Peptide hormone metabolism"], {"weight": 0.783898167626032}], ["CCR6", ["TCGA.AA.3854.01", "G alpha (i) signalling events"], {"weight": 0.95044145467571}], ["CCR6", ["TCGA.AA.3971.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.853119826089777}], ["CCR6", ["TCGA.AA.3971.01", "Glucagon-type ligand receptors"], {"weight": 0.867722980252575}], ["CCR6", ["TCGA.AA.3971.01", "G beta:gamma signalling through BTK"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Activation of G protein gated Potassium channels"], {"weight": 0.852137025973339}], ["CCR6", ["TCGA.AA.3971.01", "G protein gated Potassium channels"], {"weight": 0.852137025973339}], ["CCR6", ["TCGA.AA.3971.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.852137025973339}], ["CCR6", ["TCGA.AA.3971.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "G beta:gamma signalling through CDC42"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.732958074153509}], ["CCR6", ["TCGA.AA.3971.01", "Presynaptic function of Kainate receptors"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Inwardly rectifying K+ channels"], {"weight": 0.852137025973339}], ["CCR6", ["TCGA.AA.3971.01", "G-protein activation"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Thromboxane signalling through TP receptor"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Ca2+ pathway"], {"weight": 0.693148465407961}], ["CCR6", ["TCGA.AA.3971.01", "Extra-nuclear estrogen signaling"], {"weight": 0.752548146338337}], ["CCR6", ["TCGA.AA.3971.01", "GPCR ligand binding"], {"weight": 0.888650453952745}], ["CCR6", ["TCGA.AA.3971.01", "G-protein beta:gamma signalling"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Signal amplification"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.811326959409553}], ["CCR6", ["TCGA.AA.3971.01", "Phase 4 - resting membrane potential"], {"weight": 0.558115887032373}], ["CCR6", ["TCGA.AA.A022.01", "Cardiac conduction"], {"weight": 0.937151831567802}], ["CCR6", ["TCGA.AA.A022.01", "Potassium Channels"], {"weight": 0.954230985452024}], ["CCR6", ["TCGA.AA.A022.01", "Inwardly rectifying K+ channels"], {"weight": 0.926132946375453}], ["CCR6", ["TCGA.AA.A022.01", "Phase 4 - resting membrane potential"], {"weight": 0.872208979906729}], ["CCR6", ["TCGA.AA.A02Y.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.763964467910621}], ["CCR6", ["TCGA.AZ.6607.01", "GPCR ligand binding"], {"weight": 0.920502034507142}], ["CCR6", ["TCGA.CA.5255.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.785178422112365}], ["CCR6", ["TCGA.D5.5541.01", "G alpha (i) signalling events"], {"weight": 0.94883021827056}], ["CCR6", ["TCGA.DM.A28K.01", "Immune System"], {"weight": 0.891589252623897}], ["CCR6", ["TCGA.F4.6704.01", "GPCR ligand binding"], {"weight": 0.842947057201032}], ["CCR6", ["TCGA.F4.6704.01", "Peptide ligand-binding receptors"], {"weight": 0.836419868438484}], ["CCR6", ["TCGA.G4.6299.01", "G alpha (i) signalling events"], {"weight": 0.957744374492547}], ["CCR6", ["TCGA.G4.6306.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.752954789554697}], ["CCR6", ["TCGA.NH.A6GA.01", "Peptide ligand-binding receptors"], {"weight": 0.88986339130463}], ["CCR6", ["TCGA.NH.A6GA.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.891452918663263}], ["CCR6", ["TCGA.NH.A6GB.01", "Biological oxidations"], {"weight": 0.934352156140958}], ["CCR6", ["TCGA.NH.A6GB.01", "GPCR ligand binding"], {"weight": 0.925849955198238}], ["CCR6", ["TCGA.NH.A6GB.01", "G alpha (i) signalling events"], {"weight": 0.953859967309072}], ["CCR6", ["TCGA.NH.A6GB.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.932959814901633}], ["CCR6", ["TCGA.NH.A6GB.01", "Chemokine receptors bind chemokines"], {"weight": 0.942578071313773}], ["CCR6", ["TCGA.NH.A6GB.01", "Regulation of insulin secretion"], {"weight": 0.924181585273321}], ["CCR6", ["TCGA.NH.A6GB.01", "Peptide ligand-binding receptors"], {"weight": 0.931191930010598}], ["CCR6", ["TCGA.NH.A6GB.01", "Glucagon-type ligand receptors"], {"weight": 0.938334433185409}], ["CCR6", ["TCGA.NH.A6GB.01", "Phase I - Functionalization of compounds"], {"weight": 0.94830241918748}], ["MYO6", ["TCGA.4T.AA8H.01", "Phase 0 - rapid depolarisation"], {"weight": 0.932775438296808}], ["MYO6", ["TCGA.4T.AA8H.01", "Ion transport by P-type ATPases"], {"weight": 0.894275336096556}], ["MYO6", ["TCGA.4T.AA8H.01", "Trafficking of AMPA receptors"], {"weight": 0.928255046293709}], ["MYO6", ["TCGA.4T.AA8H.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.928255046293709}], ["MYO6", ["TCGA.4T.AA8H.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.928871521571336}], ["MYO6", ["TCGA.4T.AA8H.01", "LGI-ADAM interactions"], {"weight": 0.913568341222931}], ["MYO6", ["TCGA.4T.AA8H.01", "Long-term potentiation"], {"weight": 0.929715220923455}], ["MYO6", ["TCGA.5M.AATA.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.922027990412672}], ["MYO6", ["TCGA.5M.AATA.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.909190783494106}], ["MYO6", ["TCGA.5M.AATA.01", "Phase 0 - rapid depolarisation"], {"weight": 0.920525122434417}], ["MYO6", ["TCGA.A6.2686.01", "L1CAM interactions"], {"weight": 0.864380347172436}], ["MYO6", ["TCGA.A6.6652.01", "Phase 0 - rapid depolarisation"], {"weight": 0.937045643353538}], ["MYO6", ["TCGA.A6.6652.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.925011447318752}], ["MYO6", ["TCGA.A6.6652.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.918377439120755}], ["MYO6", ["TCGA.A6.6652.01", "Long-term potentiation"], {"weight": 0.922304373276268}], ["MYO6", ["TCGA.AA.3655.01", "Synaptic adhesion-like molecules"], {"weight": 0.843997592343735}], ["MYO6", ["TCGA.AA.3655.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.929517176592738}], ["MYO6", ["TCGA.AA.3655.01", "GABA receptor activation"], {"weight": 0.879897802239767}], ["MYO6", ["TCGA.AA.3655.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.90900411455166}], ["MYO6", ["TCGA.AA.3655.01", "LGI-ADAM interactions"], {"weight": 0.757684561378798}], ["MYO6", ["TCGA.AA.3660.01", "Phase 0 - rapid depolarisation"], {"weight": 0.906347570711996}], ["MYO6", ["TCGA.AA.3837.01", "Scavenging of heme from plasma"], {"weight": 0.557389565007063}], ["MYO6", ["TCGA.AA.3837.01", "LGI-ADAM interactions"], {"weight": 0.80351651644133}], ["MYO6", ["TCGA.AA.3841.01", "RHOBTB GTPase Cycle"], {"weight": 0.744290990233608}], ["MYO6", ["TCGA.AA.3841.01", "RHOBTB2 GTPase cycle"], {"weight": 0.881262665049739}], ["MYO6", ["TCGA.AA.3841.01", "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"], {"weight": 0.901669213766915}], ["MYO6", ["TCGA.AA.3841.01", "Phase 0 - rapid depolarisation"], {"weight": 0.903569848302359}], ["MYO6", ["TCGA.AA.3841.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.893490507981207}], ["MYO6", ["TCGA.AA.3844.01", "Phase 0 - rapid depolarisation"], {"weight": 0.920150318934751}], ["MYO6", ["TCGA.AA.3875.01", "Trafficking of AMPA receptors"], {"weight": 0.551858246289498}], ["MYO6", ["TCGA.AA.3875.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.551858246289498}], ["MYO6", ["TCGA.AA.3939.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.907560063067983}], ["MYO6", ["TCGA.AA.3939.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.876114985116066}], ["MYO6", ["TCGA.AA.3966.01", "Extracellular matrix organization"], {"weight": 0.890817378171653}], ["MYO6", ["TCGA.AA.3966.01", "Synaptic adhesion-like molecules"], {"weight": 0.820081568093206}], ["MYO6", ["TCGA.AA.3966.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.91914439907764}], ["MYO6", ["TCGA.AA.3966.01", "Trafficking of AMPA receptors"], {"weight": 0.91892589172392}], ["MYO6", ["TCGA.AA.3966.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.91892589172392}], ["MYO6", ["TCGA.AA.3966.01", "Phase 0 - rapid depolarisation"], {"weight": 0.882758035212321}], ["MYO6", ["TCGA.AA.3966.01", "Protein-protein interactions at synapses"], {"weight": 0.857560077538963}], ["MYO6", ["TCGA.AA.3966.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.903925775915777}], ["MYO6", ["TCGA.AA.A01X.01", "Scavenging of heme from plasma"], {"weight": 0.602154823528876}], ["MYO6", ["TCGA.AA.A02Y.01", "Phase 0 - rapid depolarisation"], {"weight": 0.951199191982193}], ["MYO6", ["TCGA.AA.A02Y.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.94079961903923}], ["MYO6", ["TCGA.AA.A02Y.01", "LGI-ADAM interactions"], {"weight": 0.935219065400639}], ["MYO6", ["TCGA.AA.A02Y.01", "Synaptic adhesion-like molecules"], {"weight": 0.90500322675086}], ["MYO6", ["TCGA.AA.A02Y.01", "CRMPs in Sema3A signaling"], {"weight": 0.919286318429544}], ["MYO6", ["TCGA.AA.A02Y.01", "Long-term potentiation"], {"weight": 0.942784628203795}], ["MYO6", ["TCGA.AA.A02Y.01", "Ion transport by P-type ATPases"], {"weight": 0.916855840874881}], ["MYO6", ["TCGA.AA.A02Y.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.933050972294494}], ["MYO6", ["TCGA.AD.6888.01", "Phase 0 - rapid depolarisation"], {"weight": 0.925454341416552}], ["MYO6", ["TCGA.AD.6888.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.92785439113358}], ["MYO6", ["TCGA.AD.6888.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.885141566789752}], ["MYO6", ["TCGA.AM.5820.01", "Synaptic adhesion-like molecules"], {"weight": 0.888126046855526}], ["MYO6", ["TCGA.AM.5820.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.892981612947442}], ["MYO6", ["TCGA.AM.5820.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.884544802705301}], ["MYO6", ["TCGA.AZ.6598.01", "Phase 0 - rapid depolarisation"], {"weight": 0.948118526903891}], ["MYO6", ["TCGA.AZ.6598.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.937715875198465}], ["MYO6", ["TCGA.AZ.6598.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.894365800961514}], ["MYO6", ["TCGA.AZ.6598.01", "Synaptic adhesion-like molecules"], {"weight": 0.857834708818573}], ["MYO6", ["TCGA.AZ.6598.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.929277505302795}], ["MYO6", ["TCGA.AZ.6606.01", "Synaptic adhesion-like molecules"], {"weight": 0.836270293360544}], ["MYO6", ["TCGA.AZ.6607.01", "Phase 0 - rapid depolarisation"], {"weight": 0.91042171636987}], ["MYO6", ["TCGA.AZ.6608.01", "Transmission across Chemical Synapses"], {"weight": 0.948542446306965}], ["MYO6", ["TCGA.AZ.6608.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.934937470588783}], ["MYO6", ["TCGA.AZ.6608.01", "Ion homeostasis"], {"weight": 0.94145300619989}], ["MYO6", ["TCGA.AZ.6608.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.939919099723801}], ["MYO6", ["TCGA.AZ.6608.01", "Phase 0 - rapid depolarisation"], {"weight": 0.950811300162504}], ["MYO6", ["TCGA.AZ.6608.01", "G-protein mediated events"], {"weight": 0.922683133180269}], ["MYO6", ["TCGA.AZ.6608.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.940228806054254}], ["MYO6", ["TCGA.CA.5254.01", "Transmission across Chemical Synapses"], {"weight": 0.926752896679617}], ["MYO6", ["TCGA.CA.5254.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.912259829035837}], ["MYO6", ["TCGA.CA.5254.01", "Phase 0 - rapid depolarisation"], {"weight": 0.936614853834949}], ["MYO6", ["TCGA.CA.5254.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.895576783812652}], ["MYO6", ["TCGA.CA.5254.01", "Trafficking of AMPA receptors"], {"weight": 0.928431125207557}], ["MYO6", ["TCGA.CA.5254.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.928431125207557}], ["MYO6", ["TCGA.CA.5254.01", "Synaptic adhesion-like molecules"], {"weight": 0.827918645311399}], ["MYO6", ["TCGA.CA.5254.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.900092894513203}], ["MYO6", ["TCGA.CA.5254.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.923294446699163}], ["MYO6", ["TCGA.CA.5254.01", "Phase 2 - plateau phase"], {"weight": 0.742676155024282}], ["MYO6", ["TCGA.CA.5254.01", "Scavenging of heme from plasma"], {"weight": 0.810032320118582}], ["MYO6", ["TCGA.CA.5255.01", "Phase 0 - rapid depolarisation"], {"weight": 0.936554951109028}], ["MYO6", ["TCGA.CA.5255.01", "Synaptic adhesion-like molecules"], {"weight": 0.849033961399651}], ["MYO6", ["TCGA.CA.5255.01", "Trafficking of AMPA receptors"], {"weight": 0.939300377853131}], ["MYO6", ["TCGA.CA.5255.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.939300377853131}], ["MYO6", ["TCGA.CA.5255.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.922048719410509}], ["MYO6", ["TCGA.CA.5255.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.927485402118819}], ["MYO6", ["TCGA.CA.5256.01", "Phase 0 - rapid depolarisation"], {"weight": 0.92977960705131}], ["MYO6", ["TCGA.CA.5256.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.928803819480991}], ["MYO6", ["TCGA.CA.5256.01", "Long-term potentiation"], {"weight": 0.926402683600051}], ["MYO6", ["TCGA.CK.4952.01", "Neuronal System"], {"weight": 0.956072235068488}], ["MYO6", ["TCGA.CK.4952.01", "Transmission across Chemical Synapses"], {"weight": 0.95004279834931}], ["MYO6", ["TCGA.CK.4952.01", "Synaptic adhesion-like molecules"], {"weight": 0.893754444925633}], ["MYO6", ["TCGA.CK.4952.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.944524424406136}], ["MYO6", ["TCGA.CK.4952.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.933479995155422}], ["MYO6", ["TCGA.CK.4952.01", "Trafficking of AMPA receptors"], {"weight": 0.951728062925587}], ["MYO6", ["TCGA.CK.4952.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.951728062925587}], ["MYO6", ["TCGA.CK.5915.01", "Phase 0 - rapid depolarisation"], {"weight": 0.941366179881757}], ["MYO6", ["TCGA.CK.5915.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.94479897429919}], ["MYO6", ["TCGA.CK.5915.01", "Synaptic adhesion-like molecules"], {"weight": 0.840415907964781}], ["MYO6", ["TCGA.CM.5348.01", "Neuronal System"], {"weight": 0.880211395835668}], ["MYO6", ["TCGA.CM.5348.01", "Transmission across Chemical Synapses"], {"weight": 0.881410329835017}], ["MYO6", ["TCGA.CM.5863.01", "LGI-ADAM interactions"], {"weight": 0.70254607579407}], ["MYO6", ["TCGA.CM.6172.01", "GABA receptor activation"], {"weight": 0.80265882040545}], ["MYO6", ["TCGA.CM.6675.01", "Phase 0 - rapid depolarisation"], {"weight": 0.938823029034065}], ["MYO6", ["TCGA.CM.6675.01", "Synaptic adhesion-like molecules"], {"weight": 0.849552054512314}], ["MYO6", ["TCGA.CM.6675.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.930220162620437}], ["MYO6", ["TCGA.CM.6675.01", "Long-term potentiation"], {"weight": 0.895944014180658}], ["MYO6", ["TCGA.CM.6675.01", "Ion homeostasis"], {"weight": 0.944131618857204}], ["MYO6", ["TCGA.CM.6675.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.906386085868753}], ["MYO6", ["TCGA.CM.6676.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.943897201515431}], ["MYO6", ["TCGA.CM.6676.01", "Phase 0 - rapid depolarisation"], {"weight": 0.908026073031863}], ["MYO6", ["TCGA.CM.6676.01", "Trafficking of AMPA receptors"], {"weight": 0.92937849139289}], ["MYO6", ["TCGA.CM.6676.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.92937849139289}], ["MYO6", ["TCGA.CM.6676.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.90749257602319}], ["MYO6", ["TCGA.CM.6678.01", "Phase 0 - rapid depolarisation"], {"weight": 0.845270190270316}], ["MYO6", ["TCGA.D5.5537.01", "Phase 0 - rapid depolarisation"], {"weight": 0.924296605774534}], ["MYO6", ["TCGA.D5.5537.01", "Scavenging of heme from plasma"], {"weight": 0.690997746668637}], ["MYO6", ["TCGA.D5.5537.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.919161786072333}], ["MYO6", ["TCGA.D5.5537.01", "LGI-ADAM interactions"], {"weight": 0.821627730567754}], ["MYO6", ["TCGA.D5.5537.01", "Long-term potentiation"], {"weight": 0.921266853930693}], ["MYO6", ["TCGA.D5.6529.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.908508098907179}], ["MYO6", ["TCGA.D5.6535.01", "Cardiac conduction"], {"weight": 0.909142692758205}], ["MYO6", ["TCGA.D5.6535.01", "Muscle contraction"], {"weight": 0.901142696746897}], ["MYO6", ["TCGA.D5.6535.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.913748098140542}], ["MYO6", ["TCGA.D5.6535.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.844772772368804}], ["MYO6", ["TCGA.D5.6535.01", "Synaptic adhesion-like molecules"], {"weight": 0.824308651137541}], ["MYO6", ["TCGA.D5.6537.01", "Phase 0 - rapid depolarisation"], {"weight": 0.940235438914167}], ["MYO6", ["TCGA.D5.6537.01", "Ion homeostasis"], {"weight": 0.934489316465792}], ["MYO6", ["TCGA.D5.6537.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.94497563121258}], ["MYO6", ["TCGA.D5.6537.01", "Trafficking of AMPA receptors"], {"weight": 0.93996894527146}], ["MYO6", ["TCGA.D5.6537.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.93996894527146}], ["MYO6", ["TCGA.D5.6537.01", "Ion transport by P-type ATPases"], {"weight": 0.902327189962021}], ["MYO6", ["TCGA.D5.6537.01", "Long-term potentiation"], {"weight": 0.927697742635161}], ["MYO6", ["TCGA.D5.6537.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.904876816513495}], ["MYO6", ["TCGA.D5.6537.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.923910386803538}], ["MYO6", ["TCGA.D5.6537.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.919713902161058}], ["MYO6", ["TCGA.DM.A0X9.01", "Phase 0 - rapid depolarisation"], {"weight": 0.92837137461645}], ["MYO6", ["TCGA.DM.A28F.01", "Synaptic adhesion-like molecules"], {"weight": 0.894759660854495}], ["MYO6", ["TCGA.DM.A28F.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.938655617168958}], ["MYO6", ["TCGA.F4.6856.01", "G alpha (i) signalling events"], {"weight": 0.946031467592858}], ["MYO6", ["TCGA.F4.6856.01", "Transmission across Chemical Synapses"], {"weight": 0.939235398874203}], ["MYO6", ["TCGA.F4.6856.01", "Phase 0 - rapid depolarisation"], {"weight": 0.931045296727172}], ["MYO6", ["TCGA.F4.6856.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.92671863521305}], ["MYO6", ["TCGA.F4.6856.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.922341079144824}], ["MYO6", ["TCGA.F4.6856.01", "Ion channel transport"], {"weight": 0.896789203793117}], ["MYO6", ["TCGA.F4.6856.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.921761621132929}], ["MYO6", ["TCGA.F4.6856.01", "Trafficking of AMPA receptors"], {"weight": 0.930474081292527}], ["MYO6", ["TCGA.F4.6856.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.930474081292527}], ["MYO6", ["TCGA.F4.6856.01", "Synaptic adhesion-like molecules"], {"weight": 0.819708612581221}], ["MYO6", ["TCGA.F4.6856.01", "Long-term potentiation"], {"weight": 0.921321448468344}], ["MYO6", ["TCGA.F4.6856.01", "Ion homeostasis"], {"weight": 0.852705251557041}], ["MYO6", ["TCGA.G4.6297.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.852774743592251}], ["MYO6", ["TCGA.G4.6306.01", "Phase 0 - rapid depolarisation"], {"weight": 0.949275911228766}], ["MYO6", ["TCGA.G4.6306.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.930703596862649}], ["MYO6", ["TCGA.G4.6306.01", "CRMPs in Sema3A signaling"], {"weight": 0.921069509939202}], ["MYO6", ["TCGA.G4.6306.01", "Ion homeostasis"], {"weight": 0.924890948869972}], ["MYO6", ["TCGA.G4.6306.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.936812296331145}], ["MYO6", ["TCGA.NH.A6GA.01", "LGI-ADAM interactions"], {"weight": 0.891563627485386}], ["MYO6", ["TCGA.NH.A6GA.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.890263984746525}], ["MYO6", ["TCGA.QL.A97D.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.92383371247394}], ["MYO6", ["TCGA.QL.A97D.01", "Phase 0 - rapid depolarisation"], {"weight": 0.9330731023799}], ["MYO6", ["TCGA.QL.A97D.01", "Cardiac conduction"], {"weight": 0.935507065833574}], ["MYO6", ["TCGA.QL.A97D.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.929064467392891}], ["MYO6", ["TCGA.QL.A97D.01", "Muscle contraction"], {"weight": 0.94024170474529}], ["MYO6", ["TCGA.QL.A97D.01", "Long-term potentiation"], {"weight": 0.929168198167988}], ["MYO6", ["TCGA.QL.A97D.01", "Synaptic adhesion-like molecules"], {"weight": 0.907741046499522}], ["MYO6", ["TCGA.QL.A97D.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.920812058196243}], ["KIF25", ["TCGA.4T.AA8H.01", "Peptide hormone metabolism"], {"weight": 0.869841352072098}], ["KIF25", ["TCGA.AA.3854.01", "Insulin processing"], {"weight": 0.730022577761565}], ["KIF25", ["TCGA.AA.3875.01", "RHO GTPases activate KTN1"], {"weight": 0.755254769867949}], ["KIF25", ["TCGA.AA.3875.01", "Kinesins"], {"weight": 0.755254769867949}], ["KIF25", ["TCGA.AA.3971.01", "Collagen formation"], {"weight": 0.757710218443653}], ["KIF25", ["TCGA.AA.A022.01", "Peptide hormone metabolism"], {"weight": 0.794502297224333}], ["KIF25", ["TCGA.CM.4743.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.922705808032023}], ["KIF25", ["TCGA.CM.4743.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.858559936546169}], ["KIF25", ["TCGA.CM.4743.01", "Synaptic adhesion-like molecules"], {"weight": 0.767023077986206}], ["KIF25", ["TCGA.CM.4743.01", "Peptide hormone metabolism"], {"weight": 0.857630276535838}], ["KIF25", ["TCGA.D5.5541.01", "Protein-protein interactions at synapses"], {"weight": 0.820479901330538}], ["KIF25", ["TCGA.NH.A6GB.01", "Peptide hormone metabolism"], {"weight": 0.749858416400774}], ["AHI1", ["TCGA.AA.3681.01", "Phase 0 - rapid depolarisation"], {"weight": 0.77998003625877}], ["AHI1", ["TCGA.AZ.6598.01", "G alpha (s) signalling events"], {"weight": 0.96403419518954}], ["AHI1", ["TCGA.CK.5915.01", "Leishmania infection"], {"weight": 0.905385475880026}], ["AHI1", ["TCGA.CM.6676.01", "Transmission across Chemical Synapses"], {"weight": 0.943764667619565}], ["OSTM1", ["TCGA.3L.AA1B.01", "Stimuli-sensing channels"], {"weight": 0.900431858022841}], ["OSTM1", ["TCGA.A6.6652.01", "Stimuli-sensing channels"], {"weight": 0.940725038383482}], ["OSTM1", ["TCGA.AA.3660.01", "Stimuli-sensing channels"], {"weight": 0.889648486295005}], ["OSTM1", ["TCGA.AA.3660.01", "Ion channel transport"], {"weight": 0.903104847562879}], ["OSTM1", ["TCGA.AA.3666.01", "Ion channel transport"], {"weight": 0.926660449488914}], ["OSTM1", ["TCGA.AA.3941.01", "Ion channel transport"], {"weight": 0.923939699604395}], ["OSTM1", ["TCGA.AA.3952.01", "Stimuli-sensing channels"], {"weight": 0.864797763004789}], ["OSTM1", ["TCGA.AA.A02H.01", "Ion channel transport"], {"weight": 0.910928542153486}], ["OSTM1", ["TCGA.AA.A02Y.01", "Ion channel transport"], {"weight": 0.948682602254311}], ["OSTM1", ["TCGA.AD.6888.01", "Ion channel transport"], {"weight": 0.942302226344236}], ["OSTM1", ["TCGA.AD.6888.01", "Stimuli-sensing channels"], {"weight": 0.925949380216858}], ["OSTM1", ["TCGA.AD.A5EK.01", "Ion channel transport"], {"weight": 0.947311785534252}], ["OSTM1", ["TCGA.AZ.6598.01", "Stimuli-sensing channels"], {"weight": 0.936693106534945}], ["OSTM1", ["TCGA.AZ.6606.01", "Ion channel transport"], {"weight": 0.946844987345887}], ["OSTM1", ["TCGA.AZ.6606.01", "Stimuli-sensing channels"], {"weight": 0.939326431881771}], ["OSTM1", ["TCGA.AZ.6608.01", "Ion channel transport"], {"weight": 0.950466160859289}], ["OSTM1", ["TCGA.AZ.6608.01", "Stimuli-sensing channels"], {"weight": 0.940050363219438}], ["OSTM1", ["TCGA.CA.5255.01", "Stimuli-sensing channels"], {"weight": 0.937341452346243}], ["OSTM1", ["TCGA.CA.5255.01", "Ion channel transport"], {"weight": 0.946074864284629}], ["OSTM1", ["TCGA.CK.5915.01", "Stimuli-sensing channels"], {"weight": 0.934791992900273}], ["OSTM1", ["TCGA.CK.5915.01", "Ion channel transport"], {"weight": 0.943838160328442}], ["OSTM1", ["TCGA.CM.5348.01", "Stimuli-sensing channels"], {"weight": 0.914463509336481}], ["OSTM1", ["TCGA.CM.5348.01", "Ion channel transport"], {"weight": 0.889579828613516}], ["OSTM1", ["TCGA.CM.5863.01", "Stimuli-sensing channels"], {"weight": 0.881867352467937}], ["OSTM1", ["TCGA.CM.5868.01", "Stimuli-sensing channels"], {"weight": 0.910983525067868}], ["OSTM1", ["TCGA.CM.5868.01", "Ion channel transport"], {"weight": 0.90934677846107}], ["OSTM1", ["TCGA.CM.6675.01", "Stimuli-sensing channels"], {"weight": 0.942673851605824}], ["OSTM1", ["TCGA.CM.6675.01", "Ion channel transport"], {"weight": 0.945839722456073}], ["OSTM1", ["TCGA.CM.6676.01", "Ion channel transport"], {"weight": 0.90059795188271}], ["OSTM1", ["TCGA.CM.6678.01", "Stimuli-sensing channels"], {"weight": 0.882214277091807}], ["OSTM1", ["TCGA.D5.5537.01", "Ion channel transport"], {"weight": 0.919620516378156}], ["OSTM1", ["TCGA.D5.5537.01", "Stimuli-sensing channels"], {"weight": 0.899774429497829}], ["OSTM1", ["TCGA.D5.6535.01", "Ion channel transport"], {"weight": 0.944229909611755}], ["OSTM1", ["TCGA.D5.6537.01", "Ion channel transport"], {"weight": 0.947770762298132}], ["OSTM1", ["TCGA.DM.A28F.01", "Stimuli-sensing channels"], {"weight": 0.940194689487139}], ["OSTM1", ["TCGA.DM.A28F.01", "Ion channel transport"], {"weight": 0.947927395233729}], ["OSTM1", ["TCGA.NH.A6GA.01", "Ion channel transport"], {"weight": 0.933629074836286}], ["THBS2", ["TCGA.AA.3852.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.915305138069103}], ["THBS2", ["TCGA.AA.3854.01", "Defective B3GALTL causes PpS"], {"weight": 0.883964470235141}], ["THBS2", ["TCGA.AA.3854.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.881119811787942}], ["THBS2", ["TCGA.AA.3854.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0427552102959626}], ["THBS2", ["TCGA.AA.3971.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.821296358098836}], ["THBS2", ["TCGA.AA.3971.01", "Regulation of signaling by NODAL"], {"weight": 0.683865787890442}], ["THBS2", ["TCGA.AA.3971.01", "Trafficking of AMPA receptors"], {"weight": 0.472944471000053}], ["THBS2", ["TCGA.AA.3971.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.472944471000053}], ["THBS2", ["TCGA.AA.A022.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.935807579364065}], ["THBS2", ["TCGA.AA.A02E.01", "Molecules associated with elastic fibres"], {"weight": 0.793632802000999}], ["THBS2", ["TCGA.AA.A02Y.01", "Developmental Biology"], {"weight": 0.91456612444823}], ["THBS2", ["TCGA.AD.6888.01", "Defective B3GALTL causes PpS"], {"weight": 0.908563202152878}], ["THBS2", ["TCGA.AD.6888.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.906663480823864}], ["THBS2", ["TCGA.AD.6888.01", "O-linked glycosylation"], {"weight": 0.91716523833191}], ["THBS2", ["TCGA.AM.5820.01", "O-linked glycosylation"], {"weight": 0.908027738655385}], ["THBS2", ["TCGA.AM.5820.01", "Defective B3GALTL causes PpS"], {"weight": 0.847888095738854}], ["THBS2", ["TCGA.AM.5820.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.843983326807188}], ["THBS2", ["TCGA.AY.4070.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.874410853194234}], ["THBS2", ["TCGA.AY.4070.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.870255153154613}], ["THBS2", ["TCGA.AY.4070.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.870255153154613}], ["THBS2", ["TCGA.AY.6196.01", "Integrin cell surface interactions"], {"weight": 0.892712780595403}], ["THBS2", ["TCGA.AY.A8YK.01", "Molecules associated with elastic fibres"], {"weight": 0.744134087013558}], ["THBS2", ["TCGA.CA.5255.01", "O-linked glycosylation"], {"weight": 0.917508504593407}], ["THBS2", ["TCGA.CM.4743.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.798145090439969}], ["THBS2", ["TCGA.CM.4743.01", "Interaction between L1 and Ankyrins"], {"weight": 0.926413484100648}], ["THBS2", ["TCGA.CM.4743.01", "Extracellular matrix organization"], {"weight": 0.861332331031462}], ["THBS2", ["TCGA.CM.4743.01", "Developmental Biology"], {"weight": 0.912819735224292}], ["THBS2", ["TCGA.CM.4743.01", "NCAM1 interactions"], {"weight": 0.912207121990445}], ["THBS2", ["TCGA.CM.4743.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.647631864631528}], ["THBS2", ["TCGA.CM.4743.01", "Collagen chain trimerization"], {"weight": 0.887429153296027}], ["THBS2", ["TCGA.CM.4743.01", "Other semaphorin interactions"], {"weight": 0.60520762635946}], ["THBS2", ["TCGA.CM.4743.01", "L1CAM interactions"], {"weight": 0.927755697392513}], ["THBS2", ["TCGA.CM.4743.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.211692205802411}], ["THBS2", ["TCGA.CM.4743.01", "ECM proteoglycans"], {"weight": 0.83733029437139}], ["THBS2", ["TCGA.CM.6167.01", "O-linked glycosylation"], {"weight": 0.827245640102393}], ["THBS2", ["TCGA.CM.6167.01", "Defective B3GALTL causes PpS"], {"weight": 0.867313773448717}], ["THBS2", ["TCGA.CM.6167.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.86726003852433}], ["THBS2", ["TCGA.D5.5537.01", "O-linked glycosylation"], {"weight": 0.876337864530393}], ["THBS2", ["TCGA.D5.5541.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.218683756348977}], ["THBS2", ["TCGA.D5.5541.01", "O-linked glycosylation"], {"weight": 0.890331553649738}], ["THBS2", ["TCGA.D5.5541.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.300976820573682}], ["THBS2", ["TCGA.D5.5541.01", "ECM proteoglycans"], {"weight": 0.894603402405038}], ["THBS2", ["TCGA.D5.6531.01", "O-linked glycosylation"], {"weight": 0.891790130639133}], ["THBS2", ["TCGA.D5.6531.01", "Defective B3GALTL causes PpS"], {"weight": 0.850602900101773}], ["THBS2", ["TCGA.D5.6531.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.84676782120379}], ["THBS2", ["TCGA.D5.6537.01", "Defective B3GALTL causes PpS"], {"weight": 0.890453987909009}], ["THBS2", ["TCGA.D5.6537.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.887768422640483}], ["THBS2", ["TCGA.DM.A28K.01", "Molecules associated with elastic fibres"], {"weight": 0.823528621711879}], ["THBS2", ["TCGA.DM.A28K.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.622154870175648}], ["THBS2", ["TCGA.DM.A28K.01", "Elastic fibre formation"], {"weight": 0.838375035287339}], ["THBS2", ["TCGA.G4.6306.01", "Defective B3GALTL causes PpS"], {"weight": 0.899399929047796}], ["THBS2", ["TCGA.G4.6306.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.897226974044671}], ["THBS2", ["TCGA.G4.6306.01", "O-linked glycosylation"], {"weight": 0.90232575260571}], ["THBS2", ["TCGA.NH.A6GB.01", "O-linked glycosylation"], {"weight": 0.891213864005321}], ["THBS2", ["TCGA.NH.A6GB.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.849202156696087}], ["NR2E1", ["TCGA.4T.AA8H.01", "Recycling of bile acids and salts"], {"weight": 0.870413431100745}], ["NR2E1", ["TCGA.A6.2686.01", "Phase II - Conjugation of compounds"], {"weight": 0.887647552064343}], ["NR2E1", ["TCGA.A6.2686.01", "Glucuronidation"], {"weight": 0.870216198061052}], ["NR2E1", ["TCGA.A6.2686.01", "Biological oxidations"], {"weight": 0.926170834143245}], ["NR2E1", ["TCGA.A6.6652.01", "Aspirin ADME"], {"weight": 0.825020993874545}], ["NR2E1", ["TCGA.AA.3560.01", "Nuclear Receptor transcription pathway"], {"weight": 0.931202520700642}], ["NR2E1", ["TCGA.AA.3655.01", "Aspirin ADME"], {"weight": 0.697297730273005}], ["NR2E1", ["TCGA.AA.3837.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.615259214604832}], ["NR2E1", ["TCGA.AA.3844.01", "Aspirin ADME"], {"weight": 0.700880299160801}], ["NR2E1", ["TCGA.AA.3848.01", "Recycling of bile acids and salts"], {"weight": 0.869009066804148}], ["NR2E1", ["TCGA.AA.3848.01", "Nuclear Receptor transcription pathway"], {"weight": 0.723869568931507}], ["NR2E1", ["TCGA.AA.A00F.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.878717273175552}], ["NR2E1", ["TCGA.AA.A00F.01", "Post-translational protein phosphorylation"], {"weight": 0.850376838060896}], ["NR2E1", ["TCGA.AA.A02H.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.66804043631736}], ["NR2E1", ["TCGA.AD.A5EK.01", "Phase I - Functionalization of compounds"], {"weight": 0.935880227124518}], ["NR2E1", ["TCGA.AY.A8YK.01", "Glucuronidation"], {"weight": 0.704941825691407}], ["NR2E1", ["TCGA.AY.A8YK.01", "Aspirin ADME"], {"weight": 0.64132710441692}], ["NR2E1", ["TCGA.AZ.6600.01", "Glucuronidation"], {"weight": 0.690560181634146}], ["NR2E1", ["TCGA.AZ.6600.01", "Aspirin ADME"], {"weight": 0.750560556408811}], ["NR2E1", ["TCGA.CA.5254.01", "Aspirin ADME"], {"weight": 0.876830568663682}], ["NR2E1", ["TCGA.CA.5254.01", "Glucuronidation"], {"weight": 0.852206599587308}], ["NR2E1", ["TCGA.CM.5860.01", "Biological oxidations"], {"weight": 0.940426962557713}], ["NR2E1", ["TCGA.CM.5860.01", "Phase I - Functionalization of compounds"], {"weight": 0.938591977080316}], ["NR2E1", ["TCGA.CM.5868.01", "Signaling by Retinoic Acid"], {"weight": 0.826627790786263}], ["NR2E1", ["TCGA.CM.6161.01", "Aspirin ADME"], {"weight": 0.814517815014795}], ["NR2E1", ["TCGA.CM.6169.01", "Drug ADME"], {"weight": 0.886190797908358}], ["NR2E1", ["TCGA.CM.6169.01", "Phase II - Conjugation of compounds"], {"weight": 0.841724468536576}], ["NR2E1", ["TCGA.CM.6169.01", "Biological oxidations"], {"weight": 0.936982660837909}], ["NR2E1", ["TCGA.CM.6169.01", "Aspirin ADME"], {"weight": 0.877058034805918}], ["NR2E1", ["TCGA.CM.6172.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.646449702568343}], ["NR2E1", ["TCGA.CM.6676.01", "Aspirin ADME"], {"weight": 0.834096413607565}], ["NR2E1", ["TCGA.CM.6676.01", "Recycling of bile acids and salts"], {"weight": 0.790032710117913}], ["NR2E1", ["TCGA.D5.6537.01", "Aspirin ADME"], {"weight": 0.758592420080927}], ["NR2E1", ["TCGA.D5.6898.01", "Glucuronidation"], {"weight": 0.747212104920042}], ["NR2E1", ["TCGA.D5.6898.01", "Aspirin ADME"], {"weight": 0.868999965364798}], ["NR2E1", ["TCGA.D5.6931.01", "Phase II - Conjugation of compounds"], {"weight": 0.694929442450596}], ["NR2E1", ["TCGA.DM.A0X9.01", "Phase II - Conjugation of compounds"], {"weight": 0.705436315941414}], ["NR2E1", ["TCGA.DM.A0X9.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.891664573603971}], ["NR2E1", ["TCGA.DM.A28F.01", "Aspirin ADME"], {"weight": 0.845404305621289}], ["NR2E1", ["TCGA.F4.6460.01", "Aspirin ADME"], {"weight": 0.660358496635456}], ["NR2E1", ["TCGA.F4.6460.01", "IRS-related events triggered by IGF1R"], {"weight": 0.810047173810365}], ["NR2E1", ["TCGA.F4.6460.01", "IGF1R signaling cascade"], {"weight": 0.810047173810365}], ["NR2E1", ["TCGA.F4.6460.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.810047173810365}], ["NR2E1", ["TCGA.F4.6460.01", "Phase I - Functionalization of compounds"], {"weight": 0.884704129377107}], ["NR2E1", ["TCGA.F4.6460.01", "IRS-mediated signalling"], {"weight": 0.807493253623744}], ["NR2E1", ["TCGA.G4.6297.01", "Glucuronidation"], {"weight": 0.664008452503754}], ["NR2E1", ["TCGA.NH.A6GA.01", "Glucuronidation"], {"weight": 0.860801020444887}], ["NR2E1", ["TCGA.NH.A6GA.01", "Aspirin ADME"], {"weight": 0.797144845097454}], ["NR2E1", ["TCGA.QL.A97D.01", "Phase I - Functionalization of compounds"], {"weight": 0.902964312431176}], ["SNX3", ["TCGA.AA.3841.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.871302526346876}], ["SNX3", ["TCGA.AA.3848.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.872774732131018}], ["SNX3", ["TCGA.AA.A02Y.01", "Transport of small molecules"], {"weight": 0.920589826481101}], ["SNX3", ["TCGA.AD.6888.01", "Transport of small molecules"], {"weight": 0.919044039625814}], ["SNX3", ["TCGA.AZ.6608.01", "Transport of small molecules"], {"weight": 0.932645928130072}], ["SNX3", ["TCGA.CK.4952.01", "Transport of small molecules"], {"weight": 0.947985945196056}], ["SNX3", ["TCGA.CK.5915.01", "Transport of small molecules"], {"weight": 0.935158586610535}], ["SNX3", ["TCGA.CM.6172.01", "Transport of small molecules"], {"weight": 0.877874789554174}], ["SNX3", ["TCGA.D5.6537.01", "Transport of small molecules"], {"weight": 0.930302767736705}], ["SNX3", ["TCGA.F4.6459.01", "Transport of small molecules"], {"weight": 0.896407366037385}], ["SNX3", ["TCGA.G4.6306.01", "Transport of small molecules"], {"weight": 0.897599738226313}], ["TCTE3", ["TCGA.AA.3852.01", "Interaction between L1 and Ankyrins"], {"weight": 0.866736419171185}], ["TCTE3", ["TCGA.AA.3971.01", "Interaction between L1 and Ankyrins"], {"weight": 0.773220505387398}], ["TCTE3", ["TCGA.AA.A02E.01", "Interaction between L1 and Ankyrins"], {"weight": 0.927312022261714}], ["TCTE3", ["TCGA.AY.4070.01", "Interaction between L1 and Ankyrins"], {"weight": 0.896163820075271}], ["TCTE3", ["TCGA.D5.5541.01", "Interaction between L1 and Ankyrins"], {"weight": 0.890667404381431}], ["TCTE3", ["TCGA.DM.A28K.01", "Neuronal System"], {"weight": 0.950996168339299}], ["TCTE3", ["TCGA.DM.A28K.01", "Transmission across Chemical Synapses"], {"weight": 0.945513927025972}], ["TCTE3", ["TCGA.DM.A28K.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.885627316283165}], ["TCTE3", ["TCGA.G4.6299.01", "Interaction between L1 and Ankyrins"], {"weight": 0.884434339383351}], ["TCTE3", ["TCGA.NH.A6GB.01", "Interaction between L1 and Ankyrins"], {"weight": 0.934058536863213}], ["FOXO3", ["TCGA.A6.2686.01", "Neuronal System"], {"weight": 0.925572747321853}], ["FOXO3", ["TCGA.A6.2686.01", "Transmission across Chemical Synapses"], {"weight": 0.924839375244885}], ["FOXO3", ["TCGA.A6.2686.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.923498753953286}], ["FOXO3", ["TCGA.AA.3666.01", "Neuronal System"], {"weight": 0.883220949093802}], ["FOXO3", ["TCGA.AA.3666.01", "Transmission across Chemical Synapses"], {"weight": 0.937985186088613}], ["FOXO3", ["TCGA.AA.3715.01", "Keratinization"], {"weight": 0.943382706913822}], ["FOXO3", ["TCGA.AA.3848.01", "SIRT1 negatively regulates rRNA expression"], {"weight": 0.772210812916647}], ["FOXO3", ["TCGA.AA.3848.01", "Heme signaling"], {"weight": 0.795887847636802}], ["FOXO3", ["TCGA.AA.3858.01", "Transmission across Chemical Synapses"], {"weight": 0.911178369425784}], ["FOXO3", ["TCGA.AA.3858.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.933151322450966}], ["FOXO3", ["TCGA.AA.3858.01", "Neuronal System"], {"weight": 0.912041436454799}], ["FOXO3", ["TCGA.AA.A00F.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.891412964934925}], ["FOXO3", ["TCGA.AA.A00F.01", "G alpha (s) signalling events"], {"weight": 0.936475845219862}], ["FOXO3", ["TCGA.AA.A00F.01", "Keratinization"], {"weight": 0.852610923015152}], ["FOXO3", ["TCGA.AA.A00F.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.886449700645393}], ["FOXO3", ["TCGA.AA.A00F.01", "Peptide hormone biosynthesis"], {"weight": 0.57214241929583}], ["FOXO3", ["TCGA.AA.A00F.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.886449700645393}], ["FOXO3", ["TCGA.AA.A00F.01", "GPER1 signaling"], {"weight": 0.886449700645393}], ["FOXO3", ["TCGA.AA.A00F.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.886449700645393}], ["FOXO3", ["TCGA.AA.A00F.01", "Aquaporin-mediated transport"], {"weight": 0.886449700645393}], ["FOXO3", ["TCGA.AA.A00F.01", "Neuronal System"], {"weight": 0.904418581491424}], ["FOXO3", ["TCGA.AA.A00J.01", "Neuronal System"], {"weight": 0.942305538514059}], ["FOXO3", ["TCGA.AA.A00J.01", "Transmission across Chemical Synapses"], {"weight": 0.941945084999415}], ["FOXO3", ["TCGA.AA.A029.01", "Signaling Pathways"], {"weight": 0.911435897071723}], ["FOXO3", ["TCGA.AA.A029.01", "Neuronal System"], {"weight": 0.935604535448518}], ["FOXO3", ["TCGA.AA.A02H.01", "Signaling Pathways"], {"weight": 0.8526026304097}], ["FOXO3", ["TCGA.AA.A02Y.01", "Neuronal System"], {"weight": 0.962855852759749}], ["FOXO3", ["TCGA.AA.A02Y.01", "Transmission across Chemical Synapses"], {"weight": 0.956286051462894}], ["FOXO3", ["TCGA.AA.A02Y.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.946842756769318}], ["FOXO3", ["TCGA.AD.6888.01", "Neuronal System"], {"weight": 0.956500625276238}], ["FOXO3", ["TCGA.AD.6888.01", "Transmission across Chemical Synapses"], {"weight": 0.945930684177386}], ["FOXO3", ["TCGA.AD.6888.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.940734179533806}], ["FOXO3", ["TCGA.AD.A5EK.01", "Neuronal System"], {"weight": 0.942462952537323}], ["FOXO3", ["TCGA.AD.A5EK.01", "Transmission across Chemical Synapses"], {"weight": 0.937211703347844}], ["FOXO3", ["TCGA.AD.A5EK.01", "Stimuli-sensing channels"], {"weight": 0.925678675185769}], ["FOXO3", ["TCGA.AD.A5EK.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.915793472234767}], ["FOXO3", ["TCGA.AM.5820.01", "FOXO-mediated transcription"], {"weight": 0.846116040385002}], ["FOXO3", ["TCGA.AM.5820.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], {"weight": 0.825602020761288}], ["FOXO3", ["TCGA.AM.5820.01", "Signaling by NODAL"], {"weight": 0.923487217531279}], ["FOXO3", ["TCGA.AM.5820.01", "FOXO-mediated transcription of cell death genes"], {"weight": 0.758292198630918}], ["FOXO3", ["TCGA.AY.A8YK.01", "Signaling Pathways"], {"weight": 0.873032488140319}], ["FOXO3", ["TCGA.AZ.6598.01", "Neuronal System"], {"weight": 0.95546686591524}], ["FOXO3", ["TCGA.AZ.6598.01", "Transmission across Chemical Synapses"], {"weight": 0.95276776700923}], ["FOXO3", ["TCGA.AZ.6598.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.93765381994606}], ["FOXO3", ["TCGA.AZ.6600.01", "FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"], {"weight": 0.709292395426306}], ["FOXO3", ["TCGA.AZ.6606.01", "Phase 0 - rapid depolarisation"], {"weight": 0.903067048025671}], ["FOXO3", ["TCGA.AZ.6608.01", "Signaling Pathways"], {"weight": 0.924590154539499}], ["FOXO3", ["TCGA.AZ.6608.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.939763931182355}], ["FOXO3", ["TCGA.CA.5255.01", "Neuronal System"], {"weight": 0.942811400757637}], ["FOXO3", ["TCGA.CA.5255.01", "Transmission across Chemical Synapses"], {"weight": 0.935657274365564}], ["FOXO3", ["TCGA.CA.5255.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.918477830521418}], ["FOXO3", ["TCGA.CA.5255.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.876936454091406}], ["FOXO3", ["TCGA.CM.5860.01", "Ethanol oxidation"], {"weight": 0.757602525125123}], ["FOXO3", ["TCGA.CM.5868.01", "Signaling Pathways"], {"weight": 0.878335303283626}], ["FOXO3", ["TCGA.CM.5868.01", "TNFs bind their physiological receptors"], {"weight": 0.481845189906295}], ["FOXO3", ["TCGA.D5.6529.01", "Phase 0 - rapid depolarisation"], {"weight": 0.829117317310678}], ["FOXO3", ["TCGA.D5.6529.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.892210832430793}], ["FOXO3", ["TCGA.D5.6531.01", "Neuronal System"], {"weight": 0.930479750706623}], ["FOXO3", ["TCGA.D5.6531.01", "Transmission across Chemical Synapses"], {"weight": 0.923855097316515}], ["FOXO3", ["TCGA.D5.6531.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.894962034252569}], ["FOXO3", ["TCGA.D5.6531.01", "Regulation of beta-cell development"], {"weight": 0.903195442080345}], ["FOXO3", ["TCGA.DM.A0X9.01", "Neuronal System"], {"weight": 0.94672204978222}], ["FOXO3", ["TCGA.DM.A0X9.01", "Transmission across Chemical Synapses"], {"weight": 0.948489428463225}], ["FOXO3", ["TCGA.DM.A28F.01", "Phase 0 - rapid depolarisation"], {"weight": 0.910355260937371}], ["DLL1", ["TCGA.4T.AA8H.01", "Molecules associated with elastic fibres"], {"weight": 0.876986837483856}], ["DLL1", ["TCGA.4T.AA8H.01", "Elastic fibre formation"], {"weight": 0.879245014437033}], ["DLL1", ["TCGA.A6.6649.01", "Extracellular matrix organization"], {"weight": 0.862930873272292}], ["DLL1", ["TCGA.A6.6652.01", "Molecules associated with elastic fibres"], {"weight": 0.808888170063447}], ["DLL1", ["TCGA.AA.3852.01", "Extracellular matrix organization"], {"weight": 0.824703962658092}], ["DLL1", ["TCGA.AA.3971.01", "Regulation of FZD by ubiquitination"], {"weight": 0.726426932236661}], ["DLL1", ["TCGA.AA.3971.01", "FGFR2 ligand binding and activation"], {"weight": 0.517464923279762}], ["DLL1", ["TCGA.AA.3971.01", "Blood group systems biosynthesis"], {"weight": 0.529312395617695}], ["DLL1", ["TCGA.AA.A00J.01", "Extracellular matrix organization"], {"weight": 0.861984998563414}], ["DLL1", ["TCGA.AA.A01D.01", "Extracellular matrix organization"], {"weight": 0.902266386628542}], ["DLL1", ["TCGA.AA.A022.01", "Extracellular matrix organization"], {"weight": 0.889596408904288}], ["DLL1", ["TCGA.AA.A022.01", "Muscle contraction"], {"weight": 0.932536401208753}], ["DLL1", ["TCGA.AA.A022.01", "Transport of small molecules"], {"weight": 0.935160861211629}], ["DLL1", ["TCGA.AA.A022.01", "Ion transport by P-type ATPases"], {"weight": 0.866319684995131}], ["DLL1", ["TCGA.AA.A022.01", "Glycogen synthesis"], {"weight": 0.815417406023694}], ["DLL1", ["TCGA.AA.A022.01", "Ion channel transport"], {"weight": 0.938144621792854}], ["DLL1", ["TCGA.AA.A02E.01", "Ion channel transport"], {"weight": 0.917427435760052}], ["DLL1", ["TCGA.AA.A02O.01", "Stimuli-sensing channels"], {"weight": 0.938687667894495}], ["DLL1", ["TCGA.AA.A02Y.01", "Molecules associated with elastic fibres"], {"weight": 0.914891769011397}], ["DLL1", ["TCGA.AD.6888.01", "Molecules associated with elastic fibres"], {"weight": 0.893256351258868}], ["DLL1", ["TCGA.AM.5820.01", "Extracellular matrix organization"], {"weight": 0.81784071679374}], ["DLL1", ["TCGA.AY.4070.01", "Blood group systems biosynthesis"], {"weight": 0.810724555836409}], ["DLL1", ["TCGA.AY.4070.01", "Lewis blood group biosynthesis"], {"weight": 0.794582966011584}], ["DLL1", ["TCGA.AY.6196.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.876958649322955}], ["DLL1", ["TCGA.AY.6196.01", "Blood group systems biosynthesis"], {"weight": 0.611439146159032}], ["DLL1", ["TCGA.AZ.4616.01", "Extracellular matrix organization"], {"weight": 0.902310741151456}], ["DLL1", ["TCGA.AZ.4616.01", "Ion transport by P-type ATPases"], {"weight": 0.785725060605048}], ["DLL1", ["TCGA.AZ.6606.01", "Molecules associated with elastic fibres"], {"weight": 0.85735091466473}], ["DLL1", ["TCGA.AZ.6608.01", "Molecules associated with elastic fibres"], {"weight": 0.906283736850824}], ["DLL1", ["TCGA.CA.5256.01", "Molecules associated with elastic fibres"], {"weight": 0.747229174251754}], ["DLL1", ["TCGA.CM.6167.01", "Extracellular matrix organization"], {"weight": 0.857944077801797}], ["DLL1", ["TCGA.D5.5541.01", "Blood group systems biosynthesis"], {"weight": 0.853449492342006}], ["DLL1", ["TCGA.D5.5541.01", "Cardiac conduction"], {"weight": 0.892755718823576}], ["DLL1", ["TCGA.D5.5541.01", "Ion channel transport"], {"weight": 0.899227943869799}], ["DLL1", ["TCGA.D5.5541.01", "O-linked glycosylation of mucins"], {"weight": 0.90119698261363}], ["DLL1", ["TCGA.D5.5541.01", "Lewis blood group biosynthesis"], {"weight": 0.835613512489135}], ["DLL1", ["TCGA.D5.5541.01", "Platelet calcium homeostasis"], {"weight": 0.866869270177757}], ["DLL1", ["TCGA.D5.5541.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.917142120977145}], ["DLL1", ["TCGA.D5.6537.01", "Molecules associated with elastic fibres"], {"weight": 0.833229014022993}], ["DLL1", ["TCGA.G4.6299.01", "Blood group systems biosynthesis"], {"weight": 0.836101927539117}], ["DLL1", ["TCGA.G4.6299.01", "Cardiac conduction"], {"weight": 0.889414846296664}], ["DLL1", ["TCGA.G4.6299.01", "Lewis blood group biosynthesis"], {"weight": 0.831358875852623}], ["DLL1", ["TCGA.G4.6306.01", "Molecules associated with elastic fibres"], {"weight": 0.89087808336288}], ["DLL1", ["TCGA.NH.A6GA.01", "L1CAM interactions"], {"weight": 0.808586913683049}], ["DLL1", ["TCGA.NH.A6GB.01", "Ion channel transport"], {"weight": 0.926531423504617}], ["DLL1", ["TCGA.NH.A6GB.01", "Extracellular matrix organization"], {"weight": 0.863553228678971}], ["DLL1", ["TCGA.NH.A6GB.01", "Ion transport by P-type ATPases"], {"weight": 0.874514967145397}], ["DLL1", ["TCGA.NH.A6GB.01", "Molecules associated with elastic fibres"], {"weight": 0.753968181817171}], ["DLL1", ["TCGA.NH.A6GB.01", "Ion homeostasis"], {"weight": 0.922629151362211}], ["DLL1", ["TCGA.NH.A6GB.01", "Sialic acid metabolism"], {"weight": 0.666501889526349}], ["DLL1", ["TCGA.NH.A6GB.01", "O-linked glycosylation of mucins"], {"weight": 0.888647958771529}], ["DLL1", ["TCGA.NH.A6GB.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.894808862906586}], ["DLL1", ["TCGA.NH.A6GB.01", "Sensory processing of sound"], {"weight": 0.897980120525502}], ["DLL1", ["TCGA.NH.A6GB.01", "Termination of O-glycan biosynthesis"], {"weight": 0.813663290255649}], ["HTR1B", ["TCGA.AA.3966.01", "G alpha (i) signalling events"], {"weight": 0.949457502970996}], ["HTR1B", ["TCGA.CK.5915.01", "G alpha (i) signalling events"], {"weight": 0.945781926296441}], ["HTR1B", ["TCGA.DM.A0X9.01", "GPCR ligand binding"], {"weight": 0.921024711404785}], ["PSMB1", ["TCGA.4T.AA8H.01", "Immune System"], {"weight": 0.866122343170311}], ["PSMB1", ["TCGA.AA.3875.01", "Diseases of mitotic cell cycle"], {"weight": 0.798551689726509}], ["PSMB1", ["TCGA.AA.3875.01", "Aberrant regulation of mitotic cell cycle due to RB1 defects"], {"weight": 0.798551689726509}], ["PSMB1", ["TCGA.AA.3875.01", "Aberrant regulation of mitotic exit in cancer due to RB1 defects"], {"weight": 0.70159775182287}], ["PSMB1", ["TCGA.AA.3939.01", "TNFs bind their physiological receptors"], {"weight": 0.332838469739762}], ["PSMB1", ["TCGA.AA.3971.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.0322837439652863}], ["PSMB1", ["TCGA.AA.3971.01", "JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1"], {"weight": 0.0655184554455513}], ["PSMB1", ["TCGA.AA.3971.01", "NOD1/2 Signaling Pathway"], {"weight": 0.478933592275979}], ["PSMB1", ["TCGA.AA.3971.01", "activated TAK1 mediates p38 MAPK activation"], {"weight": 0.0671063770493587}], ["PSMB1", ["TCGA.AA.A029.01", "Immune System"], {"weight": 0.882211903606128}], ["PSMB1", ["TCGA.AA.A02Y.01", "Signaling Pathways"], {"weight": 0.926585124016759}], ["PSMB1", ["TCGA.AA.A02Y.01", "Activation of SMO"], {"weight": 0.928316935966708}], ["PSMB1", ["TCGA.AD.6888.01", "Activation of SMO"], {"weight": 0.923340256694746}], ["PSMB1", ["TCGA.AD.6888.01", "TNFs bind their physiological receptors"], {"weight": 0.47656533388598}], ["PSMB1", ["TCGA.AZ.6606.01", "Activation of SMO"], {"weight": 0.899101315514096}], ["PSMB1", ["TCGA.AZ.6608.01", "Signaling by GPCR"], {"weight": 0.949210107297026}], ["PSMB1", ["TCGA.AZ.6608.01", "Immune System"], {"weight": 0.902248082800534}], ["PSMB1", ["TCGA.AZ.6608.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.808317015289306}], ["PSMB1", ["TCGA.CK.5915.01", "Immune System"], {"weight": 0.894395875357312}], ["PSMB1", ["TCGA.CK.5915.01", "Adaptive Immune System"], {"weight": 0.902963876209071}], ["PSMB1", ["TCGA.D5.6535.01", "Signaling by GPCR"], {"weight": 0.93167501594655}], ["PSMB1", ["TCGA.DM.A28F.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.791128194726047}], ["PSMB1", ["TCGA.DM.A28K.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.901717707933957}], ["PSMB1", ["TCGA.DM.A28K.01", "Activation of SMO"], {"weight": 0.775663392493501}], ["PSMB1", ["TCGA.G4.6299.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.776344577904289}], ["PSMB1", ["TCGA.G4.6306.01", "Activation of SMO"], {"weight": 0.900272214212667}], ["PSMB1", ["TCGA.NH.A6GB.01", "SLC-mediated transmembrane transport"], {"weight": 0.905383955865752}], ["PSMB1", ["TCGA.NH.A6GB.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.867093725124437}], ["TBP", ["TCGA.3L.AA1B.01", "Digestion and absorption"], {"weight": 0.708711950978034}], ["TBP", ["TCGA.AA.3852.01", "Keratinization"], {"weight": 0.849676664927014}], ["TBP", ["TCGA.AA.3852.01", "Phase II - Conjugation of compounds"], {"weight": 0.705891460843094}], ["TBP", ["TCGA.AA.3860.01", "Digestion and absorption"], {"weight": 0.513865914990103}], ["TBP", ["TCGA.AA.3971.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.5096385033367}], ["TBP", ["TCGA.AD.6888.01", "Muscle contraction"], {"weight": 0.952387881430808}], ["TBP", ["TCGA.AY.6196.01", "Metal ion SLC transporters"], {"weight": 0.798000952026441}], ["TBP", ["TCGA.AY.6196.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], {"weight": 0.706042168120998}], ["TBP", ["TCGA.AY.6196.01", "Aspirin ADME"], {"weight": 0.728599045009482}], ["TBP", ["TCGA.AZ.4616.01", "Cardiac conduction"], {"weight": 0.926250858039226}], ["TBP", ["TCGA.AZ.4616.01", "Muscle contraction"], {"weight": 0.927280042070121}], ["TBP", ["TCGA.AZ.4616.01", "Aspirin ADME"], {"weight": 0.802282738697688}], ["TBP", ["TCGA.AZ.4616.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], {"weight": 0.830757313743577}], ["TBP", ["TCGA.AZ.6606.01", "Cardiac conduction"], {"weight": 0.945073488162998}], ["TBP", ["TCGA.AZ.6607.01", "Digestion and absorption"], {"weight": 0.79966494932267}], ["TBP", ["TCGA.CM.6676.01", "Digestion and absorption"], {"weight": 0.74945538977826}], ["TBP", ["TCGA.CM.6678.01", "Digestion and absorption"], {"weight": 0.708926743892192}], ["TBP", ["TCGA.D5.5537.01", "Digestion and absorption"], {"weight": 0.720631312868015}], ["TBP", ["TCGA.D5.5541.01", "Transcription of E2F targets under negative control by DREAM complex"], {"weight": 0.826654977370416}], ["TBP", ["TCGA.D5.6529.01", "Digestion and absorption"], {"weight": 0.565376762756981}], ["TBP", ["TCGA.D5.6898.01", "Digestion and absorption"], {"weight": 0.686159595274416}], ["TBP", ["TCGA.DM.A28K.01", "Cardiac conduction"], {"weight": 0.950019566886106}], ["TBP", ["TCGA.DM.A28K.01", "Digestion and absorption"], {"weight": 0.713718094176995}], ["TBP", ["TCGA.F4.6704.01", "Digestion and absorption"], {"weight": 0.59704540303408}], ["TBP", ["TCGA.F4.6854.01", "Digestion and absorption"], {"weight": 0.439487548069893}], ["TBP", ["TCGA.G4.6299.01", "Metal ion SLC transporters"], {"weight": 0.77480141901851}], ["TBP", ["TCGA.NH.A6GB.01", "Cardiac conduction"], {"weight": 0.954319460647258}], ["TBP", ["TCGA.NH.A6GB.01", "Muscle contraction"], {"weight": 0.945041163465196}], ["SESN1", ["TCGA.AA.3560.01", "Cellular response to starvation"], {"weight": 0.928255229057189}], ["SESN1", ["TCGA.AA.3655.01", "Neuronal System"], {"weight": 0.933444123686511}], ["SESN1", ["TCGA.AA.3655.01", "Transmission across Chemical Synapses"], {"weight": 0.931348236281237}], ["SESN1", ["TCGA.AA.3685.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.884417002877854}], ["SESN1", ["TCGA.AA.3710.01", "Transmission across Chemical Synapses"], {"weight": 0.899296222146461}], ["SESN1", ["TCGA.AA.3710.01", "Neuronal System"], {"weight": 0.902047170189797}], ["SESN1", ["TCGA.AA.3837.01", "Carnitine metabolism"], {"weight": 0.396257754661889}], ["SESN1", ["TCGA.AA.3841.01", "Cellular response to starvation"], {"weight": 0.918207210082123}], ["SESN1", ["TCGA.AA.3848.01", "Cellular response to starvation"], {"weight": 0.933954564705479}], ["SESN1", ["TCGA.AA.3941.01", "Integration of energy metabolism"], {"weight": 0.906848829247257}], ["SESN1", ["TCGA.CA.5254.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.872600265792974}], ["SESN1", ["TCGA.CA.5256.01", "Neuronal System"], {"weight": 0.944293824615633}], ["SESN1", ["TCGA.CK.4952.01", "Carnitine metabolism"], {"weight": 0.846103553095463}], ["SESN1", ["TCGA.CM.5860.01", "Neuronal System"], {"weight": 0.898010727937078}], ["SESN1", ["TCGA.CM.5860.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.931044984312368}], ["SESN1", ["TCGA.CM.5860.01", "Integration of energy metabolism"], {"weight": 0.87732327650582}], ["PHIP", ["TCGA.AA.3966.01", "Voltage gated Potassium channels"], {"weight": 0.85341163837184}], ["PHIP", ["TCGA.CM.6675.01", "Voltage gated Potassium channels"], {"weight": 0.934859858347489}], ["ELOVL4", ["TCGA.AA.3837.01", "Glucuronidation"], {"weight": 0.504100299489194}], ["ELOVL4", ["TCGA.AA.3837.01", "Aspirin ADME"], {"weight": 0.693937996848519}], ["ELOVL4", ["TCGA.AA.3848.01", "Heme degradation"], {"weight": 0.808702990453656}], ["ELOVL4", ["TCGA.AA.3848.01", "Glucuronidation"], {"weight": 0.894314479475129}], ["ELOVL4", ["TCGA.AA.3870.01", "Glucuronidation"], {"weight": 0.843395845729592}], ["ELOVL4", ["TCGA.AA.3870.01", "Phase II - Conjugation of compounds"], {"weight": 0.889966082689853}], ["ELOVL4", ["TCGA.AA.3875.01", "Synthesis of very long-chain fatty acyl-CoAs"], {"weight": 0.817245976823999}], ["ELOVL4", ["TCGA.AA.3875.01", "Aspirin ADME"], {"weight": 0.426145201163988}], ["ELOVL4", ["TCGA.AA.3952.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.0421653886508502}], ["ELOVL4", ["TCGA.AA.3966.01", "Biological oxidations"], {"weight": 0.916455520637777}], ["ELOVL4", ["TCGA.AA.3966.01", "Phase II - Conjugation of compounds"], {"weight": 0.820141817785012}], ["ELOVL4", ["TCGA.AA.3966.01", "Glucuronidation"], {"weight": 0.937899068572243}], ["ELOVL4", ["TCGA.AA.3966.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.728827666403016}], ["ELOVL4", ["TCGA.AA.3966.01", "Aspirin ADME"], {"weight": 0.838483300661035}], ["ELOVL4", ["TCGA.AZ.6598.01", "Glucuronidation"], {"weight": 0.870003302570333}], ["ELOVL4", ["TCGA.AZ.6607.01", "Fatty acid metabolism"], {"weight": 0.908683498522563}], ["ELOVL4", ["TCGA.AZ.6608.01", "Glucuronidation"], {"weight": 0.808647362593187}], ["ELOVL4", ["TCGA.AZ.6608.01", "Aspirin ADME"], {"weight": 0.777565820320713}], ["ELOVL4", ["TCGA.CA.5254.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], {"weight": 0.897387758035105}], ["ELOVL4", ["TCGA.CK.5915.01", "Aspirin ADME"], {"weight": 0.736450377319347}], ["ELOVL4", ["TCGA.CK.5915.01", "Biosynthesis of DHA-derived SPMs"], {"weight": 0.872631716647332}], ["ELOVL4", ["TCGA.CK.5915.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], {"weight": 0.908876170697841}], ["ELOVL4", ["TCGA.D5.6529.01", "Heme degradation"], {"weight": 0.721587991498072}], ["ELOVL4", ["TCGA.D5.6529.01", "Aspirin ADME"], {"weight": 0.699044293086312}], ["ELOVL4", ["TCGA.D5.6529.01", "Porphyrin metabolism"], {"weight": 0.671227735060938}], ["ELOVL4", ["TCGA.D5.6537.01", "Heme degradation"], {"weight": 0.792391738852242}], ["ELOVL4", ["TCGA.DM.A0X9.01", "Heme degradation"], {"weight": 0.767823291970259}], ["ELOVL4", ["TCGA.DM.A28F.01", "Phase I - Functionalization of compounds"], {"weight": 0.945658667667852}], ["ELOVL4", ["TCGA.DM.A28F.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], {"weight": 0.870841329248941}], ["ELOVL4", ["TCGA.DM.A28F.01", "Cytochrome P450 - arranged by substrate type"], {"weight": 0.80775290836229}], ["ELOVL4", ["TCGA.DM.A28F.01", "Biosynthesis of DHA-derived SPMs"], {"weight": 0.782210365432625}], ["ELOVL4", ["TCGA.F4.6704.01", "Glucuronidation"], {"weight": 0.906599902847096}], ["ELOVL4", ["TCGA.F4.6704.01", "Aspirin ADME"], {"weight": 0.9369428743378}], ["SMPD2", ["TCGA.AA.3685.01", "Metabolism"], {"weight": 0.911483738517692}], ["SMPD2", ["TCGA.AA.3710.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.884565233343235}], ["SMPD2", ["TCGA.CK.5915.01", "Sialic acid metabolism"], {"weight": 0.766913731717044}], ["TTK", ["TCGA.4T.AA8H.01", "Muscle contraction"], {"weight": 0.948241436860462}], ["TTK", ["TCGA.AA.3561.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], {"weight": 0.810738535408392}], ["TTK", ["TCGA.AA.3561.01", "Mitotic Spindle Checkpoint"], {"weight": 0.937401537844521}], ["TTK", ["TCGA.AA.3561.01", "Cell Cycle"], {"weight": 0.912332074758419}], ["TTK", ["TCGA.AA.3561.01", "APC/C-mediated degradation of cell cycle proteins"], {"weight": 0.930076141301195}], ["TTK", ["TCGA.AA.3561.01", "Regulation of mitotic cell cycle"], {"weight": 0.930076141301195}], ["TTK", ["TCGA.AA.3561.01", "Resolution of Sister Chromatid Cohesion"], {"weight": 0.930965497473765}], ["TTK", ["TCGA.AA.3666.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], {"weight": 0.849126116585493}], ["TTK", ["TCGA.AA.3875.01", "Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components"], {"weight": 0.791626231698917}], ["TTK", ["TCGA.AA.3875.01", "Inactivation of APC/C via direct inhibition of the APC/C complex"], {"weight": 0.791626231698917}], ["TTK", ["TCGA.AA.3875.01", "APC-Cdc20 mediated degradation of Nek2A"], {"weight": 0.791626231698917}], ["TTK", ["TCGA.AA.3875.01", "TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest"], {"weight": 0.675548465251619}], ["TTK", ["TCGA.AZ.6606.01", "Muscle contraction"], {"weight": 0.932434311670688}], ["BCKDHB", ["TCGA.AA.3560.01", "Amino acid and derivative metabolism"], {"weight": 0.92256125040778}], ["BCKDHB", ["TCGA.AA.3560.01", "Metabolism"], {"weight": 0.910396371767505}], ["BCKDHB", ["TCGA.AA.3561.01", "Developmental Biology"], {"weight": 0.888073409730202}], ["BCKDHB", ["TCGA.AA.3837.01", "Selenoamino acid metabolism"], {"weight": 0.877314737020878}], ["BCKDHB", ["TCGA.AA.3848.01", "Signaling by Retinoic Acid"], {"weight": 0.817980863442766}], ["BCKDHB", ["TCGA.AA.3966.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.92472146591481}], ["BCKDHB", ["TCGA.AA.3966.01", "Metabolism"], {"weight": 0.909367915354867}], ["BCKDHB", ["TCGA.AA.A022.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.948819834171812}], ["BCKDHB", ["TCGA.CA.5256.01", "Metabolism"], {"weight": 0.920562557692825}], ["BCKDHB", ["TCGA.CA.5256.01", "Amino acid and derivative metabolism"], {"weight": 0.896661914279499}], ["BCKDHB", ["TCGA.D5.6931.01", "Signaling by Retinoic Acid"], {"weight": 0.694941296751683}], ["BCKDHB", ["TCGA.D5.6931.01", "Signaling by Nuclear Receptors"], {"weight": 0.500421620465271}], ["AK9", ["TCGA.4T.AA8H.01", "Platelet homeostasis"], {"weight": 0.865443623137762}], ["AK9", ["TCGA.A6.2686.01", "Metabolism"], {"weight": 0.907720951663553}], ["AK9", ["TCGA.AA.3685.01", "Cardiac conduction"], {"weight": 0.92441214471924}], ["AK9", ["TCGA.AA.3710.01", "Phase 0 - rapid depolarisation"], {"weight": 0.811223709917776}], ["AK9", ["TCGA.AA.3710.01", "Drug ADME"], {"weight": 0.804352626212046}], ["AK9", ["TCGA.AA.3837.01", "Drug ADME"], {"weight": 0.758525800401193}], ["AK9", ["TCGA.AA.3848.01", "Digestion"], {"weight": 0.296430971323062}], ["AK9", ["TCGA.AA.3848.01", "mRNA decay by 3' to 5' exoribonuclease"], {"weight": 0.533594798829175}], ["AK9", ["TCGA.AA.3848.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.746744765613288}], ["AK9", ["TCGA.AA.3858.01", "Digestion"], {"weight": 0.367715756763423}], ["AK9", ["TCGA.AA.3875.01", "Ribavirin ADME"], {"weight": 0.684405086337785}], ["AK9", ["TCGA.AA.3875.01", "Drug ADME"], {"weight": 0.651014753296907}], ["AK9", ["TCGA.AA.3952.01", "Ribavirin ADME"], {"weight": 0.773785312853272}], ["AK9", ["TCGA.AA.A00F.01", "GABA receptor activation"], {"weight": 0.815604703647888}], ["AK9", ["TCGA.AA.A00F.01", "G alpha (z) signalling events"], {"weight": 0.855002182189118}], ["AK9", ["TCGA.AZ.6598.01", "Cardiac conduction"], {"weight": 0.938906879710775}], ["AK9", ["TCGA.AZ.6600.01", "G alpha (s) signalling events"], {"weight": 0.92609836271663}], ["AK9", ["TCGA.AZ.6600.01", "Signaling by GPCR"], {"weight": 0.912990690338093}], ["AK9", ["TCGA.AZ.6600.01", "GPCR downstream signalling"], {"weight": 0.928914000992477}], ["AK9", ["TCGA.CM.5860.01", "Signaling by GPCR"], {"weight": 0.929691763995212}], ["AK9", ["TCGA.CM.5860.01", "G alpha (s) signalling events"], {"weight": 0.95323638782957}], ["AK9", ["TCGA.CM.5868.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.916824995985783}], ["AK9", ["TCGA.CM.5868.01", "Activation of the phototransduction cascade"], {"weight": 0.787867658037902}], ["AK9", ["TCGA.CM.5868.01", "Digestion"], {"weight": 0.483739164243876}], ["AK9", ["TCGA.CM.5868.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.880790837832922}], ["AK9", ["TCGA.CM.5868.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.623084605204192}], ["AK9", ["TCGA.D5.6531.01", "Cardiac conduction"], {"weight": 0.910403334097693}], ["AK9", ["TCGA.D5.6531.01", "Metabolism of vitamins and cofactors"], {"weight": 0.751276468705639}], ["IBTK", ["TCGA.4T.AA8H.01", "CD22 mediated BCR regulation"], {"weight": 0.855900656203525}], ["IBTK", ["TCGA.4T.AA8H.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.927629108195761}], ["IBTK", ["TCGA.4T.AA8H.01", "DAP12 interactions"], {"weight": 0.927787233373872}], ["IBTK", ["TCGA.4T.AA8H.01", "FCGR3A-mediated IL10 synthesis"], {"weight": 0.881170197859702}], ["IBTK", ["TCGA.4T.AA8H.01", "DAP12 signaling"], {"weight": 0.908465867690762}], ["IBTK", ["TCGA.A6.2686.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.806871178990584}], ["IBTK", ["TCGA.A6.6652.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.875702190351014}], ["IBTK", ["TCGA.A6.6652.01", "CD22 mediated BCR regulation"], {"weight": 0.907566617695819}], ["IBTK", ["TCGA.AA.3560.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.915979632619238}], ["IBTK", ["TCGA.AA.3560.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.880917643329965}], ["IBTK", ["TCGA.AA.3560.01", "Formation of the ternary complex, and subsequently, the 43S complex"], {"weight": 0.9234928091873}], ["IBTK", ["TCGA.AA.3560.01", "Ribosomal scanning and start codon recognition"], {"weight": 0.9234928091873}], ["IBTK", ["TCGA.AA.3560.01", "Translation initiation complex formation"], {"weight": 0.9234928091873}], ["IBTK", ["TCGA.AA.3560.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], {"weight": 0.9234928091873}], ["IBTK", ["TCGA.AA.3561.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.938707427313875}], ["IBTK", ["TCGA.AA.3561.01", "Peptide chain elongation"], {"weight": 0.946878359662081}], ["IBTK", ["TCGA.AA.3561.01", "Viral mRNA Translation"], {"weight": 0.946735991315591}], ["IBTK", ["TCGA.AA.3561.01", "Eukaryotic Translation Elongation"], {"weight": 0.946878359662081}], ["IBTK", ["TCGA.AA.3561.01", "Eukaryotic Translation Termination"], {"weight": 0.930960207356392}], ["IBTK", ["TCGA.AA.3561.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.913884855921479}], ["IBTK", ["TCGA.AA.3561.01", "Selenoamino acid metabolism"], {"weight": 0.935189391240994}], ["IBTK", ["TCGA.AA.3561.01", "Selenocysteine synthesis"], {"weight": 0.946735991315591}], ["IBTK", ["TCGA.AA.3561.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.946735991315591}], ["IBTK", ["TCGA.AA.3561.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.947580711031444}], ["IBTK", ["TCGA.AA.3561.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.947580711031444}], ["IBTK", ["TCGA.AA.3561.01", "Influenza Infection"], {"weight": 0.947454840705958}], ["IBTK", ["TCGA.AA.3561.01", "SARS-CoV-1-host interactions"], {"weight": 0.837748709454021}], ["IBTK", ["TCGA.AA.3561.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.944189569573195}], ["IBTK", ["TCGA.AA.3561.01", "Formation of a pool of free 40S subunits"], {"weight": 0.946735991315591}], ["IBTK", ["TCGA.AA.3561.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.946310496331218}], ["IBTK", ["TCGA.AA.3561.01", "Eukaryotic Translation Initiation"], {"weight": 0.946654136394999}], ["IBTK", ["TCGA.AA.3561.01", "Cap-dependent Translation Initiation"], {"weight": 0.946654136394999}], ["IBTK", ["TCGA.AA.3561.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.946006542355996}], ["IBTK", ["TCGA.AA.3561.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], {"weight": 0.918684309303089}], ["IBTK", ["TCGA.AA.3561.01", "Formation of the ternary complex, and subsequently, the 43S complex"], {"weight": 0.916716139139416}], ["IBTK", ["TCGA.AA.3561.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.88571281273803}], ["IBTK", ["TCGA.AA.3561.01", "Ribosomal scanning and start codon recognition"], {"weight": 0.916482759137473}], ["IBTK", ["TCGA.AA.3561.01", "Translation initiation complex formation"], {"weight": 0.916482759137473}], ["IBTK", ["TCGA.AA.3561.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.932432143657936}], ["IBTK", ["TCGA.AA.3561.01", "rRNA processing"], {"weight": 0.932432143657936}], ["IBTK", ["TCGA.AA.3561.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.946421801593258}], ["IBTK", ["TCGA.AA.3561.01", "SARS-CoV-1 Infection"], {"weight": 0.837206776568354}], ["IBTK", ["TCGA.AA.3561.01", "Signaling by ROBO receptors"], {"weight": 0.918839056792186}], ["IBTK", ["TCGA.AA.3561.01", "Regulation of expression of SLITs and ROBOs"], {"weight": 0.933885510838858}], ["IBTK", ["TCGA.AA.3561.01", "CD22 mediated BCR regulation"], {"weight": 0.845116864297757}], ["IBTK", ["TCGA.AA.3655.01", "CD22 mediated BCR regulation"], {"weight": 0.81641471505601}], ["IBTK", ["TCGA.AA.3655.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.677860104790334}], ["IBTK", ["TCGA.AA.3655.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.894114824724389}], ["IBTK", ["TCGA.AA.3939.01", "Viral mRNA Translation"], {"weight": 0.94564569753918}], ["IBTK", ["TCGA.AA.3939.01", "Peptide chain elongation"], {"weight": 0.94564569753918}], ["IBTK", ["TCGA.AA.3939.01", "Selenocysteine synthesis"], {"weight": 0.94564569753918}], ["IBTK", ["TCGA.AA.3939.01", "Selenoamino acid metabolism"], {"weight": 0.911757070085124}], ["IBTK", ["TCGA.AA.3939.01", "Eukaryotic Translation Termination"], {"weight": 0.94564569753918}], ["IBTK", ["TCGA.AA.3939.01", "Formation of a pool of free 40S subunits"], {"weight": 0.944469844666018}], ["IBTK", ["TCGA.AA.3939.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.94564569753918}], ["IBTK", ["TCGA.AA.3939.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.939905102439043}], ["IBTK", ["TCGA.AA.3939.01", "Eukaryotic Translation Initiation"], {"weight": 0.944056930843865}], ["IBTK", ["TCGA.AA.3939.01", "Cap-dependent Translation Initiation"], {"weight": 0.944056930843865}], ["IBTK", ["TCGA.AA.3939.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.94385625825392}], ["IBTK", ["TCGA.AA.3939.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.946585316186303}], ["IBTK", ["TCGA.AA.3939.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.946585316186303}], ["IBTK", ["TCGA.AA.3939.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.944406658465267}], ["IBTK", ["TCGA.AA.3939.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.887948999554904}], ["IBTK", ["TCGA.AA.3939.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.945911763999606}], ["IBTK", ["TCGA.AA.3939.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], {"weight": 0.896668224940087}], ["IBTK", ["TCGA.AA.3939.01", "Ribosomal scanning and start codon recognition"], {"weight": 0.892844860747952}], ["IBTK", ["TCGA.AA.3939.01", "Translation initiation complex formation"], {"weight": 0.892844860747952}], ["IBTK", ["TCGA.AA.3939.01", "Formation of the ternary complex, and subsequently, the 43S complex"], {"weight": 0.889255247267844}], ["IBTK", ["TCGA.AA.3966.01", "Interleukin-6 family signaling"], {"weight": 0.898397888922262}], ["IBTK", ["TCGA.AA.A029.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.934879750099171}], ["IBTK", ["TCGA.AA.A029.01", "GPVI-mediated activation cascade"], {"weight": 0.910751113444426}], ["IBTK", ["TCGA.AA.A029.01", "CD22 mediated BCR regulation"], {"weight": 0.87706968360919}], ["IBTK", ["TCGA.AA.A02Y.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.937008892264875}], ["IBTK", ["TCGA.AA.A02Y.01", "CD22 mediated BCR regulation"], {"weight": 0.880238989098389}], ["IBTK", ["TCGA.AD.6888.01", "CD22 mediated BCR regulation"], {"weight": 0.880239685905942}], ["IBTK", ["TCGA.AD.6888.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.90087650118519}], ["IBTK", ["TCGA.AD.A5EK.01", "CD22 mediated BCR regulation"], {"weight": 0.890852475916453}], ["IBTK", ["TCGA.AD.A5EK.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.936754054452273}], ["IBTK", ["TCGA.AM.5820.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.919752021243361}], ["IBTK", ["TCGA.AZ.6598.01", "CD22 mediated BCR regulation"], {"weight": 0.849995218733287}], ["IBTK", ["TCGA.AZ.6608.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.923621369561798}], ["IBTK", ["TCGA.AZ.6608.01", "Leishmania parasite growth and survival"], {"weight": 0.923621369561798}], ["IBTK", ["TCGA.AZ.6608.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.938114974892293}], ["IBTK", ["TCGA.AZ.6608.01", "CD22 mediated BCR regulation"], {"weight": 0.897844653022468}], ["IBTK", ["TCGA.CA.5254.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.883853227585832}], ["IBTK", ["TCGA.CA.5254.01", "Dectin-2 family"], {"weight": 0.856802328631469}], ["IBTK", ["TCGA.CA.5255.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.93361028576234}], ["IBTK", ["TCGA.CA.5256.01", "Viral mRNA Translation"], {"weight": 0.935693120316823}], ["IBTK", ["TCGA.CA.5256.01", "Peptide chain elongation"], {"weight": 0.935693120316823}], ["IBTK", ["TCGA.CA.5256.01", "Selenocysteine synthesis"], {"weight": 0.935693120316823}], ["IBTK", ["TCGA.CA.5256.01", "Eukaryotic Translation Termination"], {"weight": 0.935693120316823}], ["IBTK", ["TCGA.CA.5256.01", "Formation of a pool of free 40S subunits"], {"weight": 0.935091907584564}], ["IBTK", ["TCGA.CA.5256.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.935693120316823}], ["IBTK", ["TCGA.CA.5256.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.925201654460751}], ["IBTK", ["TCGA.CA.5256.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.935091907584564}], ["IBTK", ["TCGA.CA.5256.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.934985887406648}], ["IBTK", ["TCGA.CA.5256.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.936117058096748}], ["IBTK", ["TCGA.CA.5256.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.936117058096748}], ["IBTK", ["TCGA.CA.5256.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.939938835324443}], ["IBTK", ["TCGA.CA.5256.01", "rRNA processing"], {"weight": 0.939938835324443}], ["IBTK", ["TCGA.CA.5256.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.911366716631822}], ["IBTK", ["TCGA.CA.5256.01", "Regulation of expression of SLITs and ROBOs"], {"weight": 0.905939476539075}], ["IBTK", ["TCGA.CA.5256.01", "Formation of the ternary complex, and subsequently, the 43S complex"], {"weight": 0.912659371376306}], ["IBTK", ["TCGA.CA.5256.01", "Signaling by ROBO receptors"], {"weight": 0.9331816377898}], ["IBTK", ["TCGA.CA.5256.01", "Ribosomal scanning and start codon recognition"], {"weight": 0.912659371376306}], ["IBTK", ["TCGA.CA.5256.01", "Translation initiation complex formation"], {"weight": 0.912659371376306}], ["IBTK", ["TCGA.CA.5256.01", "SARS-CoV-1-host interactions"], {"weight": 0.911366716631822}], ["IBTK", ["TCGA.CA.5256.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.913297534002245}], ["IBTK", ["TCGA.CA.5256.01", "Platelet activation, signaling and aggregation"], {"weight": 0.876214380396392}], ["IBTK", ["TCGA.CK.4952.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.932963577380782}], ["IBTK", ["TCGA.CK.4952.01", "CD22 mediated BCR regulation"], {"weight": 0.884820604071728}], ["IBTK", ["TCGA.CK.4952.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.913734830351268}], ["IBTK", ["TCGA.CK.4952.01", "DAP12 signaling"], {"weight": 0.930342310391385}], ["IBTK", ["TCGA.CK.4952.01", "DAP12 interactions"], {"weight": 0.903970229705178}], ["IBTK", ["TCGA.CK.5915.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.924876426925667}], ["IBTK", ["TCGA.CK.5915.01", "CD22 mediated BCR regulation"], {"weight": 0.905984372001346}], ["IBTK", ["TCGA.CK.5915.01", "GPVI-mediated activation cascade"], {"weight": 0.92680282016467}], ["IBTK", ["TCGA.CM.6675.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.934808066165472}], ["IBTK", ["TCGA.CM.6675.01", "CD22 mediated BCR regulation"], {"weight": 0.882532744570831}], ["IBTK", ["TCGA.CM.6675.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.894185544548239}], ["IBTK", ["TCGA.CM.6676.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.92175982460369}], ["IBTK", ["TCGA.CM.6678.01", "CD22 mediated BCR regulation"], {"weight": 0.840396786353333}], ["IBTK", ["TCGA.CM.6678.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.915242257401037}], ["IBTK", ["TCGA.D5.6537.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.887445955691335}], ["IBTK", ["TCGA.D5.6537.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.939423949996917}], ["IBTK", ["TCGA.D5.6537.01", "CD22 mediated BCR regulation"], {"weight": 0.897850582682439}], ["IBTK", ["TCGA.D5.6931.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.648408791771251}], ["IBTK", ["TCGA.D5.6931.01", "Interleukin-6 family signaling"], {"weight": 0.789858229751347}], ["IBTK", ["TCGA.DM.A0X9.01", "CD22 mediated BCR regulation"], {"weight": 0.839841186599578}], ["IBTK", ["TCGA.F4.6856.01", "Leishmania infection"], {"weight": 0.804795385213473}], ["IBTK", ["TCGA.F4.6856.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.826103877524075}], ["IBTK", ["TCGA.F4.6856.01", "Leishmania parasite growth and survival"], {"weight": 0.826103877524075}], ["IBTK", ["TCGA.G4.6306.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.870484093721145}], ["WASF1", ["TCGA.4T.AA8H.01", "Drug ADME"], {"weight": 0.827952650425637}], ["WASF1", ["TCGA.AA.3848.01", "G beta:gamma signalling through CDC42"], {"weight": 0.919170787679324}], ["WASF1", ["TCGA.AA.3848.01", "G-protein beta:gamma signalling"], {"weight": 0.928170009919885}], ["WASF1", ["TCGA.AA.3848.01", "Metabolism of nitric oxide: NOS3 activation and regulation"], {"weight": 0.86102399222649}], ["WASF1", ["TCGA.AA.3848.01", "RHO GTPases activate KTN1"], {"weight": 0.892795415547786}], ["WASF1", ["TCGA.AA.3870.01", "Drug ADME"], {"weight": 0.894077866767876}], ["WASF1", ["TCGA.AA.3875.01", "E2F mediated regulation of DNA replication"], {"weight": 0.653551937679418}], ["WASF1", ["TCGA.AA.3979.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.783195674836127}], ["WASF1", ["TCGA.AA.3979.01", "GPCR downstream signalling"], {"weight": 0.945538776621328}], ["WASF1", ["TCGA.AA.3979.01", "Signaling by GPCR"], {"weight": 0.940830850691484}], ["WASF1", ["TCGA.AA.3979.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.818189946967503}], ["WASF1", ["TCGA.AA.3979.01", "Signaling Pathways"], {"weight": 0.918513397703189}], ["WASF1", ["TCGA.AA.3979.01", "GABA receptor activation"], {"weight": 0.918906179951746}], ["WASF1", ["TCGA.AA.3979.01", "Cardiac conduction"], {"weight": 0.924219254259536}], ["WASF1", ["TCGA.AA.3979.01", "G-protein beta:gamma signalling"], {"weight": 0.917099531709441}], ["WASF1", ["TCGA.AA.3979.01", "Interaction between L1 and Ankyrins"], {"weight": 0.904340592753998}], ["WASF1", ["TCGA.AA.3979.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.880705244679226}], ["WASF1", ["TCGA.AA.3979.01", "Leishmania parasite growth and survival"], {"weight": 0.880705244679226}], ["WASF1", ["TCGA.AA.3979.01", "Protein-protein interactions at synapses"], {"weight": 0.880586242570999}], ["WASF1", ["TCGA.AA.3979.01", "G1/S-Specific Transcription"], {"weight": 0.892951050183422}], ["WASF1", ["TCGA.AA.3979.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.901131832542904}], ["WASF1", ["TCGA.AA.3979.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.912928723372376}], ["WASF1", ["TCGA.AA.3979.01", "Muscle contraction"], {"weight": 0.931185771024007}], ["WASF1", ["TCGA.AA.3979.01", "Phase 0 - rapid depolarisation"], {"weight": 0.92271627174728}], ["WASF1", ["TCGA.AA.3979.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.938183004136345}], ["WASF1", ["TCGA.AA.3979.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.572117726297354}], ["WASF1", ["TCGA.AA.3979.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.900864586044048}], ["WASF1", ["TCGA.AA.3979.01", "Neurexins and neuroligins"], {"weight": 0.93928887798421}], ["WASF1", ["TCGA.AA.3979.01", "Generation of second messenger molecules"], {"weight": 0.884058823383118}], ["WASF1", ["TCGA.AA.3979.01", "DNA strand elongation"], {"weight": 0.848325581603019}], ["WASF1", ["TCGA.AA.3979.01", "Immune System"], {"weight": 0.886186480721552}], ["WASF1", ["TCGA.AA.3979.01", "GABA B receptor activation"], {"weight": 0.91790402234092}], ["WASF1", ["TCGA.AA.3979.01", "Activation of GABAB receptors"], {"weight": 0.91790402234092}], ["WASF1", ["TCGA.AA.3979.01", "G0 and Early G1"], {"weight": 0.881664585418131}], ["WASF1", ["TCGA.AA.3979.01", "Signaling by Retinoic Acid"], {"weight": -0.0195361632649727}], ["WASF1", ["TCGA.AA.3979.01", "NCAM1 interactions"], {"weight": 0.91360221304175}], ["WASF1", ["TCGA.AA.3979.01", "Signal amplification"], {"weight": 0.913525857182137}], ["WASF1", ["TCGA.AA.A00J.01", "Drug ADME"], {"weight": 0.903459695375449}], ["WASF1", ["TCGA.AZ.6607.01", "Drug ADME"], {"weight": 0.899227493597859}], ["WASF1", ["TCGA.AZ.6608.01", "Generation of second messenger molecules"], {"weight": 0.94442699860887}], ["WASF1", ["TCGA.AZ.6608.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.942936952340609}], ["WASF1", ["TCGA.AZ.6608.01", "PD-1 signaling"], {"weight": 0.943180782726096}], ["WASF1", ["TCGA.AZ.6608.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.94469837922097}], ["WASF1", ["TCGA.AZ.6608.01", "Costimulation by the CD28 family"], {"weight": 0.914290303690869}], ["WASF1", ["TCGA.CA.5254.01", "Drug ADME"], {"weight": 0.924230870727011}], ["WASF1", ["TCGA.CA.5255.01", "Generation of second messenger molecules"], {"weight": 0.918367289678949}], ["WASF1", ["TCGA.CA.5255.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.903164889715915}], ["WASF1", ["TCGA.CA.5255.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.905149827975669}], ["WASF1", ["TCGA.CA.5255.01", "PD-1 signaling"], {"weight": 0.899258675411275}], ["WASF1", ["TCGA.CA.5255.01", "G alpha (12/13) signalling events"], {"weight": 0.824615134908315}], ["WASF1", ["TCGA.CK.4952.01", "Drug ADME"], {"weight": 0.886559987080887}], ["WASF1", ["TCGA.CM.5863.01", "Drug ADME"], {"weight": 0.761473913758355}], ["WASF1", ["TCGA.CM.5868.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.91532791785157}], ["WASF1", ["TCGA.CM.5868.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.916893750363512}], ["WASF1", ["TCGA.CM.5868.01", "Generation of second messenger molecules"], {"weight": 0.924474255169102}], ["WASF1", ["TCGA.CM.5868.01", "PD-1 signaling"], {"weight": 0.909250535877514}], ["WASF1", ["TCGA.CM.5868.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.834194598000774}], ["WASF1", ["TCGA.CM.5868.01", "Scavenging of heme from plasma"], {"weight": 0.817601651451742}], ["WASF1", ["TCGA.CM.5868.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.694338326628492}], ["WASF1", ["TCGA.CM.5868.01", "Costimulation by the CD28 family"], {"weight": 0.845212945189336}], ["WASF1", ["TCGA.CM.6169.01", "Transmission across Chemical Synapses"], {"weight": 0.890273485650835}], ["WASF1", ["TCGA.CM.6169.01", "Neuronal System"], {"weight": 0.885046332897393}], ["WASF1", ["TCGA.CM.6169.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.881401331991881}], ["WASF1", ["TCGA.CM.6676.01", "Drug ADME"], {"weight": 0.868565591846827}], ["WASF1", ["TCGA.D5.6531.01", "Drug ADME"], {"weight": 0.834326598233263}], ["WASF1", ["TCGA.D5.6931.01", "Drug ADME"], {"weight": 0.859554298108368}], ["WASF1", ["TCGA.DM.A28F.01", "Drug ADME"], {"weight": 0.873706141865391}], ["WASF1", ["TCGA.F4.6704.01", "Drug ADME"], {"weight": 0.929712539009342}], ["WASF1", ["TCGA.NH.A6GA.01", "Drug ADME"], {"weight": 0.808138688744513}], ["TPBG", ["TCGA.CA.5255.01", "O-linked glycosylation of mucins"], {"weight": 0.910124642382037}], ["CDC40", ["TCGA.3L.AA1B.01", "Drug ADME"], {"weight": 0.728344087463814}], ["CDC40", ["TCGA.AA.3560.01", "Drug ADME"], {"weight": 0.846782486363313}], ["CDC40", ["TCGA.AA.3685.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.902514510583075}], ["CDC40", ["TCGA.AA.3685.01", "Influenza Infection"], {"weight": 0.902514510583075}], ["CDC40", ["TCGA.AA.3841.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.94137167127393}], ["CDC40", ["TCGA.AA.3848.01", "tRNA modification in the nucleus and cytosol"], {"weight": -0.010732901746101}], ["CDC40", ["TCGA.AA.A00F.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.389013623790711}], ["CDC40", ["TCGA.CA.5256.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.935172209713342}], ["CDC40", ["TCGA.CA.5256.01", "Influenza Infection"], {"weight": 0.935172209713342}], ["CDC40", ["TCGA.CM.5863.01", "Amino acid transport across the plasma membrane"], {"weight": 0.676261302034015}], ["DDO", ["TCGA.AA.3655.01", "Biological oxidations"], {"weight": 0.918922758987777}], ["DDO", ["TCGA.AA.3655.01", "Phase I - Functionalization of compounds"], {"weight": 0.918987637707329}], ["DDO", ["TCGA.AA.3660.01", "Drug ADME"], {"weight": 0.895602959419162}], ["DDO", ["TCGA.AA.3858.01", "Drug ADME"], {"weight": 0.908952756450404}], ["DDO", ["TCGA.AA.A00F.01", "Ethanol oxidation"], {"weight": 0.724257687005218}], ["DDO", ["TCGA.AA.A02H.01", "Sulfur amino acid metabolism"], {"weight": 0.722920391736661}], ["DDO", ["TCGA.AZ.6598.01", "Drug ADME"], {"weight": 0.920945041583441}], ["DDO", ["TCGA.CM.5348.01", "Drug ADME"], {"weight": 0.842715636566268}], ["DDO", ["TCGA.CM.5868.01", "Ethanol oxidation"], {"weight": 0.749257224975285}], ["DDO", ["TCGA.CM.5868.01", "Phase II - Conjugation of compounds"], {"weight": 0.774909283949835}], ["DDO", ["TCGA.CM.6169.01", "Metabolism"], {"weight": 0.900195359648264}], ["DDO", ["TCGA.CM.6169.01", "Ethanol oxidation"], {"weight": 0.768185656761768}], ["DDO", ["TCGA.D5.5537.01", "Drug ADME"], {"weight": 0.853267289343261}], ["DDO", ["TCGA.D5.6529.01", "Drug ADME"], {"weight": 0.869021177811144}], ["DDO", ["TCGA.D5.6898.01", "Drug ADME"], {"weight": 0.87477778285099}], ["SLC22A16", ["TCGA.3L.AA1B.01", "SLC-mediated transmembrane transport"], {"weight": 0.914104476431015}], ["SLC22A16", ["TCGA.5M.AATA.01", "SLC-mediated transmembrane transport"], {"weight": 0.862907233931673}], ["SLC22A16", ["TCGA.A6.2686.01", "SLC-mediated transmembrane transport"], {"weight": 0.899403930853258}], ["SLC22A16", ["TCGA.A6.6652.01", "SLC-mediated transmembrane transport"], {"weight": 0.914989789683802}], ["SLC22A16", ["TCGA.AA.3655.01", "SLC-mediated transmembrane transport"], {"weight": 0.90039580766918}], ["SLC22A16", ["TCGA.AA.3660.01", "SLC-mediated transmembrane transport"], {"weight": 0.908669478438976}], ["SLC22A16", ["TCGA.AA.3837.01", "SLC-mediated transmembrane transport"], {"weight": 0.856457279202904}], ["SLC22A16", ["TCGA.AA.3848.01", "SLC-mediated transmembrane transport"], {"weight": 0.902176060163219}], ["SLC22A16", ["TCGA.AA.3952.01", "SLC-mediated transmembrane transport"], {"weight": 0.898536571010489}], ["SLC22A16", ["TCGA.AA.A01D.01", "SLC-mediated transmembrane transport"], {"weight": 0.914726901937449}], ["SLC22A16", ["TCGA.AA.A01X.01", "SLC-mediated transmembrane transport"], {"weight": 0.915083041659038}], ["SLC22A16", ["TCGA.AD.A5EK.01", "SLC-mediated transmembrane transport"], {"weight": 0.931272940946139}], ["SLC22A16", ["TCGA.AY.A8YK.01", "SLC-mediated transmembrane transport"], {"weight": 0.911844709982651}], ["SLC22A16", ["TCGA.AZ.6598.01", "SLC-mediated transmembrane transport"], {"weight": 0.939192009432318}], ["SLC22A16", ["TCGA.AZ.6607.01", "SLC-mediated transmembrane transport"], {"weight": 0.92314990934055}], ["SLC22A16", ["TCGA.CA.5255.01", "SLC-mediated transmembrane transport"], {"weight": 0.931090902650486}], ["SLC22A16", ["TCGA.CK.4952.01", "SLC-mediated transmembrane transport"], {"weight": 0.951283344725718}], ["SLC22A16", ["TCGA.CM.5348.01", "SLC-mediated transmembrane transport"], {"weight": 0.890564995683644}], ["SLC22A16", ["TCGA.CM.5860.01", "SLC-mediated transmembrane transport"], {"weight": 0.898979253586084}], ["SLC22A16", ["TCGA.CM.5863.01", "SLC-mediated transmembrane transport"], {"weight": 0.89439148774145}], ["SLC22A16", ["TCGA.CM.5868.01", "Transport of small molecules"], {"weight": 0.916057521918852}], ["SLC22A16", ["TCGA.CM.6161.01", "SLC-mediated transmembrane transport"], {"weight": 0.835868305674954}], ["SLC22A16", ["TCGA.CM.6169.01", "Transport of small molecules"], {"weight": 0.928694872809583}], ["SLC22A16", ["TCGA.CM.6169.01", "SLC-mediated transmembrane transport"], {"weight": 0.886744846824014}], ["SLC22A16", ["TCGA.D5.5537.01", "SLC-mediated transmembrane transport"], {"weight": 0.91768269722688}], ["SLC22A16", ["TCGA.D5.6529.01", "SLC-mediated transmembrane transport"], {"weight": 0.891969881649062}], ["SLC22A16", ["TCGA.D5.6531.01", "SLC-mediated transmembrane transport"], {"weight": 0.903161356360187}], ["SLC22A16", ["TCGA.D5.6931.01", "SLC-mediated transmembrane transport"], {"weight": 0.815229426892661}], ["SLC22A16", ["TCGA.F4.6460.01", "SLC-mediated transmembrane transport"], {"weight": 0.865122838205691}], ["SLC22A16", ["TCGA.F4.6704.01", "SLC-mediated transmembrane transport"], {"weight": 0.904363454599095}], ["SLC22A16", ["TCGA.NH.A6GA.01", "SLC-mediated transmembrane transport"], {"weight": 0.946574142106493}], ["CDK19", ["TCGA.AA.3837.01", "Integration of energy metabolism"], {"weight": 0.768346886936814}], ["CDK19", ["TCGA.AA.3941.01", "Regulation of insulin secretion"], {"weight": 0.893905495350294}], ["CDK19", ["TCGA.AA.A00F.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.894266085380545}], ["CDK19", ["TCGA.AA.A00F.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.894266085380545}], ["CDK19", ["TCGA.AA.A00F.01", "Surfactant metabolism"], {"weight": 0.797251713398928}], ["CDK19", ["TCGA.AA.A00F.01", "Diseases of Immune System"], {"weight": 0.832650864906806}], ["CDK19", ["TCGA.AA.A00F.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.832650864906806}], ["CDK19", ["TCGA.AA.A00F.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.778810735053532}], ["CDK19", ["TCGA.AD.A5EK.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0287771433915435}], ["CDK19", ["TCGA.AZ.6598.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0237514761628323}], ["CDK19", ["TCGA.AZ.6607.01", "Transport of small molecules"], {"weight": 0.945961877684461}], ["CDK19", ["TCGA.AZ.6608.01", "Integration of energy metabolism"], {"weight": 0.941207146077717}], ["CDK19", ["TCGA.CA.5254.01", "Regulation of insulin secretion"], {"weight": 0.91445998193511}], ["CDK19", ["TCGA.CA.5254.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0279666757316641}], ["CDK19", ["TCGA.CA.5254.01", "Integration of energy metabolism"], {"weight": 0.924067081799077}], ["CDK19", ["TCGA.CK.5915.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0204441211304593}], ["CDK19", ["TCGA.CK.5915.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": -0.0252502646893633}], ["CDK19", ["TCGA.CK.5915.01", "Regulation of insulin secretion"], {"weight": 0.920441876978907}], ["CDK19", ["TCGA.CM.5860.01", "Regulation of insulin secretion"], {"weight": 0.857917187938413}], ["CDK19", ["TCGA.CM.5868.01", "Biological oxidations"], {"weight": 0.869327153128417}], ["CDK19", ["TCGA.CM.5868.01", "Recycling of bile acids and salts"], {"weight": 0.887209640413962}], ["CDK19", ["TCGA.D5.5537.01", "Regulation of insulin secretion"], {"weight": 0.897688719847471}], ["CDK19", ["TCGA.D5.5537.01", "Integration of energy metabolism"], {"weight": 0.906312393023961}], ["CDK19", ["TCGA.D5.6535.01", "Integration of energy metabolism"], {"weight": 0.898020877850127}], ["CDK19", ["TCGA.DM.A1D7.01", "Phase I - Functionalization of compounds"], {"weight": 0.955835316595323}], ["CDK19", ["TCGA.QL.A97D.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0337366867163089}], ["AMD1", ["TCGA.A6.2686.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.922701402257727}], ["AMD1", ["TCGA.AA.3715.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.953395562628129}], ["AMD1", ["TCGA.AA.3837.01", "DNA methylation"], {"weight": 0.193030157937361}], ["AMD1", ["TCGA.AA.3837.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.835170716351806}], ["AMD1", ["TCGA.AA.3841.01", "DNA methylation"], {"weight": 0.524869399178983}], ["AMD1", ["TCGA.AA.3841.01", "SUMOylation of DNA methylation proteins"], {"weight": 0.851177300852286}], ["AMD1", ["TCGA.AA.3848.01", "DNA methylation"], {"weight": 0.826557937960226}], ["AMD1", ["TCGA.AA.3848.01", "SUMOylation of DNA methylation proteins"], {"weight": 0.874254734108159}], ["AMD1", ["TCGA.AA.3858.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.914640411530657}], ["AMD1", ["TCGA.AA.3875.01", "DNA methylation"], {"weight": 0.301891381609235}], ["AMD1", ["TCGA.AA.A00F.01", "Biological oxidations"], {"weight": 0.78721009170928}], ["AMD1", ["TCGA.AA.A01D.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.901833051670819}], ["AMD1", ["TCGA.AA.A02H.01", "DNA methylation"], {"weight": 0.510174929882023}], ["AMD1", ["TCGA.CM.5860.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.925030201818965}], ["AMD1", ["TCGA.CM.5868.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.922699288458145}], ["AMD1", ["TCGA.CM.6169.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.870959527480034}], ["AMD1", ["TCGA.D5.6537.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.941171449948897}], ["GTF3C6", ["TCGA.AA.3848.01", "RNA Polymerase III Chain Elongation"], {"weight": 0.857268257946994}], ["GTF3C6", ["TCGA.AA.3848.01", "RNA Polymerase III Transcription Termination"], {"weight": 0.885277921238467}], ["GTF3C6", ["TCGA.AA.3848.01", "Signaling by FGFR2 IIIa TM"], {"weight": 0.901737249354337}], ["GTF3C6", ["TCGA.AA.3848.01", "Telomere Maintenance"], {"weight": 0.922630211983086}], ["GTF3C6", ["TCGA.AA.3848.01", "MicroRNA (miRNA) biogenesis"], {"weight": 0.724189450886547}], ["GTF3C6", ["TCGA.AA.A00F.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.854878178500484}], ["GTF3C6", ["TCGA.CM.5868.01", "Collagen chain trimerization"], {"weight": 0.88353689396496}], ["GTF3C6", ["TCGA.CM.5868.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.916137142824674}], ["GTF3C6", ["TCGA.CM.5868.01", "Collagen formation"], {"weight": 0.926241634854687}], ["GTF3C6", ["TCGA.CM.5868.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.731911429960288}], ["GTF3C6", ["TCGA.D5.6931.01", "Collagen formation"], {"weight": 0.836579475203155}], ["GTF3C6", ["TCGA.D5.6931.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.860613714126034}], ["GTF3C6", ["TCGA.D5.6931.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.814666860931932}], ["GTF3C6", ["TCGA.DM.A1D7.01", "Digestion and absorption"], {"weight": 0.429256561838223}], ["GTF3C6", ["TCGA.DM.A1D7.01", "Digestion"], {"weight": 0.533367569752598}], ["RPF2", ["TCGA.AA.3685.01", "rRNA processing"], {"weight": 0.897660846772494}], ["RPF2", ["TCGA.AA.3848.01", "rRNA processing"], {"weight": 0.920130456389957}], ["RPF2", ["TCGA.AA.3848.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.941041417569097}], ["RPF2", ["TCGA.AA.3979.01", "GPCR ligand binding"], {"weight": 0.942257792329915}], ["RPF2", ["TCGA.AA.3979.01", "Initial triggering of complement"], {"weight": 0.75297520333705}], ["ME1", ["TCGA.A6.2678.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.882391433804061}], ["ME1", ["TCGA.A6.2686.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.721819615384983}], ["ME1", ["TCGA.AA.3561.01", "Biological oxidations"], {"weight": 0.909050592786729}], ["ME1", ["TCGA.AA.3561.01", "Polo-like kinase mediated events"], {"weight": 0.874420210695799}], ["ME1", ["TCGA.AA.3561.01", "LXRs regulate gene expression linked to cholesterol transport and efflux"], {"weight": 0.898195770930173}], ["ME1", ["TCGA.AA.3561.01", "Metabolism"], {"weight": 0.912555402543149}], ["ME1", ["TCGA.AA.3561.01", "LXR-mediated signaling"], {"weight": 0.911059817336772}], ["ME1", ["TCGA.AA.3561.01", "Endogenous sterols"], {"weight": 0.554180735615586}], ["ME1", ["TCGA.AA.3655.01", "Regulation of beta-cell development"], {"weight": 0.838698681696593}], ["ME1", ["TCGA.AA.3655.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.892681589377954}], ["ME1", ["TCGA.AA.3655.01", "Regulation of gene expression in beta cells"], {"weight": 0.738282675375252}], ["ME1", ["TCGA.AA.3837.01", "Keratinization"], {"weight": 0.840988828159987}], ["ME1", ["TCGA.AA.3837.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.59068338662044}], ["ME1", ["TCGA.AA.3848.01", "G alpha (q) signalling events"], {"weight": 0.922710130569536}], ["ME1", ["TCGA.AA.3875.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.610196038082405}], ["ME1", ["TCGA.AA.3939.01", "Keratinization"], {"weight": 0.889756929352527}], ["ME1", ["TCGA.AA.3966.01", "SLC-mediated transmembrane transport"], {"weight": 0.901654222695489}], ["ME1", ["TCGA.AA.A02H.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.730757855438343}], ["ME1", ["TCGA.AZ.6603.01", "Biological oxidations"], {"weight": 0.87675129972006}], ["ME1", ["TCGA.AZ.6603.01", "Phase II - Conjugation of compounds"], {"weight": 0.792613511248813}], ["ME1", ["TCGA.AZ.6603.01", "Neuronal System"], {"weight": 0.772715164201334}], ["ME1", ["TCGA.AZ.6603.01", "Glucuronidation"], {"weight": 0.845418836782133}], ["ME1", ["TCGA.AZ.6603.01", "Ethanol oxidation"], {"weight": 0.696915828585029}], ["ME1", ["TCGA.AZ.6603.01", "Drug ADME"], {"weight": 0.795158835294002}], ["ME1", ["TCGA.AZ.6603.01", "GPCR ligand binding"], {"weight": 0.895738668629019}], ["ME1", ["TCGA.AZ.6603.01", "Transport of small molecules"], {"weight": 0.892359779912672}], ["ME1", ["TCGA.AZ.6603.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.740574042562877}], ["ME1", ["TCGA.AZ.6603.01", "Stimuli-sensing channels"], {"weight": 0.793858773769416}], ["ME1", ["TCGA.AZ.6603.01", "Signaling by GPCR"], {"weight": 0.941483745745052}], ["ME1", ["TCGA.AZ.6603.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.0166532238779476}], ["ME1", ["TCGA.AZ.6603.01", "Transmission across Chemical Synapses"], {"weight": 0.837093714021923}], ["ME1", ["TCGA.AZ.6603.01", "NCAM signaling for neurite out-growth"], {"weight": 0.611543299358574}], ["ME1", ["TCGA.AZ.6603.01", "GPCR downstream signalling"], {"weight": 0.948562390352373}], ["ME1", ["TCGA.AZ.6603.01", "Peptide hormone metabolism"], {"weight": 0.723258287646312}], ["ME1", ["TCGA.AZ.6603.01", "Ion channel transport"], {"weight": 0.837945288197897}], ["ME1", ["TCGA.AZ.6603.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.742607303796917}], ["ME1", ["TCGA.AZ.6603.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.785499854378622}], ["ME1", ["TCGA.AZ.6603.01", "Signaling by Retinoic Acid"], {"weight": 0.752849908288128}], ["ME1", ["TCGA.AZ.6603.01", "Signal amplification"], {"weight": 0.740574042562877}], ["ME1", ["TCGA.AZ.6603.01", "G alpha (q) signalling events"], {"weight": 0.927467738676994}], ["ME1", ["TCGA.AZ.6603.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.884578182370694}], ["ME1", ["TCGA.AZ.6603.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.770086663120454}], ["ME1", ["TCGA.AZ.6603.01", "Extracellular matrix organization"], {"weight": 0.702258984724784}], ["ME1", ["TCGA.AZ.6603.01", "Regulation of insulin secretion"], {"weight": 0.715031541679073}], ["ME1", ["TCGA.AZ.6603.01", "Metabolism"], {"weight": 0.864754403853981}], ["ME1", ["TCGA.AZ.6603.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.825724985042734}], ["ME1", ["TCGA.AZ.6607.01", "Keratinization"], {"weight": 0.92003684019282}], ["ME1", ["TCGA.CM.5863.01", "Keratinization"], {"weight": 0.823062391132543}], ["ME1", ["TCGA.CM.6675.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.907876672455317}], ["ME1", ["TCGA.D5.6529.01", "Keratinization"], {"weight": 0.866827434946137}], ["ME1", ["TCGA.D5.6531.01", "Regulation of gene expression by Hypoxia-inducible Factor"], {"weight": 0.909534550846507}], ["ME1", ["TCGA.D5.6531.01", "Keratinization"], {"weight": 0.861088623004679}], ["ME1", ["TCGA.D5.6931.01", "Keratinization"], {"weight": 0.862730742735235}], ["ME1", ["TCGA.D5.6931.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.86272635099961}], ["ME1", ["TCGA.D5.6931.01", "Integration of energy metabolism"], {"weight": 0.868647139770772}], ["ME1", ["TCGA.F4.6704.01", "Keratinization"], {"weight": 0.87661583467953}], ["ME1", ["TCGA.F4.6856.01", "Signaling by Retinoic Acid"], {"weight": 0.798253030073398}], ["ME1", ["TCGA.G4.6297.01", "Keratinization"], {"weight": 0.854159695667114}], ["REV3L", ["TCGA.AA.3685.01", "Translesion synthesis by POLK"], {"weight": 0.834789599402981}], ["REV3L", ["TCGA.AA.3685.01", "Translesion synthesis by POLI"], {"weight": 0.834789599402981}], ["REV3L", ["TCGA.AA.3841.01", "Polymerase switching on the C-strand of the telomere"], {"weight": 0.871909152738951}], ["REV3L", ["TCGA.AA.A00F.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.887990578856633}], ["REV3L", ["TCGA.CK.4952.01", "Homologous DNA Pairing and Strand Exchange"], {"weight": 0.884565213795891}], ["REV3L", ["TCGA.CK.4952.01", "Presynaptic phase of homologous DNA pairing and strand exchange"], {"weight": 0.89627585366526}], ["SNAP91", ["TCGA.A6.2686.01", "GPCR ligand binding"], {"weight": 0.87768046140594}], ["SNAP91", ["TCGA.AA.3666.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.854966447914838}], ["SNAP91", ["TCGA.AA.3860.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.803129693801435}], ["SNAP91", ["TCGA.AA.3941.01", "Binding and entry of HIV virion"], {"weight": 0.776044471179898}], ["SNAP91", ["TCGA.AA.3952.01", "Binding and entry of HIV virion"], {"weight": 0.670808136083804}], ["SNAP91", ["TCGA.AA.3952.01", "Cellular hexose transport"], {"weight": 0.729569227958184}], ["SNAP91", ["TCGA.AA.3952.01", "Transferrin endocytosis and recycling"], {"weight": 0.8510934803433}], ["SNAP91", ["TCGA.AA.3952.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.801073307783968}], ["SNAP91", ["TCGA.AA.3952.01", "Iron uptake and transport"], {"weight": 0.814285629875693}], ["SNAP91", ["TCGA.AA.3952.01", "Antimicrobial peptides"], {"weight": 0.367713546343983}], ["SNAP91", ["TCGA.AA.3956.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.859345288267646}], ["SNAP91", ["TCGA.AA.3956.01", "Regulation of signaling by NODAL"], {"weight": 0.613450593516761}], ["SNAP91", ["TCGA.AA.3956.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.739550533824943}], ["SNAP91", ["TCGA.AA.3956.01", "Degradation of the extracellular matrix"], {"weight": 0.851759549463869}], ["SNAP91", ["TCGA.AA.3956.01", "Regulation of FZD by ubiquitination"], {"weight": 0.629205525416366}], ["SNAP91", ["TCGA.AA.3956.01", "Collagen degradation"], {"weight": 0.564939306339678}], ["SNAP91", ["TCGA.AA.3956.01", "NCAM1 interactions"], {"weight": 0.408226993871063}], ["SNAP91", ["TCGA.AA.3956.01", "Interleukin-6 family signaling"], {"weight": 0.634948086026982}], ["SNAP91", ["TCGA.AA.3956.01", "Chemokine receptors bind chemokines"], {"weight": 0.773353342219124}], ["SNAP91", ["TCGA.AA.3956.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.494574854422099}], ["SNAP91", ["TCGA.AA.3956.01", "NCAM signaling for neurite out-growth"], {"weight": 0.52459604036027}], ["SNAP91", ["TCGA.AA.3956.01", "Antimicrobial peptides"], {"weight": -0.0183443459762781}], ["SNAP91", ["TCGA.AA.3956.01", "GPCR ligand binding"], {"weight": 0.792645932218259}], ["SNAP91", ["TCGA.AA.3956.01", "Extracellular matrix organization"], {"weight": 0.835421551005418}], ["SNAP91", ["TCGA.AA.3956.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.742450949177659}], ["SNAP91", ["TCGA.AA.3956.01", "Signaling by NODAL"], {"weight": 0.613450593516761}], ["SNAP91", ["TCGA.AA.3956.01", "Complement cascade"], {"weight": 0.496128776634993}], ["SNAP91", ["TCGA.AA.3956.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.528407730138067}], ["SNAP91", ["TCGA.AA.3956.01", "Retinoid metabolism and transport"], {"weight": 0.528407730138067}], ["SNAP91", ["TCGA.AA.3956.01", "Calcitonin-like ligand receptors"], {"weight": 0.252750701226499}], ["SNAP91", ["TCGA.AA.3966.01", "GPCR ligand binding"], {"weight": 0.915500584881002}], ["SNAP91", ["TCGA.AA.3966.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.911730041695479}], ["SNAP91", ["TCGA.AA.3966.01", "Transport of small molecules"], {"weight": 0.913735481214746}], ["SNAP91", ["TCGA.AA.3966.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.907349429704975}], ["SNAP91", ["TCGA.AA.A029.01", "Binding and entry of HIV virion"], {"weight": 0.806034584982272}], ["SNAP91", ["TCGA.AA.A02Y.01", "Peptide ligand-binding receptors"], {"weight": 0.945393404707656}], ["SNAP91", ["TCGA.AD.6888.01", "Binding and entry of HIV virion"], {"weight": 0.832660613590551}], ["SNAP91", ["TCGA.AZ.6606.01", "Peptide ligand-binding receptors"], {"weight": 0.933577318168543}], ["SNAP91", ["TCGA.AZ.6607.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.932616430749969}], ["SNAP91", ["TCGA.AZ.6608.01", "Binding and entry of HIV virion"], {"weight": 0.82739820179487}], ["SNAP91", ["TCGA.CM.5348.01", "GABA receptor activation"], {"weight": 0.833708862647802}], ["SNAP91", ["TCGA.D5.6537.01", "Regulation of FZD by ubiquitination"], {"weight": 0.92547695084417}], ["SNAP91", ["TCGA.D5.6931.01", "GABA receptor activation"], {"weight": 0.82810756021093}], ["SNAP91", ["TCGA.D5.6931.01", "L1CAM interactions"], {"weight": 0.871463590387464}], ["SNAP91", ["TCGA.D5.6931.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.887647602483362}], ["SNAP91", ["TCGA.D5.6931.01", "Recycling pathway of L1"], {"weight": 0.878788022145}], ["SNAP91", ["TCGA.F4.6856.01", "GPCR ligand binding"], {"weight": 0.92654620715181}], ["SNAP91", ["TCGA.F4.6856.01", "Protein-protein interactions at synapses"], {"weight": 0.927606183017656}], ["SNAP91", ["TCGA.F4.6856.01", "Peptide ligand-binding receptors"], {"weight": 0.92289031801444}], ["SNAP91", ["TCGA.F4.6856.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.923265234069321}], ["SNAP91", ["TCGA.F4.6856.01", "Defensins"], {"weight": 0.561019514533928}], ["SNAP91", ["TCGA.G4.6297.01", "Diseases of metabolism"], {"weight": 0.732712959823933}], ["SNAP91", ["TCGA.G4.6306.01", "Regulation of FZD by ubiquitination"], {"weight": 0.907576674789263}], ["FYN", ["TCGA.4T.AA8H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.741006953553692}], ["FYN", ["TCGA.4T.AA8H.01", "Cell surface interactions at the vascular wall"], {"weight": 0.809028498481461}], ["FYN", ["TCGA.4T.AA8H.01", "L1CAM interactions"], {"weight": 0.919242493034701}], ["FYN", ["TCGA.4T.AA8H.01", "Interaction between L1 and Ankyrins"], {"weight": 0.945243176420097}], ["FYN", ["TCGA.4T.AA8H.01", "Developmental Biology"], {"weight": 0.885809405225155}], ["FYN", ["TCGA.4T.AA8H.01", "Integration of energy metabolism"], {"weight": 0.908798811198506}], ["FYN", ["TCGA.4T.AA8H.01", "Other semaphorin interactions"], {"weight": 0.644426341875187}], ["FYN", ["TCGA.5M.AATA.01", "Interaction between L1 and Ankyrins"], {"weight": 0.932184772773833}], ["FYN", ["TCGA.A6.2678.01", "Interaction between L1 and Ankyrins"], {"weight": 0.92442013454683}], ["FYN", ["TCGA.A6.2686.01", "Axon guidance"], {"weight": 0.900820521669648}], ["FYN", ["TCGA.A6.2686.01", "Nervous system development"], {"weight": 0.891221753768786}], ["FYN", ["TCGA.A6.2686.01", "Regulation of insulin secretion"], {"weight": 0.909317869752409}], ["FYN", ["TCGA.A6.2686.01", "Protein-protein interactions at synapses"], {"weight": 0.855842249852575}], ["FYN", ["TCGA.A6.2686.01", "Integration of energy metabolism"], {"weight": 0.915928777457539}], ["FYN", ["TCGA.A6.2686.01", "Transport of small molecules"], {"weight": 0.918895035733946}], ["FYN", ["TCGA.A6.2686.01", "Dectin-2 family"], {"weight": 0.747649634722627}], ["FYN", ["TCGA.A6.4107.01", "Interaction between L1 and Ankyrins"], {"weight": 0.924847786465992}], ["FYN", ["TCGA.A6.6649.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.78394440392095}], ["FYN", ["TCGA.A6.6652.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.773137963422781}], ["FYN", ["TCGA.A6.6652.01", "Regulation of insulin secretion"], {"weight": 0.931161856137973}], ["FYN", ["TCGA.A6.6652.01", "Integration of energy metabolism"], {"weight": 0.933866796838263}], ["FYN", ["TCGA.A6.6652.01", "Immune System"], {"weight": 0.868096504470578}], ["FYN", ["TCGA.A6.6652.01", "Extracellular matrix organization"], {"weight": 0.875095237494809}], ["FYN", ["TCGA.A6.6652.01", "Interaction between L1 and Ankyrins"], {"weight": 0.949279565953645}], ["FYN", ["TCGA.A6.6652.01", "Cell surface interactions at the vascular wall"], {"weight": 0.759986653138191}], ["FYN", ["TCGA.AA.3521.01", "Regulation of insulin secretion"], {"weight": 0.87766977806485}], ["FYN", ["TCGA.AA.3560.01", "Developmental Biology"], {"weight": 0.891372189040091}], ["FYN", ["TCGA.AA.3560.01", "Nervous system development"], {"weight": 0.905325816238562}], ["FYN", ["TCGA.AA.3560.01", "Axon guidance"], {"weight": 0.908255246404144}], ["FYN", ["TCGA.AA.3655.01", "Interaction between L1 and Ankyrins"], {"weight": 0.93482412382078}], ["FYN", ["TCGA.AA.3655.01", "Extracellular matrix organization"], {"weight": 0.85596051959388}], ["FYN", ["TCGA.AA.3655.01", "Signaling Pathways"], {"weight": 0.888273601495621}], ["FYN", ["TCGA.AA.3655.01", "Visual phototransduction"], {"weight": 0.822263304209972}], ["FYN", ["TCGA.AA.3655.01", "Developmental Biology"], {"weight": 0.834774785639084}], ["FYN", ["TCGA.AA.3655.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.787366433897129}], ["FYN", ["TCGA.AA.3655.01", "Retinoid metabolism and transport"], {"weight": 0.787366433897129}], ["FYN", ["TCGA.AA.3660.01", "Interaction between L1 and Ankyrins"], {"weight": 0.915400171284741}], ["FYN", ["TCGA.AA.3660.01", "Developmental Biology"], {"weight": 0.85382477496672}], ["FYN", ["TCGA.AA.3660.01", "Protein-protein interactions at synapses"], {"weight": 0.801095925590974}], ["FYN", ["TCGA.AA.3660.01", "Extracellular matrix organization"], {"weight": 0.799257952510444}], ["FYN", ["TCGA.AA.3666.01", "Extracellular matrix organization"], {"weight": 0.824838852261404}], ["FYN", ["TCGA.AA.3666.01", "Interaction between L1 and Ankyrins"], {"weight": 0.93495531473727}], ["FYN", ["TCGA.AA.3666.01", "Transport of small molecules"], {"weight": 0.907692177858651}], ["FYN", ["TCGA.AA.3666.01", "Regulation of insulin secretion"], {"weight": 0.926977560569237}], ["FYN", ["TCGA.AA.3685.01", "Developmental Biology"], {"weight": 0.847911051361568}], ["FYN", ["TCGA.AA.3685.01", "Nervous system development"], {"weight": 0.883716736390104}], ["FYN", ["TCGA.AA.3685.01", "Axon guidance"], {"weight": 0.886338005512922}], ["FYN", ["TCGA.AA.3685.01", "Interaction between L1 and Ankyrins"], {"weight": 0.927520768983841}], ["FYN", ["TCGA.AA.3685.01", "Signaling by ROBO receptors"], {"weight": 0.85188634908655}], ["FYN", ["TCGA.AA.3685.01", "Integration of energy metabolism"], {"weight": 0.886188223467383}], ["FYN", ["TCGA.AA.3685.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.860165179437909}], ["FYN", ["TCGA.AA.3715.01", "Developmental Biology"], {"weight": 0.905210431494923}], ["FYN", ["TCGA.AA.3837.01", "Interaction between L1 and Ankyrins"], {"weight": 0.859447897518037}], ["FYN", ["TCGA.AA.3837.01", "Developmental Biology"], {"weight": 0.820925647265677}], ["FYN", ["TCGA.AA.3837.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.672148962899984}], ["FYN", ["TCGA.AA.3837.01", "Platelet sensitization by LDL"], {"weight": 0.534990881969533}], ["FYN", ["TCGA.AA.3841.01", "Integration of energy metabolism"], {"weight": 0.91130244499864}], ["FYN", ["TCGA.AA.3841.01", "Regulation of insulin secretion"], {"weight": 0.897885772509617}], ["FYN", ["TCGA.AA.3841.01", "RND1 GTPase cycle"], {"weight": 0.775102256755315}], ["FYN", ["TCGA.AA.3841.01", "Interaction between L1 and Ankyrins"], {"weight": 0.905921998770401}], ["FYN", ["TCGA.AA.3841.01", "CD209 (DC-SIGN) signaling"], {"weight": 0.745131088746069}], ["FYN", ["TCGA.AA.3844.01", "Extracellular matrix organization"], {"weight": 0.834962651187726}], ["FYN", ["TCGA.AA.3844.01", "Interaction between L1 and Ankyrins"], {"weight": 0.935123257081699}], ["FYN", ["TCGA.AA.3848.01", "Regulation of insulin secretion"], {"weight": 0.906247272230891}], ["FYN", ["TCGA.AA.3848.01", "Integration of energy metabolism"], {"weight": 0.918981824792099}], ["FYN", ["TCGA.AA.3848.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.89419796976165}], ["FYN", ["TCGA.AA.3848.01", "Interaction between L1 and Ankyrins"], {"weight": 0.939406226747294}], ["FYN", ["TCGA.AA.3848.01", "Interleukin-6 family signaling"], {"weight": 0.905379332193937}], ["FYN", ["TCGA.AA.3848.01", "Regulation of signaling by NODAL"], {"weight": 0.876434103266992}], ["FYN", ["TCGA.AA.3848.01", "Transport of vitamins, nucleosides, and related molecules"], {"weight": -0.0744324482939902}], ["FYN", ["TCGA.AA.3848.01", "RND1 GTPase cycle"], {"weight": 0.767743179264464}], ["FYN", ["TCGA.AA.3848.01", "Interleukin-27 signaling"], {"weight": 0.801481695602195}], ["FYN", ["TCGA.AA.3848.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.818819925312795}], ["FYN", ["TCGA.AA.3848.01", "Interleukin-35 Signalling"], {"weight": 0.801481695602195}], ["FYN", ["TCGA.AA.3848.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.906704857328843}], ["FYN", ["TCGA.AA.3848.01", "CD209 (DC-SIGN) signaling"], {"weight": 0.776505285878592}], ["FYN", ["TCGA.AA.3848.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.13949757244854}], ["FYN", ["TCGA.AA.3848.01", "L1CAM interactions"], {"weight": 0.864213607880104}], ["FYN", ["TCGA.AA.3858.01", "Interaction between L1 and Ankyrins"], {"weight": 0.922304254705281}], ["FYN", ["TCGA.AA.3860.01", "Transport of small molecules"], {"weight": 0.910437437425688}], ["FYN", ["TCGA.AA.3870.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.941339500658543}], ["FYN", ["TCGA.AA.3875.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.57601958191477}], ["FYN", ["TCGA.AA.3875.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.845752561977522}], ["FYN", ["TCGA.AA.3939.01", "Developmental Biology"], {"weight": 0.868777352070466}], ["FYN", ["TCGA.AA.3939.01", "Interaction between L1 and Ankyrins"], {"weight": 0.918116716947264}], ["FYN", ["TCGA.AA.3939.01", "Axon guidance"], {"weight": 0.888909327146288}], ["FYN", ["TCGA.AA.3939.01", "Nervous system development"], {"weight": 0.885252442861184}], ["FYN", ["TCGA.AA.3952.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.761305538721773}], ["FYN", ["TCGA.AA.3952.01", "Regulation of signaling by NODAL"], {"weight": 0.867560936372305}], ["FYN", ["TCGA.AA.3952.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.523386599220694}], ["FYN", ["TCGA.AA.3952.01", "L1CAM interactions"], {"weight": 0.742153157464315}], ["FYN", ["TCGA.AA.3952.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.836975491115758}], ["FYN", ["TCGA.AA.3952.01", "Extracellular matrix organization"], {"weight": 0.778969220174857}], ["FYN", ["TCGA.AA.3952.01", "Signaling by NODAL"], {"weight": 0.804888837747114}], ["FYN", ["TCGA.AA.A00F.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.942269811875438}], ["FYN", ["TCGA.AA.A00F.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.836477525651809}], ["FYN", ["TCGA.AA.A00F.01", "Leishmania parasite growth and survival"], {"weight": 0.836477525651809}], ["FYN", ["TCGA.AA.A00F.01", "G beta:gamma signalling through BTK"], {"weight": 0.863171118784118}], ["FYN", ["TCGA.AA.A00F.01", "Degradation of the extracellular matrix"], {"weight": 0.896654683945777}], ["FYN", ["TCGA.AA.A00F.01", "Signaling by GPCR"], {"weight": 0.912638262636886}], ["FYN", ["TCGA.AA.A00J.01", "Interaction between L1 and Ankyrins"], {"weight": 0.931875955364652}], ["FYN", ["TCGA.AA.A01X.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.697382074910006}], ["FYN", ["TCGA.AA.A029.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.71411941686145}], ["FYN", ["TCGA.AA.A029.01", "Interaction between L1 and Ankyrins"], {"weight": 0.94420287562633}], ["FYN", ["TCGA.AA.A029.01", "Regulation of insulin secretion"], {"weight": 0.925974413127468}], ["FYN", ["TCGA.AA.A029.01", "Integration of energy metabolism"], {"weight": 0.930575366557278}], ["FYN", ["TCGA.AA.A029.01", "Other semaphorin interactions"], {"weight": 0.567401464780551}], ["FYN", ["TCGA.AA.A029.01", "L1CAM interactions"], {"weight": 0.905973768919222}], ["FYN", ["TCGA.AA.A02H.01", "Interaction between L1 and Ankyrins"], {"weight": 0.928801612803542}], ["FYN", ["TCGA.AA.A02H.01", "Transport of small molecules"], {"weight": 0.92095691997469}], ["FYN", ["TCGA.AA.A02H.01", "L1CAM interactions"], {"weight": 0.811113302275146}], ["FYN", ["TCGA.AA.A02H.01", "Regulation of insulin secretion"], {"weight": 0.873321203373143}], ["FYN", ["TCGA.AA.A02H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.759191544463919}], ["FYN", ["TCGA.AA.A02H.01", "Leishmania parasite growth and survival"], {"weight": 0.759191544463919}], ["FYN", ["TCGA.AA.A02H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.424341350167062}], ["FYN", ["TCGA.AA.A02H.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.881611673684185}], ["FYN", ["TCGA.AA.A02H.01", "Developmental Biology"], {"weight": 0.838241293230579}], ["FYN", ["TCGA.AA.A02H.01", "Other semaphorin interactions"], {"weight": 0.314997610805998}], ["FYN", ["TCGA.AA.A02H.01", "CD22 mediated BCR regulation"], {"weight": 0.551371400313734}], ["FYN", ["TCGA.AA.A02Y.01", "Signaling by Receptor Tyrosine Kinases"], {"weight": 0.919804177948156}], ["FYN", ["TCGA.AA.A02Y.01", "Interaction between L1 and Ankyrins"], {"weight": 0.954904782064317}], ["FYN", ["TCGA.AA.A02Y.01", "L1CAM interactions"], {"weight": 0.925542989341026}], ["FYN", ["TCGA.AA.A02Y.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.925936333323929}], ["FYN", ["TCGA.AA.A02Y.01", "ERK1/ERK2 pathway"], {"weight": 0.909508279541415}], ["FYN", ["TCGA.AA.A02Y.01", "RAF/MAP kinase cascade"], {"weight": 0.914328563748695}], ["FYN", ["TCGA.AA.A02Y.01", "Nervous system development"], {"weight": 0.927505858527459}], ["FYN", ["TCGA.AA.A02Y.01", "Axon guidance"], {"weight": 0.924450040660583}], ["FYN", ["TCGA.AA.A02Y.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.698673425880527}], ["FYN", ["TCGA.AA.A02Y.01", "MAPK family signaling cascades"], {"weight": 0.910657922209292}], ["FYN", ["TCGA.AA.A02Y.01", "Regulation of insulin secretion"], {"weight": 0.947062462549837}], ["FYN", ["TCGA.AD.6888.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.792840141627882}], ["FYN", ["TCGA.AD.6888.01", "Extracellular matrix organization"], {"weight": 0.922087883230417}], ["FYN", ["TCGA.AD.6888.01", "Integration of energy metabolism"], {"weight": 0.949364063127199}], ["FYN", ["TCGA.AD.6888.01", "Cell surface interactions at the vascular wall"], {"weight": 0.856417008613207}], ["FYN", ["TCGA.AD.6888.01", "Regulation of insulin secretion"], {"weight": 0.949267653352977}], ["FYN", ["TCGA.AD.6888.01", "Interaction between L1 and Ankyrins"], {"weight": 0.953511350154711}], ["FYN", ["TCGA.AD.6888.01", "Signaling by Receptor Tyrosine Kinases"], {"weight": 0.914569501037467}], ["FYN", ["TCGA.AD.6888.01", "ERK1/ERK2 pathway"], {"weight": 0.912964359155887}], ["FYN", ["TCGA.AD.6888.01", "Other semaphorin interactions"], {"weight": 0.689302502442907}], ["FYN", ["TCGA.AD.6888.01", "RAF/MAP kinase cascade"], {"weight": 0.911578618566006}], ["FYN", ["TCGA.AD.6899.01", "Interaction between L1 and Ankyrins"], {"weight": 0.878063600663381}], ["FYN", ["TCGA.AD.A5EK.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.758080797626915}], ["FYN", ["TCGA.AD.A5EK.01", "Regulation of insulin secretion"], {"weight": 0.944257717275245}], ["FYN", ["TCGA.AD.A5EK.01", "Integration of energy metabolism"], {"weight": 0.946126573920986}], ["FYN", ["TCGA.AD.A5EK.01", "Transport of small molecules"], {"weight": 0.921113311611394}], ["FYN", ["TCGA.AD.A5EK.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.909571138481873}], ["FYN", ["TCGA.AD.A5EK.01", "Leishmania parasite growth and survival"], {"weight": 0.909571138481873}], ["FYN", ["TCGA.AD.A5EK.01", "Other semaphorin interactions"], {"weight": 0.514794111674559}], ["FYN", ["TCGA.AD.A5EK.01", "Interaction between L1 and Ankyrins"], {"weight": 0.927532345143434}], ["FYN", ["TCGA.AM.5820.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.809319448131015}], ["FYN", ["TCGA.AM.5820.01", "Immune System"], {"weight": 0.85123011623441}], ["FYN", ["TCGA.AM.5820.01", "Signaling Pathways"], {"weight": 0.893503145999588}], ["FYN", ["TCGA.AM.5820.01", "Adaptive Immune System"], {"weight": 0.878625300495598}], ["FYN", ["TCGA.AY.A8YK.01", "Interaction between L1 and Ankyrins"], {"weight": 0.934953353328642}], ["FYN", ["TCGA.AY.A8YK.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.636029931760329}], ["FYN", ["TCGA.AY.A8YK.01", "Protein-protein interactions at synapses"], {"weight": 0.874966625647958}], ["FYN", ["TCGA.AY.A8YK.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.872447136596167}], ["FYN", ["TCGA.AZ.6598.01", "Extracellular matrix organization"], {"weight": 0.910667536706228}], ["FYN", ["TCGA.AZ.6598.01", "Interaction between L1 and Ankyrins"], {"weight": 0.956653157260692}], ["FYN", ["TCGA.AZ.6598.01", "Regulation of insulin secretion"], {"weight": 0.944331731878023}], ["FYN", ["TCGA.AZ.6598.01", "Integration of energy metabolism"], {"weight": 0.946369611899068}], ["FYN", ["TCGA.AZ.6598.01", "Degradation of the extracellular matrix"], {"weight": 0.895008401804436}], ["FYN", ["TCGA.AZ.6600.01", "Metabolism"], {"weight": 0.850773165358067}], ["FYN", ["TCGA.AZ.6600.01", "Interaction between L1 and Ankyrins"], {"weight": 0.873009391523324}], ["FYN", ["TCGA.AZ.6606.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.774326174533315}], ["FYN", ["TCGA.AZ.6606.01", "Interaction between L1 and Ankyrins"], {"weight": 0.93988529494203}], ["FYN", ["TCGA.AZ.6606.01", "Extracellular matrix organization"], {"weight": 0.861296191449874}], ["FYN", ["TCGA.AZ.6606.01", "Developmental Biology"], {"weight": 0.879261014551252}], ["FYN", ["TCGA.AZ.6606.01", "Other semaphorin interactions"], {"weight": 0.654298672587381}], ["FYN", ["TCGA.AZ.6606.01", "Cell surface interactions at the vascular wall"], {"weight": 0.677257844506513}], ["FYN", ["TCGA.AZ.6607.01", "Signaling by GPCR"], {"weight": 0.940818508683125}], ["FYN", ["TCGA.AZ.6608.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.807352225962485}], ["FYN", ["TCGA.AZ.6608.01", "Extracellular matrix organization"], {"weight": 0.924638348059881}], ["FYN", ["TCGA.AZ.6608.01", "Interaction between L1 and Ankyrins"], {"weight": 0.949754946693085}], ["FYN", ["TCGA.AZ.6608.01", "Other semaphorin interactions"], {"weight": 0.763794758976763}], ["FYN", ["TCGA.AZ.6608.01", "Cell surface interactions at the vascular wall"], {"weight": 0.859720393226142}], ["FYN", ["TCGA.CA.5254.01", "Extracellular matrix organization"], {"weight": 0.884839473201582}], ["FYN", ["TCGA.CA.5254.01", "Interaction between L1 and Ankyrins"], {"weight": 0.944329807308698}], ["FYN", ["TCGA.CA.5255.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.739496679068331}], ["FYN", ["TCGA.CA.5255.01", "Interaction between L1 and Ankyrins"], {"weight": 0.940194571945826}], ["FYN", ["TCGA.CA.5255.01", "Extracellular matrix organization"], {"weight": 0.892410335484464}], ["FYN", ["TCGA.CA.5255.01", "Transport of small molecules"], {"weight": 0.918310072460054}], ["FYN", ["TCGA.CA.5255.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.877861415930198}], ["FYN", ["TCGA.CA.5255.01", "Cell surface interactions at the vascular wall"], {"weight": 0.767048323778476}], ["FYN", ["TCGA.CA.5255.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.849206993727121}], ["FYN", ["TCGA.CA.5255.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.874006667658127}], ["FYN", ["TCGA.CA.5255.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.863980839904699}], ["FYN", ["TCGA.CA.5255.01", "FCGR3A-mediated IL10 synthesis"], {"weight": 0.851205220772372}], ["FYN", ["TCGA.CA.5255.01", "Integration of energy metabolism"], {"weight": 0.923700427685911}], ["FYN", ["TCGA.CA.5255.01", "Regulation of insulin secretion"], {"weight": 0.915982722180785}], ["FYN", ["TCGA.CA.5256.01", "Interaction between L1 and Ankyrins"], {"weight": 0.934900608327482}], ["FYN", ["TCGA.CA.5256.01", "Extracellular matrix organization"], {"weight": 0.877529031699553}], ["FYN", ["TCGA.CA.5256.01", "Integration of energy metabolism"], {"weight": 0.917777876788686}], ["FYN", ["TCGA.CK.4952.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.790443139237857}], ["FYN", ["TCGA.CK.4952.01", "Interaction between L1 and Ankyrins"], {"weight": 0.953631755611353}], ["FYN", ["TCGA.CK.4952.01", "Extracellular matrix organization"], {"weight": 0.862534289027027}], ["FYN", ["TCGA.CK.5915.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.860035932314868}], ["FYN", ["TCGA.CK.5915.01", "Interaction between L1 and Ankyrins"], {"weight": 0.946552932381509}], ["FYN", ["TCGA.CK.5915.01", "Other semaphorin interactions"], {"weight": 0.716602426067092}], ["FYN", ["TCGA.CK.5915.01", "Innate Immune System"], {"weight": 0.896089958095779}], ["FYN", ["TCGA.CK.5915.01", "Endosomal/Vacuolar pathway"], {"weight": 0.873597313077905}], ["FYN", ["TCGA.CK.5915.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.916031054018409}], ["FYN", ["TCGA.CK.5915.01", "Semaphorin interactions"], {"weight": 0.79683317969148}], ["FYN", ["TCGA.CK.5915.01", "Netrin-1 signaling"], {"weight": 0.791229270606193}], ["FYN", ["TCGA.CM.5860.01", "Extracellular matrix organization"], {"weight": 0.906784761443958}], ["FYN", ["TCGA.CM.5860.01", "Degradation of the extracellular matrix"], {"weight": 0.876642055571973}], ["FYN", ["TCGA.CM.5860.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.94704715907014}], ["FYN", ["TCGA.CM.5860.01", "Protein-protein interactions at synapses"], {"weight": 0.759700496262986}], ["FYN", ["TCGA.CM.5860.01", "GPCR downstream signalling"], {"weight": 0.932541690694564}], ["FYN", ["TCGA.CM.5860.01", "Transport of small molecules"], {"weight": 0.906547602416071}], ["FYN", ["TCGA.CM.5860.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.910710181498216}], ["FYN", ["TCGA.CM.5860.01", "Neurexins and neuroligins"], {"weight": 0.904812753638018}], ["FYN", ["TCGA.CM.5860.01", "Peptide hormone metabolism"], {"weight": 0.71961658577049}], ["FYN", ["TCGA.CM.5860.01", "Synaptic adhesion-like molecules"], {"weight": 0.906569607004016}], ["FYN", ["TCGA.CM.5860.01", "NCAM signaling for neurite out-growth"], {"weight": 0.787302648876304}], ["FYN", ["TCGA.CM.5860.01", "Interaction between L1 and Ankyrins"], {"weight": 0.908952424944779}], ["FYN", ["TCGA.CM.5860.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.900857096598217}], ["FYN", ["TCGA.CM.5860.01", "Long-term potentiation"], {"weight": 0.908203188895156}], ["FYN", ["TCGA.CM.5860.01", "G alpha (q) signalling events"], {"weight": 0.897131058079084}], ["FYN", ["TCGA.CM.5863.01", "Transport of small molecules"], {"weight": 0.931421489659431}], ["FYN", ["TCGA.CM.5863.01", "TNFs bind their physiological receptors"], {"weight": 0.364775701803402}], ["FYN", ["TCGA.CM.5868.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.723233583374436}], ["FYN", ["TCGA.CM.5868.01", "Extracellular matrix organization"], {"weight": 0.87256273807507}], ["FYN", ["TCGA.CM.5868.01", "Interaction between L1 and Ankyrins"], {"weight": 0.927041431939841}], ["FYN", ["TCGA.CM.5868.01", "Platelet homeostasis"], {"weight": 0.819885896617724}], ["FYN", ["TCGA.CM.5868.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.786234213326605}], ["FYN", ["TCGA.CM.5868.01", "Visual phototransduction"], {"weight": 0.809562026729111}], ["FYN", ["TCGA.CM.5868.01", "NCAM1 interactions"], {"weight": 0.928206118049061}], ["FYN", ["TCGA.CM.5868.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.812250607851463}], ["FYN", ["TCGA.CM.5868.01", "Protein-protein interactions at synapses"], {"weight": 0.685556619144182}], ["FYN", ["TCGA.CM.5868.01", "NCAM signaling for neurite out-growth"], {"weight": 0.898092209466286}], ["FYN", ["TCGA.CM.5868.01", "Developmental Biology"], {"weight": 0.819556149626638}], ["FYN", ["TCGA.CM.5868.01", "Cell surface interactions at the vascular wall"], {"weight": 0.575473589261039}], ["FYN", ["TCGA.CM.5868.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.844705283470162}], ["FYN", ["TCGA.CM.5868.01", "Long-term potentiation"], {"weight": 0.916781892122524}], ["FYN", ["TCGA.CM.5868.01", "Acetylcholine binding and downstream events"], {"weight": 0.760342645441374}], ["FYN", ["TCGA.CM.5868.01", "Postsynaptic nicotinic acetylcholine receptors"], {"weight": 0.767767306820388}], ["FYN", ["TCGA.CM.5868.01", "Neurexins and neuroligins"], {"weight": 0.896506568852423}], ["FYN", ["TCGA.CM.6169.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.898346024195237}], ["FYN", ["TCGA.CM.6169.01", "Synaptic adhesion-like molecules"], {"weight": 0.806668032806032}], ["FYN", ["TCGA.CM.6169.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.886622505490011}], ["FYN", ["TCGA.CM.6169.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.886622505490011}], ["FYN", ["TCGA.CM.6169.01", "Long-term potentiation"], {"weight": 0.886622505490011}], ["FYN", ["TCGA.CM.6172.01", "Signaling Pathways"], {"weight": 0.81261444601125}], ["FYN", ["TCGA.CM.6172.01", "Interaction between L1 and Ankyrins"], {"weight": 0.899743969885436}], ["FYN", ["TCGA.CM.6172.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.318863529230232}], ["FYN", ["TCGA.CM.6172.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.730054175175463}], ["FYN", ["TCGA.CM.6172.01", "Retinoid metabolism and transport"], {"weight": 0.730054175175463}], ["FYN", ["TCGA.CM.6675.01", "G alpha (q) signalling events"], {"weight": 0.950850010728908}], ["FYN", ["TCGA.CM.6675.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.591497109469629}], ["FYN", ["TCGA.CM.6675.01", "Interaction between L1 and Ankyrins"], {"weight": 0.943251573182729}], ["FYN", ["TCGA.CM.6676.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.834754265865111}], ["FYN", ["TCGA.CM.6676.01", "Immune System"], {"weight": 0.837729805002827}], ["FYN", ["TCGA.CM.6676.01", "Signaling Pathways"], {"weight": 0.887612038280056}], ["FYN", ["TCGA.CM.6676.01", "Endosomal/Vacuolar pathway"], {"weight": 0.805466790333269}], ["FYN", ["TCGA.CM.6676.01", "Adaptive Immune System"], {"weight": 0.883564865306352}], ["FYN", ["TCGA.CM.6676.01", "Interaction between L1 and Ankyrins"], {"weight": 0.902551545498837}], ["FYN", ["TCGA.CM.6676.01", "Extracellular matrix organization"], {"weight": 0.854507111616433}], ["FYN", ["TCGA.CM.6678.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.790295192641717}], ["FYN", ["TCGA.CM.6678.01", "Immune System"], {"weight": 0.853334859831772}], ["FYN", ["TCGA.CM.6678.01", "Adaptive Immune System"], {"weight": 0.866031818947583}], ["FYN", ["TCGA.CM.6678.01", "Signaling Pathways"], {"weight": 0.880679925417537}], ["FYN", ["TCGA.CM.6678.01", "Interaction between L1 and Ankyrins"], {"weight": 0.912727218777366}], ["FYN", ["TCGA.CM.6678.01", "Other semaphorin interactions"], {"weight": 0.461598039830729}], ["FYN", ["TCGA.D5.5537.01", "Interaction between L1 and Ankyrins"], {"weight": 0.93891079720314}], ["FYN", ["TCGA.D5.5537.01", "Protein-protein interactions at synapses"], {"weight": 0.70020365734213}], ["FYN", ["TCGA.D5.5537.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.626437248480428}], ["FYN", ["TCGA.D5.5537.01", "Leishmania infection"], {"weight": 0.802610408067919}], ["FYN", ["TCGA.D5.6529.01", "Extracellular matrix organization"], {"weight": 0.888689870749674}], ["FYN", ["TCGA.D5.6529.01", "Interaction between L1 and Ankyrins"], {"weight": 0.887940179623034}], ["FYN", ["TCGA.D5.6529.01", "Regulation of insulin secretion"], {"weight": 0.92673686850038}], ["FYN", ["TCGA.D5.6529.01", "Integration of energy metabolism"], {"weight": 0.927839578814831}], ["FYN", ["TCGA.D5.6529.01", "Transport of small molecules"], {"weight": 0.916120109955202}], ["FYN", ["TCGA.D5.6529.01", "Developmental Biology"], {"weight": 0.80756670930367}], ["FYN", ["TCGA.D5.6531.01", "Transport of small molecules"], {"weight": 0.936927368348635}], ["FYN", ["TCGA.D5.6531.01", "Signaling by GPCR"], {"weight": 0.931090093764898}], ["FYN", ["TCGA.D5.6531.01", "GPCR downstream signalling"], {"weight": 0.936278576221597}], ["FYN", ["TCGA.D5.6531.01", "Regulation of insulin secretion"], {"weight": 0.928795012975265}], ["FYN", ["TCGA.D5.6531.01", "Integration of energy metabolism"], {"weight": 0.932318948708604}], ["FYN", ["TCGA.D5.6531.01", "Interaction between L1 and Ankyrins"], {"weight": 0.918467370207617}], ["FYN", ["TCGA.D5.6535.01", "Interaction between L1 and Ankyrins"], {"weight": 0.904293347283776}], ["FYN", ["TCGA.D5.6537.01", "Interaction between L1 and Ankyrins"], {"weight": 0.94973930478373}], ["FYN", ["TCGA.D5.6537.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.693331066110875}], ["FYN", ["TCGA.D5.6537.01", "Integration of energy metabolism"], {"weight": 0.950254530472972}], ["FYN", ["TCGA.D5.6537.01", "Regulation of insulin secretion"], {"weight": 0.951449201683019}], ["FYN", ["TCGA.D5.6537.01", "L1CAM interactions"], {"weight": 0.916059170284109}], ["FYN", ["TCGA.D5.6537.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.904393988358618}], ["FYN", ["TCGA.D5.6537.01", "Other semaphorin interactions"], {"weight": 0.710333737631669}], ["FYN", ["TCGA.D5.6537.01", "Developmental Biology"], {"weight": 0.912821606781323}], ["FYN", ["TCGA.D5.6537.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.923959082435835}], ["FYN", ["TCGA.D5.6537.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.750986270787435}], ["FYN", ["TCGA.D5.6898.01", "Extracellular matrix organization"], {"weight": 0.907672561234063}], ["FYN", ["TCGA.D5.6931.01", "Protein-protein interactions at synapses"], {"weight": 0.548299516183702}], ["FYN", ["TCGA.D5.6931.01", "Interaction between L1 and Ankyrins"], {"weight": 0.915416484243586}], ["FYN", ["TCGA.D5.6931.01", "Developmental Biology"], {"weight": 0.792375111374354}], ["FYN", ["TCGA.D5.6931.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.896683217226385}], ["FYN", ["TCGA.D5.6931.01", "Synaptic adhesion-like molecules"], {"weight": 0.729006401574155}], ["FYN", ["TCGA.D5.6931.01", "Neurexins and neuroligins"], {"weight": 0.813391617306837}], ["FYN", ["TCGA.D5.6931.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.837850919429685}], ["FYN", ["TCGA.DM.A0X9.01", "Interaction between L1 and Ankyrins"], {"weight": 0.931743127483878}], ["FYN", ["TCGA.DM.A0X9.01", "NCAM signaling for neurite out-growth"], {"weight": 0.784982768882824}], ["FYN", ["TCGA.DM.A1D7.01", "Protein-protein interactions at synapses"], {"weight": 0.912266956850189}], ["FYN", ["TCGA.DM.A1D7.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.619678176075404}], ["FYN", ["TCGA.DM.A1D7.01", "Interaction between L1 and Ankyrins"], {"weight": 0.943174146009639}], ["FYN", ["TCGA.DM.A1D7.01", "Synaptic adhesion-like molecules"], {"weight": 0.8255794948236}], ["FYN", ["TCGA.DM.A1D7.01", "Transport of small molecules"], {"weight": 0.886620677668561}], ["FYN", ["TCGA.DM.A1D7.01", "Drug ADME"], {"weight": 0.70962851135228}], ["FYN", ["TCGA.DM.A1D7.01", "Regulation of insulin secretion"], {"weight": 0.905425412310147}], ["FYN", ["TCGA.DM.A1D7.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.757012351305123}], ["FYN", ["TCGA.DM.A1D7.01", "Extracellular matrix organization"], {"weight": 0.839655398793743}], ["FYN", ["TCGA.DM.A1D7.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.802856323241579}], ["FYN", ["TCGA.DM.A28F.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.814273469325005}], ["FYN", ["TCGA.DM.A28F.01", "Interaction between L1 and Ankyrins"], {"weight": 0.949964072536973}], ["FYN", ["TCGA.DM.A28F.01", "Extracellular matrix organization"], {"weight": 0.898335464644968}], ["FYN", ["TCGA.F4.6460.01", "Metabolism"], {"weight": 0.900288096345577}], ["FYN", ["TCGA.F4.6704.01", "Signaling by GPCR"], {"weight": 0.90546932723685}], ["FYN", ["TCGA.G4.6297.01", "Extracellular matrix organization"], {"weight": 0.890675722743817}], ["FYN", ["TCGA.G4.6297.01", "Transport of small molecules"], {"weight": 0.890059376756478}], ["FYN", ["TCGA.G4.6306.01", "Signaling Pathways"], {"weight": 0.925325330581381}], ["FYN", ["TCGA.G4.6306.01", "Developmental Biology"], {"weight": 0.910193990650782}], ["FYN", ["TCGA.G4.6306.01", "Nervous system development"], {"weight": 0.920725372545661}], ["FYN", ["TCGA.G4.6306.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.908849802115548}], ["FYN", ["TCGA.G4.6306.01", "Leishmania parasite growth and survival"], {"weight": 0.908849802115548}], ["FYN", ["TCGA.G4.6306.01", "Cell surface interactions at the vascular wall"], {"weight": 0.815629813107344}], ["FYN", ["TCGA.G4.6306.01", "Regulation of insulin secretion"], {"weight": 0.923023349776395}], ["FYN", ["TCGA.G4.6306.01", "Integration of energy metabolism"], {"weight": 0.931573553894408}], ["FYN", ["TCGA.G4.6306.01", "Axon guidance"], {"weight": 0.921419574244758}], ["FYN", ["TCGA.G4.6306.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.899491415470046}], ["FYN", ["TCGA.NH.A6GA.01", "Transport of small molecules"], {"weight": 0.939682002703807}], ["FYN", ["TCGA.NH.A6GA.01", "Interaction between L1 and Ankyrins"], {"weight": 0.930768910314843}], ["FYN", ["TCGA.NH.A6GA.01", "Developmental Biology"], {"weight": 0.861902465204593}], ["FYN", ["TCGA.QL.A97D.01", "Interaction between L1 and Ankyrins"], {"weight": 0.940473543381792}], ["FYN", ["TCGA.QL.A97D.01", "Transport of small molecules"], {"weight": 0.91644022927739}], ["CYB5R4", ["TCGA.3L.AA1B.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.241976363296179}], ["CYB5R4", ["TCGA.3L.AA1B.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.337685951868353}], ["CYB5R4", ["TCGA.5M.AATA.01", "Transport of small molecules"], {"weight": 0.906475673777748}], ["CYB5R4", ["TCGA.A6.6652.01", "Transport of small molecules"], {"weight": 0.937416840330783}], ["CYB5R4", ["TCGA.AA.3560.01", "Transport of small molecules"], {"weight": 0.8824914114324}], ["CYB5R4", ["TCGA.AA.3560.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.289217275520694}], ["CYB5R4", ["TCGA.AA.3655.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.306170930629743}], ["CYB5R4", ["TCGA.AA.3655.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.406665538860177}], ["CYB5R4", ["TCGA.AA.3696.01", "Transport of small molecules"], {"weight": 0.896179341292255}], ["CYB5R4", ["TCGA.AA.3837.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.186462824646797}], ["CYB5R4", ["TCGA.AA.3837.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.237386434960419}], ["CYB5R4", ["TCGA.AA.3848.01", "Nucleotide metabolism"], {"weight": 0.939545503823642}], ["CYB5R4", ["TCGA.AA.3870.01", "Transport of small molecules"], {"weight": 0.895930453360121}], ["CYB5R4", ["TCGA.AA.3875.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.321162796735138}], ["CYB5R4", ["TCGA.AA.3875.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.321162796735138}], ["CYB5R4", ["TCGA.AA.3952.01", "Nucleotide metabolism"], {"weight": 0.842533246909088}], ["CYB5R4", ["TCGA.AA.3952.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.174426506819934}], ["CYB5R4", ["TCGA.AA.A01X.01", "Transport of small molecules"], {"weight": 0.897623846037619}], ["CYB5R4", ["TCGA.AA.A01X.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.355163069526934}], ["CYB5R4", ["TCGA.AA.A01X.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.445291731646056}], ["CYB5R4", ["TCGA.AA.A02H.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.189107408990968}], ["CYB5R4", ["TCGA.AA.A02H.01", "Nucleotide catabolism"], {"weight": 0.697824397322518}], ["CYB5R4", ["TCGA.AA.A02H.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.237551606502792}], ["CYB5R4", ["TCGA.AA.A02Y.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.264882822469643}], ["CYB5R4", ["TCGA.AA.A02Y.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.309390263453381}], ["CYB5R4", ["TCGA.AM.5820.01", "Transport of small molecules"], {"weight": 0.894293462530834}], ["CYB5R4", ["TCGA.AZ.6598.01", "Transport of small molecules"], {"weight": 0.93842154644998}], ["CYB5R4", ["TCGA.AZ.6598.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.359362101770035}], ["CYB5R4", ["TCGA.AZ.6606.01", "Transport of small molecules"], {"weight": 0.928054630561243}], ["CYB5R4", ["TCGA.CA.5254.01", "Transport of small molecules"], {"weight": 0.933380512615953}], ["CYB5R4", ["TCGA.CA.5254.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.488811014442334}], ["CYB5R4", ["TCGA.CA.5255.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.275898038621377}], ["CYB5R4", ["TCGA.CA.5255.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.361243868146333}], ["CYB5R4", ["TCGA.CA.5256.01", "Nucleotide metabolism"], {"weight": 0.910945015710035}], ["CYB5R4", ["TCGA.CM.5348.01", "Transport of small molecules"], {"weight": 0.906813216785445}], ["CYB5R4", ["TCGA.CM.5348.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.149412507874191}], ["CYB5R4", ["TCGA.CM.6161.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.395160048360995}], ["CYB5R4", ["TCGA.CM.6161.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.491053611178222}], ["CYB5R4", ["TCGA.CM.6172.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.264618335488107}], ["CYB5R4", ["TCGA.CM.6172.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.347582963942581}], ["CYB5R4", ["TCGA.CM.6675.01", "Transport of small molecules"], {"weight": 0.936908237817781}], ["CYB5R4", ["TCGA.CM.6676.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.213212303711742}], ["CYB5R4", ["TCGA.CM.6676.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.298388677599213}], ["CYB5R4", ["TCGA.CM.6678.01", "Transport of small molecules"], {"weight": 0.900365099870796}], ["CYB5R4", ["TCGA.CM.6678.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.220045767882625}], ["CYB5R4", ["TCGA.CM.6678.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.315406361816306}], ["CYB5R4", ["TCGA.D5.5537.01", "Transport of small molecules"], {"weight": 0.935684744953469}], ["CYB5R4", ["TCGA.D5.5537.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.431690264091398}], ["CYB5R4", ["TCGA.D5.6535.01", "Transport of small molecules"], {"weight": 0.924174716367502}], ["CYB5R4", ["TCGA.D5.6535.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.105784357488458}], ["CYB5R4", ["TCGA.F4.6459.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.117867601262673}], ["CYB5R4", ["TCGA.F4.6704.01", "Transport of small molecules"], {"weight": 0.912462343126882}], ["CYB5R4", ["TCGA.F4.6704.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.165546157444736}], ["CYB5R4", ["TCGA.F4.6704.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.237124065627493}], ["CYB5R4", ["TCGA.F4.6856.01", "Transport of small molecules"], {"weight": 0.925381674781144}], ["CYB5R4", ["TCGA.F4.6856.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.220842649481697}], ["CYB5R4", ["TCGA.F4.6856.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.332207961274647}], ["CYB5R4", ["TCGA.G4.6297.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.290804395285058}], ["CYB5R4", ["TCGA.G4.6297.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.360981060155551}], ["CYB5R4", ["TCGA.G4.6306.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.46386318590269}], ["CYB5R4", ["TCGA.G4.6306.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.535543428486582}], ["CYB5R4", ["TCGA.NH.A6GA.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.1983112738863}], ["CYB5R4", ["TCGA.NH.A6GA.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.279100631184749}], ["LAMA4", ["TCGA.5M.AATA.01", "Molecules associated with elastic fibres"], {"weight": 0.767864256751384}], ["LAMA4", ["TCGA.A6.2686.01", "Cardiac conduction"], {"weight": 0.903345306541846}], ["LAMA4", ["TCGA.A6.2686.01", "Muscle contraction"], {"weight": 0.933270720754682}], ["LAMA4", ["TCGA.A6.2686.01", "Extracellular matrix organization"], {"weight": 0.831229031526441}], ["LAMA4", ["TCGA.A6.2686.01", "Striated Muscle Contraction"], {"weight": 0.936178918376023}], ["LAMA4", ["TCGA.AA.3655.01", "Muscle contraction"], {"weight": 0.887569339920917}], ["LAMA4", ["TCGA.AA.3715.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.93840836374043}], ["LAMA4", ["TCGA.AA.3837.01", "Extracellular matrix organization"], {"weight": 0.823337292164136}], ["LAMA4", ["TCGA.AA.3837.01", "ECM proteoglycans"], {"weight": 0.884774046964964}], ["LAMA4", ["TCGA.AA.3837.01", "Integrin cell surface interactions"], {"weight": 0.818983920538965}], ["LAMA4", ["TCGA.AA.3875.01", "L1CAM interactions"], {"weight": 0.666338309712542}], ["LAMA4", ["TCGA.AA.A00F.01", "Extracellular matrix organization"], {"weight": 0.853017811235118}], ["LAMA4", ["TCGA.AA.A02Y.01", "Elastic fibre formation"], {"weight": 0.956900463760141}], ["LAMA4", ["TCGA.AA.A02Y.01", "Non-integrin membrane-ECM interactions"], {"weight": 0.851485197438207}], ["LAMA4", ["TCGA.AD.6888.01", "Elastic fibre formation"], {"weight": 0.926756225386031}], ["LAMA4", ["TCGA.AZ.6598.01", "L1CAM interactions"], {"weight": 0.917259950604628}], ["LAMA4", ["TCGA.AZ.6600.01", "Antimicrobial peptides"], {"weight": 0.439793150866067}], ["LAMA4", ["TCGA.AZ.6606.01", "L1CAM interactions"], {"weight": 0.914754689772984}], ["LAMA4", ["TCGA.AZ.6607.01", "Molecules associated with elastic fibres"], {"weight": 0.860209753713618}], ["LAMA4", ["TCGA.AZ.6607.01", "Elastic fibre formation"], {"weight": 0.881499792524768}], ["LAMA4", ["TCGA.AZ.6607.01", "MET activates PTK2 signaling"], {"weight": 0.888278672627443}], ["LAMA4", ["TCGA.AZ.6607.01", "MET promotes cell motility"], {"weight": 0.900410530693189}], ["LAMA4", ["TCGA.AZ.6608.01", "L1CAM interactions"], {"weight": 0.936766267307018}], ["LAMA4", ["TCGA.AZ.6608.01", "Elastic fibre formation"], {"weight": 0.934810796832076}], ["LAMA4", ["TCGA.CA.5255.01", "Molecules associated with elastic fibres"], {"weight": 0.811000901511568}], ["LAMA4", ["TCGA.CA.5255.01", "Elastic fibre formation"], {"weight": 0.867105763879551}], ["LAMA4", ["TCGA.CA.5256.01", "Axon guidance"], {"weight": 0.899987163471481}], ["LAMA4", ["TCGA.CK.4952.01", "L1CAM interactions"], {"weight": 0.919482541865574}], ["LAMA4", ["TCGA.CK.4952.01", "Molecules associated with elastic fibres"], {"weight": 0.865016170736287}], ["LAMA4", ["TCGA.CM.5860.01", "ECM proteoglycans"], {"weight": 0.82606623472128}], ["LAMA4", ["TCGA.CM.5860.01", "Integrin cell surface interactions"], {"weight": 0.876963713251007}], ["LAMA4", ["TCGA.CM.5868.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.252702571057003}], ["LAMA4", ["TCGA.CM.5868.01", "L1CAM interactions"], {"weight": 0.886559971809009}], ["LAMA4", ["TCGA.CM.5868.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.314165311544662}], ["LAMA4", ["TCGA.CM.5868.01", "ECM proteoglycans"], {"weight": 0.889407217393424}], ["LAMA4", ["TCGA.CM.6169.01", "Glycosaminoglycan metabolism"], {"weight": 0.681395370925523}], ["LAMA4", ["TCGA.CM.6169.01", "Degradation of the extracellular matrix"], {"weight": 0.707367749640123}], ["LAMA4", ["TCGA.D5.5537.01", "Extracellular matrix organization"], {"weight": 0.820971510957302}], ["LAMA4", ["TCGA.D5.5537.01", "Muscle contraction"], {"weight": 0.919954123383685}], ["LAMA4", ["TCGA.D5.6529.01", "L1CAM interactions"], {"weight": 0.771234895812502}], ["LAMA4", ["TCGA.D5.6931.01", "Extracellular matrix organization"], {"weight": 0.813437992133563}], ["LAMA4", ["TCGA.D5.6931.01", "Basigin interactions"], {"weight": 0.657092223093333}], ["LAMA4", ["TCGA.DM.A1D7.01", "Molecules associated with elastic fibres"], {"weight": 0.7380676022964}], ["LAMA4", ["TCGA.DM.A1D7.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.130457772332461}], ["LAMA4", ["TCGA.DM.A28F.01", "Netrin-1 signaling"], {"weight": 0.835163811612007}], ["LAMA4", ["TCGA.G4.6297.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.911478206089274}], ["NT5E", ["TCGA.4T.AA8H.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.859557817419592}], ["NT5E", ["TCGA.AA.3841.01", "IRS-mediated signalling"], {"weight": 0.839498919098708}], ["NT5E", ["TCGA.AA.3841.01", "Insulin receptor signalling cascade"], {"weight": 0.839312485791658}], ["NT5E", ["TCGA.AA.3841.01", "Signaling by Insulin receptor"], {"weight": 0.83209455612254}], ["NT5E", ["TCGA.AA.3848.01", "Azathioprine ADME"], {"weight": 0.908776425247559}], ["NT5E", ["TCGA.AA.3848.01", "Drug ADME"], {"weight": 0.936151088811294}], ["NT5E", ["TCGA.AA.3848.01", "Vitamin B5 (pantothenate) metabolism"], {"weight": 0.75146211379748}], ["NT5E", ["TCGA.AA.3848.01", "Nucleotide biosynthesis"], {"weight": 0.830702661100816}], ["NT5E", ["TCGA.AA.3848.01", "Purine ribonucleoside monophosphate biosynthesis"], {"weight": 0.573108391239114}], ["NT5E", ["TCGA.AA.3860.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.803910248009716}], ["NT5E", ["TCGA.AA.3875.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.790443483971895}], ["NT5E", ["TCGA.AA.3875.01", "Platelet homeostasis"], {"weight": 0.659025007713438}], ["NT5E", ["TCGA.AA.3952.01", "Purine ribonucleoside monophosphate biosynthesis"], {"weight": 0.216618641669817}], ["NT5E", ["TCGA.AA.3966.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.865877743828664}], ["NT5E", ["TCGA.AA.3966.01", "Post-translational protein phosphorylation"], {"weight": 0.810676462918995}], ["NT5E", ["TCGA.AA.3966.01", "Activation of the phototransduction cascade"], {"weight": 0.878935093406845}], ["NT5E", ["TCGA.AA.A029.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.87174229501232}], ["NT5E", ["TCGA.AD.6888.01", "Platelet homeostasis"], {"weight": 0.914086898239047}], ["NT5E", ["TCGA.AD.6888.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.914204574180159}], ["NT5E", ["TCGA.AD.6888.01", "Ca2+ pathway"], {"weight": 0.897325680099913}], ["NT5E", ["TCGA.AY.A8YK.01", "Platelet homeostasis"], {"weight": 0.845606938371967}], ["NT5E", ["TCGA.AY.A8YK.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.795637050437922}], ["NT5E", ["TCGA.AZ.6606.01", "Platelet homeostasis"], {"weight": 0.88591296854314}], ["NT5E", ["TCGA.AZ.6606.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.86991979030977}], ["NT5E", ["TCGA.AZ.6608.01", "Platelet homeostasis"], {"weight": 0.93076463518718}], ["NT5E", ["TCGA.AZ.6608.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.890163121933541}], ["NT5E", ["TCGA.CA.5254.01", "Platelet homeostasis"], {"weight": 0.877947712958211}], ["NT5E", ["TCGA.CA.5255.01", "Platelet homeostasis"], {"weight": 0.850834314395336}], ["NT5E", ["TCGA.CA.5255.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.871227989213257}], ["NT5E", ["TCGA.CA.5255.01", "Ca2+ pathway"], {"weight": 0.868772509429327}], ["NT5E", ["TCGA.CK.4952.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.809836991538195}], ["NT5E", ["TCGA.CM.6675.01", "Platelet homeostasis"], {"weight": 0.915830551198748}], ["NT5E", ["TCGA.CM.6675.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.835135868455163}], ["NT5E", ["TCGA.CM.6676.01", "Activation of the phototransduction cascade"], {"weight": 0.874298707327639}], ["NT5E", ["TCGA.CM.6676.01", "G alpha (s) signalling events"], {"weight": 0.946696402582952}], ["NT5E", ["TCGA.D5.5537.01", "GPCR downstream signalling"], {"weight": 0.955472152363115}], ["NT5E", ["TCGA.D5.5537.01", "Platelet homeostasis"], {"weight": 0.848041556343639}], ["NT5E", ["TCGA.D5.5537.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.794659451177842}], ["NT5E", ["TCGA.D5.6531.01", "Visual phototransduction"], {"weight": 0.793226503462995}], ["NT5E", ["TCGA.D5.6535.01", "Platelet homeostasis"], {"weight": 0.838431925839659}], ["NT5E", ["TCGA.D5.6535.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.850352530666053}], ["NT5E", ["TCGA.D5.6537.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.878597049910982}], ["NT5E", ["TCGA.D5.6537.01", "Platelet homeostasis"], {"weight": 0.907247270969974}], ["NT5E", ["TCGA.D5.6537.01", "Activation of the phototransduction cascade"], {"weight": 0.895646987890245}], ["NT5E", ["TCGA.D5.6931.01", "RA biosynthesis pathway"], {"weight": 0.673996799034386}], ["NT5E", ["TCGA.DM.A0X9.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.851607046836629}], ["NT5E", ["TCGA.DM.A0X9.01", "Platelet homeostasis"], {"weight": 0.87966342900787}], ["NT5E", ["TCGA.DM.A28F.01", "Platelet homeostasis"], {"weight": 0.909914478617806}], ["NT5E", ["TCGA.DM.A28F.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.894015213872451}], ["NT5E", ["TCGA.DM.A28H.01", "GPCR downstream signalling"], {"weight": 0.961342575530825}], ["NT5E", ["TCGA.DM.A28H.01", "Signaling by GPCR"], {"weight": 0.954913526311087}], ["NT5E", ["TCGA.DM.A28H.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.820413910963885}], ["NT5E", ["TCGA.DM.A28H.01", "Signaling Pathways"], {"weight": 0.923064945711302}], ["NT5E", ["TCGA.DM.A28H.01", "G alpha (i) signalling events"], {"weight": 0.960475253880794}], ["NT5E", ["TCGA.DM.A28H.01", "Interferon gamma signaling"], {"weight": 0.906533137214043}], ["NT5E", ["TCGA.DM.A28H.01", "Inflammasomes"], {"weight": 0.750591345147114}], ["NT5E", ["TCGA.DM.A28H.01", "Potassium Channels"], {"weight": 0.955133360804618}], ["NT5E", ["TCGA.DM.A28H.01", "G alpha (s) signalling events"], {"weight": 0.961803397191285}], ["NT5E", ["TCGA.DM.A28H.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.781981464006705}], ["NT5E", ["TCGA.DM.A28H.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.781981464006705}], ["NT5E", ["TCGA.DM.A28H.01", "Extracellular matrix organization"], {"weight": 0.865844928869366}], ["NT5E", ["TCGA.DM.A28H.01", "Deposition of new CENPA-containing nucleosomes at the centromere"], {"weight": 0.842699332848497}], ["NT5E", ["TCGA.DM.A28H.01", "Nucleosome assembly"], {"weight": 0.842699332848497}], ["NT5E", ["TCGA.DM.A28H.01", "Regulation of insulin secretion"], {"weight": 0.919789054519447}], ["NT5E", ["TCGA.DM.A28H.01", "Phase 0 - rapid depolarisation"], {"weight": 0.917522976469682}], ["NT5E", ["TCGA.DM.A28H.01", "Cardiac conduction"], {"weight": 0.937595409636}], ["NT5E", ["TCGA.DM.A28H.01", "Glucagon-type ligand receptors"], {"weight": 0.917860223890378}], ["NT5E", ["TCGA.DM.A28H.01", "The NLRP3 inflammasome"], {"weight": 0.682067773652366}], ["NT5E", ["TCGA.DM.A28H.01", "Chemokine receptors bind chemokines"], {"weight": 0.919336871378416}], ["NT5E", ["TCGA.DM.A28H.01", "Activation of the pre-replicative complex"], {"weight": 0.847980335568268}], ["NT5E", ["TCGA.DM.A28H.01", "Platelet homeostasis"], {"weight": 0.903548935809276}], ["NT5E", ["TCGA.DM.A28H.01", "Biological oxidations"], {"weight": 0.915471319088631}], ["NT5E", ["TCGA.DM.A28H.01", "Leishmania infection"], {"weight": 0.891446419355642}], ["NT5E", ["TCGA.DM.A28H.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.894252058044842}], ["NT5E", ["TCGA.DM.A28H.01", "Binding and entry of HIV virion"], {"weight": 0.46940398082444}], ["NT5E", ["TCGA.DM.A28H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.930602694770751}], ["NT5E", ["TCGA.DM.A28H.01", "Interferon Signaling"], {"weight": 0.907037326470949}], ["NT5E", ["TCGA.DM.A28H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.903643605100706}], ["NT5E", ["TCGA.DM.A28H.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.877996764887515}], ["NT5E", ["TCGA.DM.A28H.01", "Peptide hormone metabolism"], {"weight": 0.844028690176008}], ["NT5E", ["TCGA.DM.A28H.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.882834667136017}], ["NT5E", ["TCGA.DM.A28H.01", "Signal amplification"], {"weight": 0.898727337758187}], ["NT5E", ["TCGA.DM.A28H.01", "Cell Cycle Checkpoints"], {"weight": 0.924893686262317}], ["NT5E", ["TCGA.DM.A28H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.89504140555406}], ["NT5E", ["TCGA.DM.A28H.01", "Integration of energy metabolism"], {"weight": 0.912903305038313}], ["NT5E", ["TCGA.DM.A28H.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.904314605136218}], ["NT5E", ["TCGA.DM.A28H.01", "Elastic fibre formation"], {"weight": 0.766001595668702}], ["NT5E", ["TCGA.DM.A28H.01", "G beta:gamma signalling through BTK"], {"weight": 0.866933516401057}], ["NT5E", ["TCGA.DM.A28H.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.886787022284823}], ["NT5E", ["TCGA.DM.A28H.01", "Leishmania parasite growth and survival"], {"weight": 0.886787022284823}], ["NT5E", ["TCGA.DM.A28H.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.878850240545586}], ["NT5E", ["TCGA.DM.A28H.01", "G-protein beta:gamma signalling"], {"weight": 0.899303808105442}], ["NT5E", ["TCGA.DM.A28H.01", "Ion homeostasis"], {"weight": 0.927260607020613}], ["NT5E", ["TCGA.F4.6856.01", "Drug ADME"], {"weight": 0.851712175456569}], ["NT5E", ["TCGA.G4.6306.01", "Platelet homeostasis"], {"weight": 0.904164413110162}], ["NT5E", ["TCGA.G4.6306.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.854167043540673}], ["NT5E", ["TCGA.NH.A6GA.01", "Vitamin B5 (pantothenate) metabolism"], {"weight": 0.752463279192606}], ["NT5E", ["TCGA.QL.A97D.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.886007363916749}], ["NT5E", ["TCGA.QL.A97D.01", "Platelet homeostasis"], {"weight": 0.85395132880484}], ["KHDRBS2", ["TCGA.A6.3807.01", "Integration of energy metabolism"], {"weight": 0.847385184618736}], ["KHDRBS2", ["TCGA.AA.A00O.01", "Signaling by GPCR"], {"weight": 0.931627711511197}], ["KHDRBS2", ["TCGA.AA.A00O.01", "GPCR downstream signalling"], {"weight": 0.938056090999553}], ["PTP4A1", ["TCGA.A6.3807.01", "TNFs bind their physiological receptors"], {"weight": 0.216483126880172}], ["PTP4A1", ["TCGA.A6.3807.01", "Glucagon-type ligand receptors"], {"weight": 0.892591920042664}], ["PTP4A1", ["TCGA.A6.3807.01", "Transport of small molecules"], {"weight": 0.907841360122864}], ["PTP4A1", ["TCGA.A6.3807.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.841508868156048}], ["PTP4A1", ["TCGA.A6.3807.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.901814748535013}], ["PTP4A1", ["TCGA.A6.3807.01", "Regulation of insulin secretion"], {"weight": 0.845485016141806}], ["PTP4A1", ["TCGA.A6.3807.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.855217803852251}], ["PTP4A1", ["TCGA.AA.A00O.01", "SLC-mediated transmembrane transport"], {"weight": 0.90365756357109}], ["PTP4A1", ["TCGA.AA.A00O.01", "Drug ADME"], {"weight": 0.888818448062049}], ["PTP4A1", ["TCGA.AA.A00O.01", "Biological oxidations"], {"weight": 0.896046322258686}], ["PTP4A1", ["TCGA.AA.A00O.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.867701535660816}], ["PTP4A1", ["TCGA.AA.A00O.01", "Degradation of the extracellular matrix"], {"weight": 0.866921888902823}], ["PTP4A1", ["TCGA.AA.A00O.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.906094065588192}], ["PTP4A1", ["TCGA.AA.A00O.01", "Transport of small molecules"], {"weight": 0.919262707422764}], ["PTP4A1", ["TCGA.AA.A00O.01", "O-linked glycosylation"], {"weight": -0.0108963761898337}], ["PTP4A1", ["TCGA.AA.A00O.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.793058421837107}], ["PTP4A1", ["TCGA.AA.A00O.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.534523495157506}], ["PTP4A1", ["TCGA.AA.A00O.01", "Peptide hormone metabolism"], {"weight": 0.864898752980358}], ["PTP4A1", ["TCGA.AA.A00O.01", "Signaling by activated point mutants of FGFR3"], {"weight": 0.795344793746537}], ["PTP4A1", ["TCGA.AA.A00O.01", "FGFR3 mutant receptor activation"], {"weight": 0.795344793746537}], ["PTP4A1", ["TCGA.AA.A00O.01", "G alpha (i) signalling events"], {"weight": 0.933895493979021}], ["PTP4A1", ["TCGA.AA.A00O.01", "FGFR3 ligand binding and activation"], {"weight": 0.795344793746537}], ["PTP4A1", ["TCGA.AA.A00O.01", "FGFR3c ligand binding and activation"], {"weight": 0.795344793746537}], ["PTP4A1", ["TCGA.AA.A00O.01", "Phospholipase C-mediated cascade; FGFR3"], {"weight": 0.793978691101555}], ["PTP4A1", ["TCGA.AA.A00O.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.797598712990734}], ["PTP4A1", ["TCGA.AA.A00O.01", "Dectin-2 family"], {"weight": 0.779227477093389}], ["PTP4A1", ["TCGA.AA.A00O.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.820693965777795}], ["PTP4A1", ["TCGA.AA.A00O.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.661333434316106}], ["PTP4A1", ["TCGA.AA.A00O.01", "Extracellular matrix organization"], {"weight": 0.852155673458575}], ["PTP4A1", ["TCGA.AA.A00O.01", "Phospholipase C-mediated cascade; FGFR4"], {"weight": 0.668485867648349}], ["PTP4A1", ["TCGA.AA.A00O.01", "FRS-mediated FGFR3 signaling"], {"weight": 0.816371884299772}], ["PTP4A1", ["TCGA.F4.6704.01", "Adherens junctions interactions"], {"weight": 0.766450682854085}], ["PTP4A1", ["TCGA.F4.6856.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.730776630461502}], ["HDAC2", ["TCGA.4T.AA8H.01", "Signaling Pathways"], {"weight": 0.910534027654619}], ["HDAC2", ["TCGA.A6.2686.01", "Signaling by Retinoic Acid"], {"weight": 0.833961996887807}], ["HDAC2", ["TCGA.A6.6652.01", "Signaling Pathways"], {"weight": 0.915122477403741}], ["HDAC2", ["TCGA.A6.6652.01", "Regulation of FZD by ubiquitination"], {"weight": 0.868549120574554}], ["HDAC2", ["TCGA.AA.3837.01", "SUMOylation of intracellular receptors"], {"weight": 0.584067563880014}], ["HDAC2", ["TCGA.AA.3841.01", "RNA Polymerase I Promoter Opening"], {"weight": 0.330037533807514}], ["HDAC2", ["TCGA.AA.3848.01", "SUMOylation of intracellular receptors"], {"weight": 0.916512587044848}], ["HDAC2", ["TCGA.AA.3875.01", "SUMOylation of DNA methylation proteins"], {"weight": 0.666198564842759}], ["HDAC2", ["TCGA.AA.3875.01", "SUMOylation of intracellular receptors"], {"weight": 0.174969965709704}], ["HDAC2", ["TCGA.AA.A02H.01", "SUMOylation of DNA methylation proteins"], {"weight": 0.781562428759934}], ["HDAC2", ["TCGA.AA.A02Y.01", "Cardiac conduction"], {"weight": 0.960895152580921}], ["HDAC2", ["TCGA.AA.A02Y.01", "Muscle contraction"], {"weight": 0.966787594004506}], ["HDAC2", ["TCGA.AD.6888.01", "Diseases of metabolism"], {"weight": 0.819208292727124}], ["HDAC2", ["TCGA.AY.A8YK.01", "Regulation of FZD by ubiquitination"], {"weight": 0.788226569975488}], ["HDAC2", ["TCGA.AZ.6598.01", "Muscle contraction"], {"weight": 0.950974047185344}], ["HDAC2", ["TCGA.CA.5255.01", "Diseases of metabolism"], {"weight": 0.827770285117704}], ["HDAC2", ["TCGA.CK.5915.01", "Cardiac conduction"], {"weight": 0.958500991842908}], ["HDAC2", ["TCGA.CK.5915.01", "Signaling Pathways"], {"weight": 0.926613524037288}], ["HDAC2", ["TCGA.CK.5915.01", "Muscle contraction"], {"weight": 0.960592075635884}], ["HDAC2", ["TCGA.CM.4747.01", "Signaling by Retinoic Acid"], {"weight": 0.774907033057208}], ["HDAC2", ["TCGA.CM.5860.01", "Signaling by Retinoic Acid"], {"weight": 0.660646703217783}], ["HDAC2", ["TCGA.CM.6169.01", "Signaling by Retinoic Acid"], {"weight": 0.789968227126788}], ["HDAC2", ["TCGA.CM.6169.01", "Keratinization"], {"weight": 0.834023373201112}], ["HDAC2", ["TCGA.CM.6676.01", "Cardiac conduction"], {"weight": 0.921206894068917}], ["HDAC2", ["TCGA.CM.6678.01", "Regulation of FZD by ubiquitination"], {"weight": 0.848263794788239}], ["HDAC2", ["TCGA.D5.6531.01", "Muscle contraction"], {"weight": 0.931395230698976}], ["HDAC2", ["TCGA.D5.6531.01", "Developmental Biology"], {"weight": 0.874375975739739}], ["HDAC2", ["TCGA.D5.6535.01", "Regulation of FZD by ubiquitination"], {"weight": 0.816617230580272}], ["HDAC2", ["TCGA.D5.6537.01", "Cardiac conduction"], {"weight": 0.949166000877334}], ["HDAC2", ["TCGA.D5.6537.01", "Muscle contraction"], {"weight": 0.951828823950888}], ["HDAC2", ["TCGA.DM.A0X9.01", "Cardiac conduction"], {"weight": 0.942355771311462}], ["HDAC2", ["TCGA.DM.A1D7.01", "Phase 0 - rapid depolarisation"], {"weight": 0.931982982066958}], ["HDAC2", ["TCGA.DM.A1D7.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.922032587195283}], ["HDAC2", ["TCGA.DM.A1D7.01", "Signaling Pathways"], {"weight": 0.897378755120228}], ["HDAC2", ["TCGA.DM.A1D7.01", "Trafficking of AMPA receptors"], {"weight": 0.923937554647846}], ["HDAC2", ["TCGA.DM.A1D7.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.923937554647846}], ["HDAC2", ["TCGA.DM.A1D7.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.912585965685411}], ["HDAC2", ["TCGA.DM.A1D7.01", "Signaling by Retinoic Acid"], {"weight": 0.800545837412603}], ["HDAC2", ["TCGA.DM.A1D7.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.874164521153385}], ["HDAC2", ["TCGA.DM.A1D7.01", "Long-term potentiation"], {"weight": 0.919787149303363}], ["HDAC2", ["TCGA.DM.A28F.01", "Signaling Pathways"], {"weight": 0.915115821243006}], ["HDAC2", ["TCGA.F4.6459.01", "Signaling by Retinoic Acid"], {"weight": 0.792476352879736}], ["HDAC2", ["TCGA.G4.6306.01", "Diseases of metabolism"], {"weight": 0.843317429385841}], ["HS3ST5", ["TCGA.AA.3655.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.895010993455453}], ["HS3ST5", ["TCGA.AA.3655.01", "Collagen formation"], {"weight": 0.920619321940284}], ["HS3ST5", ["TCGA.AA.3848.01", "Chondroitin sulfate/dermatan sulfate metabolism"], {"weight": 0.848032082607944}], ["HS3ST5", ["TCGA.AA.3860.01", "Collagen formation"], {"weight": 0.910928256477666}], ["HS3ST5", ["TCGA.AA.A00F.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.703713195073424}], ["HS3ST5", ["TCGA.AA.A00F.01", "TNFs bind their physiological receptors"], {"weight": 0.140815599866079}], ["HS3ST5", ["TCGA.AA.A00F.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.849789701337802}], ["HS3ST5", ["TCGA.AD.6888.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.941265866005663}], ["HS3ST5", ["TCGA.AD.6888.01", "Retinoid metabolism and transport"], {"weight": 0.941265866005663}], ["HS3ST5", ["TCGA.AZ.4681.01", "Binding and entry of HIV virion"], {"weight": 0.816651934116751}], ["HS3ST5", ["TCGA.AZ.4681.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.895434422511024}], ["HS3ST5", ["TCGA.AZ.4681.01", "Immune System"], {"weight": 0.900570620954557}], ["HS3ST5", ["TCGA.AZ.4681.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.897387103458768}], ["HS3ST5", ["TCGA.AZ.4681.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.896306656148124}], ["HS3ST5", ["TCGA.AZ.4681.01", "Leishmania parasite growth and survival"], {"weight": 0.896306656148124}], ["HS3ST5", ["TCGA.AZ.4681.01", "G-protein beta:gamma signalling"], {"weight": 0.929893929486497}], ["HS3ST5", ["TCGA.AZ.4681.01", "G alpha (i) signalling events"], {"weight": 0.937844590524327}], ["HS3ST5", ["TCGA.AZ.4681.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.879183067519613}], ["HS3ST5", ["TCGA.AZ.4681.01", "Regulation of insulin secretion"], {"weight": 0.90599847690616}], ["HS3ST5", ["TCGA.AZ.4681.01", "G beta:gamma signalling through CDC42"], {"weight": 0.907374700133193}], ["HS3ST5", ["TCGA.AZ.4681.01", "Leishmania infection"], {"weight": 0.894066694882265}], ["HS3ST5", ["TCGA.AZ.4681.01", "Azathioprine ADME"], {"weight": 0.741133006994661}], ["HS3ST5", ["TCGA.AZ.4681.01", "Nervous system development"], {"weight": 0.907798372812837}], ["HS3ST5", ["TCGA.AZ.4681.01", "Integration of energy metabolism"], {"weight": 0.926068354848247}], ["HS3ST5", ["TCGA.AZ.4681.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.770960452051732}], ["HS3ST5", ["TCGA.AZ.4681.01", "G alpha (z) signalling events"], {"weight": 0.87647712715271}], ["HS3ST5", ["TCGA.AZ.4681.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.88933506684172}], ["HS3ST5", ["TCGA.AZ.4681.01", "GPER1 signaling"], {"weight": 0.888420796047566}], ["HS3ST5", ["TCGA.AZ.4681.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.885826477539582}], ["HS3ST5", ["TCGA.AZ.4681.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.862542979922582}], ["HS3ST5", ["TCGA.AZ.4681.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.862542979922582}], ["HS3ST5", ["TCGA.AZ.4681.01", "Axon guidance"], {"weight": 0.906543445533132}], ["HS3ST5", ["TCGA.AZ.4681.01", "Platelet homeostasis"], {"weight": 0.868224263113183}], ["HS3ST5", ["TCGA.AZ.4681.01", "Interleukin-10 signaling"], {"weight": 0.760817991631346}], ["HS3ST5", ["TCGA.AZ.4681.01", "Cell surface interactions at the vascular wall"], {"weight": 0.817593044256818}], ["HS3ST5", ["TCGA.AZ.4681.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.835698573654843}], ["HS3ST5", ["TCGA.AZ.4681.01", "Chemokine receptors bind chemokines"], {"weight": 0.902980798062101}], ["HS3ST5", ["TCGA.AZ.4681.01", "B Cell Activation"], {"weight": 0.917395755745444}], ["HS3ST5", ["TCGA.AZ.4681.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.880251513131904}], ["HS3ST5", ["TCGA.AZ.4681.01", "Infectious disease"], {"weight": 0.911585666798614}], ["HS3ST5", ["TCGA.AZ.4681.01", "Molecules associated with elastic fibres"], {"weight": 0.754479239458568}], ["HS3ST5", ["TCGA.AZ.4681.01", "GPCR downstream signalling"], {"weight": 0.943112503390731}], ["HS3ST5", ["TCGA.AZ.4681.01", "G-protein activation"], {"weight": 0.855339346550426}], ["HS3ST5", ["TCGA.AZ.4681.01", "Diseases of Immune System"], {"weight": 0.859200878162436}], ["HS3ST5", ["TCGA.AZ.4681.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.859200878162436}], ["HS3ST5", ["TCGA.AZ.4681.01", "FCGR3A-mediated IL10 synthesis"], {"weight": 0.878697306571078}], ["HS3ST5", ["TCGA.AZ.4681.01", "Aquaporin-mediated transport"], {"weight": 0.880251513131904}], ["HS3ST5", ["TCGA.AZ.4681.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.811816764197743}], ["HS3ST5", ["TCGA.AZ.4681.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.867644046891795}], ["HS3ST5", ["TCGA.AZ.4681.01", "Early Phase of HIV Life Cycle"], {"weight": 0.745974100328823}], ["HS3ST5", ["TCGA.AZ.4681.01", "CD22 mediated BCR regulation"], {"weight": 0.684962487711688}], ["HS3ST5", ["TCGA.AZ.4681.01", "Extra-nuclear estrogen signaling"], {"weight": 0.915926783826812}], ["HS3ST5", ["TCGA.AZ.4681.01", "CD28 dependent PI3K/Akt signaling"], {"weight": 0.862327906940758}], ["HS3ST5", ["TCGA.AZ.4681.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.828010063595207}], ["HS3ST5", ["TCGA.AZ.6598.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.819755126503949}], ["HS3ST5", ["TCGA.AZ.6607.01", "Non-integrin membrane-ECM interactions"], {"weight": 0.847092711089427}], ["HS3ST5", ["TCGA.AZ.6607.01", "NCAM signaling for neurite out-growth"], {"weight": 0.74899113180477}], ["HS3ST5", ["TCGA.AZ.6607.01", "Syndecan interactions"], {"weight": 0.847373811576503}], ["HS3ST5", ["TCGA.AZ.6607.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.816274481730637}], ["HS3ST5", ["TCGA.AZ.6607.01", "Retinoid metabolism and transport"], {"weight": 0.816274481730637}], ["HS3ST5", ["TCGA.CK.4952.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.939313053934468}], ["HS3ST5", ["TCGA.CK.4952.01", "Retinoid metabolism and transport"], {"weight": 0.939313053934468}], ["HS3ST5", ["TCGA.CK.5915.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.873928525920971}], ["HS3ST5", ["TCGA.CM.4747.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.761041087490515}], ["HS3ST5", ["TCGA.CM.4747.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.85809144172999}], ["HS3ST5", ["TCGA.CM.5860.01", "Collagen degradation"], {"weight": 0.902056847597902}], ["HS3ST5", ["TCGA.CM.5860.01", "Defective B3GALTL causes PpS"], {"weight": 0.844489595099786}], ["HS3ST5", ["TCGA.CM.5860.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.844489595099786}], ["HS3ST5", ["TCGA.CM.5860.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.722407333586348}], ["HS3ST5", ["TCGA.CM.5860.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.5680159085416}], ["HS3ST5", ["TCGA.CM.5860.01", "Diseases of glycosylation"], {"weight": 0.84949465382099}], ["HS3ST5", ["TCGA.CM.5860.01", "Insulin processing"], {"weight": 0.714249037366515}], ["HS3ST5", ["TCGA.CM.6676.01", "Visual phototransduction"], {"weight": 0.841816147339677}], ["HS3ST5", ["TCGA.CM.6676.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.886254777869999}], ["HS3ST5", ["TCGA.CM.6676.01", "Retinoid metabolism and transport"], {"weight": 0.886254777869999}], ["HS3ST5", ["TCGA.D5.6537.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.908937211187499}], ["HS3ST5", ["TCGA.D5.6537.01", "Retinoid metabolism and transport"], {"weight": 0.908937211187499}], ["HS3ST5", ["TCGA.D5.6537.01", "Visual phototransduction"], {"weight": 0.904563395184395}], ["HS3ST5", ["TCGA.DM.A1D7.01", "TNFs bind their physiological receptors"], {"weight": 0.260368286573205}], ["HS3ST5", ["TCGA.F4.6704.01", "Visual phototransduction"], {"weight": 0.808737793777917}], ["COL10A1", ["TCGA.AA.3660.01", "NCAM1 interactions"], {"weight": 0.908921469882865}], ["COL10A1", ["TCGA.AA.3660.01", "NCAM signaling for neurite out-growth"], {"weight": 0.919114203469387}], ["COL10A1", ["TCGA.AA.3837.01", "Collagen degradation"], {"weight": 0.893000470155862}], ["COL10A1", ["TCGA.AA.3848.01", "NCAM signaling for neurite out-growth"], {"weight": 0.896174360750506}], ["COL10A1", ["TCGA.AA.3848.01", "NCAM1 interactions"], {"weight": 0.907118264340147}], ["COL10A1", ["TCGA.AA.3939.01", "NCAM1 interactions"], {"weight": 0.907031011833956}], ["COL10A1", ["TCGA.AA.3982.01", "Aspirin ADME"], {"weight": 0.230720073113215}], ["COL10A1", ["TCGA.AA.3982.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.43278787602189}], ["COL10A1", ["TCGA.AA.3982.01", "Drug ADME"], {"weight": 0.268887625041457}], ["COL10A1", ["TCGA.AA.A02J.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.922968533522505}], ["COL10A1", ["TCGA.AA.A02J.01", "Signaling by GPCR"], {"weight": 0.932933515851919}], ["COL10A1", ["TCGA.AA.A02J.01", "GPCR downstream signalling"], {"weight": 0.940294594529992}], ["COL10A1", ["TCGA.AA.A02J.01", "Generation of second messenger molecules"], {"weight": 0.929176576750525}], ["COL10A1", ["TCGA.AA.A02J.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.925326388578588}], ["COL10A1", ["TCGA.AA.A02J.01", "Neuronal System"], {"weight": 0.941011532716168}], ["COL10A1", ["TCGA.AA.A02J.01", "PD-1 signaling"], {"weight": 0.921708307089966}], ["COL10A1", ["TCGA.AA.A02J.01", "GPCR ligand binding"], {"weight": 0.93397626151732}], ["COL10A1", ["TCGA.AA.A02J.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.904596479197452}], ["COL10A1", ["TCGA.AA.A02J.01", "Leishmania parasite growth and survival"], {"weight": 0.904596479197452}], ["COL10A1", ["TCGA.AA.A02J.01", "Signaling Pathways"], {"weight": 0.923561794954561}], ["COL10A1", ["TCGA.AA.A02J.01", "Leishmania infection"], {"weight": 0.893313067049151}], ["COL10A1", ["TCGA.AA.A02J.01", "Muscle contraction"], {"weight": 0.925988398465199}], ["COL10A1", ["TCGA.AA.A02J.01", "Complement cascade"], {"weight": 0.877454348735752}], ["COL10A1", ["TCGA.AA.A02J.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.939420145562931}], ["COL10A1", ["TCGA.AA.A02J.01", "Peptide ligand-binding receptors"], {"weight": 0.936799589737777}], ["COL10A1", ["TCGA.AA.A02J.01", "Transmission across Chemical Synapses"], {"weight": 0.932793699282808}], ["COL10A1", ["TCGA.AA.A02J.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.752092479251234}], ["COL10A1", ["TCGA.AA.A02J.01", "Platelet homeostasis"], {"weight": 0.873959177986356}], ["COL10A1", ["TCGA.AA.A02J.01", "Costimulation by the CD28 family"], {"weight": 0.917319167429743}], ["COL10A1", ["TCGA.AA.A02J.01", "G alpha (q) signalling events"], {"weight": 0.898725127929981}], ["COL10A1", ["TCGA.AA.A02J.01", "Signaling by Interleukins"], {"weight": 0.881293850453425}], ["COL10A1", ["TCGA.AA.A02J.01", "Regulation of Complement cascade"], {"weight": 0.835613413285861}], ["COL10A1", ["TCGA.AA.A02J.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.899966378786076}], ["COL10A1", ["TCGA.AA.A02J.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.927112711720747}], ["COL10A1", ["TCGA.AA.A02J.01", "Transport of small molecules"], {"weight": 0.924222150795912}], ["COL10A1", ["TCGA.AA.A02J.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.887009002612997}], ["COL10A1", ["TCGA.AA.A02J.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.904725938561726}], ["COL10A1", ["TCGA.AA.A02J.01", "NCAM1 interactions"], {"weight": 0.939051069430038}], ["COL10A1", ["TCGA.AA.A02J.01", "Response to elevated platelet cytosolic Ca2+"], {"weight": 0.734476405098134}], ["COL10A1", ["TCGA.AZ.6598.01", "NCAM1 interactions"], {"weight": 0.95004752237485}], ["COL10A1", ["TCGA.AZ.6598.01", "NCAM signaling for neurite out-growth"], {"weight": 0.951488301719299}], ["COL10A1", ["TCGA.AZ.6600.01", "Degradation of the extracellular matrix"], {"weight": 0.811089135647177}], ["COL10A1", ["TCGA.AZ.6600.01", "NCAM signaling for neurite out-growth"], {"weight": 0.764104839329776}], ["COL10A1", ["TCGA.AZ.6608.01", "NCAM1 interactions"], {"weight": 0.948277789862214}], ["COL10A1", ["TCGA.CK.5915.01", "NCAM1 interactions"], {"weight": 0.937944499457117}], ["COL10A1", ["TCGA.CK.5915.01", "NCAM signaling for neurite out-growth"], {"weight": 0.944682165611083}], ["COL10A1", ["TCGA.CM.4747.01", "Keratan sulfate biosynthesis"], {"weight": 0.849812189194761}], ["COL10A1", ["TCGA.CM.6675.01", "NCAM1 interactions"], {"weight": 0.946369145974326}], ["COL10A1", ["TCGA.D5.5538.01", "Neuronal System"], {"weight": 0.920552753476287}], ["COL10A1", ["TCGA.D5.5538.01", "Transmission across Chemical Synapses"], {"weight": 0.912586286735124}], ["COL10A1", ["TCGA.D5.5538.01", "Protein-protein interactions at synapses"], {"weight": 0.86003426298977}], ["COL10A1", ["TCGA.D5.5538.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.901061243721821}], ["COL10A1", ["TCGA.D5.5538.01", "GPCR ligand binding"], {"weight": 0.896256229321364}], ["COL10A1", ["TCGA.D5.5538.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.866199265008032}], ["COL10A1", ["TCGA.D5.5538.01", "Long-term potentiation"], {"weight": 0.877643384312886}], ["COL10A1", ["TCGA.D5.5538.01", "Transport of small molecules"], {"weight": 0.914198645654128}], ["COL10A1", ["TCGA.D5.5538.01", "Muscle contraction"], {"weight": 0.877480120316338}], ["COL10A1", ["TCGA.D5.5538.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.845463162063336}], ["COL10A1", ["TCGA.D5.5538.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.84638382076084}], ["COL10A1", ["TCGA.D5.5538.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.668926556603611}], ["COL10A1", ["TCGA.D5.5538.01", "G alpha (i) signalling events"], {"weight": 0.903867821822247}], ["COL10A1", ["TCGA.D5.5538.01", "Synaptic adhesion-like molecules"], {"weight": 0.819038160653584}], ["COL10A1", ["TCGA.D5.5538.01", "Drug ADME"], {"weight": 0.737212470769271}], ["COL10A1", ["TCGA.D5.5538.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.616706827144187}], ["COL10A1", ["TCGA.D5.5538.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.786615635644335}], ["COL10A1", ["TCGA.D5.5538.01", "Post NMDA receptor activation events"], {"weight": 0.853225388121405}], ["COL10A1", ["TCGA.D5.6529.01", "NCAM1 interactions"], {"weight": 0.79204809783145}], ["COL10A1", ["TCGA.D5.6529.01", "Collagen degradation"], {"weight": 0.918386227260456}], ["COL10A1", ["TCGA.D5.6537.01", "NCAM1 interactions"], {"weight": 0.944214826688536}], ["COL10A1", ["TCGA.D5.6537.01", "NCAM signaling for neurite out-growth"], {"weight": 0.92544126653517}], ["COL10A1", ["TCGA.DM.A28F.01", "NCAM1 interactions"], {"weight": 0.931769556485886}], ["COL10A1", ["TCGA.G4.6314.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.896023750121549}], ["COL10A1", ["TCGA.G4.6314.01", "Collagen chain trimerization"], {"weight": 0.930870621414614}], ["COL10A1", ["TCGA.G4.6314.01", "Drug ADME"], {"weight": 0.84576740609852}], ["COL10A1", ["TCGA.G4.6314.01", "Degradation of the extracellular matrix"], {"weight": 0.848099213276808}], ["COL10A1", ["TCGA.G4.6314.01", "Collagen degradation"], {"weight": 0.906524950245341}], ["COL10A1", ["TCGA.G4.6314.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.603923455024164}], ["COL10A1", ["TCGA.G4.6314.01", "Aspirin ADME"], {"weight": 0.843858469767816}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Immune System"], {"weight": 0.904925081125342}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Neuronal System"], {"weight": 0.955100885029796}], ["SYNCRIP", ["TCGA.DM.A28H.01", "GPCR ligand binding"], {"weight": 0.921586942539403}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Peptide ligand-binding receptors"], {"weight": 0.921683154541071}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.923610548063079}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Complement cascade"], {"weight": 0.941148208859075}], ["SYNCRIP", ["TCGA.DM.A28H.01", "DNA strand elongation"], {"weight": 0.874453315216259}], ["SYNCRIP", ["TCGA.DM.A28H.01", "G alpha (q) signalling events"], {"weight": 0.939804140643245}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Transmission across Chemical Synapses"], {"weight": 0.939942336599996}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Cytokine Signaling in Immune system"], {"weight": 0.892005993382518}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Regulation of Complement cascade"], {"weight": 0.933108832786991}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Other interleukin signaling"], {"weight": 0.658197144604228}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Cell Cycle, Mitotic"], {"weight": 0.927996456316604}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Chromosome Maintenance"], {"weight": 0.898703582789424}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Interferon alpha/beta signaling"], {"weight": 0.892178529062456}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Cell Cycle"], {"weight": 0.925087577285155}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Lagging Strand Synthesis"], {"weight": 0.814602795174162}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Innate Immune System"], {"weight": 0.906710706034934}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.832970784311684}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Polymerase switching"], {"weight": 0.760414610830685}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Leading Strand Synthesis"], {"weight": 0.760414610830685}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Removal of the Flap Intermediate"], {"weight": 0.775162277321029}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Processive synthesis on the lagging strand"], {"weight": 0.775162277321029}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Costimulation by the CD28 family"], {"weight": 0.844641051621508}], ["SYNCRIP", ["TCGA.DM.A28H.01", "Telomere C-strand (Lagging Strand) Synthesis"], {"weight": 0.845954633456273}], ["TRAPPC3L", ["TCGA.G4.6314.01", "Collagen formation"], {"weight": 0.912805916894244}], ["TRAPPC3L", ["TCGA.G4.6314.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.938460778603453}], ["HTR1E", ["TCGA.AD.A5EK.01", "Regulation of Complement cascade"], {"weight": 0.885530677190548}], ["HTR1E", ["TCGA.F4.6856.01", "Regulation of Complement cascade"], {"weight": 0.659127020360369}], ["CGA", ["TCGA.3L.AA1B.01", "Peptide hormone metabolism"], {"weight": 0.708599727181847}], ["CGA", ["TCGA.5M.AATA.01", "Peptide hormone metabolism"], {"weight": 0.914431737596305}], ["CGA", ["TCGA.A6.2678.01", "Peptide hormone metabolism"], {"weight": 0.744402351720248}], ["CGA", ["TCGA.A6.2686.01", "Peptide hormone metabolism"], {"weight": 0.730144647649795}], ["CGA", ["TCGA.A6.4107.01", "Peptide hormone metabolism"], {"weight": 0.808425486881631}], ["CGA", ["TCGA.A6.6649.01", "Peptide hormone biosynthesis"], {"weight": 0.842290679638071}], ["CGA", ["TCGA.A6.6652.01", "Peptide hormone metabolism"], {"weight": 0.869279147156305}], ["CGA", ["TCGA.AA.3521.01", "Peptide hormone metabolism"], {"weight": 0.667116870353504}], ["CGA", ["TCGA.AA.3561.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.913211919517519}], ["CGA", ["TCGA.AA.3655.01", "Peptide hormone metabolism"], {"weight": 0.779687684077517}], ["CGA", ["TCGA.AA.3660.01", "Peptide hormone metabolism"], {"weight": 0.722678562488074}], ["CGA", ["TCGA.AA.3837.01", "Peptide hormone metabolism"], {"weight": 0.806164935207288}], ["CGA", ["TCGA.AA.3837.01", "Peptide hormone biosynthesis"], {"weight": 0.643471975166085}], ["CGA", ["TCGA.AA.3841.01", "Peptide hormone metabolism"], {"weight": 0.829828256404082}], ["CGA", ["TCGA.AA.3841.01", "Metabolism of proteins"], {"weight": 0.852188746170842}], ["CGA", ["TCGA.AA.3841.01", "Platelet homeostasis"], {"weight": 0.846986888248363}], ["CGA", ["TCGA.AA.3848.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.919079447203593}], ["CGA", ["TCGA.AA.3848.01", "G beta:gamma signalling through BTK"], {"weight": 0.917425445550666}], ["CGA", ["TCGA.AA.3848.01", "Peptide hormone metabolism"], {"weight": 0.797124534097509}], ["CGA", ["TCGA.AA.3848.01", "Thromboxane signalling through TP receptor"], {"weight": 0.916357118998391}], ["CGA", ["TCGA.AA.3848.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.908406555602443}], ["CGA", ["TCGA.AA.3848.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.908406555602443}], ["CGA", ["TCGA.AA.3848.01", "G-protein activation"], {"weight": 0.912855143819272}], ["CGA", ["TCGA.AA.3848.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.91373390259694}], ["CGA", ["TCGA.AA.3848.01", "Glucagon-type ligand receptors"], {"weight": 0.926877780951429}], ["CGA", ["TCGA.AA.3848.01", "Peptide hormone biosynthesis"], {"weight": 0.89615746688972}], ["CGA", ["TCGA.AA.3848.01", "Presynaptic function of Kainate receptors"], {"weight": 0.908406555602443}], ["CGA", ["TCGA.AA.3848.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.911477089811926}], ["CGA", ["TCGA.AA.3848.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.916357118998391}], ["CGA", ["TCGA.AA.3870.01", "Peptide hormone metabolism"], {"weight": 0.805404926963809}], ["CGA", ["TCGA.AA.3939.01", "Peptide hormone metabolism"], {"weight": 0.809839416919316}], ["CGA", ["TCGA.AA.3952.01", "Peptide hormone biosynthesis"], {"weight": 0.877915179453106}], ["CGA", ["TCGA.AA.3952.01", "Peptide hormone metabolism"], {"weight": 0.802749456981102}], ["CGA", ["TCGA.AA.3952.01", "Signaling by Activin"], {"weight": 0.716156190482775}], ["CGA", ["TCGA.AA.3966.01", "Signaling by GPCR"], {"weight": 0.942342818111528}], ["CGA", ["TCGA.AA.3966.01", "GPCR downstream signalling"], {"weight": 0.949925644349801}], ["CGA", ["TCGA.AA.3966.01", "Peptide hormone metabolism"], {"weight": 0.823581970034226}], ["CGA", ["TCGA.AA.3966.01", "Metabolism of amine-derived hormones"], {"weight": 0.801770111363173}], ["CGA", ["TCGA.AA.3966.01", "Peptide hormone biosynthesis"], {"weight": 0.848749700230673}], ["CGA", ["TCGA.AA.A00J.01", "Peptide hormone metabolism"], {"weight": 0.801852889454616}], ["CGA", ["TCGA.AA.A02H.01", "Peptide hormone metabolism"], {"weight": 0.77552432187024}], ["CGA", ["TCGA.AD.A5EK.01", "Peptide hormone metabolism"], {"weight": 0.796059011478226}], ["CGA", ["TCGA.AY.A8YK.01", "Peptide hormone metabolism"], {"weight": 0.748046099993181}], ["CGA", ["TCGA.AZ.6598.01", "Peptide hormone metabolism"], {"weight": 0.913352203069881}], ["CGA", ["TCGA.CA.5255.01", "Peptide hormone metabolism"], {"weight": 0.791861543170412}], ["CGA", ["TCGA.CA.5256.01", "Signaling Pathways"], {"weight": 0.900984628882931}], ["CGA", ["TCGA.CA.5256.01", "Metabolism of proteins"], {"weight": 0.861240936068321}], ["CGA", ["TCGA.CK.5915.01", "Peptide hormone metabolism"], {"weight": 0.902993209595455}], ["CGA", ["TCGA.CM.5348.01", "Peptide hormone biosynthesis"], {"weight": 0.771360128240153}], ["CGA", ["TCGA.CM.5863.01", "Peptide ligand-binding receptors"], {"weight": 0.912458713103612}], ["CGA", ["TCGA.CM.5863.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.912417900734539}], ["CGA", ["TCGA.CM.5863.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.689295393435768}], ["CGA", ["TCGA.CM.6172.01", "Peptide hormone metabolism"], {"weight": 0.767503009001611}], ["CGA", ["TCGA.CM.6172.01", "Peptide hormone biosynthesis"], {"weight": 0.843293329075699}], ["CGA", ["TCGA.D5.5537.01", "Peptide hormone metabolism"], {"weight": 0.814739727279866}], ["CGA", ["TCGA.D5.6529.01", "Peptide hormone metabolism"], {"weight": 0.724125976931018}], ["CGA", ["TCGA.D5.6531.01", "Peptide hormone metabolism"], {"weight": 0.800101159024914}], ["CGA", ["TCGA.D5.6535.01", "Peptide hormone metabolism"], {"weight": 0.749981934855333}], ["CGA", ["TCGA.D5.6898.01", "Peptide hormone metabolism"], {"weight": 0.696533502508585}], ["CGA", ["TCGA.D5.6931.01", "Activation of G protein gated Potassium channels"], {"weight": 0.861014040869017}], ["CGA", ["TCGA.D5.6931.01", "G protein gated Potassium channels"], {"weight": 0.861014040869017}], ["CGA", ["TCGA.D5.6931.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.861014040869017}], ["CGA", ["TCGA.DM.A0X9.01", "Peptide hormone metabolism"], {"weight": 0.7865636184049}], ["CGA", ["TCGA.DM.A28F.01", "Peptide hormone metabolism"], {"weight": 0.836551640895053}], ["CGA", ["TCGA.F4.6704.01", "Peptide hormone metabolism"], {"weight": 0.747122070400284}], ["CGA", ["TCGA.F4.6704.01", "Peptide hormone biosynthesis"], {"weight": 0.792606824768382}], ["CGA", ["TCGA.F4.6854.01", "Peptide hormone metabolism"], {"weight": 0.88489264295912}], ["CGA", ["TCGA.F4.6856.01", "Signaling by GPCR"], {"weight": 0.949939048747517}], ["CGA", ["TCGA.F4.6856.01", "Peptide hormone metabolism"], {"weight": 0.73946421139349}], ["CGA", ["TCGA.F4.6856.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.914828921182126}], ["CGA", ["TCGA.F4.6856.01", "Glucagon-type ligand receptors"], {"weight": 0.916013634968984}], ["CGA", ["TCGA.F4.6856.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.908878035577747}], ["CGA", ["TCGA.F4.6856.01", "G beta:gamma signalling through BTK"], {"weight": 0.883887361747198}], ["CGA", ["TCGA.F4.6856.01", "G-protein beta:gamma signalling"], {"weight": 0.903912507453007}], ["CGA", ["TCGA.F4.6856.01", "G alpha (s) signalling events"], {"weight": 0.950507559841076}], ["CGA", ["TCGA.F4.6856.01", "Sensory perception of taste"], {"weight": 0.896230079463144}], ["CGA", ["TCGA.NH.A6GA.01", "Peptide hormone metabolism"], {"weight": 0.878793918705608}], ["CGA", ["TCGA.NH.A6GA.01", "Peptide hormone biosynthesis"], {"weight": 0.865933416388164}], ["CGA", ["TCGA.QL.A97D.01", "Peptide hormone metabolism"], {"weight": 0.826023662583804}], ["GPRC6A", ["TCGA.AA.3848.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.909822067174452}], ["GPRC6A", ["TCGA.AA.3982.01", "Signaling by Retinoic Acid"], {"weight": 0.607205387926608}], ["GPRC6A", ["TCGA.AA.3982.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.347064650716763}], ["GPRC6A", ["TCGA.AA.3982.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.862707939775853}], ["GPRC6A", ["TCGA.AA.3982.01", "Signal amplification"], {"weight": 0.844044469435318}], ["GPRC6A", ["TCGA.AA.3982.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.845009928655303}], ["GPRC6A", ["TCGA.AA.3982.01", "G alpha (s) signalling events"], {"weight": 0.920808538102111}], ["GPRC6A", ["TCGA.AA.3982.01", "Signaling by Nuclear Receptors"], {"weight": 0.793080113180542}], ["GPRC6A", ["TCGA.AA.3982.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.823538486671741}], ["GPRC6A", ["TCGA.AA.3982.01", "Extra-nuclear estrogen signaling"], {"weight": 0.813966214347085}], ["GPRC6A", ["TCGA.AA.3982.01", "Phase 0 - rapid depolarisation"], {"weight": 0.520683262753662}], ["GPRC6A", ["TCGA.AA.3982.01", "Complement cascade"], {"weight": 0.686163561211394}], ["GPRC6A", ["TCGA.AA.3982.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.242271146078467}], ["GPRC6A", ["TCGA.AA.3982.01", "GPER1 signaling"], {"weight": 0.850321327810322}], ["GPRC6A", ["TCGA.AA.3982.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.850321327810322}], ["GPRC6A", ["TCGA.AA.3982.01", "Regulation of Complement cascade"], {"weight": 0.644621290980122}], ["GPRC6A", ["TCGA.AA.3982.01", "Aquaporin-mediated transport"], {"weight": 0.641167351301099}], ["GPRC6A", ["TCGA.AA.3982.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.4321634948501}], ["GPRC6A", ["TCGA.AA.3982.01", "Glucagon-type ligand receptors"], {"weight": 0.848797719159601}], ["GPRC6A", ["TCGA.AA.3982.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.801569189158805}], ["GPRC6A", ["TCGA.AA.3982.01", "GPCR downstream signalling"], {"weight": 0.928767185449138}], ["GPRC6A", ["TCGA.AA.3982.01", "G alpha (z) signalling events"], {"weight": 0.850321327810322}], ["GPRC6A", ["TCGA.AA.3982.01", "G-protein activation"], {"weight": 0.809939408441824}], ["GPRC6A", ["TCGA.AA.3982.01", "Thromboxane signalling through TP receptor"], {"weight": 0.787404579835794}], ["GPRC6A", ["TCGA.AA.3982.01", "G alpha (q) signalling events"], {"weight": 0.900338684282381}], ["GPRC6A", ["TCGA.AA.3982.01", "Regulation of insulin secretion"], {"weight": 0.884501419577624}], ["GPRC6A", ["TCGA.AA.3982.01", "Phase 2 - plateau phase"], {"weight": 0.436345307511215}], ["GPRC6A", ["TCGA.AA.3982.01", "GPCR ligand binding"], {"weight": 0.897265624896159}], ["GPRC6A", ["TCGA.AA.3982.01", "Signaling by GPCR"], {"weight": 0.918517379812093}], ["GPRC6A", ["TCGA.AA.3982.01", "G-protein mediated events"], {"weight": 0.827065790839732}], ["GPRC6A", ["TCGA.AA.3982.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.525321574001525}], ["GPRC6A", ["TCGA.AA.3982.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.831897112440266}], ["GPRC6A", ["TCGA.AA.3982.01", "G beta:gamma signalling through BTK"], {"weight": 0.752251464810125}], ["GPRC6A", ["TCGA.AA.3982.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.83580204869759}], ["GPRC6A", ["TCGA.AA.3982.01", "ESR-mediated signaling"], {"weight": 0.838780078958873}], ["GPRC6A", ["TCGA.AA.3982.01", "Interleukin-12 signaling"], {"weight": -0.0129402848141616}], ["GPRC6A", ["TCGA.AA.3982.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.752251464810125}], ["GPRC6A", ["TCGA.CK.4952.01", "Chemokine receptors bind chemokines"], {"weight": 0.922656445552148}], ["GPRC6A", ["TCGA.CM.4747.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.849868941554113}], ["GPRC6A", ["TCGA.CM.4747.01", "Interleukin-10 signaling"], {"weight": 0.924629506726634}], ["GPRC6A", ["TCGA.CM.4747.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.824207483672828}], ["GPRC6A", ["TCGA.CM.6169.01", "GPCR ligand binding"], {"weight": 0.920693095738099}], ["GPRC6A", ["TCGA.CM.6169.01", "Glucagon-type ligand receptors"], {"weight": 0.884285900851275}], ["GPRC6A", ["TCGA.CM.6169.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.893371216277872}], ["GPRC6A", ["TCGA.CM.6169.01", "G alpha (q) signalling events"], {"weight": 0.928280484504558}], ["GPRC6A", ["TCGA.DM.A1D7.01", "GPCR ligand binding"], {"weight": 0.916654123798993}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Peptide ligand-binding receptors"], {"weight": 0.926633256525273}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.927389008468709}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Chemokine receptors bind chemokines"], {"weight": 0.927761256198711}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Potassium Channels"], {"weight": 0.903364342608689}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.870818280846025}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Interleukin-10 signaling"], {"weight": 0.930624483606168}], ["GPRC6A", ["TCGA.DM.A1D7.01", "G alpha (q) signalling events"], {"weight": 0.937442700355618}], ["GPRC6A", ["TCGA.DM.A1D7.01", "Glucagon-type ligand receptors"], {"weight": 0.914677547120983}], ["GPRC6A", ["TCGA.G4.6314.01", "Biological oxidations"], {"weight": 0.899423922823444}], ["GPRC6A", ["TCGA.G4.6314.01", "Transport of small molecules"], {"weight": 0.856297507891257}], ["GPRC6A", ["TCGA.G4.6314.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.74759440752996}], ["GPRC6A", ["TCGA.G4.6314.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.840359547173303}], ["GPRC6A", ["TCGA.G4.6314.01", "Stimuli-sensing channels"], {"weight": 0.823957339472439}], ["GPRC6A", ["TCGA.G4.6314.01", "GPCR ligand binding"], {"weight": 0.878027598333003}], ["GPRC6A", ["TCGA.G4.6314.01", "Peptide hormone biosynthesis"], {"weight": 0.596440062890872}], ["GPRC6A", ["TCGA.G4.6314.01", "Phase I - Functionalization of compounds"], {"weight": 0.889258877506729}], ["GPRC6A", ["TCGA.G4.6314.01", "Signaling by Activin"], {"weight": 0.63748813776235}], ["COL9A1", ["TCGA.4T.AA8H.01", "ECM proteoglycans"], {"weight": 0.876555975474641}], ["COL9A1", ["TCGA.5M.AATA.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.806573503343614}], ["COL9A1", ["TCGA.A6.2686.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.890558815236645}], ["COL9A1", ["TCGA.A6.2686.01", "Collagen formation"], {"weight": 0.943586501691917}], ["COL9A1", ["TCGA.A6.2686.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.94171597472345}], ["COL9A1", ["TCGA.AA.3521.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.942074428735646}], ["COL9A1", ["TCGA.AA.3685.01", "Degradation of the extracellular matrix"], {"weight": 0.889766348561108}], ["COL9A1", ["TCGA.AA.3685.01", "Collagen formation"], {"weight": 0.93829259909662}], ["COL9A1", ["TCGA.AA.3685.01", "Collagen degradation"], {"weight": 0.865919709971872}], ["COL9A1", ["TCGA.AA.3875.01", "Extracellular matrix organization"], {"weight": 0.816103433449385}], ["COL9A1", ["TCGA.AA.3875.01", "Collagen formation"], {"weight": 0.905683243090541}], ["COL9A1", ["TCGA.AA.3875.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.917288547247034}], ["COL9A1", ["TCGA.AA.3875.01", "Collagen degradation"], {"weight": 0.896075745907035}], ["COL9A1", ["TCGA.AA.3875.01", "NCAM1 interactions"], {"weight": 0.8547210634129}], ["COL9A1", ["TCGA.AA.3875.01", "ECM proteoglycans"], {"weight": 0.742081825429757}], ["COL9A1", ["TCGA.AA.3952.01", "NCAM1 interactions"], {"weight": 0.905147337683399}], ["COL9A1", ["TCGA.AA.3966.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.942449545804455}], ["COL9A1", ["TCGA.AA.3966.01", "Collagen formation"], {"weight": 0.952915463347292}], ["COL9A1", ["TCGA.AA.3966.01", "L1CAM interactions"], {"weight": 0.89601885623744}], ["COL9A1", ["TCGA.AA.3966.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.944925880076124}], ["COL9A1", ["TCGA.AA.3966.01", "G alpha (q) signalling events"], {"weight": 0.93264071708144}], ["COL9A1", ["TCGA.AA.A01D.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.936674252282968}], ["COL9A1", ["TCGA.AA.A01X.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.755643535793912}], ["COL9A1", ["TCGA.AA.A029.01", "Extracellular matrix organization"], {"weight": 0.884609574903001}], ["COL9A1", ["TCGA.AA.A02O.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.855175184698928}], ["COL9A1", ["TCGA.AD.6888.01", "L1CAM interactions"], {"weight": 0.876052117126642}], ["COL9A1", ["TCGA.AD.6888.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.944753629899116}], ["COL9A1", ["TCGA.AD.6899.01", "Collagen formation"], {"weight": 0.917001051152539}], ["COL9A1", ["TCGA.AD.6899.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.889656540438726}], ["COL9A1", ["TCGA.AD.6899.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.929536383736723}], ["COL9A1", ["TCGA.AZ.6598.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.950592140026478}], ["COL9A1", ["TCGA.AZ.6598.01", "Collagen formation"], {"weight": 0.952713345003621}], ["COL9A1", ["TCGA.AZ.6607.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.960235513680836}], ["COL9A1", ["TCGA.AZ.6607.01", "Signaling by PDGF"], {"weight": 0.93688258031373}], ["COL9A1", ["TCGA.AZ.6607.01", "Collagen degradation"], {"weight": 0.908455964109919}], ["COL9A1", ["TCGA.AZ.6608.01", "ECM proteoglycans"], {"weight": 0.888040531175437}], ["COL9A1", ["TCGA.CM.5348.01", "Extracellular matrix organization"], {"weight": 0.859966206607607}], ["COL9A1", ["TCGA.CM.5863.01", "Extracellular matrix organization"], {"weight": 0.909278892743459}], ["COL9A1", ["TCGA.CM.5863.01", "Collagen formation"], {"weight": 0.925511884464378}], ["COL9A1", ["TCGA.CM.5863.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.946521810751284}], ["COL9A1", ["TCGA.CM.5863.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.932749964294138}], ["COL9A1", ["TCGA.CM.5863.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.903721099473958}], ["COL9A1", ["TCGA.CM.5863.01", "Signaling by GPCR"], {"weight": 0.903058136749582}], ["COL9A1", ["TCGA.CM.5863.01", "Degradation of the extracellular matrix"], {"weight": 0.929996875642081}], ["COL9A1", ["TCGA.D5.6535.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.806819413613469}], ["COL9A1", ["TCGA.D5.6898.01", "Degradation of the extracellular matrix"], {"weight": 0.906910939584594}], ["COL9A1", ["TCGA.F4.6459.01", "Extracellular matrix organization"], {"weight": 0.877474545490636}], ["COL9A1", ["TCGA.F4.6459.01", "Collagen formation"], {"weight": 0.911939342652648}], ["COL9A1", ["TCGA.F4.6459.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.93138173604135}], ["COL9A1", ["TCGA.F4.6459.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.866923826812888}], ["COL9A1", ["TCGA.F4.6704.01", "Collagen formation"], {"weight": 0.914057822355896}], ["COL9A1", ["TCGA.F4.6704.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.942914747025734}], ["COL9A1", ["TCGA.F4.6704.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.873887991131232}], ["COL9A1", ["TCGA.F4.6704.01", "Degradation of the extracellular matrix"], {"weight": 0.798521131334923}], ["COL9A1", ["TCGA.F4.6856.01", "Extracellular matrix organization"], {"weight": 0.855166682980694}], ["COL9A1", ["TCGA.F4.6856.01", "L1CAM interactions"], {"weight": 0.933210038164565}], ["COL9A1", ["TCGA.F4.6856.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.894302028504468}], ["COL9A1", ["TCGA.F4.6856.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.945848247827954}], ["COL9A1", ["TCGA.F4.6856.01", "Collagen formation"], {"weight": 0.945200899360853}], ["COL9A1", ["TCGA.G4.6297.01", "Collagen formation"], {"weight": 0.93595727256392}], ["COL9A1", ["TCGA.G4.6297.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.949628887960754}], ["COL9A1", ["TCGA.G4.6297.01", "Diseases of glycosylation"], {"weight": 0.818597250871168}], ["ORC3", ["TCGA.AA.3561.01", "Phosphorylation of the APC/C"], {"weight": 0.906433090692465}], ["ORC3", ["TCGA.AA.3561.01", "Cell Cycle, Mitotic"], {"weight": 0.919334840693534}], ["ORC3", ["TCGA.AA.3561.01", "Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1"], {"weight": 0.852866552278067}], ["ORC3", ["TCGA.AA.3561.01", "G0 and Early G1"], {"weight": 0.873092908442892}], ["ORC3", ["TCGA.AA.3561.01", "G1/S-Specific Transcription"], {"weight": 0.882006789080639}], ["ORC3", ["TCGA.AA.3848.01", "Activation of the pre-replicative complex"], {"weight": 0.886955064583003}], ["ORC3", ["TCGA.AA.3875.01", "Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1"], {"weight": 0.765780870487754}], ["ORC3", ["TCGA.AA.3875.01", "Phosphorylation of the APC/C"], {"weight": 0.788621387059746}], ["ORC3", ["TCGA.AA.3875.01", "APC/C:Cdc20 mediated degradation of Cyclin B"], {"weight": 0.788621387059746}], ["ORC3", ["TCGA.AA.3875.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], {"weight": 0.656629176816639}], ["ORC3", ["TCGA.AA.3875.01", "Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects"], {"weight": 0.656629176816639}], ["ORC3", ["TCGA.AA.3875.01", "Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)"], {"weight": 0.656629176816639}], ["ORC3", ["TCGA.CK.4952.01", "Activation of the pre-replicative complex"], {"weight": 0.908340108578664}], ["ORC3", ["TCGA.CK.4952.01", "Activation of ATR in response to replication stress"], {"weight": 0.897289925534191}], ["ORC3", ["TCGA.CK.4952.01", "Condensation of Prometaphase Chromosomes"], {"weight": 0.820522601490099}], ["GOPC", ["TCGA.AA.3518.01", "Extracellular matrix organization"], {"weight": 0.825320958120547}], ["GOPC", ["TCGA.AA.3518.01", "Transmission across Chemical Synapses"], {"weight": 0.901845687490373}], ["GOPC", ["TCGA.AA.3518.01", "Molecules associated with elastic fibres"], {"weight": 0.670241890807495}], ["GOPC", ["TCGA.AA.3518.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.698793995124589}], ["GOPC", ["TCGA.CA.5256.01", "SARS-CoV-1 Infection"], {"weight": 0.86221438040196}], ["GOPC", ["TCGA.G4.6322.01", "GPCR ligand binding"], {"weight": 0.914225224572518}], ["GOPC", ["TCGA.G4.6322.01", "Signaling by GPCR"], {"weight": 0.93287785313049}], ["GOPC", ["TCGA.G4.6322.01", "GPCR downstream signalling"], {"weight": 0.938814052719646}], ["GOPC", ["TCGA.G4.6322.01", "Drug ADME"], {"weight": 0.830805932403983}], ["GOPC", ["TCGA.G4.6322.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.913672464908782}], ["GOPC", ["TCGA.G4.6322.01", "L1CAM interactions"], {"weight": 0.861864629119979}], ["GOPC", ["TCGA.G4.6322.01", "Protein-protein interactions at synapses"], {"weight": 0.852824663386439}], ["GOPC", ["TCGA.G4.6322.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.915233641128698}], ["GOPC", ["TCGA.G4.6322.01", "G alpha (i) signalling events"], {"weight": 0.932106170298424}], ["GOPC", ["TCGA.G4.6322.01", "Degradation of the extracellular matrix"], {"weight": 0.860688501762693}], ["GOPC", ["TCGA.G4.6322.01", "Peptide hormone metabolism"], {"weight": 0.760479163715506}], ["GOPC", ["TCGA.G4.6322.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.87335202197663}], ["GOPC", ["TCGA.G4.6322.01", "Peptide ligand-binding receptors"], {"weight": 0.898363167636387}], ["GOPC", ["TCGA.G4.6322.01", "Molecules associated with elastic fibres"], {"weight": 0.747412101606687}], ["GOPC", ["TCGA.G4.6322.01", "Complement cascade"], {"weight": 0.670323949048584}], ["GOPC", ["TCGA.G4.6322.01", "Chemokine receptors bind chemokines"], {"weight": 0.891716972541273}], ["GOPC", ["TCGA.G4.6322.01", "Chondroitin sulfate/dermatan sulfate metabolism"], {"weight": 0.775744835925582}], ["GOPC", ["TCGA.G4.6322.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.803125854808674}], ["NUS1", ["TCGA.AA.3841.01", "Cholesterol biosynthesis"], {"weight": 0.591467556316523}], ["CNR1", ["TCGA.AA.3561.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.812141064704116}], ["CNR1", ["TCGA.AA.3870.01", "Common Pathway of Fibrin Clot Formation"], {"weight": 0.915959480314528}], ["CNR1", ["TCGA.AA.3966.01", "Peptide ligand-binding receptors"], {"weight": 0.910479532691314}], ["CNR1", ["TCGA.AA.3966.01", "Chemokine receptors bind chemokines"], {"weight": 0.917862765590438}], ["CNR1", ["TCGA.AA.A02H.01", "Binding and entry of HIV virion"], {"weight": 0.736140975226496}], ["CNR1", ["TCGA.AZ.6608.01", "G alpha (s) signalling events"], {"weight": 0.967646075427582}], ["CNR1", ["TCGA.CK.4952.01", "Complement cascade"], {"weight": 0.924509297438235}], ["CNR1", ["TCGA.CK.4952.01", "Regulation of Complement cascade"], {"weight": 0.918333930347773}], ["CNR1", ["TCGA.CK.4952.01", "Initial triggering of complement"], {"weight": 0.888506245542813}], ["CNR1", ["TCGA.CM.5868.01", "G alpha (q) signalling events"], {"weight": 0.93803919205956}], ["CNR1", ["TCGA.CM.5868.01", "Chemokine receptors bind chemokines"], {"weight": 0.925620073340372}], ["CNR1", ["TCGA.CM.5868.01", "Glucagon-type ligand receptors"], {"weight": 0.919821539522894}], ["CNR1", ["TCGA.CM.5868.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.896946306895322}], ["CNR1", ["TCGA.CM.5868.01", "GABA receptor activation"], {"weight": 0.67958348884915}], ["CNR1", ["TCGA.CM.5868.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.877779458277975}], ["CNR1", ["TCGA.CM.5868.01", "G beta:gamma signalling through BTK"], {"weight": 0.901809746148241}], ["CNR1", ["TCGA.CM.5868.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.904484259077472}], ["CNR1", ["TCGA.CM.5868.01", "GABA B receptor activation"], {"weight": 0.918082727813006}], ["CNR1", ["TCGA.CM.5868.01", "Activation of GABAB receptors"], {"weight": 0.918082727813006}], ["CNR1", ["TCGA.CM.5868.01", "Potassium Channels"], {"weight": 0.94642489901676}], ["CNR1", ["TCGA.CM.5868.01", "G-protein beta:gamma signalling"], {"weight": 0.916859594872574}], ["CNR1", ["TCGA.CM.5868.01", "Inwardly rectifying K+ channels"], {"weight": 0.912944301763016}], ["CNR1", ["TCGA.CM.5868.01", "Activation of G protein gated Potassium channels"], {"weight": 0.906341774980351}], ["CNR1", ["TCGA.CM.5868.01", "G protein gated Potassium channels"], {"weight": 0.906341774980351}], ["CNR1", ["TCGA.CM.5868.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.906341774980351}], ["CNR1", ["TCGA.CM.5868.01", "Binding and entry of HIV virion"], {"weight": 0.681999668891694}], ["CNR1", ["TCGA.CM.5868.01", "G-protein activation"], {"weight": 0.902661549038058}], ["CNR1", ["TCGA.CM.5868.01", "Thromboxane signalling through TP receptor"], {"weight": 0.878363319420097}], ["CNR1", ["TCGA.CM.5868.01", "Ca2+ pathway"], {"weight": 0.845798556849471}], ["CNR1", ["TCGA.CM.5868.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.872148127834301}], ["CNR1", ["TCGA.CM.5868.01", "Sensory perception of taste"], {"weight": 0.868540832285801}], ["CNR1", ["TCGA.CM.5868.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.872148127834301}], ["CNR1", ["TCGA.CM.5868.01", "G beta:gamma signalling through CDC42"], {"weight": 0.872148127834301}], ["CNR1", ["TCGA.CM.6676.01", "Regulation of Complement cascade"], {"weight": 0.797181557349836}], ["CNR1", ["TCGA.D5.6931.01", "Defective B3GALTL causes PpS"], {"weight": 0.79797719783134}], ["CNR1", ["TCGA.D5.6931.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.79797719783134}], ["CNR1", ["TCGA.F4.6854.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.921285559321871}], ["CNR1", ["TCGA.F4.6854.01", "Peptide ligand-binding receptors"], {"weight": 0.835720182418202}], ["CNR1", ["TCGA.F4.6856.01", "Metabolism of water-soluble vitamins and cofactors"], {"weight": 0.725402090728481}], ["CNR1", ["TCGA.F4.6856.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.899147604194069}], ["CNR1", ["TCGA.F4.6856.01", "Chemokine receptors bind chemokines"], {"weight": 0.903655558125973}], ["PLN", ["TCGA.A6.2678.01", "Cardiac conduction"], {"weight": 0.905655100396413}], ["PLN", ["TCGA.A6.2678.01", "Muscle contraction"], {"weight": 0.893746296087253}], ["PLN", ["TCGA.A6.2686.01", "Sensory perception of taste"], {"weight": 0.883405796949048}], ["PLN", ["TCGA.A6.6648.01", "Neuronal System"], {"weight": 0.919209682751144}], ["PLN", ["TCGA.A6.6648.01", "Protein-protein interactions at synapses"], {"weight": 0.644181194122157}], ["PLN", ["TCGA.A6.6648.01", "Cardiac conduction"], {"weight": 0.936788230004066}], ["PLN", ["TCGA.A6.6648.01", "Interaction between L1 and Ankyrins"], {"weight": 0.892019838255145}], ["PLN", ["TCGA.A6.6648.01", "Transmission across Chemical Synapses"], {"weight": 0.895817987024219}], ["PLN", ["TCGA.A6.6648.01", "Muscle contraction"], {"weight": 0.930283764218956}], ["PLN", ["TCGA.A6.6648.01", "Neurexins and neuroligins"], {"weight": 0.897822785940415}], ["PLN", ["TCGA.A6.6648.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.902067125333404}], ["PLN", ["TCGA.A6.6648.01", "Synaptic adhesion-like molecules"], {"weight": 0.70966914236359}], ["PLN", ["TCGA.A6.6648.01", "Inwardly rectifying K+ channels"], {"weight": 0.860550671657649}], ["PLN", ["TCGA.A6.6648.01", "GABA receptor activation"], {"weight": 0.816720042188896}], ["PLN", ["TCGA.A6.6648.01", "Phase 0 - rapid depolarisation"], {"weight": 0.858907321222681}], ["PLN", ["TCGA.A6.6648.01", "GABA B receptor activation"], {"weight": 0.871158155302278}], ["PLN", ["TCGA.A6.6648.01", "Activation of GABAB receptors"], {"weight": 0.871158155302278}], ["PLN", ["TCGA.A6.6648.01", "Potassium Channels"], {"weight": 0.917511654438}], ["PLN", ["TCGA.A6.6648.01", "Complement cascade"], {"weight": 0.786109082735291}], ["PLN", ["TCGA.A6.6648.01", "L1CAM interactions"], {"weight": 0.851612695929485}], ["PLN", ["TCGA.A6.6648.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.839380771283784}], ["PLN", ["TCGA.A6.6648.01", "Regulation of Complement cascade"], {"weight": 0.699863819614225}], ["PLN", ["TCGA.A6.6648.01", "Mitotic Spindle Checkpoint"], {"weight": 0.875939708129758}], ["PLN", ["TCGA.A6.6648.01", "Activation of G protein gated Potassium channels"], {"weight": 0.840618327549431}], ["PLN", ["TCGA.A6.6648.01", "G protein gated Potassium channels"], {"weight": 0.840618327549431}], ["PLN", ["TCGA.A6.6648.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.840618327549431}], ["PLN", ["TCGA.A6.6648.01", "Molecules associated with elastic fibres"], {"weight": 0.621023459661201}], ["PLN", ["TCGA.A6.6648.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.843151573207254}], ["PLN", ["TCGA.A6.6648.01", "Long-term potentiation"], {"weight": 0.844409375673372}], ["PLN", ["TCGA.A6.6648.01", "Ion homeostasis"], {"weight": 0.874287526731206}], ["PLN", ["TCGA.A6.6648.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.777208573275601}], ["PLN", ["TCGA.A6.6648.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.827820990769808}], ["PLN", ["TCGA.A6.6648.01", "G alpha (i) signalling events"], {"weight": 0.909387254239514}], ["PLN", ["TCGA.A6.6648.01", "Glucagon-type ligand receptors"], {"weight": 0.858474180294348}], ["PLN", ["TCGA.A6.6648.01", "Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components"], {"weight": 0.705686235388289}], ["PLN", ["TCGA.A6.6648.01", "Inactivation of APC/C via direct inhibition of the APC/C complex"], {"weight": 0.705686235388289}], ["PLN", ["TCGA.A6.6648.01", "LGI-ADAM interactions"], {"weight": 0.657903675902103}], ["PLN", ["TCGA.A6.6648.01", "Amplification of signal from the kinetochores"], {"weight": 0.858424936798568}], ["PLN", ["TCGA.A6.6648.01", "Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal"], {"weight": 0.858424936798568}], ["PLN", ["TCGA.A6.6648.01", "Ras activation upon Ca2+ influx through NMDA receptor"], {"weight": 0.823035969876443}], ["PLN", ["TCGA.A6.6648.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.823035969876443}], ["PLN", ["TCGA.A6.6648.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], {"weight": 0.828234520850937}], ["PLN", ["TCGA.A6.6648.01", "Resolution of Sister Chromatid Cohesion"], {"weight": 0.865043718310088}], ["PLN", ["TCGA.A6.6648.01", "DNA Double-Strand Break Repair"], {"weight": 0.840962489520105}], ["PLN", ["TCGA.A6.6648.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.806804580745625}], ["PLN", ["TCGA.A6.6648.01", "GPCR ligand binding"], {"weight": 0.885301303897433}], ["PLN", ["TCGA.A6.6648.01", "EML4 and NUDC in mitotic spindle formation"], {"weight": 0.858424936798568}], ["PLN", ["TCGA.A6.6649.01", "Transport of small molecules"], {"weight": 0.861831645125688}], ["PLN", ["TCGA.AA.3560.01", "ABC transporters in lipid homeostasis"], {"weight": 0.707701410782475}], ["PLN", ["TCGA.AA.3655.01", "Cardiac conduction"], {"weight": 0.88740727490473}], ["PLN", ["TCGA.AA.3660.01", "Cardiac conduction"], {"weight": 0.888522845285871}], ["PLN", ["TCGA.AA.3666.01", "Cardiac conduction"], {"weight": 0.956983957570357}], ["PLN", ["TCGA.AA.3685.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.717549099733997}], ["PLN", ["TCGA.AA.3848.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.922498006026135}], ["PLN", ["TCGA.AA.3848.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.924166692544601}], ["PLN", ["TCGA.AA.3848.01", "GPER1 signaling"], {"weight": 0.924394007135225}], ["PLN", ["TCGA.AA.3848.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.924394007135225}], ["PLN", ["TCGA.AA.3848.01", "Aquaporin-mediated transport"], {"weight": 0.830217158395071}], ["PLN", ["TCGA.AA.3848.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.922498006026135}], ["PLN", ["TCGA.AA.3848.01", "Triglyceride catabolism"], {"weight": 0.766816582448604}], ["PLN", ["TCGA.AA.3860.01", "Platelet homeostasis"], {"weight": 0.811373326728558}], ["PLN", ["TCGA.AA.3860.01", "Cardiac conduction"], {"weight": 0.903012399421073}], ["PLN", ["TCGA.AA.3875.01", "ABC transporters in lipid homeostasis"], {"weight": 0.27525746027959}], ["PLN", ["TCGA.AA.3939.01", "Cardiac conduction"], {"weight": 0.893673306937349}], ["PLN", ["TCGA.AA.3952.01", "Ion channel transport"], {"weight": 0.915325099492714}], ["PLN", ["TCGA.AA.3952.01", "Cardiac conduction"], {"weight": 0.894078942586749}], ["PLN", ["TCGA.AA.3952.01", "ABC transporters in lipid homeostasis"], {"weight": 0.617073576056727}], ["PLN", ["TCGA.AA.A029.01", "Adaptive Immune System"], {"weight": 0.878511524895419}], ["PLN", ["TCGA.AA.A02H.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.833599326307526}], ["PLN", ["TCGA.AA.A02H.01", "Platelet homeostasis"], {"weight": 0.785150134665098}], ["PLN", ["TCGA.AA.A02H.01", "ABC transporters in lipid homeostasis"], {"weight": 0.540481470966331}], ["PLN", ["TCGA.AD.6888.01", "Nervous system development"], {"weight": 0.915280140987547}], ["PLN", ["TCGA.AD.6888.01", "Adaptive Immune System"], {"weight": 0.897361047310318}], ["PLN", ["TCGA.AD.A5EK.01", "Signaling Pathways"], {"weight": 0.911147268501393}], ["PLN", ["TCGA.AY.A8YK.01", "Cardiac conduction"], {"weight": 0.930361025723437}], ["PLN", ["TCGA.AZ.6598.01", "Ion homeostasis"], {"weight": 0.916800736745998}], ["PLN", ["TCGA.AZ.6600.01", "ABC transporters in lipid homeostasis"], {"weight": 0.520091478724179}], ["PLN", ["TCGA.AZ.6607.01", "Ion channel transport"], {"weight": 0.94987958194656}], ["PLN", ["TCGA.AZ.6608.01", "Platelet calcium homeostasis"], {"weight": 0.948460417921475}], ["PLN", ["TCGA.CA.5255.01", "Cardiac conduction"], {"weight": 0.926770629934911}], ["PLN", ["TCGA.CA.5256.01", "Ion channel transport"], {"weight": 0.941992543066521}], ["PLN", ["TCGA.CM.4747.01", "Signaling Pathways"], {"weight": 0.878192463091474}], ["PLN", ["TCGA.CM.4747.01", "ABC transporters in lipid homeostasis"], {"weight": 0.688759608947829}], ["PLN", ["TCGA.CM.6161.01", "Cardiac conduction"], {"weight": 0.899500637024874}], ["PLN", ["TCGA.CM.6172.01", "Platelet homeostasis"], {"weight": 0.800216369422259}], ["PLN", ["TCGA.D5.5537.01", "Cardiac conduction"], {"weight": 0.927063263303306}], ["PLN", ["TCGA.D5.5537.01", "Ion homeostasis"], {"weight": 0.894867061718365}], ["PLN", ["TCGA.D5.6529.01", "Metabolism"], {"weight": 0.896679838255492}], ["PLN", ["TCGA.D5.6529.01", "Cardiac conduction"], {"weight": 0.836363490095825}], ["PLN", ["TCGA.D5.6531.01", "Ion channel transport"], {"weight": 0.950545653258174}], ["PLN", ["TCGA.D5.6531.01", "Ion homeostasis"], {"weight": 0.876523288863926}], ["PLN", ["TCGA.DM.A1D7.01", "Neuronal System"], {"weight": 0.940714121057277}], ["PLN", ["TCGA.DM.A1D7.01", "Signaling by GPCR"], {"weight": 0.931650374568355}], ["PLN", ["TCGA.DM.A1D7.01", "GPCR downstream signalling"], {"weight": 0.944241505418683}], ["PLN", ["TCGA.DM.A1D7.01", "G alpha (i) signalling events"], {"weight": 0.931644463839544}], ["PLN", ["TCGA.DM.A1D7.01", "Transmission across Chemical Synapses"], {"weight": 0.929644110515834}], ["PLN", ["TCGA.DM.A1D7.01", "Cardiac conduction"], {"weight": 0.925500200749522}], ["PLN", ["TCGA.DM.A1D7.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.913974417374905}], ["PLN", ["TCGA.DM.A1D7.01", "Ion homeostasis"], {"weight": 0.905479930540051}], ["PLN", ["TCGA.DM.A1D7.01", "G alpha (s) signalling events"], {"weight": 0.948584498476936}], ["PLN", ["TCGA.DM.A1D7.01", "Platelet homeostasis"], {"weight": 0.840559049662835}], ["PLN", ["TCGA.DM.A1D7.01", "Ca-dependent events"], {"weight": 0.825320107990252}], ["PLN", ["TCGA.DM.A1D7.01", "Muscle contraction"], {"weight": 0.914323130696228}], ["PLN", ["TCGA.DM.A28F.01", "Cell surface interactions at the vascular wall"], {"weight": 0.848817657786179}], ["PLN", ["TCGA.F4.6460.01", "Transport of small molecules"], {"weight": 0.907999544853747}], ["PLN", ["TCGA.NH.A6GA.01", "Cardiac conduction"], {"weight": 0.92620627086425}], ["PLN", ["TCGA.NH.A6GA.01", "Ion homeostasis"], {"weight": 0.883389581946152}], ["PLN", ["TCGA.NH.A6GA.01", "Muscle contraction"], {"weight": 0.931141849143083}], ["RNGTT", ["TCGA.AA.3561.01", "Influenza Viral RNA Transcription and Replication"], {"weight": 0.933780376589265}], ["RNGTT", ["TCGA.AA.3561.01", "Chromosome Maintenance"], {"weight": 0.860543850678803}], ["RNGTT", ["TCGA.AA.3561.01", "Signaling by Nuclear Receptors"], {"weight": 0.856858509466503}], ["RNGTT", ["TCGA.AA.3966.01", "Digestion"], {"weight": 0.347019774663516}], ["RNGTT", ["TCGA.CM.4743.01", "Signaling by GPCR"], {"weight": 0.943927874314439}], ["RNGTT", ["TCGA.CM.4743.01", "GPCR downstream signalling"], {"weight": 0.951653138831392}], ["RNGTT", ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.815811704000127}], ["RNGTT", ["TCGA.CM.4743.01", "Phase I - Functionalization of compounds"], {"weight": 0.929265178611775}], ["RNGTT", ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts"], {"weight": 0.847568580588259}], ["RNGTT", ["TCGA.CM.4743.01", "Bile acid and bile salt metabolism"], {"weight": 0.849256172688196}], ["RNGTT", ["TCGA.CM.4743.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.785590039766399}], ["RNGTT", ["TCGA.CM.4743.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.756431913812362}], ["RNGTT", ["TCGA.CM.4743.01", "Recycling of bile acids and salts"], {"weight": 0.790380275323593}], ["RNGTT", ["TCGA.CM.4743.01", "Endogenous sterols"], {"weight": 0.464716142140707}], ["RNGTT", ["TCGA.F4.6856.01", "Digestion"], {"weight": 0.543752241547259}], ["MCM9", ["TCGA.A6.6648.01", "TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest"], {"weight": 0.779394927818895}], ["MCM9", ["TCGA.A6.6648.01", "Cell Cycle Checkpoints"], {"weight": 0.926719314762439}], ["MCM9", ["TCGA.A6.6648.01", "G0 and Early G1"], {"weight": 0.875639843653081}], ["MCM9", ["TCGA.A6.6648.01", "Presynaptic phase of homologous DNA pairing and strand exchange"], {"weight": 0.839565735509555}], ["MCM9", ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Impaired BRCA2 binding to PALB2"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Homologous DNA Pairing and Strand Exchange"], {"weight": 0.839565735509555}], ["MCM9", ["TCGA.A6.6648.01", "Transcription of E2F targets under negative control by DREAM complex"], {"weight": 0.859642427999146}], ["MCM9", ["TCGA.A6.6648.01", "Resolution of D-loop Structures through Holliday Junction Intermediates"], {"weight": 0.819662789000095}], ["MCM9", ["TCGA.A6.6648.01", "Cell Cycle"], {"weight": 0.914453941824967}], ["MCM9", ["TCGA.A6.6648.01", "Resolution of D-Loop Structures"], {"weight": 0.819662789000095}], ["MCM9", ["TCGA.A6.6648.01", "Diseases of DNA repair"], {"weight": 0.831173756782707}], ["MCM9", ["TCGA.A6.6648.01", "Diseases of DNA Double-Strand Break Repair"], {"weight": 0.831173756782707}], ["MCM9", ["TCGA.A6.6648.01", "Defective homologous recombination repair (HRR) due to BRCA2 loss of function"], {"weight": 0.831173756782707}], ["MCM9", ["TCGA.A6.6648.01", "Regulation of FZD by ubiquitination"], {"weight": 0.766207332078174}], ["MCM9", ["TCGA.A6.6648.01", "Cell Cycle, Mitotic"], {"weight": 0.910664708718444}], ["MCM9", ["TCGA.A6.6648.01", "Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)"], {"weight": 0.796401259826243}], ["MCM9", ["TCGA.A6.6648.01", "Impaired BRCA2 binding to RAD51"], {"weight": 0.799772465307708}], ["MCM9", ["TCGA.A6.6648.01", "TP53 Regulates Transcription of Cell Cycle Genes"], {"weight": 0.832738983343145}], ["MCM9", ["TCGA.A6.6648.01", "HDR through Homologous Recombination (HRR)"], {"weight": 0.851649120483451}], ["MCM9", ["TCGA.A6.6648.01", "G2/M DNA damage checkpoint"], {"weight": 0.822238756908771}], ["MCM9", ["TCGA.A6.6648.01", "Signaling Pathways"], {"weight": 0.859222227111937}], ["MCM9", ["TCGA.A6.6648.01", "Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"], {"weight": 0.558236350834835}], ["MCM9", ["TCGA.AA.3715.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.890539448634234}], ["MCM9", ["TCGA.AA.3715.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.890254209203343}], ["MCM9", ["TCGA.AA.3841.01", "Unwinding of DNA"], {"weight": 0.816391596807638}], ["MCM9", ["TCGA.AA.3841.01", "DNA strand elongation"], {"weight": 0.863186533572831}], ["MCM9", ["TCGA.AA.3848.01", "Unwinding of DNA"], {"weight": 0.829917220187277}], ["MCM9", ["TCGA.AA.3848.01", "DNA strand elongation"], {"weight": 0.879460816557454}], ["MCM9", ["TCGA.CK.4952.01", "Unwinding of DNA"], {"weight": 0.877464592659186}], ["MCM9", ["TCGA.CK.4952.01", "DNA strand elongation"], {"weight": 0.894588904676027}], ["MCM9", ["TCGA.CM.4747.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.691631762445575}], ["MCM9", ["TCGA.G4.6297.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.72846750389154}], ["ASF1A", ["TCGA.AA.3715.01", "APOBEC3G mediated resistance to HIV-1 infection"], {"weight": 0.837701645388308}], ["ASF1A", ["TCGA.AA.3848.01", "Inhibition of replication initiation of damaged DNA by RB1/E2F1"], {"weight": 0.833083734202915}], ["ASF1A", ["TCGA.AD.6888.01", "G alpha (z) signalling events"], {"weight": 0.903611229963123}], ["ASF1A", ["TCGA.CA.5256.01", "Cellular responses to stimuli"], {"weight": 0.868425291544052}], ["ASF1A", ["TCGA.CA.5256.01", "Cellular responses to stress"], {"weight": 0.875494570445518}], ["MAN1A1", ["TCGA.CM.4747.01", "Neuronal System"], {"weight": 0.88334364630897}], ["MAN1A1", ["TCGA.CM.4747.01", "Transmission across Chemical Synapses"], {"weight": 0.871979108676505}], ["MAN1A1", ["TCGA.CM.4747.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.855908974849595}], ["MAN1A1", ["TCGA.T9.A92H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.94283086262921}], ["MAN1A1", ["TCGA.T9.A92H.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.912332713192602}], ["MAN1A1", ["TCGA.T9.A92H.01", "Synaptic adhesion-like molecules"], {"weight": 0.831655882362574}], ["MAN1A1", ["TCGA.T9.A92H.01", "GABA receptor activation"], {"weight": 0.884955602784065}], ["MAN1A1", ["TCGA.T9.A92H.01", "Long-term potentiation"], {"weight": 0.905943314382137}], ["MAN1A1", ["TCGA.T9.A92H.01", "Interaction between L1 and Ankyrins"], {"weight": 0.909452172179125}], ["MAN1A1", ["TCGA.T9.A92H.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.902388068092576}], ["MAN1A1", ["TCGA.T9.A92H.01", "Trafficking of AMPA receptors"], {"weight": 0.903644039646223}], ["MAN1A1", ["TCGA.T9.A92H.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.903644039646223}], ["SMAP1", ["TCGA.F4.6856.01", "SUMOylation of intracellular receptors"], {"weight": 0.607726413651342}], ["GABRR2", ["TCGA.4T.AA8H.01", "Generation of second messenger molecules"], {"weight": 0.935786429147803}], ["GABRR2", ["TCGA.4T.AA8H.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.936281610144565}], ["GABRR2", ["TCGA.4T.AA8H.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.93289188635349}], ["GABRR2", ["TCGA.4T.AA8H.01", "PD-1 signaling"], {"weight": 0.935561821416447}], ["GABRR2", ["TCGA.4T.AA8H.01", "Costimulation by the CD28 family"], {"weight": 0.914438218336481}], ["GABRR2", ["TCGA.A6.6652.01", "Generation of second messenger molecules"], {"weight": 0.948170254678459}], ["GABRR2", ["TCGA.A6.6652.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.948354842161152}], ["GABRR2", ["TCGA.A6.6652.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.949988904244403}], ["GABRR2", ["TCGA.A6.6652.01", "PD-1 signaling"], {"weight": 0.9479624913284}], ["GABRR2", ["TCGA.A6.6652.01", "Costimulation by the CD28 family"], {"weight": 0.906920671597076}], ["GABRR2", ["TCGA.AA.3966.01", "Interaction between L1 and Ankyrins"], {"weight": 0.912858204615732}], ["GABRR2", ["TCGA.AD.A5EK.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.930995375152688}], ["GABRR2", ["TCGA.AD.A5EK.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.914862274705025}], ["GABRR2", ["TCGA.AD.A5EK.01", "PD-1 signaling"], {"weight": 0.914862274705025}], ["GABRR2", ["TCGA.AM.5820.01", "Generation of second messenger molecules"], {"weight": 0.929105601135522}], ["GABRR2", ["TCGA.AM.5820.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.945638787776153}], ["GABRR2", ["TCGA.AM.5820.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.927450614986024}], ["GABRR2", ["TCGA.AM.5820.01", "PD-1 signaling"], {"weight": 0.925510767289681}], ["GABRR2", ["TCGA.AM.5820.01", "Costimulation by the CD28 family"], {"weight": 0.882343013804681}], ["GABRR2", ["TCGA.AM.5820.01", "TCR signaling"], {"weight": 0.933436661141189}], ["GABRR2", ["TCGA.AM.5820.01", "MHC class II antigen presentation"], {"weight": 0.925720994295346}], ["GABRR2", ["TCGA.AM.5820.01", "Downstream TCR signaling"], {"weight": 0.928942815153504}], ["GABRR2", ["TCGA.AY.A8YK.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.875728875212095}], ["GABRR2", ["TCGA.AY.A8YK.01", "PD-1 signaling"], {"weight": 0.873360985747038}], ["GABRR2", ["TCGA.AY.A8YK.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.862341453353014}], ["GABRR2", ["TCGA.AZ.6606.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.927129284153145}], ["GABRR2", ["TCGA.AZ.6606.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.922327054624081}], ["GABRR2", ["TCGA.AZ.6606.01", "PD-1 signaling"], {"weight": 0.922714339472784}], ["GABRR2", ["TCGA.AZ.6606.01", "Generation of second messenger molecules"], {"weight": 0.882094282844575}], ["GABRR2", ["TCGA.CK.4952.01", "Sialic acid metabolism"], {"weight": 0.800401797139257}], ["GABRR2", ["TCGA.CK.5915.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.95273513333979}], ["GABRR2", ["TCGA.CK.5915.01", "Generation of second messenger molecules"], {"weight": 0.953213321641653}], ["GABRR2", ["TCGA.CK.5915.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.951934988640821}], ["GABRR2", ["TCGA.CK.5915.01", "PD-1 signaling"], {"weight": 0.950129436515926}], ["GABRR2", ["TCGA.CK.5915.01", "Costimulation by the CD28 family"], {"weight": 0.918273581925911}], ["GABRR2", ["TCGA.CM.6678.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.941559215979115}], ["GABRR2", ["TCGA.CM.6678.01", "Generation of second messenger molecules"], {"weight": 0.940188573693533}], ["GABRR2", ["TCGA.CM.6678.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.942188761813438}], ["GABRR2", ["TCGA.CM.6678.01", "PD-1 signaling"], {"weight": 0.938411499177324}], ["GABRR2", ["TCGA.CM.6678.01", "Costimulation by the CD28 family"], {"weight": 0.889154297929254}], ["GABRR2", ["TCGA.CM.6678.01", "TCR signaling"], {"weight": 0.946769051121727}], ["GABRR2", ["TCGA.D5.6537.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.937675513994559}], ["GABRR2", ["TCGA.D5.6537.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.935846042264836}], ["GABRR2", ["TCGA.D5.6537.01", "Generation of second messenger molecules"], {"weight": 0.872010684111846}], ["GABRR2", ["TCGA.D5.6537.01", "PD-1 signaling"], {"weight": 0.935846042264836}], ["GABRR2", ["TCGA.D5.6537.01", "MHC class II antigen presentation"], {"weight": 0.938145605506422}], ["GABRR2", ["TCGA.F4.6459.01", "Regulation of beta-cell development"], {"weight": 0.834242876902414}], ["GABRR2", ["TCGA.F4.6856.01", "Interaction between L1 and Ankyrins"], {"weight": 0.922286924397153}], ["GABRR2", ["TCGA.G4.6297.01", "Regulation of beta-cell development"], {"weight": 0.792907426892855}], ["UBE2J1", ["TCGA.AA.3560.01", "rRNA processing"], {"weight": 0.92756234463554}], ["UBE2J1", ["TCGA.CA.5255.01", "Immune System"], {"weight": 0.864759062916989}], ["UBE2J1", ["TCGA.CA.5255.01", "Adaptive Immune System"], {"weight": 0.856007472706242}], ["UBE2J1", ["TCGA.CK.4952.01", "GPCR ligand binding"], {"weight": 0.911977341012262}], ["RRAGD", ["TCGA.AA.3556.01", "Neuronal System"], {"weight": 0.915287089554825}], ["RRAGD", ["TCGA.AA.3556.01", "Transmission across Chemical Synapses"], {"weight": 0.908359867958439}], ["RRAGD", ["TCGA.AA.3556.01", "Transport of small molecules"], {"weight": 0.909066687839551}], ["RRAGD", ["TCGA.AA.3556.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.860111225161786}], ["RRAGD", ["TCGA.AA.3556.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.906988830858628}], ["RRAGD", ["TCGA.AA.3556.01", "Trafficking of AMPA receptors"], {"weight": 0.876135210382087}], ["RRAGD", ["TCGA.AA.3556.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.876135210382087}], ["RRAGD", ["TCGA.AA.3556.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.844069212455217}], ["RRAGD", ["TCGA.AA.3556.01", "Insulin processing"], {"weight": 0.74482319088472}], ["RRAGD", ["TCGA.AA.3556.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.420485915708797}], ["RRAGD", ["TCGA.AA.3556.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.674878100934716}], ["RRAGD", ["TCGA.AA.3556.01", "Sensory processing of sound"], {"weight": 0.877304789288657}], ["RRAGD", ["TCGA.AA.3556.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.871805240501921}], ["RRAGD", ["TCGA.AA.3556.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.629786422216302}], ["RRAGD", ["TCGA.AA.3556.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.770104646099931}], ["RRAGD", ["TCGA.AA.3556.01", "Ion channel transport"], {"weight": 0.878713895344287}], ["RRAGD", ["TCGA.AA.3561.01", "Cellular response to starvation"], {"weight": 0.929113241945913}], ["RRAGD", ["TCGA.AA.3837.01", "Cellular response to starvation"], {"weight": 0.870599570625604}], ["RRAGD", ["TCGA.AA.3837.01", "Insulin receptor recycling"], {"weight": 0.656271029117644}], ["RRAGD", ["TCGA.AA.3939.01", "Cellular response to starvation"], {"weight": 0.909887460690037}], ["RRAGD", ["TCGA.AA.3966.01", "Fatty acid metabolism"], {"weight": 0.820879693154366}], ["RRAGD", ["TCGA.AZ.6608.01", "Other interleukin signaling"], {"weight": 0.77822030536707}], ["RRAGD", ["TCGA.CM.5868.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.754718593451278}], ["RRAGD", ["TCGA.D5.6931.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.764133499548318}], ["RRAGD", ["TCGA.DM.A28F.01", "Other interleukin signaling"], {"weight": 0.698015600758547}], ["B3GAT2", ["TCGA.3L.AA1B.01", "Metabolism"], {"weight": 0.87104317716526}], ["B3GAT2", ["TCGA.4T.AA8H.01", "Glycosaminoglycan metabolism"], {"weight": 0.91874111942107}], ["B3GAT2", ["TCGA.A6.3807.01", "Peptide hormone metabolism"], {"weight": 0.710274944556994}], ["B3GAT2", ["TCGA.A6.3807.01", "Cardiac conduction"], {"weight": 0.862535216275813}], ["B3GAT2", ["TCGA.A6.3807.01", "GPCR ligand binding"], {"weight": 0.931794698950977}], ["B3GAT2", ["TCGA.AA.3848.01", "Dermatan sulfate biosynthesis"], {"weight": 0.875587906527849}], ["B3GAT2", ["TCGA.AA.A02Y.01", "Chondroitin sulfate/dermatan sulfate metabolism"], {"weight": 0.94471373885808}], ["B3GAT2", ["TCGA.AA.A02Y.01", "A tetrasaccharide linker sequence is required for GAG synthesis"], {"weight": 0.935943475121078}], ["B3GAT2", ["TCGA.AD.6888.01", "HS-GAG biosynthesis"], {"weight": 0.934057777041709}], ["B3GAT2", ["TCGA.AD.6888.01", "ECM proteoglycans"], {"weight": 0.878667869883941}], ["B3GAT2", ["TCGA.AZ.6607.01", "Chondroitin sulfate/dermatan sulfate metabolism"], {"weight": 0.885067351152156}], ["B3GAT2", ["TCGA.AZ.6608.01", "Glycosaminoglycan metabolism"], {"weight": 0.900513794855775}], ["B3GAT2", ["TCGA.AZ.6608.01", "HS-GAG biosynthesis"], {"weight": 0.942585336564775}], ["B3GAT2", ["TCGA.CA.5256.01", "Glycosaminoglycan metabolism"], {"weight": 0.82521527218291}], ["GJA1", ["TCGA.AA.3560.01", "Formation of tubulin folding intermediates by CCT/TriC"], {"weight": 0.866034278060884}], ["GJA1", ["TCGA.AA.3660.01", "Ca2+ pathway"], {"weight": 0.756068682841572}], ["GJA1", ["TCGA.AA.3841.01", "Post-chaperonin tubulin folding pathway"], {"weight": 0.894262595368328}], ["GJA1", ["TCGA.AA.3848.01", "Sealing of the nuclear envelope (NE) by ESCRT-III"], {"weight": 0.922624857698693}], ["GJA1", ["TCGA.AA.3848.01", "Post-chaperonin tubulin folding pathway"], {"weight": 0.893795703842091}], ["GJA1", ["TCGA.AA.3848.01", "Formation of tubulin folding intermediates by CCT/TriC"], {"weight": 0.869060134749589}], ["GJA1", ["TCGA.AA.A02Y.01", "Adherens junctions interactions"], {"weight": 0.889123155167051}], ["GJA1", ["TCGA.AM.5820.01", "GABA receptor activation"], {"weight": 0.869731512878638}], ["GJA1", ["TCGA.CM.4747.01", "GABA receptor activation"], {"weight": 0.827818823494949}], ["GJA1", ["TCGA.CM.4747.01", "Arachidonic acid metabolism"], {"weight": 0.857921038308675}], ["GJA1", ["TCGA.DM.A1D7.01", "Arachidonic acid metabolism"], {"weight": 0.858812196818293}], ["HSF2", ["TCGA.AA.3685.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.916147617606652}], ["HSF2", ["TCGA.AA.3841.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.766918708143108}], ["HSF2", ["TCGA.AD.6888.01", "Ion homeostasis"], {"weight": 0.906066625649105}], ["HSF2", ["TCGA.AZ.6607.01", "Transcriptional regulation of granulopoiesis"], {"weight": 0.907220379856712}], ["HSF2", ["TCGA.CM.4747.01", "Heme degradation"], {"weight": 0.715512184091749}], ["HSF2", ["TCGA.CM.4747.01", "Scavenging of heme from plasma"], {"weight": 0.71212478376158}], ["HSF2", ["TCGA.CM.4747.01", "Porphyrin metabolism"], {"weight": 0.683416098263767}], ["HSF2", ["TCGA.CM.4747.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], {"weight": 0.68542154491272}], ["HSF2", ["TCGA.CM.5863.01", "Basigin interactions"], {"weight": 0.738564443400088}], ["HSF2", ["TCGA.CM.6167.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.520927178674436}], ["HSF2", ["TCGA.CM.6172.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.533329923963656}], ["HSF2", ["TCGA.DM.A1D7.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.883758637602842}], ["HSF2", ["TCGA.DM.A1D7.01", "Interleukin-6 family signaling"], {"weight": 0.889460845204557}], ["HSF2", ["TCGA.F4.6704.01", "Glutathione conjugation"], {"weight": 0.837740643543123}], ["HSF2", ["TCGA.QL.A97D.01", "The canonical retinoid cycle in rods (twilight vision)"], {"weight": 0.745544449116265}], ["FABP7", ["TCGA.AZ.6606.01", "Ion homeostasis"], {"weight": 0.923957870478676}], ["FABP7", ["TCGA.CA.5255.01", "Sialic acid metabolism"], {"weight": 0.686854361277311}], ["RIMS1", ["TCGA.3L.AA1B.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.951218888485069}], ["RIMS1", ["TCGA.4T.AA8H.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.869001854778173}], ["RIMS1", ["TCGA.5M.AATA.01", "Neuronal System"], {"weight": 0.926025085232156}], ["RIMS1", ["TCGA.5M.AATA.01", "Transmission across Chemical Synapses"], {"weight": 0.929392196267968}], ["RIMS1", ["TCGA.5M.AATA.01", "Protein-protein interactions at synapses"], {"weight": 0.871719822056068}], ["RIMS1", ["TCGA.5M.AATA.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.907381218069516}], ["RIMS1", ["TCGA.5M.AATA.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.78561369835025}], ["RIMS1", ["TCGA.A6.2686.01", "RA biosynthesis pathway"], {"weight": 0.814717319460584}], ["RIMS1", ["TCGA.A6.3807.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.676722004020888}], ["RIMS1", ["TCGA.A6.3807.01", "Neuronal System"], {"weight": 0.880386516410636}], ["RIMS1", ["TCGA.A6.3807.01", "Signal amplification"], {"weight": 0.852896767758273}], ["RIMS1", ["TCGA.A6.3807.01", "Signaling by Retinoic Acid"], {"weight": 0.729908938506784}], ["RIMS1", ["TCGA.A6.3807.01", "RA biosynthesis pathway"], {"weight": 0.802997634109626}], ["RIMS1", ["TCGA.A6.3807.01", "Ethanol oxidation"], {"weight": 0.747362459707256}], ["RIMS1", ["TCGA.A6.6652.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.941826614305691}], ["RIMS1", ["TCGA.A6.6652.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.829220728880511}], ["RIMS1", ["TCGA.AA.3561.01", "L1CAM interactions"], {"weight": 0.907375589508602}], ["RIMS1", ["TCGA.AA.3561.01", "Glutathione conjugation"], {"weight": 0.792236076431675}], ["RIMS1", ["TCGA.AA.3660.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.920978724833451}], ["RIMS1", ["TCGA.AA.3660.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.667235373339668}], ["RIMS1", ["TCGA.AA.3666.01", "Protein-protein interactions at synapses"], {"weight": 0.870370541576516}], ["RIMS1", ["TCGA.AA.3685.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.905697911697833}], ["RIMS1", ["TCGA.AA.3837.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.249368638626478}], ["RIMS1", ["TCGA.AA.3841.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.943183911149609}], ["RIMS1", ["TCGA.AA.3841.01", "LGI-ADAM interactions"], {"weight": 0.802667044965319}], ["RIMS1", ["TCGA.AA.3841.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.848265729167603}], ["RIMS1", ["TCGA.AA.3841.01", "Insulin processing"], {"weight": 0.607886820200429}], ["RIMS1", ["TCGA.AA.3848.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.950685626017771}], ["RIMS1", ["TCGA.AA.3848.01", "Insulin processing"], {"weight": 0.658581579097988}], ["RIMS1", ["TCGA.AA.3848.01", "Sensory processing of sound"], {"weight": 0.940584673743226}], ["RIMS1", ["TCGA.AA.3848.01", "Glutamate Neurotransmitter Release Cycle"], {"weight": 0.685877154412465}], ["RIMS1", ["TCGA.AA.3875.01", "Neurotransmitter release cycle"], {"weight": 0.805999429427479}], ["RIMS1", ["TCGA.AA.3875.01", "Norepinephrine Neurotransmitter Release Cycle"], {"weight": 0.157213020569416}], ["RIMS1", ["TCGA.AA.3875.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.774879950670364}], ["RIMS1", ["TCGA.AA.3952.01", "LGI-ADAM interactions"], {"weight": 0.49533094302592}], ["RIMS1", ["TCGA.AA.3966.01", "RA biosynthesis pathway"], {"weight": 0.794189000855709}], ["RIMS1", ["TCGA.AA.3966.01", "Ethanol oxidation"], {"weight": 0.775435125171259}], ["RIMS1", ["TCGA.AA.3966.01", "Signaling by Retinoic Acid"], {"weight": 0.770955922411006}], ["RIMS1", ["TCGA.AA.A00J.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.939569994013668}], ["RIMS1", ["TCGA.AA.A01X.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.938717438707279}], ["RIMS1", ["TCGA.AA.A02O.01", "Recycling of bile acids and salts"], {"weight": 0.911578385736835}], ["RIMS1", ["TCGA.AA.A02O.01", "Regulation of insulin secretion"], {"weight": 0.890333756097517}], ["RIMS1", ["TCGA.AA.A02O.01", "Neuronal System"], {"weight": 0.944027733832167}], ["RIMS1", ["TCGA.AA.A02Y.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.921299731126683}], ["RIMS1", ["TCGA.AD.6888.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.920784731929296}], ["RIMS1", ["TCGA.AD.6888.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.949799095285865}], ["RIMS1", ["TCGA.AD.A5EK.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.958061462543189}], ["RIMS1", ["TCGA.AM.5820.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.914251753604217}], ["RIMS1", ["TCGA.AY.A8YK.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.933579508102246}], ["RIMS1", ["TCGA.AY.A8YK.01", "Serotonin Neurotransmitter Release Cycle"], {"weight": 0.9086127845184}], ["RIMS1", ["TCGA.AY.A8YK.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.853386928790364}], ["RIMS1", ["TCGA.AZ.6598.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.949079312108091}], ["RIMS1", ["TCGA.AZ.6606.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.933997393866284}], ["RIMS1", ["TCGA.AZ.6607.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.751344382080753}], ["RIMS1", ["TCGA.AZ.6608.01", "Protein-protein interactions at synapses"], {"weight": 0.940803185006839}], ["RIMS1", ["TCGA.AZ.6608.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.967923797597101}], ["RIMS1", ["TCGA.AZ.6608.01", "Neurexins and neuroligins"], {"weight": 0.955010011648491}], ["RIMS1", ["TCGA.CA.5255.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.947053368486832}], ["RIMS1", ["TCGA.CA.5255.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.87883446307439}], ["RIMS1", ["TCGA.CA.5256.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.890596754096021}], ["RIMS1", ["TCGA.CK.4952.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.958521663569221}], ["RIMS1", ["TCGA.CK.5915.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.854249638014092}], ["RIMS1", ["TCGA.CM.5348.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.887637393510411}], ["RIMS1", ["TCGA.CM.5348.01", "LGI-ADAM interactions"], {"weight": 0.822431179769758}], ["RIMS1", ["TCGA.CM.5863.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.894296643576982}], ["RIMS1", ["TCGA.CM.5863.01", "Neuronal System"], {"weight": 0.884997592337108}], ["RIMS1", ["TCGA.CM.6161.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.896602557771033}], ["RIMS1", ["TCGA.CM.6172.01", "Neuronal System"], {"weight": 0.845017869411139}], ["RIMS1", ["TCGA.CM.6172.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.902536183641403}], ["RIMS1", ["TCGA.CM.6676.01", "Protein-protein interactions at synapses"], {"weight": 0.85222967561682}], ["RIMS1", ["TCGA.CM.6678.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.93353350586844}], ["RIMS1", ["TCGA.D5.5537.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.938129599434835}], ["RIMS1", ["TCGA.D5.6529.01", "Neuronal System"], {"weight": 0.833300737474043}], ["RIMS1", ["TCGA.D5.6529.01", "Transmission across Chemical Synapses"], {"weight": 0.882048201467996}], ["RIMS1", ["TCGA.D5.6529.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.929888996859763}], ["RIMS1", ["TCGA.D5.6531.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.963283568726895}], ["RIMS1", ["TCGA.D5.6535.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.911446255544718}], ["RIMS1", ["TCGA.D5.6535.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.907377531194554}], ["RIMS1", ["TCGA.D5.6535.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], {"weight": 0.639797796606675}], ["RIMS1", ["TCGA.DM.A0X9.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.801467251727557}], ["RIMS1", ["TCGA.DM.A0X9.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.944399208263562}], ["RIMS1", ["TCGA.F4.6704.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.945733644128278}], ["RIMS1", ["TCGA.F4.6854.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.91910130946012}], ["RIMS1", ["TCGA.F4.6854.01", "SLC-mediated transmembrane transport"], {"weight": 0.894639518594292}], ["RIMS1", ["TCGA.F4.6856.01", "RA biosynthesis pathway"], {"weight": 0.824453715577873}], ["RIMS1", ["TCGA.F4.6856.01", "Neurexins and neuroligins"], {"weight": 0.913489512023952}], ["RIMS1", ["TCGA.F4.6856.01", "Ethanol oxidation"], {"weight": 0.731486386334345}], ["RIMS1", ["TCGA.F4.6856.01", "SLC-mediated transmembrane transport"], {"weight": 0.89772076766867}], ["RIMS1", ["TCGA.F4.6856.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.938741032704671}], ["RIMS1", ["TCGA.G4.6306.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.941986943313631}], ["RIMS1", ["TCGA.NH.A6GA.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.960742787251915}], ["RIMS1", ["TCGA.QL.A97D.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.832255687765667}], ["RIMS1", ["TCGA.QL.A97D.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.924471256028266}], ["RNF217", ["TCGA.A6.6652.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.931948227252862}], ["RNF217", ["TCGA.A6.6652.01", "Peptide ligand-binding receptors"], {"weight": 0.929420617467609}], ["RNF217", ["TCGA.AU.6004.01", "Extracellular matrix organization"], {"weight": 0.80846891958837}], ["RNF217", ["TCGA.AU.6004.01", "Neuronal System"], {"weight": 0.886688122787002}], ["RNF217", ["TCGA.AU.6004.01", "Transport of small molecules"], {"weight": 0.943126435947696}], ["RNF217", ["TCGA.AU.6004.01", "Transmission across Chemical Synapses"], {"weight": 0.888498828534768}], ["RNF217", ["TCGA.AU.6004.01", "Phase II - Conjugation of compounds"], {"weight": 0.692999153251711}], ["RNF217", ["TCGA.AU.6004.01", "Collagen formation"], {"weight": 0.892177812394606}], ["RNF217", ["TCGA.AU.6004.01", "Drug ADME"], {"weight": 0.767276928708617}], ["RNF217", ["TCGA.AU.6004.01", "Stimuli-sensing channels"], {"weight": 0.908366842668792}], ["RNF217", ["TCGA.AU.6004.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.855078716167852}], ["RNF217", ["TCGA.AU.6004.01", "GPCR ligand binding"], {"weight": 0.897277793708222}], ["RNF217", ["TCGA.AU.6004.01", "SLC-mediated transmembrane transport"], {"weight": 0.90915450191366}], ["RNF217", ["TCGA.AU.6004.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.869548421844758}], ["RNF217", ["TCGA.AU.6004.01", "Ion channel transport"], {"weight": 0.894442010729011}], ["RNF217", ["TCGA.AU.6004.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.852190619588832}], ["RNF217", ["TCGA.AU.6004.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.839715556088706}], ["RNF217", ["TCGA.AU.6004.01", "Potassium Channels"], {"weight": 0.899198484751777}], ["RNF217", ["TCGA.AU.6004.01", "L1CAM interactions"], {"weight": 0.869024625474101}], ["RNF217", ["TCGA.AU.6004.01", "NCAM1 interactions"], {"weight": 0.856568991767372}], ["RNF217", ["TCGA.AU.6004.01", "Integration of energy metabolism"], {"weight": 0.851752366601432}], ["RNF217", ["TCGA.AU.6004.01", "Neurexins and neuroligins"], {"weight": 0.713665120585827}], ["RNF217", ["TCGA.AU.6004.01", "NCAM signaling for neurite out-growth"], {"weight": 0.884878356661937}], ["RNF217", ["TCGA.AU.6004.01", "Cardiac conduction"], {"weight": 0.893290696316687}], ["RNF217", ["TCGA.AU.6004.01", "Protein-protein interactions at synapses"], {"weight": 0.720781875177172}], ["RNF217", ["TCGA.AU.6004.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.463324468213558}], ["RNF217", ["TCGA.AU.6004.01", "Regulation of insulin secretion"], {"weight": 0.814176986700985}], ["RNF217", ["TCGA.AU.6004.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.798302894035942}], ["RNF217", ["TCGA.AU.6004.01", "Signaling by GPCR"], {"weight": 0.911218300237062}], ["RNF217", ["TCGA.AU.6004.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.683733789588706}], ["RNF217", ["TCGA.AU.6004.01", "Integrin cell surface interactions"], {"weight": 0.712846770647213}], ["RNF217", ["TCGA.AU.6004.01", "Collagen degradation"], {"weight": 0.716558934725346}], ["RNF217", ["TCGA.AZ.6598.01", "Peptide ligand-binding receptors"], {"weight": 0.923356086968623}], ["RNF217", ["TCGA.AZ.6598.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.924459337256035}], ["RNF217", ["TCGA.CK.4952.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.919723022792535}], ["RNF217", ["TCGA.CK.4952.01", "Peptide ligand-binding receptors"], {"weight": 0.916897358193961}], ["RNF217", ["TCGA.QL.A97D.01", "GPCR ligand binding"], {"weight": 0.904182705660401}], ["TPD52L1", ["TCGA.AA.3837.01", "Scavenging by Class A Receptors"], {"weight": 0.165966361871424}], ["TPD52L1", ["TCGA.CM.4747.01", "Binding and Uptake of Ligands by Scavenger Receptors"], {"weight": 0.752355421982681}], ["TPD52L1", ["TCGA.CM.4747.01", "L1CAM interactions"], {"weight": 0.909481852002565}], ["TPD52L1", ["TCGA.DM.A1D7.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.902362842241655}], ["MAP3K7", ["TCGA.4T.AA8H.01", "Neuronal System"], {"weight": 0.95348541391912}], ["MAP3K7", ["TCGA.4T.AA8H.01", "Transmission across Chemical Synapses"], {"weight": 0.948752255913764}], ["MAP3K7", ["TCGA.4T.AA8H.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.928231351340108}], ["MAP3K7", ["TCGA.A6.2678.01", "Neuronal System"], {"weight": 0.915664614895753}], ["MAP3K7", ["TCGA.A6.2678.01", "Transmission across Chemical Synapses"], {"weight": 0.912115609083956}], ["MAP3K7", ["TCGA.A6.2678.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.910552093528856}], ["MAP3K7", ["TCGA.A6.2686.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.926192925667051}], ["MAP3K7", ["TCGA.A6.2686.01", "Glucagon-type ligand receptors"], {"weight": 0.915338408072436}], ["MAP3K7", ["TCGA.A6.2686.01", "Potassium Channels"], {"weight": 0.947359802901822}], ["MAP3K7", ["TCGA.A6.6652.01", "Cardiac conduction"], {"weight": 0.940922997962208}], ["MAP3K7", ["TCGA.A6.6652.01", "Muscle contraction"], {"weight": 0.943737908750534}], ["MAP3K7", ["TCGA.AA.3561.01", "Nervous system development"], {"weight": 0.892213502429825}], ["MAP3K7", ["TCGA.AA.3561.01", "Axon guidance"], {"weight": 0.892724710502692}], ["MAP3K7", ["TCGA.AA.3561.01", "Glucagon-type ligand receptors"], {"weight": 0.926734414368025}], ["MAP3K7", ["TCGA.AA.3561.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.756029946687065}], ["MAP3K7", ["TCGA.AA.3561.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.756029946687065}], ["MAP3K7", ["TCGA.AA.3561.01", "Signaling Pathways"], {"weight": 0.896696615874116}], ["MAP3K7", ["TCGA.AA.3561.01", "Leishmania infection"], {"weight": 0.889375532546693}], ["MAP3K7", ["TCGA.AA.3561.01", "G beta:gamma signalling through BTK"], {"weight": 0.908890139999388}], ["MAP3K7", ["TCGA.AA.3660.01", "Transmission across Chemical Synapses"], {"weight": 0.889280678020221}], ["MAP3K7", ["TCGA.AA.3660.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.894052743066615}], ["MAP3K7", ["TCGA.AA.3660.01", "Integration of energy metabolism"], {"weight": 0.852413620232582}], ["MAP3K7", ["TCGA.AA.3837.01", "Diseases of Immune System"], {"weight": 0.528572271756086}], ["MAP3K7", ["TCGA.AA.3837.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.528572271756086}], ["MAP3K7", ["TCGA.AA.3841.01", "Stimuli-sensing channels"], {"weight": 0.896025415302574}], ["MAP3K7", ["TCGA.AA.3841.01", "Trafficking and processing of endosomal TLR"], {"weight": 0.772206647163431}], ["MAP3K7", ["TCGA.AA.3848.01", "Signal amplification"], {"weight": 0.926850254310719}], ["MAP3K7", ["TCGA.AA.3848.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.918833209945565}], ["MAP3K7", ["TCGA.AA.3848.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.922330999784696}], ["MAP3K7", ["TCGA.AA.3848.01", "G alpha (z) signalling events"], {"weight": 0.924770585983972}], ["MAP3K7", ["TCGA.AA.3870.01", "Stimuli-sensing channels"], {"weight": 0.924645669119241}], ["MAP3K7", ["TCGA.AA.3952.01", "Signaling by BMP"], {"weight": 0.899250282243869}], ["MAP3K7", ["TCGA.AA.3966.01", "Interleukin-10 signaling"], {"weight": 0.775970692486431}], ["MAP3K7", ["TCGA.AA.3966.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.76429573940551}], ["MAP3K7", ["TCGA.AA.3966.01", "Neuronal System"], {"weight": 0.925904888066245}], ["MAP3K7", ["TCGA.AA.3966.01", "Transmission across Chemical Synapses"], {"weight": 0.929834270515802}], ["MAP3K7", ["TCGA.AA.3966.01", "Stimuli-sensing channels"], {"weight": 0.915513015693616}], ["MAP3K7", ["TCGA.AA.3966.01", "Purinergic signaling in leishmaniasis infection"], {"weight": 0.641299453428541}], ["MAP3K7", ["TCGA.AA.3966.01", "Cell recruitment (pro-inflammatory response)"], {"weight": 0.641299453428541}], ["MAP3K7", ["TCGA.AA.3966.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.923149826618152}], ["MAP3K7", ["TCGA.AA.3966.01", "Potassium Channels"], {"weight": 0.877414682219861}], ["MAP3K7", ["TCGA.AA.3966.01", "Glucagon-type ligand receptors"], {"weight": 0.917966197803379}], ["MAP3K7", ["TCGA.AA.A02H.01", "Trafficking and processing of endosomal TLR"], {"weight": 0.723493012835089}], ["MAP3K7", ["TCGA.AA.A02H.01", "Signaling by BMP"], {"weight": 0.789201811660393}], ["MAP3K7", ["TCGA.AD.6888.01", "Signaling Pathways"], {"weight": 0.930274394478995}], ["MAP3K7", ["TCGA.AD.6888.01", "Developmental Biology"], {"weight": 0.912182779626681}], ["MAP3K7", ["TCGA.AM.5820.01", "Cytokine Signaling in Immune system"], {"weight": 0.837321549439154}], ["MAP3K7", ["TCGA.AZ.6606.01", "Neuronal System"], {"weight": 0.925352137733612}], ["MAP3K7", ["TCGA.AZ.6606.01", "Transmission across Chemical Synapses"], {"weight": 0.91534555691954}], ["MAP3K7", ["TCGA.AZ.6608.01", "Cardiac conduction"], {"weight": 0.954763781460602}], ["MAP3K7", ["TCGA.AZ.6608.01", "Muscle contraction"], {"weight": 0.95315330580293}], ["MAP3K7", ["TCGA.AZ.6608.01", "Leishmania infection"], {"weight": 0.902735121490049}], ["MAP3K7", ["TCGA.AZ.6608.01", "Interleukin-10 signaling"], {"weight": 0.955751458554097}], ["MAP3K7", ["TCGA.AZ.6608.01", "EPH-ephrin mediated repulsion of cells"], {"weight": 0.941580232853689}], ["MAP3K7", ["TCGA.CK.4952.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.873266796293349}], ["MAP3K7", ["TCGA.CK.4952.01", "Signaling Pathways"], {"weight": 0.926875005197631}], ["MAP3K7", ["TCGA.CK.5915.01", "Neuronal System"], {"weight": 0.945318624011566}], ["MAP3K7", ["TCGA.CK.5915.01", "Transmission across Chemical Synapses"], {"weight": 0.934975933624587}], ["MAP3K7", ["TCGA.CK.5915.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.932029246209648}], ["MAP3K7", ["TCGA.CK.5915.01", "TCR signaling"], {"weight": 0.941041539898488}], ["MAP3K7", ["TCGA.CM.5868.01", "Signaling by GPCR"], {"weight": 0.941705648892762}], ["MAP3K7", ["TCGA.CM.5868.01", "GPCR downstream signalling"], {"weight": 0.951619498742341}], ["MAP3K7", ["TCGA.CM.5868.01", "Neuronal System"], {"weight": 0.894305353179732}], ["MAP3K7", ["TCGA.CM.5868.01", "Transmission across Chemical Synapses"], {"weight": 0.934626558829607}], ["MAP3K7", ["TCGA.CM.5868.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.924508543333965}], ["MAP3K7", ["TCGA.CM.5868.01", "Signal amplification"], {"weight": 0.910297933193413}], ["MAP3K7", ["TCGA.CM.5868.01", "Cardiac conduction"], {"weight": 0.903483706680507}], ["MAP3K7", ["TCGA.CM.5868.01", "G alpha (s) signalling events"], {"weight": 0.947694824132596}], ["MAP3K7", ["TCGA.CM.5868.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.909837416387073}], ["MAP3K7", ["TCGA.CM.5868.01", "Trafficking and processing of endosomal TLR"], {"weight": 0.783344303681372}], ["MAP3K7", ["TCGA.CM.5868.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.808306635952602}], ["MAP3K7", ["TCGA.CM.5868.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.904919097774329}], ["MAP3K7", ["TCGA.CM.5868.01", "Regulation of insulin secretion"], {"weight": 0.893837135077964}], ["MAP3K7", ["TCGA.CM.5868.01", "G-protein mediated events"], {"weight": 0.91247773830511}], ["MAP3K7", ["TCGA.CM.6676.01", "Trafficking and processing of endosomal TLR"], {"weight": 0.753054343575062}], ["MAP3K7", ["TCGA.D5.5537.01", "Neuronal System"], {"weight": 0.895075771018412}], ["MAP3K7", ["TCGA.D5.5537.01", "Transmission across Chemical Synapses"], {"weight": 0.94584943513212}], ["MAP3K7", ["TCGA.D5.5537.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.931588570760137}], ["MAP3K7", ["TCGA.D5.6535.01", "Neuronal System"], {"weight": 0.931084790459281}], ["MAP3K7", ["TCGA.D5.6535.01", "Transmission across Chemical Synapses"], {"weight": 0.925341793808949}], ["MAP3K7", ["TCGA.D5.6535.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.923306227365075}], ["MAP3K7", ["TCGA.DM.A28F.01", "Neuronal System"], {"weight": 0.948206032687154}], ["MAP3K7", ["TCGA.DM.A28F.01", "Transmission across Chemical Synapses"], {"weight": 0.944431577843499}], ["MAP3K7", ["TCGA.DM.A28F.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.93689990141361}], ["MAP3K7", ["TCGA.DM.A28F.01", "Leishmania infection"], {"weight": 0.869877680102068}], ["MAP3K7", ["TCGA.F4.6856.01", "Signaling Pathways"], {"weight": 0.884688062639345}], ["MAP3K7", ["TCGA.G4.6306.01", "Cardiac conduction"], {"weight": 0.946012319505885}], ["MAP3K7", ["TCGA.G4.6306.01", "Muscle contraction"], {"weight": 0.944264336987372}], ["EPHA7", ["TCGA.AA.3681.01", "Interaction between L1 and Ankyrins"], {"weight": 0.877812872342369}], ["EPHA7", ["TCGA.AA.3681.01", "Formation of the cornified envelope"], {"weight": 0.862344775413924}], ["EPHA7", ["TCGA.AA.3681.01", "L1CAM interactions"], {"weight": 0.776072496001992}], ["EPHA7", ["TCGA.AA.3841.01", "Regulation of KIT signaling"], {"weight": 0.880338255084915}], ["EPHA7", ["TCGA.AA.3848.01", "RND3 GTPase cycle"], {"weight": 0.90167497744347}], ["EPHA7", ["TCGA.AA.3966.01", "Drug ADME"], {"weight": 0.883153896186047}], ["EPHA7", ["TCGA.AA.3982.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.69545011745856}], ["EPHA7", ["TCGA.AA.3982.01", "Regulation of signaling by NODAL"], {"weight": 0.767705887772031}], ["EPHA7", ["TCGA.AA.3982.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.540086552395187}], ["EPHA7", ["TCGA.AA.3982.01", "Signaling by NODAL"], {"weight": 0.767705887772031}], ["EPHA7", ["TCGA.AA.3982.01", "p75NTR recruits signalling complexes"], {"weight": 0.462855074429308}], ["EPHA7", ["TCGA.AA.3982.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.395498200816303}], ["EPHA7", ["TCGA.AA.3982.01", "Interleukin-6 family signaling"], {"weight": 0.632137096286282}], ["EPHA7", ["TCGA.AA.3982.01", "Estrogen-dependent nuclear events downstream of ESR-membrane signaling"], {"weight": 0.594617318238062}], ["EPHA7", ["TCGA.AA.3982.01", "Integration of energy metabolism"], {"weight": 0.839021793010738}], ["EPHA7", ["TCGA.AA.3982.01", "p75NTR signals via NF-kB"], {"weight": 0.462855074429308}], ["EPHA7", ["TCGA.AA.3982.01", "Biological oxidations"], {"weight": 0.824647363562203}], ["EPHA7", ["TCGA.AA.3982.01", "EGFR downregulation"], {"weight": 0.602097908571729}], ["EPHA7", ["TCGA.AA.A00A.01", "Interaction between L1 and Ankyrins"], {"weight": 0.924444617794061}], ["EPHA7", ["TCGA.AA.A00A.01", "L1CAM interactions"], {"weight": 0.898301277161137}], ["EPHA7", ["TCGA.AA.A00A.01", "Protein-protein interactions at synapses"], {"weight": 0.732593811491631}], ["EPHA7", ["TCGA.AA.A00A.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.928601050690525}], ["EPHA7", ["TCGA.AA.A00A.01", "Degradation of the extracellular matrix"], {"weight": 0.855502063846874}], ["EPHA7", ["TCGA.AA.A00A.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.875262662694521}], ["EPHA7", ["TCGA.AA.A00A.01", "Presynaptic nicotinic acetylcholine receptors"], {"weight": 0.672186735518459}], ["EPHA7", ["TCGA.AA.A00A.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.722678870889551}], ["EPHA7", ["TCGA.AA.A029.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.890632249440653}], ["EPHA7", ["TCGA.AD.6888.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.936896720632205}], ["EPHA7", ["TCGA.AD.6888.01", "Generation of second messenger molecules"], {"weight": 0.941964157721096}], ["EPHA7", ["TCGA.AD.6888.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.939586479953313}], ["EPHA7", ["TCGA.AD.6888.01", "PD-1 signaling"], {"weight": 0.938623411602836}], ["EPHA7", ["TCGA.AD.6888.01", "Costimulation by the CD28 family"], {"weight": 0.908563647607098}], ["EPHA7", ["TCGA.CK.4952.01", "Translocation of ZAP-70 to Immunological synapse"], {"weight": 0.916792522892942}], ["EPHA7", ["TCGA.CK.4952.01", "Generation of second messenger molecules"], {"weight": 0.894795797441462}], ["EPHA7", ["TCGA.CK.4952.01", "Phosphorylation of CD3 and TCR zeta chains"], {"weight": 0.91670070138638}], ["EPHA7", ["TCGA.CK.5915.01", "FCGR activation"], {"weight": 0.8942446087226}], ["EPHA7", ["TCGA.CM.5868.01", "Peptide hormone metabolism"], {"weight": 0.753419168324894}], ["EPHA7", ["TCGA.CM.5868.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.878130139250056}], ["EPHA7", ["TCGA.CM.5868.01", "Leishmania parasite growth and survival"], {"weight": 0.878130139250056}], ["EPHA7", ["TCGA.CM.5868.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.895654145147656}], ["EPHA7", ["TCGA.CM.5868.01", "Arachidonic acid metabolism"], {"weight": 0.861261658097234}], ["EPHA7", ["TCGA.G4.6306.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], {"weight": 0.88060852637189}], ["HEY2", ["TCGA.A6.6652.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.89878203473162}], ["HEY2", ["TCGA.AA.3560.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.858939655509039}], ["HEY2", ["TCGA.AA.3660.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.832097029763124}], ["HEY2", ["TCGA.AA.3660.01", "Muscle contraction"], {"weight": 0.891348343907879}], ["HEY2", ["TCGA.AA.3685.01", "Blood group systems biosynthesis"], {"weight": 0.667078072540316}], ["HEY2", ["TCGA.AA.3685.01", "Lewis blood group biosynthesis"], {"weight": 0.695312888228912}], ["HEY2", ["TCGA.AA.3837.01", "Physiological factors"], {"weight": 0.568120308787417}], ["HEY2", ["TCGA.AA.3875.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.873623146675639}], ["HEY2", ["TCGA.AA.3875.01", "Physiological factors"], {"weight": 0.511048588239613}], ["HEY2", ["TCGA.AA.3875.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], {"weight": 0.534362572512996}], ["HEY2", ["TCGA.AA.3875.01", "Cardiac conduction"], {"weight": 0.70739342230536}], ["HEY2", ["TCGA.AA.3952.01", "Attenuation phase"], {"weight": 0.608418587161342}], ["HEY2", ["TCGA.AA.3952.01", "SARS-CoV-1 targets host intracellular signalling and regulatory pathways"], {"weight": 0.367603668974716}], ["HEY2", ["TCGA.AA.A029.01", "Cardiac conduction"], {"weight": 0.944472168927179}], ["HEY2", ["TCGA.AA.A02H.01", "Cardiac conduction"], {"weight": 0.901354323476503}], ["HEY2", ["TCGA.AA.A02H.01", "Molecules associated with elastic fibres"], {"weight": 0.71753664277381}], ["HEY2", ["TCGA.AD.6888.01", "Cardiac conduction"], {"weight": 0.948409420744542}], ["HEY2", ["TCGA.AD.A5EK.01", "Cardiac conduction"], {"weight": 0.933886270689963}], ["HEY2", ["TCGA.AD.A5EK.01", "Muscle contraction"], {"weight": 0.923827038642761}], ["HEY2", ["TCGA.AZ.6600.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.779805688707481}], ["HEY2", ["TCGA.AZ.6600.01", "Physiological factors"], {"weight": 0.750395056644908}], ["HEY2", ["TCGA.AZ.6600.01", "Cardiac conduction"], {"weight": 0.788456701261769}], ["HEY2", ["TCGA.AZ.6600.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], {"weight": 0.679665069143911}], ["HEY2", ["TCGA.CA.5254.01", "Cardiac conduction"], {"weight": 0.931839429776017}], ["HEY2", ["TCGA.CA.5254.01", "Muscle contraction"], {"weight": 0.926465109269596}], ["HEY2", ["TCGA.CA.5254.01", "Termination of O-glycan biosynthesis"], {"weight": 0.895891783976493}], ["HEY2", ["TCGA.CA.5254.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.885528522009595}], ["HEY2", ["TCGA.CA.5255.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.929791843186065}], ["HEY2", ["TCGA.CA.5255.01", "Termination of O-glycan biosynthesis"], {"weight": 0.863886617636701}], ["HEY2", ["TCGA.CK.4952.01", "Cardiac conduction"], {"weight": 0.946189198005243}], ["HEY2", ["TCGA.CK.4952.01", "Muscle contraction"], {"weight": 0.94363523703429}], ["HEY2", ["TCGA.CK.5915.01", "Molecules associated with elastic fibres"], {"weight": 0.830056885509453}], ["HEY2", ["TCGA.CM.4747.01", "Transcriptional regulation of testis differentiation"], {"weight": 0.921661166549802}], ["HEY2", ["TCGA.CM.4747.01", "Cardiac conduction"], {"weight": 0.88684348902891}], ["HEY2", ["TCGA.CM.4747.01", "O-linked glycosylation of mucins"], {"weight": 0.873058485937233}], ["HEY2", ["TCGA.CM.4747.01", "Physiological factors"], {"weight": 0.69222072831143}], ["HEY2", ["TCGA.CM.4747.01", "O-linked glycosylation"], {"weight": 0.64397126612684}], ["HEY2", ["TCGA.CM.4747.01", "Aspirin ADME"], {"weight": 0.644170786324445}], ["HEY2", ["TCGA.CM.4747.01", "Blood group systems biosynthesis"], {"weight": 0.652758564761419}], ["HEY2", ["TCGA.CM.6675.01", "Cardiac conduction"], {"weight": 0.9498037027459}], ["HEY2", ["TCGA.CM.6675.01", "Muscle contraction"], {"weight": 0.944596365038245}], ["HEY2", ["TCGA.CM.6676.01", "Regulation of beta-cell development"], {"weight": 0.828662544617142}], ["HEY2", ["TCGA.DM.A28F.01", "Cardiac conduction"], {"weight": 0.938806614686643}], ["HEY2", ["TCGA.DM.A28F.01", "Muscle contraction"], {"weight": 0.932071313001791}], ["HEY2", ["TCGA.F4.6459.01", "Physiological factors"], {"weight": 0.847715112526449}], ["HEY2", ["TCGA.F4.6460.01", "Peptide hormone metabolism"], {"weight": 0.837402973469404}], ["HEY2", ["TCGA.F4.6704.01", "Formation of the cornified envelope"], {"weight": 0.858114421722116}], ["HEY2", ["TCGA.F4.6854.01", "Blood group systems biosynthesis"], {"weight": 0.517427026420973}], ["HEY2", ["TCGA.F4.6854.01", "Glucuronidation"], {"weight": 0.779353998396638}], ["NCOA7", ["TCGA.A6.6652.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.840197944571017}], ["NCOA7", ["TCGA.AA.3848.01", "Chaperonin-mediated protein folding"], {"weight": 0.829878770692169}], ["NCOA7", ["TCGA.AA.3848.01", "Protein folding"], {"weight": 0.839335484163446}], ["NCOA7", ["TCGA.AA.A029.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.954208750740762}], ["NCOA7", ["TCGA.AA.A02H.01", "SUMOylation of intracellular receptors"], {"weight": 0.697650454727324}], ["NCOA7", ["TCGA.AA.A02H.01", "Nuclear Receptor transcription pathway"], {"weight": 0.713351476835672}], ["NCOA7", ["TCGA.AA.A02H.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.686367797840789}], ["NCOA7", ["TCGA.AD.6888.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.927532932864343}], ["NCOA7", ["TCGA.AD.6888.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.965155283665475}], ["NCOA7", ["TCGA.AD.6888.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.96499998370774}], ["NCOA7", ["TCGA.AD.6888.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.928269366595044}], ["NCOA7", ["TCGA.AD.A5EK.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.879823862635054}], ["NCOA7", ["TCGA.AM.5820.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.891459134852104}], ["NCOA7", ["TCGA.AM.5820.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.939208214603706}], ["NCOA7", ["TCGA.AM.5820.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.893265221554043}], ["NCOA7", ["TCGA.AM.5820.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.878669364637722}], ["NCOA7", ["TCGA.AZ.6598.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.881332476060459}], ["NCOA7", ["TCGA.AZ.6608.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.90897082302046}], ["NCOA7", ["TCGA.CA.5256.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.913392350531553}], ["NCOA7", ["TCGA.CK.4952.01", "Resolution of D-loop Structures through Holliday Junction Intermediates"], {"weight": 0.841159304986294}], ["NCOA7", ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function"], {"weight": 0.836742948253734}], ["NCOA7", ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function"], {"weight": 0.836742948253734}], ["NCOA7", ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function"], {"weight": 0.836742948253734}], ["NCOA7", ["TCGA.CK.4952.01", "Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function"], {"weight": 0.836742948253734}], ["NCOA7", ["TCGA.CK.4952.01", "Impaired BRCA2 binding to PALB2"], {"weight": 0.836742948253734}], ["NCOA7", ["TCGA.CK.4952.01", "Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)"], {"weight": 0.828089210827288}], ["NCOA7", ["TCGA.CK.4952.01", "Resolution of D-Loop Structures"], {"weight": 0.841159304986294}], ["NCOA7", ["TCGA.CK.4952.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.90138583300636}], ["NCOA7", ["TCGA.CK.4952.01", "SUMOylation of intracellular receptors"], {"weight": 0.791121836144944}], ["NCOA7", ["TCGA.CM.4747.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.893927984273153}], ["NCOA7", ["TCGA.CM.4747.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.837977316394657}], ["NCOA7", ["TCGA.CM.4747.01", "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"], {"weight": 0.805836782922218}], ["NCOA7", ["TCGA.CM.4747.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.87215126807499}], ["NCOA7", ["TCGA.CM.4747.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.893615265023832}], ["NCOA7", ["TCGA.CM.4747.01", "IRS-related events triggered by IGF1R"], {"weight": 0.789993965468265}], ["NCOA7", ["TCGA.CM.4747.01", "IGF1R signaling cascade"], {"weight": 0.789993965468265}], ["NCOA7", ["TCGA.CM.6172.01", "Signaling by Nuclear Receptors"], {"weight": 0.821635856150869}], ["NCOA7", ["TCGA.CM.6678.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.885160220205237}], ["NCOA7", ["TCGA.CM.6678.01", "SUMOylation of intracellular receptors"], {"weight": 0.652839641483378}], ["NCOA7", ["TCGA.D5.6537.01", "SUMOylation of intracellular receptors"], {"weight": 0.800098634947946}], ["NCOA7", ["TCGA.D5.6537.01", "Nuclear Receptor transcription pathway"], {"weight": 0.854020087704312}], ["NCOA7", ["TCGA.DM.A28F.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.873149386312943}], ["NCOA7", ["TCGA.DM.A28F.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.941506517058795}], ["NCOA7", ["TCGA.DM.A28F.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.940163603785197}], ["NCOA7", ["TCGA.DM.A28F.01", "Nuclear signaling by ERBB4"], {"weight": 0.817590079739604}], ["NCOA7", ["TCGA.DM.A28F.01", "PI3K/AKT Signaling in Cancer"], {"weight": 0.872669905905742}], ["NCOA7", ["TCGA.DM.A28F.01", "Signaling by ERBB4"], {"weight": 0.878257680879494}], ["NCOA7", ["TCGA.F4.6854.01", "TFAP2 (AP-2) family regulates transcription of growth factors and their receptors"], {"weight": 0.848945529108191}], ["UFL1", ["TCGA.D5.6932.01", "Drug ADME"], {"weight": 0.807470365902436}], ["UFL1", ["TCGA.D5.6932.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.864048567393028}], ["UFL1", ["TCGA.D5.6932.01", "Cardiac conduction"], {"weight": 0.885360625210879}], ["UFL1", ["TCGA.D5.6932.01", "L1CAM interactions"], {"weight": 0.844033978041049}], ["UFL1", ["TCGA.D5.6932.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.900258538768648}], ["UFL1", ["TCGA.D5.6932.01", "Peptide ligand-binding receptors"], {"weight": 0.894675827002927}], ["UFL1", ["TCGA.D5.6932.01", "Ion channel transport"], {"weight": 0.913028745024393}], ["UFL1", ["TCGA.D5.6932.01", "Collagen formation"], {"weight": 0.855722917228084}], ["UFL1", ["TCGA.D5.6932.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.803628698185037}], ["KCNQ5", ["TCGA.4T.AA8H.01", "Phase 4 - resting membrane potential"], {"weight": 0.926740883841907}], ["KCNQ5", ["TCGA.AA.3518.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.900725596762668}], ["KCNQ5", ["TCGA.AA.3518.01", "Neuronal System"], {"weight": 0.906384204731453}], ["KCNQ5", ["TCGA.AA.3518.01", "Interaction between L1 and Ankyrins"], {"weight": 0.901627170445707}], ["KCNQ5", ["TCGA.AA.3518.01", "Protein-protein interactions at synapses"], {"weight": 0.853624768145579}], ["KCNQ5", ["TCGA.AA.3518.01", "L1CAM interactions"], {"weight": 0.870852415421436}], ["KCNQ5", ["TCGA.AA.3521.01", "Potassium Channels"], {"weight": 0.943309274982673}], ["KCNQ5", ["TCGA.AA.3561.01", "Interaction between L1 and Ankyrins"], {"weight": 0.913961229530444}], ["KCNQ5", ["TCGA.AA.3710.01", "Interaction between L1 and Ankyrins"], {"weight": 0.896062687925431}], ["KCNQ5", ["TCGA.AA.3710.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.884338099279251}], ["KCNQ5", ["TCGA.AA.3710.01", "Stimuli-sensing channels"], {"weight": 0.537400360261353}], ["KCNQ5", ["TCGA.AA.3841.01", "Phase 2 - plateau phase"], {"weight": 0.77607285136972}], ["KCNQ5", ["TCGA.AA.3848.01", "Inwardly rectifying K+ channels"], {"weight": 0.880531204472532}], ["KCNQ5", ["TCGA.AA.3848.01", "Potassium Channels"], {"weight": 0.936474702258992}], ["KCNQ5", ["TCGA.AA.3982.01", "GRB2 events in EGFR signaling"], {"weight": 0.594155110701608}], ["KCNQ5", ["TCGA.AA.3982.01", "GABA B receptor activation"], {"weight": 0.876212075457708}], ["KCNQ5", ["TCGA.AA.3982.01", "Activation of GABAB receptors"], {"weight": 0.876212075457708}], ["KCNQ5", ["TCGA.AA.3982.01", "Adenylate cyclase inhibitory pathway"], {"weight": 0.624598517960613}], ["KCNQ5", ["TCGA.AA.3982.01", "SHC1 events in EGFR signaling"], {"weight": 0.594122622274042}], ["KCNQ5", ["TCGA.AA.3982.01", "GAB1 signalosome"], {"weight": 0.610244966807001}], ["KCNQ5", ["TCGA.AA.3982.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.754404706897267}], ["KCNQ5", ["TCGA.AA.3982.01", "Interaction between L1 and Ankyrins"], {"weight": 0.770734812901419}], ["KCNQ5", ["TCGA.AA.3982.01", "GABA receptor activation"], {"weight": 0.876212075457708}], ["KCNQ5", ["TCGA.AA.3982.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.629503620500868}], ["KCNQ5", ["TCGA.AA.3982.01", "APC-Cdc20 mediated degradation of Nek2A"], {"weight": 0.353227351825087}], ["KCNQ5", ["TCGA.AA.3982.01", "ERBB2 Regulates Cell Motility"], {"weight": 0.629503620500868}], ["KCNQ5", ["TCGA.AA.3982.01", "GRB2 events in ERBB2 signaling"], {"weight": 0.629503620500868}], ["KCNQ5", ["TCGA.AA.3982.01", "PI3K events in ERBB2 signaling"], {"weight": 0.629503620500868}], ["KCNQ5", ["TCGA.AA.3982.01", "PKA activation in glucagon signalling"], {"weight": 0.488711300879186}], ["KCNQ5", ["TCGA.AA.3982.01", "Activation of G protein gated Potassium channels"], {"weight": 0.828427490148073}], ["KCNQ5", ["TCGA.AA.3982.01", "G protein gated Potassium channels"], {"weight": 0.828427490148073}], ["KCNQ5", ["TCGA.AA.3982.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.828427490148073}], ["KCNQ5", ["TCGA.AZ.6607.01", "Phase 2 - plateau phase"], {"weight": 0.838101464799724}], ["KCNQ5", ["TCGA.CA.5254.01", "Potassium Channels"], {"weight": 0.957911955609276}], ["KCNQ5", ["TCGA.CK.5915.01", "Phase 4 - resting membrane potential"], {"weight": 0.946644878844925}], ["KCNQ5", ["TCGA.CM.5348.01", "Potassium Channels"], {"weight": 0.939940749670115}], ["KCNQ5", ["TCGA.CM.6676.01", "Potassium Channels"], {"weight": 0.948432526881574}], ["KCNQ5", ["TCGA.D5.5537.01", "Phase 4 - resting membrane potential"], {"weight": 0.904011582957715}], ["KCNQ5", ["TCGA.D5.6535.01", "Phase 4 - resting membrane potential"], {"weight": 0.849161398548819}], ["KCNQ5", ["TCGA.D5.6537.01", "GABA receptor activation"], {"weight": 0.916976552467864}], ["KCNQ5", ["TCGA.DM.A28F.01", "GABA B receptor activation"], {"weight": 0.940778150718935}], ["KCNQ5", ["TCGA.DM.A28F.01", "Activation of GABAB receptors"], {"weight": 0.940778150718935}], ["KCNQ5", ["TCGA.DM.A28F.01", "Phase 4 - resting membrane potential"], {"weight": 0.925217951530277}], ["KCNQ5", ["TCGA.F4.6856.01", "Cardiac conduction"], {"weight": 0.923044564343402}], ["KCNQ5", ["TCGA.F4.6856.01", "Muscle contraction"], {"weight": 0.932227715172865}], ["KCNQ5", ["TCGA.F4.6856.01", "GABA receptor activation"], {"weight": 0.89446602163929}], ["FHL5", ["TCGA.A6.2678.01", "Transport of small molecules"], {"weight": 0.876944956456751}], ["FHL5", ["TCGA.A6.2678.01", "TNFs bind their physiological receptors"], {"weight": 0.328242683399691}], ["FHL5", ["TCGA.A6.2686.01", "TNFs bind their physiological receptors"], {"weight": 0.358246423840927}], ["FHL5", ["TCGA.AA.3681.01", "Cardiac conduction"], {"weight": 0.830633081432391}], ["FHL5", ["TCGA.AA.3681.01", "Neuronal System"], {"weight": 0.832468365542298}], ["FHL5", ["TCGA.AA.3966.01", "TNFs bind their physiological receptors"], {"weight": 0.362944902106676}], ["FHL5", ["TCGA.AA.3979.01", "Neuronal System"], {"weight": 0.930759274684368}], ["FHL5", ["TCGA.AA.3979.01", "G alpha (i) signalling events"], {"weight": 0.955965078399785}], ["FHL5", ["TCGA.AA.3979.01", "Transmission across Chemical Synapses"], {"weight": 0.926652373992305}], ["FHL5", ["TCGA.AA.3979.01", "Regulation of insulin secretion"], {"weight": 0.911722757628634}], ["FHL5", ["TCGA.AA.3979.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.911795965949061}], ["FHL5", ["TCGA.AA.3979.01", "Extracellular matrix organization"], {"weight": 0.887430112007783}], ["FHL5", ["TCGA.AA.3979.01", "Molecules associated with elastic fibres"], {"weight": -0.0303462575558861}], ["FHL5", ["TCGA.AA.A01X.01", "Neuronal System"], {"weight": 0.916130348730314}], ["FHL5", ["TCGA.AZ.6608.01", "Neuronal System"], {"weight": 0.953271155054525}], ["FHL5", ["TCGA.AZ.6608.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.890446688370609}], ["FHL5", ["TCGA.CA.5255.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.842612726579563}], ["FHL5", ["TCGA.CK.5915.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.919856994672916}], ["FHL5", ["TCGA.CM.5860.01", "TNFs bind their physiological receptors"], {"weight": 0.486458968630209}], ["FHL5", ["TCGA.CM.6675.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.886194365757835}], ["FHL5", ["TCGA.D5.5537.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.872880341866849}], ["FHL5", ["TCGA.D5.6932.01", "Biological oxidations"], {"weight": 0.918138483699248}], ["FHL5", ["TCGA.D5.6932.01", "Phase II - Conjugation of compounds"], {"weight": 0.793029311844377}], ["FHL5", ["TCGA.D5.6932.01", "Transport of small molecules"], {"weight": 0.912320619648732}], ["FHL5", ["TCGA.D5.6932.01", "Signaling by GPCR"], {"weight": 0.950886069078514}], ["FHL5", ["TCGA.D5.6932.01", "GPCR downstream signalling"], {"weight": 0.95434004918378}], ["FHL5", ["TCGA.D5.6932.01", "G alpha (i) signalling events"], {"weight": 0.942155666015498}], ["FHL5", ["TCGA.D5.6932.01", "G alpha (s) signalling events"], {"weight": 0.941306537144101}], ["FHL5", ["TCGA.D5.6932.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.870633888585235}], ["FHL5", ["TCGA.D5.6932.01", "Signaling Pathways"], {"weight": 0.88241829492832}], ["FHL5", ["TCGA.D5.6932.01", "TNFs bind their physiological receptors"], {"weight": 0.35705258147158}], ["FHL5", ["TCGA.DM.A28F.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.871667638485677}], ["FHL5", ["TCGA.DM.A28F.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.842156533284278}], ["FHL5", ["TCGA.QL.A97D.01", "Assembly and cell surface presentation of NMDA receptors"], {"weight": 0.905227358291634}], ["NDUFAF4", ["TCGA.A6.2686.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.881681646763952}], ["NDUFAF4", ["TCGA.AA.3966.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.766257316002311}], ["NDUFAF4", ["TCGA.AA.3966.01", "Amino acid transport across the plasma membrane"], {"weight": 0.653899526442798}], ["NDUFAF4", ["TCGA.AA.A00A.01", "Phase II - Conjugation of compounds"], {"weight": 0.7603846243705}], ["NDUFAF4", ["TCGA.CM.5860.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.881564847075158}], ["NDUFAF4", ["TCGA.CM.5868.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.73582265401495}], ["NDUFAF4", ["TCGA.CM.6169.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.86874593053717}], ["NDUFAF4", ["TCGA.D5.6931.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.59738086440285}], ["NDUFAF4", ["TCGA.D5.6931.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.794124874490964}], ["CENPW", ["TCGA.A6.5660.01", "Biological oxidations"], {"weight": 0.896394974315799}], ["CENPW", ["TCGA.A6.5660.01", "Drug ADME"], {"weight": 0.789963826862337}], ["CENPW", ["TCGA.A6.5660.01", "Phase I - Functionalization of compounds"], {"weight": 0.915950927773373}], ["CENPW", ["TCGA.A6.5660.01", "Regulation of FZD by ubiquitination"], {"weight": 0.745464366601304}], ["CENPW", ["TCGA.A6.5660.01", "Signaling by Retinoic Acid"], {"weight": 0.711591884384214}], ["RSPO3", ["TCGA.AA.3660.01", "Regulation of FZD by ubiquitination"], {"weight": 0.865278154341535}], ["RSPO3", ["TCGA.AA.3952.01", "Regulation of FZD by ubiquitination"], {"weight": 0.781838953403184}], ["RSPO3", ["TCGA.AA.A02H.01", "Regulation of FZD by ubiquitination"], {"weight": 0.866105547640574}], ["RSPO3", ["TCGA.CM.4743.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], {"weight": 0.738540671757023}], ["RSPO3", ["TCGA.D5.5537.01", "Regulation of FZD by ubiquitination"], {"weight": 0.899337939284516}], ["RSPO3", ["TCGA.D5.6898.01", "Regulation of FZD by ubiquitination"], {"weight": 0.870428792140347}], ["RNF146", ["TCGA.CM.4743.01", "Transport of small molecules"], {"weight": 0.926663051990262}], ["RNF146", ["TCGA.CM.4743.01", "Phase II - Conjugation of compounds"], {"weight": 0.805883089518981}], ["FBXL4", ["TCGA.A6.6652.01", "Ion channel transport"], {"weight": 0.948436764131776}], ["FBXL4", ["TCGA.AA.3848.01", "Signaling by NOTCH1 HD Domain Mutants in Cancer"], {"weight": 0.886454565240653}], ["FBXL4", ["TCGA.AA.3848.01", "Constitutive Signaling by NOTCH1 HD Domain Mutants"], {"weight": 0.886454565240653}], ["FBXL4", ["TCGA.AA.3848.01", "Activated NOTCH1 Transmits Signal to the Nucleus"], {"weight": 0.916812627134637}], ["FBXL4", ["TCGA.CM.5868.01", "GPCR ligand binding"], {"weight": 0.905887291547392}], ["FBXL4", ["TCGA.CM.5868.01", "Peptide ligand-binding receptors"], {"weight": 0.907475234477614}], ["FBXL4", ["TCGA.CM.5868.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.908381261134577}], ["ECHDC1", ["TCGA.3L.AA1B.01", "RA biosynthesis pathway"], {"weight": 0.634031464451643}], ["ECHDC1", ["TCGA.5M.AATA.01", "Ethanol oxidation"], {"weight": 0.83824298396019}], ["ECHDC1", ["TCGA.A6.6649.01", "Ethanol oxidation"], {"weight": 0.684293668562558}], ["ECHDC1", ["TCGA.A6.6652.01", "Biological oxidations"], {"weight": 0.939789960447223}], ["ECHDC1", ["TCGA.A6.6652.01", "Ethanol oxidation"], {"weight": 0.87088255910872}], ["ECHDC1", ["TCGA.A6.6652.01", "RA biosynthesis pathway"], {"weight": 0.89756006765355}], ["ECHDC1", ["TCGA.A6.6652.01", "Phase I - Functionalization of compounds"], {"weight": 0.940597673646426}], ["ECHDC1", ["TCGA.AA.3521.01", "Ethanol oxidation"], {"weight": 0.812600211722097}], ["ECHDC1", ["TCGA.AA.3655.01", "RA biosynthesis pathway"], {"weight": 0.886085699782177}], ["ECHDC1", ["TCGA.AA.3655.01", "Ethanol oxidation"], {"weight": 0.943294080152547}], ["ECHDC1", ["TCGA.AA.3660.01", "RA biosynthesis pathway"], {"weight": 0.842604610441813}], ["ECHDC1", ["TCGA.AA.3660.01", "Ethanol oxidation"], {"weight": 0.79042812464043}], ["ECHDC1", ["TCGA.AA.3685.01", "RA biosynthesis pathway"], {"weight": 0.682580757160061}], ["ECHDC1", ["TCGA.AA.3685.01", "Ethanol oxidation"], {"weight": 0.71413228354762}], ["ECHDC1", ["TCGA.AA.3837.01", "Ethanol oxidation"], {"weight": 0.748400256017957}], ["ECHDC1", ["TCGA.AA.3837.01", "Recycling of bile acids and salts"], {"weight": 0.754998131352994}], ["ECHDC1", ["TCGA.AA.3837.01", "RA biosynthesis pathway"], {"weight": 0.747846938766298}], ["ECHDC1", ["TCGA.AA.3837.01", "Signaling by Retinoic Acid"], {"weight": 0.605117941235788}], ["ECHDC1", ["TCGA.AA.3837.01", "Bile acid and bile salt metabolism"], {"weight": 0.735576469174761}], ["ECHDC1", ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.655378285828681}], ["ECHDC1", ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts"], {"weight": 0.655378285828681}], ["ECHDC1", ["TCGA.AA.3841.01", "Ethanol oxidation"], {"weight": 0.800727925946322}], ["ECHDC1", ["TCGA.AA.3841.01", "Signaling by Nuclear Receptors"], {"weight": 0.839892700911627}], ["ECHDC1", ["TCGA.AA.3848.01", "RA biosynthesis pathway"], {"weight": 0.896757664489375}], ["ECHDC1", ["TCGA.AA.3848.01", "Ethanol oxidation"], {"weight": 0.811585342493812}], ["ECHDC1", ["TCGA.AA.3858.01", "Ethanol oxidation"], {"weight": 0.801647625825536}], ["ECHDC1", ["TCGA.AA.3860.01", "RA biosynthesis pathway"], {"weight": 0.851468959704793}], ["ECHDC1", ["TCGA.AA.3860.01", "Ethanol oxidation"], {"weight": 0.816890583536809}], ["ECHDC1", ["TCGA.AA.3952.01", "Ethanol oxidation"], {"weight": 0.759119076440937}], ["ECHDC1", ["TCGA.AA.3952.01", "RA biosynthesis pathway"], {"weight": 0.543457611496366}], ["ECHDC1", ["TCGA.AA.A00J.01", "RA biosynthesis pathway"], {"weight": 0.767957719459921}], ["ECHDC1", ["TCGA.AA.A02H.01", "Ethanol oxidation"], {"weight": 0.704322403522538}], ["ECHDC1", ["TCGA.AA.A02H.01", "Biotin transport and metabolism"], {"weight": 0.224838007690572}], ["ECHDC1", ["TCGA.AA.A02Y.01", "RA biosynthesis pathway"], {"weight": 0.88850763377508}], ["ECHDC1", ["TCGA.AD.6899.01", "Ethanol oxidation"], {"weight": 0.751326300368771}], ["ECHDC1", ["TCGA.AD.6899.01", "RA biosynthesis pathway"], {"weight": 0.672201451472452}], ["ECHDC1", ["TCGA.AD.A5EK.01", "RA biosynthesis pathway"], {"weight": 0.931090266733413}], ["ECHDC1", ["TCGA.AM.5820.01", "RA biosynthesis pathway"], {"weight": 0.674183957412415}], ["ECHDC1", ["TCGA.AY.A8YK.01", "RA biosynthesis pathway"], {"weight": 0.860641012626801}], ["ECHDC1", ["TCGA.AY.A8YK.01", "Ethanol oxidation"], {"weight": 0.826416972608075}], ["ECHDC1", ["TCGA.AZ.6600.01", "Biological oxidations"], {"weight": 0.846737276599106}], ["ECHDC1", ["TCGA.AZ.6600.01", "mitochondrial fatty acid beta-oxidation of saturated fatty acids"], {"weight": 0.760588746035093}], ["ECHDC1", ["TCGA.AZ.6600.01", "Ethanol oxidation"], {"weight": 0.709475734768491}], ["ECHDC1", ["TCGA.AZ.6600.01", "Mitochondrial Fatty Acid Beta-Oxidation"], {"weight": 0.686687273864053}], ["ECHDC1", ["TCGA.AZ.6606.01", "Ethanol oxidation"], {"weight": 0.892290613152346}], ["ECHDC1", ["TCGA.AZ.6607.01", "Biological oxidations"], {"weight": 0.959731747634866}], ["ECHDC1", ["TCGA.AZ.6607.01", "Ethanol oxidation"], {"weight": 0.851355914188197}], ["ECHDC1", ["TCGA.AZ.6607.01", "Phase I - Functionalization of compounds"], {"weight": 0.957038131663839}], ["ECHDC1", ["TCGA.AZ.6607.01", "mitochondrial fatty acid beta-oxidation of saturated fatty acids"], {"weight": 0.825105138891571}], ["ECHDC1", ["TCGA.AZ.6607.01", "Signaling by Retinoic Acid"], {"weight": 0.816777311254668}], ["ECHDC1", ["TCGA.AZ.6608.01", "Ethanol oxidation"], {"weight": 0.89760986811421}], ["ECHDC1", ["TCGA.CA.5254.01", "Recycling of bile acids and salts"], {"weight": 0.891667362083018}], ["ECHDC1", ["TCGA.CK.4952.01", "Neurotransmitter release cycle"], {"weight": 0.823228701757433}], ["ECHDC1", ["TCGA.CK.4952.01", "RA biosynthesis pathway"], {"weight": 0.896020236340017}], ["ECHDC1", ["TCGA.CK.4952.01", "Ethanol oxidation"], {"weight": 0.835922538780779}], ["ECHDC1", ["TCGA.CM.4743.01", "Neuronal System"], {"weight": 0.952520605333748}], ["ECHDC1", ["TCGA.CM.4743.01", "Biological oxidations"], {"weight": 0.905703284377641}], ["ECHDC1", ["TCGA.CM.4743.01", "Transmission across Chemical Synapses"], {"weight": 0.949520120804986}], ["ECHDC1", ["TCGA.CM.4743.01", "Ethanol oxidation"], {"weight": 0.815422475090741}], ["ECHDC1", ["TCGA.CM.4743.01", "Arachidonic acid metabolism"], {"weight": 0.886852537478408}], ["ECHDC1", ["TCGA.CM.4743.01", "Glucuronidation"], {"weight": 0.868959819139639}], ["ECHDC1", ["TCGA.CM.4747.01", "Ethanol oxidation"], {"weight": 0.886312049142232}], ["ECHDC1", ["TCGA.CM.4747.01", "RA biosynthesis pathway"], {"weight": 0.878016480606501}], ["ECHDC1", ["TCGA.CM.5348.01", "RA biosynthesis pathway"], {"weight": 0.825363046007132}], ["ECHDC1", ["TCGA.CM.5863.01", "Ethanol oxidation"], {"weight": 0.678560550691024}], ["ECHDC1", ["TCGA.CM.5863.01", "Biological oxidations"], {"weight": 0.825993898812644}], ["ECHDC1", ["TCGA.CM.6161.01", "Biological oxidations"], {"weight": 0.951595402114599}], ["ECHDC1", ["TCGA.CM.6161.01", "Ethanol oxidation"], {"weight": 0.836479618742386}], ["ECHDC1", ["TCGA.CM.6167.01", "RA biosynthesis pathway"], {"weight": 0.660527030461066}], ["ECHDC1", ["TCGA.CM.6172.01", "RA biosynthesis pathway"], {"weight": 0.798460309891794}], ["ECHDC1", ["TCGA.CM.6172.01", "Ethanol oxidation"], {"weight": 0.731431074341433}], ["ECHDC1", ["TCGA.CM.6676.01", "Ethanol oxidation"], {"weight": 0.752793814022937}], ["ECHDC1", ["TCGA.D5.5537.01", "Ethanol oxidation"], {"weight": 0.9109886920907}], ["ECHDC1", ["TCGA.D5.5537.01", "RA biosynthesis pathway"], {"weight": 0.868867139470661}], ["ECHDC1", ["TCGA.D5.6529.01", "Ethanol oxidation"], {"weight": 0.822471707440683}], ["ECHDC1", ["TCGA.D5.6535.01", "Ethanol oxidation"], {"weight": 0.836831885778826}], ["ECHDC1", ["TCGA.D5.6535.01", "RA biosynthesis pathway"], {"weight": 0.843729177267977}], ["ECHDC1", ["TCGA.D5.6898.01", "Ethanol oxidation"], {"weight": 0.816750857947392}], ["ECHDC1", ["TCGA.D5.6898.01", "RA biosynthesis pathway"], {"weight": 0.847869698142782}], ["ECHDC1", ["TCGA.DM.A1D7.01", "Biological oxidations"], {"weight": 0.927185438571465}], ["ECHDC1", ["TCGA.DM.A1D7.01", "RA biosynthesis pathway"], {"weight": 0.891889877906535}], ["ECHDC1", ["TCGA.DM.A1D7.01", "Aspirin ADME"], {"weight": 0.604802855003326}], ["ECHDC1", ["TCGA.DM.A1D7.01", "Ethanol oxidation"], {"weight": 0.883223248601505}], ["ECHDC1", ["TCGA.DM.A28F.01", "RA biosynthesis pathway"], {"weight": 0.914859765381305}], ["ECHDC1", ["TCGA.DM.A28F.01", "Ethanol oxidation"], {"weight": 0.89762353770955}], ["ECHDC1", ["TCGA.F4.6459.01", "RA biosynthesis pathway"], {"weight": 0.843276264681495}], ["ECHDC1", ["TCGA.F4.6460.01", "Ethanol oxidation"], {"weight": 0.686078710276931}], ["ECHDC1", ["TCGA.F4.6704.01", "Ethanol oxidation"], {"weight": 0.794160861685577}], ["ECHDC1", ["TCGA.F4.6704.01", "Phase I - Functionalization of compounds"], {"weight": 0.954035718945695}], ["ECHDC1", ["TCGA.F4.6854.01", "Biological oxidations"], {"weight": 0.877925256002407}], ["ECHDC1", ["TCGA.G4.6297.01", "Ethanol oxidation"], {"weight": 0.812039758011651}], ["ECHDC1", ["TCGA.G4.6306.01", "Ethanol oxidation"], {"weight": 0.86464840200287}], ["ECHDC1", ["TCGA.G4.6306.01", "Phase I - Functionalization of compounds"], {"weight": 0.944443101731335}], ["ECHDC1", ["TCGA.NH.A6GA.01", "Ethanol oxidation"], {"weight": 0.846855982619308}], ["ECHDC1", ["TCGA.QL.A97D.01", "RA biosynthesis pathway"], {"weight": 0.89096552859696}], ["ECHDC1", ["TCGA.QL.A97D.01", "Ethanol oxidation"], {"weight": 0.839453613003952}], ["EEF1A1", ["TCGA.A6.2686.01", "Response of EIF2AK4 (GCN2) to amino acid deficiency"], {"weight": 0.87820441815418}], ["EEF1A1", ["TCGA.A6.2686.01", "Eukaryotic Translation Elongation"], {"weight": 0.928218678572306}], ["EEF1A1", ["TCGA.A6.2686.01", "Eukaryotic Translation Termination"], {"weight": 0.925484276500192}], ["EEF1A1", ["TCGA.A6.2686.01", "Viral mRNA Translation"], {"weight": 0.922831134376494}], ["EEF1A1", ["TCGA.A6.2686.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.925484276500192}], ["EEF1A1", ["TCGA.A6.2686.01", "Peptide chain elongation"], {"weight": 0.924267414809188}], ["EEF1A1", ["TCGA.A6.2686.01", "Selenocysteine synthesis"], {"weight": 0.922831134376494}], ["EEF1A1", ["TCGA.AA.3837.01", "Peptide chain elongation"], {"weight": 0.935322256628387}], ["EEF1A1", ["TCGA.AA.3837.01", "Eukaryotic Translation Elongation"], {"weight": 0.935283158744359}], ["EEF1A1", ["TCGA.AA.3841.01", "Peptide chain elongation"], {"weight": 0.942438280194325}], ["EEF1A1", ["TCGA.AA.3841.01", "Eukaryotic Translation Elongation"], {"weight": 0.94241246870857}], ["EEF1A1", ["TCGA.AA.3848.01", "Selenoamino acid metabolism"], {"weight": 0.911614399682549}], ["EEF1A1", ["TCGA.AA.3848.01", "Selenocysteine synthesis"], {"weight": 0.94060091047919}], ["EEF1A1", ["TCGA.AA.3848.01", "Viral mRNA Translation"], {"weight": 0.941660271134163}], ["EEF1A1", ["TCGA.AA.3848.01", "Peptide chain elongation"], {"weight": 0.942597641750819}], ["EEF1A1", ["TCGA.AA.3848.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.940128099834178}], ["EEF1A1", ["TCGA.AA.3848.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.893491335830033}], ["EEF1A1", ["TCGA.AA.3848.01", "Formation of a pool of free 40S subunits"], {"weight": 0.940247288043622}], ["EEF1A1", ["TCGA.AA.3848.01", "Eukaryotic Translation Elongation"], {"weight": 0.942575478466548}], ["EEF1A1", ["TCGA.AA.3848.01", "Eukaryotic Translation Termination"], {"weight": 0.941660271134163}], ["EEF1A1", ["TCGA.AA.3875.01", "Eukaryotic Translation Elongation"], {"weight": 0.913346466532048}], ["EEF1A1", ["TCGA.AA.3875.01", "Peptide chain elongation"], {"weight": 0.92589393246342}], ["EEF1A1", ["TCGA.AA.3939.01", "Eukaryotic Translation Elongation"], {"weight": 0.94611719204739}], ["EEF1A1", ["TCGA.CA.5256.01", "Eukaryotic Translation Elongation"], {"weight": 0.936020351107972}], ["EEF1A1", ["TCGA.CA.5256.01", "Translation"], {"weight": 0.903618452363991}], ["PTPRK", ["TCGA.A6.6649.01", "Amino acid transport across the plasma membrane"], {"weight": 0.391215124329426}], ["PTPRK", ["TCGA.AA.3560.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.948568858381125}], ["PTPRK", ["TCGA.AA.3655.01", "Amino acid transport across the plasma membrane"], {"weight": 0.61334765326656}], ["PTPRK", ["TCGA.AA.3685.01", "Amino acid transport across the plasma membrane"], {"weight": 0.600184029069136}], ["PTPRK", ["TCGA.AA.3841.01", "Amino acid transport across the plasma membrane"], {"weight": 0.774978482602437}], ["PTPRK", ["TCGA.AA.3841.01", "APOBEC3G mediated resistance to HIV-1 infection"], {"weight": 0.346848306850205}], ["PTPRK", ["TCGA.AA.3848.01", "Amino acid transport across the plasma membrane"], {"weight": 0.832834787293181}], ["PTPRK", ["TCGA.AA.3952.01", "FCERI mediated Ca+2 mobilization"], {"weight": 0.795856693283625}], ["PTPRK", ["TCGA.AA.A017.01", "Peptide hormone metabolism"], {"weight": 0.766562035124301}], ["PTPRK", ["TCGA.AA.A017.01", "Signal amplification"], {"weight": 0.900841271549986}], ["PTPRK", ["TCGA.AA.A017.01", "Glucagon-type ligand receptors"], {"weight": 0.884979019895159}], ["PTPRK", ["TCGA.AA.A017.01", "Potassium Channels"], {"weight": 0.919044409983275}], ["PTPRK", ["TCGA.AA.A017.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.858976928333309}], ["PTPRK", ["TCGA.AA.A017.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.885751278085626}], ["PTPRK", ["TCGA.AA.A017.01", "Platelet homeostasis"], {"weight": 0.832008824830353}], ["PTPRK", ["TCGA.AA.A017.01", "GPCR ligand binding"], {"weight": 0.90310915015909}], ["PTPRK", ["TCGA.AA.A02H.01", "APOBEC3G mediated resistance to HIV-1 infection"], {"weight": 0.554655468495742}], ["PTPRK", ["TCGA.AY.A8YK.01", "Amino acid transport across the plasma membrane"], {"weight": 0.574144235089156}], ["PTPRK", ["TCGA.AZ.6598.01", "Amino acid transport across the plasma membrane"], {"weight": 0.780644821441555}], ["PTPRK", ["TCGA.AZ.6600.01", "Extracellular matrix organization"], {"weight": 0.832033672389434}], ["PTPRK", ["TCGA.AZ.6606.01", "Amino acid transport across the plasma membrane"], {"weight": 0.707649430504229}], ["PTPRK", ["TCGA.AZ.6608.01", "Amino acid transport across the plasma membrane"], {"weight": 0.819000320335654}], ["PTPRK", ["TCGA.CA.5255.01", "FCERI mediated Ca+2 mobilization"], {"weight": 0.866103598312518}], ["PTPRK", ["TCGA.CK.4952.01", "Amino acid transport across the plasma membrane"], {"weight": 0.821060708227678}], ["PTPRK", ["TCGA.CM.4743.01", "GPCR ligand binding"], {"weight": 0.917674827966235}], ["PTPRK", ["TCGA.CM.4743.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.937162191249792}], ["PTPRK", ["TCGA.CM.4743.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.918506510166663}], ["PTPRK", ["TCGA.CM.4743.01", "G alpha (i) signalling events"], {"weight": 0.954252390564565}], ["PTPRK", ["TCGA.CM.4743.01", "Peptide ligand-binding receptors"], {"weight": 0.915968622063116}], ["PTPRK", ["TCGA.CM.4743.01", "Drug ADME"], {"weight": 0.892028096474754}], ["PTPRK", ["TCGA.CM.4743.01", "Signaling Pathways"], {"weight": 0.92326223473952}], ["PTPRK", ["TCGA.CM.4743.01", "Protein-protein interactions at synapses"], {"weight": 0.914817535779278}], ["PTPRK", ["TCGA.CM.4743.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.892713033235341}], ["PTPRK", ["TCGA.CM.4743.01", "Metabolism of fat-soluble vitamins"], {"weight": 0.911827551932436}], ["PTPRK", ["TCGA.CM.4743.01", "Retinoid metabolism and transport"], {"weight": 0.911827551932436}], ["PTPRK", ["TCGA.CM.4743.01", "Amino acid transport across the plasma membrane"], {"weight": 0.836843987542946}], ["PTPRK", ["TCGA.CM.4743.01", "Muscle contraction"], {"weight": 0.937046266773698}], ["PTPRK", ["TCGA.CM.4743.01", "Cardiac conduction"], {"weight": 0.933871293416816}], ["PTPRK", ["TCGA.CM.4743.01", "Ion channel transport"], {"weight": 0.934617488595354}], ["PTPRK", ["TCGA.CM.4743.01", "Stimuli-sensing channels"], {"weight": 0.918924909485724}], ["PTPRK", ["TCGA.CM.4743.01", "Regulation of Complement cascade"], {"weight": 0.867737313829305}], ["PTPRK", ["TCGA.CM.4743.01", "Complement cascade"], {"weight": 0.907609530782995}], ["PTPRK", ["TCGA.CM.4743.01", "Regulation of signaling by NODAL"], {"weight": 0.834172295969633}], ["PTPRK", ["TCGA.CM.4743.01", "SLC-mediated transmembrane transport"], {"weight": 0.924038239528326}], ["PTPRK", ["TCGA.CM.4743.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.957786959779606}], ["PTPRK", ["TCGA.CM.4743.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.92544518544011}], ["PTPRK", ["TCGA.CM.4743.01", "G alpha (s) signalling events"], {"weight": 0.949678160576956}], ["PTPRK", ["TCGA.CM.4743.01", "Scavenging by Class A Receptors"], {"weight": 0.537496553057001}], ["PTPRK", ["TCGA.CM.4743.01", "CD22 mediated BCR regulation"], {"weight": 0.748474232326237}], ["PTPRK", ["TCGA.CM.4743.01", "Glucagon-type ligand receptors"], {"weight": 0.891896839294786}], ["PTPRK", ["TCGA.CM.4743.01", "PI3K events in ERBB2 signaling"], {"weight": 0.920904523140348}], ["PTPRK", ["TCGA.CM.4743.01", "Glycosaminoglycan metabolism"], {"weight": 0.840619271924363}], ["PTPRK", ["TCGA.CM.4743.01", "Neurexins and neuroligins"], {"weight": 0.934677873613086}], ["PTPRK", ["TCGA.CM.4743.01", "Regulation of gene expression in beta cells"], {"weight": 0.719363732509586}], ["PTPRK", ["TCGA.CM.4743.01", "IL-6-type cytokine receptor ligand interactions"], {"weight": 0.80855014581827}], ["PTPRK", ["TCGA.CM.4743.01", "Regulation of beta-cell development"], {"weight": 0.776744560909873}], ["PTPRK", ["TCGA.CM.4743.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.897902965525734}], ["PTPRK", ["TCGA.CM.4747.01", "ERK1/ERK2 pathway"], {"weight": 0.844559392952135}], ["PTPRK", ["TCGA.CM.4747.01", "ERBB2 Activates PTK6 Signaling"], {"weight": 0.855905769553315}], ["PTPRK", ["TCGA.CM.4747.01", "FGFR4 ligand binding and activation"], {"weight": 0.779631588213471}], ["PTPRK", ["TCGA.CM.4747.01", "MAPK family signaling cascades"], {"weight": 0.818391206967428}], ["PTPRK", ["TCGA.CM.4747.01", "RAF/MAP kinase cascade"], {"weight": 0.849251783971883}], ["PTPRK", ["TCGA.D5.6531.01", "Amino acid transport across the plasma membrane"], {"weight": 0.856351561689049}], ["PTPRK", ["TCGA.DM.A1D7.01", "Trafficking and processing of endosomal TLR"], {"weight": 0.794210557012884}], ["PTPRK", ["TCGA.DM.A28F.01", "Amino acid transport across the plasma membrane"], {"weight": 0.755644334324664}], ["PTPRK", ["TCGA.F4.6460.01", "Activated point mutants of FGFR2"], {"weight": 0.794505408254732}], ["PTPRK", ["TCGA.F4.6460.01", "Phospholipase C-mediated cascade; FGFR2"], {"weight": 0.792973869056564}], ["PTPRK", ["TCGA.NH.A6GA.01", "Tryptophan catabolism"], {"weight": 0.630820702215687}], ["PTPRK", ["TCGA.QL.A97D.01", "Amino acid transport across the plasma membrane"], {"weight": 0.676046718558615}], ["LAMA2", ["TCGA.A6.2685.01", "Extracellular matrix organization"], {"weight": 0.868055895190937}], ["LAMA2", ["TCGA.A6.2685.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.677074448269301}], ["LAMA2", ["TCGA.A6.2685.01", "Integrin cell surface interactions"], {"weight": 0.887680012762797}], ["LAMA2", ["TCGA.A6.2685.01", "ECM proteoglycans"], {"weight": 0.875640241072889}], ["LAMA2", ["TCGA.A6.2685.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.74693396744038}], ["LAMA2", ["TCGA.A6.2685.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.870801269042583}], ["LAMA2", ["TCGA.AA.3685.01", "Viral mRNA Translation"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Peptide chain elongation"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Selenocysteine synthesis"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Formation of a pool of free 40S subunits"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Eukaryotic Translation Initiation"], {"weight": 0.904586915362389}], ["LAMA2", ["TCGA.AA.3685.01", "Cap-dependent Translation Initiation"], {"weight": 0.904591305323138}], ["LAMA2", ["TCGA.AA.3685.01", "GTP hydrolysis and joining of the 60S ribosomal subunit"], {"weight": 0.927819036637493}], ["LAMA2", ["TCGA.AA.3685.01", "Nonsense-Mediated Decay (NMD)"], {"weight": 0.92781595835976}], ["LAMA2", ["TCGA.AA.3685.01", "Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)"], {"weight": 0.92781595835976}], ["LAMA2", ["TCGA.AA.3685.01", "SRP-dependent cotranslational protein targeting to membrane"], {"weight": 0.926910531400419}], ["LAMA2", ["TCGA.AA.3685.01", "Regulation of expression of SLITs and ROBOs"], {"weight": 0.873555052981473}], ["LAMA2", ["TCGA.AA.3850.01", "Interaction between L1 and Ankyrins"], {"weight": 0.882024741096958}], ["LAMA2", ["TCGA.AA.3850.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.893182032106745}], ["LAMA2", ["TCGA.AA.3850.01", "L1CAM interactions"], {"weight": 0.808331638922532}], ["LAMA2", ["TCGA.AA.3850.01", "Degradation of the extracellular matrix"], {"weight": 0.788141188075865}], ["LAMA2", ["TCGA.AA.A017.01", "Interaction between L1 and Ankyrins"], {"weight": 0.908133948214435}], ["LAMA2", ["TCGA.AA.A017.01", "Signaling by GPCR"], {"weight": 0.937723265748482}], ["LAMA2", ["TCGA.AA.A017.01", "GPCR downstream signalling"], {"weight": 0.953432038225262}], ["LAMA2", ["TCGA.AA.A017.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.867491791750014}], ["LAMA2", ["TCGA.AA.A017.01", "O2/CO2 exchange in erythrocytes"], {"weight": -0.0327971733648752}], ["LAMA2", ["TCGA.AA.A017.01", "Stimuli-sensing channels"], {"weight": 0.901970590167702}], ["LAMA2", ["TCGA.AZ.6607.01", "Laminin interactions"], {"weight": 0.891422390723213}], ["LAMA2", ["TCGA.CA.5254.01", "ECM proteoglycans"], {"weight": 0.884906992210304}], ["LAMA2", ["TCGA.CM.4747.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.665347705303347}], ["LAMA2", ["TCGA.CM.4747.01", "O2/CO2 exchange in erythrocytes"], {"weight": 0.254648007797285}], ["LAMA2", ["TCGA.CM.4747.01", "Erythrocytes take up carbon dioxide and release oxygen"], {"weight": 0.333589701014278}], ["LAMA2", ["TCGA.CM.4747.01", "Other semaphorin interactions"], {"weight": 0.344113018848758}], ["LAMA2", ["TCGA.G4.6306.01", "Elastic fibre formation"], {"weight": 0.925910473202149}], ["EPB41L2", ["TCGA.4T.AA8H.01", "Protein-protein interactions at synapses"], {"weight": 0.930236551530091}], ["EPB41L2", ["TCGA.5M.AATA.01", "Neurexins and neuroligins"], {"weight": 0.912389186297726}], ["EPB41L2", ["TCGA.A6.2678.01", "Protein-protein interactions at synapses"], {"weight": 0.859462616328916}], ["EPB41L2", ["TCGA.A6.2678.01", "Neurexins and neuroligins"], {"weight": 0.898120269240103}], ["EPB41L2", ["TCGA.A6.6652.01", "Protein-protein interactions at synapses"], {"weight": 0.928474323865051}], ["EPB41L2", ["TCGA.A6.6652.01", "Neurexins and neuroligins"], {"weight": 0.956900005890751}], ["EPB41L2", ["TCGA.AA.3655.01", "Neurexins and neuroligins"], {"weight": 0.945256149675478}], ["EPB41L2", ["TCGA.AA.3685.01", "Protein-protein interactions at synapses"], {"weight": 0.72637264806638}], ["EPB41L2", ["TCGA.AA.3685.01", "Extracellular matrix organization"], {"weight": 0.845371720587602}], ["EPB41L2", ["TCGA.AA.3685.01", "Neurexins and neuroligins"], {"weight": 0.931520377261501}], ["EPB41L2", ["TCGA.AA.3715.01", "Protein-protein interactions at synapses"], {"weight": 0.923380483441163}], ["EPB41L2", ["TCGA.AA.3860.01", "Extracellular matrix organization"], {"weight": 0.845736255097951}], ["EPB41L2", ["TCGA.AA.3939.01", "Neuronal System"], {"weight": 0.911931679402361}], ["EPB41L2", ["TCGA.AA.3939.01", "Extracellular matrix organization"], {"weight": 0.843286847473307}], ["EPB41L2", ["TCGA.AA.A02Y.01", "Protein-protein interactions at synapses"], {"weight": 0.945301866352872}], ["EPB41L2", ["TCGA.AA.A02Y.01", "Neurexins and neuroligins"], {"weight": 0.953111844912459}], ["EPB41L2", ["TCGA.AD.6888.01", "Protein-protein interactions at synapses"], {"weight": 0.940457416783811}], ["EPB41L2", ["TCGA.AD.6899.01", "Extracellular matrix organization"], {"weight": 0.850845351620919}], ["EPB41L2", ["TCGA.AM.5820.01", "Neurexins and neuroligins"], {"weight": 0.889676634079936}], ["EPB41L2", ["TCGA.AZ.6598.01", "Protein-protein interactions at synapses"], {"weight": 0.932427359788034}], ["EPB41L2", ["TCGA.AZ.6598.01", "Neurexins and neuroligins"], {"weight": 0.928903385481687}], ["EPB41L2", ["TCGA.AZ.6606.01", "Protein-protein interactions at synapses"], {"weight": 0.898819495380418}], ["EPB41L2", ["TCGA.CA.5254.01", "Protein-protein interactions at synapses"], {"weight": 0.922121146786822}], ["EPB41L2", ["TCGA.CA.5254.01", "Neurexins and neuroligins"], {"weight": 0.916202582379182}], ["EPB41L2", ["TCGA.CA.5255.01", "Protein-protein interactions at synapses"], {"weight": 0.918983578123757}], ["EPB41L2", ["TCGA.CA.5256.01", "Protein-protein interactions at synapses"], {"weight": 0.938260624511101}], ["EPB41L2", ["TCGA.CK.4952.01", "Protein-protein interactions at synapses"], {"weight": 0.951042766709944}], ["EPB41L2", ["TCGA.CK.4952.01", "Neurexins and neuroligins"], {"weight": 0.949662019592533}], ["EPB41L2", ["TCGA.CK.5915.01", "Protein-protein interactions at synapses"], {"weight": 0.933840052622928}], ["EPB41L2", ["TCGA.CM.4747.01", "Extracellular matrix organization"], {"weight": 0.846983198639954}], ["EPB41L2", ["TCGA.CM.6676.01", "Neuronal System"], {"weight": 0.944344129528579}], ["EPB41L2", ["TCGA.D5.6529.01", "Protein-protein interactions at synapses"], {"weight": 0.677267533537707}], ["EPB41L2", ["TCGA.D5.6529.01", "Neurexins and neuroligins"], {"weight": 0.890594636293429}], ["EPB41L2", ["TCGA.D5.6535.01", "Protein-protein interactions at synapses"], {"weight": 0.856662033977939}], ["EPB41L2", ["TCGA.D5.6537.01", "Protein-protein interactions at synapses"], {"weight": 0.942013570792662}], ["EPB41L2", ["TCGA.DM.A28F.01", "Protein-protein interactions at synapses"], {"weight": 0.920071418242581}], ["EPB41L2", ["TCGA.DM.A28F.01", "Neurexins and neuroligins"], {"weight": 0.945908145146545}], ["EPB41L2", ["TCGA.G4.6306.01", "Protein-protein interactions at synapses"], {"weight": 0.936902694108138}], ["EPB41L2", ["TCGA.G4.6306.01", "Neurexins and neuroligins"], {"weight": 0.950524792404}], ["EPB41L2", ["TCGA.NH.A6GA.01", "Protein-protein interactions at synapses"], {"weight": 0.656668493284178}], ["EPB41L2", ["TCGA.QL.A97D.01", "Protein-protein interactions at synapses"], {"weight": 0.920727095978711}], ["AKAP7", ["TCGA.A6.5660.01", "Neuronal System"], {"weight": 0.927237153329079}], ["AKAP7", ["TCGA.A6.5660.01", "GPCR ligand binding"], {"weight": 0.907505157374099}], ["AKAP7", ["TCGA.A6.5660.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.618309385196365}], ["AKAP7", ["TCGA.A6.5660.01", "Transmission across Chemical Synapses"], {"weight": 0.917944582849503}], ["AKAP7", ["TCGA.A6.5660.01", "Signaling by GPCR"], {"weight": 0.948945721782852}], ["AKAP7", ["TCGA.A6.5660.01", "GPCR downstream signalling"], {"weight": 0.961808809081538}], ["AKAP7", ["TCGA.A6.5660.01", "Transport of small molecules"], {"weight": 0.899826024274234}], ["AKAP7", ["TCGA.A6.5660.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.933743972976368}], ["AKAP7", ["TCGA.A6.5660.01", "G alpha (s) signalling events"], {"weight": 0.952079028954662}], ["AKAP7", ["TCGA.A6.5660.01", "G alpha (i) signalling events"], {"weight": 0.963003801580248}], ["AKAP7", ["TCGA.A6.5660.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.904161243353073}], ["AKAP7", ["TCGA.A6.5660.01", "Potassium Channels"], {"weight": 0.877991431320677}], ["AKAP7", ["TCGA.A6.5660.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.928656579706811}], ["AKAP7", ["TCGA.A6.5660.01", "Peptide ligand-binding receptors"], {"weight": 0.888285151154373}], ["AKAP7", ["TCGA.A6.5660.01", "Cardiac conduction"], {"weight": 0.89550657500627}], ["AKAP7", ["TCGA.A6.5660.01", "Voltage gated Potassium channels"], {"weight": 0.847479008122491}], ["AKAP7", ["TCGA.A6.5660.01", "Extracellular matrix organization"], {"weight": 0.848410910239734}], ["AKAP7", ["TCGA.A6.5660.01", "Peptide hormone metabolism"], {"weight": 0.747933477060293}], ["AKAP7", ["TCGA.A6.5660.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.922147258131225}], ["AKAP7", ["TCGA.A6.5660.01", "Glucagon-type ligand receptors"], {"weight": 0.898584889525313}], ["AKAP7", ["TCGA.A6.5660.01", "Signaling Pathways"], {"weight": 0.879313101183752}], ["AKAP7", ["TCGA.A6.5660.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.873569974845366}], ["AKAP7", ["TCGA.A6.5660.01", "Interaction between L1 and Ankyrins"], {"weight": 0.895692886463762}], ["AKAP7", ["TCGA.A6.5660.01", "Phase 0 - rapid depolarisation"], {"weight": 0.889581534447424}], ["AKAP7", ["TCGA.A6.5660.01", "Platelet homeostasis"], {"weight": 0.841176392002022}], ["AKAP7", ["TCGA.A6.5660.01", "NCAM1 interactions"], {"weight": 0.878263663522231}], ["AKAP7", ["TCGA.A6.5660.01", "Protein-protein interactions at synapses"], {"weight": -0.0153927589432945}], ["AKAP7", ["TCGA.A6.5660.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], {"weight": 0.784248922471749}], ["AKAP7", ["TCGA.A6.5660.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.896693235410856}], ["AKAP7", ["TCGA.A6.5660.01", "Leishmania parasite growth and survival"], {"weight": 0.896693235410856}], ["AKAP7", ["TCGA.A6.5660.01", "Regulation of insulin secretion"], {"weight": 0.914345808138247}], ["AKAP7", ["TCGA.A6.5660.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.848472555124573}], ["AKAP7", ["TCGA.A6.5660.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], {"weight": 0.811311594781223}], ["AKAP7", ["TCGA.A6.5660.01", "NCAM signaling for neurite out-growth"], {"weight": 0.8935242226709}], ["AKAP7", ["TCGA.A6.6652.01", "G alpha (i) signalling events"], {"weight": 0.960825432561089}], ["AKAP7", ["TCGA.A6.6652.01", "G-protein mediated events"], {"weight": 0.907274279311413}], ["AKAP7", ["TCGA.A6.6652.01", "G alpha (s) signalling events"], {"weight": 0.963114786924449}], ["AKAP7", ["TCGA.A6.6652.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.900262332966049}], ["AKAP7", ["TCGA.A6.6652.01", "Leishmania parasite growth and survival"], {"weight": 0.900262332966049}], ["AKAP7", ["TCGA.A6.6652.01", "Ca-dependent events"], {"weight": 0.86543121655938}], ["AKAP7", ["TCGA.A6.6652.01", "Calmodulin induced events"], {"weight": 0.889834547900875}], ["AKAP7", ["TCGA.A6.6652.01", "CaM pathway"], {"weight": 0.889834547900875}], ["AKAP7", ["TCGA.A6.6652.01", "DAG and IP3 signaling"], {"weight": 0.889834547900875}], ["AKAP7", ["TCGA.A6.6652.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.940470272920388}], ["AKAP7", ["TCGA.A6.6652.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.938179506300737}], ["AKAP7", ["TCGA.A6.6652.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.92539948514255}], ["AKAP7", ["TCGA.AA.3521.01", "Transmission across Chemical Synapses"], {"weight": 0.889141163675033}], ["AKAP7", ["TCGA.AA.3521.01", "GPER1 signaling"], {"weight": 0.893629948289936}], ["AKAP7", ["TCGA.AA.3521.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.893629948289936}], ["AKAP7", ["TCGA.AA.3560.01", "Signaling by ROBO receptors"], {"weight": 0.952630823389481}], ["AKAP7", ["TCGA.AA.3666.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.917809376153935}], ["AKAP7", ["TCGA.AA.3841.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.914637791258604}], ["AKAP7", ["TCGA.AA.3841.01", "Transport of small molecules"], {"weight": 0.90104678471383}], ["AKAP7", ["TCGA.AA.3841.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.920873224822535}], ["AKAP7", ["TCGA.AA.3841.01", "GPER1 signaling"], {"weight": 0.920044377812824}], ["AKAP7", ["TCGA.AA.3841.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.920044377812824}], ["AKAP7", ["TCGA.AA.3841.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.914637791258604}], ["AKAP7", ["TCGA.AA.3841.01", "Aquaporin-mediated transport"], {"weight": 0.914637791258604}], ["AKAP7", ["TCGA.AA.3841.01", "Neuronal System"], {"weight": 0.92249537108101}], ["AKAP7", ["TCGA.AA.3841.01", "Transmission across Chemical Synapses"], {"weight": 0.926004141708179}], ["AKAP7", ["TCGA.AA.3844.01", "Neuronal System"], {"weight": 0.922218032045186}], ["AKAP7", ["TCGA.AA.3844.01", "Transport of small molecules"], {"weight": 0.892882562224013}], ["AKAP7", ["TCGA.AA.3858.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.904825841148699}], ["AKAP7", ["TCGA.AA.3858.01", "GPER1 signaling"], {"weight": 0.905676521390217}], ["AKAP7", ["TCGA.AA.3858.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.905676521390217}], ["AKAP7", ["TCGA.AA.3858.01", "Aquaporin-mediated transport"], {"weight": 0.776578821149014}], ["AKAP7", ["TCGA.AA.3860.01", "G alpha (s) signalling events"], {"weight": 0.947164541289493}], ["AKAP7", ["TCGA.AA.3860.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.899376041989514}], ["AKAP7", ["TCGA.AA.3860.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.914640564866034}], ["AKAP7", ["TCGA.AA.3860.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.90205198014928}], ["AKAP7", ["TCGA.AA.3860.01", "GPER1 signaling"], {"weight": 0.90205198014928}], ["AKAP7", ["TCGA.AA.3860.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.90205198014928}], ["AKAP7", ["TCGA.AA.3952.01", "Interaction between L1 and Ankyrins"], {"weight": 0.871022137441201}], ["AKAP7", ["TCGA.AA.3952.01", "Phase 0 - rapid depolarisation"], {"weight": 0.829960379998206}], ["AKAP7", ["TCGA.AA.A00J.01", "G alpha (i) signalling events"], {"weight": 0.951030580913152}], ["AKAP7", ["TCGA.AA.A01D.01", "Transport of small molecules"], {"weight": 0.931905292871157}], ["AKAP7", ["TCGA.AA.A02H.01", "G alpha (i) signalling events"], {"weight": 0.939883961058044}], ["AKAP7", ["TCGA.AA.A02H.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.904475542224705}], ["AKAP7", ["TCGA.AA.A02H.01", "GPCR downstream signalling"], {"weight": 0.944581651200701}], ["AKAP7", ["TCGA.AA.A02H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.904475542224705}], ["AKAP7", ["TCGA.AA.A02H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.893929593604387}], ["AKAP7", ["TCGA.AA.A02H.01", "GPER1 signaling"], {"weight": 0.893929593604387}], ["AKAP7", ["TCGA.AA.A02H.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.893929593604387}], ["AKAP7", ["TCGA.AA.A02H.01", "Aquaporin-mediated transport"], {"weight": 0.893929593604387}], ["AKAP7", ["TCGA.AA.A02H.01", "LGI-ADAM interactions"], {"weight": 0.610795693885233}], ["AKAP7", ["TCGA.AA.A02H.01", "Phase 0 - rapid depolarisation"], {"weight": 0.878131382430772}], ["AKAP7", ["TCGA.AA.A02H.01", "Neuronal System"], {"weight": 0.871581262388892}], ["AKAP7", ["TCGA.AA.A02H.01", "Ion transport by P-type ATPases"], {"weight": 0.791610270546419}], ["AKAP7", ["TCGA.AA.A02H.01", "PKA activation in glucagon signalling"], {"weight": 0.829659456394517}], ["AKAP7", ["TCGA.AA.A02Y.01", "G alpha (s) signalling events"], {"weight": 0.960678710339912}], ["AKAP7", ["TCGA.AA.A02Y.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.944771517341076}], ["AKAP7", ["TCGA.AA.A02Y.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.911368709423481}], ["AKAP7", ["TCGA.AA.A02Y.01", "Leishmania parasite growth and survival"], {"weight": 0.911368709423481}], ["AKAP7", ["TCGA.AA.A02Y.01", "Aquaporin-mediated transport"], {"weight": 0.868729341338855}], ["AKAP7", ["TCGA.AA.A02Y.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.94750655860832}], ["AKAP7", ["TCGA.AA.A02Y.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.918055264899104}], ["AKAP7", ["TCGA.AA.A02Y.01", "GPER1 signaling"], {"weight": 0.915506035041152}], ["AKAP7", ["TCGA.AA.A02Y.01", "Leishmania infection"], {"weight": 0.883830551002658}], ["AKAP7", ["TCGA.AA.A02Y.01", "Calmodulin induced events"], {"weight": 0.91330228505107}], ["AKAP7", ["TCGA.AA.A02Y.01", "CaM pathway"], {"weight": 0.91330228505107}], ["AKAP7", ["TCGA.AA.A02Y.01", "Integration of energy metabolism"], {"weight": 0.939725760542349}], ["AKAP7", ["TCGA.AA.A02Y.01", "DAG and IP3 signaling"], {"weight": 0.914411257973684}], ["AKAP7", ["TCGA.AA.A02Y.01", "Ca-dependent events"], {"weight": 0.91330228505107}], ["AKAP7", ["TCGA.AA.A02Y.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.939888571761049}], ["AKAP7", ["TCGA.AD.6888.01", "G alpha (s) signalling events"], {"weight": 0.968236922463539}], ["AKAP7", ["TCGA.AD.6888.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.927935960776236}], ["AKAP7", ["TCGA.AD.6888.01", "Leishmania parasite growth and survival"], {"weight": 0.927935960776236}], ["AKAP7", ["TCGA.AD.6888.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.94065362673326}], ["AKAP7", ["TCGA.AD.6888.01", "Leishmania infection"], {"weight": 0.913923577279491}], ["AKAP7", ["TCGA.AD.6888.01", "Aquaporin-mediated transport"], {"weight": 0.892995521445952}], ["AKAP7", ["TCGA.AD.6888.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.944351798488992}], ["AKAP7", ["TCGA.AD.6888.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.939565203114505}], ["AKAP7", ["TCGA.AD.6888.01", "GPER1 signaling"], {"weight": 0.937847757352417}], ["AKAP7", ["TCGA.AD.6888.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.937847757352417}], ["AKAP7", ["TCGA.AD.6888.01", "Calmodulin induced events"], {"weight": 0.907290201383162}], ["AKAP7", ["TCGA.AD.6888.01", "CaM pathway"], {"weight": 0.907290201383162}], ["AKAP7", ["TCGA.AD.6888.01", "FCGR3A-mediated IL10 synthesis"], {"weight": 0.897140174065924}], ["AKAP7", ["TCGA.AD.6888.01", "Ca-dependent events"], {"weight": 0.907290201383162}], ["AKAP7", ["TCGA.AD.A5EK.01", "G alpha (i) signalling events"], {"weight": 0.961038527414006}], ["AKAP7", ["TCGA.AD.A5EK.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.933400538739105}], ["AKAP7", ["TCGA.AD.A5EK.01", "Leishmania infection"], {"weight": 0.874853276417315}], ["AKAP7", ["TCGA.AD.A5EK.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.928842392456359}], ["AKAP7", ["TCGA.AD.A5EK.01", "G alpha (s) signalling events"], {"weight": 0.957750733069032}], ["AKAP7", ["TCGA.AD.A5EK.01", "Aquaporin-mediated transport"], {"weight": 0.789932978101824}], ["AKAP7", ["TCGA.AZ.6598.01", "G alpha (i) signalling events"], {"weight": 0.963537580499663}], ["AKAP7", ["TCGA.AZ.6598.01", "Signaling by GPCR"], {"weight": 0.945500981096858}], ["AKAP7", ["TCGA.AZ.6598.01", "GPCR downstream signalling"], {"weight": 0.946647775585817}], ["AKAP7", ["TCGA.AZ.6598.01", "Calmodulin induced events"], {"weight": 0.908720247329783}], ["AKAP7", ["TCGA.AZ.6598.01", "CaM pathway"], {"weight": 0.908720247329783}], ["AKAP7", ["TCGA.AZ.6598.01", "DAG and IP3 signaling"], {"weight": 0.910305606119957}], ["AKAP7", ["TCGA.AZ.6598.01", "Ca-dependent events"], {"weight": 0.908720247329783}], ["AKAP7", ["TCGA.AZ.6598.01", "G-protein mediated events"], {"weight": 0.912957342581915}], ["AKAP7", ["TCGA.AZ.6598.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.934581613215044}], ["AKAP7", ["TCGA.AZ.6598.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.927838246058401}], ["AKAP7", ["TCGA.AZ.6600.01", "G alpha (i) signalling events"], {"weight": 0.909395539642}], ["AKAP7", ["TCGA.AZ.6600.01", "Transport of small molecules"], {"weight": 0.92742176272679}], ["AKAP7", ["TCGA.AZ.6600.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.81253005028658}], ["AKAP7", ["TCGA.AZ.6600.01", "Transmission across Chemical Synapses"], {"weight": 0.863804991738665}], ["AKAP7", ["TCGA.AZ.6600.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.863433900977527}], ["AKAP7", ["TCGA.CA.5255.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.912131256524847}], ["AKAP7", ["TCGA.CA.5255.01", "Leishmania parasite growth and survival"], {"weight": 0.912131256524847}], ["AKAP7", ["TCGA.CA.5255.01", "Leishmania infection"], {"weight": 0.894972255790566}], ["AKAP7", ["TCGA.CA.5255.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.933168356608676}], ["AKAP7", ["TCGA.CA.5255.01", "Calmodulin induced events"], {"weight": 0.904507414751455}], ["AKAP7", ["TCGA.CA.5255.01", "CaM pathway"], {"weight": 0.904507414751455}], ["AKAP7", ["TCGA.CA.5255.01", "G alpha (s) signalling events"], {"weight": 0.957609758292593}], ["AKAP7", ["TCGA.CA.5255.01", "Ca-dependent events"], {"weight": 0.904507414751455}], ["AKAP7", ["TCGA.CA.5255.01", "Aquaporin-mediated transport"], {"weight": 0.832223228392608}], ["AKAP7", ["TCGA.CA.5255.01", "DAG and IP3 signaling"], {"weight": 0.904507414751455}], ["AKAP7", ["TCGA.CA.5255.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.930506644904455}], ["AKAP7", ["TCGA.CA.5255.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.893416924473581}], ["AKAP7", ["TCGA.CA.5255.01", "GPER1 signaling"], {"weight": 0.92508709264145}], ["AKAP7", ["TCGA.CA.5255.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.92508709264145}], ["AKAP7", ["TCGA.CK.4952.01", "Signaling by GPCR"], {"weight": 0.954146465121647}], ["AKAP7", ["TCGA.CK.4952.01", "GPCR downstream signalling"], {"weight": 0.955877060822071}], ["AKAP7", ["TCGA.CK.4952.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.940713809669809}], ["AKAP7", ["TCGA.CK.4952.01", "DAG and IP3 signaling"], {"weight": 0.918280517653564}], ["AKAP7", ["TCGA.CK.4952.01", "Calmodulin induced events"], {"weight": 0.918296162388945}], ["AKAP7", ["TCGA.CK.4952.01", "CaM pathway"], {"weight": 0.918296162388945}], ["AKAP7", ["TCGA.CM.4747.01", "Interaction between L1 and Ankyrins"], {"weight": 0.881586800736775}], ["AKAP7", ["TCGA.CM.4747.01", "Phase 0 - rapid depolarisation"], {"weight": 0.807302035860238}], ["AKAP7", ["TCGA.CM.6167.01", "Regulation of beta-cell development"], {"weight": 0.703181927800322}], ["AKAP7", ["TCGA.D5.6529.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.899232878796147}], ["AKAP7", ["TCGA.D5.6529.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.903386511162339}], ["AKAP7", ["TCGA.D5.6529.01", "Aquaporin-mediated transport"], {"weight": 0.713914544489114}], ["AKAP7", ["TCGA.D5.6531.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.919215064984039}], ["AKAP7", ["TCGA.D5.6535.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.774046134999272}], ["AKAP7", ["TCGA.D5.6537.01", "Neuronal System"], {"weight": 0.95981744136688}], ["AKAP7", ["TCGA.D5.6537.01", "Transmission across Chemical Synapses"], {"weight": 0.957968734223462}], ["AKAP7", ["TCGA.D5.6537.01", "G alpha (i) signalling events"], {"weight": 0.962838486882914}], ["AKAP7", ["TCGA.D5.6537.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.943938509377022}], ["AKAP7", ["TCGA.D5.6537.01", "G-protein mediated events"], {"weight": 0.924680050514952}], ["AKAP7", ["TCGA.D5.6537.01", "Ca-dependent events"], {"weight": 0.918548875011244}], ["AKAP7", ["TCGA.D5.6537.01", "PLC beta mediated events"], {"weight": 0.919409113729827}], ["AKAP7", ["TCGA.D5.6537.01", "Calmodulin induced events"], {"weight": 0.917874801276541}], ["AKAP7", ["TCGA.D5.6537.01", "CaM pathway"], {"weight": 0.917874801276541}], ["AKAP7", ["TCGA.D5.6537.01", "DAG and IP3 signaling"], {"weight": 0.919055855655442}], ["AKAP7", ["TCGA.D5.6537.01", "G alpha (s) signalling events"], {"weight": 0.965238887739311}], ["AKAP7", ["TCGA.D5.6537.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.919041975861987}], ["AKAP7", ["TCGA.D5.6537.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.94180520752065}], ["AKAP7", ["TCGA.D5.6537.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.892501074027884}], ["AKAP7", ["TCGA.D5.6537.01", "Leishmania parasite growth and survival"], {"weight": 0.892501074027884}], ["AKAP7", ["TCGA.D5.6537.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.936937923081413}], ["AKAP7", ["TCGA.D5.6537.01", "GPER1 signaling"], {"weight": 0.931057135334913}], ["AKAP7", ["TCGA.D5.6537.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.931057135334913}], ["AKAP7", ["TCGA.D5.6537.01", "Leishmania infection"], {"weight": 0.876177910541988}], ["AKAP7", ["TCGA.D5.6537.01", "Aquaporin-mediated transport"], {"weight": 0.817872232413498}], ["AKAP7", ["TCGA.D5.6537.01", "PKA activation in glucagon signalling"], {"weight": 0.900185247411081}], ["AKAP7", ["TCGA.F4.6704.01", "Transmission across Chemical Synapses"], {"weight": 0.894438597889092}], ["AKAP7", ["TCGA.F4.6704.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.865489152105271}], ["AKAP7", ["TCGA.G4.6297.01", "Signaling by GPCR"], {"weight": 0.929817337043066}], ["AKAP7", ["TCGA.G4.6297.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.875522463504243}], ["AKAP7", ["TCGA.G4.6306.01", "G alpha (s) signalling events"], {"weight": 0.963812338940048}], ["AKAP7", ["TCGA.G4.6306.01", "Transmission across Chemical Synapses"], {"weight": 0.947967236561184}], ["AKAP7", ["TCGA.G4.6306.01", "G alpha (i) signalling events"], {"weight": 0.951283305123}], ["AKAP7", ["TCGA.G4.6306.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.933001547712653}], ["AKAP7", ["TCGA.G4.6306.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.934830849744929}], ["AKAP7", ["TCGA.G4.6306.01", "Leishmania infection"], {"weight": 0.913376145641158}], ["AKAP7", ["TCGA.G4.6306.01", "G-protein mediated events"], {"weight": 0.909992460714685}], ["AKAP7", ["TCGA.NH.A6GA.01", "Signaling by GPCR"], {"weight": 0.940591289219048}], ["AKAP7", ["TCGA.NH.A6GA.01", "G alpha (i) signalling events"], {"weight": 0.946115352047185}], ["AKAP7", ["TCGA.NH.A6GA.01", "GPCR downstream signalling"], {"weight": 0.953175829893067}], ["AKAP7", ["TCGA.NH.A6GA.01", "Transmission across Chemical Synapses"], {"weight": 0.913367986549525}], ["AKAP7", ["TCGA.NH.A6GA.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.913375120181129}], ["AKAP7", ["TCGA.QL.A97D.01", "Neuronal System"], {"weight": 0.941699472939729}], ["AKAP7", ["TCGA.QL.A97D.01", "Transmission across Chemical Synapses"], {"weight": 0.937495008039595}], ["AKAP7", ["TCGA.QL.A97D.01", "G alpha (i) signalling events"], {"weight": 0.949229641167128}], ["AKAP7", ["TCGA.QL.A97D.01", "Activation of NMDA receptors and postsynaptic events"], {"weight": 0.899931173971768}], ["AKAP7", ["TCGA.QL.A97D.01", "G-protein mediated events"], {"weight": 0.89035180993378}], ["AKAP7", ["TCGA.QL.A97D.01", "Calmodulin induced events"], {"weight": 0.870997111977105}], ["AKAP7", ["TCGA.QL.A97D.01", "CaM pathway"], {"weight": 0.870997111977105}], ["AKAP7", ["TCGA.QL.A97D.01", "Ca-dependent events"], {"weight": 0.870997111977105}], ["ARG1", ["TCGA.AA.3841.01", "Metabolism of nitric oxide: NOS3 activation and regulation"], {"weight": 0.864463340005093}], ["ARG1", ["TCGA.AA.3952.01", "ROS and RNS production in phagocytes"], {"weight": 0.933630087258889}], ["ARG1", ["TCGA.AA.A02H.01", "Glutathione conjugation"], {"weight": 0.641709264003345}], ["ARG1", ["TCGA.AA.A02Y.01", "Ion homeostasis"], {"weight": 0.931371491725984}], ["ARG1", ["TCGA.AA.A02Y.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.947811210701285}], ["ARG1", ["TCGA.AZ.6607.01", "Glutathione synthesis and recycling"], {"weight": 0.534528425327112}], ["ARG1", ["TCGA.CM.4747.01", "Signaling by Erythropoietin"], {"weight": 0.805630821567492}], ["ARG1", ["TCGA.F4.6704.01", "Biosynthesis of DHA-derived SPMs"], {"weight": 0.731763806452916}], ["ARG1", ["TCGA.F4.6704.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], {"weight": 0.811859397524588}], ["MED23", ["TCGA.CM.4747.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.902187791671113}], ["MED23", ["TCGA.CM.4747.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.902187791671113}], ["MED23", ["TCGA.CM.4747.01", "Drug ADME"], {"weight": 0.751539609386539}], ["MED23", ["TCGA.CM.4747.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.810826492637831}], ["MED23", ["TCGA.CM.4747.01", "Diseases of Immune System"], {"weight": 0.85620990232407}], ["MED23", ["TCGA.CM.4747.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.85620990232407}], ["MED23", ["TCGA.CM.4747.01", "IRS-mediated signalling"], {"weight": 0.737958252949767}], ["ENPP3", ["TCGA.3L.AA1B.01", "Phase II - Conjugation of compounds"], {"weight": 0.759479735107149}], ["ENPP3", ["TCGA.3L.AA1B.01", "Biological oxidations"], {"weight": 0.910071811895577}], ["ENPP3", ["TCGA.3L.AA1B.01", "Glucuronidation"], {"weight": 0.847036045368735}], ["ENPP3", ["TCGA.3L.AA1B.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.900571493543054}], ["ENPP3", ["TCGA.5M.AATA.01", "Biological oxidations"], {"weight": 0.912884724459321}], ["ENPP3", ["TCGA.5M.AATA.01", "Phase II - Conjugation of compounds"], {"weight": 0.766781173341937}], ["ENPP3", ["TCGA.5M.AATA.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.832918946812513}], ["ENPP3", ["TCGA.A6.2678.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.736407898425722}], ["ENPP3", ["TCGA.A6.2678.01", "Phase II - Conjugation of compounds"], {"weight": 0.704618895172691}], ["ENPP3", ["TCGA.A6.6652.01", "Glucuronidation"], {"weight": 0.935186971929104}], ["ENPP3", ["TCGA.A6.6652.01", "Phase II - Conjugation of compounds"], {"weight": 0.836960424603872}], ["ENPP3", ["TCGA.AA.3521.01", "Biological oxidations"], {"weight": 0.901957726074343}], ["ENPP3", ["TCGA.AA.3521.01", "Phase II - Conjugation of compounds"], {"weight": 0.773732960800682}], ["ENPP3", ["TCGA.AA.3655.01", "Phase II - Conjugation of compounds"], {"weight": 0.763274314768396}], ["ENPP3", ["TCGA.AA.3655.01", "Glucuronidation"], {"weight": 0.9159714102479}], ["ENPP3", ["TCGA.AA.3655.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.777753153490223}], ["ENPP3", ["TCGA.AA.3660.01", "Glucuronidation"], {"weight": 0.881658840617459}], ["ENPP3", ["TCGA.AA.3660.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.683988741934758}], ["ENPP3", ["TCGA.AA.3660.01", "Phase II - Conjugation of compounds"], {"weight": 0.713959879914165}], ["ENPP3", ["TCGA.AA.3685.01", "Selenoamino acid metabolism"], {"weight": 0.896987725331747}], ["ENPP3", ["TCGA.AA.3685.01", "Amino acid and derivative metabolism"], {"weight": 0.896801668161199}], ["ENPP3", ["TCGA.AA.3715.01", "Phase II - Conjugation of compounds"], {"weight": 0.880388354127635}], ["ENPP3", ["TCGA.AA.3841.01", "Biological oxidations"], {"weight": 0.930465788032034}], ["ENPP3", ["TCGA.AA.3841.01", "Glucuronidation"], {"weight": 0.899982824155797}], ["ENPP3", ["TCGA.AA.3841.01", "Glycogen breakdown (glycogenolysis)"], {"weight": 0.818808227387945}], ["ENPP3", ["TCGA.AA.3844.01", "Biological oxidations"], {"weight": 0.898511859025761}], ["ENPP3", ["TCGA.AA.3844.01", "Phase II - Conjugation of compounds"], {"weight": 0.748854408694164}], ["ENPP3", ["TCGA.AA.3858.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.824477384686062}], ["ENPP3", ["TCGA.AA.3858.01", "Phase II - Conjugation of compounds"], {"weight": 0.853283381611403}], ["ENPP3", ["TCGA.AA.3860.01", "Biological oxidations"], {"weight": 0.931175018859944}], ["ENPP3", ["TCGA.AA.3860.01", "Phase II - Conjugation of compounds"], {"weight": 0.828860147257491}], ["ENPP3", ["TCGA.AA.3860.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.918712587247634}], ["ENPP3", ["TCGA.AA.3860.01", "Glucuronidation"], {"weight": 0.906254070550314}], ["ENPP3", ["TCGA.AA.3875.01", "Digestion"], {"weight": 0.334860456740736}], ["ENPP3", ["TCGA.AA.3875.01", "Digestion and absorption"], {"weight": 0.334860456740736}], ["ENPP3", ["TCGA.AA.3952.01", "Glucuronidation"], {"weight": 0.91741763888529}], ["ENPP3", ["TCGA.AA.A00J.01", "Phase II - Conjugation of compounds"], {"weight": 0.810461144007637}], ["ENPP3", ["TCGA.AA.A00J.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.840173127961312}], ["ENPP3", ["TCGA.AA.A02H.01", "Phase II - Conjugation of compounds"], {"weight": 0.852557559705426}], ["ENPP3", ["TCGA.AA.A02H.01", "Glucuronidation"], {"weight": 0.903299678131094}], ["ENPP3", ["TCGA.AA.A02H.01", "Biological oxidations"], {"weight": 0.91292394760529}], ["ENPP3", ["TCGA.AA.A02H.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.894561889011134}], ["ENPP3", ["TCGA.AD.6888.01", "Biological oxidations"], {"weight": 0.948233120571057}], ["ENPP3", ["TCGA.AD.6899.01", "Biological oxidations"], {"weight": 0.89085833416569}], ["ENPP3", ["TCGA.AD.6899.01", "Phase II - Conjugation of compounds"], {"weight": 0.765398218551864}], ["ENPP3", ["TCGA.AD.A5EK.01", "Biological oxidations"], {"weight": 0.94423711904302}], ["ENPP3", ["TCGA.AD.A5EK.01", "Phase II - Conjugation of compounds"], {"weight": 0.754641535529381}], ["ENPP3", ["TCGA.AM.5820.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.917255002460241}], ["ENPP3", ["TCGA.AZ.6598.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.831494163681307}], ["ENPP3", ["TCGA.AZ.6600.01", "Phase II - Conjugation of compounds"], {"weight": 0.694670730953458}], ["ENPP3", ["TCGA.AZ.6600.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.730089238596386}], ["ENPP3", ["TCGA.AZ.6607.01", "Collagen formation"], {"weight": 0.965725801422367}], ["ENPP3", ["TCGA.AZ.6607.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.953100054601617}], ["ENPP3", ["TCGA.AZ.6607.01", "Phase II - Conjugation of compounds"], {"weight": 0.890479247809074}], ["ENPP3", ["TCGA.AZ.6607.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.920762890706524}], ["ENPP3", ["TCGA.CA.5254.01", "Phase II - Conjugation of compounds"], {"weight": 0.849432102552848}], ["ENPP3", ["TCGA.CA.5254.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.833760806180385}], ["ENPP3", ["TCGA.CA.5256.01", "Selenoamino acid metabolism"], {"weight": 0.92449716964303}], ["ENPP3", ["TCGA.CA.5256.01", "Biological oxidations"], {"weight": 0.914482699392869}], ["ENPP3", ["TCGA.CA.5256.01", "Phase II - Conjugation of compounds"], {"weight": 0.8416633372657}], ["ENPP3", ["TCGA.CM.4747.01", "Biological oxidations"], {"weight": 0.8908016552671}], ["ENPP3", ["TCGA.CM.4747.01", "Phase II - Conjugation of compounds"], {"weight": 0.736423478663635}], ["ENPP3", ["TCGA.CM.4747.01", "Glucuronidation"], {"weight": 0.908150258987031}], ["ENPP3", ["TCGA.CM.5348.01", "Biological oxidations"], {"weight": 0.883632732431821}], ["ENPP3", ["TCGA.CM.5348.01", "Glucuronidation"], {"weight": 0.906542471519928}], ["ENPP3", ["TCGA.CM.5348.01", "Phase II - Conjugation of compounds"], {"weight": 0.818236703663994}], ["ENPP3", ["TCGA.CM.5348.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.733897404917158}], ["ENPP3", ["TCGA.CM.5863.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.66804728000256}], ["ENPP3", ["TCGA.CM.6161.01", "Glucuronidation"], {"weight": 0.928458096774475}], ["ENPP3", ["TCGA.CM.6167.01", "Biological oxidations"], {"weight": 0.931572933094857}], ["ENPP3", ["TCGA.CM.6167.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.896999551078081}], ["ENPP3", ["TCGA.CM.6167.01", "Phase II - Conjugation of compounds"], {"weight": 0.890158179994019}], ["ENPP3", ["TCGA.CM.6676.01", "Biological oxidations"], {"weight": 0.906898975534912}], ["ENPP3", ["TCGA.CM.6676.01", "Phase II - Conjugation of compounds"], {"weight": 0.814442152755889}], ["ENPP3", ["TCGA.CM.6676.01", "Glucuronidation"], {"weight": 0.936271864090286}], ["ENPP3", ["TCGA.CM.6676.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.832673625635253}], ["ENPP3", ["TCGA.CM.6678.01", "Glucuronidation"], {"weight": 0.881271441085778}], ["ENPP3", ["TCGA.D5.6529.01", "Biological oxidations"], {"weight": 0.890432323719245}], ["ENPP3", ["TCGA.D5.6529.01", "Phase II - Conjugation of compounds"], {"weight": 0.735962553943573}], ["ENPP3", ["TCGA.D5.6529.01", "Glucuronidation"], {"weight": 0.852050491615773}], ["ENPP3", ["TCGA.D5.6529.01", "Glycogen breakdown (glycogenolysis)"], {"weight": 0.816230762764928}], ["ENPP3", ["TCGA.D5.6531.01", "Phase II - Conjugation of compounds"], {"weight": 0.884012047964389}], ["ENPP3", ["TCGA.D5.6531.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.942912742689264}], ["ENPP3", ["TCGA.D5.6531.01", "Biological oxidations"], {"weight": 0.930315872778775}], ["ENPP3", ["TCGA.D5.6535.01", "Phase II - Conjugation of compounds"], {"weight": 0.778332420891075}], ["ENPP3", ["TCGA.D5.6535.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.772424809668669}], ["ENPP3", ["TCGA.D5.6537.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.928242869352624}], ["ENPP3", ["TCGA.D5.6898.01", "Phase II - Conjugation of compounds"], {"weight": 0.726698077445726}], ["ENPP3", ["TCGA.DM.A28F.01", "Glucuronidation"], {"weight": 0.929752852791811}], ["ENPP3", ["TCGA.DM.A28F.01", "Phase II - Conjugation of compounds"], {"weight": 0.786604030284623}], ["ENPP3", ["TCGA.F4.6460.01", "Biological oxidations"], {"weight": 0.919160488462245}], ["ENPP3", ["TCGA.F4.6460.01", "Phase II - Conjugation of compounds"], {"weight": 0.799842954460498}], ["ENPP3", ["TCGA.F4.6460.01", "Glucuronidation"], {"weight": 0.892526462989334}], ["ENPP3", ["TCGA.F4.6460.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.904922798384041}], ["ENPP3", ["TCGA.F4.6704.01", "Biological oxidations"], {"weight": 0.954495365280492}], ["ENPP3", ["TCGA.F4.6704.01", "Phase II - Conjugation of compounds"], {"weight": 0.919639945468494}], ["ENPP3", ["TCGA.F4.6704.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.934633091097485}], ["ENPP3", ["TCGA.G4.6297.01", "Phase II - Conjugation of compounds"], {"weight": 0.779079421903753}], ["ENPP3", ["TCGA.G4.6297.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.712369643392262}], ["ENPP3", ["TCGA.G4.6306.01", "Biological oxidations"], {"weight": 0.909736437840779}], ["ENPP3", ["TCGA.G4.6306.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.841663291762964}], ["ENPP3", ["TCGA.NH.A6GA.01", "Biological oxidations"], {"weight": 0.918821698138324}], ["ENPP3", ["TCGA.NH.A6GA.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.930799279468769}], ["ENPP3", ["TCGA.NH.A6GA.01", "Phase II - Conjugation of compounds"], {"weight": 0.866710443107383}], ["ENPP3", ["TCGA.QL.A97D.01", "Phase II - Conjugation of compounds"], {"weight": 0.7729820673899}], ["ENPP3", ["TCGA.QL.A97D.01", "Glucuronidation"], {"weight": 0.90151879026263}], ["ENPP3", ["TCGA.QL.A97D.01", "Cytosolic sulfonation of small molecules"], {"weight": 0.686888832364615}], ["OR2A4", ["TCGA.3L.AA1B.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.830385852705683}], ["OR2A4", ["TCGA.4T.AA8H.01", "Signaling by GPCR"], {"weight": 0.942209765119388}], ["OR2A4", ["TCGA.4T.AA8H.01", "GPCR downstream signalling"], {"weight": 0.949581673258851}], ["OR2A4", ["TCGA.4T.AA8H.01", "GPCR ligand binding"], {"weight": 0.933356832830844}], ["OR2A4", ["TCGA.4T.AA8H.01", "G alpha (i) signalling events"], {"weight": 0.940356115573228}], ["OR2A4", ["TCGA.4T.AA8H.01", "Potassium Channels"], {"weight": 0.961081596651366}], ["OR2A4", ["TCGA.4T.AA8H.01", "G-protein beta:gamma signalling"], {"weight": 0.932463953944917}], ["OR2A4", ["TCGA.4T.AA8H.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.923437527019585}], ["OR2A4", ["TCGA.4T.AA8H.01", "Glucagon-type ligand receptors"], {"weight": 0.941064919842352}], ["OR2A4", ["TCGA.4T.AA8H.01", "Inwardly rectifying K+ channels"], {"weight": 0.941366899353567}], ["OR2A4", ["TCGA.4T.AA8H.01", "Activation of SMO"], {"weight": 0.926712577216453}], ["OR2A4", ["TCGA.4T.AA8H.01", "G beta:gamma signalling through BTK"], {"weight": 0.915364003282609}], ["OR2A4", ["TCGA.4T.AA8H.01", "GABA receptor activation"], {"weight": 0.925901593725684}], ["OR2A4", ["TCGA.4T.AA8H.01", "G beta:gamma signalling through CDC42"], {"weight": 0.912920169365649}], ["OR2A4", ["TCGA.4T.AA8H.01", "GABA B receptor activation"], {"weight": 0.937192728308796}], ["OR2A4", ["TCGA.4T.AA8H.01", "Activation of GABAB receptors"], {"weight": 0.937192728308796}], ["OR2A4", ["TCGA.4T.AA8H.01", "Activation of G protein gated Potassium channels"], {"weight": 0.930910028546556}], ["OR2A4", ["TCGA.4T.AA8H.01", "G protein gated Potassium channels"], {"weight": 0.930910028546556}], ["OR2A4", ["TCGA.4T.AA8H.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.930910028546556}], ["OR2A4", ["TCGA.4T.AA8H.01", "Ion homeostasis"], {"weight": 0.888275233958859}], ["OR2A4", ["TCGA.4T.AA8H.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.927002725418427}], ["OR2A4", ["TCGA.4T.AA8H.01", "G alpha (z) signalling events"], {"weight": 0.902478337146068}], ["OR2A4", ["TCGA.4T.AA8H.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.861931258931907}], ["OR2A4", ["TCGA.4T.AA8H.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.926957854076544}], ["OR2A4", ["TCGA.4T.AA8H.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.909902362723144}], ["OR2A4", ["TCGA.4T.AA8H.01", "Thromboxane signalling through TP receptor"], {"weight": 0.909902362723144}], ["OR2A4", ["TCGA.4T.AA8H.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.903898540301026}], ["OR2A4", ["TCGA.4T.AA8H.01", "Aquaporin-mediated transport"], {"weight": 0.861931258931907}], ["OR2A4", ["TCGA.4T.AA8H.01", "Presynaptic function of Kainate receptors"], {"weight": 0.903898540301026}], ["OR2A4", ["TCGA.4T.AA8H.01", "Signal amplification"], {"weight": 0.920149201752144}], ["OR2A4", ["TCGA.4T.AA8H.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.874025057382264}], ["OR2A4", ["TCGA.4T.AA8H.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.909460649085542}], ["OR2A4", ["TCGA.4T.AA8H.01", "G alpha (q) signalling events"], {"weight": 0.943291696440169}], ["OR2A4", ["TCGA.4T.AA8H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.919193193218434}], ["OR2A4", ["TCGA.5M.AATA.01", "GPCR ligand binding"], {"weight": 0.916244011940606}], ["OR2A4", ["TCGA.A6.2678.01", "Phase 0 - rapid depolarisation"], {"weight": 0.872890183848036}], ["OR2A4", ["TCGA.A6.2678.01", "Potassium Channels"], {"weight": 0.949303292981482}], ["OR2A4", ["TCGA.A6.2678.01", "GPCR downstream signalling"], {"weight": 0.936875824029745}], ["OR2A4", ["TCGA.A6.2678.01", "G alpha (i) signalling events"], {"weight": 0.928284102575119}], ["OR2A4", ["TCGA.A6.6652.01", "Leishmania infection"], {"weight": 0.882210342599131}], ["OR2A4", ["TCGA.A6.6652.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.930016356843828}], ["OR2A4", ["TCGA.A6.6652.01", "Signal amplification"], {"weight": 0.937825601824343}], ["OR2A4", ["TCGA.A6.6652.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.941127701559587}], ["OR2A4", ["TCGA.A6.6652.01", "G-protein beta:gamma signalling"], {"weight": 0.94489615238128}], ["OR2A4", ["TCGA.A6.6652.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.902000085250787}], ["OR2A4", ["TCGA.A6.6652.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.93400200237682}], ["OR2A4", ["TCGA.A6.6652.01", "Glucagon-type ligand receptors"], {"weight": 0.941964339742672}], ["OR2A4", ["TCGA.A6.6652.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.934367249021106}], ["OR2A4", ["TCGA.A6.6652.01", "G beta:gamma signalling through BTK"], {"weight": 0.932541202845337}], ["OR2A4", ["TCGA.A6.6652.01", "Activation of the phototransduction cascade"], {"weight": 0.919463695954636}], ["OR2A4", ["TCGA.A6.6652.01", "G-protein activation"], {"weight": 0.929019324935167}], ["OR2A4", ["TCGA.A6.6652.01", "Thromboxane signalling through TP receptor"], {"weight": 0.915014897952719}], ["OR2A4", ["TCGA.A6.6652.01", "G beta:gamma signalling through CDC42"], {"weight": 0.928626215228838}], ["OR2A4", ["TCGA.A6.6652.01", "Ion homeostasis"], {"weight": 0.881848276546212}], ["OR2A4", ["TCGA.A6.6652.01", "Sensory perception of taste"], {"weight": 0.883807464231364}], ["OR2A4", ["TCGA.A6.6652.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], {"weight": 0.877349157287297}], ["OR2A4", ["TCGA.AA.3521.01", "Signal amplification"], {"weight": 0.876597327880676}], ["OR2A4", ["TCGA.AA.3521.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.916994742092136}], ["OR2A4", ["TCGA.AA.3521.01", "Neuronal System"], {"weight": 0.898946160857573}], ["OR2A4", ["TCGA.AA.3521.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.855572535005449}], ["OR2A4", ["TCGA.AA.3521.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.901915317909889}], ["OR2A4", ["TCGA.AA.3521.01", "G beta:gamma signalling through BTK"], {"weight": 0.878802992859251}], ["OR2A4", ["TCGA.AA.3521.01", "Glucagon-type ligand receptors"], {"weight": 0.891134791826788}], ["OR2A4", ["TCGA.AA.3521.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.878802992859251}], ["OR2A4", ["TCGA.AA.3521.01", "GABA B receptor activation"], {"weight": 0.90218111896801}], ["OR2A4", ["TCGA.AA.3521.01", "Activation of GABAB receptors"], {"weight": 0.90218111896801}], ["OR2A4", ["TCGA.AA.3521.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.878802992859251}], ["OR2A4", ["TCGA.AA.3521.01", "G beta:gamma signalling through CDC42"], {"weight": 0.878802992859251}], ["OR2A4", ["TCGA.AA.3560.01", "Signal amplification"], {"weight": 0.895892464508905}], ["OR2A4", ["TCGA.AA.3560.01", "SUMOylation of intracellular receptors"], {"weight": 0.623977122156433}], ["OR2A4", ["TCGA.AA.3655.01", "GPCR ligand binding"], {"weight": 0.904254679518346}], ["OR2A4", ["TCGA.AA.3655.01", "Potassium Channels"], {"weight": 0.950014388231084}], ["OR2A4", ["TCGA.AA.3655.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.867263466153659}], ["OR2A4", ["TCGA.AA.3655.01", "Phase 0 - rapid depolarisation"], {"weight": 0.868262301400194}], ["OR2A4", ["TCGA.AA.3660.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.89529029338308}], ["OR2A4", ["TCGA.AA.3660.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.872496020022485}], ["OR2A4", ["TCGA.AA.3660.01", "G alpha (z) signalling events"], {"weight": 0.887844947626328}], ["OR2A4", ["TCGA.AA.3660.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.868857259730032}], ["OR2A4", ["TCGA.AA.3660.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.868371307745126}], ["OR2A4", ["TCGA.AA.3660.01", "Glucagon-type ligand receptors"], {"weight": 0.88838569833268}], ["OR2A4", ["TCGA.AA.3660.01", "GPER1 signaling"], {"weight": 0.875193417295781}], ["OR2A4", ["TCGA.AA.3660.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.875193417295781}], ["OR2A4", ["TCGA.AA.3660.01", "G beta:gamma signalling through BTK"], {"weight": 0.836148545540552}], ["OR2A4", ["TCGA.AA.3685.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.924318477062022}], ["OR2A4", ["TCGA.AA.3685.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.895575761854864}], ["OR2A4", ["TCGA.AA.3696.01", "GPCR ligand binding"], {"weight": 0.928059756858924}], ["OR2A4", ["TCGA.AA.3837.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.804290479641494}], ["OR2A4", ["TCGA.AA.3837.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.878776212029775}], ["OR2A4", ["TCGA.AA.3837.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.751874154893067}], ["OR2A4", ["TCGA.AA.3837.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.706672915877616}], ["OR2A4", ["TCGA.AA.3837.01", "Glucagon-type ligand receptors"], {"weight": 0.842455712767604}], ["OR2A4", ["TCGA.AA.3837.01", "Inwardly rectifying K+ channels"], {"weight": 0.688024695218704}], ["OR2A4", ["TCGA.AA.3837.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.628028415260403}], ["OR2A4", ["TCGA.AA.3837.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.813373310943231}], ["OR2A4", ["TCGA.AA.3841.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.902539975504512}], ["OR2A4", ["TCGA.AA.3841.01", "Signal amplification"], {"weight": 0.912738965106763}], ["OR2A4", ["TCGA.AA.3841.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.914638004774662}], ["OR2A4", ["TCGA.AA.3841.01", "G beta:gamma signalling through CDC42"], {"weight": 0.906985617536325}], ["OR2A4", ["TCGA.AA.3841.01", "G beta:gamma signalling through BTK"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.917060196480084}], ["OR2A4", ["TCGA.AA.3841.01", "G-protein activation"], {"weight": 0.912024768414011}], ["OR2A4", ["TCGA.AA.3841.01", "Thromboxane signalling through TP receptor"], {"weight": 0.891347854592564}], ["OR2A4", ["TCGA.AA.3841.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Presynaptic function of Kainate receptors"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Glucagon-type ligand receptors"], {"weight": 0.91387487726242}], ["OR2A4", ["TCGA.AA.3841.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Inwardly rectifying K+ channels"], {"weight": 0.866831234680652}], ["OR2A4", ["TCGA.AA.3841.01", "G-protein beta:gamma signalling"], {"weight": 0.906985617536325}], ["OR2A4", ["TCGA.AA.3841.01", "G alpha (z) signalling events"], {"weight": 0.91851916203946}], ["OR2A4", ["TCGA.AA.3841.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.891347854592564}], ["OR2A4", ["TCGA.AA.3841.01", "GABA B receptor activation"], {"weight": 0.917488101652656}], ["OR2A4", ["TCGA.AA.3841.01", "Activation of GABAB receptors"], {"weight": 0.917488101652656}], ["OR2A4", ["TCGA.AA.3841.01", "Activation of G protein gated Potassium channels"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "G protein gated Potassium channels"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.900439712341869}], ["OR2A4", ["TCGA.AA.3841.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], {"weight": 0.891347854592564}], ["OR2A4", ["TCGA.AA.3858.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.925531654148382}], ["OR2A4", ["TCGA.AA.3858.01", "GABA receptor activation"], {"weight": 0.897930739663085}], ["OR2A4", ["TCGA.AA.3858.01", "Signal amplification"], {"weight": 0.88243315252554}], ["OR2A4", ["TCGA.AA.3858.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.917277005212625}], ["OR2A4", ["TCGA.AA.3858.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.857928579993548}], ["OR2A4", ["TCGA.AA.3858.01", "GABA B receptor activation"], {"weight": 0.918492804247692}], ["OR2A4", ["TCGA.AA.3858.01", "Activation of GABAB receptors"], {"weight": 0.918492804247692}], ["OR2A4", ["TCGA.AA.3858.01", "Glucagon-type ligand receptors"], {"weight": 0.909482952265068}], ["OR2A4", ["TCGA.AA.3860.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.91829854497419}], ["OR2A4", ["TCGA.AA.3860.01", "Glucagon-type ligand receptors"], {"weight": 0.919647523725818}], ["OR2A4", ["TCGA.AA.3860.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.86013419835598}], ["OR2A4", ["TCGA.AA.3860.01", "Signal amplification"], {"weight": 0.872226415077309}], ["OR2A4", ["TCGA.AA.3860.01", "GPCR ligand binding"], {"weight": 0.918228784519165}], ["OR2A4", ["TCGA.AA.3860.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.911552352237057}], ["OR2A4", ["TCGA.AA.3860.01", "G beta:gamma signalling through BTK"], {"weight": 0.885438167848125}], ["OR2A4", ["TCGA.AA.3860.01", "GABA receptor activation"], {"weight": 0.842683115287675}], ["OR2A4", ["TCGA.AA.3860.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.885438167848125}], ["OR2A4", ["TCGA.AA.3860.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.885438167848125}], ["OR2A4", ["TCGA.AA.3860.01", "G beta:gamma signalling through CDC42"], {"weight": 0.885438167848125}], ["OR2A4", ["TCGA.AA.3860.01", "GABA B receptor activation"], {"weight": 0.914618063152605}], ["OR2A4", ["TCGA.AA.3860.01", "Activation of GABAB receptors"], {"weight": 0.914618063152605}], ["OR2A4", ["TCGA.AA.3860.01", "Inwardly rectifying K+ channels"], {"weight": 0.912889529073219}], ["OR2A4", ["TCGA.AA.3860.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.916019721536252}], ["OR2A4", ["TCGA.AA.3875.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.806465846638213}], ["OR2A4", ["TCGA.AA.3875.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.862223189628517}], ["OR2A4", ["TCGA.AA.3875.01", "Phase 0 - rapid depolarisation"], {"weight": 0.708765818995576}], ["OR2A4", ["TCGA.AA.3875.01", "Signal amplification"], {"weight": 0.806465846638213}], ["OR2A4", ["TCGA.AA.3875.01", "Glucagon-type ligand receptors"], {"weight": 0.851415900307061}], ["OR2A4", ["TCGA.AA.3875.01", "G-protein activation"], {"weight": 0.801907566302085}], ["OR2A4", ["TCGA.AA.3875.01", "Thromboxane signalling through TP receptor"], {"weight": 0.775968681858317}], ["OR2A4", ["TCGA.AA.3875.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.741224614544639}], ["OR2A4", ["TCGA.AA.3875.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.837218591135758}], ["OR2A4", ["TCGA.AA.3875.01", "Activation of G protein gated Potassium channels"], {"weight": 0.795878672334205}], ["OR2A4", ["TCGA.AA.3875.01", "G protein gated Potassium channels"], {"weight": 0.795878672334205}], ["OR2A4", ["TCGA.AA.3875.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.795878672334205}], ["OR2A4", ["TCGA.AA.3875.01", "GABA B receptor activation"], {"weight": 0.842370073366932}], ["OR2A4", ["TCGA.AA.3875.01", "Activation of GABAB receptors"], {"weight": 0.842370073366932}], ["OR2A4", ["TCGA.AA.3875.01", "G beta:gamma signalling through BTK"], {"weight": 0.728140996866047}], ["OR2A4", ["TCGA.AA.3939.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.901727708805672}], ["OR2A4", ["TCGA.AA.3939.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.890607123560395}], ["OR2A4", ["TCGA.AA.3939.01", "GPCR ligand binding"], {"weight": 0.886305768392165}], ["OR2A4", ["TCGA.AA.3941.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.92342204761499}], ["OR2A4", ["TCGA.AA.3952.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.904261891766239}], ["OR2A4", ["TCGA.AA.3952.01", "GPCR ligand binding"], {"weight": 0.914350571911875}], ["OR2A4", ["TCGA.AA.3952.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.891573658397081}], ["OR2A4", ["TCGA.AA.3952.01", "Glucagon-type ligand receptors"], {"weight": 0.899458210206636}], ["OR2A4", ["TCGA.AA.3952.01", "G alpha (z) signalling events"], {"weight": 0.849708570547546}], ["OR2A4", ["TCGA.AA.A00J.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.930639227664724}], ["OR2A4", ["TCGA.AA.A01X.01", "GPCR downstream signalling"], {"weight": 0.952054363066288}], ["OR2A4", ["TCGA.AA.A01X.01", "Signaling by GPCR"], {"weight": 0.951555547844486}], ["OR2A4", ["TCGA.AA.A01X.01", "G alpha (s) signalling events"], {"weight": 0.951911484133642}], ["OR2A4", ["TCGA.AA.A01X.01", "G alpha (i) signalling events"], {"weight": 0.949172242757461}], ["OR2A4", ["TCGA.AA.A02H.01", "GPCR ligand binding"], {"weight": 0.923633751155037}], ["OR2A4", ["TCGA.AA.A02H.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.887304593291218}], ["OR2A4", ["TCGA.AA.A02H.01", "Signal amplification"], {"weight": 0.895492670591244}], ["OR2A4", ["TCGA.AA.A02H.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.892567146338941}], ["OR2A4", ["TCGA.AA.A02H.01", "Glucagon-type ligand receptors"], {"weight": 0.898728356116334}], ["OR2A4", ["TCGA.AA.A02H.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.892487363724309}], ["OR2A4", ["TCGA.AA.A02H.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.900452641819672}], ["OR2A4", ["TCGA.AA.A02H.01", "G-protein beta:gamma signalling"], {"weight": 0.892567146338941}], ["OR2A4", ["TCGA.AA.A02H.01", "G-protein activation"], {"weight": 0.889376488054829}], ["OR2A4", ["TCGA.AA.A02H.01", "Thromboxane signalling through TP receptor"], {"weight": 0.863759975891158}], ["OR2A4", ["TCGA.AA.A02H.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.893923704749658}], ["OR2A4", ["TCGA.AA.A02H.01", "G beta:gamma signalling through BTK"], {"weight": 0.855367267700073}], ["OR2A4", ["TCGA.AA.A02H.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.855367267700073}], ["OR2A4", ["TCGA.AA.A02H.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.855367267700073}], ["OR2A4", ["TCGA.AA.A02H.01", "G beta:gamma signalling through CDC42"], {"weight": 0.855367267700073}], ["OR2A4", ["TCGA.AA.A02H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.897370688732651}], ["OR2A4", ["TCGA.AA.A02H.01", "Platelet activation, signaling and aggregation"], {"weight": 0.862369515011214}], ["OR2A4", ["TCGA.AA.A02H.01", "Sensory perception of taste"], {"weight": 0.821762187320128}], ["OR2A4", ["TCGA.AA.A02H.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.863759975891158}], ["OR2A4", ["TCGA.AA.A02H.01", "GABA B receptor activation"], {"weight": 0.887473211286621}], ["OR2A4", ["TCGA.AA.A02H.01", "Activation of GABAB receptors"], {"weight": 0.887473211286621}], ["OR2A4", ["TCGA.AA.A02H.01", "G alpha (q) signalling events"], {"weight": 0.892154065309607}], ["OR2A4", ["TCGA.AA.A02H.01", "Sensory perception of sweet, bitter, and umami (glutamate) taste"], {"weight": 0.806361684943557}], ["OR2A4", ["TCGA.AA.A02Y.01", "GPCR ligand binding"], {"weight": 0.950789293699153}], ["OR2A4", ["TCGA.AA.A02Y.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.9487633409853}], ["OR2A4", ["TCGA.AA.A02Y.01", "Potassium Channels"], {"weight": 0.967196962389936}], ["OR2A4", ["TCGA.AA.A02Y.01", "G-protein beta:gamma signalling"], {"weight": 0.944143561437786}], ["OR2A4", ["TCGA.AA.A02Y.01", "G alpha (z) signalling events"], {"weight": 0.921371133494564}], ["OR2A4", ["TCGA.AA.A02Y.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.938418198428467}], ["OR2A4", ["TCGA.AA.A02Y.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.939669422197706}], ["OR2A4", ["TCGA.AA.A02Y.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.94669380575322}], ["OR2A4", ["TCGA.AA.A02Y.01", "Glucagon-type ligand receptors"], {"weight": 0.953898770680035}], ["OR2A4", ["TCGA.AA.A02Y.01", "G beta:gamma signalling through BTK"], {"weight": 0.935063600518433}], ["OR2A4", ["TCGA.AA.A02Y.01", "GABA receptor activation"], {"weight": 0.930993787428775}], ["OR2A4", ["TCGA.AA.A02Y.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.930297361292814}], ["OR2A4", ["TCGA.AA.A02Y.01", "G beta:gamma signalling through CDC42"], {"weight": 0.932924253732726}], ["OR2A4", ["TCGA.AA.A02Y.01", "GABA B receptor activation"], {"weight": 0.943137896356788}], ["OR2A4", ["TCGA.AA.A02Y.01", "Activation of GABAB receptors"], {"weight": 0.943137896356788}], ["OR2A4", ["TCGA.AA.A02Y.01", "WNT ligand biogenesis and trafficking"], {"weight": 0.887214311131574}], ["OR2A4", ["TCGA.AA.A02Y.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.932451292170805}], ["OR2A4", ["TCGA.AA.A02Y.01", "Inwardly rectifying K+ channels"], {"weight": 0.942181520995266}], ["OR2A4", ["TCGA.AA.A02Y.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.932060646539749}], ["OR2A4", ["TCGA.AA.A02Y.01", "Thromboxane signalling through TP receptor"], {"weight": 0.930326164074649}], ["OR2A4", ["TCGA.AA.A02Y.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.928683866896705}], ["OR2A4", ["TCGA.AA.A02Y.01", "Activation of G protein gated Potassium channels"], {"weight": 0.933625327076754}], ["OR2A4", ["TCGA.AA.A02Y.01", "G protein gated Potassium channels"], {"weight": 0.933625327076754}], ["OR2A4", ["TCGA.AA.A02Y.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.933625327076754}], ["OR2A4", ["TCGA.AA.A02Y.01", "G alpha (12/13) signalling events"], {"weight": 0.835807752611933}], ["OR2A4", ["TCGA.AD.6888.01", "Potassium Channels"], {"weight": 0.966489870962555}], ["OR2A4", ["TCGA.AD.6888.01", "G alpha (q) signalling events"], {"weight": 0.943719986551544}], ["OR2A4", ["TCGA.AD.6888.01", "G-protein beta:gamma signalling"], {"weight": 0.948743080169614}], ["OR2A4", ["TCGA.AD.6888.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.941567426950591}], ["OR2A4", ["TCGA.AD.6888.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.94200274615477}], ["OR2A4", ["TCGA.AD.6888.01", "G beta:gamma signalling through BTK"], {"weight": 0.93390700905531}], ["OR2A4", ["TCGA.AD.6888.01", "Glucagon-type ligand receptors"], {"weight": 0.950088218889976}], ["OR2A4", ["TCGA.AD.6888.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.924488813051217}], ["OR2A4", ["TCGA.AD.6888.01", "GABA receptor activation"], {"weight": 0.928893629641252}], ["OR2A4", ["TCGA.AD.6888.01", "G beta:gamma signalling through CDC42"], {"weight": 0.931606100600814}], ["OR2A4", ["TCGA.AD.6888.01", "Signal amplification"], {"weight": 0.917080604403092}], ["OR2A4", ["TCGA.AD.6888.01", "G-protein activation"], {"weight": 0.935819641195163}], ["OR2A4", ["TCGA.AD.6888.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.910028011481969}], ["OR2A4", ["TCGA.AD.6888.01", "Thromboxane signalling through TP receptor"], {"weight": 0.905949149380859}], ["OR2A4", ["TCGA.AD.6888.01", "Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding"], {"weight": 0.920438938588931}], ["OR2A4", ["TCGA.AD.6888.01", "GABA B receptor activation"], {"weight": 0.940824989797542}], ["OR2A4", ["TCGA.AD.6888.01", "Activation of GABAB receptors"], {"weight": 0.940824989797542}], ["OR2A4", ["TCGA.AD.6888.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.930385170021429}], ["OR2A4", ["TCGA.AD.6888.01", "Inwardly rectifying K+ channels"], {"weight": 0.938127196962636}], ["OR2A4", ["TCGA.AD.6888.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.93557206352713}], ["OR2A4", ["TCGA.AD.6888.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.923976256321414}], ["OR2A4", ["TCGA.AD.A5EK.01", "Potassium Channels"], {"weight": 0.962985875030245}], ["OR2A4", ["TCGA.AD.A5EK.01", "GPCR ligand binding"], {"weight": 0.935959804267071}], ["OR2A4", ["TCGA.AD.A5EK.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.933504501957121}], ["OR2A4", ["TCGA.AD.A5EK.01", "Inwardly rectifying K+ channels"], {"weight": 0.936741046955657}], ["OR2A4", ["TCGA.AD.A5EK.01", "Glucagon-type ligand receptors"], {"weight": 0.93324413686737}], ["OR2A4", ["TCGA.AD.A5EK.01", "Platelet homeostasis"], {"weight": 0.904943386762703}], ["OR2A4", ["TCGA.AD.A5EK.01", "Activation of G protein gated Potassium channels"], {"weight": 0.927235902354466}], ["OR2A4", ["TCGA.AD.A5EK.01", "G protein gated Potassium channels"], {"weight": 0.927235902354466}], ["OR2A4", ["TCGA.AD.A5EK.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.927235902354466}], ["OR2A4", ["TCGA.AD.A5EK.01", "GABA receptor activation"], {"weight": 0.894521399209458}], ["OR2A4", ["TCGA.AD.A5EK.01", "G-protein beta:gamma signalling"], {"weight": 0.929969915003734}], ["OR2A4", ["TCGA.AD.A5EK.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.909691701730222}], ["OR2A4", ["TCGA.AD.A5EK.01", "GABA B receptor activation"], {"weight": 0.930461887406808}], ["OR2A4", ["TCGA.AD.A5EK.01", "Activation of GABAB receptors"], {"weight": 0.930461887406808}], ["OR2A4", ["TCGA.AD.A5EK.01", "G beta:gamma signalling through BTK"], {"weight": 0.916991608173672}], ["OR2A4", ["TCGA.AM.5820.01", "Inwardly rectifying K+ channels"], {"weight": 0.923867816288474}], ["OR2A4", ["TCGA.AM.5820.01", "Activation of G protein gated Potassium channels"], {"weight": 0.916843538324149}], ["OR2A4", ["TCGA.AM.5820.01", "G protein gated Potassium channels"], {"weight": 0.916843538324149}], ["OR2A4", ["TCGA.AM.5820.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.916843538324149}], ["OR2A4", ["TCGA.AM.5820.01", "Potassium Channels"], {"weight": 0.948478727477744}], ["OR2A4", ["TCGA.AY.A8YK.01", "G alpha (i) signalling events"], {"weight": 0.93565492757289}], ["OR2A4", ["TCGA.AY.A8YK.01", "Potassium Channels"], {"weight": 0.926549365455601}], ["OR2A4", ["TCGA.AY.A8YK.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.908968512772806}], ["OR2A4", ["TCGA.AY.A8YK.01", "GPCR ligand binding"], {"weight": 0.873794535598698}], ["OR2A4", ["TCGA.AY.A8YK.01", "Signal amplification"], {"weight": 0.873864793347494}], ["OR2A4", ["TCGA.AY.A8YK.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.903358876706755}], ["OR2A4", ["TCGA.AY.A8YK.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.90647523046765}], ["OR2A4", ["TCGA.AY.A8YK.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.826312393744473}], ["OR2A4", ["TCGA.AY.A8YK.01", "Leishmania parasite growth and survival"], {"weight": 0.826312393744473}], ["OR2A4", ["TCGA.AY.A8YK.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.842280890964924}], ["OR2A4", ["TCGA.AY.A8YK.01", "G beta:gamma signalling through BTK"], {"weight": 0.891393715312865}], ["OR2A4", ["TCGA.AY.A8YK.01", "G-protein beta:gamma signalling"], {"weight": 0.907245513721562}], ["OR2A4", ["TCGA.AY.A8YK.01", "G alpha (q) signalling events"], {"weight": 0.882532509217663}], ["OR2A4", ["TCGA.AY.A8YK.01", "G alpha (z) signalling events"], {"weight": 0.903664419032355}], ["OR2A4", ["TCGA.AY.A8YK.01", "G beta:gamma signalling through CDC42"], {"weight": 0.886174358607425}], ["OR2A4", ["TCGA.AZ.6598.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.925772773348285}], ["OR2A4", ["TCGA.AZ.6598.01", "G alpha (q) signalling events"], {"weight": 0.945549824248992}], ["OR2A4", ["TCGA.AZ.6598.01", "GABA receptor activation"], {"weight": 0.928296759251188}], ["OR2A4", ["TCGA.AZ.6598.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.940709528434222}], ["OR2A4", ["TCGA.AZ.6598.01", "Glucagon-type ligand receptors"], {"weight": 0.945468153606467}], ["OR2A4", ["TCGA.AZ.6600.01", "GPCR ligand binding"], {"weight": 0.849479834222537}], ["OR2A4", ["TCGA.AZ.6600.01", "Inwardly rectifying K+ channels"], {"weight": 0.794026064977048}], ["OR2A4", ["TCGA.AZ.6600.01", "Sensory perception of taste"], {"weight": 0.810847976190956}], ["OR2A4", ["TCGA.AZ.6600.01", "Signal amplification"], {"weight": 0.877785413626641}], ["OR2A4", ["TCGA.AZ.6600.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.854281595204543}], ["OR2A4", ["TCGA.AZ.6606.01", "G alpha (i) signalling events"], {"weight": 0.951452780854589}], ["OR2A4", ["TCGA.AZ.6606.01", "GPCR ligand binding"], {"weight": 0.926625691241525}], ["OR2A4", ["TCGA.AZ.6606.01", "G alpha (s) signalling events"], {"weight": 0.960463092382072}], ["OR2A4", ["TCGA.AZ.6606.01", "Glucagon-type ligand receptors"], {"weight": 0.9407083043576}], ["OR2A4", ["TCGA.AZ.6606.01", "Potassium Channels"], {"weight": 0.95804767284349}], ["OR2A4", ["TCGA.AZ.6606.01", "G-protein beta:gamma signalling"], {"weight": 0.9223744643055}], ["OR2A4", ["TCGA.AZ.6606.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.892771814735638}], ["OR2A4", ["TCGA.AZ.6607.01", "Inwardly rectifying K+ channels"], {"weight": 0.881044266599183}], ["OR2A4", ["TCGA.AZ.6607.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.928183711708285}], ["OR2A4", ["TCGA.AZ.6607.01", "Neuronal System"], {"weight": 0.907122286727896}], ["OR2A4", ["TCGA.AZ.6607.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.912081867223532}], ["OR2A4", ["TCGA.AZ.6607.01", "Activation of G protein gated Potassium channels"], {"weight": 0.916278098837212}], ["OR2A4", ["TCGA.AZ.6607.01", "G protein gated Potassium channels"], {"weight": 0.916278098837212}], ["OR2A4", ["TCGA.AZ.6607.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.916278098837212}], ["OR2A4", ["TCGA.CA.5254.01", "GPCR ligand binding"], {"weight": 0.929103012726489}], ["OR2A4", ["TCGA.CA.5254.01", "Glucagon-type ligand receptors"], {"weight": 0.941404264522129}], ["OR2A4", ["TCGA.CA.5254.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.920365153841434}], ["OR2A4", ["TCGA.CA.5254.01", "G alpha (q) signalling events"], {"weight": 0.954555547094379}], ["OR2A4", ["TCGA.CA.5254.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.931941389144019}], ["OR2A4", ["TCGA.CA.5254.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.926480050171945}], ["OR2A4", ["TCGA.CA.5254.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.924948501399196}], ["OR2A4", ["TCGA.CA.5254.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.905934309609968}], ["OR2A4", ["TCGA.CA.5255.01", "GPCR ligand binding"], {"weight": 0.934090207829695}], ["OR2A4", ["TCGA.CA.5255.01", "G-protein beta:gamma signalling"], {"weight": 0.934088130204954}], ["OR2A4", ["TCGA.CA.5255.01", "G alpha (q) signalling events"], {"weight": 0.947862086259651}], ["OR2A4", ["TCGA.CA.5255.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.924841003210898}], ["OR2A4", ["TCGA.CA.5255.01", "G beta:gamma signalling through BTK"], {"weight": 0.915546151327555}], ["OR2A4", ["TCGA.CA.5255.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.927873873431207}], ["OR2A4", ["TCGA.CA.5255.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.898427130912778}], ["OR2A4", ["TCGA.CA.5255.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.912611406342457}], ["OR2A4", ["TCGA.CA.5255.01", "G beta:gamma signalling through CDC42"], {"weight": 0.91287790298154}], ["OR2A4", ["TCGA.CA.5255.01", "Platelet activation, signaling and aggregation"], {"weight": 0.918282678532485}], ["OR2A4", ["TCGA.CA.5255.01", "Potassium Channels"], {"weight": 0.95401789515347}], ["OR2A4", ["TCGA.CA.5255.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.91371116446633}], ["OR2A4", ["TCGA.CA.5255.01", "Signal amplification"], {"weight": 0.91960616024185}], ["OR2A4", ["TCGA.CA.5255.01", "Glucagon-type ligand receptors"], {"weight": 0.934246582992847}], ["OR2A4", ["TCGA.CA.5255.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.903383615799421}], ["OR2A4", ["TCGA.CA.5255.01", "Activation of G protein gated Potassium channels"], {"weight": 0.926850020992103}], ["OR2A4", ["TCGA.CA.5255.01", "G protein gated Potassium channels"], {"weight": 0.926850020992103}], ["OR2A4", ["TCGA.CA.5255.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.926850020992103}], ["OR2A4", ["TCGA.CA.5255.01", "Thromboxane signalling through TP receptor"], {"weight": 0.911731130568102}], ["OR2A4", ["TCGA.CA.5255.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.903383615799421}], ["OR2A4", ["TCGA.CA.5255.01", "G alpha (z) signalling events"], {"weight": 0.934347708018794}], ["OR2A4", ["TCGA.CA.5255.01", "GABA B receptor activation"], {"weight": 0.934402359865188}], ["OR2A4", ["TCGA.CA.5255.01", "Activation of GABAB receptors"], {"weight": 0.934402359865188}], ["OR2A4", ["TCGA.CA.5256.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.933251220334646}], ["OR2A4", ["TCGA.CA.5256.01", "G-protein beta:gamma signalling"], {"weight": 0.929481644823925}], ["OR2A4", ["TCGA.CA.5256.01", "G alpha (z) signalling events"], {"weight": 0.898453072825805}], ["OR2A4", ["TCGA.CA.5256.01", "GABA B receptor activation"], {"weight": 0.929259887705711}], ["OR2A4", ["TCGA.CA.5256.01", "Activation of GABAB receptors"], {"weight": 0.929259887705711}], ["OR2A4", ["TCGA.CA.5256.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.920735446033124}], ["OR2A4", ["TCGA.CA.5256.01", "Adenylate cyclase inhibitory pathway"], {"weight": 0.881410532400088}], ["OR2A4", ["TCGA.CK.4952.01", "G alpha (i) signalling events"], {"weight": 0.959472596500179}], ["OR2A4", ["TCGA.CK.5915.01", "Potassium Channels"], {"weight": 0.967009966907049}], ["OR2A4", ["TCGA.CK.5915.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.935321273301452}], ["OR2A4", ["TCGA.CK.5915.01", "Glucagon-type ligand receptors"], {"weight": 0.95238522192248}], ["OR2A4", ["TCGA.CK.5915.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.92339411236593}], ["OR2A4", ["TCGA.CK.5915.01", "Leishmania parasite growth and survival"], {"weight": 0.92339411236593}], ["OR2A4", ["TCGA.CK.5915.01", "GABA B receptor activation"], {"weight": 0.943008652209272}], ["OR2A4", ["TCGA.CK.5915.01", "Activation of GABAB receptors"], {"weight": 0.943008652209272}], ["OR2A4", ["TCGA.CK.5915.01", "G alpha (s) signalling events"], {"weight": 0.96418815077717}], ["OR2A4", ["TCGA.CK.5915.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.938712788774383}], ["OR2A4", ["TCGA.CK.5915.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.930835521765319}], ["OR2A4", ["TCGA.CK.5915.01", "Activation of G protein gated Potassium channels"], {"weight": 0.941973701411573}], ["OR2A4", ["TCGA.CK.5915.01", "G protein gated Potassium channels"], {"weight": 0.941973701411573}], ["OR2A4", ["TCGA.CK.5915.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.941973701411573}], ["OR2A4", ["TCGA.CK.5915.01", "G alpha (z) signalling events"], {"weight": 0.949579531089229}], ["OR2A4", ["TCGA.CK.5915.01", "Inwardly rectifying K+ channels"], {"weight": 0.944142146596201}], ["OR2A4", ["TCGA.CK.5915.01", "G-protein beta:gamma signalling"], {"weight": 0.942819922885088}], ["OR2A4", ["TCGA.CK.5915.01", "Ion homeostasis"], {"weight": 0.928025854292838}], ["OR2A4", ["TCGA.CK.5915.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.936333474155095}], ["OR2A4", ["TCGA.CK.5915.01", "G beta:gamma signalling through BTK"], {"weight": 0.927954046655674}], ["OR2A4", ["TCGA.CK.5915.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.890097195890397}], ["OR2A4", ["TCGA.CK.5915.01", "G beta:gamma signalling through CDC42"], {"weight": 0.92213589982507}], ["OR2A4", ["TCGA.CK.5915.01", "Vasopressin regulates renal water homeostasis via Aquaporins"], {"weight": 0.896810078147989}], ["OR2A4", ["TCGA.CK.5915.01", "GPER1 signaling"], {"weight": 0.936732528990241}], ["OR2A4", ["TCGA.CK.5915.01", "ADORA2B mediated anti-inflammatory cytokines production"], {"weight": 0.936732528990241}], ["OR2A4", ["TCGA.CM.4747.01", "Signaling by GPCR"], {"weight": 0.953252273303309}], ["OR2A4", ["TCGA.CM.4747.01", "GPCR downstream signalling"], {"weight": 0.959407834012148}], ["OR2A4", ["TCGA.CM.4747.01", "G alpha (i) signalling events"], {"weight": 0.935703969315714}], ["OR2A4", ["TCGA.CM.4747.01", "GPCR ligand binding"], {"weight": 0.926858990198782}], ["OR2A4", ["TCGA.CM.4747.01", "Peptide hormone metabolism"], {"weight": 0.707363280378101}], ["OR2A4", ["TCGA.CM.4747.01", "Transport of small molecules"], {"weight": 0.921838206513595}], ["OR2A4", ["TCGA.CM.4747.01", "Leishmania infection"], {"weight": 0.825022828727795}], ["OR2A4", ["TCGA.CM.4747.01", "G-protein beta:gamma signalling"], {"weight": 0.913641783102164}], ["OR2A4", ["TCGA.CM.4747.01", "Potassium Channels"], {"weight": 0.951810580658651}], ["OR2A4", ["TCGA.CM.4747.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.895621401036963}], ["OR2A4", ["TCGA.CM.4747.01", "Erythropoietin activates Phosphoinositide-3-kinase (PI3K)"], {"weight": 0.711770388106148}], ["OR2A4", ["TCGA.CM.4747.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.852267383604737}], ["OR2A4", ["TCGA.CM.4747.01", "Leishmania parasite growth and survival"], {"weight": 0.852267383604737}], ["OR2A4", ["TCGA.CM.4747.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.890304054277206}], ["OR2A4", ["TCGA.CM.4747.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.830371181769361}], ["OR2A4", ["TCGA.CM.4747.01", "G beta:gamma signalling through BTK"], {"weight": 0.885066701968056}], ["OR2A4", ["TCGA.CM.4747.01", "G alpha (q) signalling events"], {"weight": 0.923209978760376}], ["OR2A4", ["TCGA.CM.4747.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.891563864886705}], ["OR2A4", ["TCGA.CM.4747.01", "G beta:gamma signalling through CDC42"], {"weight": 0.87883905480689}], ["OR2A4", ["TCGA.CM.5348.01", "GPCR ligand binding"], {"weight": 0.881266271840926}], ["OR2A4", ["TCGA.CM.5348.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.84951206683768}], ["OR2A4", ["TCGA.CM.5348.01", "Glucagon-type ligand receptors"], {"weight": 0.901192014572437}], ["OR2A4", ["TCGA.CM.5348.01", "Activation of G protein gated Potassium channels"], {"weight": 0.899370460363655}], ["OR2A4", ["TCGA.CM.5348.01", "G protein gated Potassium channels"], {"weight": 0.899370460363655}], ["OR2A4", ["TCGA.CM.5348.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.899370460363655}], ["OR2A4", ["TCGA.CM.5863.01", "GPCR ligand binding"], {"weight": 0.887645287994427}], ["OR2A4", ["TCGA.CM.5863.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.782602445706044}], ["OR2A4", ["TCGA.CM.5863.01", "GPCR downstream signalling"], {"weight": 0.922330860024595}], ["OR2A4", ["TCGA.CM.6161.01", "Glucagon-type ligand receptors"], {"weight": 0.914915312174019}], ["OR2A4", ["TCGA.CM.6167.01", "Transport of small molecules"], {"weight": 0.880710370677776}], ["OR2A4", ["TCGA.CM.6167.01", "GPCR ligand binding"], {"weight": 0.863910333407808}], ["OR2A4", ["TCGA.CM.6167.01", "Signaling by GPCR"], {"weight": 0.878996106825672}], ["OR2A4", ["TCGA.CM.6167.01", "GPCR downstream signalling"], {"weight": 0.885021999739825}], ["OR2A4", ["TCGA.CM.6167.01", "G alpha (q) signalling events"], {"weight": 0.871168262225238}], ["OR2A4", ["TCGA.CM.6172.01", "GPCR ligand binding"], {"weight": 0.897644709450626}], ["OR2A4", ["TCGA.CM.6172.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.875033945313178}], ["OR2A4", ["TCGA.CM.6172.01", "G alpha (s) signalling events"], {"weight": 0.939571748003297}], ["OR2A4", ["TCGA.CM.6172.01", "Glucagon-type ligand receptors"], {"weight": 0.901649224900111}], ["OR2A4", ["TCGA.CM.6172.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.890370356746602}], ["OR2A4", ["TCGA.CM.6172.01", "Thrombin signalling through proteinase activated receptors (PARs)"], {"weight": 0.893018042125363}], ["OR2A4", ["TCGA.CM.6172.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.885979813394859}], ["OR2A4", ["TCGA.CM.6172.01", "G-protein activation"], {"weight": 0.897906695630001}], ["OR2A4", ["TCGA.CM.6172.01", "G beta:gamma signalling through BTK"], {"weight": 0.857488596143944}], ["OR2A4", ["TCGA.CM.6172.01", "G alpha (z) signalling events"], {"weight": 0.852211483812368}], ["OR2A4", ["TCGA.CM.6172.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.89883101566874}], ["OR2A4", ["TCGA.CM.6172.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.857488596143944}], ["OR2A4", ["TCGA.CM.6172.01", "Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)"], {"weight": 0.889700883476569}], ["OR2A4", ["TCGA.CM.6172.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.857488596143944}], ["OR2A4", ["TCGA.CM.6172.01", "G beta:gamma signalling through CDC42"], {"weight": 0.857488596143944}], ["OR2A4", ["TCGA.CM.6172.01", "Presynaptic function of Kainate receptors"], {"weight": 0.857488596143944}], ["OR2A4", ["TCGA.CM.6172.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.89087889625133}], ["OR2A4", ["TCGA.CM.6172.01", "Signal amplification"], {"weight": 0.890370356746602}], ["OR2A4", ["TCGA.CM.6675.01", "Potassium Channels"], {"weight": 0.965698026028907}], ["OR2A4", ["TCGA.CM.6675.01", "GPCR ligand binding"], {"weight": 0.937851019967366}], ["OR2A4", ["TCGA.CM.6675.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.939175655468341}], ["OR2A4", ["TCGA.CM.6675.01", "G beta:gamma signalling through BTK"], {"weight": 0.930628091736967}], ["OR2A4", ["TCGA.CM.6675.01", "G-protein beta:gamma signalling"], {"weight": 0.939627344367293}], ["OR2A4", ["TCGA.CM.6675.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.902027698310739}], ["OR2A4", ["TCGA.CM.6675.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], {"weight": 0.93407223550133}], ["OR2A4", ["TCGA.CM.6675.01", "Glucagon-type ligand receptors"], {"weight": 0.937990611884728}], ["OR2A4", ["TCGA.CM.6675.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.92884990915815}], ["OR2A4", ["TCGA.CM.6675.01", "G beta:gamma signalling through CDC42"], {"weight": 0.929261190455082}], ["OR2A4", ["TCGA.CM.6675.01", "Activation of G protein gated Potassium channels"], {"weight": 0.936793648058999}], ["OR2A4", ["TCGA.CM.6675.01", "G protein gated Potassium channels"], {"weight": 0.936793648058999}], ["OR2A4", ["TCGA.CM.6675.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.936793648058999}], ["OR2A4", ["TCGA.CM.6676.01", "GPCR ligand binding"], {"weight": 0.915095695862904}], ["OR2A4", ["TCGA.CM.6676.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.906424218566657}], ["OR2A4", ["TCGA.CM.6676.01", "Glucagon-type ligand receptors"], {"weight": 0.913630324947869}], ["OR2A4", ["TCGA.CM.6676.01", "G beta:gamma signalling through BTK"], {"weight": 0.900770286375848}], ["OR2A4", ["TCGA.CM.6676.01", "Inwardly rectifying K+ channels"], {"weight": 0.920310877768263}], ["OR2A4", ["TCGA.CM.6676.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.896290676386057}], ["OR2A4", ["TCGA.CM.6676.01", "G-protein beta:gamma signalling"], {"weight": 0.915570884628728}], ["OR2A4", ["TCGA.CM.6676.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.897701332307469}], ["OR2A4", ["TCGA.CM.6676.01", "Activation of G protein gated Potassium channels"], {"weight": 0.904530155235342}], ["OR2A4", ["TCGA.CM.6676.01", "G protein gated Potassium channels"], {"weight": 0.904530155235342}], ["OR2A4", ["TCGA.CM.6676.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.904530155235342}], ["OR2A4", ["TCGA.CM.6676.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.871319702010856}], ["OR2A4", ["TCGA.CM.6676.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.896740066747601}], ["OR2A4", ["TCGA.CM.6678.01", "GPCR ligand binding"], {"weight": 0.891537819801977}], ["OR2A4", ["TCGA.CM.6678.01", "G alpha (q) signalling events"], {"weight": 0.898519294040029}], ["OR2A4", ["TCGA.CM.6678.01", "Leishmania infection"], {"weight": 0.844737631407839}], ["OR2A4", ["TCGA.CM.6678.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.862124894118677}], ["OR2A4", ["TCGA.CM.6678.01", "Leishmania parasite growth and survival"], {"weight": 0.862124894118677}], ["OR2A4", ["TCGA.D5.5537.01", "Signaling by GPCR"], {"weight": 0.940511984594335}], ["OR2A4", ["TCGA.D5.5537.01", "G alpha (i) signalling events"], {"weight": 0.954382437449836}], ["OR2A4", ["TCGA.D5.5537.01", "GPCR ligand binding"], {"weight": 0.901696868863982}], ["OR2A4", ["TCGA.D5.5537.01", "Potassium Channels"], {"weight": 0.950682451540437}], ["OR2A4", ["TCGA.D5.5537.01", "G alpha (s) signalling events"], {"weight": 0.953096502635528}], ["OR2A4", ["TCGA.D5.5537.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.922808560423711}], ["OR2A4", ["TCGA.D5.5537.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.901166241319094}], ["OR2A4", ["TCGA.D5.5537.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.899650726521202}], ["OR2A4", ["TCGA.D5.5537.01", "G-protein beta:gamma signalling"], {"weight": 0.916235959667735}], ["OR2A4", ["TCGA.D5.5537.01", "Signal amplification"], {"weight": 0.908317327208087}], ["OR2A4", ["TCGA.D5.5537.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.85568912936232}], ["OR2A4", ["TCGA.D5.5537.01", "Leishmania parasite growth and survival"], {"weight": 0.85568912936232}], ["OR2A4", ["TCGA.D5.5537.01", "Glucagon-type ligand receptors"], {"weight": 0.918686343963118}], ["OR2A4", ["TCGA.D5.5537.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.922261220218573}], ["OR2A4", ["TCGA.D5.5537.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.841323524886437}], ["OR2A4", ["TCGA.D5.5537.01", "G alpha (q) signalling events"], {"weight": 0.938234773001191}], ["OR2A4", ["TCGA.D5.5537.01", "G beta:gamma signalling through BTK"], {"weight": 0.899633354987159}], ["OR2A4", ["TCGA.D5.5537.01", "Aquaporin-mediated transport"], {"weight": 0.816033630887337}], ["OR2A4", ["TCGA.D5.6529.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.88795375441565}], ["OR2A4", ["TCGA.D5.6529.01", "Glucagon-type ligand receptors"], {"weight": 0.915595307804161}], ["OR2A4", ["TCGA.D5.6529.01", "Signal amplification"], {"weight": 0.88795375441565}], ["OR2A4", ["TCGA.D5.6529.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.907424258868767}], ["OR2A4", ["TCGA.D5.6529.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.901222851254996}], ["OR2A4", ["TCGA.D5.6529.01", "Presynaptic function of Kainate receptors"], {"weight": 0.888972771239236}], ["OR2A4", ["TCGA.D5.6529.01", "GPCR ligand binding"], {"weight": 0.920482369164032}], ["OR2A4", ["TCGA.D5.6529.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.895754480443366}], ["OR2A4", ["TCGA.D5.6529.01", "G-protein activation"], {"weight": 0.894208384896639}], ["OR2A4", ["TCGA.D5.6529.01", "Thromboxane signalling through TP receptor"], {"weight": 0.869710769991294}], ["OR2A4", ["TCGA.D5.6529.01", "G alpha (q) signalling events"], {"weight": 0.879819067566842}], ["OR2A4", ["TCGA.D5.6529.01", "GABA B receptor activation"], {"weight": 0.90408628527793}], ["OR2A4", ["TCGA.D5.6529.01", "Activation of GABAB receptors"], {"weight": 0.90408628527793}], ["OR2A4", ["TCGA.D5.6529.01", "G beta:gamma signalling through BTK"], {"weight": 0.861613130274218}], ["OR2A4", ["TCGA.D5.6529.01", "Inwardly rectifying K+ channels"], {"weight": 0.90559299193506}], ["OR2A4", ["TCGA.D5.6531.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.899145747832443}], ["OR2A4", ["TCGA.D5.6535.01", "GABA receptor activation"], {"weight": 0.907975666145735}], ["OR2A4", ["TCGA.D5.6535.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.914479395656681}], ["OR2A4", ["TCGA.D5.6535.01", "G alpha (i) signalling events"], {"weight": 0.958883471952755}], ["OR2A4", ["TCGA.D5.6535.01", "Glucagon-type ligand receptors"], {"weight": 0.918305631491369}], ["OR2A4", ["TCGA.D5.6535.01", "Potassium Channels"], {"weight": 0.8840732022195}], ["OR2A4", ["TCGA.D5.6535.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.897320942260721}], ["OR2A4", ["TCGA.D5.6535.01", "G alpha (s) signalling events"], {"weight": 0.949033916922078}], ["OR2A4", ["TCGA.D5.6535.01", "GPCR ligand binding"], {"weight": 0.902803472005396}], ["OR2A4", ["TCGA.D5.6535.01", "Signal amplification"], {"weight": 0.847998716842781}], ["OR2A4", ["TCGA.D5.6535.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.833731301135061}], ["OR2A4", ["TCGA.D5.6535.01", "GPCR downstream signalling"], {"weight": 0.948220353643909}], ["OR2A4", ["TCGA.D5.6535.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.857247158246008}], ["OR2A4", ["TCGA.D5.6535.01", "Inwardly rectifying K+ channels"], {"weight": 0.867169251782733}], ["OR2A4", ["TCGA.D5.6535.01", "Activation of G protein gated Potassium channels"], {"weight": 0.903610614699398}], ["OR2A4", ["TCGA.D5.6535.01", "G protein gated Potassium channels"], {"weight": 0.903610614699398}], ["OR2A4", ["TCGA.D5.6535.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.903610614699398}], ["OR2A4", ["TCGA.D5.6535.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.794836233899929}], ["OR2A4", ["TCGA.D5.6535.01", "G beta:gamma signalling through BTK"], {"weight": 0.852371771701067}], ["OR2A4", ["TCGA.D5.6535.01", "G alpha (z) signalling events"], {"weight": 0.899371113447517}], ["OR2A4", ["TCGA.D5.6535.01", "Prostacyclin signalling through prostacyclin receptor"], {"weight": 0.852371771701067}], ["OR2A4", ["TCGA.D5.6535.01", "Glucagon signaling in metabolic regulation"], {"weight": 0.89642058154547}], ["OR2A4", ["TCGA.D5.6535.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.852371771701067}], ["OR2A4", ["TCGA.D5.6535.01", "G beta:gamma signalling through CDC42"], {"weight": 0.852371771701067}], ["OR2A4", ["TCGA.D5.6535.01", "Presynaptic function of Kainate receptors"], {"weight": 0.852371771701067}], ["OR2A4", ["TCGA.D5.6537.01", "GPCR ligand binding"], {"weight": 0.927062271430922}], ["OR2A4", ["TCGA.D5.6537.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.917935306983019}], ["OR2A4", ["TCGA.D5.6537.01", "Potassium Channels"], {"weight": 0.965736825807861}], ["OR2A4", ["TCGA.D5.6537.01", "Glucagon-type ligand receptors"], {"weight": 0.948520681398353}], ["OR2A4", ["TCGA.D5.6537.01", "GABA B receptor activation"], {"weight": 0.944199870086316}], ["OR2A4", ["TCGA.D5.6537.01", "Activation of GABAB receptors"], {"weight": 0.944199870086316}], ["OR2A4", ["TCGA.D5.6537.01", "Post NMDA receptor activation events"], {"weight": 0.942182491377647}], ["OR2A4", ["TCGA.D5.6537.01", "G-protein beta:gamma signalling"], {"weight": 0.938078884403916}], ["OR2A4", ["TCGA.D5.6537.01", "Signal amplification"], {"weight": 0.922859605434082}], ["OR2A4", ["TCGA.D5.6537.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.925110226415111}], ["OR2A4", ["TCGA.D5.6537.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.909143082108946}], ["OR2A4", ["TCGA.D5.6537.01", "Adenylate cyclase inhibitory pathway"], {"weight": 0.908532249815175}], ["OR2A4", ["TCGA.D5.6537.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.941972059791453}], ["OR2A4", ["TCGA.D5.6537.01", "G alpha (z) signalling events"], {"weight": 0.94454360199535}], ["OR2A4", ["TCGA.D5.6537.01", "Inwardly rectifying K+ channels"], {"weight": 0.941610149840785}], ["OR2A4", ["TCGA.D5.6537.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.928083512556255}], ["OR2A4", ["TCGA.D5.6898.01", "GPCR ligand binding"], {"weight": 0.901027964389032}], ["OR2A4", ["TCGA.D5.6898.01", "Potassium Channels"], {"weight": 0.941755751446354}], ["OR2A4", ["TCGA.D5.6898.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.896816297282449}], ["OR2A4", ["TCGA.DM.A28F.01", "Potassium Channels"], {"weight": 0.965672891503056}], ["OR2A4", ["TCGA.DM.A28F.01", "Signaling by GPCR"], {"weight": 0.939186110319268}], ["OR2A4", ["TCGA.DM.A28F.01", "GPCR downstream signalling"], {"weight": 0.946273396463292}], ["OR2A4", ["TCGA.DM.A28F.01", "G alpha (i) signalling events"], {"weight": 0.946728726988478}], ["OR2A4", ["TCGA.DM.A28F.01", "GPCR ligand binding"], {"weight": 0.928707864171262}], ["OR2A4", ["TCGA.DM.A28F.01", "GABA receptor activation"], {"weight": 0.918417335915561}], ["OR2A4", ["TCGA.DM.A28F.01", "G alpha (s) signalling events"], {"weight": 0.964533168391838}], ["OR2A4", ["TCGA.DM.A28F.01", "Inwardly rectifying K+ channels"], {"weight": 0.938627367612404}], ["OR2A4", ["TCGA.DM.A28F.01", "G-protein beta:gamma signalling"], {"weight": 0.935018650080663}], ["OR2A4", ["TCGA.DM.A28F.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.927746766922863}], ["OR2A4", ["TCGA.DM.A28F.01", "Activation of G protein gated Potassium channels"], {"weight": 0.934844613264545}], ["OR2A4", ["TCGA.DM.A28F.01", "G protein gated Potassium channels"], {"weight": 0.934844613264545}], ["OR2A4", ["TCGA.DM.A28F.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.934844613264545}], ["OR2A4", ["TCGA.DM.A28F.01", "Anti-inflammatory response favouring Leishmania parasite infection"], {"weight": 0.887763336908842}], ["OR2A4", ["TCGA.DM.A28F.01", "Leishmania parasite growth and survival"], {"weight": 0.887763336908842}], ["OR2A4", ["TCGA.DM.A28F.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.923588479708869}], ["OR2A4", ["TCGA.DM.A28F.01", "G beta:gamma signalling through BTK"], {"weight": 0.912073853775934}], ["OR2A4", ["TCGA.F4.6459.01", "GPCR ligand binding"], {"weight": 0.857429399013932}], ["OR2A4", ["TCGA.F4.6704.01", "G alpha (q) signalling events"], {"weight": 0.936005567431591}], ["OR2A4", ["TCGA.F4.6704.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.827360452735053}], ["OR2A4", ["TCGA.F4.6704.01", "Glucagon-type ligand receptors"], {"weight": 0.885008367789106}], ["OR2A4", ["TCGA.G4.6297.01", "GPCR ligand binding"], {"weight": 0.91663473223102}], ["OR2A4", ["TCGA.G4.6297.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.894105143402434}], ["OR2A4", ["TCGA.G4.6306.01", "GPCR ligand binding"], {"weight": 0.943672067297376}], ["OR2A4", ["TCGA.G4.6306.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.936048750755936}], ["OR2A4", ["TCGA.G4.6306.01", "G-protein beta:gamma signalling"], {"weight": 0.934993316338381}], ["OR2A4", ["TCGA.G4.6306.01", "G beta:gamma signalling through PI3Kgamma"], {"weight": 0.924881251500828}], ["OR2A4", ["TCGA.G4.6306.01", "Glucagon-type ligand receptors"], {"weight": 0.942098000714716}], ["OR2A4", ["TCGA.G4.6306.01", "Ca2+ pathway"], {"weight": 0.881852379990555}], ["OR2A4", ["TCGA.G4.6306.01", "GABA B receptor activation"], {"weight": 0.937083246636606}], ["OR2A4", ["TCGA.G4.6306.01", "Activation of GABAB receptors"], {"weight": 0.937083246636606}], ["OR2A4", ["TCGA.G4.6306.01", "G alpha (q) signalling events"], {"weight": 0.927932236296521}], ["OR2A4", ["TCGA.G4.6306.01", "ADP signalling through P2Y purinoceptor 12"], {"weight": 0.924879512056412}], ["OR2A4", ["TCGA.G4.6306.01", "G beta:gamma signalling through BTK"], {"weight": 0.916266723310644}], ["OR2A4", ["TCGA.G4.6306.01", "Activation of kainate receptors upon glutamate binding"], {"weight": 0.922354749647131}], ["OR2A4", ["TCGA.G4.6306.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.931181448105319}], ["OR2A4", ["TCGA.G4.6306.01", "Potassium Channels"], {"weight": 0.953001951134378}], ["OR2A4", ["TCGA.G4.6306.01", "ADP signalling through P2Y purinoceptor 1"], {"weight": 0.916648494497269}], ["OR2A4", ["TCGA.G4.6306.01", "Thromboxane signalling through TP receptor"], {"weight": 0.910657357564786}], ["OR2A4", ["TCGA.G4.6306.01", "G beta:gamma signalling through PLC beta"], {"weight": 0.909778763651648}], ["OR2A4", ["TCGA.G4.6306.01", "G beta:gamma signalling through CDC42"], {"weight": 0.91319856918859}], ["OR2A4", ["TCGA.G4.6306.01", "Activation of G protein gated Potassium channels"], {"weight": 0.918669426643769}], ["OR2A4", ["TCGA.G4.6306.01", "G protein gated Potassium channels"], {"weight": 0.918669426643769}], ["OR2A4", ["TCGA.G4.6306.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.918669426643769}], ["OR2A4", ["TCGA.NH.A6GA.01", "Potassium Channels"], {"weight": 0.950040225801694}], ["OR2A4", ["TCGA.NH.A6GA.01", "Inwardly rectifying K+ channels"], {"weight": 0.921561018977313}], ["OR2A4", ["TCGA.NH.A6GA.01", "Activation of G protein gated Potassium channels"], {"weight": 0.908396575238366}], ["OR2A4", ["TCGA.NH.A6GA.01", "G protein gated Potassium channels"], {"weight": 0.908396575238366}], ["OR2A4", ["TCGA.NH.A6GA.01", "Phase 0 - rapid depolarisation"], {"weight": 0.862320908935733}], ["OR2A4", ["TCGA.NH.A6GA.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], {"weight": 0.908396575238366}], ["OR2A4", ["TCGA.QL.A97D.01", "G alpha (s) signalling events"], {"weight": 0.958313923710206}], ["OR2A4", ["TCGA.QL.A97D.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.879539494057768}], ["ENPP1", ["TCGA.AA.3655.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.937171888505437}], ["ENPP1", ["TCGA.AA.3660.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.930290881431793}], ["ENPP1", ["TCGA.AA.3660.01", "Collagen chain trimerization"], {"weight": 0.889918449225259}], ["ENPP1", ["TCGA.AA.3660.01", "Collagen formation"], {"weight": 0.91096974383272}], ["ENPP1", ["TCGA.AA.A01D.01", "Collagen chain trimerization"], {"weight": 0.915860297452217}], ["ENPP1", ["TCGA.AA.A02H.01", "Glycosaminoglycan metabolism"], {"weight": 0.77623155484406}], ["ENPP1", ["TCGA.AA.A02Y.01", "NCAM1 interactions"], {"weight": 0.94960617048467}], ["ENPP1", ["TCGA.AA.A02Y.01", "Collagen chain trimerization"], {"weight": 0.92810290062767}], ["ENPP1", ["TCGA.AA.A02Y.01", "NCAM signaling for neurite out-growth"], {"weight": 0.95438152235543}], ["ENPP1", ["TCGA.AA.A02Y.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.948087378270086}], ["ENPP1", ["TCGA.AA.A02Y.01", "Glycosaminoglycan metabolism"], {"weight": 0.925326905342856}], ["ENPP1", ["TCGA.AD.6888.01", "Glycosaminoglycan metabolism"], {"weight": 0.935996768176921}], ["ENPP1", ["TCGA.AD.6888.01", "NCAM1 interactions"], {"weight": 0.94351312837528}], ["ENPP1", ["TCGA.AD.6888.01", "NCAM signaling for neurite out-growth"], {"weight": 0.927210109667546}], ["ENPP1", ["TCGA.AD.6888.01", "Collagen formation"], {"weight": 0.949258457834418}], ["ENPP1", ["TCGA.AZ.6598.01", "Collagen chain trimerization"], {"weight": 0.934924385260431}], ["ENPP1", ["TCGA.AZ.6600.01", "Collagen formation"], {"weight": 0.889455353597414}], ["ENPP1", ["TCGA.AZ.6600.01", "Collagen chain trimerization"], {"weight": 0.893503848861602}], ["ENPP1", ["TCGA.AZ.6607.01", "NCAM1 interactions"], {"weight": 0.761693407099574}], ["ENPP1", ["TCGA.AZ.6607.01", "Glycosaminoglycan metabolism"], {"weight": 0.87915457300382}], ["ENPP1", ["TCGA.CA.5254.01", "Collagen chain trimerization"], {"weight": 0.923932804447974}], ["ENPP1", ["TCGA.CA.5254.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.913630335007071}], ["ENPP1", ["TCGA.CA.5255.01", "NCAM1 interactions"], {"weight": 0.929290648062808}], ["ENPP1", ["TCGA.CA.5255.01", "Glycosaminoglycan metabolism"], {"weight": 0.880440939578885}], ["ENPP1", ["TCGA.CA.5255.01", "NCAM signaling for neurite out-growth"], {"weight": 0.937995658963671}], ["ENPP1", ["TCGA.CM.5348.01", "Collagen chain trimerization"], {"weight": 0.904310441030996}], ["ENPP1", ["TCGA.CM.5863.01", "Collagen chain trimerization"], {"weight": 0.903696662715724}], ["ENPP1", ["TCGA.CM.6167.01", "Collagen formation"], {"weight": 0.931456982396035}], ["ENPP1", ["TCGA.CM.6167.01", "Collagen chain trimerization"], {"weight": 0.886988091609399}], ["ENPP1", ["TCGA.CM.6678.01", "Collagen formation"], {"weight": 0.939769321742887}], ["ENPP1", ["TCGA.CM.6678.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.930062411563607}], ["ENPP1", ["TCGA.D5.5537.01", "NCAM signaling for neurite out-growth"], {"weight": 0.90549798937383}], ["ENPP1", ["TCGA.D5.5537.01", "Collagen chain trimerization"], {"weight": 0.908553744628405}], ["ENPP1", ["TCGA.D5.5537.01", "NCAM1 interactions"], {"weight": 0.919881087333824}], ["ENPP1", ["TCGA.D5.6529.01", "Collagen chain trimerization"], {"weight": 0.921097799237982}], ["ENPP1", ["TCGA.D5.6529.01", "Assembly of collagen fibrils and other multimeric structures"], {"weight": 0.915257689146783}], ["ENPP1", ["TCGA.D5.6537.01", "Glycosaminoglycan metabolism"], {"weight": 0.87304037916819}], ["ENPP1", ["TCGA.F4.6459.01", "Collagen chain trimerization"], {"weight": 0.906937111274851}], ["ENPP1", ["TCGA.F4.6704.01", "Collagen chain trimerization"], {"weight": 0.915426895819572}], ["ENPP1", ["TCGA.G4.6297.01", "Collagen chain trimerization"], {"weight": 0.928056637426356}], ["ENPP1", ["TCGA.G4.6297.01", "NCAM signaling for neurite out-growth"], {"weight": 0.866681452352793}], ["ENPP1", ["TCGA.G4.6297.01", "NCAM1 interactions"], {"weight": 0.893459475445355}], ["ENPP1", ["TCGA.G4.6306.01", "NCAM1 interactions"], {"weight": 0.935432383411687}], ["ENPP1", ["TCGA.QL.A97D.01", "Glycosaminoglycan metabolism"], {"weight": 0.840649478938406}], ["CTGF", ["TCGA.AA.3715.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.881382330582673}], ["CTGF", ["TCGA.AA.3837.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], {"weight": 0.241798430813384}], ["CTGF", ["TCGA.AA.3858.01", "Biological oxidations"], {"weight": 0.919227012072195}], ["CTGF", ["TCGA.AA.3858.01", "Recycling of bile acids and salts"], {"weight": 0.830218745312688}], ["CTGF", ["TCGA.AA.3939.01", "Biological oxidations"], {"weight": 0.90001824270391}], ["CTGF", ["TCGA.AA.3939.01", "Signaling by Retinoic Acid"], {"weight": 0.688964826564483}], ["CTGF", ["TCGA.AA.3939.01", "Phase I - Functionalization of compounds"], {"weight": 0.944390193749725}], ["CTGF", ["TCGA.AA.3952.01", "Recycling of bile acids and salts"], {"weight": 0.701908534951323}], ["CTGF", ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.862685650341387}], ["CTGF", ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.781953710149877}], ["CTGF", ["TCGA.AA.3952.01", "Bile acid and bile salt metabolism"], {"weight": 0.823527287089206}], ["CTGF", ["TCGA.AA.3952.01", "Synthesis of bile acids and bile salts"], {"weight": 0.790823165518731}], ["CTGF", ["TCGA.AZ.6607.01", "TGF-beta receptor signaling activates SMADs"], {"weight": 0.866716907760113}], ["CTGF", ["TCGA.CK.4952.01", "Biological oxidations"], {"weight": 0.913049648175015}], ["CTGF", ["TCGA.CK.4952.01", "Phase I - Functionalization of compounds"], {"weight": 0.950247935050121}], ["CTGF", ["TCGA.CK.4952.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.879114107589277}], ["CTGF", ["TCGA.CK.5915.01", "Biological oxidations"], {"weight": 0.937841270557669}], ["CTGF", ["TCGA.CK.5915.01", "Phase I - Functionalization of compounds"], {"weight": 0.948756051650045}], ["CTGF", ["TCGA.D5.6537.01", "Biological oxidations"], {"weight": 0.94635056772925}], ["CTGF", ["TCGA.D5.6537.01", "Recycling of bile acids and salts"], {"weight": 0.942945143658295}], ["CTGF", ["TCGA.D5.6537.01", "Phase I - Functionalization of compounds"], {"weight": 0.961990835135123}], ["STX7", ["TCGA.AA.3837.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.399119807917072}], ["STX7", ["TCGA.CK.6746.01", "Neuronal System"], {"weight": 0.961016577888023}], ["STX7", ["TCGA.CK.6746.01", "Transmission across Chemical Synapses"], {"weight": 0.955836077672381}], ["STX7", ["TCGA.CK.6746.01", "Protein-protein interactions at synapses"], {"weight": 0.942789693501761}], ["STX7", ["TCGA.CK.6746.01", "Nitric oxide stimulates guanylate cyclase"], {"weight": 0.871808362839336}], ["STX7", ["TCGA.CK.6746.01", "Extracellular matrix organization"], {"weight": 0.888497607890828}], ["STX7", ["TCGA.CK.6746.01", "Regulation of insulin secretion"], {"weight": 0.935604046069591}], ["STX7", ["TCGA.CK.6746.01", "GPCR ligand binding"], {"weight": 0.926663542655825}], ["STX7", ["TCGA.CK.6746.01", "Muscle contraction"], {"weight": 0.953811524586433}], ["STX7", ["TCGA.CK.6746.01", "Receptor-type tyrosine-protein phosphatases"], {"weight": 0.895860927389387}], ["STX7", ["TCGA.CK.6746.01", "Cardiac conduction"], {"weight": 0.946227224540886}], ["STX7", ["TCGA.CK.6746.01", "Collagen biosynthesis and modifying enzymes"], {"weight": 0.924930639394785}], ["STX7", ["TCGA.CK.6746.01", "Bile acid and bile salt metabolism"], {"weight": 0.899043964547671}], ["STX7", ["TCGA.CK.6746.01", "Neurotransmitter receptors and postsynaptic signal transmission"], {"weight": 0.93691306608051}], ["STX7", ["TCGA.CK.6746.01", "Integration of energy metabolism"], {"weight": 0.930427402179009}], ["STX7", ["TCGA.CK.6746.01", "Signaling by GPCR"], {"weight": 0.955718378113162}], ["STX7", ["TCGA.CK.6746.01", "O-linked glycosylation"], {"weight": 0.936771358926024}], ["STX7", ["TCGA.CK.6746.01", "G alpha (i) signalling events"], {"weight": 0.95738589806437}], ["STX7", ["TCGA.CK.6746.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.890224977934229}], ["STX7", ["TCGA.CK.6746.01", "Metabolism"], {"weight": 0.9414305538906}], ["STX7", ["TCGA.CK.6746.01", "Neurotransmitter release cycle"], {"weight": 0.795555852915753}], ["STX7", ["TCGA.CK.6746.01", "Peptide ligand-binding receptors"], {"weight": 0.924221961668177}], ["STX7", ["TCGA.CK.6746.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], {"weight": 0.922123810365245}], ["STX7", ["TCGA.CK.6746.01", "Phase 0 - rapid depolarisation"], {"weight": 0.930958787706634}], ["STX7", ["TCGA.CK.6746.01", "Neurexins and neuroligins"], {"weight": 0.932066949473335}], ["STX7", ["TCGA.CK.6746.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.899779196772162}], ["STX7", ["TCGA.CK.6746.01", "Presynaptic depolarization and calcium channel opening"], {"weight": 0.868784002998573}], ["STX7", ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts"], {"weight": 0.888122612073096}], ["STX7", ["TCGA.CK.6746.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.918927663946753}], ["STX7", ["TCGA.CK.6746.01", "Transport of small molecules"], {"weight": 0.93344458194898}], ["STX7", ["TCGA.CK.6746.01", "GPCR downstream signalling"], {"weight": 0.958003930630955}], ["STX7", ["TCGA.CK.6746.01", "NCAM1 interactions"], {"weight": 0.920830518398991}], ["STX7", ["TCGA.CK.6746.01", "SLC-mediated transmembrane transport"], {"weight": 0.919783771384602}], ["STX7", ["TCGA.CK.6746.01", "Platelet homeostasis"], {"weight": 0.900280491442412}], ["STX7", ["TCGA.CK.6746.01", "Adherens junctions interactions"], {"weight": 0.881288134619704}], ["STX7", ["TCGA.CK.6746.01", "Regulation of beta-cell development"], {"weight": 0.85102657759993}], ["STX7", ["TCGA.CK.6746.01", "Class B/2 (Secretin family receptors)"], {"weight": 0.904891832958925}], ["STX7", ["TCGA.CK.6746.01", "Diseases of glycosylation"], {"weight": 0.898430831540826}], ["STX7", ["TCGA.CK.6746.01", "Trafficking of GluR2-containing AMPA receptors"], {"weight": 0.882310318574751}], ["STX7", ["TCGA.CK.6746.01", "Interaction between L1 and Ankyrins"], {"weight": 0.930403813820225}], ["STX7", ["TCGA.CK.6746.01", "Regulation of gene expression in beta cells"], {"weight": 0.822022231299432}], ["STX7", ["TCGA.CK.6746.01", "Glycosaminoglycan metabolism"], {"weight": 0.800640307819453}], ["STX7", ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], {"weight": 0.703220869563885}], ["STX7", ["TCGA.CK.6746.01", "Unblocking of NMDA receptors, glutamate binding and activation"], {"weight": 0.923920888739502}], ["STX7", ["TCGA.CK.6746.01", "Ion homeostasis"], {"weight": 0.905219530219727}], ["STX7", ["TCGA.CK.6746.01", "Trafficking of AMPA receptors"], {"weight": 0.913402124891362}], ["STX7", ["TCGA.CK.6746.01", "Glutamate binding, activation of AMPA receptors and synaptic plasticity"], {"weight": 0.913402124891362}], ["STX7", ["TCGA.CK.6746.01", "Triglyceride metabolism"], {"weight": 0.866544302770609}], ["STX7", ["TCGA.CK.6746.01", "Diseases of metabolism"], {"weight": 0.850509939459102}], ["STX7", ["TCGA.CK.6746.01", "Scavenging by Class A Receptors"], {"weight": 0.37623023072375}], ["STX7", ["TCGA.CK.6746.01", "Collagen formation"], {"weight": 0.924925348463501}], ["STX7", ["TCGA.CK.6746.01", "G alpha (q) signalling events"], {"weight": 0.934863681854965}], ["STX7", ["TCGA.CK.6746.01", "Adrenaline,noradrenaline inhibits insulin secretion"], {"weight": 0.910725317625927}], ["STX7", ["TCGA.CK.6746.01", "Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol"], {"weight": 0.84765883412599}], ["STX7", ["TCGA.CK.6746.01", "Acetylcholine Neurotransmitter Release Cycle"], {"weight": 0.509354755691914}], ["STX7", ["TCGA.CK.6746.01", "L1CAM interactions"], {"weight": 0.88370862187034}], ["STX7", ["TCGA.CK.6746.01", "Initial triggering of complement"], {"weight": 0.849610418022714}], ["STX7", ["TCGA.CK.6746.01", "NPAS4 regulates expression of target genes"], {"weight": 0.811992810606809}], ["TAAR5", ["TCGA.AA.3660.01", "G alpha (s) signalling events"], {"weight": 0.941464250342711}], ["TAAR5", ["TCGA.AA.3837.01", "Calcitonin-like ligand receptors"], {"weight": 0.781745048053115}], ["TAAR5", ["TCGA.AA.A02H.01", "G alpha (s) signalling events"], {"weight": 0.938046530265219}], ["TAAR5", ["TCGA.AZ.6606.01", "Phase I - Functionalization of compounds"], {"weight": 0.944343000816023}], ["TAAR5", ["TCGA.CA.5254.01", "G alpha (s) signalling events"], {"weight": 0.961719643384028}], ["TAAR5", ["TCGA.CM.6678.01", "G alpha (s) signalling events"], {"weight": 0.94271245659373}], ["TAAR5", ["TCGA.CM.6678.01", "Potassium Channels"], {"weight": 0.941803143852089}], ["TAAR5", ["TCGA.G4.6306.01", "Calcitonin-like ligand receptors"], {"weight": 0.913573700599421}], ["TAAR2", ["TCGA.3L.AA1B.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.708452084522892}], ["TAAR2", ["TCGA.4T.AA8H.01", "Phase I - Functionalization of compounds"], {"weight": 0.944274770654301}], ["TAAR2", ["TCGA.4T.AA8H.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.762689134552027}], ["TAAR2", ["TCGA.5M.AATA.01", "Phase I - Functionalization of compounds"], {"weight": 0.937815371973827}], ["TAAR2", ["TCGA.A6.4107.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.720890295111332}], ["TAAR2", ["TCGA.A6.6652.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.849765827005952}], ["TAAR2", ["TCGA.AA.3655.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.736657320479108}], ["TAAR2", ["TCGA.AA.3837.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.652206828562499}], ["TAAR2", ["TCGA.AA.3837.01", "Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)"], {"weight": 0.858042113513547}], ["TAAR2", ["TCGA.AA.3837.01", "Incretin synthesis, secretion, and inactivation"], {"weight": 0.858042113513547}], ["TAAR2", ["TCGA.AA.A02H.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.687622414673181}], ["TAAR2", ["TCGA.AA.A02Y.01", "Calcitonin-like ligand receptors"], {"weight": 0.885613621421486}], ["TAAR2", ["TCGA.AD.6888.01", "Calcitonin-like ligand receptors"], {"weight": 0.90175377218772}], ["TAAR2", ["TCGA.AY.A8YK.01", "G alpha (s) signalling events"], {"weight": 0.944146826061094}], ["TAAR2", ["TCGA.AZ.6600.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.840109941814096}], ["TAAR2", ["TCGA.AZ.6600.01", "Peptide ligand-binding receptors"], {"weight": 0.83664028695361}], ["TAAR2", ["TCGA.CM.4747.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.926585689315879}], ["TAAR2", ["TCGA.CM.4747.01", "Peptide ligand-binding receptors"], {"weight": 0.908930925724118}], ["TAAR2", ["TCGA.CM.4747.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.677774539142569}], ["TAAR2", ["TCGA.CM.5348.01", "Peptide ligand-binding receptors"], {"weight": 0.841806856471023}], ["TAAR2", ["TCGA.CM.6172.01", "Peptide ligand-binding receptors"], {"weight": 0.888337840566387}], ["TAAR2", ["TCGA.CM.6675.01", "G alpha (s) signalling events"], {"weight": 0.964942926191436}], ["TAAR2", ["TCGA.D5.5537.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.765442360421121}], ["TAAR2", ["TCGA.D5.6531.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.726805096020269}], ["TAAR2", ["TCGA.DM.A28F.01", "Peptide ligand-binding receptors"], {"weight": 0.934924172211965}], ["TAAR2", ["TCGA.F4.6854.01", "GPCR ligand binding"], {"weight": 0.82509918587339}], ["TAAR2", ["TCGA.NH.A6GA.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.718022095614604}], ["TAAR1", ["TCGA.AD.6888.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.818634783743196}], ["TAAR1", ["TCGA.AD.6888.01", "Platelet activation, signaling and aggregation"], {"weight": 0.933657036348356}], ["TAAR1", ["TCGA.D5.6537.01", "Class A/1 (Rhodopsin-like receptors)"], {"weight": 0.926857264364007}], ["TAAR1", ["TCGA.QL.A97D.01", "Synthesis, secretion, and deacylation of Ghrelin"], {"weight": 0.764061707579393}], ["SLC18B1", ["TCGA.AA.3841.01", "RND3 GTPase cycle"], {"weight": 0.915237947987268}], ["RPS12", ["TCGA.AA.3560.01", "APC/C-mediated degradation of cell cycle proteins"], {"weight": 0.912322148511757}], ["RPS12", ["TCGA.AA.3560.01", "Regulation of mitotic cell cycle"], {"weight": 0.912322148511757}], ["RPS12", ["TCGA.AA.3560.01", "APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1"], {"weight": 0.907651894834875}], ["RPS12", ["TCGA.AA.3560.01", "Regulation of RUNX2 expression and activity"], {"weight": 0.793183759370742}], ["RPS12", ["TCGA.AA.3685.01", "L13a-mediated translational silencing of Ceruloplasmin expression"], {"weight": 0.91783544984762}], ["RPS12", ["TCGA.AA.3685.01", "SARS-CoV-1 modulates host translation machinery"], {"weight": 0.889914783155506}], ["RPS12", ["TCGA.AA.3685.01", "SARS-CoV-2 modulates host translation machinery"], {"weight": 0.855512011410602}], ["RPS12", ["TCGA.AA.3685.01", "Formation of the ternary complex, and subsequently, the 43S complex"], {"weight": 0.894400457949203}], ["RPS12", ["TCGA.AA.3685.01", "Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S"], {"weight": 0.850820393003748}], ["RPS12", ["TCGA.AA.3685.01", "Ribosomal scanning and start codon recognition"], {"weight": 0.894351048710237}], ["RPS12", ["TCGA.AA.3685.01", "Translation initiation complex formation"], {"weight": 0.894342910387828}], ["RPS12", ["TCGA.AA.3685.01", "SARS-CoV-1-host interactions"], {"weight": 0.889914783155506}], ["RPS12", ["TCGA.AM.5820.01", "Response of EIF2AK1 (HRI) to heme deficiency"], {"weight": 0.788471373605249}], ["RPS12", ["TCGA.CA.5256.01", "Major pathway of rRNA processing in the nucleolus and cytosol"], {"weight": 0.940576638003749}], ["RPS12", ["TCGA.CM.4747.01", "Stimuli-sensing channels"], {"weight": 0.874334368688504}], ["EYA4", ["TCGA.AA.3518.01", "Drug ADME"], {"weight": 0.786127823271464}], ["EYA4", ["TCGA.AU.6004.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.875302523561373}], ["EYA4", ["TCGA.AU.6004.01", "Degradation of the extracellular matrix"], {"weight": 0.753804725035359}], ["EYA4", ["TCGA.AU.6004.01", "Biological oxidations"], {"weight": 0.855534335454712}], ["EYA4", ["TCGA.AU.6004.01", "Developmental Biology"], {"weight": 0.740816860849137}], ["EYA4", ["TCGA.AU.6004.01", "Peptide hormone metabolism"], {"weight": 0.656149508251469}], ["EYA4", ["TCGA.AU.6004.01", "Regulation of gene expression in beta cells"], {"weight": 0.609063378239277}], ["EYA4", ["TCGA.AU.6004.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], {"weight": 0.663430523693692}], ["EYA4", ["TCGA.CK.6746.01", "Biological oxidations"], {"weight": 0.92146606065993}], ["EYA4", ["TCGA.CK.6746.01", "Drug ADME"], {"weight": 0.916086159925137}], ["EYA4", ["TCGA.CK.6746.01", "Phase I - Functionalization of compounds"], {"weight": 0.929428758171513}], ["EYA4", ["TCGA.CK.6746.01", "Cytochrome P450 - arranged by substrate type"], {"weight": 0.851291340969954}], ["EYA4", ["TCGA.CK.6746.01", "Arachidonic acid metabolism"], {"weight": 0.886200976954913}], ["EYA4", ["TCGA.CK.6746.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.905020302126484}], ["EYA4", ["TCGA.CK.6746.01", "Transcriptional regulation of pluripotent stem cells"], {"weight": 0.906046166864781}], ["EYA4", ["TCGA.CK.6746.01", "Interleukin-4 and Interleukin-13 signaling"], {"weight": 0.754708067312984}], ["EYA4", ["TCGA.CK.6746.01", "Ion channel transport"], {"weight": 0.944797598319853}], ["EYA4", ["TCGA.CK.6746.01", "Stimuli-sensing channels"], {"weight": 0.920993016776055}], ["EYA4", ["TCGA.CK.6746.01", "Signaling by Retinoic Acid"], {"weight": 0.845464607444541}], ["EYA4", ["TCGA.CK.6746.01", "Developmental Biology"], {"weight": 0.918189921620629}], ["SGK1", ["TCGA.3L.AA1B.01", "Ion channel transport"], {"weight": 0.878150410302243}], ["SGK1", ["TCGA.5M.AATA.01", "Insulin processing"], {"weight": 0.90485499701993}], ["SGK1", ["TCGA.A6.4107.01", "Insulin processing"], {"weight": 0.785638779548015}], ["SGK1", ["TCGA.AA.3679.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.861170257358096}], ["SGK1", ["TCGA.AA.3679.01", "G beta:gamma signalling through BTK"], {"weight": 0.865220887945717}], ["SGK1", ["TCGA.AA.3679.01", "NCAM1 interactions"], {"weight": 0.872451838355207}], ["SGK1", ["TCGA.AA.3679.01", "G-protein activation"], {"weight": 0.87085702722489}], ["SGK1", ["TCGA.AA.3679.01", "Formation of Fibrin Clot (Clotting Cascade)"], {"weight": 0.817429019221411}], ["SGK1", ["TCGA.AA.3679.01", "Metabolism of Angiotensinogen to Angiotensins"], {"weight": 0.833369855376683}], ["SGK1", ["TCGA.AA.3679.01", "Intrinsic Pathway of Fibrin Clot Formation"], {"weight": 0.802417244593458}], ["SGK1", ["TCGA.AA.3679.01", "NCAM signaling for neurite out-growth"], {"weight": 0.842594168368473}], ["SGK1", ["TCGA.AA.3679.01", "Interaction between L1 and Ankyrins"], {"weight": 0.87755433097569}], ["SGK1", ["TCGA.AA.3837.01", "Insulin processing"], {"weight": 0.717172782634805}], ["SGK1", ["TCGA.AD.6899.01", "Stimuli-sensing channels"], {"weight": 0.834428585775332}], ["SGK1", ["TCGA.AZ.6607.01", "Stimuli-sensing channels"], {"weight": 0.929582367701781}], ["SGK1", ["TCGA.CA.5255.01", "Insulin processing"], {"weight": 0.769131886948153}], ["SGK1", ["TCGA.CA.5256.01", "Stimuli-sensing channels"], {"weight": 0.931465449955298}], ["SGK1", ["TCGA.CK.5915.01", "Insulin processing"], {"weight": 0.843374848110587}], ["SGK1", ["TCGA.CM.6167.01", "Ion channel transport"], {"weight": 0.86203158076757}], ["SGK1", ["TCGA.CM.6172.01", "Insulin processing"], {"weight": 0.77027513091998}], ["SGK1", ["TCGA.CM.6678.01", "Ion channel transport"], {"weight": 0.894761080935704}], ["SGK1", ["TCGA.D5.6529.01", "NCAM signaling for neurite out-growth"], {"weight": 0.728915206440966}], ["SGK1", ["TCGA.D5.6531.01", "Stimuli-sensing channels"], {"weight": 0.943368680832158}], ["SGK1", ["TCGA.D5.6531.01", "Insulin processing"], {"weight": 0.806776951789651}], ["SGK1", ["TCGA.D5.6535.01", "Stimuli-sensing channels"], {"weight": 0.939816831297083}], ["SGK1", ["TCGA.D5.6898.01", "Transport of small molecules"], {"weight": 0.899738720312971}], ["SGK1", ["TCGA.F4.6459.01", "Stimuli-sensing channels"], {"weight": 0.864070554642767}], ["SGK1", ["TCGA.QL.A97D.01", "Ion channel transport"], {"weight": 0.941878742890222}], ["RARS2", ["TCGA.D5.6535.01", "Aspartate and asparagine metabolism"], {"weight": 0.690855054413014}], ["TRMT11", ["TCGA.AA.3685.01", "Eukaryotic Translation Termination"], {"weight": 0.906979624880814}], ["TRMT11", ["TCGA.AA.3685.01", "rRNA processing in the nucleus and cytosol"], {"weight": 0.920054204881477}], ["TRMT11", ["TCGA.AA.3685.01", "Biological oxidations"], {"weight": 0.91547414039244}], ["TRMT11", ["TCGA.AA.3685.01", "Phase II - Conjugation of compounds"], {"weight": 0.770052341759343}], ["TRMT11", ["TCGA.AA.3685.01", "Translation"], {"weight": 0.866857540672419}], ["TRMT11", ["TCGA.AA.3685.01", "rRNA modification in the nucleus and cytosol"], {"weight": 0.826183001939505}], ["TRMT11", ["TCGA.AA.3685.01", "tRNA modification in the nucleus and cytosol"], {"weight": 0.0829426236430766}], ["TRMT11", ["TCGA.AA.3837.01", "Phase II - Conjugation of compounds"], {"weight": 0.536783045289323}], ["TRMT11", ["TCGA.AA.3837.01", "Methylation"], {"weight": 0.298411786800313}], ["TRMT11", ["TCGA.AA.3848.01", "Biological oxidations"], {"weight": 0.949322524775783}], ["TRMT11", ["TCGA.AA.3848.01", "Methylation"], {"weight": 0.799042005041658}], ["TRMT11", ["TCGA.AA.3848.01", "Phase II - Conjugation of compounds"], {"weight": 0.920397021412254}], ["TRMT11", ["TCGA.AZ.6598.01", "Biological oxidations"], {"weight": 0.933988369461744}], ["TRMT11", ["TCGA.AZ.6608.01", "Biological oxidations"], {"weight": 0.91067454404962}], ["TRMT11", ["TCGA.AZ.6608.01", "Phase II - Conjugation of compounds"], {"weight": 0.716628573837036}], ["TRMT11", ["TCGA.D5.6535.01", "Biological oxidations"], {"weight": 0.909973477867779}], ["TRMT11", ["TCGA.DM.A1D7.01", "Phase II - Conjugation of compounds"], {"weight": 0.689136359972211}], ["TRMT11", ["TCGA.F4.6854.01", "Phase II - Conjugation of compounds"], {"weight": 0.685603795921884}], ["RNASET2", ["TCGA.D5.5541.01", "Drug ADME"], {"weight": 0.901500266318315}], ["RNASET2", ["TCGA.NH.A6GB.01", "Drug ADME"], {"weight": 0.816757193472978}], ["FUT9", ["TCGA.3L.AA1B.01", "Blood group systems biosynthesis"], {"weight": 0.680132548862733}], ["FUT9", ["TCGA.3L.AA1B.01", "Lewis blood group biosynthesis"], {"weight": 0.487432999267247}], ["FUT9", ["TCGA.3L.AA1B.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.768043911409392}], ["FUT9", ["TCGA.4T.AA8H.01", "Sialic acid metabolism"], {"weight": 0.795063295511037}], ["FUT9", ["TCGA.5M.AATA.01", "Blood group systems biosynthesis"], {"weight": 0.877227230412543}], ["FUT9", ["TCGA.5M.AATA.01", "Lewis blood group biosynthesis"], {"weight": 0.872871862859476}], ["FUT9", ["TCGA.A6.2678.01", "Lewis blood group biosynthesis"], {"weight": 0.663696111944339}], ["FUT9", ["TCGA.A6.2678.01", "Blood group systems biosynthesis"], {"weight": 0.71863530264807}], ["FUT9", ["TCGA.A6.2686.01", "Defective GALNT3 causes HFTC"], {"weight": 0.779887881048445}], ["FUT9", ["TCGA.A6.2686.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.779887881048445}], ["FUT9", ["TCGA.A6.2686.01", "Blood group systems biosynthesis"], {"weight": 0.807918223371535}], ["FUT9", ["TCGA.A6.2686.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.778192977777672}], ["FUT9", ["TCGA.AA.3561.01", "Blood group systems biosynthesis"], {"weight": 0.789989146772712}], ["FUT9", ["TCGA.AA.3561.01", "Lewis blood group biosynthesis"], {"weight": 0.735539750241793}], ["FUT9", ["TCGA.AA.3715.01", "O-linked glycosylation of mucins"], {"weight": 0.953010854554745}], ["FUT9", ["TCGA.AA.3860.01", "Blood group systems biosynthesis"], {"weight": 0.794022972336447}], ["FUT9", ["TCGA.AA.3875.01", "Blood group systems biosynthesis"], {"weight": 0.737179075258905}], ["FUT9", ["TCGA.AA.3875.01", "Lewis blood group biosynthesis"], {"weight": 0.631564991883893}], ["FUT9", ["TCGA.AA.3939.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.78916684738446}], ["FUT9", ["TCGA.AA.3939.01", "Blood group systems biosynthesis"], {"weight": 0.74775162820251}], ["FUT9", ["TCGA.AA.3939.01", "Lewis blood group biosynthesis"], {"weight": 0.649745180348181}], ["FUT9", ["TCGA.AA.3952.01", "Blood group systems biosynthesis"], {"weight": 0.846001741726121}], ["FUT9", ["TCGA.AA.3952.01", "Lewis blood group biosynthesis"], {"weight": 0.768384961776362}], ["FUT9", ["TCGA.AA.3966.01", "Blood group systems biosynthesis"], {"weight": 0.837495753014117}], ["FUT9", ["TCGA.AA.3982.01", "Blood group systems biosynthesis"], {"weight": 0.79906164180983}], ["FUT9", ["TCGA.AA.3982.01", "Lewis blood group biosynthesis"], {"weight": 0.736504761706809}], ["FUT9", ["TCGA.AA.A00A.01", "Blood group systems biosynthesis"], {"weight": 0.876680706113342}], ["FUT9", ["TCGA.AA.A00J.01", "Blood group systems biosynthesis"], {"weight": 0.798484452847857}], ["FUT9", ["TCGA.AA.A02H.01", "Blood group systems biosynthesis"], {"weight": 0.837484750976734}], ["FUT9", ["TCGA.AA.A02H.01", "Lewis blood group biosynthesis"], {"weight": 0.76464776869039}], ["FUT9", ["TCGA.AA.A02Y.01", "Sialic acid metabolism"], {"weight": 0.833396815226673}], ["FUT9", ["TCGA.AD.6888.01", "Immune System"], {"weight": 0.887001324069716}], ["FUT9", ["TCGA.AD.6888.01", "Innate Immune System"], {"weight": 0.904348428610762}], ["FUT9", ["TCGA.AD.6888.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.85483433865397}], ["FUT9", ["TCGA.AD.6888.01", "Blood group systems biosynthesis"], {"weight": 0.881426599464166}], ["FUT9", ["TCGA.AD.6888.01", "Sialic acid metabolism"], {"weight": 0.740145301496766}], ["FUT9", ["TCGA.AD.A5EK.01", "Blood group systems biosynthesis"], {"weight": 0.863612957169863}], ["FUT9", ["TCGA.AD.A5EK.01", "Lewis blood group biosynthesis"], {"weight": 0.776412841164162}], ["FUT9", ["TCGA.AM.5820.01", "Blood group systems biosynthesis"], {"weight": 0.745834980659545}], ["FUT9", ["TCGA.AM.5820.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.823058512155732}], ["FUT9", ["TCGA.AM.5820.01", "Lewis blood group biosynthesis"], {"weight": 0.608556344327071}], ["FUT9", ["TCGA.AZ.6606.01", "Sialic acid metabolism"], {"weight": 0.785179600717377}], ["FUT9", ["TCGA.AZ.6608.01", "Sialic acid metabolism"], {"weight": 0.840553808155924}], ["FUT9", ["TCGA.CA.5254.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.857419253213195}], ["FUT9", ["TCGA.CA.5254.01", "Blood group systems biosynthesis"], {"weight": 0.888353909557217}], ["FUT9", ["TCGA.CA.5254.01", "Lewis blood group biosynthesis"], {"weight": 0.784408141556617}], ["FUT9", ["TCGA.CA.5254.01", "Defective GALNT3 causes HFTC"], {"weight": 0.852806681370962}], ["FUT9", ["TCGA.CA.5254.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.852806681370962}], ["FUT9", ["TCGA.CA.5255.01", "Dectin-2 family"], {"weight": 0.581407119398382}], ["FUT9", ["TCGA.CA.5255.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.816808220120355}], ["FUT9", ["TCGA.CA.5256.01", "Blood group systems biosynthesis"], {"weight": 0.889885007771714}], ["FUT9", ["TCGA.CA.5256.01", "Lewis blood group biosynthesis"], {"weight": 0.837697288628874}], ["FUT9", ["TCGA.CK.5915.01", "Blood group systems biosynthesis"], {"weight": 0.938976922484982}], ["FUT9", ["TCGA.CK.5915.01", "Lewis blood group biosynthesis"], {"weight": 0.940701510121736}], ["FUT9", ["TCGA.CM.5860.01", "Blood group systems biosynthesis"], {"weight": 0.798602181521257}], ["FUT9", ["TCGA.CM.5868.01", "Blood group systems biosynthesis"], {"weight": 0.751236814104103}], ["FUT9", ["TCGA.CM.5868.01", "Lewis blood group biosynthesis"], {"weight": 0.618372498654179}], ["FUT9", ["TCGA.CM.6161.01", "Lewis blood group biosynthesis"], {"weight": 0.892835596598544}], ["FUT9", ["TCGA.CM.6161.01", "Blood group systems biosynthesis"], {"weight": 0.892835596598544}], ["FUT9", ["TCGA.CM.6161.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.815142647848889}], ["FUT9", ["TCGA.CM.6161.01", "Termination of O-glycan biosynthesis"], {"weight": 0.854536682833697}], ["FUT9", ["TCGA.CM.6169.01", "Blood group systems biosynthesis"], {"weight": 0.729103497914508}], ["FUT9", ["TCGA.D5.6529.01", "Blood group systems biosynthesis"], {"weight": 0.666654607541363}], ["FUT9", ["TCGA.D5.6531.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.86983020893588}], ["FUT9", ["TCGA.D5.6531.01", "Blood group systems biosynthesis"], {"weight": 0.8667263330626}], ["FUT9", ["TCGA.D5.6537.01", "Blood group systems biosynthesis"], {"weight": 0.934600648541525}], ["FUT9", ["TCGA.D5.6537.01", "Lewis blood group biosynthesis"], {"weight": 0.897053837829428}], ["FUT9", ["TCGA.D5.6898.01", "Blood group systems biosynthesis"], {"weight": 0.921920332087336}], ["FUT9", ["TCGA.D5.6898.01", "Lewis blood group biosynthesis"], {"weight": 0.920398686959788}], ["FUT9", ["TCGA.DM.A0X9.01", "Blood group systems biosynthesis"], {"weight": 0.763231173235955}], ["FUT9", ["TCGA.DM.A0X9.01", "Lewis blood group biosynthesis"], {"weight": 0.627767267672594}], ["FUT9", ["TCGA.F4.6459.01", "Blood group systems biosynthesis"], {"weight": 0.839556375098337}], ["FUT9", ["TCGA.F4.6459.01", "O-linked glycosylation of mucins"], {"weight": 0.900209142738945}], ["FUT9", ["TCGA.F4.6459.01", "Defective GALNT3 causes HFTC"], {"weight": 0.705478864048267}], ["FUT9", ["TCGA.F4.6459.01", "Defective GALNT12 causes CRCS1"], {"weight": 0.705478864048267}], ["FUT9", ["TCGA.F4.6459.01", "Defective C1GALT1C1 causes TNPS"], {"weight": 0.703161362663692}], ["FUT9", ["TCGA.F4.6459.01", "Dectin-2 family"], {"weight": 0.832725849737639}], ["FUT9", ["TCGA.F4.6704.01", "Blood group systems biosynthesis"], {"weight": 0.842076728395091}], ["FUT9", ["TCGA.F4.6704.01", "Lewis blood group biosynthesis"], {"weight": 0.836074074924678}], ["FUT9", ["TCGA.F4.6856.01", "O-linked glycosylation of mucins"], {"weight": 0.934373197902509}], ["FUT9", ["TCGA.G4.6306.01", "Blood group systems biosynthesis"], {"weight": 0.822401477371828}], ["FUT9", ["TCGA.G4.6306.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.847435290345841}], ["FUT9", ["TCGA.G4.6306.01", "Lewis blood group biosynthesis"], {"weight": 0.810955040144325}], ["FUT9", ["TCGA.NH.A6GA.01", "Blood group systems biosynthesis"], {"weight": 0.880115290139925}], ["FUT9", ["TCGA.NH.A6GA.01", "Lewis blood group biosynthesis"], {"weight": 0.827153968893582}], ["FUT9", ["TCGA.QL.A97D.01", "Keratan sulfate biosynthesis"], {"weight": 0.93209530289687}], ["FUT9", ["TCGA.QL.A97D.01", "Keratan sulfate/keratin metabolism"], {"weight": 0.93209530289687}], ["RAET1G", ["TCGA.AA.3655.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.905308372891656}], ["RAET1G", ["TCGA.AA.3837.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.360798316234107}], ["RAET1G", ["TCGA.AA.A029.01", "DAP12 signaling"], {"weight": 0.899364653665245}], ["RAET1G", ["TCGA.AA.A02H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.880431996638928}], ["RAET1G", ["TCGA.AD.6888.01", "DAP12 interactions"], {"weight": 0.928014351625509}], ["RAET1G", ["TCGA.AD.6888.01", "DAP12 signaling"], {"weight": 0.917391360740731}], ["RAET1G", ["TCGA.AY.6196.01", "Other semaphorin interactions"], {"weight": 0.609715377402844}], ["RAET1G", ["TCGA.AZ.6608.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.9312096729718}], ["RAET1G", ["TCGA.CA.5255.01", "DAP12 interactions"], {"weight": 0.92609705744132}], ["RAET1G", ["TCGA.CA.5255.01", "DAP12 signaling"], {"weight": 0.904031330376775}], ["RAET1G", ["TCGA.CK.5915.01", "DAP12 signaling"], {"weight": 0.925413818195086}], ["RAET1G", ["TCGA.CK.5915.01", "DAP12 interactions"], {"weight": 0.9305889228825}], ["RAET1G", ["TCGA.DM.A28K.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.934014022391927}], ["ULBP1", ["TCGA.AA.3854.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.893081166595949}], ["ULBP1", ["TCGA.DM.A28F.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.930631572680501}], ["ULBP3", ["TCGA.DM.A28K.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.761662116562223}], ["PPP1R14C", ["TCGA.AA.3664.01", "Molecules associated with elastic fibres"], {"weight": 0.746801822553269}], ["BCLAF1", ["TCGA.AA.A017.01", "L1CAM interactions"], {"weight": 0.866387579721076}], ["UST", ["TCGA.4T.AA8H.01", "Keratan sulfate biosynthesis"], {"weight": 0.930491818730753}], ["UST", ["TCGA.4T.AA8H.01", "Keratan sulfate/keratin metabolism"], {"weight": 0.930491818730753}], ["UST", ["TCGA.AA.3854.01", "Degradation of the extracellular matrix"], {"weight": 0.840311982201095}], ["UST", ["TCGA.AA.A02H.01", "Keratan sulfate biosynthesis"], {"weight": 0.901295291681068}], ["UST", ["TCGA.AA.A02H.01", "Keratan sulfate/keratin metabolism"], {"weight": 0.901295291681068}], ["UST", ["TCGA.AA.A02Y.01", "Keratan sulfate biosynthesis"], {"weight": 0.938923014412761}], ["UST", ["TCGA.AD.6888.01", "Keratan sulfate biosynthesis"], {"weight": 0.938553441896162}], ["UST", ["TCGA.AD.6888.01", "Keratan sulfate/keratin metabolism"], {"weight": 0.938553441896162}], ["UST", ["TCGA.AY.6196.01", "Diseases of glycosylation"], {"weight": 0.857445829419549}], ["UST", ["TCGA.AY.6196.01", "Diseases of metabolism"], {"weight": 0.788205147034319}], ["UST", ["TCGA.AY.6196.01", "ECM proteoglycans"], {"weight": 0.840775207053138}], ["UST", ["TCGA.AY.6196.01", "Chondroitin sulfate biosynthesis"], {"weight": 0.891605934244082}], ["UST", ["TCGA.AY.6196.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.954457066190091}], ["UST", ["TCGA.AZ.6608.01", "Keratan sulfate biosynthesis"], {"weight": 0.942430200399037}], ["UST", ["TCGA.CA.5254.01", "O-linked glycosylation"], {"weight": 0.924561090152883}], ["UST", ["TCGA.CA.5254.01", "O-linked glycosylation of mucins"], {"weight": 0.933422114825461}], ["UST", ["TCGA.CA.5255.01", "Keratan sulfate biosynthesis"], {"weight": 0.917225112411665}], ["UST", ["TCGA.CK.5915.01", "Keratan sulfate biosynthesis"], {"weight": 0.949242761333597}], ["UST", ["TCGA.D5.6529.01", "O-linked glycosylation"], {"weight": 0.827689200027181}], ["UST", ["TCGA.D5.6529.01", "Carbohydrate metabolism"], {"weight": 0.761664932495556}], ["UST", ["TCGA.D5.6535.01", "Keratan sulfate biosynthesis"], {"weight": 0.850658161556831}], ["UST", ["TCGA.DM.A28F.01", "Keratan sulfate biosynthesis"], {"weight": 0.933548814166456}], ["PREP", ["TCGA.A6.6652.01", "Voltage gated Potassium channels"], {"weight": 0.951205695089162}], ["PREP", ["TCGA.A6.6652.01", "Potassium Channels"], {"weight": 0.915234113311072}], ["PREP", ["TCGA.AA.3655.01", "Voltage gated Potassium channels"], {"weight": 0.867674987227544}], ["PREP", ["TCGA.AA.3660.01", "Potassium Channels"], {"weight": 0.824504572298315}], ["PREP", ["TCGA.AA.3841.01", "Potassium Channels"], {"weight": 0.923002382057879}], ["PREP", ["TCGA.AA.A02H.01", "Potassium Channels"], {"weight": 0.856186800474387}], ["PREP", ["TCGA.AA.A02Y.01", "Voltage gated Potassium channels"], {"weight": 0.940644382401305}], ["PREP", ["TCGA.AD.6888.01", "Voltage gated Potassium channels"], {"weight": 0.898883090685303}], ["PREP", ["TCGA.AD.A5EK.01", "Voltage gated Potassium channels"], {"weight": 0.890044001029642}], ["PREP", ["TCGA.AY.A8YK.01", "Voltage gated Potassium channels"], {"weight": 0.884426256910459}], ["PREP", ["TCGA.AZ.6608.01", "Potassium Channels"], {"weight": 0.922033296711017}], ["PREP", ["TCGA.AZ.6608.01", "Voltage gated Potassium channels"], {"weight": 0.878251370721757}], ["PREP", ["TCGA.CK.5915.01", "Voltage gated Potassium channels"], {"weight": 0.849931576070038}], ["PREP", ["TCGA.CM.5860.01", "Voltage gated Potassium channels"], {"weight": 0.906911116648823}], ["PREP", ["TCGA.CM.5860.01", "Sensory processing of sound by inner hair cells of the cochlea"], {"weight": 0.905798106245114}], ["PREP", ["TCGA.CM.6172.01", "Potassium Channels"], {"weight": 0.82165226431683}], ["PREP", ["TCGA.D5.6537.01", "Voltage gated Potassium channels"], {"weight": 0.933656532232796}], ["PREP", ["TCGA.DM.A28F.01", "Voltage gated Potassium channels"], {"weight": 0.917968920996511}], ["PREP", ["TCGA.QL.A97D.01", "Potassium Channels"], {"weight": 0.907281121163907}], ["PGM3", ["TCGA.AA.3561.01", "Amino acid and derivative metabolism"], {"weight": 0.905143889222243}], ["PGM3", ["TCGA.AD.A5EK.01", "Sialic acid metabolism"], {"weight": 0.721892872496726}], ["PGM3", ["TCGA.CM.6161.01", "Sialic acid metabolism"], {"weight": 0.625532476354555}], ["PGM3", ["TCGA.D5.6531.01", "Sialic acid metabolism"], {"weight": 0.679538030158651}], ["PGM3", ["TCGA.NH.A6GA.01", "Sialic acid metabolism"], {"weight": 0.654654448862848}], ["DSE", ["TCGA.4T.AA8H.01", "Diseases associated with glycosaminoglycan metabolism"], {"weight": 0.896913670454325}], ["DSE", ["TCGA.AA.3848.01", "Diseases associated with glycosaminoglycan metabolism"], {"weight": 0.872746270913517}], ["DSE", ["TCGA.AA.3870.01", "Extracellular matrix organization"], {"weight": 0.877651283082622}], ["DSE", ["TCGA.AA.3982.01", "Signaling by EGFR in Cancer"], {"weight": 0.588118385891186}], ["DSE", ["TCGA.AA.3982.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.668165624422709}], ["DSE", ["TCGA.AA.A02H.01", "Dermatan sulfate biosynthesis"], {"weight": 0.721343271985321}], ["DSE", ["TCGA.AA.A02J.01", "Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell"], {"weight": 0.810036953222881}], ["DSE", ["TCGA.AA.A02J.01", "Immune System"], {"weight": 0.896116214383642}], ["DSE", ["TCGA.AA.A02J.01", "MyD88 deficiency (TLR2/4)"], {"weight": 0.911872393873677}], ["DSE", ["TCGA.AA.A02J.01", "IRAK4 deficiency (TLR2/4)"], {"weight": 0.911872393873677}], ["DSE", ["TCGA.AA.A02J.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.88687774698625}], ["DSE", ["TCGA.AA.A02J.01", "Extracellular matrix organization"], {"weight": 0.902847944438817}], ["DSE", ["TCGA.AA.A02J.01", "Diseases of Immune System"], {"weight": 0.897052992128638}], ["DSE", ["TCGA.AA.A02J.01", "Diseases associated with the TLR signaling cascade"], {"weight": 0.897052992128638}], ["DSE", ["TCGA.AA.A02J.01", "Regulation of TLR by endogenous ligand"], {"weight": 0.896810207936032}], ["DSE", ["TCGA.AA.A02J.01", "Cytokine Signaling in Immune system"], {"weight": 0.870886575953205}], ["DSE", ["TCGA.AA.A02J.01", "Platelet activation, signaling and aggregation"], {"weight": 0.915643040959471}], ["DSE", ["TCGA.AA.A02J.01", "Cell surface interactions at the vascular wall"], {"weight": 0.804248394818181}], ["DSE", ["TCGA.AA.A02J.01", "Negative regulation of the PI3K/AKT network"], {"weight": 0.886104827459176}], ["DSE", ["TCGA.AA.A02J.01", "Adaptive Immune System"], {"weight": 0.902264517383979}], ["DSE", ["TCGA.AA.A02J.01", "G alpha (s) signalling events"], {"weight": 0.948440707936472}], ["DSE", ["TCGA.AA.A02J.01", "Molecules associated with elastic fibres"], {"weight": -0.0280698185490915}], ["DSE", ["TCGA.AA.A02J.01", "PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"], {"weight": 0.876551657321467}], ["DSE", ["TCGA.AA.A02J.01", "L1CAM interactions"], {"weight": 0.916782872929147}], ["DSE", ["TCGA.AA.A02J.01", "Keratan sulfate biosynthesis"], {"weight": 0.900620820592115}], ["DSE", ["TCGA.AA.A02J.01", "Other interleukin signaling"], {"weight": 0.656555643495238}], ["DSE", ["TCGA.AA.A02J.01", "Interferon gamma signaling"], {"weight": 0.903267278214546}], ["DSE", ["TCGA.AA.A02J.01", "Defensins"], {"weight": 0.693448002905006}], ["DSE", ["TCGA.AA.A02Y.01", "Diseases of glycosylation"], {"weight": 0.90911521926657}], ["DSE", ["TCGA.AA.A02Y.01", "ECM proteoglycans"], {"weight": 0.917650710722013}], ["DSE", ["TCGA.AA.A02Y.01", "Diseases associated with glycosaminoglycan metabolism"], {"weight": 0.921717579416547}], ["DSE", ["TCGA.AA.A02Y.01", "Defective B4GALT7 causes EDS, progeroid type"], {"weight": 0.917010615586652}], ["DSE", ["TCGA.AA.A02Y.01", "Defective B3GAT3 causes JDSSDHD"], {"weight": 0.917010615586652}], ["DSE", ["TCGA.AA.A02Y.01", "Defective B3GALT6 causes EDSP2 and SEMDJL1"], {"weight": 0.917010615586652}], ["DSE", ["TCGA.AA.A02Y.01", "Dermatan sulfate biosynthesis"], {"weight": 0.912529484121757}], ["DSE", ["TCGA.AA.A02Y.01", "Chondroitin sulfate biosynthesis"], {"weight": 0.917064288212477}], ["DSE", ["TCGA.AD.6888.01", "Diseases of glycosylation"], {"weight": 0.885687902279355}], ["DSE", ["TCGA.AZ.6600.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.821244328500537}], ["DSE", ["TCGA.AZ.6607.01", "ECM proteoglycans"], {"weight": 0.938821300103908}], ["DSE", ["TCGA.AZ.6607.01", "Chondroitin sulfate biosynthesis"], {"weight": 0.913469793903943}], ["DSE", ["TCGA.AZ.6607.01", "Diseases of glycosylation"], {"weight": 0.878877705017563}], ["DSE", ["TCGA.AZ.6608.01", "Diseases of glycosylation"], {"weight": 0.894898105299023}], ["DSE", ["TCGA.CA.5255.01", "Chondroitin sulfate biosynthesis"], {"weight": 0.886187979130367}], ["DSE", ["TCGA.CA.5255.01", "Diseases of glycosylation"], {"weight": 0.89686434947749}], ["DSE", ["TCGA.CM.6678.01", "Degradation of the extracellular matrix"], {"weight": 0.774389738435138}], ["DSE", ["TCGA.D5.5538.01", "Activation of Matrix Metalloproteinases"], {"weight": 0.860494884832612}], ["DSE", ["TCGA.D5.5538.01", "Extracellular matrix organization"], {"weight": 0.797653447621293}], ["DSE", ["TCGA.D5.5538.01", "Degradation of the extracellular matrix"], {"weight": 0.707602035604554}], ["DSE", ["TCGA.D5.5538.01", "O-linked glycosylation"], {"weight": 0.860504069251747}], ["DSE", ["TCGA.D5.5538.01", "L1CAM interactions"], {"weight": 0.864594974788085}], ["DSE", ["TCGA.D5.5538.01", "Signaling by GPCR"], {"weight": 0.914944596179797}], ["DSE", ["TCGA.D5.5538.01", "Diseases associated with O-glycosylation of proteins"], {"weight": 0.429229679906971}], ["DSE", ["TCGA.D5.5538.01", "G alpha (s) signalling events"], {"weight": 0.920416349462406}], ["DSE", ["TCGA.D5.5538.01", "Peptide hormone metabolism"], {"weight": 0.680279504866428}], ["DSE", ["TCGA.D5.5538.01", "Defective B3GALTL causes PpS"], {"weight": 0.749803555090502}], ["DSE", ["TCGA.D5.5538.01", "GPCR downstream signalling"], {"weight": 0.932832892285295}], ["DSE", ["TCGA.D5.5538.01", "O-glycosylation of TSR domain-containing proteins"], {"weight": 0.745747055340978}], ["DSE", ["TCGA.D5.5538.01", "Diseases of glycosylation"], {"weight": 0.828138139043017}], ["DSE", ["TCGA.D5.5538.01", "NCAM1 interactions"], {"weight": 0.874689042929669}], ["DSE", ["TCGA.F4.6704.01", "Chondroitin sulfate biosynthesis"], {"weight": 0.869680945580761}], ["DSE", ["TCGA.G4.6297.01", "ECM proteoglycans"], {"weight": 0.866872157189469}], ["DSE", ["TCGA.G4.6306.01", "ECM proteoglycans"], {"weight": 0.87153717796813}], ["DSE", ["TCGA.G4.6306.01", "Diseases of glycosylation"], {"weight": 0.891800158949336}], ["DSE", ["TCGA.G4.6314.01", "Extracellular matrix organization"], {"weight": 0.885764562913603}], ["DSE", ["TCGA.G4.6314.01", "Metabolism"], {"weight": 0.898331972483839}], ["DSE", ["TCGA.G4.6314.01", "ECM proteoglycans"], {"weight": 0.78286801100341}], ["KPNA5", ["TCGA.AA.3939.01", "Influenza Infection"], {"weight": 0.946694813429893}], ["KPNA5", ["TCGA.AA.3982.01", "Constitutive Signaling by Aberrant PI3K in Cancer"], {"weight": 0.644815985163915}], ["VNN1", ["TCGA.4T.AA8H.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.917176368683704}], ["VNN1", ["TCGA.AA.3685.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.826568000394837}], ["VNN1", ["TCGA.AA.3715.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.868245653955007}], ["VNN1", ["TCGA.AA.3837.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.879768118943249}], ["VNN1", ["TCGA.AA.3841.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.808446498769175}], ["VNN1", ["TCGA.AA.A02H.01", "Vitamin B5 (pantothenate) metabolism"], {"weight": 0.749432886625413}], ["VNN1", ["TCGA.AA.A02Y.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.936983849155554}], ["VNN1", ["TCGA.AD.6888.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.907821322265983}], ["VNN1", ["TCGA.AY.A8YK.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.884865413125676}], ["VNN1", ["TCGA.AZ.6607.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.879967763164449}], ["VNN1", ["TCGA.CM.4747.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.887879617573544}], ["VNN1", ["TCGA.D5.6537.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.927976063017453}], ["VNN1", ["TCGA.F4.6704.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.871730785857008}], ["VNN2", ["TCGA.A6.2678.01", "Post-translational modification: synthesis of GPI-anchored proteins"], {"weight": 0.857149555760545}], ["TUBE1", ["TCGA.AA.3837.01", "Carboxyterminal post-translational modifications of tubulin"], {"weight": 0.287324616568404}], ["FUCA2", ["TCGA.AA.3655.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.925789459474075}], ["FUCA2", ["TCGA.AA.3685.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.913091227009635}], ["FUCA2", ["TCGA.AA.3715.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.856623642237165}], ["FUCA2", ["TCGA.AA.3837.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.894934483727421}], ["FUCA2", ["TCGA.AA.3841.01", "Post-translational protein phosphorylation"], {"weight": 0.891285775455374}], ["FUCA2", ["TCGA.AA.3841.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.909567106340083}], ["FUCA2", ["TCGA.AA.3860.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.903119838440424}], ["FUCA2", ["TCGA.AA.3875.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.831122230255583}], ["FUCA2", ["TCGA.AA.3939.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.857399638810533}], ["FUCA2", ["TCGA.AA.3941.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.891379963216934}], ["FUCA2", ["TCGA.AA.A00J.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.890790606750214}], ["FUCA2", ["TCGA.AA.A02Y.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.971481256341981}], ["FUCA2", ["TCGA.AA.A02Y.01", "Post-translational protein phosphorylation"], {"weight": 0.971469411088604}], ["FUCA2", ["TCGA.AD.6888.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.970614368937555}], ["FUCA2", ["TCGA.AD.A5EK.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.850465786489188}], ["FUCA2", ["TCGA.AD.A5EK.01", "Post-translational protein phosphorylation"], {"weight": 0.864087369026342}], ["FUCA2", ["TCGA.AZ.6598.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.884541106699972}], ["FUCA2", ["TCGA.AZ.6607.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.849869363857167}], ["FUCA2", ["TCGA.AZ.6608.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.970113448600598}], ["FUCA2", ["TCGA.AZ.6608.01", "Post-translational protein phosphorylation"], {"weight": 0.968517601852748}], ["FUCA2", ["TCGA.CA.5254.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.915425477272023}], ["FUCA2", ["TCGA.CA.5255.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.963006431054758}], ["FUCA2", ["TCGA.CA.5255.01", "Post-translational protein phosphorylation"], {"weight": 0.964653721137657}], ["FUCA2", ["TCGA.CM.5348.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.864309624328622}], ["FUCA2", ["TCGA.F4.6459.01", "Post-translational protein phosphorylation"], {"weight": 0.807579393440406}], ["FUCA2", ["TCGA.G4.6297.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.757291687449125}], ["FUCA2", ["TCGA.G4.6306.01", "Regulation of IGF Activity by IGFBP"], {"weight": 0.966627286185436}], ["ADAT2", ["TCGA.AA.3841.01", "tRNA modification in the nucleus and cytosol"], {"weight": 0.0658712244544708}]], "not_cover_set": ["IL22RA2", "MTRF1L", "PEX7", "HECA", "HACE1", "FBXO30", "BEND3", "SEC63", "FRMD1", "PHF10", "MICAL1", "UBE3D", "DOPEY1", "MDN1", "CLVS2", "TAAR8", "TAAR6", "TBPL1", "ZBTB2", "RAET1E", "ULBP2", "RAET1L", "PNISR", "CLDN20", "MAP7", "MPC1", "QRSL1", "FIG4", "RWDD1", "SRSF12", "COQ3", "GABRR1", ["TCGA.A6.2685.01", "Amino acid transport across the plasma membrane"], ["TCGA.A6.5660.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.A6.5660.01", "RA biosynthesis pathway"], ["TCGA.A6.5660.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.A6.5660.01", "CD22 mediated BCR regulation"], ["TCGA.A6.5660.01", "Amino acid transport across the plasma membrane"], ["TCGA.A6.5660.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.A6.5660.01", "Blood group systems biosynthesis"], ["TCGA.A6.5660.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.5660.01", "Aspirin ADME"], ["TCGA.A6.5660.01", "Heme degradation"], ["TCGA.A6.5660.01", "Collagen chain trimerization"], ["TCGA.A6.6137.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.A6.6142.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.6142.01", "Collagen formation"], ["TCGA.A6.6142.01", "Collagen chain trimerization"], ["TCGA.A6.6142.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.A6.6142.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.6142.01", "Interaction between L1 and Ankyrins"], ["TCGA.A6.6142.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.A6.6142.01", "ECM proteoglycans"], ["TCGA.A6.6142.01", "Metal ion SLC transporters"], ["TCGA.A6.6142.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.A6.6142.01", "Interleukin-6 family signaling"], ["TCGA.A6.6142.01", "NCAM1 interactions"], ["TCGA.A6.6142.01", "Amino acid transport across the plasma membrane"], ["TCGA.A6.6142.01", "NCAM signaling for neurite out-growth"], ["TCGA.A6.6142.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.A6.6142.01", "Neurexins and neuroligins"], ["TCGA.A6.6142.01", "Keratinization"], ["TCGA.A6.6142.01", "Zinc transporters"], ["TCGA.A6.6142.01", "Glycosaminoglycan metabolism"], ["TCGA.A6.6142.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.A6.6142.01", "Heme degradation"], ["TCGA.A6.6142.01", "Collagen degradation"], ["TCGA.A6.6142.01", "ERBB2 Activates PTK6 Signaling"], ["TCGA.A6.6648.01", "DNA methylation"], ["TCGA.A6.6648.01", "Initial triggering of complement"], ["TCGA.A6.6648.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.A6.6648.01", "Classical antibody-mediated complement activation"], ["TCGA.A6.6648.01", "Amino acid transport across the plasma membrane"], ["TCGA.A6.6648.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.A6.6648.01", "Arachidonic acid metabolism"], ["TCGA.A6.6654.01", "Collagen formation"], ["TCGA.A6.6654.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.A6.6654.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.A6.6654.01", "Collagen chain trimerization"], ["TCGA.A6.6654.01", "Activation of Matrix Metalloproteinases"], ["TCGA.A6.6654.01", "Collagen degradation"], ["TCGA.A6.6654.01", "Ethanol oxidation"], ["TCGA.A6.6654.01", "RA biosynthesis pathway"], ["TCGA.A6.6654.01", "Chondroitin sulfate biosynthesis"], ["TCGA.A6.6654.01", "O-linked glycosylation"], ["TCGA.A6.6654.01", "Keratinization"], ["TCGA.A6.6654.01", "Glycosaminoglycan metabolism"], ["TCGA.A6.6654.01", "Integrin cell surface interactions"], ["TCGA.A6.6654.01", "Defective B3GALTL causes PpS"], ["TCGA.A6.6654.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.A6.6654.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.A6.6654.01", "ECM proteoglycans"], ["TCGA.A6.6654.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.A6.6654.01", "Signaling by PDGF"], ["TCGA.A6.6654.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.A6.6654.01", "Blood group systems biosynthesis"], ["TCGA.A6.6654.01", "Diseases of glycosylation"], ["TCGA.A6.6654.01", "TNFs bind their physiological receptors"], ["TCGA.A6.6654.01", "Class B/2 (Secretin family receptors)"], ["TCGA.A6.6654.01", "Interleukin-6 family signaling"], ["TCGA.A6.A56B.01", "Phase II - Conjugation of compounds"], ["TCGA.A6.A56B.01", "Glucuronidation"], ["TCGA.A6.A56B.01", "Ethanol oxidation"], ["TCGA.A6.A56B.01", "RA biosynthesis pathway"], ["TCGA.A6.A56B.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.A6.A56B.01", "Aspirin ADME"], ["TCGA.A6.A56B.01", "Blood group systems biosynthesis"], ["TCGA.A6.A56B.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.A6.A56B.01", "Digestion and absorption"], ["TCGA.A6.A56B.01", "Lewis blood group biosynthesis"], ["TCGA.A6.A56B.01", "Mitochondrial Fatty Acid Beta-Oxidation"], ["TCGA.A6.A56B.01", "APAP ADME"], ["TCGA.A6.A56B.01", "Classical antibody-mediated complement activation"], ["TCGA.A6.A56B.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.A6.A56B.01", "Defective GALNT12 causes CRCS1"], ["TCGA.A6.A56B.01", "mitochondrial fatty acid beta-oxidation of saturated fatty acids"], ["TCGA.A6.A56B.01", "O-linked glycosylation of mucins"], ["TCGA.A6.A56B.01", "Digestion"], ["TCGA.AA.3556.01", "Defective GALNT12 causes CRCS1"], ["TCGA.AA.3556.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3556.01", "Synaptic adhesion-like molecules"], ["TCGA.AA.3556.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3556.01", "Defective GALNT3 causes HFTC"], ["TCGA.AA.3556.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.AA.3556.01", "RA biosynthesis pathway"], ["TCGA.AA.3556.01", "Termination of O-glycan biosynthesis"], ["TCGA.AA.3556.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.3556.01", "APAP ADME"], ["TCGA.AA.3556.01", "Erythrocytes take up carbon dioxide and release oxygen"], "ZBTB24", "KLHL32", ["TCGA.AA.3664.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3664.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.3664.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.3814.01", "Phase II - Conjugation of compounds"], "RAB32", ["TCGA.AA.3842.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3842.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.3842.01", "Collagen chain trimerization"], ["TCGA.AA.3842.01", "Cardiac conduction"], ["TCGA.AA.3842.01", "Blood group systems biosynthesis"], ["TCGA.AA.3842.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3842.01", "Phase 2 - plateau phase"], ["TCGA.AA.3842.01", "Glucuronidation"], ["TCGA.AA.3842.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.3848.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3848.01", "Integration of provirus"], ["TCGA.AA.3875.01", "Binding and entry of HIV virion"], ["TCGA.AA.3875.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3952.01", "Uptake and function of anthrax toxins"], ["TCGA.AA.3956.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.3956.01", "Blood group systems biosynthesis"], ["TCGA.AA.3956.01", "Presynaptic nicotinic acetylcholine receptors"], ["TCGA.AA.3956.01", "Binding and entry of HIV virion"], ["TCGA.AA.3956.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.3956.01", "Defensins"], ["TCGA.AA.3956.01", "Heme degradation"], ["TCGA.AA.3956.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3956.01", "Recycling of bile acids and salts"], ["TCGA.AA.3956.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.AA.3956.01", "Basigin interactions"], ["TCGA.AA.3956.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3956.01", "Acetylcholine binding and downstream events"], ["TCGA.AA.3956.01", "Postsynaptic nicotinic acetylcholine receptors"], ["TCGA.AA.3956.01", "Carboxyterminal post-translational modifications of tubulin"], ["TCGA.AA.3956.01", "IL-6-type cytokine receptor ligand interactions"], ["TCGA.AA.3956.01", "JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1"], ["TCGA.AA.3956.01", "Lewis blood group biosynthesis"], ["TCGA.AA.3956.01", "Scavenging by Class A Receptors"], ["TCGA.AA.3956.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3956.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AA.3956.01", "Regulation of gene expression in beta cells"], ["TCGA.AA.3956.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3956.01", "Integration of provirus"], ["TCGA.AA.3956.01", "Collagen chain trimerization"], ["TCGA.AA.3956.01", "Nucleotide catabolism"], ["TCGA.AA.3956.01", "Binding and Uptake of Ligands by Scavenger Receptors"], ["TCGA.AA.3971.01", "Ethanol oxidation"], ["TCGA.AA.3971.01", "RA biosynthesis pathway"], ["TCGA.AA.3971.01", "Binding and entry of HIV virion"], ["TCGA.AA.3971.01", "Heme degradation"], ["TCGA.AA.3971.01", "Recycling of bile acids and salts"], ["TCGA.AA.3971.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3971.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3971.01", "Scavenging by Class A Receptors"], ["TCGA.AA.3971.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3971.01", "Bile acid and bile salt metabolism"], ["TCGA.AA.3971.01", "Synthesis of Leukotrienes (LT) and Eoxins (EX)"], ["TCGA.AA.3971.01", "Integration of provirus"], ["TCGA.AA.3979.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.3979.01", "Ethanol oxidation"], ["TCGA.AA.3979.01", "RA biosynthesis pathway"], ["TCGA.AA.3982.01", "RA biosynthesis pathway"], ["TCGA.AA.3982.01", "DNA methylation"], ["TCGA.AA.3982.01", "Digestion"], ["TCGA.AA.3982.01", "Glucuronidation"], ["TCGA.AA.3982.01", "Digestion and absorption"], ["TCGA.AA.3982.01", "Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components"], ["TCGA.AA.3982.01", "Inactivation of APC/C via direct inhibition of the APC/C complex"], ["TCGA.AA.3982.01", "Ethanol oxidation"], ["TCGA.AA.3982.01", "Binding and entry of HIV virion"], ["TCGA.AA.3982.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.AA.3982.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.AA.3982.01", "Physiological factors"], ["TCGA.AA.3982.01", "Triglyceride biosynthesis"], ["TCGA.AA.3982.01", "Ribavirin ADME"], ["TCGA.AA.3982.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.3982.01", "Recycling of bile acids and salts"], ["TCGA.AA.3982.01", "alpha-linolenic (omega3) and linoleic (omega6) acid metabolism"], ["TCGA.AA.3982.01", "alpha-linolenic acid (ALA) metabolism"], ["TCGA.AA.3982.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.AA.3982.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.3982.01", "Metabolism of folate and pterines"], ["TCGA.AA.3982.01", "Basigin interactions"], ["TCGA.AA.3982.01", "Signaling by Activin"], ["TCGA.AA.3982.01", "Glutamate Neurotransmitter Release Cycle"], ["TCGA.AA.3982.01", "Biosynthesis of DHA-derived SPMs"], ["TCGA.AA.3982.01", "Aberrant regulation of mitotic exit in cancer due to RB1 defects"], ["TCGA.AA.3982.01", "Amino acid transport across the plasma membrane"], ["TCGA.AA.3982.01", "Metabolism of amine-derived hormones"], ["TCGA.AA.3982.01", "Nucleotide salvage"], ["TCGA.AA.3982.01", "Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase"], ["TCGA.AA.3982.01", "Phosphorylation of the APC/C"], ["TCGA.AA.3982.01", "Synthesis, secretion, and deacylation of Ghrelin"], ["TCGA.AA.3982.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.AA.A00A.01", "RA biosynthesis pathway"], ["TCGA.AA.A00A.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.AA.A00O.01", "Defective GALNT12 causes CRCS1"], ["TCGA.AA.A00O.01", "APAP ADME"], ["TCGA.AA.A00O.01", "Phase II - Conjugation of compounds"], ["TCGA.AA.A00O.01", "O-linked glycosylation of mucins"], ["TCGA.AA.A00O.01", "Transport of bile salts and organic acids, metal ions and amine compounds"], ["TCGA.AA.A00O.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AA.A00O.01", "Defective GALNT3 causes HFTC"], ["TCGA.AA.A00O.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.AA.A00O.01", "Digestion"], ["TCGA.AA.A00O.01", "Termination of O-glycan biosynthesis"], ["TCGA.AA.A00O.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A00O.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AA.A00O.01", "FGFRL1 modulation of FGFR1 signaling"], ["TCGA.AA.A00O.01", "Aspirin ADME"], ["TCGA.AA.A00O.01", "FGFR4 ligand binding and activation"], ["TCGA.AA.A00O.01", "Blood group systems biosynthesis"], ["TCGA.AA.A017.01", "Ethanol oxidation"], ["TCGA.AA.A017.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.A017.01", "Blood group systems biosynthesis"], ["TCGA.AA.A02E.01", "RA biosynthesis pathway"], ["TCGA.AA.A02H.01", "Degradation of cysteine and homocysteine"], ["TCGA.AA.A02J.01", "Cardiac conduction"], ["TCGA.AA.A02J.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AA.A02J.01", "Regulation of insulin secretion"], ["TCGA.AA.A02J.01", "Chemokine receptors bind chemokines"], ["TCGA.AA.A02J.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AA.A02J.01", "Classical antibody-mediated complement activation"], ["TCGA.AA.A02J.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AA.A02J.01", "Interaction between L1 and Ankyrins"], ["TCGA.AA.A02J.01", "Initial triggering of complement"], ["TCGA.AA.A02J.01", "Potassium Channels"], ["TCGA.AA.A02J.01", "G beta:gamma signalling through BTK"], ["TCGA.AA.A02J.01", "Phase 0 - rapid depolarisation"], ["TCGA.AA.A02J.01", "Antigen activates B Cell Receptor (BCR) leading to generation of second messengers"], ["TCGA.AA.A02J.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AA.A02J.01", "Glucagon-type ligand receptors"], ["TCGA.AA.A02J.01", "Interleukin-10 signaling"], ["TCGA.AA.A02J.01", "Glucagon-like Peptide-1 (GLP1) regulates insulin secretion"], ["TCGA.AA.A02J.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AA.A02J.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.AA.A02J.01", "Creation of C4 and C2 activators"], ["TCGA.AA.A02J.01", "Signal amplification"], ["TCGA.AA.A02J.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.AA.A02J.01", "Presynaptic function of Kainate receptors"], ["TCGA.AA.A02J.01", "Binding and entry of HIV virion"], ["TCGA.AA.A02J.01", "FCGR activation"], ["TCGA.AA.A02J.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AA.A02J.01", "G alpha (z) signalling events"], ["TCGA.AA.A02J.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AA.A02J.01", "Blood group systems biosynthesis"], ["TCGA.AA.A02J.01", "Purinergic signaling in leishmaniasis infection"], ["TCGA.AA.A02J.01", "Cell recruitment (pro-inflammatory response)"], ["TCGA.AA.A02J.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AA.A02J.01", "G-protein mediated events"], ["TCGA.AA.A02J.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AA.A02J.01", "Ca-dependent events"], ["TCGA.AA.A02J.01", "YAP1- and WWTR1 (TAZ)-stimulated gene expression"], ["TCGA.AA.A02J.01", "CD22 mediated BCR regulation"], ["TCGA.AA.A02J.01", "Lewis blood group biosynthesis"], ["TCGA.AA.A02J.01", "Unwinding of DNA"], ["TCGA.AA.A02J.01", "Ion homeostasis"], ["TCGA.AA.A02J.01", "Aquaporin-mediated transport"], ["TCGA.AA.A02J.01", "Calmodulin induced events"], ["TCGA.AA.A02J.01", "CaM pathway"], ["TCGA.AA.A02J.01", "PLC beta mediated events"], ["TCGA.AA.A02J.01", "Heme degradation"], ["TCGA.AA.A02J.01", "Physiological factors"], ["TCGA.AU.6004.01", "Interaction between L1 and Ankyrins"], ["TCGA.AU.6004.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AU.6004.01", "Collagen chain trimerization"], ["TCGA.AU.6004.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.AU.6004.01", "Glucuronidation"], ["TCGA.AU.6004.01", "O-linked glycosylation"], ["TCGA.AU.6004.01", "Aspirin ADME"], ["TCGA.AU.6004.01", "RA biosynthesis pathway"], ["TCGA.AU.6004.01", "Inwardly rectifying K+ channels"], ["TCGA.AU.6004.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.AU.6004.01", "Cytosolic sulfonation of small molecules"], ["TCGA.AU.6004.01", "Phase 0 - rapid depolarisation"], ["TCGA.AU.6004.01", "Ethanol oxidation"], ["TCGA.AU.6004.01", "O-linked glycosylation of mucins"], ["TCGA.AU.6004.01", "GABA receptor activation"], ["TCGA.AU.6004.01", "Keratinization"], ["TCGA.AU.6004.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AU.6004.01", "Activation of G protein gated Potassium channels"], ["TCGA.AU.6004.01", "G protein gated Potassium channels"], ["TCGA.AU.6004.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AY.6197.01", "Cardiac conduction"], ["TCGA.AY.6197.01", "Interaction between L1 and Ankyrins"], ["TCGA.AY.6197.01", "Class B/2 (Secretin family receptors)"], ["TCGA.AY.6197.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AY.6197.01", "Sialic acid metabolism"], ["TCGA.AY.6197.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AY.6197.01", "Phase 0 - rapid depolarisation"], ["TCGA.AY.6197.01", "Transcriptional regulation of testis differentiation"], ["TCGA.AY.6197.01", "Blood group systems biosynthesis"], ["TCGA.AY.6197.01", "Ion homeostasis"], ["TCGA.AY.6197.01", "SLC-mediated transmembrane transport"], ["TCGA.AY.6197.01", "Potassium Channels"], ["TCGA.AY.6197.01", "Glucagon signaling in metabolic regulation"], ["TCGA.AY.6197.01", "Glucagon-type ligand receptors"], ["TCGA.AY.6197.01", "Lewis blood group biosynthesis"], ["TCGA.AY.6197.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AY.6197.01", "Scavenging by Class A Receptors"], ["TCGA.AY.6197.01", "Platelet calcium homeostasis"], ["TCGA.AY.6197.01", "O-linked glycosylation of mucins"], ["TCGA.AY.6197.01", "Neurotransmitter release cycle"], ["TCGA.AY.6197.01", "Keratan sulfate biosynthesis"], ["TCGA.AY.6197.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.AY.6197.01", "Initial triggering of complement"], ["TCGA.AY.6197.01", "Insulin processing"], ["TCGA.AY.6197.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.AY.6197.01", "RA biosynthesis pathway"], ["TCGA.AY.6197.01", "Termination of O-glycan biosynthesis"], ["TCGA.AY.6197.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.AZ.4681.01", "Unwinding of DNA"], ["TCGA.AZ.4681.01", "DNA strand elongation"], ["TCGA.AZ.4681.01", "G beta:gamma signalling through PI3Kgamma"], ["TCGA.AZ.4681.01", "G beta:gamma signalling through BTK"], ["TCGA.AZ.4681.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.AZ.4681.01", "ADP signalling through P2Y purinoceptor 1"], ["TCGA.AZ.4681.01", "Post-chaperonin tubulin folding pathway"], ["TCGA.AZ.4681.01", "tRNA modification in the nucleus and cytosol"], ["TCGA.AZ.4681.01", "Signal amplification"], ["TCGA.AZ.4681.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.AZ.4681.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.4681.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.AZ.4681.01", "G beta:gamma signalling through PLC beta"], ["TCGA.AZ.4681.01", "Thromboxane signalling through TP receptor"], ["TCGA.AZ.4681.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.AZ.4681.01", "Presynaptic function of Kainate receptors"], ["TCGA.AZ.4681.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.AZ.4681.01", "Telomere Maintenance"], ["TCGA.AZ.4681.01", "Chromosome Maintenance"], ["TCGA.AZ.4681.01", "Recycling of bile acids and salts"], ["TCGA.AZ.4681.01", "Activation of G protein gated Potassium channels"], ["TCGA.AZ.4681.01", "G protein gated Potassium channels"], ["TCGA.AZ.4681.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.4681.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.AZ.4681.01", "Digestion"], ["TCGA.AZ.4681.01", "GABA B receptor activation"], ["TCGA.AZ.4681.01", "Activation of GABAB receptors"], ["TCGA.AZ.4681.01", "GABA receptor activation"], ["TCGA.AZ.4681.01", "Activation of the pre-replicative complex"], ["TCGA.AZ.6600.01", "Amino acid transport across the plasma membrane"], ["TCGA.AZ.6600.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.AZ.6603.01", "RA biosynthesis pathway"], ["TCGA.AZ.6603.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.AZ.6603.01", "Protein-protein interactions at synapses"], ["TCGA.AZ.6603.01", "Interaction between L1 and Ankyrins"], ["TCGA.AZ.6603.01", "APAP ADME"], ["TCGA.AZ.6603.01", "Glucagon-type ligand receptors"], ["TCGA.AZ.6603.01", "Class B/2 (Secretin family receptors)"], ["TCGA.CK.6746.01", "Phase II - Conjugation of compounds"], ["TCGA.CK.6746.01", "Glucuronidation"], ["TCGA.CK.6746.01", "Potassium Channels"], ["TCGA.CK.6746.01", "Aspirin ADME"], ["TCGA.CK.6746.01", "Defective GALNT3 causes HFTC"], ["TCGA.CK.6746.01", "Defective GALNT12 causes CRCS1"], ["TCGA.CK.6746.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.CK.6746.01", "Cytosolic sulfonation of small molecules"], ["TCGA.CK.6746.01", "APAP ADME"], ["TCGA.CK.6746.01", "Blood group systems biosynthesis"], ["TCGA.CK.6746.01", "Uptake and actions of bacterial toxins"], ["TCGA.CK.6746.01", "Ethanol oxidation"], ["TCGA.CK.6746.01", "RA biosynthesis pathway"], ["TCGA.CK.6746.01", "Voltage gated Potassium channels"], ["TCGA.CK.6746.01", "Dectin-2 family"], ["TCGA.CK.6746.01", "Collagen chain trimerization"], ["TCGA.CK.6746.01", "O-linked glycosylation of mucins"], ["TCGA.CK.6746.01", "Termination of O-glycan biosynthesis"], ["TCGA.CK.6746.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.CK.6746.01", "Lewis blood group biosynthesis"], ["TCGA.CK.6746.01", "CD22 mediated BCR regulation"], ["TCGA.CK.6746.01", "Digestion"], ["TCGA.CK.6746.01", "Ion transport by P-type ATPases"], ["TCGA.CK.6746.01", "Heme degradation"], ["TCGA.CK.6746.01", "Sodium/Calcium exchangers"], ["TCGA.CK.6746.01", "CRMPs in Sema3A signaling"], ["TCGA.CK.6746.01", "Aflatoxin activation and detoxification"], ["TCGA.CK.6746.01", "Glucagon-type ligand receptors"], ["TCGA.CM.4743.01", "Phase 0 - rapid depolarisation"], ["TCGA.CM.4743.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.CM.4743.01", "Classical antibody-mediated complement activation"], ["TCGA.CM.4752.01", "Ethanol oxidation"], ["TCGA.CM.4752.01", "Heme degradation"], ["TCGA.CM.5860.01", "RA biosynthesis pathway"], ["TCGA.CM.5868.01", "RA biosynthesis pathway"], ["TCGA.CM.6167.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.CM.6169.01", "RA biosynthesis pathway"], ["TCGA.D5.5538.01", "Neurexins and neuroligins"], ["TCGA.D5.5538.01", "Interaction between L1 and Ankyrins"], ["TCGA.D5.5538.01", "Cardiac conduction"], ["TCGA.D5.5538.01", "Phase 0 - rapid depolarisation"], ["TCGA.D5.5538.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.D5.5538.01", "Ethanol oxidation"], ["TCGA.D5.5538.01", "Dopamine Neurotransmitter Release Cycle"], ["TCGA.D5.5538.01", "Biological oxidations"], ["TCGA.D5.5538.01", "RA biosynthesis pathway"], ["TCGA.D5.5538.01", "Ion channel transport"], ["TCGA.D5.5538.01", "Serotonin Neurotransmitter Release Cycle"], ["TCGA.D5.5538.01", "Neurotransmitter release cycle"], ["TCGA.D5.5538.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.D5.5538.01", "Potassium Channels"], ["TCGA.D5.5538.01", "Defective GALNT12 causes CRCS1"], ["TCGA.D5.5538.01", "O-linked glycosylation of mucins"], ["TCGA.D5.5538.01", "Glucagon-type ligand receptors"], ["TCGA.D5.5538.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.D5.5538.01", "GABA receptor activation"], ["TCGA.D5.5538.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.D5.5538.01", "Cytosolic sulfonation of small molecules"], ["TCGA.D5.5538.01", "Stimuli-sensing channels"], ["TCGA.D5.5538.01", "Transport of inorganic cations/anions and amino acids/oligopeptides"], ["TCGA.D5.5538.01", "Phase I - Functionalization of compounds"], ["TCGA.D5.5538.01", "Ion homeostasis"], ["TCGA.D5.5538.01", "Ion transport by P-type ATPases"], ["TCGA.D5.5538.01", "Lewis blood group biosynthesis"], ["TCGA.D5.5538.01", "Signaling by Retinoic Acid"], ["TCGA.D5.5538.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.D5.5538.01", "Phase 4 - resting membrane potential"], ["TCGA.D5.5538.01", "Blood group systems biosynthesis"], ["TCGA.D5.5538.01", "Defective GALNT3 causes HFTC"], ["TCGA.D5.5538.01", "Voltage gated Potassium channels"], ["TCGA.D5.5538.01", "Regulation of insulin secretion"], ["TCGA.D5.5538.01", "Glucuronidation"], ["TCGA.D5.5538.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.D5.5538.01", "Phase II - Conjugation of compounds"], ["TCGA.D5.5538.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.D5.5541.01", "Amino acid transport across the plasma membrane"], ["TCGA.D5.6932.01", "Glucuronidation"], ["TCGA.D5.6932.01", "Aspirin ADME"], ["TCGA.D5.6932.01", "Amino acid transport across the plasma membrane"], ["TCGA.D5.6932.01", "Ethanol oxidation"], ["TCGA.D5.6932.01", "Post-translational modification: synthesis of GPI-anchored proteins"], ["TCGA.D5.6932.01", "Cytosolic sulfonation of small molecules"], ["TCGA.DM.A28H.01", "Translocation of ZAP-70 to Immunological synapse"], ["TCGA.DM.A28H.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.DM.A28H.01", "PD-1 signaling"], ["TCGA.DM.A28H.01", "Generation of second messenger molecules"], ["TCGA.DM.A28H.01", "Initial triggering of complement"], ["TCGA.DM.A28H.01", "Classical antibody-mediated complement activation"], ["TCGA.DM.A28H.01", "Unwinding of DNA"], ["TCGA.DM.A28H.01", "Creation of C4 and C2 activators"], ["TCGA.DM.A28H.01", "Interaction between L1 and Ankyrins"], ["TCGA.DM.A28H.01", "Molecules associated with elastic fibres"], ["TCGA.DM.A28H.01", "Blood group systems biosynthesis"], ["TCGA.DM.A28H.01", "Endosomal/Vacuolar pathway"], ["TCGA.DM.A28H.01", "Activation of ATR in response to replication stress"], ["TCGA.DM.A28H.01", "Lewis blood group biosynthesis"], ["TCGA.DM.A28H.01", "Interleukin-35 Signalling"], ["TCGA.DM.A28H.01", "Voltage gated Potassium channels"], ["TCGA.DM.A28H.01", "Protein-protein interactions at synapses"], ["TCGA.DM.A28H.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.DM.A28H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.DM.A28H.01", "APOBEC3G mediated resistance to HIV-1 infection"], ["TCGA.DM.A28H.01", "Trafficking and processing of endosomal TLR"], ["TCGA.DM.A28H.01", "Interleukin-27 signaling"], ["TCGA.DM.A28H.01", "Interleukin-2 family signaling"], ["TCGA.F4.6856.01", "Classical antibody-mediated complement activation"], ["TCGA.G4.6299.01", "Amino acid transport across the plasma membrane"], ["TCGA.G4.6314.01", "Phase II - Conjugation of compounds"], ["TCGA.G4.6314.01", "Glucuronidation"], ["TCGA.G4.6314.01", "RA biosynthesis pathway"], ["TCGA.G4.6314.01", "Ethanol oxidation"], ["TCGA.G4.6314.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.G4.6314.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6314.01", "APAP ADME"], ["TCGA.G4.6314.01", "Aflatoxin activation and detoxification"], ["TCGA.G4.6314.01", "Peroxisomal lipid metabolism"], ["TCGA.G4.6322.01", "Interaction between L1 and Ankyrins"], ["TCGA.G4.6322.01", "Phase I - Functionalization of compounds"], ["TCGA.G4.6322.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6322.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.G4.6322.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.G4.6322.01", "Aspirin ADME"], ["TCGA.G4.6322.01", "Arachidonic acid metabolism"], ["TCGA.G4.6322.01", "Bile acid and bile salt metabolism"], ["TCGA.G4.6322.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.G4.6626.01", "Class A/1 (Rhodopsin-like receptors)"], ["TCGA.G4.6626.01", "Initial triggering of complement"], ["TCGA.G4.6626.01", "Peptide ligand-binding receptors"], ["TCGA.G4.6626.01", "Classical antibody-mediated complement activation"], ["TCGA.G4.6626.01", "Other interleukin signaling"], ["TCGA.G4.6626.01", "Complement cascade"], ["TCGA.G4.6626.01", "MyD88 deficiency (TLR2/4)"], ["TCGA.G4.6626.01", "IRAK4 deficiency (TLR2/4)"], ["TCGA.G4.6626.01", "Diseases of Immune System"], ["TCGA.G4.6626.01", "Diseases associated with the TLR signaling cascade"], ["TCGA.G4.6626.01", "Creation of C4 and C2 activators"], ["TCGA.G4.6626.01", "Glucuronidation"], ["TCGA.G4.6626.01", "Phase II - Conjugation of compounds"], ["TCGA.G4.6626.01", "Regulation of Complement cascade"], ["TCGA.G4.6626.01", "Activation of Matrix Metalloproteinases"], ["TCGA.G4.6626.01", "Arachidonic acid metabolism"], ["TCGA.G4.6626.01", "Acetylcholine Neurotransmitter Release Cycle"], ["TCGA.G4.6626.01", "Chemokine receptors bind chemokines"], ["TCGA.G4.6626.01", "Phosphorylation of CD3 and TCR zeta chains"], ["TCGA.G4.6626.01", "POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation"], ["TCGA.G4.6626.01", "CD22 mediated BCR regulation"], ["TCGA.G4.6626.01", "Cytosolic sulfonation of small molecules"], ["TCGA.G4.6626.01", "Transcriptional regulation of testis differentiation"], ["TCGA.G4.6626.01", "Negative regulation of TCF-dependent signaling by WNT ligand antagonists"], ["TCGA.G4.6626.01", "Regulation of TLR by endogenous ligand"], ["TCGA.G4.6626.01", "Interleukin-10 signaling"], ["TCGA.G4.6626.01", "NCAM1 interactions"], ["TCGA.G4.6626.01", "Biosynthesis of specialized proresolving mediators (SPMs)"], ["TCGA.G4.6626.01", "FCGR3A-mediated IL10 synthesis"], ["TCGA.G4.6626.01", "Insulin processing"], ["TCGA.G4.6626.01", "Bile acid and bile salt metabolism"], ["TCGA.G4.6626.01", "Sialic acid metabolism"], ["TCGA.NH.A6GB.01", "Amino acid transport across the plasma membrane"], ["TCGA.NH.A6GB.01", "RA biosynthesis pathway"], ["TCGA.T9.A92H.01", "Nitric oxide stimulates guanylate cyclase"], ["TCGA.T9.A92H.01", "Creation of C4 and C2 activators"], ["TCGA.T9.A92H.01", "Potassium Channels"], ["TCGA.T9.A92H.01", "Cardiac conduction"], ["TCGA.T9.A92H.01", "O2/CO2 exchange in erythrocytes"], ["TCGA.T9.A92H.01", "Classical antibody-mediated complement activation"], ["TCGA.T9.A92H.01", "Erythrocytes take up carbon dioxide and release oxygen"], ["TCGA.T9.A92H.01", "Receptor-type tyrosine-protein phosphatases"], ["TCGA.T9.A92H.01", "Assembly and cell surface presentation of NMDA receptors"], ["TCGA.T9.A92H.01", "Ion homeostasis"], ["TCGA.T9.A92H.01", "Presynaptic depolarization and calcium channel opening"], ["TCGA.T9.A92H.01", "Adrenaline,noradrenaline inhibits insulin secretion"], ["TCGA.T9.A92H.01", "Glucagon-type ligand receptors"], ["TCGA.T9.A92H.01", "GABA B receptor activation"], ["TCGA.T9.A92H.01", "Activation of GABAB receptors"], ["TCGA.T9.A92H.01", "Activation of G protein gated Potassium channels"], ["TCGA.T9.A92H.01", "G protein gated Potassium channels"], ["TCGA.T9.A92H.01", "Phase 0 - rapid depolarisation"], ["TCGA.T9.A92H.01", "Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits"], ["TCGA.T9.A92H.01", "Keratan sulfate biosynthesis"], ["TCGA.T9.A92H.01", "Negative regulation of NMDA receptor-mediated neuronal transmission"], ["TCGA.T9.A92H.01", "Inwardly rectifying K+ channels"], ["TCGA.T9.A92H.01", "ADP signalling through P2Y purinoceptor 12"], ["TCGA.T9.A92H.01", "Synthesis of Prostaglandins (PG) and Thromboxanes (TX)"], ["TCGA.T9.A92H.01", "G beta:gamma signalling through BTK"], ["TCGA.T9.A92H.01", "Arachidonic acid metabolism"], ["TCGA.T9.A92H.01", "Glucagon signaling in metabolic regulation"], ["TCGA.T9.A92H.01", "Ca-dependent events"], ["TCGA.T9.A92H.01", "Blood group systems biosynthesis"], ["TCGA.T9.A92H.01", "Keratan sulfate/keratin metabolism"], ["TCGA.T9.A92H.01", "Platelet calcium homeostasis"], ["TCGA.T9.A92H.01", "Presynaptic function of Kainate receptors"], ["TCGA.T9.A92H.01", "RA biosynthesis pathway"], ["TCGA.T9.A92H.01", "Calmodulin induced events"], ["TCGA.T9.A92H.01", "CaM pathway"], ["TCGA.T9.A92H.01", "DAG and IP3 signaling"], ["TCGA.T9.A92H.01", "Activation of kainate receptors upon glutamate binding"], ["TCGA.T9.A92H.01", "G alpha (z) signalling events"], ["TCGA.T9.A92H.01", "Chemokine receptors bind chemokines"], ["TCGA.T9.A92H.01", "Lewis blood group biosynthesis"], ["TCGA.T9.A92H.01", "G-protein mediated events"], ["TCGA.T9.A92H.01", "Acetylcholine binding and downstream events"], ["TCGA.T9.A92H.01", "Synthesis of bile acids and bile salts via 24-hydroxycholesterol"], ["TCGA.T9.A92H.01", "Postsynaptic nicotinic acetylcholine receptors"], ["TCGA.T9.A92H.01", "PLC beta mediated events"], ["TCGA.T9.A92H.01", "Prostacyclin signalling through prostacyclin receptor"], ["TCGA.T9.A92H.01", "G-protein activation"], ["TCGA.T9.A92H.01", "Synthesis of bile acids and bile salts via 27-hydroxycholesterol"], ["TCGA.WS.AB45.01", "Collagen formation"], ["TCGA.WS.AB45.01", "Collagen biosynthesis and modifying enzymes"], ["TCGA.WS.AB45.01", "Assembly of collagen fibrils and other multimeric structures"], ["TCGA.WS.AB45.01", "Collagen chain trimerization"], ["TCGA.WS.AB45.01", "Diseases associated with O-glycosylation of proteins"], ["TCGA.WS.AB45.01", "Defective B3GALTL causes PpS"], ["TCGA.WS.AB45.01", "O-glycosylation of TSR domain-containing proteins"], ["TCGA.WS.AB45.01", "Diseases of glycosylation"], ["TCGA.WS.AB45.01", "O-linked glycosylation"], ["TCGA.WS.AB45.01", "Ethanol oxidation"], ["TCGA.WS.AB45.01", "Chondroitin sulfate biosynthesis"], ["TCGA.WS.AB45.01", "Elastic fibre formation"], ["TCGA.WS.AB45.01", "Glucuronidation"], ["TCGA.WS.AB45.01", "RA biosynthesis pathway"], ["TCGA.WS.AB45.01", "APAP ADME"], ["TCGA.WS.AB45.01", "Scavenging by Class A Receptors"], ["TCGA.WS.AB45.01", "Aspirin ADME"], ["TCGA.WS.AB45.01", "Aflatoxin activation and detoxification"], ["TCGA.WS.AB45.01", "Glycosaminoglycan metabolism"], ["TCGA.WS.AB45.01", "Metal ion SLC transporters"], ["TCGA.WS.AB45.01", "Collagen degradation"], ["TCGA.WS.AB45.01", "Laminin interactions"], ["TCGA.WS.AB45.01", "Dectin-2 family"], ["TCGA.WS.AB45.01", "Defective GALNT3 causes HFTC"], ["TCGA.WS.AB45.01", "Defective GALNT12 causes CRCS1"], ["TCGA.WS.AB45.01", "Keratan sulfate biosynthesis"], ["TCGA.WS.AB45.01", "Defective C1GALT1C1 causes TNPS"], ["TCGA.WS.AB45.01", "Blood group systems biosynthesis"], ["TCGA.WS.AB45.01", "Degradation of cysteine and homocysteine"], ["TCGA.WS.AB45.01", "Chondroitin sulfate/dermatan sulfate metabolism"], ["TCGA.WS.AB45.01", "The canonical retinoid cycle in rods (twilight vision)"], ["TCGA.WS.AB45.01", "Termination of O-glycan biosynthesis"], ["TCGA.WS.AB45.01", "Acetylcholine Neurotransmitter Release Cycle"]], "total_weight": 6186.372901372719, "total_sum_of_weights": 427873.0442768014}